Injecting	O
most	O
benzodiazepines	O
is	O
dangerous	O
because	O
of	O
their	O
relative	O
insolubility	O
in	O
water	O
with	O
the	O
exception	O
midazolam	B-Drug
leading	O
to	O
potentially	O
serious	O
adverse	O
health	O
consequences	O
for	O
users	O

However	O
it	O
is	O
now	O
known	O
that	O
only	O
around	O
10%	O
of	O
a	O
dose	O
PCP	B-Drug
removed	O
by	O
the	O
kidneys	O
which	O
would	O
make	O
increased	O
urinary	O
clearance	O
little	O
consequence;	O
furthermore	O
acidification	O
dangerous	O
as	O
may	O
induce	O
acidosis	O
and	O
worsen	O
rhabdomyolysis	O
muscle	O
breakdowna	O
not-unusual	O
manifestation	O
toxicity	O

The	O
commercial	O
SABAs	O
salbutamol	B-Drug
and	O
terbutaline	O
are	O
resistant	O
to	O
COMT	O
but	O
slowly	O
metabolised	O
by	O
MAO	O
while	O
the	O
LABAs	O
both	O

Addition	O
of	O
a	O
33-dimethyl	O
moiety	O
to	O
the	O
piperidine	O
ring	O
increases	O
potency	O
by	O
45x	O
compared	O
title	O
compound	O
and	O
3D	O
overlay	O
using	O
CHARMM	O
shows	O
that	O
this	O
class	O
overlays	O
fentanyl	B-Drug
scaffold	O
in	O
positioning	O
aryl	O
groups	O
basic	O
nitrogen	O
amide	O
moieties	O
perfectly	O

Sublingual	O
fentanyl	B-Drug
dissolves	O
quickly	O
and	O
is	O
absorbed	O
through	O
the	O
sublingual	O
mucosa	O
to	O
provide	O
rapid	O
analgesia	O

In	O
addition	O
to	O
serotonergic	O
activity	O
tramadol	B-Drug
is	O
also	O
a	O
norepinephrine	O
reuptake	O
inhibitor	O

In	O
turn	O
N-methylphenethylamine	O
is	O
metabolized	O
from	O
phenethylamine	B-Drug
by	O
phenylethanolamine	O
N-methyltransferase	O
the	O
same	O
enzyme	O
that	O
metabolizes	O
norepinephrine	O
into	O
epinephrine	O

As	O
the	O
19th	O
century	O
progressed	O
however	O
doctor	O
Hamilton	O
Wright	O
worked	O
to	O
decrease	O
use	O
of	O
opium	B-Drug
in	O
US	O
by	O
submitting	O
Harrison	O
Act	O
congress	O

Androstenedione	B-Drug
was	O
legal	O
and	O
able	O
to	O
be	O
purchased	O
over	O
the	O
counter	O
as	O
a	O
consequence	O
it	O
in	O
common	O
use	O
Major	O
League	O
Baseball	O
throughout	O
1990s	O
by	O
record-breaking	O
sluggers	O
like	O
Mark	O
McGwire	O

More	O
recent	O
examples	O
are	O
cimetidine	B-Drug
and	O
loratadine	B-Drug
in	O
the	O
United	O
States	O
ibuprofen	B-Drug
Australia	O

This	O
discovery	O
was	O
stimulated	O
by	O
earlier	O
studies	O
on	O
other	O
naturally	O
occurring	O
analogues	O
of	O
ibogaine	B-Drug
such	O
as	O
coronaridine	O
and	O
voacangine	O
that	O
showed	O
these	O
compounds	O
also	O
have	O
anti-addictive	O
properties	O

Although	O
cocaine	B-Drug
use	O
had	O
not	O
significantly	O
changed	O
over	O
the	O
six	O
years	O
prior	O
to	O
1999	O
number	O
of	O
first-time	O
users	O
went	O
up	O
from	O
574000	O
in	O
1991	O
934000	O
1998	O
an	O
increase	O
63%	O

Androgenic	O
side	O
effects	O
are	O
of	O
concern	O
as	O
some	O
women	O
taking	O
danazol	B-Drug
may	O
experience	O
unwanted	O
hair	O
growth	O
hirsutism	O
acne	O
irreversible	O
deepening	O
the	O
voice	O
or	O
adverse	O
blood	O
lipid	O
profiles	O

With	O
radio	O
receptor	O
assay	O
techniques	O
the	O
terminal	O
half-life	O
is	O
of	O
up	O
to	O
90	O
hours	O
including	O
all	O
metabolites	O
mifepristone	B-Drug
able	O
bind	O
progesterone	O
receptors	O

Meloxicam	B-Drug
is	O
also	O
licensed	O
for	O
use	O
in	O
horses	O
to	O
relieve	O
the	O
pain	O
associated	O
with	O
musculoskeletal	O
disorders	O

However	O
in	O
1950	O
the	O
actual	O
production	O
of	O
morphine	B-Drug
from	O
poppy	O
straw	O
was	O
reported	O
to	O
be	O
11663	O
kilograms	O
25713	O
lb	O

The	O
phase	O
I	O
products	O
are	O
the	O
same	O
in	O
cats	O
and	O
dogs:	O
allopregnatrione	O
3-alfaxalone	O
20-hydroxy-3-alfaxalone	O
2-hydroxyalfaxalone	O
alfaxalone	B-Drug

Jim	O
DeRogatis	O
wrote	O
that	O
peyote	O
a	O
small	O
cactus	O
containing	O
the	O
psychedelic	O
alkaloid	O
mescaline	B-Drug
was	O
widely	O
available	O
in	O
Austin	O
Texas	O
countercultural	O
hub	O
early	O
1960s	O

The	O
peculiarity	O
of	O
this	O
invention	O
compared	O
to	O
former	O
treatment	O
approaches	O
for	O
treating	O
sleep	O
disorders	O
is	O
the	O
so	O
far	O
unknown	O
therapeutic	O
efficacy	O
R-phenylpiracetam	O
which	O
presumably	O
based	O
at	O
least	O
in	O
part	O
on	O
newly	O
identified	O
activity	O
as	O
dopamine	O
re-uptake	O
inhibitor	O
Phenylpiracetam	B-Drug
may	O
also	O
act	O
a	O
noradrenaline	O
reuptake	O
making	O
it	O
an	O
NDRI	O

However	O
there	O
have	O
been	O
multiple	O
studies	O
verifying	O
the	O
ability	O
of	O
methadone	B-Drug
maintenance	O
patients	O
to	O
drive	O

It	O
is	O
a	O
structural	O
analog	O
of	O
phenazepam	B-Drug
in	O
which	O
the	O
chlorine	O
atom	O
has	O
been	O
replaced	O
by	O
fluorine	O

As	O
CMA	O
does	O
not	O
inhibit	O
cytochrome	O
P450	O
enzymes	O
it	O
may	O
have	O
a	O
lower	O
risk	O
of	O
drug	O
interactions	O
than	O
19-nortestosterone	B-Drug
progestins	O

This	O
chemical	O
proves	O
very	O
useful	O
for	O
opening	O
up	O
and	O
expressing	O
oneself	O
much	O
like	O
MDMA	B-Drug
34-methylenedioxymethamphetamine	O
may	O
be	O
a	O
in	O
psychedelic	O
therapy	O
methylenedioxymethamphetamine	B-Drug

It	O
was	O
developed	O
by	O
screening	O
chemicals	O
similar	O
to	O
pethidine	B-Drug
meperidine	B-Drug
for	O
opioid	O
activity	O

Ethylestrenol	B-Drug
along	O
with	O
other	O
AAS	O
is	O
a	O
schedule	O
III	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act	O

While	O
the	O
rates	O
of	O
opioid	O
prescriptions	O
increased	O
between	O
2001	O
and	O
2010	O
prescription	O
non-opioid	O
pain	O
relievers	O
aspirin	B-Drug
ibuprofen	B-Drug
etc	O

Taken	O
orally	O
Nimetazepam	B-Drug
has	O
very	O
good	O
bioavailability	O
with	O
nearly	O
100%	O
being	O
absorbed	O
from	O
the	O
gut	O

Because	O
of	O
fentanyl's	O
high	O
lipid	O
solubility	O
its	O
effects	O
are	O
more	O
localized	O
than	O
morphine	B-Drug
and	O
some	O
clinicians	O
prefer	O
to	O
use	O
get	O
a	O
wider	O
spread	O
analgesia	O
fentanyl	B-Drug

Hashish	B-Drug
production	O
in	O
Spain	O
has	O
also	O
become	O
more	O
popular	O
and	O
is	O
on	O
the	O
rise	O
however	O
demand	O
for	O
relatively	O
cheap	O
high	O
quality	O
Moroccan	O
hash	B-Drug
still	O
extremely	O

Chaloupka	O
estimated	O
that	O
a	O
10%	O
reduction	O
in	O
the	O
price	O
of	O
cocaine	B-Drug
would	O
lead	O
to	O
14%	O
increase	O
frequency	O
use	O

LSD	B-Drug
is	O
Schedule	O
I	O
in	O
the	O
United	O
States	O
according	O
to	O
Controlled	O
Substances	O
Act	O
of	O
1970	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2	O

In	O
2008	O
the	O
FDA	O
gave	O
bevacizumab	B-Drug
provisional	O
approval	O
for	O
metastatic	O
breast	O
cancer	O
subject	O
to	O
further	O
studies	O

this	O
behalf	O
by	O
the	O
Central	O
Government;	O
prescribe	O
forms	O
and	O
conditions	O
of	O
licenses	O
for	O
cultivation	O
opium	B-Drug
poppy	I-Drug
production	O
manufacture	O
opium;	O
fees	O
that	O
may	O
be	O
charged	O
therefor;	O
authorities	O
which	O
such	O
granted	O
withheld	O
refused	O
or	O
cancelled	O
before	O
appeals	O
against	O
order	O
withholding	O
refusal	O
cancellation	O
shall	O
lie;	O
weighed	O
examined	O
classified	O
according	O
to	O
its	O
quality	O
consistence	O
officers	O
authorized	O
in	O
Government	O
presence	O
cultivator	O
at	O
time	O
delivery	O
cultivator;	O
empower	O
fix	O
from	O
price	O
paid	O
cultivators	O
delivered;	O
provide	O
weighment	O
examination	O
classification	O
received	O
factory	O
deductions	O
additions	O
if	O
any	O
standard	O
made	O
accordance	O
with	O
result	O
examination;	O
decisions	O
regard	O
require	O
delivered	O
a	O
found	O
as	O
adulterated	O
confiscated	O
manufactured	O
drugs	O
therefor	O
permits	O
possession	O
transport	O
import	O
inter-State	O
export	O
sale	O
purchase	O
consumption	O
use	O
psychotropic	O
substances	O
ports	O
other	O
places	O
kind	O
narcotic	O
imported	O
into	O
India	O
exported	O
transshipped;	O
certificates	O
authorizations	O
case	O
transhipment;	O
certificate	O

By	O
April	O
1966	O
LSD	B-Drug
use	O
had	O
become	O
so	O
widespread	O
that	O
Time	O
Magazine	O
warned	O
about	O
its	O
dangers	O

This	O
enzyme	O
appears	O
to	O
be	O
induced	O
by	O
cAMP	O
levels	O
meaning	O
substances	O
that	O
elevate	O
such	O
as	O
forskolin	O
and	O
vinpocetine	O
may	O
increase	O
GHB	B-Drug
synthesis	O
release	O

Vitamin	B-Drug
C	I-Drug
is	O
especially	O
prone	O
to	O
oxidation	O
during	O
cooking	O
and	O
may	O
be	O
completely	O
destroyed	O
by	O
protracted	O

This	O
study	O
suggested	O
that	O
25I-NBOMe	B-Drug
is	O
approximately	O
14-fold	O
more	O
potent	O
than	O
2C-I	O
in-vivo	O

However	O
this	O
timing	O
cannot	O
be	O
recommended	O
for	O
enteric-coated	O
aspirin	B-Drug

By	O
April	O
1966	O
LSD	B-Drug
use	O
had	O
become	O
so	O
widespread	O
that	O
Time	O
magazine	O
warned	O
about	O
its	O
dangers	O

Lastly	O
Vint	O
Russian	O
for	O
a	O
screw	O
refers	O
to	O
very	O
impure	O
homemade	O
form	O
of	O
methamphetamine	B-Drug
in	O
Russia	O

As	O
of	O
November	O
2012	O
Sepracor	O
has	O
not	O
resubmitted	O
its	O
authorization	O
application	O
and	O
eszopiclone	B-Drug
is	O
available	O
in	O
Europe	O

Cocaine	B-Drug
heroin	B-Drug
cannabis	O
and	O
other	O
such	O
drugs	O
continued	O
to	O
be	O
legally	O
available	O
without	O
prescription	O
as	O
long	O
they	O
were	O
labeled	O

Clobazam	B-Drug
was	O
originally	O
marketed	O
as	O
an	O
anxioselective	O
anxiolytic	O
since	O
1970	O
and	O
anticonvulsant	O
1984	O

Antifolates	O
such	O
as	O
trimethoprim	B-Drug
methotrexate	B-Drug
pemetrexed	O
and	O
raltitrexed	O

0	O
million	O
prescriptions	O
for	O
spironolactone	B-Drug
in	O
the	O
United	O
States	O
2016	O
alone	O

Other	O
isomers	O
of	O
this	O
compound	O
have	O
also	O
been	O
explored	O
with	O
the	O
1-pentylamide	O
being	O
around	O
75%	O
potency	O
LSD	B-Drug
while	O
R-2-pentylamide	O
shows	O
similar	O
5-HT2A	O
binding	O
affinity	O
to	O
in	O
vitro	O
but	O
has	O
only	O
half	O
producing	O
drug-appropriate	O
responding	O
mice	O
and	O
S-2-pentylamide	O
is	O
inactive	O

This	O
is	O
because	O
a	O
unique	O
metabolite	O
6-monoacetylmorphine	O
produced	O
from	O
heroin	B-Drug
use	O
that	O
never	O
consuming	O
any	O
other	O
substance	O
even	O
opiates	O
like	O
the	O
ones	O
present	O
in	O
poppy	O
seeds	O

Clair	O
in	O
order	O
to	O
prevent	O
Communist	O
party	O
members	O
from	O
being	O
elected	O
Italy	O
following	O
World	O
War	O
II	O
the	O
CIA	O
worked	O
closely	O
with	O
Sicilian	O
Mafia	O
protecting	O
them	O
and	O
assisting	O
their	O
worldwide	O
heroin	B-Drug
smuggling	O
operations	O

The	O
common	O
name	O
opium	B-Drug
poppy	O
is	O
increasingly	O
a	O
misnomer	O
as	O
many	O
varieties	O
have	O
been	O
bred	O
that	O
do	O
not	O
produce	O
significant	O
quantity	O
of	O

Drostanolone	B-Drug
and	O
drostanolone	O
propionate	O
were	O
first	O
described	O
in	O
1959	O

The	O
recreational	O
use	O
is	O
not	O
particularly	O
widespread	O
in	O
the	O
EU	O
with	O
exception	O
of	O
Tallinn	O
Estonia	O
where	O
it	O
has	O
largely	O
replaced	O
heroin	B-Drug

Lorazepam's	O
anticonvulsant	O
properties	O
and	O
pharmacokinetic	O
profile	O
make	O
intravenous	O
use	O
reliable	O
for	O
terminating	O
acute	O
seizures	O
but	O
induce	O
prolonged	O
sedation	O
Lorazepam	B-Drug

In	O
other	O
nations	O
such	O
as	O
Canada	O
schedule	O
I	O
drug	O
the	O
Netherlands	O
List	O
United	O
States	O
II	O
Australia	O
8	O
Thailand	O
category	O
1	O
narcotic	O
and	O
Kingdom	O
class	O
B	O
amphetamine	B-Drug
is	O
in	O
a	O
restrictive	O
national	O
that	O
allows	O
for	O
its	O
use	O
medical	O
treatment	O

When	O
methylphenidate	B-Drug
is	O
coingested	O
with	O
ethanol	O
a	O
metabolite	B-Drug
called	O
ethylphenidate	O
formed	O
via	O
hepatic	O
transesterification	O
not	O
unlike	O
the	O
formation	O
of	O
cocaethylene	B-Drug
from	O
cocaine	B-Drug
and	O

In	O
general	O
there	O
are	O
far	O
lower	O
risks	O
of	O
pulmonary	O
complications	O
for	O
regular	O
cannabis	O
smokers	O
when	O
compared	O
with	O
those	O
tobacco	B-Drug

It	O
has	O
a	O
slightly	O
higher	O
potency	O
and	O
effectiveness	O
as	O
an	O
analgesic	O
than	O
codeine	B-Drug
but	O
is	O
weaker	O
morphine	B-Drug

The	O
name	O
of	O
cohoba	O
refers	O
to	O
the	O
finely	O
ground	O
cinnamon-colored	O
snuff	B-Drug
itself	O
as	O
well	O
ceremonial	O
practice	O
using	O
it	O
by	O
South	O
American	O
tribes	O

However	O
some	O
sedating	O
antihistamines	O
such	O
as	O
orphenadrine	B-Drug
can	O
produce	O
a	O
synergistic	O
pain	O
relieving	O
effect	O
permitting	O
smaller	O
doses	O
of	O
opioids	O
be	O
used	O

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family	O

The	O
S-+	O
enantiomer	O
of	O
mirtazapine	B-Drug
is	O
responsible	O
for	O
antagonism	O
the	O
serotonin	O
5-HT2A	O
and	O
5-HT2C	O
receptors	O
while	O
R-	O
5-HT3	O
receptor	O

65	O
nM	O
respectively	O
and	O
than	O
the	O
4-methoxy	O
compound	O
JWH-081	B-Drug
CB1	O
Ki	O
1	O

In	O
some	O
formulations	O
paracetamol	B-Drug
is	O
combined	O
with	O
the	O
opiate	O
codeine	B-Drug
sometimes	O
referred	O
to	O
as	O
co-codamol	O
BAN	O
and	O
Panadeine	O
in	O
Australia	O

Haloperidol	B-Drug
was	O
discovered	O
by	O
Paul	O
Janssen	O

Partly	O
due	O
to	O
the	O
global	O
supply	O
shortage	O
of	O
sassafras	O
oila	O
problem	O
largely	O
assuaged	O
by	O
use	O
improved	O
or	O
alternative	O
modern	O
methods	O
synthesisthe	O
purity	O
substances	O
sold	O
as	O
molly	B-Drug
have	O
been	O
found	O
vary	O
widely	O

Nasal	O
insufflation	O
known	O
colloquially	O
as	O
snorting	O
sniffing	O
or	O
blowing	O
is	O
a	O
common	O
method	O
of	O
ingestion	O
recreational	O
powdered	O
cocaine	B-Drug

Both	O
exhibit	O
optical	O
isomerism	O
and	O
alphaprodine	B-Drug
betaprodine	B-Drug
are	O
racemates	O

Their	O
stage	O
performance	O
involved	O
the	O
use	O
of	O
strobe	O
lights	O
to	O
reproduce	O
LSD's	O
surrealistic	O
fragmenting	O
or	O
vivid	O
isolating	O
caught	O
moments	O
LSD	B-Drug

Ethisterone	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
danazol	B-Drug
23-isoxazolethisterone	O
and	O
thought	O
to	O
contribute	O
importantly	O
its	O
effects	O

State	O
and	O
local	O
governments	O
may	O
also	O
regulate	O
cannabidiol	B-Drug

Infrequent	O
adverse	O
reactions	O
in	O
patients	O
taking	O
opioids	O
for	O
pain	O
relief	O
include:	O
dose-related	O
respiratory	O
depression	O
especially	O
with	O
more	O
potent	O
confusion	O
hallucinations	O
delirium	O
urticaria	O
hypothermia	O
bradycardia/tachycardia	O
orthostatic	O
hypotension	O
dizziness	O
headache	O
urinary	O
retention	O
ureteric	O
or	O
biliary	O
spasm	O
muscle	O
rigidity	O
myoclonus	O
high	O
doses	O
and	O
flushing	O
due	O
to	O
histamine	O
release	O
except	O
fentanyl	B-Drug
remifentanil	B-Drug

Still	O
others	O
describe	O
experiences	O
with	O
illegal	O
LSD	B-Drug
obtained	O
for	O
philosophic	O
artistic	O
therapeutic	O
spiritual	O
or	O
recreational	O
purposes	O

Ephedrine	B-Drug
and	O
phenylephrine	B-Drug
as	O
amine	O
hydrochlorides	O
are	O
used	O
decongestants	O

Respiratory	O
depression	O
is	O
a	O
potentially	O
serious	O
or	O
fatal	O
adverse	O
drug	O
reaction	O
associated	O
with	O
the	O
use	O
of	O
codeine	B-Drug
but	O
mainly	O
danger	O
lies	O
in	O
much	O
more	O
potent	O
and	O
CNS-depressing	O
phenothiazine-related	O
antihistamine	O
promethazine	B-Drug

to	O
describe	O
the	O
death	O
of	O
ego	O
in	O
first	O
phase	O
an	O
LSD	B-Drug
trip	O
which	O
a	O
complete	O
transcendence	O
self	O
occurs	O

It	O
is	O
a	O
prodrug	O
of	O
norethisterone	B-Drug
with	O
both	O
quingestanol	O
and	O
acetate	O
serving	O
as	O
intermediates	O
in	O
the	O
transformation	O

Desogestrel	B-Drug
via	O
etonogestrel	B-Drug
is	O
a	O
very	O
potent	O
progestogen	O
and	O
inhibits	O
ovulation	O
at	O
low	O
doses	O
in	O
the	O
microgram	O
range	O

Along	O
with	O
desogestrel	B-Drug
it	O
is	O
one	O
of	O
the	O
only	O
progestins	O
that	O
widely	O
available	O
as	O
a	O
progestogen-only	O
mini	O
pill	O
for	O
birth	O
control	O

Depressants	O
and	O
PCP	B-Drug
are	O
Schedule	O
III	O
drugs	O
various	O
prescription	O
a	O
II	O

In	O
the	O
European	O
Union	O
Subutex	B-Drug
and	O
Suboxone	B-Drug
buprenorphine's	O
high-dose	O
sublingual	O
tablet	O
preparations	O
were	O
approved	O
for	O
opioid	O
use	O
disorder	O
treatment	O
in	O
September	O
2006	O
buprenorphine	B-Drug

Due	O
to	O
the	O
effect	O
pH	O
has	O
on	O
absorption	O
proton	O
pump	O
inhibitors	O
which	O
reduce	O
gastric	O
acid	O
are	O
known	O
interact	O
with	O
methamphetamine	B-Drug

The	O
benzamide	O
neuroleptics	O
including	O
sulpiride	O
amisulpride	B-Drug
and	O
sultopride	O
have	O
been	O
shown	O
to	O
activate	O
the	O
endogenous	O
gamma-hydroxybutyrate	O
receptor	O
in	O
vivo	O
at	O
therapeutic	O
concentrations	O

Ranitidine	B-Drug
was	O
first	O
prepared	O
in	O
England	O
as	O
AH19065	O
by	O
John	O
Bradshaw	O
the	O
summer	O
of	O
1977	O
Ware	O
research	O
laboratories	O
Allen	O
and	O
Hanburys	O
part	O
larger	O
Glaxo	O
organisation	O

2%	O
of	O
what	O
they	O
need	O
and	O
90%	O
all	O
the	O
morphine	B-Drug
in	O
world	O
is	O
used	O
by	O
world's	O
richest	O
10%	O

This	O
was	O
lower	O
than	O
cannabis-induced	O
psychosis	O
34%	O
but	O
higher	O
amphetamine	B-Drug
22%	O
opioid	O
12%	O
alcohol	O
10%	O
and	O
sedative	O
9%	O
induced	O
psychoses	O

6-	O
and	O
6-hydromorphol	O
are	O
also	O
formed	O
the	O
metabolites	O
of	O
hydrocodone	B-Drug
conjugated	O
via	O
glucuronidation	O

These	O
results	O
suggest	O
that	O
PCP	B-Drug
is	O
a	O
highly	O
selective	O
ligand	O
of	O
the	O
NMDAR	O
and	O
2	O
receptor	O

Cannabis	O
is	O
a	O
popular	O
recreational	O
drug	O
around	O
the	O
world	O
only	O
behind	O
alcohol	O
caffeine	O
and	O
tobacco	B-Drug

Nonetheless	O
the	O
success	O
of	O
program	O
was	O
only	O
temporary	O
with	O
opium	B-Drug
use	O
rapidly	O
increasing	O
during	O
disorder	O
following	O
death	O
Yuan	O
Shikai	O
in	O
1916	O

Perampanel	B-Drug
reduced	O
the	O
effectiveness	O
of	O
levonorgestrel	B-Drug
oral	O
contraceptives	O
by	O
about	O
40%	O

Hydrocodone	B-Drug
and	O
acetaminophen	B-Drug
are	O
present	O
in	O
breast	O
milk	O

However	O
some	O
sedating	O
antihistamines	O
such	O
as	O
orphenadrine	B-Drug
can	O
produce	O
a	O
synergistic	O
pain	O
relieving	O
effect	O
permitting	O
smaller	O
doses	O
of	O
opioids	O
be	O
used	O

Pharmaceutical	O
pills	O
are	O
sometimes	O
sold	O
as	O
ecstasy	B-Drug
well	O
that	O
contain	O
no	O
psychoactive	O
chemicals	O
at	O
all	O

Methadone	B-Drug
is	O
made	O
by	O
chemical	O
synthesis	O
and	O
acts	O
on	O
opioid	O
receptors	O

Snorting	O
heroin	B-Drug
becomes	O
an	O
often	O
unwanted	O
route	O
once	O
a	O
user	O
begins	O
to	O
inject	O
the	O
drug	O

Dutasteride	B-Drug
is	O
approved	O
for	O
the	O
treatment	O
of	O
male	O
androgenetic	O
alopecia	O
in	O
South	O
Korea	O
and	O
Japan	O
at	O
a	O
dosage	O
0	O

In	O
December	O
2002	O
clozapine	B-Drug
was	O
approved	O
in	O
the	O
US	O
for	O
reducing	O
risk	O
of	O
suicide	O
schizophrenic	O
or	O
schizoaffective	O
patients	O
judged	O
to	O
be	O
at	O
chronic	O
suicidal	O
behavior	O

Nandrolone	B-Drug
is	O
the	O
parent	O
compound	O
of	O
a	O
large	O
group	O
AAS	O

However	O
the	O
initial	O
5-reduced	O
metabolite	O
of	O
D4A	O
3-keto-5-abiraterone	O
is	O
an	O
agonist	O
AR	O
and	O
promotes	O
prostate	O
cancer	O
progression	O
abiraterone	B-Drug

In	O
June	O
2013	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
CDC	O
issued	O
a	O
health	O
advisory	O
to	O
emergency	O
departments	O
alerting	O
14	O
overdose	O
deaths	O
among	O
intravenous	O
drug	O
users	O
in	O
Rhode	O
Island	O
associated	O
with	O
acetylfentanyl	B-Drug
synthetic	O
opioid	O
analog	O
of	O
fentanyl	B-Drug
that	O
has	O
never	O
been	O
licensed	O
medical	O
use	O

Sofosbuvir's	O
U	O
Sofosbuvir	B-Drug

Lorazepam's	O
relatively	O
short	O
serum	O
half-life	O
its	O
confinement	O
mainly	O
to	O
blood	O
and	O
inactive	O
metabolite	O
can	O
result	O
in	O
interdose	O
withdrawal	O
phenomena	O
next-dose	O
cravings	O
that	O
may	O
reinforce	O
psychological	O
dependence	O
Lorazepam	B-Drug

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches	O

Thus	O
high	O
extracellular	O
MDMA	B-Drug
can	O
reverse	O
the	O
transport	O

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio	O

The	O
absolute	O
bioavailability	O
of	O
darolutamide	B-Drug
with	O
oral	O
administration	O
a	O
single	O
300-mg	O
dose	O
without	O
food	O
is	O
approximately	O
30%	O

In	O
contrast	O
to	O
flutamide	O
and	O
hydroxyflutamide	O
which	O
severely	O
compromise	O
hepatocyte	O
cellular	O
respiration	O
in	O
vitro	O
bicalutamide	B-Drug
does	O
not	O
significantly	O
do	O
so	O
at	O
the	O
same	O
concentrations	O
is	O
regarded	O
as	O
non-mitotoxic	O

From	O
the	O
1850s	O
onwards	O
Chinese	O
immigrants	O
came	O
to	O
British	O
Columbia	O
in	O
droves	O
establishing	O
opium	B-Drug
dens	O
their	O
isolated	O
communities	O

In	O
the	O
US	O
ketorolac	B-Drug
is	O
only	O
widely	O
available	O
intravenous	O
NSAID	O

This	O
may	O
play	O
a	O
role	O
in	O
explaining	O
diazepam's	O
anticonvulsant	O
properties	O
diazepam	B-Drug

In	O
recent	O
years	O
fentanyl	B-Drug
has	O
disrupted	O
the	O
North	O
American	O
drug	O
market	O
capitalizing	O
on	O
pre-existing	O
demand	O
for	O
opiates	O
such	O
as	O
heroin	B-Drug
and	O
prescription	O
pharmaceuticals	O

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
increased	O
delta	O
decreased	O
alpha	O
and	O
hippocampus	O
increase	O
theta	O
bursts	O
that	O
were	O
those	O

In	O
turn	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas	O
thus	O
leading	O
gateway	O
sequence	O
those	O
individuals	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered	O

Blotter	O
LSD	B-Drug
mimics	O
can	O
have	O
relatively	O
small	O
dose	O
squares;	O
a	O
sample	O
of	O
blotter	O
paper	O
containing	O
DOC	O
seized	O
by	O
Concord	O
California	O
police	O
had	O
markings	O
approximately	O
6	O
mm	O
apart	O

doses	O
given	O
to	O
oneself	O
in	O
humans	O
but	O
it	O
is	O
not	O
an	O
effective	O
monotherapy	O
for	O
amphetamine	B-Drug
addiction	O

Phenobarbital	B-Drug
is	O
a	O
cytochrome	O
P450	O
hepatic	O
enzyme	O
inducer	O

In	O
addition	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
codeine	B-Drug
morphine	B-Drug
synthetic	O
pure-opioid	O
agonists	O
oxycodone	B-Drug
hydromorphone	B-Drug
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion	O

Morphine-N-oxide	O
can	O
also	O
form	O
as	O
a	O
decomposition	O
product	O
of	O
morphine	B-Drug
outside	O
the	O
body	O
and	O
may	O
show	O
up	O
in	O
assays	O
opium	B-Drug
poppy	O
straw	O
concentrate	O

The	O
254	O
pounds	O
115	O
kg	O
of	O
fentanyl	B-Drug
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3	O

Lisdexamfetamine	B-Drug
is	O
an	O
inactive	O
prodrug	O
that	O
converted	O
in	O
the	O
body	O
to	O
dextroamphetamine	B-Drug
a	O
pharmacologically	O
active	O
compound	O
which	O
responsible	O
for	O
drug's	O
activity	O

In	O
the	O
early	O
2000s	O
contamination	O
of	O
androstenedione	B-Drug
products	O
with	O
traces	O
bolandione	B-Drug
caused	O
false	O
positives	O
for	O
doping	O
tests	O
nandrolone	B-Drug
because	O
19-norandrosterone	O
is	O
a	O
metabolite	O
both	O
and	O

Bicalutamide	B-Drug
may	O
be	O
used	O
to	O
treat	O
hyperandrogenism	O
and	O
associated	O
benign	O
prostatic	O
hyperplasia	O
secondary	O
hyperadrenocorticism	O
caused	O
by	O
excessive	O
adrenal	O
androgens	O
in	O
male	O
ferrets	O

Trenbolone	B-Drug
enanthate	I-Drug
is	O
also	O
a	O
very	O
commonly	O
used	O
AAS	O
and	O
lasts	O
much	O
longer	O
than	O
trenbolone	B-Drug
acetate	O
with	O
intramuscular	O
injection	O

In	O
palliative	O
care	O
transdermal	O
fentanyl	B-Drug
patches	B-Drug
have	O
a	O
definitive	O
but	O
limited	O
role	O
for:	O
people	O
already	O
stabilized	O
on	O
other	O
opioids	O
who	O
persistent	O
swallowing	O
problems	O
and	O
cannot	O
tolerate	O
parenteral	O
routes	O
such	O
as	O
subcutaneous	O
administration	O

Celecoxib	B-Drug
and	O
other	O
COX-2	O
selective	O
inhibitors	O
valdecoxib	O
parecoxib	O
mavacoxib	O
were	O
discovered	O
by	O
a	O
team	O
at	O
the	O
Searle	O
division	O
of	O
Monsanto	O
led	O
John	O
Talley	O

In	O
1712	O
Engelbert	O
Kaempfer	O
described	O
addiction	O
to	O
madak:	O
No	O
commodity	O
throughout	O
the	O
Indies	O
is	O
retailed	O
with	O
greater	O
profit	O
by	O
Batavians	O
than	O
opium	B-Drug
which	O
[its]	O
users	O
cannot	O
do	O
without	O
nor	O
can	O
they	O
come	O
it	O
except	O
be	O
brought	O
ships	O
of	O
from	O
Bengal	O
and	O
Coromandel	O

2]oct-5-ene	O
and	O
cesium	O
carbonate	O
in	O
acetonitrile	O
the	O
ibogaine	B-Drug
precursor	O
7-ethyl-2-2-2-iodo-1H-indol-3-ylethyl-2-azabicyclo[2	O

A	O
kilogram	O
of	O
heroin	B-Drug
laced	O
with	O
fentanyl	B-Drug
may	O
sell	O
for	O
more	O
than	O
US$100000	O
but	O
the	O
itself	O
be	O
produced	O
far	O
cheaply	O
about	O
US$6000	O
per	O

Fentanyl's	O
most	O
common	O
side	O
effects	O
which	O
affect	O
more	O
than	O
10%	O
of	O
people	O
include	O
diarrhea	O
nausea	O
constipation	O
dry	O
mouth	O
somnolence	O
confusion	O
asthenia	O
weakness	O
sweating	O
Fentanyl	B-Drug

The	O
drug	O
showed	O
advantages	O
over	O
earlier	O
opioid	O
antagonists	O
such	O
as	O
cyclazocine	O
nalorphine	O
and	O
naloxone	B-Drug
including	O
its	O
oral	O
activity	O
a	O
long	O
duration	O
of	O
action	O
allowing	O
for	O
once-daily	O
administration	O
lack	O
dysphoria	O
was	O
selected	O
further	O
development	O

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O
Sleep	O
Older	O
age	O
Concomitant	O
use	O
CNS	O
depressants	O
like	O
benzodiazepines	O
barbiturates	O
alcohol	O
and	O
inhaled	O
anesthetics	O
Hyperventilation	O
Decreased	O
CO2	O
levels	O
in	O
serum	O
Respiratory	O
acidosis	O
clearance	O
from	O
body	O
blood	O
flow	O
to	O
liver	O
Renal	O
insufficiencySustained	O
release	O
preparations	O
such	O
as	O
patches	O
may	O
also	O
produce	O
unexpected	O
delayed	O

Actual	O
full	O
synthesis	O
of	O
cocaine	B-Drug
is	O
rarely	O
done	O

Marketed	O
by	O
Roche	O
using	O
an	O
advertising	O
campaign	O
conceived	O
the	O
William	O
Douglas	O
McAdams	O
Agency	O
under	O
leadership	O
of	O
Arthur	O
Sackler	O
diazepam	B-Drug
was	O
top-selling	O
pharmaceutical	O
in	O
United	O
States	O
from	O
1969	O
to	O
1982	O
with	O
peak	O
annual	O
sales	O
1978	O
2	O

It	O
is	O
an	O
inactive	O
prodrug	O
of	O
etonogestrel	B-Drug
with	O
essentially	O
no	O
affinity	O
for	O
the	O
PR	O
itself	O
about	O
1%	O
that	O
promegestone	O

Oral	O
desogestrel	B-Drug
is	O
clinically	O
on	O
the	O
order	O
of	O
5000	O
times	O
more	O
potent	O
than	O
oral	O
micronized	O
progesterone	O
which	O
has	O
an	O
effective	O
ovulation-inhibiting	O
dosage	O
300	O
mg/day	O
in	O
humans	O

Diazepam	B-Drug
and	O
propranolol	B-Drug
are	O
common	O
examples;	O
ethanol	O
cannabis	O
also	O
used	O
occasionally	O

It	O
was	O
concluded	O
that	O
meloxicam	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
cats	O
chronic	O
kidney	O
disease	O

Ketoconazole	B-Drug
has	O
been	O
found	O
to	O
displace	O
dihydrotestosterone	O
and	O
estradiol	O
from	O
sex	O
hormone-binding	O
globulin	O
in	O
vitro	O
but	O
this	O
was	O
not	O
be	O
relevant	O
vivo	O

CsA	B-Drug
also	O
inhibits	O
the	O
phosphatase	O
calcineurin	O
pathway	O
14	O

As	O
a	O
prodrug	O
psilocybin	O
is	O
quickly	O
converted	O
by	O
the	O
body	O
to	O
psilocin	B-Drug
which	O
has	O
mind-altering	O
effects	O
similar	O
in	O
some	O
aspects	O
those	O
of	O
LSD	B-Drug
mescaline	B-Drug
and	O
DMT	O

Although	O
25I-NBOMe	B-Drug
was	O
discovered	O
in	O
2003	O
it	O
did	O
not	O
emerge	O
as	O
a	O
common	O
recreational	O
drug	O
until	O
2010	O
when	O
first	O
sold	O
by	O
vendors	O
specializing	O
the	O
supply	O
of	O
designer	O
drugs	O

Nonetheless	O
in	O
October	O
1996	O
the	O
Expert	O
Committee	O
considered	O
controlling	O
nicotine	B-Drug
especially	O
products	O
such	O
as	O
gum	O
patches	O
nasal	O
spray	O
and	O
inhalers	O

Zolpidem	B-Drug
is	O
a	O
ligand	O
of	O
high-affinity	O
positive	O
modulator	O
sites	O
GABAA	O
receptors	O
which	O
enhances	O
GABAergic	O
inhibition	O
neurotransmission	O
in	O
the	O
central	O
nervous	O
system	O

On	O
13	O
March	O
2012	O
Haji	O
Bagcho	O
with	O
ties	O
to	O
the	O
Taliban	O
was	O
convicted	O
by	O
a	O
US	O
District	O
Court	O
of	O
conspiracy	O
distribution	O
heroin	B-Drug
for	O
importation	O
into	O
United	O
States	O
and	O
narco-terrorism	O

Thompson	O
wrote	O
an	O
extremely	O
detailed	O
account	O
of	O
his	O
first	O
use	O
mescaline	B-Drug
in	O
First	O
Visit	O
with	O
Mescalito	O
and	O
it	O
appeared	O
book	O
Songs	O
the	O
Doomed	O
as	O
well	O
featuring	O
heavily	O
novel	O
Fear	O
Loathing	O
Las	O
Vegas	O

The	O
DEA	O
ACSCN	O
for	O
hydromorphone	B-Drug
is	O
9150	O

Levomethorphan	B-Drug
-	O
A	O
potent	O
opioid	O
analgesic	O
that	O
was	O
never	O
clinically	O
developed;	O
the	O
codeine	B-Drug
analogue	O
of	O
powerful	O
agonist	O
levorphanol	B-Drug
Levo-Dromoran	O

The	O
promethazine	B-Drug
and	O
codeine	B-Drug
concoction	O
first	O
gained	O
popularity	O
in	O
the	O
underground	O
hip	O
hop	O
scene	O
Houston	O
where	O
musician	O
Big	O
Hawk	O
said	O
it	O
was	O
consumed	O
as	O
early	O
1960s	O
1970s	O
becoming	O
more	O
widely	O
used	O
1990s	O

As	O
with	O
other	O
opioid	O
analgesics	O
central	O
nervous	O
system	O
effects	O
such	O
as	O
sedation	O
confusion	O
and	O
dizziness	O
are	O
considerations	O
butorphanol	B-Drug

Although	O
not	O
currently	O
a	O
standard	O
treatment	O
for	O
menorrhagia	O
danazol	B-Drug
demonstrated	O
significant	O
relief	O
in	O
young	O
women	O
with	O
study	O
and	O
because	O
of	O
lack	O
adverse	O
effects	O
it	O
was	O
proposed	O
as	O
an	O
alternative	O

Although	O
Islamic	O
law	O
is	O
often	O
interpreted	O
as	O
prohibiting	O
all	O
intoxicants	O
not	O
only	O
alcohol	O
the	O
ancient	O
practice	O
of	O
hashish	B-Drug
smoking	O
has	O
continued	O
throughout	O
history	O
Islam	O
against	O
varying	O
degrees	O
resistance	O

Androstenedione	B-Drug
was	O
manufactured	O
as	O
a	O
dietary	O
supplement	O
often	O
called	O
andro	O
or	O
andros	O
for	O
short	O

Rolicyclidine	B-Drug
PCPy	O
is	O
a	O
dissociative	O
anesthetic	O
drug	O
with	O
hallucinogenic	O
and	O
sedative	O
effects	O

4	O
tonnes	O
of	O
cocaine	B-Drug
the	O
largest	O
seizure	O
a	O
single	O
shipment	O
in	O
Australian	O
history	O

Diazepam	B-Drug
was	O
the	O
most	O
commonly	O
detected	O
benzodiazepine	O

The	O
resolution	O
does	O
not	O
mention	O
JWH-018	B-Drug
or	O
other	O
synthetic	O
cannabinoids	O

Still	O
most	O
of	O
the	O
people	O
who	O
use	O
BZP	B-Drug
even	O
though	O
they	O
say	O
it	O
is	O
quite	O
easy	O
to	O
stop	O
do	O
not	O
want	O
and	O
continue	O
drug	O
feeling	O
that	O
helps	O
them	O
reach	O
higher	O
levels	O
mood	O
sociability	O
energy	O

In	O
addition	O
to	O
their	O
medical	O
use	O
nandrolone	B-Drug
esters	O
are	O
used	O
improve	O
physique	O
and	O
performance	O
said	O
be	O
the	O
most	O
widely	O
AAS	O
for	O
such	O
purposes	O

Methyltestosterone	B-Drug
is	O
also	O
known	O
by	O
its	O
former	O
developmental	O
code	O
name	O
NSC-9701	O

Hydrocodone	B-Drug
is	O
second	O
among	O
the	O
list	O
of	O
top	O
prescribed	O
opioid	O
painkillers	O
but	O
it	O
also	O
high	O
on	O
most	O
abused	O

Caution	O
in	O
those	O
suffering	O
from	O
hypotension	O
nitrazepam	B-Drug
may	O
worsen	O

The	O
drug	O
discrimination	O
assay	O
for	O
LSD	B-Drug
in	O
rats	O
involves	O
both	O
5-HT1A	O
and	O
5-HT2A	O
mediated	O
components	O
while	O
lysergic	O
acid	B-Drug
2-butyl	O
amide	O
is	O
more	O
potent	O
than	O
as	O
a	O
agonist	O
it	O
slightly	O
less	O
so	O
would	O
probably	O
be	O
hallucinogen	O
humans	O

It	O
was	O
incorrectly	O
claimed	O
as	O
early	O
1968	O
that	O
the	O
name	O
'Acapulco	O
Gold'	O
had	O
been	O
trademarked	O
in	O
anticipation	O
of	O
marijuana	O
legalization;	O
August	O
1969	O
Harlan	O
Ellison	O
asserted	O
trademark	O
registered	O
to	O
tobacco	B-Drug
company	O
Liggett	O
&	O
Myers	O

A	O
binding	O
study	O
assessed	O
PCP	B-Drug
at	O
56	O
sites	O
including	O
neurotransmitter	O
receptors	O
and	O
transporters	O
found	O
that	O
had	O
Ki	O
values	O
of	O
>10000	O
nM	O
all	O
except	O
the	O
dizocilpine	O
MK-801	O
site	O
NMDA	O
receptor	O
136	O
serotonin	O
transporter	O
=	O
2234	O

Haloperidol	B-Drug
was	O
discovered	O
in	O
1958	O
by	O
Paul	O
Janssen	O

Contraindications	O
include	O
hypersensitivity	O
to	O
abiraterone	B-Drug
acetate	O

Crack	O
cocaine	B-Drug
is	O
popularly	O
thought	O
to	O
be	O
the	O
most	O
addictive	O
form	O
of	O

LSD	B-Drug
has	O
also	O
been	O
studied	O
in	O
depression	O
anxiety	O
and	O
drug	O
dependence	O
with	O
positive	O
preliminary	O
results	O

At	O
this	O
time	O
he	O
had	O
a	O
series	O
of	O
psychedelic	O
experiences	O
that	O
helped	O
to	O
shape	O
his	O
further	O
goals	O
and	O
research	O
the	O
first	O
which	O
was	O
brought	O
on	O
by	O
mescaline	B-Drug

A	O
Guttmacher	O
Institute	O
survey	O
of	O
abortion	O
providers	O
estimated	O
that	O
medical	O
abortions	O
accounted	O
for	O
17%	O
all	O
and	O
slightly	O
over	O
25%	O
before	O
9	O
weeks	O
gestation	O
in	O
the	O
United	O
States	O
2008	O
94%	O
nonhospital	O
used	O
mifepristone	B-Drug
misoprostol	B-Drug
6%	O
methotrexate	B-Drug

In	O
October	O
2010	O
it	O
was	O
reported	O
that	O
the	O
use	O
of	O
cocaine	B-Drug
in	O
Australia	O
has	O
doubled	O
since	O
monitoring	O
began	O
2003	O

Aldous	O
Huxley's	O
1953	O
essay	O
The	O
Doors	O
of	O
Perception	O
describing	O
his	O
experiences	O
with	O
mescaline	B-Drug
and	O
R	O

When	O
nonselective	O
COX-1/COX-2	O
inhibitors	O
such	O
as	O
aspirin	B-Drug
ibuprofen	B-Drug
and	O
naproxen	B-Drug
lower	O
stomach	O
prostaglandin	O
levels	O
ulcers	O
of	O
the	O
or	O
duodenum	O
internal	O
bleeding	O
can	O
result	O

Long-acting	O
injectable	O
naltrexone	B-Drug
decreases	O
heroin	O
use	O
more	O
than	O
placebo	O

Phenobarbital	B-Drug
was	O
among	O
the	O
most	O
widely	O
used	O
drugs	O
for	O
treatment	O
of	O
epilepsy	O
through	O
1970s	O
and	O
as	O
2014	O
remains	O
on	O
World	O
Health	O
Organizations	O
list	O
essential	O
medications	O

A	O
case	O
report	O
found	O
that	O
the	O
pharmacokinetics	O
of	O
methyprylon	B-Drug
were	O
not	O
concentration	O
dependent	O
in	O
an	O
overdose	O
case;	O
explanations	O
included	O
saturation	O
or	O
inhibition	O
metabolic	O
pathways	O

Tobacco	B-Drug
smokers	O
may	O
also	O
experience	O
more	O
powerful	O
effects	O
with	O
psilocybin	O
because	O
tobacco	O
smoke	O
exposure	O
decreases	O
the	O
activity	O
of	O
MAO	O
in	O
brain	O
and	O
peripheral	O
organs	O

Seizures	O
have	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
with	O
enzalutamide	B-Drug
clinical	O
trials	O

4%	O
bufotenin	B-Drug

It	O
is	O
suggested	O
that	O
methadone	B-Drug
does	O
not	O
function	O
as	O
much	O
to	O
curb	O
addiction	O
redirect	O
it	O
and	O
maintain	O
dependency	O
on	O
authorised	O
channels	O

This	O
includes	O
paracetamol/acetaminophen	O
or	O
NSAIDs	O
like	O
ibuprofen	B-Drug
naproxen	B-Drug
paracetamol	B-Drug
acetaminophen	B-Drug

After	O
prolonged	O
exposure	O
to	O
heat	O
in	O
alkaline	O
pH	O
conditions	O
10	O
15%	O
of	O
the	O
parent	O
LSD	B-Drug
epimerized	O
iso-LSD	O

Lidocaine	B-Drug
should	O
be	O
given	O
for	O
this	O
indication	O
after	O
defibrillation	O
CPR	O
and	O
vasopressors	O
have	O
been	O
initiated	O

At	O
the	O
same	O
time	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	O
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights	O

This	O
recommendation	O
was	O
followed	O
by	O
the	O
placement	O
of	O
Etizolam	B-Drug
into	O
Schedule	O
IV	O
in	O
March	O
2020	O
is	O
a	O
4	O
substance	O
under	O
Poisons	O
Standard	O
June	O
2018	O
as	O
it	O
classed	O
benzodiazepine	O
derivative	O

Illicitly	O
synthesized	O
fentanyl	B-Drug
powder	O
has	O
also	O
appeared	O
on	O
the	O
United	O
States	O
market	O

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths	O

Apalutamide	B-Drug
is	O
marketed	O
under	O
the	O
brand	O
names	O
Erleada	O
and	O
Erlyand	O

The	O
symptoms	O
of	O
a	O
moderate	O
acute	O
overdose	O
on	O
methylphenidate	B-Drug
primarily	O
arise	O
from	O
central	O
nervous	O
system	O
overstimulation;	O
these	O
include:	O
vomiting	O
nausea	O
agitation	O
tremors	O
hyperreflexia	O
muscle	O
twitching	O
euphoria	O
confusion	O
hallucinations	O
delirium	O
hyperthermia	O
sweating	O
flushing	O
headache	O
tachycardia	O
heart	O
palpitations	O
cardiac	O
arrhythmias	O
hypertension	O
mydriasis	O
and	O
dryness	O
mucous	O
membranes	O

Cannabidiol	B-Drug
has	O
low	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
and	O
CB2	O
receptors	O
although	O
it	O
can	O
act	O
as	O
an	O
antagonist	O
of	O
CB1/CB2	O
agonists	O
despite	O
this	O

Recently	O
phenazepam	B-Drug
has	O
gained	O
popularity	O
as	O
a	O
recreational	O
drug;	O
misuse	O
been	O
reported	O
in	O
the	O
United	O
Kingdom	O
Finland	O
Sweden	O
and	O
States	O

Although	O
nalbuphine	B-Drug
possesses	O
opioid	O
antagonist	O
activity	O
there	O
is	O
evidence	O
that	O
in	O
nondependent	O
patients	O
it	O
will	O
not	O
antagonize	O
an	O
analgesic	O
administered	O
just	O
before	O
concurrently	O
or	O
after	O
injection	O

The	O
same	O
motif	O
can	O
be	O
found	O
in	O
reboxetine	B-Drug
where	O
it	O
is	O
constrained	O
a	O
morpholine	O
ring	O
system	O

From	O
Cuba	O
cocaine	B-Drug
would	O
be	O
transported	O
to	O
Miami	O
Florida;	O
and	O
Union	O
City	O
New	O
Jersey	O

testosterone	O
dihydrotestosterone	O
androstenedione	B-Drug
androstenediol	O
dehydroepiandrosterone	O
Synthetic	O
androgens	O
e	O

As	O
a	O
result	O
norketamine	O
plasma	O
levels	O
are	O
several-fold	O
higher	O
than	O
ketamine	B-Drug
following	O
oral	O
administration	O
and	O
may	O
play	O
role	O
in	O
anesthetic	O
analgesic	O
action	O
of	O

Marks	O
then	O
travelled	O
to	O
the	O
Far	O
East	O
set	O
up	O
cannabis	O
deals	O
with	O
Salim	O
Malik	O
a	O
Pakistani	O
hashish	B-Drug
exporter	O
who	O
he	O
had	O
met	O
through	O
Durrani	O
since	O
suffered	O
fatal	O
heart	O
attack	O
and	O
Phil	O
Sparrowhawk	O
an	O
from	O
Bangkok;	O
they	O
would	O
smuggle	O
their	O
product	O
over	O
Ernie	O
Combs	O
in	O
America	O

As	O
his	O
distribution	O
empire	O
grew	O
to	O
include	O
forty-two	O
cities	O
the	O
price	O
he	O
paid	O
per	O
kg	O
of	O
powder	O
cocaine	B-Drug
dropped	O
from	O
as	O
much	O
$60000	O
low	O
$10000	O

CBD	B-Drug
has	O
been	O
shown	O
to	O
act	O
as	O
a	O
serotonin	O
5-HT1A	O
receptor	O
partial	O
agonist	O

When	O
used	O
in	O
the	O
palliative	O
care	O
of	O
cancer	O
patients	O
diamorphine	B-Drug
is	O
often	O
injected	O
using	O
a	O
syringe	O
driver	O

While	O
rare	O
it	O
is	O
sometimes	O
sold	O
as	O
a	O
substitute	O
for	O
LSD	B-Drug
or	O
even	O
falsely	O
which	O
may	O
be	O
dangerous	O
because	O
DOI	O
does	O
not	O
have	O
the	O
same	O
established	O
safety	O
profile	O

In	O
the	O
European	O
Union	O
naldemedine	B-Drug
is	O
also	O
approved	O
for	O
treatment	O
of	O
opioid	O
induced	O
constipation	O
in	O
adults	O
but	O
as	O
a	O
second-line	O
therapy	O
after	O
with	O
laxative	O

Designer	O
stimulants	O
that	O
attracted	O
media	O
attention	O
in	O
2010	O
included	O
mephedrone	B-Drug
ephedrone	O
and	O
fluoroamphetamines	O
which	O
have	O
chemical	O
structures	O
effects	O
similar	O
to	O
ephedrine	B-Drug
amphetamine	B-Drug

The	O
codeine	B-Drug
analog	O
of	O
chloromorphide	O
is	O
-chlorocodide	O
alphachlorcodide	O
an	O
intermediate	O
in	O
one	O
method	O
desomorphine	B-Drug
synthesis	O
which	O
uses	O
as	O
precursor	O

Like	O
morphine	B-Drug
pethidine	B-Drug
exerts	O
its	O
analgesic	O
effects	O
by	O
acting	O
as	O
an	O
agonist	O
at	O
the	O
-opioid	O
receptor	O

In	O
addition	O
buspirone	B-Drug
does	O
not	O
produce	O
euphoria	O
and	O
is	O
a	O
drug	O
of	O
abuse	O

This	O
was	O
shown	O
when	O
nociceptin	O
compounds	O
were	O
used	O
as	O
a	O
pain	O
medication	O
substitution	O
for	O
morphine	B-Drug

A	O
single	O
case	O
of	O
desomorphine	B-Drug
use	O
was	O
reported	O
in	O
Spain	O
2014	O
with	O
the	O
drug	O
consumed	O
orally	O
rather	O
than	O
by	O
injection	O

UNODC	O
calculates	O
that	O
more	O
than	O
800000	O
Pakistanis	O
aged	O
between	O
15	O
and	O
64	O
use	O
heroin	B-Drug
regularly	O

The	O
optical	O
rotation	O
of	O
a	O
given	O
enantiomer	O
ketamine	B-Drug
can	O
vary	O
between	O
its	O
salts	O
and	O
free	O
base	O
form	O

Mitragynine	B-Drug
consumption	O
for	O
medicinal	O
and	O
recreation	O
purposes	O
dates	O
back	O
centuries	O
although	O
early	O
use	O
was	O
primarily	O
limited	O
to	O
Southeast	O
Asian	O
countries	O
such	O
as	O
Indonesia	O
Thailand	O
where	O
the	O
plant	O
grows	O
indigenously	O

Androstenedione	B-Drug
is	O
produced	O
in	O
the	O
adrenal	O
glands	O
and	O
gonads	O

See	O
psilocin	B-Drug
for	O
more	O
details	O

Some	O
studies	O
found	O
that	O
like	O
other	O
NMDA	O
receptor	O
antagonists	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats	O

The	O
buprenorphine/naloxone	O
sublingual	O
film	O
e	O
buprenorphine	B-Drug
naloxone	B-Drug

In	O
1958	O
Chemie	O
Grnenthal	O
reached	O
an	O
agreement	O
with	O
William	O
S	O
Merrell	O
Company	O
in	O
Cincinnati	O
Ohio	O
later	O
Richardson-Merrell	O
now	O
part	O
of	O
Sanofi	O
to	O
market	O
and	O
distribute	O
thalidomide	B-Drug
throughout	O
the	O
USThe	O
US	O
FDA	O
refused	O
approve	O
for	O
marketing	O
distribution	O

Mifepristone	B-Drug
was	O
developed	O
in	O
1980	O
and	O
came	O
into	O
use	O
France	O
1987	O

DMHP	B-Drug
has	O
three	O
stereocenters	O
and	O
consequently	O
eight	O
possible	O
stereoisomers	O
which	O
differ	O
considerably	O
in	O
potency	O

Other	O
sources	O
rich	O
in	O
vitamin	B-Drug
C	I-Drug
are	O
fruits	O
such	O
as	O
lemons	O
limes	O
oranges	O
papaya	O
and	O
strawberries	O

Eight	O
minutes	O
after	O
administration	O
morphine	B-Drug
appeared	O
rapidly	O
and	O
had	O
a	O
half	O
life	O
of	O
1	O

Patients	O
already	O
prescribed	O
oxycodone	B-Drug
will	O
receive	O
coverage	O
for	O
an	O
additional	O
year	O
OxyNeo	O
and	O
after	O
that	O
it	O
be	O
disallowed	O
unless	O
designated	O
under	O
the	O
exceptional	O
access	O
program	O

Additionally	O
nociceptin	O
may	O
have	O
lower	O
tolerance	O
development	O
than	O
drugs	O
such	O
as	O
morphine	B-Drug

The	O
risk	O
of	O
experiencing	O
severe	O
withdrawal	O
symptoms	O
is	O
high	O
if	O
a	O
patient	O
has	O
become	O
physically	O
dependent	O
and	O
discontinues	O
oxycodone	B-Drug
abruptly	O

Unlike	O
dextromoramide	B-Drug
which	O
is	O
a	O
potent	O
analgesic	O
with	O
high	O
abuse	O
potential	O
levomoramide	B-Drug
virtually	O
without	O
activity	O

A	O
high	O
dosage	O
of	O
20	O
mg/day	O
norethisterone	B-Drug
or	O
NETA	O
has	O
been	O
found	O
to	O
significantly	O
stimulate	O
the	O
sebaceous	O
glands	O
whereas	O
lower	O
dosages	O
5	O
and	O
2	O

It	O
was	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
on	O
23	O
March	O
1943	O
for	O
sale	O
in	O
United	O
States	O
Health	O
Canada	O
under	O
brand	O
name	O
Hycodan	B-Drug

They	O
had	O
also	O
studied	O
his	O
hospital	O
records	O
which	O
included	O
two	O
admissions	O
for	O
drug	O
detoxification	O
and	O
methadone	B-Drug
treatments	O

If	O
use	O
of	O
amitriptyline	B-Drug
is	O
warranted	O
therapeutic	O
drug	O
monitoring	O
recommended	O
to	O
guide	O
dose	O
adjustments	O

The	O
major	O
metabolites	O
of	O
diamorphine	B-Drug
6-MAM	O
morphine	B-Drug
morphine-3-glucuronide	O
and	O
morphine-6-glucuronide	O
may	O
be	O
quantitated	O
in	O
blood	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use	O
confirm	O
a	O
diagnosis	O
poisoning	O
assist	O
medicolegal	O
death	O
investigation	O

As	O
of	O
August	O
2015	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States	O

JWH-196	B-Drug
is	O
a	O
synthetic	O
cannabinoid	O
receptor	O
ligand	O
from	O
the	O
naphthylmethylindole	O
family	O

PMMA	B-Drug
is	O
the	O
4-methoxy	O
analog	O
of	O
methamphetamine	B-Drug

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

Cortisol	O
prolactin	O
and	O
oxytocin	O
quantities	O
in	O
blood	O
serum	O
are	O
increased	O
by	O
MDMA	B-Drug

Constricting	O
blood	O
vessels	O
causes	O
tissues	O
to	O
receive	O
insufficient	O
flow	O
killing	O
cells	O
but	O
this	O
effect	O
is	O
less	O
pronounced	O
with	O
cocaine	B-Drug
than	O
nicotine	B-Drug

In	O
April	O
2019	O
the	O
United	O
Kingdom	O
scheduled	O
gabapentin	B-Drug
and	O
pregabalin	B-Drug
as	O
Class	O
C	O
drugs	O
under	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
Schedule	O
3	O
Regulations	O
2001	O

In	O
the	O
Film	O
The	O
Highwaymen	O
2019	O
Bonnie	O
Parker	O
Emily	O
Brobst	O
of	O
and	O
Clyde	O
Fame	O
is	O
addicted	O
to	O
laudanum	B-Drug

Although	O
25I-NBOMe	B-Drug
was	O
discovered	O
in	O
2003	O
it	O
did	O
not	O
emerge	O
as	O
a	O
common	O
recreational	O
drug	O
until	O
2010	O
when	O
first	O
sold	O
by	O
vendors	O
specializing	O
the	O
supply	O
of	O
designer	O
drugs	O

This	O
means	O
LSD	B-Drug
is	O
illegal	O
to	O
manufacture	O
buy	O
possess	O
process	O
or	O
distribute	O
without	O
a	O
license	O
from	O
the	O
Drug	O
Enforcement	O
Administration	O
DEA	O

Methylphenobarbital	B-Drug
INN	O
also	O
known	O
as	O
mephobarbital	B-Drug
USAN	O
JAN	O
and	O
mephobarbitone	O
BAN	O
marketed	O
under	O
brand	O
names	O
such	O
Mebaral	O
Mephyltaletten	O
Phemiton	O
Prominal	O
is	O
a	O
drug	O
which	O
barbiturate	O
derivative	O
used	O
primarily	O
an	O
anticonvulsant	O
but	O
sedative	O
anxiolytic	O

The	O
BAN	O
was	O
formerly	O
ethyloestrenol	B-Drug
but	O
it	O
eventually	O
changed	O

conveyance	O
means	O
a	O
of	O
any	O
description	O
whatsoever	O
and	O
includes	O
aircraft	O
vehicle	O
or	O
vessel;	O
illicit	O
traffic	O
in	O
relation	O
to	O
narcotic	O
drugs	O
psychotropic	O
substances	O
means:	O
i	O
cultivating	O
coca	B-Drug
plant	O
gathering	O
portion	O
plant;	O
ii	O
the	O
opium	B-Drug
poppy	I-Drug
cannabis	O
iii	O
engaging	O
production	O
manufacture	O
possession	O
sale	O
purchase	O
transportation	O
warehousing	O
concealment	O
use	O
consumption	O
import	O
inter-State	O
export	O
into	O
India	O
from	O
transshipment	O
substances;	O
iv	O
dealing	O
activities	O
other	O
than	O
those	O
referred	O
sub-clauses	O
iii;	O
v	O
handling	O
letting	O
out	O
premises	O
for	O
carrying	O
on	O
permitted	O
under	O
this	O
Act	O
rule	O
order	O
made	O
condition	O
license	O
term	O
authorization	O
issued	O
thereunder	O
includes:	O
1	O
financing	O
directly	O
indirectly	O
aforementioned	O
activities;	O
2	O
abetting	O
conspiring	O
furtherance	O
support	O
doing	O
3	O
harboring	O
persons	O
engaged	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety	O
agitation	O
and	O
in	O
rare	O
cases	O
generally	O
with	O
non-regular	O
JWH	O
users	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC	O

This	O
is	O
thought	O
to	O
result	O
in	O
a	O
much	O
lower	O
incidence	O
and	O
magnitude	O
of	O
facial/body	O
hair	O
growth	O
scalp	O
loss	O
possibly	O
prostate	O
issues	O
like	O
enlargement	O
cancer	O
with	O
nandrolone	B-Drug
esters	O
relative	O
testosterone	O

Gabapentin	B-Drug
prevents	O
delivery	O
of	O
the	O
calcium	O
channels	O
to	O
cell	O
membrane	O
reduces	O
activation	O
by	O
2	O
subunit	O
decreases	O
signaling	O
leading	O
neurotransmitters	O
release	O
and	O
disrupts	O
interactions	O
with	O
NMDA	O
receptors	O
neurexins	O
thrombospondins	O

The	O
song	O
was	O
inspired	O
by	O
Grimes	O
losing	O
six	O
of	O
her	O
friends	O
to	O
heroin	B-Drug
overdoses	O
and	O
the	O
numbness	O
felt	O
following	O
their	O
deaths	O

An	O
individual	O
who	O
has	O
consumed	O
excess	O
chlordiazepoxide	B-Drug
may	O
display	O
some	O
of	O
the	O
following	O
symptoms:	O
Somnolence	O
difficulty	O
staying	O
awake	O
Mental	O
confusion	O
Hypotension	O
Hypoventilation	O
Impaired	O
motor	O
functions	O
reflexes	O
coordination	O
balance	O
Dizziness	O
Muscle	O
weakness	O
ComaChlordiazepoxide	O
is	O
a	O
drug	O
that	O
very	O
frequently	O
involved	O
in	O
intoxication	O
including	O
overdose	O

Due	O
to	O
difficulties	O
in	O
procuring	O
heroin	B-Drug
combined	O
with	O
easy	O
and	O
cheap	O
access	O
over-the-counter	O
pharmacy	O
products	O
containing	O
codeine	B-Drug
Russia	O
use	O
of	O
krokodil	O
increased	O
until	O
2012	O

Cesamet	B-Drug
has	O
remained	O
a	O
Schedule	O
II	O
drug	O
since	O
its	O
first	O
introduction	O

It	O
can	O
be	O
cut	O
into	O
or	O
even	O
replace	O
entirely	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates	O

If	O
an	O
antipsychotic	O
is	O
given	O
intramuscular	O
haloperidol	B-Drug
has	O
been	O
recommended	O

Selegiline	B-Drug
was	O
discovered	O
by	O
Zoltan	O
Ecseri	O
at	O
the	O
Hungarian	O
drug	O
company	O
Chinoin	O
part	O
of	O
Sanofi	O
since	O
1993	O
which	O
they	O
called	O
E-250	O

The	O
active	O
metabolites	O
of	O
quazepam	B-Drug
are	O
2-oxoquazepam	O
and	O
N-desalkyl-2-oxoquazepam	O

The	O
fentanyl	B-Drug
patch	O
is	O
one	O
of	O
a	O
few	O
medications	O
that	O
may	O
be	O
especially	O
harmful	O
and	O
in	O
some	O
cases	O
fatal	O
with	O
just	O
dose	O
if	O
used	O
by	O
someone	O
other	O
than	O
the	O
person	O
for	O
whom	O
medication	O
was	O
prescribed	O

A	O
part	O
of	O
the	O
study	O
was	O
recuperated	O
and	O
published	O
in	O
2010	O
including	O
profiles	O
cocaine	B-Drug
use	O
20	O
countries	O
but	O
are	O
unavailable	O
as	O
2015	O

In	O
countries	O
where	O
alcohol	O
and	O
tobacco	B-Drug
are	O
legal	O
certain	O
measures	O
frequently	O
undertaken	O
to	O
discourage	O
use	O
of	O
these	O
drugs	O

Methadone	B-Drug
is	O
metabolized	O
by	O
CYP3A4	O
CYP2B6	O
CYP2D6	O
and	O
a	O
substrate	O
or	O
in	O
this	O
case	O
target	O
for	O
the	O
P-glycoprotein	O
efflux	O
protein	O
which	O
helps	O
pump	O
foreign	O
substances	O
out	O
of	O
cells	O
intestines	O
brain	O

discontinued	O
Orlaam	B-Drug
in	O
the	O
US	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
increased	O
delta	O
decreased	O
alpha	O
and	O
hippocampus	O
increase	O
theta	O
bursts	O
that	O
were	O
those	O

The	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
severe	O
cardiopulmonary	O
depression	O
has	O
caused	O
etorphine	B-Drug
to	O
fall	O
into	O
disfavor	O
in	O
general	O
veterinary	O
practice	O

In	O
August	O
2020	O
the	O
Australian	O
Therapeutic	O
Goods	O
Administration	O
required	O
Product	O
Information	O
PI	O
and	O
Consumer	O
Medicine	O
CMI	O
for	O
medicines	O
containing	O
hydrochlorothiazide	B-Drug
to	O
be	O
updated	O
include	O
details	O
about	O
an	O
increased	O
risk	O
of	O
non-melanoma	O
skin	O
cancer	O

One	O
such	O
method	O
of	O
heroin	B-Drug
production	O
involves	O
isolation	O
the	O
water-soluble	O
components	O
raw	O
opium	B-Drug
including	O
morphine	B-Drug
in	O
a	O
strongly	O
basic	O
aqueous	O
solution	O
followed	O
by	O
recrystallization	O
base	O
addition	O
ammonium	O
chloride	O

Cyproheptadine	B-Drug
is	O
a	O
very	O
potent	O
antihistamine	O
or	O
inverse	O
agonist	O
of	O
the	O
H1	O
receptor	O

Ethylmorphine	B-Drug
also	O
known	O
as	O
codethyline	O
dionine	O
and	O
ethyl	O
morphine	B-Drug
is	O
an	O
opioid	O
analgesic	O
antitussive	O

Hydrocortisone	B-Drug
is	O
the	O
name	O
used	O
for	O
pharmaceutical	O
preparations	O
of	O
cortisol	O

This	O
might	O
have	O
been	O
due	O
to	O
additional	O
ethinylestradiol	O
generated	O
by	O
higher	O
doses	O
of	O
norethisterone	B-Drug

Like	O
other	O
2C-X-NBOMe	O
molecules	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL	O

Lorazepam	B-Drug
is	O
sometimes	O
used	O
as	O
an	O
alternative	O
to	O
midazolam	B-Drug
in	O
palliative	O
sedation	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine	B-Drug

APINACA	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic	O

25I-NBOMe	B-Drug
2C-I-NBOMe	B-Drug
Cimbi-5	O
also	O
shortened	O
to	O
25I	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes	O

In	O
PTEN	O
negative	O
tumors	O
leflunomide	B-Drug
causes	O
synthetic	O
lethality	O
potentially	O
due	O
to	O
increased	O
demand	O
on	O
pyrimidines	O
in	O
these	O
faster	O
growing	O
cells	O

However	O
it	O
still	O
continues	O
to	O
occasionally	O
be	O
encountered	O
as	O
a	O
result	O
of	O
home	O
manufacture	O
from	O
morphine	B-Drug
by	O
drug	O
users	O

it	O
is	O
also	O
a	O
weak	O
opioid	O
agonist	O
so	O
naloxone	B-Drug
remains	O
significant	O
therapeutic	O
tool	O
in	O
suspected	O
cases	O
of	O
overdose	O

He	O
frequently	O
entertained	O
friends	O
and	O
many	O
others	O
with	O
parties	O
he	O
called	O
Acid	B-Drug
Tests	O
involving	O
music	O
such	O
as	O
Kesey's	O
favorite	O
band	O
The	O
Warlocks	O
later	O
known	O
the	O
Grateful	O
Dead	O
black	O
lights	O
fluorescent	O
paint	O
strobes	O
other	O
psychedelic	O
effects	O
of	O
course	O
LSD	B-Drug

Nandrolone	B-Drug
decanoate	I-Drug
is	O
available	O
widely	O
throughout	O
the	O
world	O
including	O
in	O
United	O
Kingdom	O
other	O
European	O
countries	O
Australia	O
New	O
Zealand	O
Latin	O
America	O
Asia	O
and	O
elsewhere	O

Boldenone	B-Drug
is	O
a	O
substrate	O
for	O
5-reductase	O
and	O
may	O
be	O
converted	O
by	O
this	O
enzyme	O
into	O
1-testosterone	B-Drug
1-dihydrotestosterone	O
1-DHT	O
dihydroboldenone	O
in	O
tissues	O
that	O
express	O
it	O
such	O
as	O
the	O
skin	O
hair	O
follicles	O
prostate	O
gland	O

Overall	O
any	O
decrease	O
due	O
to	O
eradication	O
has	O
been	O
tempered	O
by	O
an	O
increase	O
in	O
productivity	O
as	O
estimated	O
coca	B-Drug
production	O
grew	O
from	O
463	O
metric	O
tons	O
2001	O
610	O
2006	O

The	O
National	O
Assembly	O
on	O
Friday	O
submitted	O
its	O
amendments	O
to	O
the	O
Ministry	O
of	O
Health	O
which	O
would	O
place	O
marijuana	O
and	O
vegetable	O
kratom	B-Drug
in	O
category	O
allowing	O
their	O
licensed	O
possession	O
distribution	O
regulated	O
conditions	O

The	O
amine	O
oxides	O
of	O
this	O
type	O
form	O
as	O
oxidation	O
products	O
the	O
parent	O
chemical;	O
virtually	O
every	O
morphine/codeine	O
class	O
opioid	O
has	O
an	O
equivalent	O
nitrogen	O
derivative	O
such	O
hydromorphone-N-oxide	O
morphine	B-Drug
codeine	B-Drug

Some	O
variation	O
in	O
drug	O
scheduling	O
exists	O
individual	O
countries;	O
for	O
example	O
the	O
United	O
Kingdom	O
midazolam	B-Drug
and	O
temazepam	B-Drug
are	O
Schedule	O
III	O
controlled	O
drugs	O

R-MDMA	O
has	O
notable	O
agonism	O
towards	O
5-HT2AR	O
which	O
supposedly	O
contributes	O
to	O
the	O
mild	O
psychedelic	O
hallucinations	O
induced	O
by	O
high	O
doses	O
of	O
MDMA	B-Drug
in	O
humans	O

On	O
the	O
basis	O
of	O
available	O
research	O
it	O
has	O
been	O
said	O
that	O
EM-5854	O
may	O
possibly	O
have	O
70-	O
to	O
140-fold	O
antiandrogenic	O
potency	O
bicalutamide	B-Drug
in	O
humans	O

Nalbuphine	B-Drug
is	O
available	O
in	O
two	O
concentrations	O
10	O
mg	O
and	O
20	O
of	O
nalbuphine	B-Drug
hydrochloride	O
per	O
mL	O

Laboratory	O
seizures	O
indicate	O
some	O
local	O
GHB	B-Drug
and	O
LSD	B-Drug
production	O

Possible	O
symptoms	O
may	O
include:	O
Somnolence	O
Coma	O
Serotonin	O
syndrome	O
Seizures	O
Syncope	O
Tachycardia	O
Hypotension	O
Hypertension	O
Hyperthermia	O
Vomiting	O
Overdose	O
is	O
usually	O
treated	O
symptomatically	O
especially	O
in	O
the	O
case	O
of	O
serotonin	O
which	O
requires	O
treatment	O
with	O
cyproheptadine	B-Drug
and	O
temperature	O
control	O
based	O
on	O
progression	O
toxicity	O

25	O
mg/kg	O
in	O
recreational	O
methamphetamine	B-Drug
users	O
produced	O
scores	O
of	O
drug	O
liking	O
similar	O
to	O
racemic	O
but	O
the	O
effects	O
were	O
shorter	O
lived	O

25I-NBOMe	B-Drug
was	O
put	O
on	O
the	O
list	O
of	O
prohibited	O
substances	O
in	O
March	O
2015	O

FDA	O
began	O
the	O
DESI	O
review	O
process	O
to	O
ensure	O
safety	O
and	O
efficacy	O
of	O
drugs	O
approved	O
under	O
more	O
lenient	O
pre-1962	O
standards	O
including	O
Dianabol	B-Drug

The	O
Cochrane	O
reviews	O
on	O
the	O
treatment	O
of	O
ADHD	O
in	O
children	O
adolescents	O
and	O
adults	O
with	O
pharmaceutical	O
amphetamines	B-Drug
stated	O
that	O
short-term	O
studies	O
have	O
demonstrated	O
these	O
drugs	O
decrease	O
severity	O
symptoms	O
but	O
they	O
higher	O
discontinuation	O
rates	O
than	O
non-stimulant	O
medications	O
due	O
to	O
their	O
adverse	O
side	O
effects	O

The	O
metabolism	O
of	O
mephedrone	B-Drug
has	O
been	O
studied	O
in	O
rats	O
and	O
humans	O
the	O
metabolites	O
can	O
be	O
detected	O
urine	O
after	O
usage	O

For	O
the	O
illegal	O
drug	O
trade	O
morphine	B-Drug
is	O
extracted	O
from	O
opium	B-Drug
latex	O
reducing	O
bulk	O
weight	O
by	O
88%	O

While	O
chemically	O
related	O
both	O
to	O
psychedelics	O
and	O
stimulants	O
the	O
psychological	O
effects	O
experienced	O
with	O
MDMA	B-Drug
were	O
reported	O
provide	O
obvious	O
striking	O
aspects	O
of	O
personal	O
relatedness	O
feelings	O
connectedness	O
communion	O
others	O
ability	O
feel	O
what	O
feelin	O
short	O
an	O
empathic	O
resonance	O
is	O
consistently	O
evoked	O

However	O
despite	O
the	O
numerous	O
case	O
reports	O
presented	O
by	O
veterinary	O
neurologists	O
supporting	O
benefits	O
of	O
CBD	B-Drug
as	O
adjunctive	O
therapy	O
December	O
2020	O
published	O
controlled	O
studies	O
have	O
not	O
shown	O
a	O
statistically	O
significant	O
decrease	O
in	O
number	O
seizures	O
across	O
groups	O
receiving	O

Cocaine	B-Drug
has	O
a	O
small	O
number	O
of	O
accepted	O
medical	O
uses	O
such	O
as	O
numbing	O
and	O
decreasing	O
bleeding	O
during	O
nasal	O
surgery	O

In	O
the	O
male	O
HCG	O
injections	B-Drug
are	O
used	O
to	O
stimulate	O
Leydig	O
cells	O
synthesize	O
testosterone	O

Cocaine	B-Drug
can	O
be	O
in	O
the	O
form	O
of	O
fine	O
white	O
powder	O
bitter	O
to	O
taste	O

Fentanyl	B-Drug
is	O
used	O
orally	O
smoked	O
snorted	O
or	O
injected	O

Alphameprodine	B-Drug
ACSCN	O
9604	O
and	O
betameprodine	B-Drug
9608	O
are	O
both	O
Schedule	O
I	O
Narcotic	O
controlled	O
substances	O
in	O
the	O
United	O
States	O
with	O
annual	O
aggregate	O
manufacturing	O
quotas	O
of	O
2	O
grammes	O
as	O
2014	O

PCP	B-Drug
can	O
be	O
ingested	O
through	O
smoking	O

Lopinavir/ritonavir	B-Drug
was	O
once	O
a	O
preferred	O
combination	O
for	O
HIV	O
first-line	O
therapy	O
in	O
the	O
United	O
States	O

The	O
FDA	O
advised	O
companies	O
to	O
recall	O
their	O
ranitidine	B-Drug
if	O
testing	O
shows	O
levels	O
of	O
NDMA	O
above	O
the	O
acceptable	O
daily	O
intake	O
96	O
nanograms	O
per	O
day	O
or	O
0	O

L-dopa	B-Drug
is	O
a	O
precursor	O
for	O
dopamine	O
the	O
neurotransmitter	O
whose	O
lack	O
produces	O
Parkinson's	O
symptoms	O

As	O
of	O
2018	O
there	O
have	O
been	O
no	O
formal	O
trials	O
to	O
study	O
the	O
efficacy	O
or	O
safety	O
kratom	B-Drug
treat	O
opioid	O
addiction	O

Case	O
reports	O
of	O
seven	O
British	O
males	O
who	O
presented	O
to	O
an	O
emergency	O
room	O
following	O
analytically	O
confirmed	O
25I-NBOMe	B-Drug
intoxication	O
suggest	O
the	O
potential	O
adverse	O
effects:	O
tachycardia	O
n	O
=	O
7	O
hypertension	O
4	O
agitation	O
6	O
aggression	O
visual	O
and	O
auditory	O
hallucinations	O
seizures	O
3	O
hyperpyrexia	O
clonus	O
2	O
elevated	O
white	O
cell	O
count	O
creatine	O
kinase	O
metabolic	O
acidosis	O
acute	O
kidney	O
injury	O
1	O

The	O
result	O
was	O
a	O
99%	O
reduction	O
in	O
the	O
area	O
of	O
opium	B-Drug
poppy	I-Drug
farming	O
Taliban-controlled	O
areas	O
roughly	O
three	O
quarters	O
world's	O
supply	O
heroin	B-Drug
at	O
time	O

D-Lysergic	O
acid	B-Drug
ethylamide	O
LAE-32	O
is	O
a	O
derivative	O
of	O
ergine	O

While	O
the	O
19-nortestosterone	B-Drug
progestins	O
are	O
consistently	O
grouped	O
into	O
generations	O
pregnane	O
that	O
or	O
have	O
been	O
used	O
in	O
birth	O
control	O
pills	O
typically	O
omitted	O
from	O
such	O
classifications	O
simply	O
as	O
miscellaneous	O
pregnanes	O

It	O
contained	O
6	O
mg	O
cocaine	B-Drug
per	O
ounce	O
of	O
wine	O
but	O
Vin	O
Mariani	O
which	O
was	O
to	O
be	O
exported	O
7	O

005%	O
5-OH-DMT	B-Drug
Phalaris	O
arundinacea	O
0	O

Some	O
athletes	O
who	O
were	O
found	O
to	O
have	O
used	O
modafinil	B-Drug
protested	O
as	O
the	O
drug	O
was	O
not	O
on	O
prohibited	O
list	O
at	O
time	O
of	O
their	O
offence	O
however	O
World	O
Anti-Doping	O
Agency	O
WADA	O
maintains	O
it	O
is	O
a	O
substance	O
related	O
those	O
already	O
banned	O
so	O
decisions	O
stand	O

Amineptine	B-Drug
the	O
most	O
closely	O
related	O
drug	O
to	O
have	O
been	O
widely	O
studied	O
is	O
a	O
dopamine	O
reuptake	O
inhibitor	O
with	O
no	O
significant	O
effect	O
on	O
serotonin	O
levels	O
nor	O
opioid	O
agonist	O
activity	O

It	O
was	O
developed	O
chiefly	O
as	O
a	O
morphine	B-Drug
substitute	O
for	O
cough	O
suppressants	O
that	O
did	O
not	O
have	O
morphine's	O
addictive	O
side-effects	O

Experts	O
estimate	O
that	O
the	O
drug	O
thalidomide	B-Drug
led	O
to	O
death	O
of	O
about	O
2000	O
children	O
and	O
serious	O
birth	O
defects	O
in	O
more	O
than	O
10000	O
5000	O
them	O
West	O
Germany	O

Pure	O
difenoxin	B-Drug
in	O
Schedule	O
I	O
has	O
a	O
quota	O
of	O
50	O
grammes	O
and	O
an	O
ACSCN	O
9168	O

Cocaine	B-Drug
became	O
associated	O
with	O
laborers	O
youths	O
black	O
people	O
and	O
the	O
urban	O
underworld	O

When	O
codeine	B-Drug
is	O
taken	O
in	O
very	O
large	O
amounts	O
it	O
can	O
cause	O
one	O
to	O
stop	O
breathing	O

Abuse	O
of	O
fenethylline	B-Drug
the	O
brand	O
name	O
Captagon	B-Drug
is	O
most	O
common	O
in	O
Arab	O
countries	O
and	O
counterfeit	O
versions	O
drug	O
continue	O
to	O
be	O
available	O
despite	O
its	O
illegality	O

Tobacco	O
harm	O
reduction	O
describes	O
actions	O
taken	O
to	O
lower	O
the	O
health	O
risks	O
associated	O
with	O
using	O
tobacco	B-Drug
especially	O
combustible	O
forms	O
without	O
abstaining	O
completely	O
from	O
and	O
nicotine	B-Drug

This	O
human	O
study	O
also	O
indicates	O
that	O
bretazenil	O
is	O
possibly	O
more	O
sedative	O
than	O
diazepam	B-Drug

Therefore	O
slow	O
administration	O
of	O
flumazenil	B-Drug
is	O
necessary	O
to	O
prevent	O
the	O
occurrence	O
a	O
seizure	O

3-Methylfentanyl	B-Drug
has	O
similar	O
effects	O
to	O
fentanyl	B-Drug
but	O
is	O
far	O
more	O
potent	O
due	O
increased	O
binding	O
affinity	O
its	O
target	O
site	O

Succinic	O
semialdehyde	O
dehydrogenase	O
deficiency	O
is	O
a	O
disease	O
that	O
causes	O
GHB	B-Drug
to	O
accumulate	O
in	O
the	O
blood	O

Grapefruit	O
juice	O
may	O
double	O
bioavailability	O
of	O
oral	O
budesonide	B-Drug

The	O
xxmg	O
in	O
the	O
name	O
refers	O
to	O
strengthfor	O
example	O
Phenytoin	B-Drug
sodium	O
25	O
mg	O
Flynn	O
Hard	O
Capsules	O

46	O
mg	O
dihydrocodeine	B-Drug
as	O
co-dydramol	O
7	O

An	O
analysis	O
of	O
samples	O
acquired	O
four	O
weeks	O
after	O
the	O
German	O
prohibition	O
JWH-018	B-Drug
took	O
place	O
found	O
that	O
manufacturers	O
had	O
shortened	O
alkyl	O
chain	O
by	O
one	O
carbon	O
to	O
circumvent	O
ban	O

Additionally	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014	O

This	O
study	O
compared	O
the	O
MDMA	B-Drug
group	O
with	O
a	O
placebo	O

Cocaine	B-Drug
acts	O
by	O
inhibiting	O
the	O
reuptake	O
of	O
serotonin	O
norepinephrine	O
and	O
dopamine	O

Conversely	O
however	O
studies	O
with	O
EE-containing	O
contraceptive	O
vaginal	O
rings	O
and	O
patches	B-Drug
have	O
shown	O
similar	O
metabolic	O
effects	O
VTE	O
risk	O
as	O
combined	O
birth	O
control	O
pills	O
containing	O
EE	O

Oxymorphone	B-Drug
Immediate	O
Release	O
is	O
indicated	O
for	O
the	O
relief	O
of	O
moderate	O
to	O
severe	O
pain	O
such	O
as	O
treatment	O
acute	O
post	O
surgical	O

High	O
levels	O
can	O
lead	O
to	O
loss	O
of	O
MAO-B	O
selectivity	O
and	O
selegiline	B-Drug
may	O
begin	O
inhibition	O
MAO-A	O
as	O
well	O

When	O
powder	O
cocaine	B-Drug
is	O
dissolved	O
and	O
injected	O
the	O
absorption	O
into	O
bloodstream	O
at	O
least	O
as	O
rapid	O
of	O
drug	O
which	O
occurs	O
when	O
crack	O
smoked	O
similar	O
euphoria	O
may	O
be	O
experienced	O

CBD	B-Drug
is	O
also	O
a	O
5-HT1A	O
receptor	O
serotonin	O
agonist	O
which	O
may	O
contribute	O
to	O
an	O
anxiolytic-content	O
effect	O

In	O
late	O
2006	O
Gibraltar	O
lawmakers	O
passed	O
the	O
Children	O
and	O
Young	O
Persons	O
Alcohol	O
Tobacco	B-Drug
Gaming	O
Act	O
which	O
raised	O
minimum	O
purchase	O
age	O
from	O
16	O
to	O
18	O
years	O

In	O
2013	O
overdose	O
on	O
amphetamine	B-Drug
methamphetamine	B-Drug
and	O
other	O
compounds	O
implicated	O
in	O
an	O
use	O
disorder	O
resulted	O
estimated	O
3788	O
deaths	O
worldwide	O
34254145	O
95%	O
confidence	O

The	O
usual	O
human	O
dosage	O
is	O
200400	O
milligrams	O
of	O
mescaline	B-Drug
sulfate	O
or	O
178356	O
hydrochloride	I-Drug

Lysergic	O
acid	B-Drug
received	O
its	O
name	O
as	O
it	O
was	O
a	O
product	O
of	O
the	O
lysis	O
various	O
ergot	O
alkaloids	O

A	O
bad	O
trip	O
also	O
known	O
as	O
acute	O
intoxication	O
from	O
hallucinogens	O
psychedelic	O
crisis	O
or	O
emergence	O
phenomenon	O
is	O
a	O
frightening	O
and	O
unpleasant	O
experience	O
triggered	O
by	O
psychoactive	O
drugs	O
especially	O
such	O
LSD	B-Drug
Psilocybin	O
mushroom	O

Following	O
the	O
patch	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq	B-Drug
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain	O

When	O
fermentation	O
begins	O
add	O
to	O
it	O
a	O
solution	O
of	O
4	O
ounces	O
selected	O
opium	B-Drug
in	O
12	O
water	O

By	O
1999	O
King	O
Pharmaceuticals	O
had	O
finalized	O
approval	O
with	O
the	O
American	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
to	O
market	O
zaleplon	B-Drug
Sonata	B-Drug
Starnoc	O
across	O
US	O

They	O
may	O
also	O
be	O
ergogenic	O
in	O
contrast	O
to	O
reboxetine	B-Drug
which	O
is	O
solely	O
a	O
reuptake	O
inhibitor	O

0%	O
of	O
the	O
dry	O
weight	O
tobacco	B-Drug

Difenoxin	B-Drug
Motofen	O
R-15403	O
is	O
an	O
opioid	O
drug	O
used	O
often	O
in	O
combination	O
with	O
atropine	O
to	O
treat	O
diarrhea	O

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
such	O
as	O
haloperidol	B-Drug
in	O
treatment	O
psychosis	O

Within	O
the	O
body	O
imipramine	B-Drug
is	O
converted	O
into	O
desipramine	B-Drug
desmethylimipramine	O
as	O
a	O
metabolite	O

The	O
MDMA	B-Drug
concentration	O
in	O
the	O
blood	O
stream	O
starts	O
to	O
rise	O
after	O
about	O
30	O
minutes	O
and	O
reaches	O
its	O
maximal	O
between	O
1	O

In	O
contrast	O
the	O
current	O
version	O
of	O
Laudanum	B-Drug
contains	O
about	O
18%	O
alcohol	O

East	O
India	O
Company	O
merchants	O
balanced	O
an	O
economic	O
deficit	O
from	O
the	O
importation	O
of	O
Chinese	O
tea	O
by	O
selling	O
Indian	O
opium	B-Drug
which	O
was	O
smuggled	O
into	O
China	O
in	O
defiance	O
Qing	O
government	O
bans	O

2C	O
analog:	O
2C-G-3	O
25-Dimethoxy-34-tetramethyleneamphetamine:	O
Dosage:	O
unknown	O
Duration:	O
Effects:	O
2C-G-4	O
36-Dimethoxy-4-2-aminopropylbenzonorbornane:	O
1420	O
mg	O
16-30	O
h	O
2C-G-5	O
14-Dimethoxynaphthyl-2-isopropylamine:	O
2C-G-N	O
This	O
substance	B-Drug
is	O
a	O
Class	O
A	O
drug	O
in	O
the	O
Drugs	O
controlled	O
by	O
UK	O
Misuse	O
of	O
Act	O

2C-E	O
is	O
a	O
psychedelic	O
phenethylamine	B-Drug
of	O
the	O
2C	O
family	O

As	O
of	O
2002	O
there	O
were	O
two	O
case	O
reports	O
people	O
experiencing	O
withdrawal	O
symptoms	O
when	O
discontinuing	O
bupropion	B-Drug
taken	O
to	O
aid	O
smoking	O
cessation;	O
the	O
prescribing	O
information	O
states	O
that	O
dose	O
tapering	O
is	O
not	O
required	O
treatment	O
for	O
cessation	O

Short-term	O
exposure	O
to	O
high	O
concentrations	O
of	O
chemical	O
vapors	O
that	O
exist	O
in	O
black-market	O
methamphetamine	B-Drug
laboratories	O
can	O
cause	O
severe	O
health	O
problems	O
and	O
death	O

It	O
has	O
been	O
sold	O
in	O
the	O
form	O
of	O
blotters	O
similar	O
to	O
distribution	O
method	O
LSD	B-Drug
which	O
led	O
confusion	O
and	O
reports	O
mistakenly	O
consuming	O
Bromo-DragonFly	O

In	O
the	O
EU	O
bevacizumab	B-Drug
in	O
combination	O
with	O
interferon	O
alfa-2a	O
is	O
indicated	O
for	O
first-line	O
treatment	O
of	O
adults	O
advanced	O
and/or	O
metastatic	O
renal	O
cell	O
cancer	O

In	O
spite	O
of	O
its	O
demonstrated	O
neurotoxicity	O
see	O
relevant	O
section	O
above	O
GHB	B-Drug
has	O
neuroprotective	O
properties	O
and	O
been	O
found	O
to	O
protect	O
cells	O
from	O
hypoxia	O

Nandrolone	B-Drug
has	O
also	O
been	O
found	O
to	O
produce	O
penile	O
growth	O
in	O
prepubertal	O
boys	O

Side	O
effects	O
are	O
similar	O
to	O
those	O
of	O
morphine	B-Drug
but	O
pentazocine	B-Drug
due	O
its	O
action	O
at	O
the	O
kappa	O
opioid	O
receptor	O
is	O
more	O
likely	O
invoke	O
psychotomimetic	O

One	O
acre	O
harvested	O
in	O
this	O
way	O
can	O
produce	O
three	O
to	O
five	O
kilograms	O
of	O
raw	O
opium	B-Drug

Since	O
2003	O
the	O
Council	O
has	O
called	O
for	O
licensing	O
of	O
poppy	O
cultivation	O
in	O
Afghanistan	O
order	O
to	O
manufacture	O
poppy-based	O
medicines	O
such	O
as	O
morphine	B-Drug
and	O
codeine	B-Drug
combat	O
poverty	O
rural	O
communities	O
breaking	O
ties	O
with	O
illicit	O
drugs	O
trade	O

The	O
patent	O
for	O
Vicoprofen	B-Drug
was	O
filed	O
in	O
December	O
1984	O
and	O
U	O

Nicotine	B-Drug
is	O
used	O
widely	O
throughout	O
the	O
world	O
for	O
its	O
stimulating	O
and	O
relaxing	O
effects	O

The	O
opium	B-Drug
tincture	O
is	O
gradually	O
tapered	O
over	O
a	O
3-	O
to	O
5-week	O
period	O
at	O
which	O
point	O
the	O
newborn	O
should	O
be	O
completely	O
free	O
of	O
withdrawal	O
symptoms	O

5	O
parts	O
opium	B-Drug
extract	O

In	O
a	O
controversial	O
2009	O
article	O
in	O
the	O
New	O
England	O
Journal	O
of	O
Medicine	O
Lost	O
Transmission	O
FDA	O
Drug	O
Information	O
That	O
Never	O
Reaches	O
Clinicians	O
it	O
was	O
reported	O
that	O
largest	O
three	O
Lunesta	B-Drug
trials	O
found	O
compared	O
to	O
placebo	O
superior	O
while	O
only	O
shortened	O
initial	O
time	O
falling	O
asleep	O
by	O
15	O
minutes	O
on	O
average	O

Nitrazepam	B-Drug
is	O
a	O
nitrobenzodiazepine	O

Bufotenin	B-Drug
is	O
a	O
chemical	O
constituent	O
in	O
the	O
secretions	O
and	O
eggs	O
of	O
several	O
species	O
toads	O
belonging	O
to	O
genus	O
Bufo	O
but	O
Colorado	O
River	O
toad	O
Incillius	O
alvarius	O
only	O
which	O
bufotenin	B-Drug
present	O
large	O
enough	O
quantities	O
for	O
psychoactive	O
effect	O

Foremost	O
amongst	O
these	O
are	O
nefopam	O
orphenadrine	B-Drug
and	O
perhaps	O
phenyltoloxamine	O
or	O
some	O
other	O
antihistamines	O

Its	O
fairly	O
short	O
half-life	O
means	O
that	O
several	O
repeated	O
doses	O
would	O
have	O
to	O
be	O
given	O
over	O
an	O
extended	O
period	O
since	O
if	O
only	O
one	O
dose	O
were	O
used	O
it	O
wear	O
off	O
before	O
the	O
alcohol	O
had	O
been	O
metabolised	O
and	O
patient	O
relapse	O
similar	O
problems	O
with	O
renarcotization	O
seen	O
when	O
treating	O
overdoses	O
of	O
long-acting	O
opioids	O
such	O
as	O
methadone	B-Drug
short-acting	O
antagonists	O
naloxone	B-Drug

Particular	O
care	O
should	O
be	O
taken	O
with	O
drugs	O
that	O
potentiate	O
the	O
effects	O
of	O
diazepam	B-Drug
such	O
as	O
barbiturates	O
phenothiazines	O
opioids	O
and	O
antidepressants	O

The	O
Alan	O
Guttmacher	O
Institute	O
has	O
speculated	O
that	O
United	O
States	O
approval	O
of	O
DMPA	B-Drug
may	O
increase	O
its	O
availability	O
and	O
acceptability	O
in	O
developing	O
countries	O

Growth	O
of	O
new	O
receptors	O
and	O
recoupling	O
after	O
prolonged	O
flumazenil	B-Drug
exposure	O
has	O
also	O
been	O
observed	O

MDMA	B-Drug
ecstasy	B-Drug
one	O
of	O
the	O
party	O
drugs	O
is	O
third	O
most	O
abused	O
drug	O
next	O
to	O
cannabis	O
and	O
methamphetamine	B-Drug

Accordingly	O
while	O
gabapentin	B-Drug
has	O
nanomolar	O
affinity	O
for	O
the	O
2	O
subunit	O
its	O
potency	O
in	O
vivo	O
is	O
low	O
micromolar	O
range	O
and	O
competition	O
binding	O
by	O
endogenous	O
L-amino	O
acids	O
likely	O
to	O
be	O
responsible	O
this	O
discrepancy	O

The	O
reaction	O
between	O
the	O
2--dialkylaminoalkylamine-5-nitroaniline	O
and	O
HCl	O
salt	O
of	O
imino	O
ethyl	O
ether	O
results	O
in	O
formation	O
etonitazene	B-Drug

Fentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
abuse	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
medicolegal	O
death	O
investigation	O

It	O
is	O
closely	O
related	O
to	O
normethandrone	O
17-methyl-19-nortestosterone	O
and	O
ethylestrenol	B-Drug
3-deketo-17-ethyl-19-nortestosterone	O

Intravenous	O
use	O
of	O
heroin	B-Drug
and	O
any	O
other	O
substance	O
with	O
needles	O
syringes	O
or	O
related	O
equipment	O
may	O
lead	O
to:	O
Contracting	O
blood-borne	O
pathogens	O
such	O
as	O
HIV	O
hepatitis	O
via	O
the	O
sharing	O
bacterial	O
fungal	O
endocarditis	O
possibly	O
venous	O
sclerosis	O
Abscesses	O
Poisoning	O
from	O
contaminants	O
added	O
to	O
cut	O
dilute	O
Decreased	O
kidney	O
function	O
nephropathy	O
although	O
it	O
is	O
not	O
currently	O
known	O
if	O
this	O
because	O
adulterants	O
infectious	O
diseases	O
The	O
withdrawal	O
syndrome	O
begin	O
within	O
little	O
two	O
hours	O
discontinuation	O
drug;	O
however	O
time	O
frame	O
can	O
fluctuate	O
degree	O
tolerance	O
well	O
amount	O
last	O
consumed	O
dose	O
more	O
typically	O
begins	O
624	O
after	O
cessation	O

Since	O
amitriptyline	B-Drug
and	O
its	O
active	O
metabolite	O
nortriptyline	B-Drug
are	O
primarily	O
metabolized	O
by	O
cytochromes	O
CYP2D6	O
CYP2C19	O
see	O
Amitriptyline#Pharmacology	O
the	O
inhibitors	O
of	O
these	O
enzymes	O
expected	O
to	O
exhibit	O
pharmacokinetic	O
interactions	O
with	O

Although	O
some	O
small	O
non-controlled	O
studies	O
in	O
the	O
1990smostly	O
sponsored	O
by	O
gabapentin's	O
manufacturersuggested	O
that	O
treatment	O
for	O
bipolar	O
disorder	O
with	O
gabapentin	B-Drug
may	O
be	O
promising	O
preponderance	O
of	O
evidence	O
suggests	O
it	O
is	O
not	O
effective	O

The	O
findings	O
of	O
a	O
2005	O
naltrexone	B-Drug
study	O
were	O
slightly	O
less	O
promising	O
with	O
an	O
average	O
30%	O
reduction	O
symptoms	O
as	O
measured	O
by	O
three	O
validated	O
dissociation	O
scales	O

Psychological	O
dependence	O
is	O
more	O
common	O
in	O
those	O
who	O
abuse	O
carisoprodol	B-Drug
and	O
have	O
a	O
history	O
of	O
drug	O
particularly	O
sedatives	O
or	O
alcohol	O

In	O
2010	O
the	O
World	O
Health	O
Organization	O
WHO	O
stated	O
that	O
it	O
did	O
not	O
recommend	O
thalidomide	B-Drug
for	O
leprosy	O
due	O
to	O
difficulty	O
of	O
adequately	O
controlling	O
its	O
use	O
and	O
availability	O
clofazimine	B-Drug

In	O
1859	O
the	O
ship	O
finished	O
its	O
travels	O
and	O
Whler	O
received	O
a	O
trunk	O
full	O
of	O
coca	B-Drug

Apalutamide	B-Drug
is	O
used	O
in	O
conjunction	O
with	O
castration	O
either	O
via	O
bilateral	O
orchiectomy	O
or	O
gonadotropin-releasing	O
hormone	O
analogue	O
GnRH	O
therapy	O
as	O
a	O
method	O
of	O
androgen	O
deprivation	O
the	O
treatment	O
NM-CRPC	O

In	O
the	O
final	O
step	O
hyoscyamine	B-Drug
undergoes	O
epoxidation	O
catalyzed	O
by	O
6beta-hydroxyhyoscyamine	O
epoxidase	O
yielding	O
hyoscine	O

Subgroup	O
analyses	O
showed	O
that	O
personal	O
and	O
social	O
conditions	O
such	O
as	O
gender	O
age	O
marital	O
status	O
mental	O
disorders	O
family	O
history	O
of	O
substance	O
abuse	O
overlapping	O
illegal	O
drug	O
distribution	O
channels	O
alcohol	O
use	O
disorder	O
nicotine	B-Drug
dependence	O
ethnicity	O
urbanicity	O
educational	O
attainment	O
influenced	O
the	O
height	O
probability	O

Alprazolam	B-Drug
was	O
not	O
found	O
in	O
his	O
bloodstream	O
at	O
the	O
time	O
of	O
death	O

As	O
a	O
structural	O
analog	O
of	O
NN-dimethyltryptamine	O
DMT	O
5-MeO-DMT	B-Drug
is	O
Schedule	O
9	O
prohibited	O
substance	O
under	O
the	O
Poisons	O
Standard	O

As	O
such	O
ethisterone	O
does	O
not	O
appear	O
to	O
share	O
the	O
estrogenic	O
activity	O
of	O
norethisterone	B-Drug
at	O
least	O
in	O
humans	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
releasing	O
more	O
fentanyl	B-Drug
together	O
with	O
acidosis	O
which	O
reduces	O
protein	O
binding	O
of	O
yet	O

Norethisterone	B-Drug
has	O
an	O
elimination	O
half-life	O
of	O
5	O

Neither	O
the	O
crown	O
fruit	O
mescal	O
button	O
of	O
Peyote	O
cactus	O
nor	O
roots	O
plant	O
Mimosa	O
hostilis	O
Psilocybe	O
mushrooms	O
themselves	O
are	O
included	O
in	O
Schedule	O
1	O
but	O
only	O
their	O
respective	O
principles	O
Mescaline	B-Drug
DMT	O
and	O
Psilocybin	O

Scott	O
test's	O
chemical	O
solution	O
shows	O
up	O
as	O
a	O
faint	O
blue	O
for	O
cocaine	B-Drug
base	O

Niemann	O
described	O
every	O
step	O
he	O
took	O
to	O
isolate	O
cocaine	B-Drug
in	O
his	O
dissertation	O
titled	O
ber	O
eine	O
neue	O
organische	O
Base	O
den	O
Cocablttern	O
On	O
a	O
New	O
Organic	O
the	O
Coca	B-Drug
Leaves	O
which	O
was	O
published	O
1860it	O
earned	O
him	O
PhD	O
and	O
is	O
now	O
British	O
Library	O

In	O
Sweden	O
a	O
33-year-old	O
man	O
has	O
been	O
sentenced	O
to	O
six	O
years	O
in	O
prison	O
by	O
an	O
appellate	O
court	O
Hovrtt	O
for	O
possession	O
of	O
250	O
grams	O
MDPV	B-Drug
that	O
had	O
acquired	O
prior	O
criminalization	O

Chemically	O
lisdexamfetamine	B-Drug
is	O
composed	O
of	O
the	O
amino	O
acid	O
L-lysine	O
attached	O
to	O
dextroamphetamine	B-Drug

In	O
emergency	O
medicine	O
safe	O
administration	O
of	O
intranasal	O
fentanyl	B-Drug
with	O
a	O
low	O
rate	O
side	O
effects	O
and	O
promising	O
pain	O
reducing	O
effect	O
was	O
demonstrated	O
in	O
prospective	O
observational	O
study	O
about	O
900	O
out-of-hospital	O
patients	O

Respiratory	O
depression	O
is	O
a	O
potentially	O
serious	O
or	O
fatal	O
adverse	O
drug	O
reaction	O
associated	O
with	O
the	O
use	O
of	O
codeine	B-Drug
but	O
mainly	O
danger	O
lies	O
in	O
much	O
more	O
potent	O
and	O
CNS-depressing	O
phenothiazine-related	O
antihistamine	O
promethazine	B-Drug

Dexamethasone	B-Drug
may	O
be	O
given	O
to	O
women	O
at	O
risk	O
of	O
delivering	O
prematurely	O
promote	O
maturation	O
the	O
fetus'	O
lungs	O

Diazepam	B-Drug
along	O
with	O
oxazepam	B-Drug
nitrazepam	B-Drug
and	O
temazepam	B-Drug
represents	O
82%	O
of	O
the	O
benzodiazepine	O
market	O
in	O
Australia	O

O-Acetylpsilocin	B-Drug
is	O
believed	O
to	O
be	O
a	O
prodrug	O
of	O
psilocin	B-Drug

Additionally	O
because	O
cocaine	B-Drug
is	O
a	O
vasoconstrictor	O
and	O
usage	O
often	O
entails	O
multiple	O
injections	O
within	O
several	O
hours	O
or	O
less	O
subsequent	O
are	O
progressively	O
more	O
difficult	O
to	O
administer	O
which	O
in	O
turn	O
may	O
lead	O
injection	O
attempts	O
consequences	O
from	O
improperly	O
performed	O

In	O
cases	O
where	O
pharmacists	O
have	O
misinterpreted	O
DTO	O
and	O
given	O
deodorized	O
tincture	O
of	O
opium	B-Drug
when	O
diluted	O
was	O
meant	O
infants	O
received	O
a	O
massive	O
25-fold	O
overdose	O
morphine	B-Drug
sometimes	O
resulting	O
in	O
fatalities	O

Exemestane	B-Drug
went	O
through	O
clinical	O
trials	O
in	O
the	O
1990s	O
and	O
received	O
FDA	O
approval	O
1999	O
marketed	O
as	O
Aromasin	O

It	O
was	O
also	O
evaluated	O
whether	O
thalidomide	B-Drug
can	O
be	O
combined	O
with	O
melphalan	O
and	O
prednisone	B-Drug
for	O
patients	O
multiple	O
myeloma	O

The	O
Melbourne	O
inner-city	O
suburbs	O
of	O
Richmond	O
and	O
Abbotsford	O
are	O
locations	O
in	O
which	O
the	O
use	O
dealing	O
heroin	B-Drug
has	O
been	O
concentrated	O
for	O
a	O
protracted	O
time	O
period	O

In	O
February	O
2010	O
Medsafe	O
announced	O
Paradex	B-Drug
and	O
Capadex	B-Drug
forms	O
of	O
dextropropoxyphene	B-Drug
were	O
being	O
withdrawn	O
from	O
the	O
marketplace	O
due	O
to	O
health	O
issues	O
withdrawal	O
in	O
other	O
countries	O

Although	O
this	O
information	O
was	O
not	O
immediately	O
published	O
in	O
July	O
1978	O
when	O
Bourne	O
the	O
midst	O
of	O
a	O
scandal	O
over	O
writing	O
an	O
illegal	O
prescription	O
cocaine	B-Drug
revelation	O
came	O
to	O
light	O

Like	O
other	O
first-generation	O
NSAAs	O
and	O
enzalutamide	B-Drug
it	O
has	O
been	O
found	O
to	O
act	O
as	O
a	O
weak	O
non-competitive	O
inhibitor	O
of	O
GABAA	O
receptor-mediated	O
currents	O
in	O
vitro	O
IC50	O
=	O
5	O

Beginning	O
in	O
2015	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine	B-Drug

However	O
cocaine	B-Drug
does	O
often	O
cause	O
involuntary	O
tooth	O
grinding	O
known	O
as	O
bruxism	O
which	O
can	O
deteriorate	O
enamel	O
and	O
lead	O
to	O
gingivitis	O

However	O
natural	O
cocaine	B-Drug
remains	O
the	O
lowest	O
cost	O
and	O
highest	O
quality	O
supply	O
of	O

In	O
the	O
United	O
Kingdom	O
mescaline	B-Drug
in	O
purified	O
powder	O
form	O
is	O
a	O
Class	O
A	O
drug	O

Methadone	B-Drug
usage	O
history	O
is	O
considered	O
in	O
interpreting	O
the	O
results	O
as	O
a	O
chronic	O
user	O
can	O
develop	O
tolerance	O
to	O
doses	O
that	O
would	O
incapacitate	O
an	O
opioid-naive	O
individual	O

Naloxone	B-Drug
administered	O
intramuscularly	O
are	O
provided	O
through	O
pre-filled	O
syringes	O
vials	O
and	O
auto-injector	O

The	O
onset	O
of	O
heroin's	O
effects	O
depends	O
upon	O
the	O
route	O
administration	O
heroin	B-Drug

Dipipanone	B-Drug
was	O
also	O
available	O
as	O
an	O
oral	O
mixture	O
10	O
mg/5ml	O
without	O
the	O
cyclizine	B-Drug
during	O
1970s1980s	O
in	O
United	O
Kingdom	O

However	O
zopiclone	B-Drug
increases	O
the	O
normal	O
transmission	O
of	O
neurotransmitter	O
gamma-aminobutyric	O
acid	O
GABA	O
in	O
central	O
nervous	O
system	O
via	O
modulating	O
benzodiazepine	O
receptors	O
same	O
way	O
that	O
drugs	O
do	O

Cannabidiol	B-Drug
is	O
classified	O
as	O
a	O
medical	O
product	O
in	O
Sweden	O

Phenethylamine	B-Drug
is	O
the	O
parent	O
compound	O
of	O
amphetamine	B-Drug
while	O
N-methylphenethylamine	O
a	O
positional	O
isomer	O
that	O
differs	O
only	O
in	O
placement	O
methyl	O
group	O

The	O
increase	O
in	O
recreational	O
use	O
prompted	O
ketamine	B-Drug
to	O
be	O
placed	O
Schedule	O
III	O
of	O
the	O
United	O
States	O
Controlled	O
Substance	O
Act	O
August	O
1999	O

As	O
such	O
fatalities	O
involving	O
mitragynine	B-Drug
tend	O
to	O
involve	O
additional	O
drugs	O
including	O
other	O
opioids	O
and	O
cough	O
suppressants	O

In	O
the	O
same	O
month	O
in	O
Sweden	O
another	O
man	O
died	O
from	O
ecstasy	B-Drug
laced	O
with	O
PMMA	B-Drug

The	O
exploration	O
of	O
the	O
antiangiogenic	O
and	O
immunomodulatory	O
activities	O
thalidomide	B-Drug
has	O
led	O
to	O
study	O
creation	O
analogs	O

Dicoumarol	O
INN	O
or	O
dicumarol	O
USAN	O
is	O
a	O
naturally	O
occurring	O
anticoagulant	O
drug	O
that	O
depletes	O
stores	O
of	O
vitamin	O
K	O
similar	O
to	O
warfarin	B-Drug
dicoumarol	O
inspired	O

Methadone	B-Drug
and	O
its	O
major	O
metabolite	O
2-ethylidene-15-dimethyl-33-diphenylpyrrolidine	O
EDDP	O
are	O
often	O
measured	O
in	O
urine	O
as	O
part	O
of	O
a	O
drug	O
abuse	O
testing	O
program	O
plasma	O
or	O
serum	O
to	O
confirm	O
diagnosis	O
poisoning	O
hospitalized	O
victims	O
whole	O
blood	O
assist	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
case	O
sudden	O
death	O

It	O
is	O
by	O
giving	O
voice	O
to	O
cancer	O
patients	O
using	O
Tamoxifen	B-Drug
and	O
so	O
helping	O
push	O
it	O
forward	O
justifying	O
both	O
morally	O
scientifically	O
corporations	O

Isbell	O
and	O
Vogel	O
1949	O
investigated	O
methadone	B-Drug
a	O
synthetic	O
opioid	O
developed	O
in	O
Germany	O
1937	O

Naloxone	B-Drug
displaces	O
the	O
opioid	O
molecules	O
from	O
brain's	O
receptors	O
and	O
reverses	O
respiratory	O
depression	O
caused	O
by	O
an	O
overdose	O
within	O
two	O
to	O
eight	O
minutes	O

Rapid	O
eye	O
movement	O
behavior	O
disorder	O
responds	O
well	O
to	O
low	O
doses	O
of	O
clonazepam	B-Drug

A	O
2018	O
systematic	O
review	O
and	O
network	O
meta-analysis	O
of	O
50	O
trials	O
involving	O
12	O
different	O
psychosocial	O
interventions	O
for	O
amphetamine	B-Drug
methamphetamine	B-Drug
or	O
cocaine	B-Drug
addiction	O
found	O
that	O
combination	O
therapy	O
with	O
both	O
contingency	O
management	O
community	O
reinforcement	O
approach	O
had	O
the	O
highest	O
efficacy	O
i	O

Cannabidiol	B-Drug
has	O
also	O
been	O
shown	O
to	O
act	O
as	O
a	O
5-HT1A	O
receptor	O
agonist	O

Some	O
substances	O
used	O
to	O
cut	O
illegal	O
drugs	O
are	O
not	O
inherently	O
harmful	O
as	O
they	O
just	O
pad	O
or	O
bulk	O
out	O
a	O
quantity	O
of	O
the	O
drug	O
and	O
increase	O
profits	O
such	O
lactose	O
milk	O
sugar	O
white	O
powder	O
often	O
added	O
heroin	B-Drug

A	O
November	O
2016	O
article	O
in	O
Time	O
Heroin	B-Drug
Is	O
Being	O
Laced	O
With	O
a	O
Terrifying	O
New	O
Substance:	O
What	O
to	O
Know	O
About	O
Carfentanil	B-Drug
reports	O
over	O
300	O
cases	O
of	O
overdose	O
related	O
fentanyl	B-Drug
and	O
analogues	O
several	O
deaths	O
connected	O
the	O
drug	O
since	O
August	O
United	O
States	O
including	O
Ohio	O
West	O
Virginia	O
Indiana	O
Kentucky	O
Florida	O

Acute	O
intoxication	O
Lorazepam	B-Drug
may	O
interact	O
synergistically	O
with	O
the	O
effects	O
of	O
alcohol	O
narcotics	O
or	O
other	O
psychoactive	O
substances	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
therefore	O
dangerous	O

The	O
morphine	B-Drug
base	O
is	O
then	O
reacted	O
with	O
acetic	O
anhydride	O
which	O
forms	O
heroin	B-Drug

The	O
House	O
passed	O
the	O
Combat	O
Methamphetamine	B-Drug
Epidemic	O
Act	O
of	O
2005	O
as	O
an	O
amendment	O
to	O
renewal	O
USA	O
PATRIOT	O

They	O
have	O
been	O
marketed	O
as	O
herbal	O
incense	O
or	O
smoking	O
blends	O
and	O
sold	O
under	O
common	O
names	O
like	O
K2	O
Spice	O
Synthetic	O
Marijuana	B-Drug

Methamphetamine	B-Drug
in	O
soils	O
has	O
shown	O
to	O
be	O
a	O
persistent	O
pollutant	O

Subsequent	O
testing	O
identified	O
5F-ADB	B-Drug
to	O
have	O
been	O
present	O
in	O
a	O
total	O
of	O
ten	O
people	O
who	O
had	O
died	O
from	O
unexplained	O
drug	O
overdoses	O
Japan	O
between	O
September	O
2014	O
and	O
December	O

Ranitidine	B-Drug
is	O
contraindicated	O
for	O
people	O
with	O
acute	O
porphyria	O
in	O
the	O
past	O
because	O
links	O
may	O
exist	O
between	O
taking	O
ranitidine	B-Drug
and	O

It	O
was	O
proposed	O
that	O
naloxone	B-Drug
induced	O
a	O
state	O
of	O
frustrative	O
nonreward	O

Amphetamine	B-Drug
is	O
eliminated	O
via	O
the	O
kidneys	O
with	O
3040%	O
of	O
drug	O
being	O
excreted	O
unchanged	O
at	O
normal	O
urinary	O
pH	O

morphine	B-Drug
antibacterial	O
e	O

Since	O
the	O
latter	O
salt	O
is	O
unusual	O
in	O
pharmacopeia	O
manufacturer	O
increased	O
amount	O
of	O
oxycodone	B-Drug
hydrochloride	O
to	O
4	O

Flurazepam	B-Drug
could	O
be	O
therefore	O
unsuitable	O
as	O
a	O
sleeping	O
medication	O
for	O
some	O
individuals	O
due	O
to	O
next-day	O
sedation;	O
however	O
this	O
same	O
effect	O
may	O
also	O
provide	O
anxiety	O
relief	O

Examples	O
of	O
quinazolinones	O
include	O
cloroqualone	O
diproqualone	O
etaqualone	O
Aolan	O
Athinazone	O
Ethinazone	O
mebroqualone	O
mecloqualone	B-Drug
Nubarene	O
Casfen	O
and	O
methaqualone	B-Drug
Quaalude	B-Drug

John	O
Belushi	O
actor/comedian	O
from	O
cocaine	B-Drug
and	O
heroin	B-Drug
'speedball'	O
Elisa	O
Bridges	O
actress	O
methamphetamine	B-Drug
pethidine	B-Drug
alprazolam	B-Drug
Ken	O
Caminiti	O
baseball	O
athlete	O
opioid	O
painkillers	O
Chris	O
Farley	O
Zac	O
Foley	O
bass	O
player	O
for	O
EMF	O
multiple	O
illegal	O
drugs	O
Trevor	O
Goddard	O
actor	O
temazepam	B-Drug
Mitch	O
Hedberg	O
stand-up	O
comedian	O
also	O
Philip	O
Seymour	O
Hoffman	O
Oscar-winning	O
amphetamines	B-Drug
Kahn	O
a	O
Jerry	O
Garcia	O
collaborator	O
member	O
of	O
the	O
Band	O
fluoxetine	B-Drug
Mac	O
Daddy	O
Kelly	O
Kris	O
Kross	O
Brent	O
Mydland	O
keyboardist	O
The	O
Grateful	O
Dead	O
River	O
Phoenix	O
Layne	O
Staley	O
Alice	O
in	O
Chains	O
Scott	O
Weiland	O
Stone	O
Temple	O
Pilots/Velvet	O
Revolver	O
Methylenedioxyamphetamine	O
MDA	O
alcohol	O
buprenorphine	B-Drug
right-to-die	O
case	O
then-comatose	O
Karen	O
Ann	O
Quinlan	O
March	O
29	O
1954	O
June	O
11	O
1985	O
made	O
legal	O
history	O
1975	O
1976	O
stimulating	O
public	O
scrutiny	O
ethical	O
moral	O
implications	O
her	O

The	O
Russian	O
Health	O
Minister	O
later	O
stated	O
that	O
the	O
gas	O
was	O
based	O
on	O
fentanyl	B-Drug
but	O
exact	O
chemical	O
agent	O
has	O
not	O
been	O
identified	O

Illegal	O
possession	O
of	O
dihydrocodeine	B-Drug
can	O
result	O
in	O
up	O
to	O
5	O
years	O
prison	O
or	O
an	O
unlimited	O
fine	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma	O

Overapplication	O
of	O
oral	O
anesthetics	O
such	O
as	O
benzocaine	B-Drug
can	O
increase	O
the	O
risk	O
pulmonary	O
aspiration	O
by	O
relaxing	O
gag-reflex	O
and	O
allowing	O
regurgitated	O
stomach	O
contents	O
or	O
secretions	O
to	O
enter	O
airway	O

Benzodiazepines	O
such	O
as	O
lorazepam	B-Drug
are	O
the	O
drugs	O
of	O
choice	O
to	O
control	O
agitation	O
and	O
seizures	O
when	O
present	O

5-Methyl-MDA	B-Drug
is	O
not	O
scheduled	O
by	O
the	O
United	O
Nations'	O
Convention	O
on	O
Psychotropic	O
Substances	O

In	O
addition	O
to	O
CMA	O
mammary	O
tumors	O
were	O
found	O
in	O
dogs	O
with	O
various	O
other	O
17-hydroxyprogesterone	O
derivatives	O
including	O
medroxyprogesterone	B-Drug
acetate	I-Drug
megestrol	O
and	O
anagestone	O
they	O
also	O
discontinued	O
for	O
the	O
indication	O
of	O
hormonal	O
contraception	O
although	O
has	O
since	O
been	O
reintroduced	O

Caution	O
is	O
also	O
required	O
if	O
clonazepam	B-Drug
used	O
during	O
breastfeeding	O

Because	O
of	O
the	O
potential	O
for	O
adverse	O
reaction	O
in	O
nursing	O
infants	O
should	O
be	O
discontinued	O
while	O
verapamil	B-Drug
is	O
administered	O

Fentanyl	B-Drug
was	O
among	O
many	O
substances	O
identified	O
in	O
counterfeit	O
pills	O
recovered	O
from	O
his	O
home	O
especially	O
some	O
that	O
were	O
mislabeled	O
as	O
Watson	O
385	O
a	O
combination	O
of	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug

Zopiclone	B-Drug
reduces	O
both	O
delta	O
waves	O
and	O
the	O
number	O
of	O
high-amplitude	O
whilst	O
increasing	O
low-amplitude	O

Opium	B-Drug
was	O
used	O
for	O
treating	O
asthma	O
stomach	O
illnesses	O
and	O
bad	O
eyesight	O

8%	O
had	O
used	O
MDMA	B-Drug
in	O
the	O
last	O
1	O

In	O
the	O
1920s	O
and	O
1930s	O
local	O
Razor	O
Gangs	O
achieved	O
such	O
a	O
level	O
of	O
notoriety	O
through	O
their	O
violent	O
attempts	O
to	O
control	O
cocaine	B-Drug
trade	O
that	O
Darlinghurst	O
became	O
colloquially	O
known	O
as	O
Razorhurst	O

The	O
affinities	O
of	O
triamcinolone	B-Drug
acetonide	O
for	O
the	O
androgen	O
and	O
estrogen	O
receptors	O
are	O
both	O
<0	O

Nalbuphine	B-Drug
in	O
the	O
15	O
to	O
60	O
mg	O
range	O
had	O
similar	O
analgesic	O
effects	O
immediate	O
release	O
codeine	B-Drug
30	O
Kantor	O
et	O
al	O

There	O
is	O
no	O
specific	O
antidote	O
for	O
abiraterone	B-Drug
acetate	O
overdose	O
and	O
treatment	O
should	O
consist	O
of	O
general	O
supportive	O
measures	O
including	O
monitoring	O
cardiac	O
liver	O
function	O

The	O
anticonvulsant	O
properties	O
of	O
diazepam	B-Drug
and	O
other	O
benzodiazepines	O
may	O
be	O
in	O
part	O
or	O
entirely	O
due	O
to	O
binding	O
voltage-dependent	O
sodium	O
channels	O
rather	O
than	O
benzodiazepine	O
receptors	O

Like	O
other	O
opioid	O
drugs	O
pethidine	B-Drug
has	O
the	O
potential	O
to	O
cause	O
physical	O
dependence	O
or	O
addiction	O

Congress	O
passed	O
laws	O
that	O
created	O
a	O
100	O
to	O
1	O
sentencing	O
disparity	O
for	O
the	O
trafficking	O
or	O
possession	O
of	O
crack	O
when	O
compared	O
penalties	O
powder	O
cocaine	B-Drug
which	O
had	O
been	O
widely	O
criticized	O
as	O
discriminatory	O
against	O
minorities	O
mostly	O
blacks	O
who	O
were	O
more	O
likely	O
use	O
than	O

In	O
Australia	O
during	O
2010	O
it	O
was	O
not	O
specifically	O
listed	O
as	O
prohibited	O
but	O
the	O
Australian	O
Federal	O
Police	O
stated	O
is	O
an	O
analogue	O
to	O
methcathinone	B-Drug
and	O
therefore	O
illegal	O

Ibogaine	B-Drug
is	O
a	O
tryptamine	O

In	O
medical	O
abortion	O
regimens	O
mifepristone	B-Drug
blockade	O
of	O
progesterone	O
receptors	O
directly	O
causes	O
endometrial	O
decidual	O
degeneration	O
cervical	O
softening	O
and	O
dilatation	O
release	O
endogenous	O
prostaglandins	O
an	O
increase	O
in	O
the	O
sensitivity	O
myometrium	O
to	O
contractile	O
effects	O

The	O
amount	O
of	O
methamphetamine	B-Drug
seized	O
could	O
allow	O
drug	O
users	O
in	O
Japan	O
to	O
use	O
it	O
503000	O
times	O

In	O
1976	O
it	O
began	O
to	O
appear	O
mixed	O
with	O
china	O
white	O
heroin	B-Drug
as	O
an	O
additive	O

After	O
the	O
Allied	O
occupation	O
of	O
Japan	O
pharmaceutical	O
companies	O
and	O
military	O
put	O
methamphetamine	B-Drug
stocks	O
on	O
market	O

Carbamazepine	B-Drug
an	O
anticonvulsant	O
appears	O
to	O
have	O
some	O
beneficial	O
effects	O
in	O
the	O
treatment	O
and	O
management	O
of	O
benzodiazepine	O
withdrawal;	O
however	O
research	O
is	O
limited	O
thus	O
ability	O
experts	O
make	O
recommendations	O
on	O
its	O
use	O
for	O
withdrawal	O
not	O
possible	O
at	O
present	O

Clomifene	B-Drug
has	O
also	O
been	O
used	O
with	O
other	O
assisted	O
reproductive	O
technology	O
to	O
increase	O
success	O
rates	O
of	O
these	O
modalities	O

Due	O
to	O
a	O
successful	O
marketing	O
campaign	O
thalidomide	B-Drug
was	O
widely	O
used	O
by	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy	O

It	O
has	O
similar	O
effects	O
to	O
morphine	B-Drug
including	O
analgesia	O
sedation	O
and	O
respiratory	O
depression	O

Morphine	B-Drug
was	O
initially	O
hailed	O
as	O
a	O
wonder	O
drug	O
for	O
its	O
ability	O
to	O
ease	O
pain	O

Bezitramide	B-Drug
is	O
an	O
opioid	O
analgesic	O

A	O
meta-analysis	O
also	O
supported	O
the	O
use	O
of	O
phenytoin	B-Drug
in	O
managing	O
various	O
ulcers	O

In	O
addition	O
to	O
serotonergic	O
activity	O
tramadol	B-Drug
is	O
also	O
a	O
norepinephrine	O
reuptake	O
inhibitor	O

Limited	O
evidence	O
supports	O
the	O
use	O
of	O
gabapentin	B-Drug
or	O
carbamazepine	B-Drug
for	O
treatment	O
mild	O
moderate	O
alcohol	O
withdrawal	O
as	O
sole	O
combination	O
therapy	O
with	O
other	O
medications;	O
however	O
does	O
not	O
appear	O
to	O
be	O
effective	O
severe	O
and	O
is	O
therefore	O
recommended	O
in	O
this	O
setting	O

Cases	O
of	O
intentional	O
suicide	O
by	O
overdose	O
using	O
etizolam	B-Drug
in	O
combination	O
with	O
GABA	O
agonists	O
have	O
been	O
reported	O

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells	O
creating	O
infection	O
via	O
neutropenia	O
leukopenia	O
and	O
lymphopenia	O
risks	O
will	O
not	O
clot	O
thrombocytopenia	O

It	O
has	O
been	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
some	O
cases	O
gynecomastia	O
but	O
it	O
is	O
not	O
as	O
effective	O
tamoxifen	B-Drug
or	O
raloxifene	O
for	O
this	O
indication	O

Beta-receptor	O
blockers	O
such	O
as	O
propranolol	B-Drug
and	O
oxprenolol	O
although	O
not	O
anxiolytics	O
can	O
be	O
used	O
to	O
combat	O
the	O
somatic	O
symptoms	O
of	O
anxiety	O
tachycardia	O
palpitations	O

In	O
1963	O
its	O
improved	O
version	O
Valium	B-Drug
was	O
released	O
and	O
became	O
astonishingly	O
popular:	O
between	O
1969	O
1982	O
it	O
the	O
most	O
prescribed	O
drug	O
in	O
America	O
with	O
over	O
2	O

Phenampromide	B-Drug
is	O
an	O
opioid	O
analgesic	O
from	O
the	O
ampromide	O
family	O
of	O
drugs	O
related	O
to	O
other	O
such	O
as	O
propiram	B-Drug
and	O
diampromide	B-Drug

In	O
its	O
pill	O
form	O
selegiline	B-Drug
is	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson's	O
disease	O

In	O
4560	O
women	O
after	O
35	O
months	O
the	O
administration	O
of	O
exemestane	B-Drug
at	O
a	O
dose	O
25	O
mg/day	O
resulted	O
in	O
65%	O
reduction	O
risk	O
breast	O
cancer	O
compared	O
with	O
placebo;	O
annual	O
incidence	O
rates	O
were	O
0	O

Diazepam	B-Drug
is	O
a	O
long-acting	O
classical	O
benzodiazepine	O

First	O
and	O
most	O
notably	O
high	O
oral	O
doses	O
of	O
ketoconazole	B-Drug
e	O

Alternatively	O
coca	B-Drug
leaves	O
can	O
be	O
infused	O
in	O
liquid	O
and	O
consumed	O
like	O
tea	O

However	O
it	O
is	O
notable	O
that	O
the	O
anabolic	O
steroid	O
methyltestosterone	B-Drug
which	O
benorterone	O
differs	O
from	O
in	O
chemical	O
structure	O
only	O
by	O
removal	O
of	O
a	O
carbon	O
atom	O
B	O
ring	O
aromatized	O
into	O
estrogen	O
methylestradiol	O
and	O
has	O
potent	O
estrogenic	O
activity	O

The	O
defense	O
presented	O
at	O
his	O
trial	O
claimed	O
that	O
the	O
defendants	O
had	O
made	O
ALD-52	O
instead	O
of	O
LSD-25	B-Drug

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

The	O
androgen	O
synthesis	O
inhibitors	O
aminoglutethimide	O
and	O
ketoconazole	B-Drug
were	O
first	O
marketed	O
in	O
1960	O
1977	O
respectively	O
the	O
newer	O
drug	O
abiraterone	B-Drug
acetate	O
was	O
introduced	O
2011	O

A	O
24-hour	O
kinetic	O
examination	O
in	O
dogs	O
showed	O
that	O
the	O
absorption	O
of	O
cannabidiolic	O
acid	O
CBDA	O
does	O
occur	O
and	O
this	O
molecule	O
is	O
absorbed	O
least	O
twice	O
as	O
well	O
CBD	B-Drug
post	O
oral	O
ingestion	O

Most	O
severe	O
overdoses	O
occur	O
when	O
users	O
combine	O
cocaine	B-Drug
with	O
other	O
substances	O
like	O
alcohol	O
or	O
heroin	B-Drug
which	O
increase	O
the	O
effects	O
and	O
heighten	O
chances	O
of	O
having	O
a	O
dangerous	O
overdose	O

The	O
report	O
also	O
stated	O
that	O
average	O
strength	O
of	O
crystal	B-Drug
methamphetamine	I-Drug
doubled	O
in	O
most	O
jurisdictions	O
within	O
a	O
12-month	O
period	O
and	O
the	O
majority	O
laboratory	O
closures	O
involved	O
small	O
addict-based	O
operations	O

Unlike	O
17-alkylated	O
AAS	O
such	O
as	O
methyltestosterone	B-Drug
nandrolone	B-Drug
decanoate	O
is	O
not	O
associated	O
with	O
liver	O
toxicity	O

Daff	O
was	O
dealing	O
marijuana	B-Drug
and	O
Thompson	O
began	O
collecting	O
payments	O
for	O
him	O

The	O
Cochrane	O
review	O
of	O
preoperative	O
analgesics	O
for	O
additional	O
pain	O
relief	O
in	O
children	O
and	O
adolescents	O
shows	O
no	O
evidence	O
benefit	O
taking	O
paracetamol	B-Drug
before	O
dental	O
treatment	O
to	O
help	O
reduce	O
after	O
procedures	O
under	O
local	O
anaesthetic	O
but	O
the	O
quality	O
is	O
low	O

Non-clinical	O
use	O
of	O
opium	B-Drug
was	O
criminalized	O
in	O
the	O
United	O
States	O
by	O
Harrison	O
Narcotics	O
Tax	O
Act	O
1914	O
and	O
many	O
other	O
laws	O

The	O
neurosteroid	O
ganaxolone	O
an	O
analog	O
of	O
the	O
progesterone	O
metabolite	O
allopregnanolone	B-Drug
has	O
been	O
extensively	O
investigated	O
in	O
animal	O
models	O
and	O
is	O
currently	O
clinical	O
trials	O
for	O
treatment	O
epilepsy	O

Shops	O
typically	O
place	O
signs	O
stating	O
that	O
the	O
products	O
sold	O
are	O
for	O
tobacco	B-Drug
use	O
only	O
or	O
not	O
with	O
illegal	O
substances	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself	O
which	O
include	O
itching	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
can	O
be	O
life-threatening	O

Nasal	O
insufflation	O
known	O
colloquially	O
as	O
snorting	O
sniffing	O
or	O
blowing	O
is	O
a	O
common	O
method	O
of	O
ingestion	O
recreational	O
powdered	O
cocaine	B-Drug

A	O
1:1	O
mixture	O
of	O
zolazepam	O
and	O
tiletamine	B-Drug
is	O
sold	O
under	O
the	O
name	O
Telazol	O

More	O
recently	O
a	O
participant	O
in	O
an	O
endurance	O
walking	O
race	O
Britain	O
Abraham	O
Wood	O
said	O
1807	O
that	O
he	O
had	O
used	O
laudanum	B-Drug
which	O
contains	O
opiates	O
to	O
keep	O
him	O
awake	O
for	O
24	O
hours	O
while	O
competing	O
against	O
Robert	O
Barclay	O
Allardyce	O

Marijuana	O
or	O
marihuana	B-Drug
herbal	O
cannabis	O
consists	O
of	O
the	O
dried	O
flowers	O
and	O
fruits	O
subtending	O
leaves	O
stems	O
female	O
Cannabis	O
plant	O

All	O
methoxyphenyl	O
regioisomers	O
and	O
N-butyl	O
homologues	O
of	O
RCS-4	B-Drug
its	O
also	O
display	O
potent	O
agonist	O
activities	O
at	O
CB1	O
CB2	O
receptors	O

According	O
to	O
the	O
American	O
Heart	O
Association	O
Nicotine	B-Drug
addiction	O
has	O
historically	O
been	O
one	O
of	O
hardest	O
addictions	O
break	O

The	O
contribution	O
of	O
these	O
receptors	O
to	O
the	O
overall	O
pharmacology	O
heroin	B-Drug
remains	O
unknown	O

The	O
volume	O
of	O
distribution	O
cimetidine	B-Drug
is	O
0	O

Another	O
combination	O
is	O
budesonide/formoterol	B-Drug
brand	O
name	O
Symbicort	B-Drug

For	O
sublingual	O
and	O
buccal	O
administration	O
25I-NBOMe	B-Drug
is	O
often	O
applied	O
to	O
sheets	O
of	O
blotter	O
paper	O
which	O
small	O
portions	O
tabs	O
are	O
held	O
in	O
the	O
mouth	O
allow	O
absorption	O
through	O
oral	O
mucosa	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression	O

Alprazolam	B-Drug
regular	O
release	O
and	O
orally	O
disintegrating	O
tablets	O
are	O
available	O
as	O
0	O

A	O
2007	O
UK	O
study	O
ranked	O
MDMA	B-Drug
18th	O
in	O
harmfulness	O
out	O
of	O
20	O
recreational	O
drugs	O

As	O
of	O
2001	O
5-MeO-DMT	B-Drug
is	O
listed	O
as	O
a	O
controlled	O
substance	O

Naltrexone	B-Drug
is	O
the	O
N-cyclopropylmethyl	O
derivative	O
of	O
oxymorphone	B-Drug

Diazepam	B-Drug
inhibits	O
acetylcholine	O
release	O
in	O
mouse	O
hippocampal	O
synaptosomes	O

Heroin	B-Drug
can	O
be	O
dissolved	O
and	O
withdrawn	O
into	O
an	O
oral	O
syringe	O
which	O
may	O
then	O
lubricated	O
inserted	O
the	O
anus	O
or	O
vagina	O
before	O
plunger	O
is	O
pushed	O

The	O
use	O
of	O
danazol	B-Drug
for	O
endometriosis	O
has	O
been	O
linked	O
to	O
an	O
increased	O
risk	O
ovarian	O
cancer	O

Recurring	O
visual	O
patterns	O
observed	O
during	O
the	O
mescaline	B-Drug
experience	O
include	O
stripes	O
checkerboards	O
angular	O
spikes	O
multicolor	O
dots	O
and	O
very	O
simple	O
fractals	O
that	O
turn	O
complex	O

2005	O
cannabis	O
and	O
inhalants	O
Wall	O
Street	O
1987	O
cocaine	I-Drug
mushrooms	O
mentioned	O
Walk	O
Hard:	O
The	O
Dewey	O
Cox	O
Story	O
2007	O
Quaaludes	B-Drug
PCP	B-Drug
amphetamine	B-Drug
pills	O
uppers	O
downers	O
LSD	B-Drug
Viagra	B-Drug
the	O
Line	O
Warriors	O
marijuana	O
Wash	O
2001	O
We	O
Need	O
to	O
Talk	O
About	O
Kevin	O
2011	O
prozac	B-Drug
fluoxetine	B-Drug
Weekend	O
at	O
Bernie's	O
1989	O
fictional	O
lethal	O
injection	O
drug	O
Weirdsville	O
heroin	B-Drug
We're	O
Millers	O
2013	O
What	O
Just	O
Happened	O
2008	O
hydromorphone	B-Drug
benzodiazepines	O
is	O
referred	O
Where	O
Boys	O
Are	O
'84	O
1984	O
Buffalo	O
Roam	O
1980	O
mescaline	B-Drug
Day	O
Takes	O
You	O
1992	O
multiple	O
drugs	O
While	O
Young	O
2015	O
ayahuasca	O
Who'll	O
Stop	O
Rain	O
1978	O
Why	O
Do	O
Fools	O
Fall	O
in	O
Love	O
1998	O
Wild	O
Angels	O
1966	O
Streets	O
1968	O
Winter's	O
Bone	O
2010	O
methamphetamine	B-Drug
Withnail	O
I	O
speed	B-Drug
other	O
Without	O
a	O
Paddle	O
2004	O
Wolf	O
of	O
crack	B-Drug
mention	O
Xanax	B-Drug
morphine	B-Drug
Woodstock	O
1970	O
psychedelics	O
Wonderland	O
2003	O
Y	O
Tu	O
Mam	O
Tambin	O
Yellow	O
Submarine	O
-	O
largely	O
considered	O
be	O
like	O
an	O
trip	O
Nurses	O
1973	O
Your	O
Highness	O
unnamed	O
herb	O
that	O
cause	O
hallucinations	O
Youth	O
In	O
Revolt	O
2009	O
Zapped!	O
1982	O
Zombieland	O

At	O
one	O
point	O
it	O
was	O
estimated	O
that	O
70	O
to	O
80	O
tons	O
of	O
cocaine	B-Drug
were	O
being	O
shipped	O
from	O
Colombia	O
the	O
United	O
States	O
every	O
month	O

Hash	B-Drug
oil	I-Drug
is	O
usually	O
consumed	O
by	O
smoking	O
vaporizing	O
or	O
eating	O

Similarly	O
to	O
the	O
related	O
second-generation	O
NSAA	O
enzalutamide	B-Drug
but	O
unlike	O
first-generation	O
NSAAs	O
like	O
flutamide	O
and	O
bicalutamide	B-Drug
elevated	O
liver	O
enzymes	O
hepatotoxicity	O
have	O
not	O
been	O
reported	O
with	O
apalutamide	B-Drug

The	O
Canon	O
of	O
Medicine	O
the	O
standard	O
medical	O
textbook	O
Paracelsus	O
burned	O
in	O
a	O
public	O
bonfire	O
three	O
weeks	O
after	O
being	O
appointed	O
professor	O
at	O
University	O
Basel	O
also	O
described	O
use	O
opium	B-Drug
though	O
many	O
Latin	O
translations	O
were	O
poor	O
quality	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2	O
2019	O
by	O
U	O

In	O
the	O
US	O
fentanyl	B-Drug
and	O
analogs	O
caused	O
over	O
29000	O
deaths	O
in	O
2017	O
a	O
large	O
increase	O
previous	O
four	O
years	O

His	O
two	O
prototype	O
drugs	O
were	O
methadone	B-Drug
and	O
pethidine	B-Drug
each	O
which	O
had	O
been	O
invented	O
in	O
1930s	O
by	O
Otto	O
Eisleb	O
who	O
worked	O
for	O
IG	O
Farben	O

It	O
was	O
announced	O
that	O
on	O
1	O
May	O
2019	O
Canada	O
would	O
introduce	O
excise	O
tax	O
all	O
products	O
containing	O
THC	O
and	O
three	O
new	O
product	O
classes	O
for	O
recreational	O
sale:	O
cannabis	O
edibles	O
extracts	B-Drug
topicals	O

However	O
it	O
may	O
degrade	O
in	O
some	O
product	O
containers	O
into	O
desoxymethyltestosterone	B-Drug
DMT;	O
3-desoxy-17-methyl-2-DHT	O
which	O
contrast	O
is	O
a	O
controlled	O
substance	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

They	O
found	O
about	O
70000	O
pills	B-Drug
in	O
the	O
appearance	O
of	O
oxycodone	B-Drug
and	O
more	O
than	O
25000	O
Xanax	B-Drug

Dihydrocodeine	B-Drug
is	O
used	O
as	O
an	O
alternative	O
to	O
codeine	B-Drug

Micronization	O
has	O
been	O
found	O
to	O
significantly	O
improve	O
the	O
oral	O
bioavailability	O
of	O
norethisterone	B-Drug
by	O
increasing	O
intestinal	O
absorption	O
and	O
reducing	O
metabolism	O

Bicalutamide	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
in	O
English	O
and	O
French	O
its	O
INN	O
USAN	O
USP	O
BAN	O
DCF	O
AAN	O
JAN	O

Chemically	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class	O
and	O
pharmacologically	O
it	O
dissociative	O
anesthetic	O

Approximately	O
33	O
million	O
people	O
use	O
codeine	B-Drug
each	O
year	O

In	O
addition	O
cetrorelix	B-Drug
can	O
be	O
used	O
to	O
treat	O
hormone-sensitive	O
cancers	O
of	O
the	O
prostate	O
and	O
breast	O
in	O
pre-/perimenopausal	O
women	O
some	O
benign	O
gynaecological	O
disorders	O
endometriosis	O
uterine	O
fibroids	O
endometrial	O
thinning	O

However	O
buspirone	B-Drug
has	O
been	O
reported	O
to	O
have	O
shown	O
significant	O
and	O
selective	O
intrinsic	O
efficacy	O
at	O
the	O
1-adrenergic	O
receptor	O
expressed	O
in	O
a	O
tissue-	O
species-dependent	O
manner	O

Cocaine	O
addiction	O
is	O
a	O
psychological	O
desire	O
to	O
use	O
cocaine	B-Drug
regularly	O

There	O
were	O
signs	O
of	O
increasing	O
drug	O
use;	O
hashish	B-Drug
was	O
smoked	O
openly	O
in	O
major	O
cities	O
the	O
late	O
60s	O

Many	O
question	O
this	O
as	O
cocaine	B-Drug
is	O
synthesised	O
heroin	B-Drug
and	O
both	O
are	O
produced	O
extracts	O
from	O
plants	O

There	O
are	O
many	O
social	O
services	O
groups	O
like	O
Capital	O
Area	O
Human	O
Services	O
providing	O
therapy	O
as	O
well	O
opioid-reversal	O
drugs;	O
and	O
No	O
Overdose	O
Baton	O
Rouge	O
which	O
offers	O
clean	O
syringes	O
the	O
opioid	O
antagonist	O
nasal	O
spray	O
Narcan	B-Drug
sterile	O
smoking	O
devices	O
attempting	O
to	O
help	O

Use	O
of	O
perampanel	B-Drug
with	O
CNS	O
depressants	O
like	O
alcohol	O
may	O
increase	O
the	O
effect	O
depressant	O

6%	O
per	O
cycle	O
with	O
clomifene	B-Drug
treatment	O
vs	O

In	O
one	O
of	O
the	O
only	O
double-blind	O
randomized	O
studies	O
to	O
date	O
those	O
given	O
microdoses	O
LSD	B-Drug
did	O
not	O
perform	O
better	O
than	O
placebo	O
on	O
cognitive	O
tasks	O

Lupron	B-Drug
depot	O
for	O
monthly	O
intramuscular	O
injection	O
was	O
first	O
approved	O
by	O
the	O
FDA	O
palliative	O
treatment	O
of	O
advanced	O
prostate	O
cancer	O
on	O
January	O
26	O
1989	O
and	O
subsequently	O
in	O
22	O

While	O
strong	O
opiates	O
are	O
heavily	O
regulated	O
within	O
the	O
European	O
Union	O
there	O
is	O
a	O
hidden	O
addiction	O
with	O
codeine	B-Drug

The	O
Partnership	O
for	O
a	O
Drug-Free	O
America	O
reports	O
that	O
2C-T-7	O
can	O
be	O
lethal	O
even	O
in	O
small	O
doses;	O
however	O
they	O
provide	O
no	O
source	O
their	O
claim	O
and	O
of	O
the	O
three	O
known	O
deaths	O
intoxicated	O
individuals	O
all	O
involved	O
either	O
excessive	O
insufflated	O
doses	O
or	O
concomitant	O
ingestion	O
other	O
stimulants	O
such	O
as	O
ephedrine	B-Drug
MDMA	B-Drug

Cocaine's	O
binding	O
properties	O
are	O
such	O
that	O
it	O
attaches	O
so	O
this	O
hydrogen	O
bond	O
will	O
not	O
form	O
and	O
is	O
blocked	O
from	O
formation	O
due	O
to	O
the	O
tightly	O
locked	O
orientation	O
of	O
cocaine	B-Drug
molecule	O
Cocaine	B-Drug

The	O
Movie	O
2012	O
cannabis	O
cocaine	B-Drug
Smokin'	O
Aces	O
2007	O
ritalin	B-Drug
Social	O
Network	O
2010	O
Something	O
Weird	O
1967	O
LSD	B-Drug
Sorted	O
2000	O
heroin	B-Drug
MDMA	B-Drug
methamphetamine	B-Drug
pills	O
Sorry	O
to	O
Bother	O
You	O
2018	O
Cannabis	O
Soul	O
Plane	O
2004	O
mushrooms	O
Southwest	O
Nine	O
Spring	O
Break	O
1983	O
marijuana	O
Breakers	O
2013	O
crack/cocaine	O
Spun	O
2002	O
ephedrine	B-Drug
Square	O
Grouper:	O
Godfathers	O
of	O
Ganja	O
2011	O
Squeeze	O
1997	O
Stark	O
Raving	O
Mad	O
GHB	B-Drug
Starsky	O
&	O
Hutch	O
State	O
Property	O
Steal	O
This	O
Steppenwolf	O
1974	O
Steve-O:	O
Demise	O
And	O
Rise	O
PCP	B-Drug
nitrous	O
oxide	O
Stoned	O
2005	O
hashish	B-Drug
DMT	O
psilocybin	O
alcohol	O
amphetamines	B-Drug
barbiturates	O
Age	O
1994	O
Stoned:	O
In	O
Beginning	O
sleeping	O
crack	B-Drug
Strange	O
Days	O
1995	O
fictional	O
drug	O
SQUID	O
Wilderness	O
2008	O
Streets	O
Blood	O
2009	O
cocaine/crack	O
Stripes	O
1981	O
Stuck	O
in	O
Love	O
2012-	O
Student	O
Nurses	O
1970	O
Substance:	O
Albert	O
Hofmann's	O
Sugarhouse	O
Summer	O
Sam	O
1999	O
Sunset	O
Strip	O
Super	O
Fly	O
1972	O
High	O
Me	O
Troopers	O
2001	O
psychedelic	O
Superbad	O
Surfer	O
Dude	O
S	O

Physiological	O
and	O
psychotropic	O
effects	O
from	O
nasally	O
insufflated	O
cocaine	B-Drug
are	O
sustained	O
for	O
approximately	O
4060	O
minutes	O
after	O
the	O
peak	O
attained	O

Buprenorphine/naloxone	B-Drug
when	O
taken	O
in	O
excess	O
can	O
produce	O
dysphoric	O
symptoms	O
for	O
non	O
opioid-dependent/tolerant	O
individuals	O
due	O
to	O
buprenorphine	B-Drug
being	O
a	O
partial	O
opioid	O
agonist	O

The	O
series	O
follows	O
the	O
troubled	O
journey	O
of	O
a	O
large	O
shipment	O
cocaine	B-Drug
from	O
Monterrey	O
Mexico	O
to	O
Gioia	O
Tauro	O
Italy	O

Mirtazapine	B-Drug
was	O
first	O
synthesized	O
at	O
Organon	O
and	O
published	O
in	O
1989	O
approved	O
for	O
use	O
major	O
depressive	O
disorder	O
the	O
Netherlands	O
1994	O
introduced	O
United	O
States	O
1996	O
under	O
brand	O
name	O
Remeron	B-Drug

In	O
some	O
countries	O
such	O
as	O
the	O
United	O
States	O
Australia	O
and	O
New	O
Zealand	O
all	O
of	O
these	O
compounds	O
would	O
be	O
considered	O
controlled	O
substance	O
analogs	O
PCP	B-Drug
under	O
Federal	O
Analog	O
Act	O
are	O
hence	O
illegal	O
drugs	O
if	O
sold	O
for	O
human	O
consumption	O

In	O
the	O
Netherlands	O
diamorphine	B-Drug
is	O
a	O
List	O
I	O
drug	O
of	O
Opium	O
Law	O

3%	O
of	O
secondary	O
school	O
students	O
in	O
Texas	O
had	O
taken	O
codeine	B-Drug
syrup	O
to	O
get	O
high	O

Ipratropium	B-Drug
is	O
administered	O
by	O
inhalation	O
for	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
and	O
asthma	O
exacerbation	O

Less	O
frequently	O
in	O
3-10%	O
of	O
people	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain	O
headache	O
fatigue	O
anorexia	O
and	O
weight	O
loss	O
dizziness	O
nervousness	O
hallucinations	O
anxiety	O
depression	O
flu-like	O
symptoms	O
dyspepsia	O
indigestion	O
shortness	O
breath	O
hypoventilation	O
apnoea	O
urinary	O
retention	O

Opioid	O
drugs	O
include	O
partial	O
agonists	O
like	O
the	O
anti-diarrhea	O
drug	O
loperamide	B-Drug
and	O
antagonists	O
naloxegol	B-Drug
for	O
opioid-induced	O
constipation	O

2	O
percent	O
morphine	B-Drug
codeine	B-Drug
and	O
thebaine	O
in	O
its	O
latex	O
alkaloids	O
whereas	O
the	O
of	O
condiment	O
cultivar	O
Marianne	O
these	O
three	O
total	O
only	O
14	O

Treatment	O
to	O
address	O
an	O
ibuprofen	B-Drug
overdose	O
is	O
based	O
on	O
how	O
the	O
symptoms	O
present	O

In	O
addition	O
to	O
its	O
medical	O
use	O
boldenone	B-Drug
undecylenate	I-Drug
is	O
used	O
improve	O
physique	O
and	O
performance	O

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths	O

Analogously	O
to	O
nandrolone	B-Drug
and	O
norethandrolone	B-Drug
5-dihydronormethandrone	O
the	O
5-reduced	O
metabolite	O
of	O
normethandrone	O
shows	O
reduced	O
affinity	O
for	O
androgen	O
receptor	O
relative	O

theophylline	B-Drug
ciprofloxacin	B-Drug
fluvoxamine	B-Drug
CYP1A2	O
may	O
increase	O
or	O
decrease	O
respectively	O
the	O
metabolism	O
of	O
clozapine	B-Drug

Testosterone	O
is	O
usually	O
used	O
for	O
this	O
purpose	O
although	O
methyltestosterone	B-Drug
also	O

In	O
the	O
northern	O
provinces	O
of	O
Ningxia	O
and	O
Suiyuan	O
in	O
China	O
Chinese	O
Muslim	O
General	O
Ma	O
Fuxiang	O
both	O
prohibited	O
engaged	O
opium	B-Drug
trade	O

Tisagenlecleucel	B-Drug
is	O
an	O
adoptive	O
cell	O
transfer	O
therapy	O
for	O
B-cell	O
acute	O
lymphoblastic	O
leukemia;	O
T	O
cells	O
from	O
a	O
person	O
with	O
cancer	O
are	O
removed	O
genetically	O
engineered	O
to	O
make	O
specific	O
T-cell	O
receptor	O
chimeric	O
or	O
CAR-T	O
that	O
reacts	O
the	O
and	O
administered	O
back	O

Metoclopramide	B-Drug
might	O
influence	O
on	O
mood	O
because	O
of	O
its	O
blockade	O
action	O
5-HT4	O
and	O
5-HT3	O

Until	O
it	O
was	O
banned	O
in	O
2011	O
products	O
containing	O
MDPV	B-Drug
and	O
labeled	O
as	O
bath	O
salts	O
were	O
sold	O
recreational	O
drugs	O
gas	O
stations	O
convenience	O
stores	O
the	O
United	O
States	O
similar	O
to	O
marketing	O
for	O
Spice	O
K2	O
incense	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

Temazepam	B-Drug
similar	O
to	O
other	O
benzodiazepines	O
and	O
nonbenzodiazepine	O
hypnotic	O
drugs	O
causes	O
impairments	O
in	O
body	O
balance	O
standing	O
steadiness	O
individuals	O
who	O
wake	O
up	O
at	O
night	O
or	O
the	O
next	O
morning	O

Apalutamide	B-Drug
was	O
approved	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O
in	O
2018	O

There	O
are	O
known	O
cases	O
of	O
doping	O
in	O
sports	O
with	O
metenolone	B-Drug
enanthate	O
by	O
professional	O
athletes	O

The	O
trans-isomer	O
was	O
found	O
to	O
be	O
around	O
591	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
in	O
animal	O
studies	O

The	O
related	O
AAS	O
oxymetholone	B-Drug
and	O
methasterone	B-Drug
methyldrostanolone	O
were	O
first	O
described	O
in	O
the	O
same	O
paper	O
as	O
well	O

According	O
to	O
The	O
New	O
York	O
Post	O
Court	O
records	O
show	O
Blanco	O
was	O
a	O
drug	O
addict	O
who	O
consumed	O
vast	O
quantities	O
of	O
'basuco'	O
potent	O
form	O
smokeable	O
unrefined	O
cocaine	B-Drug

Many	O
cacti	O
are	O
known	O
to	O
be	O
psychoactive	O
containing	O
phenethylamine	B-Drug
alkaloids	O
such	O
as	O
mescaline	B-Drug

2C-H	O
has	O
been	O
found	O
in	O
trace	O
amounts	O
by	O
the	O
DEA's	O
south	O
central	O
laboratory	O
tablets	O
that	O
were	O
suspected	O
of	O
containing	O
MDMA	B-Drug

NSAIDs	O
aside	O
from	O
aspirin	B-Drug
increase	O
the	O
risk	O
of	O
myocardial	O
infarction	O
and	O
stroke	O

This	O
allows	O
500	O
ml	O
of	O
the	O
oil	O
to	O
produce	O
between	O
150	O
and	O
340	O
grams	O
MDMA	B-Drug

For	O
both	O
emergency	O
and	O
palliative	O
use	O
intranasal	O
fentanyl	B-Drug
is	O
available	O
in	O
doses	O
of	O
50	O
100	O
200	O
g	O

Oxycodone	B-Drug
is	O
in	O
Schedule	O
I	O
derived	O
from	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
of	O
Commonwealth's	O
Act	O
1967	O

The	O
chemical	O
name	O
of	O
imipramine	B-Drug
is	O
3-1011-dihydro-5H-dibenzo[bf]azepin-5-yl-NN-dimethylpropan-1-amine	O
and	O
its	O
free	O
base	O
form	O
has	O
a	O
formula	O
C19H24N2	O
with	O
molecular	O
weight	O
280	O

alprazolam	B-Drug
diazepam	B-Drug
etc	O

There	O
are	O
similar	O
compounds	O
in	O
cannabis	O
that	O
do	O
not	O
exhibit	O
psychoactive	O
response	O
but	O
obligatory	O
for	O
functionality:	O
cannabidiol	B-Drug
CBD	B-Drug
an	O
isomer	O
of	O
THC;	O
cannabivarin	O
CBV	O
analog	O
cannabinol	O
CBN	O
with	O
a	O
different	O
side	O
chain	O
cannabidivarin	O
CBDV	O
and	O
cannabinolic	O
acid	O

As	O
a	O
member	O
of	O
Parliament	O
Gladstone	O
called	O
it	O
most	O
infamous	O
and	O
atrocious	O
referring	O
to	O
the	O
opium	B-Drug
trade	O
between	O
China	O
British	O
India	O
in	O
particular	O

JWH-018	B-Drug
will	O
not	O
be	O
detected	O
by	O
older	O
methods	O
employed	O
for	O
detecting	O
THC	O
and	O
other	O
cannabis	O
terpenoids	O

Naloxone	B-Drug
is	O
poorly	O
absorbed	O
when	O
taken	O
by	O
mouth	O
so	O
it	O
commonly	O
combined	O
with	O
a	O
number	O
of	O
oral	O
opioid	O
preparations	O
including	O
buprenorphine	B-Drug
and	O
pentazocine	B-Drug
that	O
only	O
the	O
has	O
an	O
effect	O

recalled	O
one	O
lot	O
and	O
later	O
additional	O
lots	O
of	O
fentanyl	B-Drug
brand	O
name:	O
Duragesic	B-Drug
patches	O
because	O
seal	O
breaches	O
which	O
might	O
have	O
allowed	O
the	O
medication	O
to	O
leak	O
from	O
patch	O

Marijuana	B-Drug
had	O
been	O
a	O
traditional	O
medicine	O
for	O
centuries	O
before	O
it	O
was	O
banned	O
in	O
the	O
1930s	O

In	O
February	O
2004	O
a	O
leading	O
fentanyl	B-Drug
supplier	O
Janssen	O
Pharmaceutica	O
Products	O
L	O

In	O
contrast	O
the	O
methamphetamine	B-Drug
hydrochloride	I-Drug
salt	O
is	O
odorless	O
with	O
a	O
bitter	O
taste	O

Relapses	O
fell	O
from	O
an	O
average	O
of	O
four	O
times	O
per	O
month	O
before	O
treatment	O
with	O
coca	B-Drug
tea	O
to	O
one	O
during	O
the	O

Sensational	O
media	O
attention	O
was	O
given	O
to	O
the	O
proposed	O
criminalization	O
and	O
reaction	O
of	O
MDMA	B-Drug
proponents	O
effectively	O
advertising	O
drug	O

Erivedge	O
vismodegib	B-Drug
for	O
basal-cell	O
carcinoma	O

Case	O
C	O
FDA	O
Warning	O
on	O
Codeine	B-Drug
Overdose	O
for	O
InfantsOn	O
February	O
20	O
2013	O
the	O
released	O
a	O
statement	O
addressing	O
serious	O
concern	O
regarding	O
connection	O
between	O
children	O
who	O
are	O
known	O
as	O
CYP2D6	O
UM	O
and	O
fatal	O
reactions	O
to	O
codeine	B-Drug
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
surgery	O
remove	O
tonsils	O
adenoids	O

On	O
September	O
16	O
2014	O
Genentech	O
reclassified	O
bevacizumab	B-Drug
as	O
a	O
specialty	O
drug	O
which	O
are	O
only	O
available	O
through	O
pharmacies	O

However	O
in	O
2016	O
an	O
investigation	O
by	O
the	O
Los	O
Angeles	O
Times	O
found	O
that	O
drug	O
weans	O
off	O
hours	O
early	O
many	O
people	O
inducing	O
symptoms	O
of	O
opiate	O
withdrawal	O
and	O
intense	O
cravings	O
for	O
OxyContin	B-Drug

Rapid	O
eye	O
movement	O
sleep	O
behavior	O
disorder	O
responds	O
well	O
to	O
low	O
doses	O
of	O
clonazepam	B-Drug

Due	O
to	O
concerns	O
about	O
the	O
potential	O
of	O
JWH-018	B-Drug
and	O
other	O
synthetic	O
cannabinoids	O
cause	O
psychosis	O
in	O
vulnerable	O
individuals	O
it	O
has	O
been	O
recommended	O
that	O
people	O
with	O
risk	O
factors	O
for	O
psychotic	O
illnesses	O
like	O
a	O
past	O
or	O
family	O
history	O
not	O
use	O
these	O
substances	O

O-Acetylpsilocin	B-Drug
is	O
more	O
resistant	O
than	O
psilocin	B-Drug
to	O
oxidation	O
under	O
basic	O
conditions	O
due	O
its	O
acetoxy	O
group	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation	O

In	O
a	O
study	O
of	O
the	O
levels	O
cannabis	O
cocaine	B-Drug
MDMA	B-Drug
methamphetamine	B-Drug
and	O
other	O
amphetamine	B-Drug
in	O
wastewater	O
from	O
42	O
major	O
cities	O
Europe	O
Amsterdam	O
came	O
near	O
top	O
list	O
every	O
category	O
but	O

The	O
US	O
DEA	O
Administrative	O
Controlled	O
Substance	O
Control	O
Number	O
assigned	O
by	O
the	O
Substances	O
Act	O
1970	O
for	O
thebacon	B-Drug
and	O
all	O
of	O
its	O
salts	O
is	O
9737	O

It	O
is	O
a	O
racemic	O
mixture	O
of	O
stereoisomers	O
dextronorgestrel	O
the	O
C13	O
isomer;	O
l-norgestrel	O
L-norgestrel	O
or	O
+-norgestrel	O
and	O
levonorgestrel	B-Drug
d-norgestrel	O
D-norgestrel	O
-norgestrel	O
former	O
which	O
inactive	O
making	O
norgestrel	B-Drug
exactly	O
half	O
as	O
potent	O

Believing	O
MDMA	B-Drug
allowed	O
users	O
to	O
strip	O
away	O
habits	O
and	O
perceive	O
the	O
world	O
clearly	O
Shulgin	O
called	O
drug	O
window	O

S-Propylhexedrine	O
can	O
be	O
synthesized	O
from	O
dextromethamphetamine	B-Drug

There	O
was	O
a	O
long	O
controversial	O
history	O
regarding	O
the	O
approval	O
of	O
DMPA	B-Drug
by	O
U	O

Alfaxalone	B-Drug
is	O
marketed	O
for	O
veterinary	O
use	O
under	O
the	O
brand	O
name	O
Alfaxan	O
in	O
a	O
number	O
of	O
countries	O
including	O
Australia	O
Belgium	O
Canada	O
France	O
Germany	O
Ireland	O
Japan	O
Netherlands	O
New	O
Zealand	O
South	O
Africa	O
Korea	O
Spain	O
Taiwan	O
United	O
Kingdom	O
and	O
States	O

Indole	O
alkaloids	O
which	O
make	O
up	O
about	O
6%	O
of	O
the	O
root	O
chemical	O
composition	O
iboga	O
include:	O
Ibogaine	B-Drug
Ibogamine	O
Noribogaine	B-Drug
Voacangine	O
18-Methoxycoronaridine	B-Drug
The	O
Iboga	O
tree	O
is	O
central	O
to	O
Bwiti	O
spiritual	O
practices	O
in	O
West-Central	O
Africa	O
mainly	O
Gabon	O
Cameroon	O
and	O
Republic	O
Congo	O
where	O
alkaloid-containing	O
roots	O
or	O
bark	O
are	O
used	O
various	O
ceremonies	O
create	O
a	O
near-death	O
experience	O

Given	O
the	O
known	O
metabolic	O
liberation	O
and	O
presence	O
as	O
an	O
impurity	O
of	O
amantadine	B-Drug
in	O
related	O
compound	O
APINACA	B-Drug
it	O
is	O
suspected	O
that	O
hydrolysis	O
amide	O
group	O
5F-NNE1	O
may	O
release	O
1-naphthylamine	O
a	O
carcinogen	O

Taken	O
together	O
like	O
desogestrel	B-Drug
gestodene	O
appears	O
to	O
have	O
a	O
low	O
potential	O
for	O
androgenic	O
effects	O

Taken	O
together	O
flutamide	O
appears	O
to	O
be	O
a	O
considerably	O
less	O
potent	O
and	O
efficacious	O
antiandrogen	O
than	O
is	O
bicalutamide	B-Drug

Other	O
techniques	O
used	O
in	O
the	O
management	O
of	O
chronic	O
pain	O
may	O
also	O
be	O
use;	O
these	O
include	O
massage	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
trigger	O
point	O
injections	B-Drug
surgical	O
ablation	O
and	O
non-interventional	O
therapies	O
such	O
as	O
meditation	O
yoga	O
music	O
art	O
therapy	O

This	O
is	O
likely	O
due	O
to	O
venlafaxine's	O
relatively	O
short	O
half-life	O
and	O
therefore	O
rapid	O
clearance	O
upon	O
discontinuation	O
venlafaxine	B-Drug

There	O
has	O
been	O
one	O
reported	O
death	O
due	O
to	O
4-methylaminorex	B-Drug
and	O
diazepam	B-Drug

Morphine	B-Drug
was	O
the	O
first	O
alkaloid	O
to	O
be	O
isolated	O
from	O
any	O
medicinal	O
plant	O
beginning	O
of	O
modern	O
scientific	O
drug	O
discovery	O

Even	O
relatively	O
safe	O
and	O
well	O
understood	O
OTC	O
drugs	O
such	O
as	O
aspirin	B-Drug
can	O
be	O
dangerous	O
if	O
used	O
incorrectly	O

The	O
Harrison	O
Narcotics	O
Tax	O
Act	O
of	O
1914	O
restricted	O
the	O
manufacture	O
and	O
distribution	O
opiates	O
including	O
laudanum	B-Drug
coca	B-Drug
derivatives	O
in	O
US	O

For	O
those	O
with	O
bronchospasm	O
propofol	B-Drug
also	O
has	O
mild	O
bronchodilating	O
effect	O

The	O
law	O
regulated	O
the	O
import	O
and	O
export	O
of	O
some	O
opiates	O
cocaine	B-Drug

2C-T-7	O
is	O
a	O
psychedelic	O
phenethylamine	B-Drug
of	O
the	O
2C	O
family	O

In	O
2011	O
researchers	O
at	O
John	O
Jay	O
College	O
of	O
Criminal	O
Justice	O
reported	O
that	O
dietary	O
zinc	O
supplements	O
can	O
mask	O
the	O
presence	O
cocaine	B-Drug
and	O
other	O
drugs	O
in	O
urine	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
banned	O
the	O
sale	O
of	O
supplements	O
containing	O
ephedrine	B-Drug
alkaloids	O
in	O
2004	O

It	O
also	O
refers	O
to	O
opium's	O
potential	O
as	O
a	O
poison	O
opium	B-Drug

Leuprorelin	B-Drug
is	O
marketed	O
by	O
Bayer	O
AG	O
under	O
the	O
brand	O
name	O
Viadur	O
Tolmar	O
names	O
Eligard	O
and	O
Fensolvi	O
TAP	O
Pharmaceuticals	O
19852008	O
Varian	O
Darou	O
Pajooh	O
Leupromer	O
Abbott	O
Laboratories	O
2008present	O
Lupron	B-Drug

Until	O
the	O
full	O
ban	O
on	O
opium-based	O
products	O
came	O
into	O
effect	O
just	O
after	O
beginning	O
of	O
twentieth	O
century	O
physicians	O
in	O
US	O
considered	O
opium	B-Drug
a	O
miracle	O
drug	O
that	O
could	O
help	O
with	O
many	O
ailments	O

Short-term	O
addiction	O
studies	O
by	O
the	O
same	O
researchers	O
demonstrated	O
that	O
tolerance	O
developed	O
at	O
a	O
similar	O
rate	O
to	O
both	O
heroin	B-Drug
and	O
morphine	B-Drug

Hyoscine	O
produces	O
detrimental	O
effects	O
on	O
short-term	O
memory	O
acquisition	O
learning	O
visual	O
recognition	O
visuospatial	O
praxis	O
visuoperceptual	O
function	O
verbal	O
recall	O
and	O
psychomotor	O
speed	B-Drug

The	O
FDA	O
cited	O
statements	O
made	O
on	O
Cocaine's	O
packaging	O
and	O
website	O
as	O
evidence	O
for	O
their	O
claims	O
Cocaine	B-Drug

Currently	O
metopon	B-Drug
which	O
has	O
a	O
DEA	O
ACSCN	O
of	O
9260	O
does	O
not	O
have	O
an	O
annual	O
manufacturing	O
quota	O
listed	O
in	O
the	O
Federal	O
Register	O
and	O
bulk	O
research	O
on	O
drug	O
at	O
this	O
time	O
is	O
taking	O
place	O
Germany	O
Switzerland	O
Austria	O

Until	O
2017	O
products	O
containing	O
cannabidiol	B-Drug
marketed	O
for	O
medical	O
purposes	O
were	O
classed	O
as	O
medicines	O
by	O
the	O
UK	O
regulatory	O
body	O
Medicines	O
and	O
Healthcare	O
Regulatory	O
Agency	O
MHRA	O
could	O
not	O
be	O
without	O
approval	O
claims	O

Flurazepam	B-Drug
shares	O
cross	O
tolerance	O
with	O
barbiturates	O
and	O
can	O
easily	O
be	O
substituted	O
by	O
flurazepam	B-Drug
in	O
those	O
who	O
are	O
habituated	O
to	O
barbiturate	O
sedative	O
hypnotics	O

Many	O
cite	O
the	O
potential	O
side	O
effects	O
of	O
retroperitoneal/retropulmonary	O
fibrosis	O
as	O
prime	O
reason	O
methysergide	B-Drug
is	O
no	O
longer	O
frequently	O
prescribed	O
but	O
retroperitoneal	O
and	O
retropulmonary	O
were	O
documented	O
early	O
1966	O
1967	O
respectively	O

On	O
April	O
4	O
2003	O
the	O
United	O
States	O
DEA	O
added	O
both	O
5-MeO-DiPT	O
and	O
alpha-methyltryptamine	B-Drug
AMT	B-Drug
to	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act	O
under	O
emergency	O
scheduling	O
procedures	O

The	O
duration	O
of	O
diazepam's	O
peak	O
pharmacological	O
effects	O
is	O
15	O
minutes	O
to	O
one	O
hour	O
for	O
both	O
routes	O
administration	O
diazepam	B-Drug

This	O
weaning	O
process	O
may	O
be	O
over	O
a	O
few	O
days	O
if	O
the	O
course	O
of	O
prednisone	B-Drug
was	O
short	O
but	O
take	O
weeks	O
or	O
months	O
patient	O
had	O
been	O
on	O
long-term	O
treatment	O

However	O
for	O
two	O
of	O
the	O
three	O
cases	O
post-mortem	O
GHB	B-Drug
concentrations	O
were	O
141	O
and	O
110	O
mg/L	O
which	O
is	O
within	O
expected	O
range	O
after	O
death	O
third	O
case	O
was	O
a	O
patient	O
with	O
history	O
intentional	O
drug	O
overdose	O

Nalbuphine	B-Drug
belongs	O
to	O
this	O
group	O
of	O
substances	O

Quantification	O
of	O
alprazolam	B-Drug
in	O
blood	O
and	O
plasma	O
samples	O
may	O
be	O
necessary	O
to	O
confirm	O
a	O
diagnosis	O
intoxication	O
hospitalized	O
patients	O
or	O
provide	O
evidence	O
the	O
case	O
crimes	O
e	O

However	O
LSD	B-Drug
and	O
iso-LSD	O
the	O
two	O
C-8	O
isomers	O
rapidly	O
interconvert	O
in	O
presence	O
of	O
bases	O
as	O
alpha	O
proton	O
is	O
acidic	O
can	O
be	O
deprotonated	O
reprotonated	O

Clonazepam	B-Drug
decreases	O
release	O
of	O
acetylcholine	O
in	O
the	O
feline	O
brain	O
and	O
prolactin	O
rats	O

On	O
15	O
October	O
2019	O
the	O
Department	O
of	O
Health	O
and	O
Social	O
Care	O
United	O
Kingdom	O
issued	O
a	O
supply	O
distribution	O
alert	O
SDA/2019/005	O
for	O
all	O
oral	O
formulations	O
ranitidine	B-Drug

The	O
group	O
of	O
men	O
responsible	O
travelled	O
from	O
New	O
Zealand	O
to	O
a	O
'mothership'	O
in	O
the	O
South	O
Pacific	O
Ocean	O
on	O
yacht	O
where	O
they	O
collected	O
cocaine	B-Drug
and	O
attempted	O
sail	O
into	O
Australia	O
but	O
were	O
intercepted	O
south	O
coast	O

In	O
addition	O
spironolactone	B-Drug
a	O
steroidal	O
antimineralocorticoid	O
that	O
was	O
introduced	O
for	O
medical	O
use	O
in	O
1959	O
discovered	O
to	O
possess	O
potent	O
antiandrogenic	O
activity	O
1969	O
and	O
became	O
widely	O
used	O
clinically	O
as	O
an	O
antiandrogen	O
after	O
its	O
first	O
androgen-dependent	O
condition	O
1978	O

Bupivacaine	B-Drug
is	O
a	O
safe	O
alternative	O
in	O
this	O
case	O

Mephedrone	B-Drug
had	O
been	O
reported	O
to	O
be	O
used	O
in	O
Singapore	O
February	O
2010	O
but	O
it	O
was	O
made	O
illegal	O
November	O

Methyltestosterone	B-Drug
is	O
available	O
at	O
a	O
low-dose	O
in	O
combination	O
with	O
esterified	O
estrogens	O
for	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
like	O
hot	O
flashes	O
women	O
under	O
brand	O
names	O
Covaryx	O
Essian	O
Estratest	B-Drug
Menogen	O
and	O
Syntest	O

All	O
of	O
these	O
derivatives	O
are	O
likely	O
to	O
share	O
some	O
their	O
psychoactive	O
effects	O
with	O
PCP	B-Drug
itself	O
although	O
a	O
range	O
potencies	O
and	O
varying	O
mixtures	O
anesthetic	O
dissociative	O
stimulant	O
known	O
depending	O
on	O
the	O
particular	O
drug	O
its	O
substituents	O

Despite	O
this	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010	O

Possession	O
of	O
more	O
than	O
100	O
grams	O
diamorphine	B-Drug
or	O
a	O
mixture	O
containing	O
is	O
punishable	O
with	O
minimum	O
mandatory	O
sentence	O
5	O
years	O
imprisonment	O
in	O
federal	O
prison	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O

The	O
requirement	O
of	O
retinol	B-Drug
to	O
rescue	O
reproduction	O
in	O
vitamin	B-Drug
A	I-Drug
deficient	O
rats	O
is	O
now	O
known	O
be	O
due	O
a	O
for	O
local	O
synthesis	O
retinoic	O
acid	O
from	O
testis	O
and	O
embryos	O

In	O
November	O
2010	O
the	O
British	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
MHRA	O
received	O
an	O
allegation	O
that	O
Grnenthal	O
promoted	O
its	O
unlicensed	O
product	O
Tapentadol	B-Drug
to	O
health	O
professionals	O

In	O
addition	O
to	O
its	O
medical	O
use	O
fluoxymesterone	B-Drug
is	O
used	O
improve	O
physique	O
and	O
performance	O

Androstanedione	O
is	O
a	O
5-reduced	O
metabolite	O
of	O
4-androstenedione	B-Drug
which	O
serves	O
as	O
an	O
intermediate	O
in	O
the	O
biosynthesis	O
androgen	O
and	O
neurosteroid	O
androsterone	O

0	O
followed	O
by	O
Temazepam	B-Drug
11	O

45-Dihydrogenated	O
derivatives	O
of	O
testosterone	O
such	O
as	O
DHT	O
cannot	O
be	O
aromatized	O
whereas	O
19-nortestosterone	B-Drug
like	O
nandrolone	B-Drug
can	O
but	O
to	O
a	O
greatly	O
reduced	O
extent	O

Doctors	O
are	O
free	O
to	O
prescribe	O
bevacizumab	B-Drug
off	O
label	O
although	O
insurance	O
companies	O
less	O
likely	O
approve	O
off-label	O
treatments	O

An	O
impure	O
form	O
of	O
methamphetamine	B-Drug
is	O
sold	O
as	O
a	O
crumbly	O
brown	O
or	O
off-white	O
rock	O
commonly	O
referred	O
to	O
peanut	O
butter	O
crank	O

Both	O
the	O
inhibition	O
and	O
increase	O
of	O
dopamine	O
release	O
by	O
GHB	O
are	O
inhibited	O
opioid	O
antagonists	O
such	O
as	O
naloxone	B-Drug
naltrexone	B-Drug

The	O
vast	O
majority	O
of	O
narcotic	O
painkillers	O
along	O
with	O
cocaine	B-Drug
and	O
most	O
amphetamines	O
are	O
regulated	O
under	O
the	O
Narcotics	O
Act	O

He	O
has	O
been	O
open	O
about	O
having	O
taken	O
LSD	B-Drug
many	O
times	O
himself	O
but	O
was	O
always	O
opposed	O
to	O
the	O
growing	O
use	O
of	O
amongst	O
members	O
counterculture	O
movement	O

No	O
craving	O
for	O
the	O
further	O
use	O
of	O
cocaine	B-Drug
appears	O
after	O
first	O
or	O
even	O
repeated	O
taking	O
drug	O

Tamoxifen	B-Drug
is	O
used	O
for	O
ovulation	O
induction	O
to	O
treat	O
infertility	O
in	O
women	O
with	O
anovulatory	O
disorders	O

Among	O
those	O
using	O
oxandrolone	B-Drug
for	O
nonmedical	O
purposes	O
it	O
is	O
often	O
referred	O
to	O
colloquially	O
as	O
Var	O
a	O
shortened	O
form	O
of	O
the	O
brand	O
name	O
Anavar	O

Loperamide	B-Drug
oxide	O
has	O
a	O
different	O
research	O
code:	O
R-58425	O

4%	O
Cannabis	O
is	O
at	O
times	O
linked	O
to	O
young	O
people	O
beginning	O
smoke	O
tobacco	B-Drug
as	O
cannabis	O
often	O
smoked	O
with	O
in	O
the	O
United	O
Kingdom	O
unlike	O
many	O
other	O
parts	O
of	O
world	O

There	O
have	O
been	O
three	O
studies	O
studying	O
possible	O
neurotoxicity	O
of	O
4-methylaminorex	B-Drug

The	O
pharmacokinetics	O
of	O
spironolactone	B-Drug
have	O
not	O
been	O
studied	O
well	O
which	O
is	O
in	O
part	O
because	O
it	O
an	O
old	O
medication	O
that	O
was	O
developed	O
the	O
1950s	O

Ketoconazole	B-Drug
and	O
itraconazole	B-Drug
have	O
a	O
profound	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
triazolam	B-Drug
leading	O
to	O
greatly	O
enhanced	O
effects	O

Nitrazepam	B-Drug
for	O
example	O
is	O
commonly	O
abused	O
in	O
Nepal	O
and	O
the	O
United	O
Kingdom	O
whereas	O
States	O
of	O
America	O
where	O
nitrazepam	B-Drug
not	O
available	O
on	O
prescription	O
other	O
benzodiazepines	O
are	O
more	O

34-Methylenedioxymethamphetamine	O
MDMA	B-Drug
commonly	O
known	O
as	O
ecstasy	B-Drug
E	O
or	O
molly	B-Drug
is	O
a	O
psychoactive	O
drug	O
primarily	O
used	O
for	O
recreational	O
purposes	O
Methylenedioxymethamphetamine	B-Drug

charas	O
A	O
traditional	O
form	O
of	O
Indian	O
hashish	B-Drug

Fentanyl	B-Drug
has	O
been	O
discovered	O
for	O
sale	O
in	O
illicit	O
markets	O
Australia	O
2017	O
and	O
New	O
Zealand	O
2018	O

After	O
a	O
court	O
case	O
brought	O
by	O
Right	O
to	O
Life	O
New	O
Zealand	O
failed	O
use	O
of	O
mifepristone	B-Drug
was	O
permitted	O

The	O
medicinal	O
chemistry	O
work	O
turned	O
to	O
improving	O
the	O
lead	O
compound	O
into	O
a	O
suitable	O
drug:	O
result	O
was	O
thalidomide	B-Drug

PCP	B-Drug
is	O
a	O
Schedule	O
II	O
substance	O
in	O
the	O
United	O
States	O
and	O
its	O
ACSCN	O
7471	O

The	O
mixture	O
separates	O
into	O
two	O
layers	O
the	O
top	O
solvent	O
layer	O
containing	O
dissolved	O
cocaine	B-Drug

Liver	O
and	O
urinary	O
toxicity	O
are	O
common	O
among	O
regular	O
users	O
of	O
high	O
doses	O
ketamine	B-Drug
for	O
recreational	O
purposes	O

The	O
bioavailability	O
of	O
oral	O
administration	O
oxycodone	B-Drug
averages	O
within	O
a	O
range	O
60	O
to	O
87%	O
with	O
rectal	O
yielding	O
the	O
same	O
results;	O
intranasal	O
varies	O
between	O
individuals	O
mean	O
46%	O

It	O
acts	O
as	O
a	O
potent	O
-opioid	O
agonist	O
and	O
was	O
found	O
to	O
be	O
around	O
30-60	O
times	O
more	O
than	O
the	O
related	O
drug	O
levorphanol	B-Drug
in	O
animal	O
experiments	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959	O

In	O
the	O
United	O
States	O
MPPP	B-Drug
is	O
now	O
in	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act	O
with	O
a	O
zero	O
aggregate	O
manufacturing	O
quota	O
as	O
2014	O

Brand	O
names	O
include	O
Sublimaze	O
Actiq	B-Drug
Durogesic	O
Duragesic	B-Drug
Fentora	B-Drug
Matrifen	O
Haldid	O
Onsolis	O
Instanyl	O
Abstral	O
Lazanda	B-Drug
and	O
others	O

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco	B-Drug

One	O
published	O
study	O
that	O
analysed	O
samples	O
of	O
mephedrone	B-Drug
bought	O
using	O
the	O
internet	O
in	O
UK	O
2010	O
found	O
it	O
was	O
racemic	O
a	O
mixture	O
both	O
stereoisomers	O
and	O
high	O
purity	O

The	O
people	O
in	O
the	O
trial	O
were	O
randomized	O
to	O
receive	O
either	O
ivacaftor	B-Drug
or	O
placebo	O
for	O
eight	O
weeks	O

Methylprednisolone	B-Drug
Depo-Medrol	O
Medrol	O
Solu-Medrol	O
is	O
a	O
synthetic	O
glucocorticoid	O
primarily	O
prescribed	O
for	O
its	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O

Using	O
a	O
small	O
stolen	O
plane	O
and	O
professional	O
pilot	O
the	O
pair	O
began	O
to	O
fly	O
cocaine	B-Drug
into	O
United	O
States	O
via	O
Bahamas	O
in	O
process	O
increasing	O
their	O
financial	O
resources	O
building	O
connections	O
trust	O
with	O
Colombian	O
suppliers	O
while	O
spreading	O
money	O
around	O
among	O
Bahamian	O
government	O
officials	O
for	O
political	O
judicial	O
protection	O

The	O
orange	O
pigment	O
of	O
carrots	O
beta-carotene	O
can	O
be	O
represented	O
as	O
two	O
connected	O
retinyl	B-Drug
groups	O
which	O
are	O
used	O
in	O
the	O
body	O
to	O
contribute	O
vitamin	O
A	O
levels	O

The	O
film	O
highlights	O
the	O
abuse	O
of	O
prescription	O
drug	O
oxycodone	B-Drug

In	O
November	O
2016	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights	O
Utah	O

Psilocybin	O
is	O
chemically	O
far	O
more	O
stable	O
than	O
psilocin	B-Drug
the	O
latter	O
compound	O
being	O
largely	O
lost	O
when	O
mushroom	O
heated	O
or	O
dried	O

Benzodiazepines	O
such	O
as	O
lorazepam	B-Drug
enhance	O
the	O
effects	O
of	O
GABA	O
at	O
GABAA	O
receptor	O
via	O
increasing	O
frequency	O
opening	O
chloride	O
ion	O
channel	O
on	O
receptors;	O
which	O
results	O
in	O
therapeutic	O
actions	O
benzodiazepines	O

Spironolactone	B-Drug
is	O
also	O
known	O
by	O
the	O
following	O
equivalent	O
chemical	O
names:	O
7-Acetylthio-17-hydroxy-3-oxopregn-4-ene-21-carboxylic	O
acid	O
-lactone	O
7-Acetylthio-3-oxo-17-pregn-4-ene-2117-carbolactone	O
3-3-Oxo-7-acetylthio-17-hydroxyandrost-4-en-17-ylpropionic	O
lactone	O
7-Acetylthio-17-2-carboxyethylandrost-4-en-17-ol-3-one	O
7-Acetylthio-17-2-carboxyethyltestosterone	O
closely	O
related	O
structurally	O
to	O
other	O
clinically	O
used	O
spirolactones	O
such	O
as	O
canrenone	O
potassium	O
canrenoate	O
drospirenone	O
and	O
eplerenone	B-Drug
well	O
never-marketed	O
SC-5233	O
67-dihydrocanrenone;	O
7-desthioacetylspironolactone	O
SC-8109	O
19-nor-67-dihydrocanrenone	O
spiroxasone	O
prorenone	O
SC-23133	O
mexrenone	O
SC-25152	O
ZK-32055	O
dicirenone	O
SC-26304	O
spirorenone	O
ZK-35973	O
mespirenone	O
ZK-94679	O

Between	O
1970	O
and	O
1990	O
smoking	O
of	O
5-MeO-DMT	B-Drug
on	O
parsley	O
was	O
probably	O
one	O
the	O
two	O
most	O
common	O
forms	O
ingestion	O
in	O
United	O
States	O

As	O
such	O
it	O
has	O
a	O
high	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity	O
similarly	O
other	O
nandrolone	B-Drug
derivatives	O

5	O
million	O
people	O
in	O
the	O
United	O
States	O
used	O
cocaine	B-Drug
2010	O
down	O
from	O
2	O

The	O
FDA	O
also	O
said	O
that	O
coincidental	O
natural	O
mood	O
variation	O
is	O
the	O
most	O
likely	O
explanation	O
for	O
apparent	O
worsening	O
of	O
depression	O
after	O
switch	O
from	O
Wellbutrin	B-Drug
XL	O
to	O
Budeprion	O

Buspirone	B-Drug
was	O
primarily	O
sold	O
under	O
the	O
brand	O
name	O
Buspar	B-Drug

In	O
a	O
study	O
of	O
cocaine	B-Drug
users	O
the	O
average	O
time	O
taken	O
to	O
reach	O
peak	O
subjective	O
effects	O
was	O
14	O

5	O
mg/day	O
oral	O
methyltestosterone	B-Drug
in	O
women	O
are	O
the	O
range	O
of	O
20	O
to	O
30	O
ng/dL	O

tobacco	B-Drug

Following	O
extended	O
discussions	O
with	O
Richwood	O
Pharmaceuticals	O
regarding	O
the	O
resolution	O
of	O
a	O
large	O
number	O
issues	O
related	O
to	O
company's	O
numerous	O
violations	O
FDA	O
regulations	O
formally	O
approved	O
first	O
Obetrol	B-Drug
labeling/sNDA	O
revisions	O
in	O
1996	O
including	O
name	O
change	O
Adderall	B-Drug
and	O
restoration	O
its	O
status	O
as	O
an	O
drug	O
product	O

Mercdes	O
Benegbi	O
born	O
with	O
phocomelia	O
of	O
both	O
arms	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide	B-Drug

Desogestrel	B-Drug
3-deketoetonogestrel	O
a	O
prodrug	O
of	O
etonogestrel	B-Drug
was	O
introduced	O
for	O
medical	O
use	O
in	O
1981	O

The	O
active	O
ingredients	O
are	O
morphine	B-Drug
sulfate	I-Drug
and	O
naltrexone	B-Drug
hydrochloride;	O
being	O
an	O
opioid	O
receptor	O
agonist	O
antagonist	O
hydrochloride	I-Drug

Ltd	O
now	O
part	O
of	O
Diageo	O
plc	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK	O
Australia	O
and	O
New	O
Zealand	O
under	O
brand	O
name	O
Distaval	O
as	O
a	O
remedy	O
for	O
morning	O
sickness	O

When	O
taken	O
in	O
prescribed	O
quantities	O
cough	O
syrup	O
is	O
quite	O
safe	O
but	O
dangers	O
arise	O
higher	O
doses	O
since	O
promethazine	B-Drug
a	O
depressant	O
of	O
the	O
central	O
nervous	O
system	O
CNS	O
and	O
codeine	B-Drug
respiratory	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

Dextromethorphan	B-Drug
is	O
also	O
used	O
recreationally	O

The	O
sodium	B-Drug
salt	O
of	O
the	O
acid	O
is	O
valproate	B-Drug
and	O
a	O
coordination	O
complex	O
two	O
known	O
as	O
semisodium	I-Drug

Because	O
significant	O
tolerance	O
to	O
respiratory	O
depression	O
develops	O
quickly	O
with	O
continued	O
use	O
and	O
is	O
lost	O
just	O
as	O
during	O
withdrawal	O
it	O
often	O
difficult	O
determine	O
whether	O
a	O
heroin	B-Drug
lethal	O
overdose	O
was	O
accidental	O
suicide	O
or	O
homicide	O

Fentanyl	B-Drug
in	O
injectable	O
formulation	O
is	O
commonly	O
used	O
for	O
analgesia	O
and	O
as	O
a	O
component	O
of	O
balanced	O
sedation	O
general	O
anesthesia	O
small	O
animal	O
patients	O

The	O
activity	O
of	O
alprazolam	B-Drug
in	O
the	O
central	O
nervous	O
system	O
is	O
dose	O
dependent	O

Paracetamol	B-Drug
hepatotoxicity	O
is	O
by	O
far	O
the	O
most	O
common	O
cause	O
of	O
acute	O
liver	O
failure	O
in	O
both	O
United	O
States	O
and	O
Kingdom	O

Studies	O
examining	O
this	O
effect	O
have	O
used	O
high	O
ratios	O
of	O
CBD	B-Drug
to	O
THC	O
and	O
it	O
is	O
unclear	O
what	O
extent	O
these	O
laboratory	O
studies	O
translate	O
the	O
types	O
cannabis	O
by	O
real	O
life	O
users	O

Clonazepam	B-Drug
has	O
also	O
been	O
found	O
effective	O
in	O
treating	O
other	O
anxiety	O
disorders	O
such	O
as	O
social	O
phobia	O
but	O
this	O
is	O
an	O
off-label	O
use	O

As	O
with	O
prodine	B-Drug
there	O
are	O
two	O
isomers	O
of	O
meprodine	B-Drug
alpha-meprodine	O
and	O
beta-meprodine	O
the	O
alpha	O
isomer	O
having	O
been	O
more	O
widely	O
used	O

Haloperidol	B-Drug
is	O
heavily	O
protein	O
bound	O
in	O
human	O
plasma	O
with	O
a	O
free	O
fraction	O
of	O
only	O
7	O

In	O
1985	O
MDMA	B-Drug
and	O
its	O
analogues	O
were	O
under	O
review	O
by	O
the	O
American	O
government	O
as	O
a	O
drug	O
for	O
potential	O
of	O
abuse	O

It	O
has	O
similar	O
binding	O
affinity	O
to	O
LSD	B-Drug
itself	O
as	O
both	O
a	O
5-HT1A	O
and	O
5-HT2A	O
agonist	O
produces	O
behavioral	O
physiological	O
responses	O
in	O
animals	O
with	O
only	O
slightly	O
lower	O
potency	O
than	O

In	O
1964	O
Israeli	O
physician	O
Jacob	O
Sheskin	O
administered	O
thalidomide	B-Drug
to	O
a	O
patient	O
critically	O
ill	O
with	O
leprosy	O

Naldemedine	B-Drug
is	O
their	O
only	O
gastroenterology	O
product	O
in	O
the	O
United	O
States	O

Alphacetylmethadol	B-Drug
is	O
very	O
similar	O
in	O
structure	O
to	O
methadone	B-Drug
a	O
widely	O
prescribed	O
treatment	O
for	O
opioid	O
addiction	O

Chinotto	O
Tree	O
N-Methylated	O
tryptamine	O
derivative	O
in	O
leaf	O
Citrus	O
medica	O
Species	O
Alkaloid	O
Content	O
Fresh	O
-	O
Dried	O
Coryphantha	O
contains	O
various	O
phenethylamine	B-Drug
alkaloids	O
including	O
macromerine	O
coryphanthine	O
O-methyl-candicine	O
corypalmine	O
and	O
N-methyl-corypalmine	O

Codeine	B-Drug
and	O
the	O
semi-synthetics	O
such	O
as	O
heroin	B-Drug
dihydrocodeine	B-Drug
dihydromorphine	B-Drug
hydromorphone	B-Drug
hydrocodone	B-Drug
also	O
have	O
equivalent	O
amine	O
oxide	O
derivatives	O

Kief	O
is	O
a	O
powder	O
rich	O
in	O
trichomes	O
which	O
can	O
be	O
sifted	O
from	O
the	O
leaves	O
flowers	O
and	O
fruits	O
of	O
cannabis	O
plants	O
either	O
consumed	O
form	O
or	O
compressed	O
to	O
produce	O
cakes	O
hashish	B-Drug

Lorazepam	B-Drug
is	O
highly	O
protein	O
bound	O
and	O
extensively	O
metabolized	O
into	O
pharmacologically	O
inactive	O
metabolites	O

Flunitrazepam	B-Drug
can	O
be	O
measured	O
in	O
blood	O
or	O
plasma	O
to	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
hospitalized	O
patients	O
provide	O
evidence	O
an	O
impaired	O
driving	O
arrest	O
assist	O
medicolegal	O
death	O
investigation	O

These	O
changes	O
have	O
coincided	O
with	O
other	O
in	O
Ontario's	O
legislation	O
to	O
target	O
the	O
misuse	O
of	O
painkillers	O
and	O
high	O
addiction	O
rates	O
drugs	O
such	O
as	O
oxycodone	B-Drug

Pomalidomide	B-Drug
was	O
approved	O
in	O
February	O
2013	O
by	O
the	O
U	O

At	O
subanesthetic	O
doses	O
ketamine	B-Drug
produces	O
a	O
dissociative	O
state	O
characterised	O
by	O
sense	O
of	O
detachment	O
from	O
one's	O
physical	O
body	O
and	O
the	O
external	O
world	O
which	O
is	O
known	O
as	O
depersonalization	O
derealization	O

Fry	O
or	O
sherm	O
are	O
street	O
terms	O
for	O
marijuana	O
tobacco	O
cigarettes	O
that	O
dipped	O
in	O
PCP	B-Drug
and	O
then	O
dried	O

The	O
CBD	B-Drug
drug	O
Epidiolex	O
has	O
been	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
treatment	O
of	O
two	O
rare	O
severe	O
forms	O
epilepsy	O
Dravet	O
Lennox-Gastaut	O
syndromes	O

Because	O
significant	O
tolerance	O
to	O
respiratory	O
depression	O
develops	O
quickly	O
with	O
continued	O
use	O
and	O
is	O
lost	O
just	O
as	O
during	O
withdrawal	O
it	O
often	O
difficult	O
determine	O
whether	O
a	O
heroin	B-Drug
lethal	O
overdose	O
was	O
accidental	O
suicide	O
or	O
homicide	O

It	O
can	O
be	O
cut	O
into	O
or	O
even	O
replace	O
entirely	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates	O

There	O
was	O
an	O
extensive	O
and	O
complicated	O
system	O
of	O
BEIC	O
agencies	O
involved	O
in	O
the	O
supervision	O
management	O
opium	B-Drug
production	O
distribution	O
India	O

The	O
elimination	O
half-life	O
of	O
gabapentin	B-Drug
has	O
been	O
found	O
to	O
be	O
extended	O
with	O
increasing	O
doses;	O
in	O
one	O
series	O
studies	O
it	O
was	O
5	O

The	O
China	O
White	O
form	O
of	O
fentanyl	B-Drug
refers	O
to	O
any	O
a	O
number	O
clandestinely	O
produced	O
analogues	O
especially	O
-methylfentanyl	O
AMF	O

The	O
illegal	O
possession	O
or	O
consumption	O
of	O
Nimetazepam	B-Drug
is	O
punishable	O
by	O
up	O
to	O
10	O
years	O
imprisonment	O
a	O
fine	O
20000	O
Singapore	O
dollars	O
both	O

Street	O
terms	O
for	O
temazepam	B-Drug
include	O
king	O
kong	O
pills	O
formerly	O
referred	O
to	O
barbiturates	O
now	O
more	O
commonly	O
refers	O
jellies	O
jelly	O
Edinburgh	O
eccies	O
tams	O
mazzies	O
temazies	O
tammies	O
temmies	O
beans	O
eggs	O
green	O
wobbly	O
knockouts	O
hardball	O
norries	O
oranges	O
common	O
term	O
in	O
Australia	O
and	O
New	O
Zealand	O
rugby	O
balls	O
ruggers	O
terminators	O
red	O
blue	O
no-gos	O
num	O
nums	O
blackout	O
devils	O
drunk	O
brainwash	O
mind	O
erasers	O
neurotrashers	O
tem-tem's	O
combined	O
with	O
buprenorphine	B-Drug
mommy's	O
big	O
helper	O
vitamin	O
T	O
TZ	O
The	O
Mazepam	O
Resties	O
North	O
America	O
others	O

Four	O
experiments	O
then	O
quantified	O
tolerance	O
effects	O
the	O
extent	O
to	O
which	O
repeated	O
doses	O
of	O
LSD	B-Drug
cause	O
a	O
reduction	O
in	O
effect	O
subsequent	O
dose	O

All	O
-opioids	O
with	O
any	O
even	O
slight	O
agonist	O
effect	O
such	O
as	O
partial	O
list	O
morphine	B-Drug
heroin	O
codeine	B-Drug
oxycodone	B-Drug
buprenorphine	B-Drug
nalbuphine	B-Drug
methadone	B-Drug
and	O
fentanyl	B-Drug
but	O
not	O
agonists	O
specific	O
to	O
non-	O
opioid	O
receptors	O
salvinorin	O
A	O
a	O
k-opioid	O
nor	O
antagonists	O
or	O
inverse	O
naltrexone	B-Drug
universal	O
GABA	O
positive	O
allosteric	O
modulators	O
of	O
both	O
the	O
GABA-A	O
ionotropic	O
receptor	O
GABA-B	O
metabotropic	O
subunits	O
including	O
list:	O
alcohol	O
alcoholic	O
beverage	O
cf	O

A	O
university-led	O
study	O
including	O
several	O
authors	O
who	O
are	O
advisors	O
to	O
companies	O
such	O
as	O
Pfizer	O
in	O
103	O
women	O
comparing	O
alfatradiol	B-Drug
minoxidil	B-Drug
another	O
topical	O
hair	O
loss	O
treatment	O
found	O
the	O
latter	O
be	O
more	O
effective	O

From	O
2013	O
until	O
2016	O
overdose	O
deaths	O
involving	O
fentanyl	B-Drug
increased	O
113%	O
per	O
year	O

5	O
mg	O
dextroamphetamine	B-Drug
sulfateObetrol	O
was	O
also	O
available	O
in	O
20	O

Similar	O
to	O
THC	O
CBD	B-Drug
has	O
poor	O
oral	O
bioavailability	O
approximately	O
6%	O

However	O
single	O
very	O
high	O
doses	O
of	O
diazepam	B-Drug
have	O
been	O
found	O
to	O
cause	O
lifelong	O
immunosuppression	O
in	O
neonatal	O
rats	O

Loperamide	B-Drug
is	O
a	O
substrate	O
of	O
P-glycoprotein;	O
therefore	O
the	O
concentration	O
loperamide	B-Drug
increases	O
when	O
given	O
with	O
P-glycoprotein	O
inhibitor	O

It	O
is	O
possible	O
that	O
venlafaxine	B-Drug
use	O
actually	O
exacerbated	O
cannabis	O
withdrawal	O
symptoms	O
leading	O
people	O
to	O
more	O
than	O
placebo	O
alleviate	O
their	O
discomfort	O

The	O
prototype	O
for	O
this	O
subgroup	O
of	O
semi-synthetic	O
opiates	O
is	O
heroin	B-Drug
and	O
the	O
group	O
also	O
includes	O
dipropanoylmorphine	B-Drug
diacetyldihydromorphine	B-Drug
disalicylmorphine	O
others	O

Ketamine	B-Drug
is	O
especially	O
useful	O
in	O
the	O
prehospital	O
setting	O
due	O
to	O
its	O
effectiveness	O
and	O
low	O
risk	O
of	O
respiratory	O
depression	O

They	O
fed	O
guinea	O
pigs	O
their	O
test	O
diet	O
of	O
grains	O
and	O
flour	O
which	O
had	O
earlier	O
produced	O
beriberi	B-Drug
in	O
pigeons	O
were	O
surprised	O
when	O
classic	O
scurvy	O
resulted	O
instead	O

This	O
act	O
put	O
taxes	O
and	O
restrictions	O
on	O
the	O
sale	O
prescription	O
of	O
opium	B-Drug
as	O
well	O
trying	O
to	O
stigmatize	O
poppy	O
its	O
derivatives	O
demon	O
drugs	O
try	O
scare	O
people	O
away	O
from	O
them	O

Following	O
chlordiazepoxide	B-Drug
diazepam	B-Drug
marketed	O
by	O
HoffmannLa	O
Roche	O
under	O
the	O
brand	O
name	O
Valium	B-Drug
in	O
1963	O
and	O
for	O
a	O
while	O
two	O
were	O
most	O
commercially	O
successful	O
drugs	O

The	O
medication	O
naltrexone	B-Drug
may	O
also	O
be	O
useful	O
to	O
prevent	O
relapse	O

Mirtazapine	B-Drug
is	O
marketed	O
under	O
many	O
brand	O
names	O
worldwide	O
including	O
Adco-Mirteron	O
Afloyan	O
Amirel	O
Arintapin	O
Smelt	O
Avanza	O
Axit	O
Azapin	O
Beron	O
Bilanz	O
Calixta	O
Ciblex	O
Combar	O
Comenter	O
Depreram	O
Divaril	O
Esprital	O
Maz	O
Menelat	O
Mepirzapine	O
Merdaten	O
Meronin	O
Mi	O
Er	O
Ning	O
Milivin	O
Minelza	O
Minivane	O
Mirastad	O
Mirazep	O
Miro	O
Miron	O
Mirrador	O
Mirt	O
Mirta	O
Mirtabene	O
Mirtadepi	O
Mirtagamma	O
Mirtagen	O
Mirtalan	O
Mirtamor	O
Mirtamylan	O
Mirtan	O
Mirtaneo	O
Mirtapax	O
Mirtapil	O
Mirtapine	O
Mirtaron	O
Mirtastad	O
Mirtax	O
Mirtaz	O
Mirtazap	O
Mirtazapin	O
Mirtazapina	O
Mirtazapinum	O
Mirtazelon	O
Mirtazon	O
Mirtazonal	O
Mirtel	O
Mirtimash	O
Mirtin	O
Mirtine	O
Mirzapine	O
Mirzaten	O
Mirzest	O
Mitaprex	O
Mitaxind	O
Mitocent	O
Mitrazin	O
Mizapin	O
Motofen	O
Mytra	O
Norset	O
Noxibel	O
Pharmataz	O
Promyrtil	O
Rapizapine	O
Ramure	O
Razapina	O
Redepra	O
Reflex	O
Remergil	O
Remergon	O
Remeron	B-Drug
Remirta	O
Rexer	O
Saxib	O
Sinmaron	O
Smilon	O
Tazepin	O
Tazimed	O
Tetrazic	O
Tifona	O
U-Mirtaron	O
U-zepine	O
Valdren	O
Vastat	O
Velorin	O
Yarocen	O
Zania	O
Zapex	O
Zestat	O
Zismirt	O
Zispin	O
Zuleptan	O
and	O
Zulin	O

Mitragynine	B-Drug
is	O
primarily	O
metabolized	O
in	O
the	O
liver	O
producing	O
many	O
metabolites	O
during	O
both	O
phase	O
I	O
and	O
II	O

Participation	O
in	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
treatment	O
reduces	O
the	O
risk	O
of	O
mortality	O
due	O
to	O
overdose	O

At	O
the	O
height	O
of	O
Cali	O
Cartel's	O
reign	O
from	O
1993-1995	O
they	O
were	O
cited	O
as	O
having	O
control	O
over	O
80%	O
world's	O
cocaine	B-Drug
market	O
and	O
said	O
to	O
be	O
directly	O
responsible	O
for	O
growth	O
in	O
Europe	O
controlling	O
there	O
well	O

Moore	O
received	O
a	O
lethal	O
injection	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious	O

Most	O
commercial	O
immunoassays	O
for	O
the	O
benzodiazepine	O
class	O
of	O
drugs	O
cross-react	O
with	O
diazepam	B-Drug
but	O
confirmation	O
and	O
quantitation	O
are	O
usually	O
performed	O
using	O
chromatographic	O
techniques	O

Warfarin	B-Drug
works	O
by	O
inhibiting	O
VKOR	O
which	O
is	O
encoded	O
the	O
VKORC1	O
gene	O

The	O
crash	O
following	O
the	O
use	O
of	O
methamphetamine	B-Drug
in	O
this	O
manner	O
is	O
very	O
often	O
severe	O
with	O
marked	O
hypersomnia	O

The	O
phenobarbital	B-Drug
is	O
followed	O
by	O
a	O
one-	O
to	O
two-week	O
taper	O
although	O
slow	O
from	O
preferred	O

In	O
September	O
2018	O
at	O
least	O
10	O
people	O
overdosed	O
on	O
a	O
synthetic	O
cannabinoid	O
either	O
AMB-FUBINACA	B-Drug
or	O
AB	O
in	O
Christchurch	O
New	O
Zealand	O
over	O
two	O
days	O

Despite	O
this	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010	O

Apalutamide	B-Drug
is	O
a	O
structural	O
analogue	O
of	O
enzalutamide	B-Drug
and	O
RD-162	O

The	O
typical	O
treatment	O
of	O
alcohol	O
withdrawal	O
is	O
with	O
benzodiazepines	O
such	O
as	O
chlordiazepoxide	B-Drug
or	O
diazepam	B-Drug

The	O
synthesis	O
of	O
cannabidiol	B-Drug
has	O
been	O
accomplished	O
by	O
several	O
research	O
groups	O

The	O
Marquis	O
Color	O
test	O
may	O
also	O
be	O
used	O
to	O
detect	O
the	O
presence	O
of	O
fentanyl	B-Drug

As	O
such	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O

As	O
the	O
dose	O
of	O
buprenorphine	B-Drug
increases	O
its	O
analgesic	O
effects	O
reach	O
a	O
plateau	O
and	O
then	O
it	O
starts	O
to	O
act	O
like	O
an	O
antagonist	O

In	O
addition	O
to	O
abiraterone	B-Drug
itself	O
part	O
of	O
the	O
activity	O
drug	O
has	O
been	O
found	O
be	O
due	O
a	O
more	O
potent	O
active	O
metabolite	O
4-abiraterone	O
D4A	O
which	O
is	O
formed	O
from	O
by	O
3-HSD	O

Diazepam	B-Drug
is	O
mainly	O
used	O
to	O
treat	O
anxiety	O
insomnia	O
panic	O
attacks	O
and	O
symptoms	O
of	O
acute	O
alcohol	O
withdrawal	O

Androstenedione	B-Drug
is	O
released	O
into	O
the	O
blood	O
by	O
theca	O
cells	O

Valproate	B-Drug
was	O
first	O
made	O
in	O
1881	O
and	O
came	O
into	O
medical	O
use	O
1962	O

The	O
metabolites	O
of	O
clonazepam	B-Drug
include	O
7-aminoclonazepam	O
7-acetaminoclonazepam	O
and	O
3-hydroxy	O

Lorazepam	B-Drug
and	O
oxazepam	B-Drug
are	O
indicated	O
in	O
patients	O
with	O
impaired	O
liver	O
function	O
because	O
they	O
metabolised	O
outside	O
of	O
the	O

In	O
Denmark	O
temazepam	B-Drug
is	O
listed	O
as	O
a	O
Class	O
D	O
substance	O
under	O
the	O
Executive	O
Order	O
698	O
of	O
1993	O
on	O
Euphoric	O
Substances	O
which	O
means	O
it	O
has	O
high	O
potential	O
for	O
abuse	O
but	O
used	O
medical	O
and	O
scientific	O
purposes	O

Clonidine	B-Drug
or	O
lofexidine	B-Drug
can	O
help	O
treat	O
the	O
symptoms	O
of	O
withdrawal	O

Piritramide	B-Drug
was	O
developed	O
and	O
patented	O
in	O
Belgium	O
at	O
Janssen	O
1960	O

In	O
early	O
1999	O
a	O
15-year-old	O
girl	O
Samantha	O
Reid	O
of	O
Rockwood	O
Michigan	O
died	O
from	O
GHB	B-Drug
poisoning	O

Examples	O
of	O
notable	O
designer	O
steroids	O
include	O
1-testosterone	B-Drug
dihydroboldenone	O
methasterone	B-Drug
trenbolone	B-Drug
enanthate	I-Drug
desoxymethyltestosterone	B-Drug
tetrahydrogestrinone	B-Drug
and	O
methylstenbolone	O

Eletriptan	B-Drug
is	O
marketed	O
and	O
manufactured	O
by	O
Pfizer	O
Inc	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds	O
reversibly	O
non-competitively	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell	O
thereby	O
inhibiting	O
depolarisation	O

As	O
a	O
-receptor	O
agonist	O
fentanyl	B-Drug
binds	O
50	O
to	O
100	O
times	O
more	O
potently	O
than	O
morphine	B-Drug

Compared	O
to	O
heroin	B-Drug
it	O
is	O
more	O
potent	O
has	O
higher	O
profit	O
margins	O
and	O
because	O
compact	O
simpler	O
logistics	O

Toradol	B-Drug
ketorolac	B-Drug
for	O
pain	O
management	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O
is	O
therefore	O
no	O
longer	O
preferred;	O
are	O
particularly	O
risky	O
they	O
lower	O
the	O
seizure	O
threshold	O
worsen	O
hyperthermia	O
boost	O
anticholinergic	O
of	O
PCP	B-Drug

In	O
2016	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day	O

General	O
side	O
effects	O
of	O
bicalutamide	B-Drug
that	O
may	O
occur	O
in	O
either	O
sex	O
include	O
diarrhea	O
constipation	O
abdominal	O
pain	O
nausea	O
dry	O
skin	O
itching	O
and	O
rash	O

Conversely	O
following	O
a	O
single	O
5	O
mg	O
dose	O
of	O
finasteride	B-Drug
mean	O
peak	O
levels	O
were	O
37	O
ng/mL	O
99	O
nmol/L	O
and	O
plasma	O
concentrations	O
increased	O
by	O
47	O
to	O
54%	O
2	O

RCS-8	B-Drug
also	O
known	O
as	O
1-2-cyclohexylethyl-3-2-methoxyphenylacetylindole	O
SR-18	O
and	O
BTM-8	O
is	O
a	O
synthetic	O
cannabinoid	O
that	O
has	O
been	O
found	O
an	O
ingredient	O
of	O
herbal	O
cannabis	O
blends	O

Following	O
oral	O
administration	O
amphetamine	B-Drug
appears	O
in	O
urine	O
within	O
3	O
hours	O

The	O
ethers	O
of	O
morphine	B-Drug
and	O
codeine	B-Drug
as	O
well	O
dihydromorphine	B-Drug
dihydrocodeine	B-Drug
number	O
close	O
to	O
100	O
include	O
such	O
obscure	O
opioids	O
formylallopseudoisocodeine	O

Exactly	O
when	O
the	O
world	O
became	O
aware	O
of	O
opium	B-Drug
in	O
India	O
and	O
China	O
is	O
uncertain	O
but	O
was	O
mentioned	O
Chinese	O
medical	O
work	O
K'ai-pao-pen-tsdo	O
973	O
AD	O
By	O
1590	O
poppies	O
were	O
a	O
staple	O
spring	O
crop	O
Subahs	O
Agra	O
region	O

Researchers	O
examined	O
84	O
trials	O
with	O
11980	O
people	O
receiving	O
ondansetron	B-Drug
published	O
between	O
1991	O
and	O
September	O
1996	O

Treatment	O
of	O
heroin	B-Drug
addiction	O
often	O
includes	O
behavioral	O
therapy	O
and	O
medications	O

The	O
codeine	B-Drug
is	O
retrieved	O
from	O
over-the-counter	O
medicine	O
and	O
then	O
mixed	O
with	O
ethanol	O
gasoline	O
red	O
phosphorus	O
iodine	O
hydrochloric	O
acid	O
paint	O
thinner	O

Nalmefene	O
is	O
a	O
derivative	O
of	O
naltrexone	B-Drug
and	O
was	O
first	O
reported	O
in	O
1975	O

Side	O
effects	O
of	O
stanozolol	B-Drug
include	O
virilization	O
masculinization	O
hepatotoxicity	O
cardiovascular	O
disease	O
and	O
hypertension	O

Acetylfentanyl	B-Drug
was	O
discovered	O
at	O
the	O
same	O
time	O
as	O
fentanyl	B-Drug
itself	O
and	O
had	O
only	O
rarely	O
been	O
encountered	O
on	O
illicit	O
market	O
in	O
late	O
1980s	O

MDAL	O
produces	O
few	O
to	O
no	O
effects	O
on	O
its	O
own	O
but	O
may	O
enhance	O
the	O
of	O
LSD	B-Drug

The	O
deduced	O
structure	O
of	O
the	O
active	O
nonapeptide	O
is:	O
Cys	O
Tyr	O
Ile	O
Gln	B-Drug
Asn	O
Pro	O
Leu	O
Gly	O
NH2	O
or	O
CYIQNCPLG-NH2	O

Carisoprodol	B-Drug
withdrawal	O
can	O
be	O
life-threatening	O
especially	O
in	O
high	O
dose	O
users	O
and	O
those	O
who	O
attempt	O
to	O
quit	O
cold	O
turkey	O

Cocaine	B-Drug
heroin	B-Drug
cannabis	O
and	O
other	O
such	O
drugs	O
continued	O
to	O
be	O
legally	O
available	O
without	O
prescription	O
as	O
long	O
they	O
were	O
labeled	O

Between	O
the	O
1970s	O
and	O
mid-1980s	O
this	O
network	O
of	O
MDMA	B-Drug
users	O
consumed	O
an	O
estimated	O
500000	O
doses	O

Vicodin	B-Drug
generically	O
known	O
as	O
hydrocodone	B-Drug
via	O
the	O
Internet	O
without	O
a	O
prescription	O
issued	O
by	O
doctor/practitioner	O
who	O
has	O
an	O
established	O
doctor-patient	O
relationship	O

The	O
Thai	O
government	O
had	O
passed	O
the	O
Kratom	B-Drug
Act	O
2486	O
effective	O
3	O
August	O
1943	O
which	O
made	O
planting	O
tree	O
illegal	O
in	O
response	O
to	O
a	O
rise	O
its	O
use	O
when	O
opium	B-Drug
became	O
very	O
expensive	O
Thailand	O
and	O
was	O
attempting	O
gain	O
control	O
of	O
market	O

Drinking	O
alcohol	O
when	O
taking	O
ibuprofen	B-Drug
may	O
increase	O
the	O
risk	O
of	O
stomach	O
bleeding	O

The	O
released	O
serotonin	O
binds	O
to	O
various	O
receptors	O
and	O
activates	O
them	O
in	O
excess	O
which	O
is	O
the	O
primary	O
mechanism	O
through	O
MDMA	B-Drug
causes	O
intoxication	O

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy	O

The	O
1908	O
drug	O
law	O
created	O
a	O
black	O
market	O
for	O
opium	B-Drug
and	O
enforcement	O
officials	O
believed	O
that	O
the	O
only	O
way	O
to	O
stop	O
this	O
was	O
through	O
imprisonment	O
offenders	O
so	O
Opium	B-Drug
Drugs	O
Act	O
1911	O
passed	O
by	O
Parliament	O

Further	O
research	O
is	O
therefore	O
needed	O
to	O
compare	O
nalbuphine	B-Drug
with	O
other	O
postoperative	O
opioids	O

The	O
Dutch	O
British	O
and	O
French	O
system	O
called	O
the	O
System	O
of	O
Objectified	O
Judgement	O
Analysis	O
for	O
assessing	O
whether	O
drugs	O
should	O
be	O
included	O
in	O
drug	O
formularies	O
based	O
on	O
clinical	O
efficacy	O
adverse	O
effects	O
pharmacokinetic	O
properties	O
toxicity	O
interactions	O
was	O
used	O
to	O
assess	O
nitrazepam	B-Drug

Additionally	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014	O

Initial	O
studies	O
estimated	O
that	O
it	O
was	O
around	O
10000	O
times	O
the	O
strength	O
of	O
morphine	B-Drug
in	O
animal	O
models	O

Diazepam	B-Drug
gel	O
was	O
better	O
than	O
placebo	O
in	O
reducing	O
the	O
risk	O
of	O
non-cessation	O
seizures	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

25I-NBOMe	B-Drug
has	O
been	O
implicated	O
in	O
multiple	O
deaths	O
Australia	O

The	O
power	O
of	O
the	O
Colombian	O
drug	O
barons	O
took	O
off	O
in	O
1970s	O
fueled	O
by	O
a	O
massive	O
demand	O
for	O
cocaine	B-Drug
United	O
States	O
and	O
Europe	O

The	O
onset	O
of	O
heroin's	O
effects	O
depends	O
upon	O
the	O
route	O
administration	O
heroin	B-Drug

Androstanedione	O
is	O
a	O
5-reduced	O
metabolite	O
of	O
4-androstenedione	B-Drug
which	O
serves	O
as	O
an	O
intermediate	O
in	O
the	O
biosynthesis	O
androgen	O
and	O
neurosteroid	O
androsterone	O

The	O
typical	O
intravenous	O
antidepressant	O
dosage	O
of	O
ketamine	B-Drug
used	O
to	O
treat	O
depression	O
is	O
low	O
and	O
results	O
in	O
maximal	O
plasma	O
concentrations	O
70	O
200	O
ng/mL	O
0	O

The	O
opposite	O
is	O
true	O
of	O
CYP3A4	O
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
itraconazole	B-Drug
and	O
clarithromycin:	O
they	O
might	O
increase	O
etonogestrel	B-Drug
concentrations	O
in	O
the	O
body	O

A	O
subsequent	O
PET	O
scan	O
following	O
a	O
three	O
day	O
cocaine	B-Drug
binge	O
showed	O
decrease	O
in	O
KOR	O
availability	O
interpreted	O
as	O
increased	O
endogenous	O
dynorphin	O
competing	O
with	O
the	O
radioligand	O
at	O
binding	O
sites	O

An	O
adhesive	O
transdermal	O
patch	O
containing	O
a	O
5%	O
concentration	O
of	O
lidocaine	B-Drug
in	O
hydrogel	O
bandage	O
is	O
approved	O
by	O
the	O
US	O
FDA	O
for	O
reducing	O
nerve	O
pain	O
caused	O
shingles	O

The	O
film	O
explores	O
the	O
rise	O
of	O
cocaine	B-Drug
and	O
Miami	O
Drug	O
War	O
resulting	O
crime	O
epidemic	O
that	O
swept	O
American	O
city	O
Florida	O
in	O
1970s	O
1980s	O

Naltrexone	B-Drug
should	O
not	O
be	O
started	O
until	O
several	O
typically	O
7-10	O
days	O
of	O
abstinence	O
from	O
opioids	O
have	O
been	O
achieved	O

Metoclopramide	B-Drug
is	O
excreted	O
into	O
milk	O

Pentobarbital	B-Drug
was	O
widely	O
abused	O
and	O
known	O
on	O
the	O
streets	O
as	O
yellow	O
jackets	O
due	O
to	O
capsule	O
of	O
Nembutal	B-Drug
brand	O

Unlike	O
muscimol	O
the	O
principal	O
psychoactive	O
constituent	O
of	O
Amanita	O
muscaria	O
that	O
is	O
understood	O
to	O
cause	O
sedation	O
and	O
delirium	O
ibotenic	O
acid's	O
effects	O
are	O
not	O
known	O
independent	O
its	O
serving	O
as	O
a	O
prodrug	O
however	O
it	O
may	O
be	O
speculated	O
would	O
act	O
stimulant	O
acid	B-Drug

In	O
2013	O
cocaine	B-Drug
use	O
directly	O
resulted	O
in	O
4300	O
deaths	O
up	O
from	O
2400	O
1990	O

1P-ETH-LAD	O
1-propionyl-6-ethyl-6-nor-lysergic	O
acid	B-Drug
diethyamide	O
is	O
an	O
analog	O
of	O
LSD	B-Drug

The	O
waiver	O
which	O
can	O
be	O
granted	O
after	O
the	O
completion	O
of	O
an	O
eight-hour	O
course	O
is	O
required	O
for	O
outpatient	O
treatment	O
opioid	O
addiction	O
with	O
buprenorphine	B-Drug

Racetams	O
such	O
as	O
piracetam	B-Drug
oxiracetam	B-Drug
phenylpiracetam	B-Drug
and	O
aniracetam	O
are	O
often	O
marketed	O
cognitive	O
enhancers	O
sold	O
over-the-counter	O

Diluted	O
tincture	O
of	O
opium	B-Drug
also	O
known	O
as	O
Camphorated	O
Tincture	O
Opium	B-Drug
Paregoric	O
is	O
a	O
1:25	O
mixture	O
to	O
water	O
prescribed	O
treat	O
withdrawal	O
symptoms	O
in	O
newborns	O
whose	O
mothers	O
were	O
using	O
opioids	O
while	O
pregnant	O

Amino	O
acids	O
such	O
as	O
D-Ala	O
and	O
butenyl-methyl-L-threonine	O
Bmt	O
indicate	O
cyclosporin	B-Drug
synthetase	O
requires	O
the	O
action	O
of	O
other	O
enzymes	O

2	O
2004	O
cocaine	B-Drug
Kill	O
Your	O
Darlings	O
2013	O
marijuana	O
nitrous	O
oxide	O
benzedrine	B-Drug
and	O
methamphetamine	B-Drug
Killer	O
Bud	O
2001	O
Killing	O
Zoe	O
1994	O
heroin	B-Drug
King	O
of	O
New	O
York	O
1990	O
Kinjite:	O
Forbidden	O
Subjects	O
1989	O
Kiss	O
the	O
Dragon	O
Knocked	O
Up	O
2007	O
psychedelic	O
mushrooms	O
Kush	O
L	O

It	O
is	O
also	O
used	O
in	O
depression	O
that	O
not	O
responsive	O
to	O
reuptake	O
inhibitor	O
antidepressants	O
such	O
as	O
the	O
SSRIs	O
TCAs	O
or	O
bupropion	B-Drug

The	O
short	O
term	O
effects	O
of	O
cannabis	O
can	O
be	O
altered	O
if	O
it	O
has	O
been	O
laced	O
with	O
opioid	O
drugs	O
such	O
as	O
heroin	B-Drug
or	O
fentanyl	B-Drug

People	O
with	O
cancer	O
undergoing	O
chemotherapy	O
are	O
often	O
given	O
dexamethasone	B-Drug
to	O
counteract	O
certain	O
side	O
effects	O
of	O
their	O
antitumor	O
treatments	O

Dutasteride	B-Drug
is	O
used	O
for	O
treating	O
benign	O
prostatic	O
hyperplasia	O
BPH;	O
colloquially	O
known	O
as	O
an	O
enlarged	O
prostate	O

Unlike	O
other	O
members	O
of	O
the	O
2C	O
family	O
2C-G	O
is	O
nearly	O
as	O
potent	O
its	O
amphetamine	B-Drug
cousin	O

Fludrocortisone	B-Drug
was	O
also	O
the	O
first	O
fluorine-containing	O
pharmaceutical	O
drug	O
to	O
be	O
marketed	O

Like	O
its	O
close	O
relatives	O
DMT	O
and	O
bufotenin	B-Drug
5-HO-DMT	B-Drug
it	O
has	O
been	O
used	O
as	O
an	O
entheogen	O
in	O
South	O
America	O

Cephalon	O
began	O
to	O
market	O
armodafinil	B-Drug
the	O
R-enantiomer	O
of	O
modafinil	B-Drug
in	O
United	O
States	O
2007	O

Set	O
in	O
1992	O
the	O
film	O
is	O
largely	O
narrated	O
by	O
Cosby	O
a	O
small-time	O
cocaine	B-Drug
dealer	O
from	O
broken	O
home	O
located	O
Oakland's	O
inner-city	O

The	O
first	O
death	O
reported	O
to	O
be	O
caused	O
by	O
mephedrone	B-Drug
use	O
was	O
that	O
of	O
46-year-old	O
John	O
Sterling	O
Smith	O
who	O
had	O
underlying	O
health	O
problems	O
and	O
repeatedly	O
injected	O
the	O
drug	O

Syrup	O
Depakene	B-Drug
by	O
Abbott	O
Laboratories	O
its	O
generic	O
formulations	O
include	O
Apo-Valproic	O
and	O
ratio-Valproic	O

Imipramine	B-Drug
is	O
the	O
English	O
and	O
French	O
generic	O
name	O
of	O
drug	O
its	O
INN	O
BAN	O
DCF	O
while	O
imipramine	B-Drug
hydrochloride	O
USAN	O
USP	O
BANM	O
JAN	O

Peak	O
concentrations	O
of	O
etonogestrel	B-Drug
occur	O
about	O
1	O

For	O
women	O
who	O
have	O
had	O
intrathecal	O
opioids	O
there	O
should	O
be	O
a	O
minimum	O
hourly	O
observation	O
of	O
respiratory	O
rate	O
sedation	O
and	O
pain	O
scores	O
for	O
at	O
least	O
12	O
hours	O
diamorphine	B-Drug
24	O
morphine	B-Drug

The	O
opium	B-Drug
industry	O
shifted	O
from	O
Pakistan	O
into	O
Afghanistan	O
during	O
the	O
1980s	O

Clenbuterol	B-Drug
is	O
prescribed	O
for	O
treatment	O
of	O
respiratory	O
diseases	O
horses	O
and	O
as	O
an	O
obstetrical	O
aid	O
in	O
cattle	O

Octreotide	B-Drug
has	O
not	O
been	O
adequately	O
studied	O
for	O
the	O
treatment	O
of	O
children	O
as	O
well	O
pregnant	O
and	O
lactating	O
women	O

Other	O
drugs	O
including	O
the	O
benzodiazepines	O
and	O
zolpidem	B-Drug
are	O
also	O
found	O
in	O
high	O
numbers	O
of	O
suspected	O
drugged	O
drivers	O

Death	O
also	O
known	O
as	O
4-methoxyamphetamine	B-Drug
4-MA	O
is	O
a	O
designer	O
drug	O
of	O
the	O
amphetamine	B-Drug
class	O
with	O
serotonergic	O
effects	O

Opium	B-Drug
is	O
mentioned	O
in	O
the	O
most	O
important	O
medical	O
texts	O
of	O
ancient	O
world	O
including	O
Ebers	O
Papyrus	O
and	O
writings	O
Dioscorides	O
Galen	O
Avicenna	O

Because	O
cocaine	B-Drug
is	O
hydrolyzed	O
and	O
rendered	O
inactive	O
in	O
the	O
acidic	O
stomach	O
it	O
not	O
readily	O
absorbed	O
when	O
ingested	O
alone	O

Diamorphine	B-Drug
is	O
used	O
medically	O
in	O
several	O
countries	O
to	O
relieve	O
pain	O
such	O
as	O
during	O
childbirth	O
or	O
a	O
heart	O
attack	O
well	O
opioid	O
replacement	O
therapy	O

The	O
ergoline	O
antimigraine	O
agent	O
ergotamine	B-Drug
also	O
acts	O
on	O
this	O
receptor	O

Between	O
2005	O
and	O
2012	O
the	O
number	O
of	O
people	O
who	O
used	O
heroin	B-Drug
almost	O
doubled	O
from	O
380000	O
to	O
670000	O
in	O
2010	O
there	O
were	O
a	O
total	O
2789	O
fatal	O
overdoses	O
an	O
50%	O
increase	O
years	O
prior	O

The	O
higher	O
relative	O
price	O
of	O
cannabis	O
compared	O
to	O
the	O
rest	O
world	O
remains	O
most	O
likely	O
explanation	O
for	O
mixing	O
with	O
tobacco	B-Drug
although	O
many	O
users	O
do	O
this	O
purely	O
ensure	O
joint	O
smokes	O
correctly	O
and	O
prevent	O
it	O
from	O
going	O
out	O

lamotrigine	B-Drug

Metoclopramide	B-Drug
is	O
commonly	O
used	O
to	O
treat	O
nausea	O
and	O
vomiting	O
associated	O
with	O
conditions	O
such	O
as	O
uremia	O
radiation	O
sickness	O
cancer	O
the	O
effects	O
of	O
chemotherapy	O
labor	O
infection	O
emetogenic	O
drugs	O

It	O
binds	O
more	O
strongly	O
than	O
other	O
drugs	O
so	O
that	O
when	O
someone	O
is	O
overdosing	O
on	O
opioids	O
naloxone	B-Drug
can	O
be	O
administered	O
allowing	O
it	O
to	O
take	O
the	O
place	O
of	O
opioid	O
drug	O
in	O
person's	O
receptors	O
turning	O
them	O
off	O

No	O
further	O
increase	O
in	O
exposure	O
to	O
darolutamide	B-Drug
was	O
observed	O
at	O
a	O
dosage	O
of	O
900	O
mg	O
twice	O
per	O
day	O
or	O
1	O

Ibogaine	B-Drug
is	O
also	O
a	O
KOR	O
agonist	O
and	O
this	O
property	O
may	O
contribute	O
to	O
the	O
drug's	O
anti-addictive	O
efficacy	O

Surveys	O
in	O
many	O
countries	O
show	O
that	O
temazepam	B-Drug
MDMA	B-Drug
nimetazepam	B-Drug
and	O
methamphetamine	B-Drug
rank	O
among	O
the	O
top	O
illegal	O
drugs	O
most	O
frequently	O
abused	O

mescaline	B-Drug
2C-B	B-Drug
25I-NBOMe	B-Drug
and	O
amphetamines	B-Drug
e	O

One	O
clinical	O
study	O
of	O
14	O
samples	O
the	O
material	O
collected	O
at	O
various	O
geographical	O
locations	O
in	O
South	O
Africa	O
tested	O
for	O
its	O
affinity	O
GABA-benzodiazepine	O
receptor	O
a	O
neurologic	O
site	O
that	O
is	O
effective	O
treatment	O
seizures	O
with	O
benzodiazapines	O
such	O
as	O
diazepam	B-Drug
and	O
lorazepam	B-Drug
western	O
medicine	O

Analogously	O
to	O
nandrolone	B-Drug
and	O
its	O
5-reduced	O
metabolite	O
5-dihydronandrolone	O
5-DHNMT	O
shows	O
reduced	O
affinity	O
for	O
the	O
androgen	O
receptor	O
relative	O
normethandrone	O

Australia	O
In	O
dihydrocodeine	B-Drug
is	O
a	O
'pharmacist	O
only'	O
Schedule	O
3	O
drug	O
only	O
when	O
indicated	O
for	O
cough	O
suppression	O
and	O
compounded	O
with	O
one	O
or	O
more	O
other	O
therapeutically	O
active	O
substances	O
not	O
exceeding	O
15	O
mg	O
per	O
dose	O

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O

It	O
is	O
considered	O
an	O
oxidized	O
derivative	O
of	O
mitragynine	B-Drug

While	O
loop	O
diuretics	O
remain	O
first-line	O
for	O
most	O
people	O
with	O
heart	O
failure	O
spironolactone	B-Drug
has	O
shown	O
to	O
reduce	O
both	O
morbidity	O
and	O
mortality	O
in	O
numerous	O
studies	O
remains	O
an	O
important	O
agent	O
treating	O
fluid	O
retention	O
edema	O
symptoms	O
of	O

It	O
is	O
the	O
C17	O
butanoate	O
ester	O
of	O
levonorgestrel	B-Drug
and	O
acts	O
as	O
a	O
prodrug	O
in	O
body	O

In	O
addition	O
to	O
seizures	O
other	O
potentially	O
GABAA	O
receptor-related	O
side	O
effects	O
observed	O
with	O
enzalutamide	B-Drug
treatment	O
in	O
clinical	O
trials	O
have	O
included	O
anxiety	O
insomnia	O
vertigo	O
paresthesia	O
and	O
headache	O

BU-LAD	B-Drug
is	O
a	O
psychedelic	O
drug	O
similar	O
to	O
LSD	B-Drug
but	O
significantly	O
less	O
potent	O
than	O
with	O
dose	O
of	O
500	O
micrograms	O
producing	O
only	O
mild	O
effects	O

Difenoxin	B-Drug
with	O
atropine	O
Motofen	O
has	O
been	O
moved	O
to	O
Schedule	O
IV	O

In	O
The	O
Hallucinogens	O
by	O
Hoffer	O
and	O
Osmond	O
1967	O
ALD-52	O
is	O
listed	O
as	O
having	O
a	O
lower	O
approximately	O
1/5	O
intravenous	O
toxicity	O
in	O
rabbits	O
1/8	O
pyretogenic	O
effect	O
an	O
equal	O
psychological	O
humans	O
double	O
the	O
antiserotonin	O
compared	O
with	O
LSD	B-Drug

JWH-198	B-Drug
is	O
a	O
drug	O
from	O
the	O
aminoalkylindole	O
and	O
naphthoylindole	O
families	O
which	O
acts	O
as	O
cannabinoid	O
receptor	O
agonist	O

Like	O
other	O
progestins	O
with	O
antiandrogenic	O
activity	O
such	O
as	O
CPA	O
megestrol	O
acetate	O
and	O
spironolactone	B-Drug
but	O
unlike	O
nonsteroidal	O
antiandrogens	O
flutamide	O
bicalutamide	B-Drug
CMA	O
is	O
not	O
a	O
silent	O
antagonist	O
of	O
the	O
AR	O
rather	O
weak	O
partial	O
agonist	O
capacity	O
to	O
activate	O
receptor	O
in	O
absence	O
more	O
efficacious	O
agonists	O
testosterone	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
as	O
heroin	B-Drug
or	O
oxycodone	B-Drug
leading	O
to	O
overdoses	O

Fludrocortisone	B-Drug
is	O
the	O
generic	O
name	O
of	O
fludrocortisone	B-Drug
and	O
its	O
INN	O
USAN	O
BAN	O
DCF	O
DCIT	O
whereas	O
acetate	I-Drug
USP	O
BANM	O
JAN	O

The	O
maintenance	O
therapy	O
with	O
ketamine	B-Drug
from	O
twice	O
a	O
week	O
to	O
once	O
in	O
two	O
weeks	O
appears	O
be	O
promising	O
option	O
although	O
the	O
evidence	O
firmly	O
recommend	O
it	O
is	O
insufficient	O

Amphetamines	O
like	O
MDMA	B-Drug
MDEA	O
MDA	O
and	O
MBDB	O
among	O
other	O
relatives	O
see	O
MDxx	O
are	O
recreational	O
drugs	O
termed	O
entactogens	O

Afghanistan's	O
rugged	O
terrain	O
encourages	O
local	O
autonomy	O
which	O
in	O
some	O
cases	O
means	O
leadership	O
committed	O
to	O
an	O
opium	B-Drug
economy	O

In	O
2014	O
a	O
Pew	O
Research	O
Center	O
poll	O
found	O
that	O
67	O
percent	O
of	O
Americans	O
feel	O
movement	O
towards	O
treatment	O
for	O
drugs	O
like	O
cocaine	B-Drug
and	O
heroin	B-Drug
is	O
better	O
versus	O
the	O
26	O
who	O
prosecution	O
route	O

Canada	O
criminalized	O
cannabis	O
in	O
The	O
Opium	B-Drug
and	O
Narcotic	O
Drug	O
Act	O
1923	O
before	O
any	O
reports	O
of	O
the	O
use	O
drug	O
but	O
eventually	O
legalized	O
its	O
consumption	O
for	O
recreational	O
medicinal	O
purposes	O
2018	O

Nabilone	B-Drug
is	O
another	O
cannabinoid	O
drug	O
that	O
has	O
been	O
approved	O
by	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
MHRA	O
but	O
a	O
synthetic	O
form	O
of	O
THC	O
not	O
naturally	O
derived	O
from	O
plant	O

Milnacipran	B-Drug
is	O
structurally	O
different	O
from	O
other	O
SNRIs	O

In	O
a	O
study	O
of	O
cocaine	B-Drug
users	O
the	O
average	O
time	O
taken	O
to	O
reach	O
peak	O
subjective	O
effects	O
was	O
14	O

Additionally	O
because	O
cocaine	B-Drug
is	O
a	O
vasoconstrictor	O
and	O
usage	O
often	O
entails	O
multiple	O
injections	O
within	O
several	O
hours	O
or	O
less	O
subsequent	O
are	O
progressively	O
more	O
difficult	O
to	O
administer	O
which	O
in	O
turn	O
may	O
lead	O
injection	O
attempts	O
consequences	O
from	O
improperly	O
performed	O

Nabumetone	O
Paracetamol	B-Drug
acetaminophen	B-Drug
Metamizole	O
banned	O
in	O
over	O
30	O
countries	O
for	O
causing	O
agranulocytosis	O
The	O
U	O

When	O
fentanyl	B-Drug
binds	O
downstream	O
signaling	O
leads	O
to	O
the	O
inhibitory	O
effects	O
such	O
as	O
decreased	O
cAMP	O
production	O
calcium	O
ion	O
influx	O
and	O
increased	O
potassium	O
efflux	O

Shulgin	O
may	O
have	O
suspected	O
he	O
played	O
a	O
role	O
in	O
the	O
emergence	O
of	O
MDMA	B-Drug
Chicago	O

Paul	O
Halverson	O
director	O
and	O
state	O
health	O
officer	O
for	O
the	O
Arkansas	O
Department	O
of	O
Health	O
approved	O
an	O
emergency	O
rule	O
to	O
ban	O
sale	O
distribution	O
phenazepam	B-Drug
shortly	O
after	O
Louisiana	O

With	O
respect	O
to	O
equianalgesic	O
dosing	O
when	O
used	O
sublingually	O
the	O
potency	O
of	O
buprenorphine	B-Drug
is	O
about	O
40	O
70	O
times	O
that	O
morphine	B-Drug

It	O
can	O
increase	O
the	O
risk	O
for	O
adverse	O
effects	O
of	O
methotrexate	B-Drug
and	O
lithium	O
by	O
lowering	O
their	O
excretion	O
via	O
kidneys	O

Oxymesterone	O
INN	O
BAN	O
brand	O
names	O
Anamidol	O
Balnimax	O
Oranabol	O
Sanaboral	O
Theranabol	O
Tubil	O
also	O
known	O
as	O
methandrostenediolone	O
well	O
4-hydroxy-17-methyltestosterone	O
or	O
17-methylandrost-4-en-417-diol-3-one	O
is	O
an	O
orally	O
active	O
anabolic-androgenic	O
steroid	O
AAS	O
methyltestosterone	B-Drug

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines	O

Clomifene	B-Drug
is	O
a	O
prodrug	O
most	O
importantly	O
of	O
4-hydroxyclomifene	O
and	O
4-hydroxy-N-desmethylclomifene	O
which	O
are	O
the	O
active	O
its	O
metabolites	O

Combination	O
of	O
alprazolam	B-Drug
with	O
the	O
herb	O
kava	O
can	O
result	O
in	O
development	O
a	O
semi-comatose	O
state	O

Ross	O
used	O
his	O
profit	O
to	O
purchase	O
more	O
cocaine	B-Drug
sell	O
expanding	O
small	O
operation	O

In	O
2019/2020	O
record	O
overdoses	O
from	O
illicit	O
Fentanyl	B-Drug
tablets	O
or	O
as	O
a	O
deadly	O
adulterant	O
in	O
heroin	B-Drug
have	O
ravaged	O
North	O
America	O

The	O
pharmacokinetics	O
of	O
zopiclone	B-Drug
are	O
altered	O
by	O
aging	O
and	O
influenced	O
renal	O
hepatic	O
functions	O

UR-144	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic	O

Szra	O
who	O
later	O
worked	O
for	O
the	O
US	O
National	O
Institutes	O
of	O
Health	O
had	O
turned	O
his	O
attention	O
to	O
DMT	O
after	O
order	O
LSD	B-Drug
from	O
Swiss	O
company	O
Sandoz	O
Laboratories	O
was	O
rejected	O
on	O
grounds	O
that	O
powerful	O
psychotropic	O
could	O
be	O
dangerous	O
in	O
hands	O
a	O
communist	O
country	O

Tolerance	O
to	O
benzodiazepines	O
can	O
be	O
demonstrated	O
by	O
injecting	O
diazepam	B-Drug
into	O
long-term	O
users	O

In	O
March	O
2012	O
a	O
man	O
in	O
Australia	O
died	O
from	O
injuries	O
sustained	O
by	O
running	O
into	O
trees	O
and	O
power	O
poles	O
while	O
intoxicated	O
25I-NBOMe	B-Drug

These	O
adverse	O
effects	O
completely	O
resolved	O
in	O
all	O
cases	O
when	O
the	O
men	O
were	O
switched	O
from	O
cimetidine	B-Drug
to	O
ranitidine	B-Drug

In	O
the	O
United	O
States	O
it	O
is	O
still	O
used	O
as	O
an	O
adulterant	O
in	O
ecstasy	B-Drug
mimic	O
tablets	O

Coca	B-Drug
leaf	I-Drug
cocaine	B-Drug
and	O
ecgonine:	O
coca	B-Drug
the	O
of	O
bush	O
plant	O
material	O
except	O
a	O
from	O
which	O
all	O
ecgonine	O
any	O
other	O
alkaloids	O
have	O
been	O
removed	O
methyl	O
ester	O
benzoylecgonine	O
an	O
alkaloid	O
found	O
in	O
leaves	O
or	O
prepared	O
by	O
synthesis	O
its	O
esters	O
derivatives	O
are	O
convertible	O
to	O
cocaineNatural	O
opioids	O
sources:	O
opium	O
coagulated	O
juice	O
poppy	O
species	O
Papaver	O
somniferum	O
L	O

Its	O
principal	O
active	O
metabolites	O
are	O
chlordesmethyldiazepam	O
also	O
known	O
as	O
chloronordiazepam	O
or	O
delorazepam	B-Drug
trade	O
name	O
Dadumir	O
and	O
chloroxazepam	O
lorazepam	B-Drug
Ativan	B-Drug

Barbiturates	O
like	O
phenobarbital	B-Drug
bind	O
domains	O
and	O
increase	O
the	O
duration	O
of	O
each	O
opening	O
but	O
not	O
frequency	O

MDMA	B-Drug
is	O
illegal	O
in	O
most	O
countries	O
and	O
as	O
of	O
2018	O
has	O
no	O
approved	O
medical	O
uses	O

Sublingual	O
fentanyl	B-Drug
dissolves	O
quickly	O
and	O
is	O
absorbed	O
through	O
the	O
sublingual	O
mucosa	O
to	O
provide	O
rapid	O
analgesia	O

Cannabidiol	B-Drug
CBD	B-Drug
is	O
another	O
major	O
constituent	O
of	O
the	O
plant	O

Unlike	O
other	O
third-generation	O
progestins	O
like	O
desogestrel	B-Drug
and	O
norgestimate	B-Drug
gestodene	O
is	O
not	O
a	O
prodrug	O

Withdrawal	O
of	O
methamphetamine	B-Drug
in	O
dependent	O
persons	O
may	O
lead	O
to	O
post-acute	O
withdrawal	O
which	O
persists	O
months	O
beyond	O
the	O
typical	O
period	O

Abbott	O
discontinued	O
their	O
Nembutal	B-Drug
brand	O
of	O
Pentobarbital	B-Drug
capsules	O
in	O
1999	O
largely	O
replaced	O
by	O
the	O
Benzodiazepine	O
family	O
drugs	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds	O
reversibly	O
non-competitively	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell	O
thereby	O
inhibiting	O
depolarisation	O

Oral	O
anticoagulants	O
blood	O
thinners	O
lithium	O
captopril	O
triamterene	B-Drug
and	O
antihypertensives	O
may	O
also	O
interact	O
with	O
metamizole	O
as	O
other	O
pyrazolones	O
are	O
known	O
to	O
adversely	O
these	O
substances	O

Other	O
observations	O
include	O
possible	O
increased	O
risk	O
from	O
each	O
cigarette;	O
lack	O
of	O
research	O
on	O
the	O
effect	O
cannabis	O
smoke	O
alone;	O
low	O
rate	O
addiction	O
compared	O
to	O
tobacco;	O
and	O
episodic	O
nature	O
use	O
steady	O
frequent	O
smoking	O
tobacco	B-Drug

Given	O
that	O
a	O
chest	O
of	O
opium	B-Drug
was	O
worth	O
nearly	O
US$1000	O
in	O
1800	O
this	O
substantial	O
economic	O
loss	O

Around	O
1970	O
Shulgin	O
sent	O
instructions	O
for	O
N-methylated	O
MDA	O
MDMA	B-Drug
synthesis	O
to	O
the	O
founder	O
of	O
a	O
Los	O
Angeles	O
chemical	O
company	O
who	O
had	O
requested	O
them	O

It	O
is	O
transformed	O
into	O
androstenedione	B-Drug
by	O
3-hydroxysteroid	O
dehydrogenase	O
3-HSD	O
and	O
androstenediol	O
17-hydroxysteroid	O
17-HSD	O

The	O
half-life	O
of	O
medazepam	B-Drug
is	O
36200	O
hours	O

Weber	O
described	O
various	O
ways	O
carfentanil	B-Drug
could	O
be	O
used	O
as	O
a	O
weapon	O
such	O
knocking	O
troops	O
out	O
and	O
taking	O
them	O
hostage	O
or	O
killing	O
civilians	O
in	O
enclosed	O
spaces	O
railway	O
stations	O

O-Acetylpsilocin	B-Drug
can	O
be	O
obtained	O
by	O
acetylation	O
of	O
psilocin	B-Drug
under	O
alkaline	O
or	O
strongly	O
acidic	O
conditions	O

Fluoxymesterone	B-Drug
has	O
an	O
elimination	O
half-life	O
of	O
approximately	O
9	O

19-Nor-DHEA	O
may	O
occur	O
as	O
a	O
metabolite	O
of	O
bolandione	B-Drug
and	O
related	O
steroids	O

As	O
azo-compounds	O
are	O
highly	O
coloured	O
they	O
widely	O
used	O
in	O
dyeing	O
industries	O
such	O
as:	O
Methyl	O
orange	O
Direct	O
brown	O
138	O
Sunset	O
yellow	O
FCF	O
Ponceau	O
Many	O
drugs	O
designed	O
to	O
mimic	O
or	O
interfere	O
with	O
the	O
action	O
of	O
natural	O
amine	O
neurotransmitters	O
exemplified	O
by	O
drugs:	O
Chlorpheniramine	B-Drug
is	O
an	O
antihistamine	O
that	O
helps	O
relieve	O
allergic	O
disorders	O
due	O
cold	O
hay	O
fever	O
itchy	O
skin	O
insect	O
bites	O
and	O
stings	O

Agranulocytosis	O
occurs	O
rarely	O
when	O
dapsone	B-Drug
is	O
used	O
alone	O
but	O
more	O
frequently	O
in	O
combination	O
regimens	O
for	O
malaria	O
prophylaxis	O

Fentanyl	B-Drug
is	O
sometimes	O
given	O
intrathecally	O
as	O
part	O
of	O
spinal	O
anesthesia	O
or	O
epidurally	O
for	O
epidural	O
anaesthesia	O
and	O
analgesia	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
including	O
opioids	O
alcohol	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances	O

The	O
relationship	O
between	O
ergot	O
and	O
ergotism	O
was	O
established	O
only	O
in	O
1717	O
the	O
alkaloid	O
ergotamine	B-Drug
one	O
of	O
main	O
active	O
ingredients	O
isolated	O
1918	O

The	O
antidote	O
for	O
an	O
overdose	O
of	O
diazepam	B-Drug
or	O
any	O
other	O
benzodiazepine	O
is	O
flumazenil	B-Drug
Anexate	O

The	O
law	O
allows	O
only	O
physicians	O
dentists	O
and	O
veterinarians	O
to	O
prescribe	O
oxycodone	B-Drug
the	O
federal	O
government	O
regulate	O
prescriptions	O
e	O

Several	O
physicians	O
including	O
John	O
Jones	O
Brown	O
and	O
George	O
Young	O
the	O
last	O
of	O
whom	O
published	O
a	O
comprehensive	O
medical	O
text	O
entitled	O
Treatise	O
on	O
Opium	B-Drug
extolled	O
virtues	O
laudanum	B-Drug
recommended	O
drug	O
for	O
practically	O
every	O
ailment	O

Methasterone	B-Drug
is	O
hepatotoxic	O
toxic	O
to	O
the	O
liver	O

Loperamide	B-Drug
metabolizes	O
into	O
an	O
MPTP-like	O
compound	O
but	O
is	O
unlikely	O
to	O
exert	O
neurotoxicity	O

It	O
is	O
similar	O
in	O
structure	O
to	O
the	O
other	O
psychedelics	O
of	O
tryptamine	O
class	O
such	O
as	O
dimethyltryptamine	B-Drug
DMT	O
and	O
-methyltryptamine	O
-MT	O

With	O
long-term	O
benzodiazepine	O
use	O
it	O
is	O
unclear	O
whether	O
cognitive	O
impairments	O
fully	O
return	O
to	O
normal	O
after	O
stopping	O
lorazepam	B-Drug
use;	O
deficits	O
persist	O
for	O
at	O
least	O
six	O
months	O
withdrawal	O
but	O
longer	O
than	O
may	O
be	O
required	O
recovery	O
of	O
function	O

The	O
report	O
published	O
by	O
the	O
committee	O
noted	O
that	O
while	O
methadone	B-Drug
was	O
potentially	O
addictive	O
it	O
produced	O
less	O
sedation	O
and	O
respiratory	O
depression	O
than	O
morphine	B-Drug
thus	O
interesting	O
as	O
a	O
commercial	O
drug	O

The	O
treatment	O
of	O
overdose	O
is	O
mostly	O
supportive	O
as	O
no	O
specific	O
antidote	O
for	O
amitriptyline	B-Drug
available	O

Gabapentin	B-Drug
is	O
approved	O
for	O
the	O
former	O
indication	O
in	O
US	O

In	O
non-nmCRPC	O
individuals	O
with	O
moderate	O
hepatic	O
impairment	O
darolutamide	B-Drug
exposure	O
was	O
increased	O
by	O
about	O
1	O

When	O
Broomhall	O
was	O
dying	O
his	O
son	O
Marshall	O
read	O
to	O
him	O
from	O
The	O
Times	O
the	O
welcome	O
news	O
that	O
an	O
agreement	O
had	O
been	O
signed	O
ensuring	O
end	O
of	O
opium	B-Drug
trade	O
within	O
two	O
years	O

He	O
notes	O
that	O
Paul	O
Rabe	O
was	O
an	O
extremely	O
experienced	O
alkaloid	O
chemist	O
he	O
had	O
ample	O
opportunity	O
to	O
compare	O
his	O
quinine	B-Drug
reaction	O
product	O
with	O
authentic	O
samples	O
and	O
the	O
described	O
1918	O
chemistry	O
repeated	O
by	O
although	O
not	O
quinotoxine	O
itself	O
but	O
still	O
closely	O
related	O
derivatives	O

Menthol	O
also	O
shares	O
anaesthetic	O
properties	O
similar	O
to	O
propofol	B-Drug
by	O
modulating	O
the	O
same	O
sites	O
of	O
GABAA	O
receptor	O

Fueled	O
in	O
part	O
by	O
the	O
1729	O
ban	O
on	O
madak	O
which	O
at	O
first	O
effectively	O
exempted	O
pure	O
opium	B-Drug
as	O
a	O
potentially	O
medicinal	O
product	O
smoking	O
of	O
became	O
more	O
popular	O
18th	O
century	O

Hood;	O
61%	O
of	O
subjects	O
reported	O
a	O
complete	O
mystical	O
experience	O
after	O
their	O
psilocybin	O
session	O
while	O
only	O
13%	O
such	O
an	O
outcome	O
with	O
methylphenidate	B-Drug

On	O
Nov	O
15	O
2013	O
the	O
DEA	O
added	O
25I-NBOMe	B-Drug
and	O
25C-	O
25B-NBOMe	B-Drug
to	O
Schedule	O
I	O
using	O
their	O
emergency	O
scheduling	O
powers	O
making	O
those	O
NBOMe	O
compounds	O
temporarily	O
in	O
for	O
2	O
years	O

Use	O
of	O
eszopiclone	B-Drug
may	O
lead	O
to	O
physical	O
and	O
psychological	O
dependence	O

Injecting	O
methadone	B-Drug
pills	O
can	O
cause	O
collapsed	O
veins	O
bruising	O
swelling	O
and	O
possibly	O
other	O
harmful	O
effects	O

Meperidine	B-Drug
is	O
a	O
fully	O
synthetic	O
opioid	O
and	O
other	O
members	O
of	O
the	O
phenylpiperidine	O
family	O
like	O
alfentanil	B-Drug
sufentanil	B-Drug
are	O
complex	O
versions	O
this	O
structure	O

Secobarbital	B-Drug
>	O
pentobarbital	B-Drug
amobarbital	B-Drug
phenobarbital	B-Drug
barbital	B-Drug
It	O
has	O
an	O
LD50	O
in	O
mice	O
of	O
212	O
mg/kg	O
s	O

This	O
means	O
that	O
the	O
racemic	O
mix	O
of	O
two	O
enantiomers	O
is	O
a	O
mixed	O
agonist-antagonist	O
with	O
relatively	O
low	O
abuse	O
potential	O
and	O
little	O
-opioid	O
activity	O
tends	O
to	O
cause	O
problems	O
other	O
opioid	O
agonist-antagonists	O
such	O
as	O
pentazocine	B-Drug

Hydromorphone	B-Drug
and	O
midazolam	B-Drug
was	O
injected	O
intravenously	O
to	O
execute	O
double-murderer	O
Joseph	O
Wood	O
in	O
Arizona	O
on	O
24	O
July	O
2014	O

JWH-073	B-Drug
CP-55940	O
produced	O
in	O
1974	O
this	O
synthetic	O
cannabinoid	O
receptor	O
agonist	O
is	O
many	O
times	O
more	O
potent	O
than	O
THC	O

Inocybe	O
aeruginascens	O
contains	O
the	O
formerly	O
known	O
alkaloids	O
psilocybin	O
psilocin	B-Drug
baeocystin	O
as	O
well	O
a	O
newly	O
discovered	O
indoleamine	O
4-phosphoryloxy-NNN-trimethyltryptamine	O

After	O
its	O
discovery	O
amphetamine	B-Drug
was	O
purified	O
and	O
put	O
into	O
medical	O
use	O
in	O
the	O
1900s	O

Following	O
the	O
introduction	O
of	O
mesterolone	B-Drug
as	O
Proviron	O
Schering	O
continued	O
to	O
market	O
testosterone	O
propionate	O
under	O
brand	O
name	O
Testoviron	O

The	O
alcohol	O
content	O
of	O
Laudanum	B-Drug
probably	O
varied	O
substantially;	O
on	O
the	O
labels	O
turn-of-the-century	O
bottles	O
alcoholic	O
is	O
stated	O
as	O
48%	O

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body	O
to	O
develop	O
safer	O
analogs	O
find	O
further	O
uses	O
for	O

NMDA	O
antagonists	O
such	O
as	O
dextromethorphan	B-Drug
DXM	B-Drug
a	O
cough	O
suppressant	O
ketamine	B-Drug
dissociative	O
anaesthetic	O
tiletamine	B-Drug
veterinary	O
and	O
ibogaine	B-Drug
from	O
the	O
African	O
tree	O
Tabernanthe	O
iboga	O
are	O
being	O
studied	O
for	O
their	O
role	O
in	O
decreasing	O
development	O
of	O
tolerance	O
to	O
opioids	O
possible	O
eliminating	O
addiction/tolerance/withdrawal	O
possibly	O
by	O
disrupting	O
memory	O
circuitry	O

Abbreviations	O
are	O
used	O
in	O
the	O
list	O
as	O
follows:	O
INN	O
British	O
Approved	O
Name	O
USAN	O
List	O
of	O
lists	O
drugs	O
General	O
By	O
chemical	O
structure	O
===	O
2C-*	O
benzodiazepines	O
cocaine	B-Drug
analogues	O
DO*	O
androgen	O
esters	O
corticosteroid	O
estrogen	O
tetracyclic	O
antidepressants	O
tricyclic	O
substituted	O
-alkyltryptamines	O
amphetamines	O
benzofurans	O
cathinones	O
methylenedioxyphenethylamines	O
phenethylamines	O
tryptamines	O
androgens/anabolic	O
steroids	O
anaesthetic	O
antiandrogens	O
antibiotics	O
antipsychotics	O
antiviral	O
corticosteroids	O
designer	O
affected	O
by	O
grapefruit	O
nasal	O
decongestants	O
nonsteroidal	O
anti-inflammatory	O
drug	O
opioids	O
progestogens	O
psychedelic	O
psychotropic	O
medications	O
selective	O
receptor	O
modulators	O
investigational	O
analgesics	O
anxiolytics	O
hormonal	O
agents	O
sexual	O
dysfunction	O
psychiatric	O
condition	O
treated	O
veterinary	O
approved	O
controlled	O
United	O
Kingdom	O
banned	O
from	O
Olympics	O
Schedule	O
I	O
US	O
II	O
III	O
IV	O
V	O
withdrawn	O
World	O
Health	O
Organization	O
Essential	O
Medicines	O

In	O
the	O
United	O
States	O
midazolam	B-Drug
DEA	O
number	O
2884	O
is	O
on	O
Schedule	O
IV	O
list	O
of	O
Controlled	O
Substances	O
Act	O
as	O
a	O
non-narcotic	O
agent	O
with	O
low	O
potential	O
for	O
abuse	O

Due	O
to	O
its	O
similarity	O
in	O
effects	O
PCP	B-Drug
TCP	O
was	O
placed	O
into	O
the	O
Schedule	O
I	O
list	O
of	O
illegal	O
drugs	O
1970s	O
although	O
it	O
only	O
briefly	O
used	O
and	O
1980s	O
is	O
now	O
little	O
known	O

The	O
hydrogen	O
iodide	O
is	O
used	O
to	O
reduce	O
either	O
ephedrine	B-Drug
or	O
pseudoephedrine	O
methamphetamine	B-Drug

Butorphanol	B-Drug
exhibits	O
partial	O
agonist	O
and	O
antagonist	O
activity	O
at	O
the	O
-opioid	O
receptor	O
as	O
well	O
Ki	O
57	O
nM;	O
Emax	O
=	O
57%	O

Arnold	O
produced	O
desoxymethyltestosterone	B-Drug
and	O
supplied	O
it	O
to	O
Victor	O
Conte	O
of	O
Bay	O
Area	O
Laboratory	O
Co-operative	O
BALCO	O
an	O
American	O
nutritional	O
supplement	O
company	O
steroid	O
supplier	O

In	O
vivo	O
an	O
equimolar	O
dose	O
of	O
1-testosterone	B-Drug
has	O
the	O
same	O
potency	O
to	O
stimulate	O
growth	O
prostate	O
seminal	O
vesicles	O
and	O
androgen-sensitive	O
levator	O
ani	O
muscle	O
as	O
reference	O
anabolic	O
steroid	O
testosterone	O
propionate	O
but	O
unlike	O
also	O
increases	O
liver	O
weight	O

These	O
prices	O
are	O
all	O
for	O
generic	O
equivalents	O
of	O
Vicoprofen	B-Drug

PCP	B-Drug
is	O
metabolized	O
into	O
PCHP	O
PPC	O
and	O
PCAA	O

It	O
is	O
a	O
ring-methylated	O
homologue	O
of	O
MDA	O
and	O
structural	O
isomer	O
MDMA	B-Drug

Metenolone	B-Drug
enanthate	I-Drug
is	O
marketed	O
in	O
Spain	O
and	O
Turkey	O

Tentative	O
evidence	O
suggests	O
that	O
family	O
history	O
and	O
presence	O
of	O
the	O
Asn40Asp	O
polymorphism	O
predicts	O
naltrexone	B-Drug
being	O
effective	O

Janiger	O
had	O
Murdoch	O
paint	O
still-lives	O
both	O
on	O
and	O
off	O
LSD	B-Drug
including	O
a	O
Kachina	O
doll	O
that	O
he	O
reportedly	O
70	O
other	O
patients	O
also	O

Buprenorphine	B-Drug
is	O
metabolized	O
by	O
the	O
liver	O
via	O
CYP3A4	O
also	O
CYP2C8	O
seems	O
to	O
be	O
involved	O
isozymes	O
of	O
cytochrome	O
P450	O
enzyme	O
system	O
into	O
norbuprenorphine	O
N-dealkylation	O

The	O
weakness	O
of	O
the	O
government	O
in	O
China	O
and	O
conditions	O
civil	O
war	O
enabled	O
heroin	B-Drug
production	O
to	O
take	O
root	O
there	O

Imipramine	B-Drug
is	O
taken	O
by	O
mouth	O

Triazolam	B-Drug
belongs	O
to	O
the	O
Pregnancy	O
Category	O
X	O
of	O
FDA	O

com	O
and	O
The	O
People's	O
Pharmacy	O
released	O
the	O
results	O
of	O
comparative	O
tests	O
different	O
brands	O
bupropion	B-Drug

Ephedra	O
extracts	O
not	O
containing	O
ephedrine	B-Drug
have	O
been	O
banned	O
by	O
the	O
FDA	O
and	O
are	O
still	O
sold	O
legally	O

Unlike	O
morphine	B-Drug
and	O
other	O
opioids	O
that	O
are	O
used	O
to	O
alleviate	O
pain	O
nociceptin's	O
role	O
in	O
nociception	O
is	O
not	O
straightforward	O

Flunitrazepam	B-Drug
overdose	O
responds	O
to	O
the	O
GABAA	O
receptor	O
antagonist	O
flumazenil	B-Drug
which	O
thus	O
can	O
be	O
used	O
as	O
a	O
treatment	O

Novartis	O
also	O
emphasised	O
that	O
it	O
continues	O
to	O
be	O
committed	O
good	O
access	O
its	O
drugs;	O
according	O
by	O
2013	O
95%	O
of	O
patients	O
in	O
Indiaroughly	O
16000	O
peoplereceive	O
Glivec	B-Drug
free	O
charge	O

Normal	O
between-cigarettes	O
discontinuation	O
in	O
unrestricted	O
smokers	O
causes	O
mild	O
but	O
measurable	O
nicotine	B-Drug
withdrawal	O
symptoms	O

Traces	O
of	O
the	O
drug	O
have	O
also	O
been	O
found	O
in	O
other	O
recreational	O
drugs	O
including	O
cocaine	B-Drug
MDMA	B-Drug
and	O
heroin	B-Drug

It	O
is	O
suggested	O
that	O
methadone	B-Drug
does	O
not	O
function	O
as	O
much	O
to	O
curb	O
addiction	O
redirect	O
it	O
and	O
maintain	O
dependency	O
on	O
authorised	O
channels	O

Tramadol	B-Drug
is	O
metabolized	O
by	O
CYP2D6	O
enzymes	O
which	O
contribute	O
to	O
the	O
metabolism	O
of	O
approximately	O
25%	O
all	O
medications	O

In	O
the	O
US	O
etorphine	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
I	O
drug	O
with	O
an	O
ACSCN	O
of	O
9056	O
although	O
its	O
hydrochloride	O
salt	O
classified	O
II	O
9059	O

76%	O
almost	O
triple	O
that	O
of	O
4-androstenedione	B-Drug
due	O
to	O
utilization	O
a	O
different	O
enzymatic	O
pathway	O

The	O
contraceptive	O
effects	O
of	O
desogestrel	B-Drug
in	O
women	O
are	O
mediated	O
not	O
only	O
by	O
prevention	O
ovulation	O
via	O
its	O
antigonadotropic	O
but	O
also	O
marked	O
progestogenic	O
and	O
antiestrogenic	O
on	O
cervical	O
mucus	O
the	O
endometrium	O

Its	O
affinity	O
for	O
the	O
serotonin	O
transporter	O
is	O
less	O
than	O
that	O
of	O
methamphetamine	B-Drug

Budesonide	B-Drug
BUD	O
sold	O
under	O
the	O
brand	O
name	O
Pulmicort	O
among	O
others	O
is	O
a	O
medication	O
of	O
corticosteroid	O
type	O

Reviews	O
of	O
clinical	O
stimulant	O
research	O
have	O
established	O
the	O
safety	O
and	O
effectiveness	O
long-term	O
continuous	O
amphetamine	B-Drug
use	O
for	O
treatment	O
ADHD	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

About	O
half	O
of	O
those	O
with	O
methamphetamine	B-Drug
addiction	O
continue	O
use	O
over	O
a	O
ten-year	O
period	O
while	O
the	O
other	O
reduce	O
starting	O
at	O
about	O
one	O
to	O
four	O
years	O
after	O
initial	O

An	O
infusion	O
of	O
Calabar	O
bean	O
seeds	O
was	O
given	O
to	O
people	O
accused	O
crime	O
in	O
Nigeria:	O
its	O
rejection	O
by	O
stomach	O
regarded	O
as	O
a	O
sign	O
innocence	O
otherwise	O
the	O
person	O
killed	O
via	O
action	O
physostigmine	B-Drug
which	O
is	O
present	O
plant	O
and	O
causes	O
paralysis	O
heart	O
lungs	O

It	O
may	O
be	O
supplied	O
as	O
CBD	B-Drug
oil	I-Drug
containing	O
only	O
the	O
active	O
ingredient	O
excluding	O
tetrahydrocannabinol	O
[THC]	O
or	O
terpenes	O
CBD-dominant	O
hemp	O
extract	O
capsules	O
dried	O
cannabis	O
prescription	O
liquid	O
solution	O

Cocaine	B-Drug
is	O
readily	O
available	O
in	O
all	O
major	O
countries'	O
metropolitan	O
areas	O

In	O
1978	O
People	O
magazine	O
and	O
Mike	O
Wallace	O
of	O
60	O
Minutes	O
called	O
PCP	B-Drug
the	O
country's	O
number	O
one	O
drug	O
problem	O

Although	O
there	O
have	O
been	O
reported	O
fatalities	O
due	O
to	O
GHB	B-Drug
withdrawal	O
reports	O
are	O
inconclusive	O
and	O
further	O
research	O
is	O
needed	O

This	O
causes	O
confounding	O
factors	O
where	O
questions	O
arise	O
as	O
to	O
whether	O
the	O
tobacco	B-Drug
cannabis	O
or	O
both	O
that	O
have	O
caused	O
a	O
cancer	O

There	O
is	O
a	O
risk	O
of	O
neonatal	O
withdrawal	O
symptom	O
in	O
the	O
newborn	O
if	O
pregnant	O
women	O
take	O
oxymorphone	B-Drug
for	O
prolonged	O
period	O

For	O
instance	O
indometacin	B-Drug
inhibits	O
both	O
cyclooxygenase-1	O
and	O
cyclooxygenase-2	O
which	O
then	O
the	O
production	O
of	O
prostaglandins	O
in	O
stomach	O
intestines	O
responsible	O
for	O
maintaining	O
mucous	O
lining	O
gastrointestinal	O
tract	O

Opium	B-Drug
production	O
in	O
that	O
country	O
has	O
increased	O
rapidly	O
since	O
reaching	O
an	O
all-time	O
high	O
2006	O

It	O
is	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers	O
dexfenfluramine	B-Drug
and	O
levofenfluramine	O

To	O
induce	O
anesthesia	O
it	O
is	O
given	O
with	O
a	O
sedative-hypnotic	O
like	O
propofol	B-Drug
or	O
thiopental	B-Drug
and	O
muscle	O
relaxant	O

In	O
2019	O
the	O
first	O
generic	O
form	O
of	O
mifepristone	B-Drug
in	O
United	O
States	O
became	O
available	O
manufactured	O
by	O
GenBioPro	O

A	O
small	O
recreational	O
market	O
for	O
MDMA	B-Drug
developed	O
by	O
the	O
late	O
1970s	O
consuming	O
perhaps	O
10000	O
doses	O
in	O
1976	O

JWH-018	B-Drug
produces	O
bradycardia	O
and	O
hypothermia	O
in	O
rats	O
at	O
doses	O
of	O
0	O

1%	O
at	O
daily	O
dosages	O
of	O
less	O
than	O
300	O
mg	O
bupropion	B-Drug
and	O
0	O

Trenbolone	B-Drug
also	O
known	O
as	O
19-nor-911-testosterone	O
or	O
estra-4911-trien-17-ol-3-one	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
derivative	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug

Mannitol	B-Drug
is	O
contraindicated	O
in	O
people	O
with	O
anuria	O
severe	O
hypovolemia	O
pre-existing	O
pulmonary	O
vascular	O
congestion	O
or	O
edema	O
and	O
active	O
intracranial	O
bleeding	O
except	O
during	O
craniotomy	O

Preparations	O
of	O
hash	B-Drug
oil	I-Drug
may	O
be	O
solid	O
or	O
colloidal	O
depending	O
on	O
both	O
production	O
method	O
and	O
temperature	O
are	O
usually	O
identified	O
by	O
their	O
appearance	O
characteristics	O

Amphetamine	B-Drug
contracted	O
from	O
alpha-methylphenethylamine	O
is	O
a	O
central	O
nervous	O
system	O
CNS	O
stimulant	O
that	O
used	O
in	O
the	O
treatment	O
of	O
attention	O
deficit	O
hyperactivity	O
disorder	O
ADHD	O
narcolepsy	O
and	O
obesity	O

Sonata	B-Drug
zaleplon	B-Drug
a	O
non-benzodiazepine	O
hypnotic	O

Following	O
the	O
appearance	O
of	O
-methylfentanyl	O
on	O
market	O
over	O
ten	O
new	O
analogs	O
fentanyl	B-Drug
have	O
been	O
reported	O
starting	O
with	O
para-fluorofentanyl	B-Drug
followed	O
by	O
-methylacetylfentanyl	O
then	O
highly	O
potent	O
3-methylfentanyl	B-Drug
and	O
subsequently	O
many	O
others	O
such	O
as	O
-hydroxyfentanyl	O
ohmefentanyl	B-Drug
-hydroxythiofentanyl	O
-hydroxy-4-methylfentanyl	O

Tobacco	B-Drug
leaf	I-Drug
is	O
often	O
added	O
to	O
the	O
mixture	O
thereby	O
adding	O
effect	O
of	O
nicotine	B-Drug

Propetandrol	O
INN	O
brand	O
name	O
Solevar;	O
former	O
developmental	O
code	O
SC-7294	O
or	O
propethandrol	O
also	O
known	O
as	O
17-ethyl-19-nortestosterone	O
3-propionate	O
17-ethyl-19-nor-4-androstenediol	O
well	O
17-ethylestr-4-en-317-diol	O
is	O
a	O
synthetic	O
and	O
orally	O
active	O
anabolicandrogenic	O
steroid	O
AAS	O
progestogen	O
17-alkylated	O
derivative	O
of	O
19-nortestosterone	B-Drug

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

The	O
immediate	O
metabolism	O
of	O
oxycodone	B-Drug
in	O
humans	O
is	O
as	O
follows:	O
N-Demethylation	O
to	O
noroxycodone	O
predominantly	O
via	O
CYP3A4	O
O-Demethylation	O
oxymorphone	B-Drug
CYP2D6	O
6-Ketoreduction	O
6-	O
and	O
6-oxycodol	O
N-Oxidation	O
oxycodone-N-oxideIn	O
N-demethylation	O
by	O
the	O
major	O
metabolic	O
pathway	O
accounting	O
for	O
45%	O
21%	O
a	O
dose	O
while	O
O-demethylation	O
into	O
6-ketoreduction	O
6-oxycodols	O
represent	O
relatively	O
minor	O
pathways	O
11%	O
6%	O
8%	O
respectively	O

However	O
LSD	B-Drug
dramatically	O
decreased	O
in	O
popularity	O
the	O
mid-1970s	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

Hemp	O
CBD	B-Drug
products	O
may	O
not	O
be	O
sold	O
into	O
general	O
commerce	O
but	O
rather	O
are	O
allowed	O
only	O
for	O
research	O

In	O
humans	O
the	O
only	O
post-synaptic	O
receptor	O
at	O
which	O
amphetamine	B-Drug
is	O
known	O
to	O
bind	O
5-HT1A	O
where	O
it	O
acts	O
as	O
an	O
agonist	O
with	O
low	O
micromolar	O
affinity	O

In	O
1975	O
after	O
reports	O
of	O
agranulocytosis	O
leading	O
to	O
death	O
in	O
some	O
clozapine-treated	O
patients	O
clozapine	B-Drug
was	O
voluntarily	O
withdrawn	O
by	O
the	O
manufacturer	O

However	O
it	O
has	O
been	O
reported	O
that	O
bicalutamide	B-Drug
weak	O
affinity	O
for	O
the	O
progesterone	O
receptor	O
PR	O
where	O
is	O
an	O
antagonist	O
and	O
hence	O
could	O
have	O
some	O
antiprogestogenic	O
activity	O

Cocaine	B-Drug
freebase	O
white	O
tornado	O
is	O
prepared	O
from	O
cocaine	B-Drug
hydrochloride	I-Drug
by	O
extracting	O
the	O
with	O
an	O
alkaline	O
solution	O
sodium	O
hydroxide	O
or	O
ammonia	O
and	O
adding	O
a	O
non-polar	O
solvent	O
such	O
as	O
diethyl	O
ether	O
benzene	O

The	O
pure	O
cocaine	B-Drug
base	O
can	O
be	O
recovered	O
from	O
the	O
mixture	O
by	O
extraction	O
freebase	O
or	O
acid-base	O
hydrochloride	O
using	O
common	O
organic	O
solvents	O
such	O
as	O
methylene	O
chloride	O
acetone	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Regeneron	O
and	O
Sanofi	O
were	O
allowed	O
to	O
continue	O
marketing	O
alirocumab	B-Drug
during	O
the	O
appeals	O
process	O

Marijuana	B-Drug
and	O
its	O
cannabinoids	O

LSD	B-Drug
also	O
has	O
enamine-type	O
reactivity	O
because	O
of	O
the	O
electron-donating	O
effects	O
indole	O
ring	O

In	O
2019	O
the	O
cannabis	O
manufacturer	O
Canopy	O
Growth	O
acquired	O
majority	O
ownership	O
of	O
BioSteel	O
Sports	O
Nutrition	O
which	O
is	O
developing	O
CBD	B-Drug
products	O
under	O
endorsement	O
by	O
numerous	O
professional	O
athletes	O

There	O
also	O
appears	O
to	O
be	O
a	O
combination	O
with	O
ethoheptazine	B-Drug
an	O
opioid	O
analgesic	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

The	O
derivative	O
substituted	O
on	O
the	O
phenyl	O
ring	O
with	O
a	O
p-nitro	O
group	O
is	O
more	O
potent	O
than	O
parent	O
compound	O
around	O
25x	O
potency	O
of	O
morphine	B-Drug

The	O
drug	O
has	O
been	O
marketed	O
under	O
the	O
name	O
NRG-1	O
although	O
only	O
a	O
minority	O
of	O
samples	O
substances	O
sold	O
this	O
have	O
found	O
to	O
actually	O
contain	O
naphyrone	B-Drug
and	O
even	O
that	O
proved	O
genuine	O
-naphyrone	O
were	O
in	O
some	O
cases	O
also	O
1-naphthyl	O
isomer	O
varying	O
proportions	O
further	O
confusing	O
reported	O
effects	O
profile	O

As	O
of	O
this	O
date	O
Flurazepam	B-Drug
is	O
now	O
again	O
available	O
in	O
the	O
United	O
States	O

Shortly	O
afterward	O
the	O
officer	O
begins	O
tripping	O
very	O
hard	O
and	O
stares	O
into	O
space	O
since	O
swig	O
of	O
water	O
he	O
took	O
actually	O
contained	O
numerous	O
hits	O
LSD	B-Drug

Androstanedione	O
is	O
a	O
5-reduced	O
metabolite	O
of	O
4-androstenedione	B-Drug
which	O
serves	O
as	O
an	O
intermediate	O
in	O
the	O
biosynthesis	O
androgen	O
and	O
neurosteroid	O
androsterone	O

Benzodiazepines	O
were	O
implicated	O
in	O
39%	O
of	O
suicides	O
by	O
drug	O
poisoning	O
Sweden	O
with	O
nitrazepam	B-Drug
and	O
flunitrazepam	B-Drug
accounting	O
for	O
90%	O
benzodiazepine	O
the	O
elderly	O
over	O
a	O
period	O
2	O
decades	O

GHB	B-Drug
can	O
be	O
detected	O
in	O
hair	O

Tolerance	O
to	O
opioids	O
is	O
attenuated	O
by	O
a	O
number	O
of	O
substances	O
including:	O
calcium	O
channel	O
blockers	O
intrathecal	O
magnesium	O
and	O
zinc	O
NMDA	O
antagonists	O
such	O
as	O
dextromethorphan	B-Drug
ketamine	B-Drug
memantine	B-Drug

Approximate	O
cocaine	B-Drug
purity	O
can	O
be	O
determined	O
using	O
1	O
mL	O
2%	O
cupric	O
sulfate	O
pentahydrate	O
in	O
dilute	O
HCl	O
potassium	O
thiocyanate	O
and	O
2	O
of	O
chloroform	O

Risperidone	B-Drug
has	O
been	O
classified	O
as	O
a	O
qualitatively	O
atypical	O
antipsychotic	O
agent	O
with	O
relatively	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
when	O
given	O
at	O
doses	O
that	O
more	O
pronounced	O
serotonin	O
antagonism	O
than	O
dopamine	O

Klein	O
said	O
that	O
he	O
occasionally	O
had	O
given	O
Jackson	O
pethidine	B-Drug
to	O
sedate	O
him	O
but	O
administered	O
nothing	O
stronger	O
and	O
turned	O
his	O
records	O
over	O
the	O
medical	O
examiner	O

Overdoses	O
from	O
opioids	O
are	O
highest	O
among	O
individuals	O
who	O
between	O
the	O
ages	O
of	O
40	O
and	O
50	O
in	O
contrast	O
to	O
heroin	B-Drug
overdoses	O
which	O
20	O
30	O

Hash	B-Drug
oil	I-Drug
is	O
a	O
resinous	O
matrix	O
of	O
cannabinoids	O
obtained	O
from	O
the	O
Cannabis	O
plant	O
by	O
solvent	O
extraction	O
formed	O
into	O
hardened	O
or	O
viscous	O
mass	O

In	O
April	O
1984	O
the	O
FDA	O
announced	O
that	O
data	O
was	O
not	O
sufficient	O
and	O
withdrew	O
marketing	O
authority	O
for	O
stanozolol	B-Drug
senile	O
postmenopausal	O
osteoporosis	O
raising	O
hemoglobin	O
levels	O
in	O
aplastic	O
anemia	O

It	O
modifies	O
the	O
LSD	B-Drug
molecule	O
by	O
adding	O
a	O
propionyl	O
group	O
to	O
nitrogen	O
of	O
LSD's	O
indole	O

Ivacaftor	B-Drug
is	O
a	O
drug	O
used	O
to	O
treat	O
cystic	O
fibrosis	O
in	O
people	O
with	O
certain	O
mutations	O
the	O
transmembrane	O
conductance	O
regulator	O
CFTR	O
gene	O
primarily	O
G551D	O
mutation	O
who	O
account	O
for	O
45%	O
cases	O
of	O

Like	O
all	O
of	O
its	O
chemical	O
relatives	O
in	O
this	O
class	O
codeine-based	O
semi-synthetic	O
narcotic	O
antitussives	O
thebacon	B-Drug
exerts	O
analgesic	O
effect	O
and	O
a	O
large	O
part	O
antitussive	O
antiperistaltic	O
action	O
as	O
prodrug	O
for	O
stronger	O
and/or	O
longer-lasting	O
opioids	O
primarily	O
hydromorphone	B-Drug
which	O
is	O
formed	O
the	O
liver	O
by	O
cytochrome	O
P450	O
2D6	O
CYP2D6	O
enzyme	O
pathway	O
well	O
acetylmorphone	O

As	O
of	O
2007	O
companies	O
produced	O
for	O
export	O
US$13	O
million	O
worth	O
ephedrine	B-Drug
from	O
30000	O
tons	O
ephedra	O
annually	O
or	O
about	O
ten	O
times	O
the	O
amount	O
used	O
in	O
traditional	O
Chinese	O
medicine	O

The	O
Temple	O
of	O
the	O
True	O
Inner	O
Light	O
is	O
a	O
temple	O
in	O
Manhattan	O
which	O
believes	O
Entheogens	O
such	O
as	O
Dipropyltryptamine	O
THC	O
LSD-25	B-Drug
Mescaline	B-Drug
Psilocybin	O
and	O
DMT	O
to	O
be	O
God	O
that	O
religions	O
Christianity	O
Judaism	O
Buddhism	O
Hinduism	O
Islam	O
etc	O

Acute	O
amphetamine	B-Drug
administration	O
in	O
humans	O
increases	O
endogenous	O
opioid	O
release	O
several	O
brain	O
structures	O
the	O
reward	O
system	O

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family	O

Efavirenz	B-Drug
is	O
safe	O
to	O
use	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy	O

Even	O
small	O
quantities	O
of	O
25I-NBOMe	B-Drug
can	O
produce	O
a	O
large	O
number	O
blotters	O

5%	O
owner	O
Hoechst	O
AG	O
of	O
Germany	O
Roussel-Uclaf's	O
executives	O
and	O
board	O
directors	O
voted	O
16	O
to	O
4	O
stop	O
distribution	O
mifepristone	B-Drug
which	O
they	O
announced	O
on	O
October	O
26	O
1988	O

See	O
psilocin	B-Drug
for	O
more	O
details	O

On	O
the	O
other	O
hand	O
C910	O
double	O
bond	O
of	O
dienogest	O
appears	O
to	O
inhibit	O
metabolism	O
via	O
5-reductase	O
and/or	O
which	O
is	O
major	O
metabolic	O
route	O
for	O
19-nortestosterone	B-Drug
progestins	O
like	O
norethisterone	B-Drug
norgestrel	B-Drug
and	O
etonogestrel	B-Drug
this	O
may	O
serve	O
improve	O
stability	O
potency	O

Since	O
fentanyl	B-Drug
itself	O
is	O
highly	O
potent	O
and	O
notorious	O
for	O
causing	O
fatal	O
overdoses	O
when	O
abused	O
also	O
very	O
short	O
lasting	O
with	O
recreational	O
users	O
often	O
administering	O
doses	O
every	O
hour	O
-methylfentanyl	O
could	O
have	O
several	O
advantages	O
over	O
the	O
parent	O
compound	O
as	O
a	O
drug	O

Ranitidine	B-Drug
is	O
a	O
competitive	O
reversible	O
inhibitor	O
of	O
the	O
action	O
histamine	O
at	O
H2	O
receptors	O
found	O
in	O
gastric	O
parietal	O
cells	O

Nine	O
of	O
the	O
15	O
patients	O
had	O
a	O
Glasgow	O
coma	O
scale	O
GCS	O
indicating	O
they	O
were	O
in	O
normal	O
mental	O
state	O
four	O
below	O
8	O
but	O
these	O
all	O
reported	O
using	O
central	O
nervous	O
system	O
depressant	O
most	O
commonly	O
GHB	B-Drug
with	O
mephedrone	B-Drug

Clonazepam	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
as	O
a	O
generic	O
drug	O
1997	O
and	O
is	O
now	O
manufactured	O
marketed	O
by	O
several	O
companies	O

Heroin	B-Drug
for	O
pain	O
has	O
been	O
mixed	O
with	O
sterile	O
water	O
on	O
site	O
by	O
the	O
attending	O
physician	O
and	O
administered	O
using	O
a	O
syringe	O
nebulizer	O
tip	O

The	O
birth	O
defects	O
caused	O
by	O
thalidomide	B-Drug
led	O
to	O
the	O
development	O
of	O
greater	O
drug	O
regulation	O
and	O
monitoring	O
in	O
many	O
countries	O

A	O
2020	O
review	O
concluded	O
that	O
users'	O
perception	O
modafinil	B-Drug
is	O
an	O
effective	O
cognitive	O
enhancer	O
not	O
supported	O
by	O
the	O
evidence	O
in	O
healthy	O
non-sleep-deprived	O
adults	O

The	O
active	O
components	O
in	O
cohoba	O
responsible	O
for	O
the	O
hallucinogenic	O
effects	O
are	O
DMT	O
NN-dimethyltryptamine	O
and	O
bufotenine	B-Drug

A	O
2014	O
study	O
which	O
included	O
1118	O
male	O
kratom	B-Drug
users	O
indicated	O
that	O
more	O
than	O
half	O
of	O
the	O
regular	O
67%	O
total	O
subjects	O
experienced	O
withdrawal	O
when	O
attempting	O
to	O
discontinue	O
with	O
symptoms	O
pain	O
muscle	O
spasms	O
and	O
insomnia	O

In	O
1964	O
the	O
Brain	O
Committee	O
recommended	O
that	O
only	O
selected	O
approved	O
doctors	O
working	O
at	O
specialized	O
centres	O
be	O
allowed	O
to	O
prescribe	O
diamorphine	B-Drug
and	O
cocaine	B-Drug
users	O

When	O
compared	O
to	O
the	O
opioids	O
hydromorphone	B-Drug
fentanyl	B-Drug
oxycodone	B-Drug
and	O
pethidine	B-Drug
meperidine	B-Drug
former	O
addicts	O
showed	O
a	O
strong	O
preference	O
for	O
heroin	B-Drug
morphine	B-Drug
suggesting	O
that	O
are	O
particularly	O
susceptible	O
misuse	O
causing	O
dependence	O

Enzalutamide	B-Drug
is	O
an	O
antiandrogen	O
and	O
acts	O
as	O
antagonist	O
of	O
the	O
androgen	O
receptor	O
biological	O
target	O
androgens	O
like	O
testosterone	O
dihydrotestosterone	O

More	O
recent	O
research	O
has	O
found	O
zolpidem	B-Drug
treatment	O
to	O
be	O
effective	O
in	O
the	O
short	O
term	O
but	O
only	O
a	O
small	O
proportion	O
of	O
cases	O
estimated	O
at	O
around	O
5%	O
and	O
when	O
brain	O
injury	O
is	O
specific	O
type	O

Opium	B-Drug
tincture	O
is	O
one	O
of	O
the	O
most	O
potent	O
oral	O
formulations	O
morphine	B-Drug
available	O
by	O
prescription	O

The	O
side	O
effects	O
of	O
spironolactone	B-Drug
are	O
usually	O
mild	O
and	O
rarely	O
result	O
in	O
discontinuation	O

Domestic	O
production	O
of	O
ephedrine	B-Drug
from	O
ephedra	O
bushes	O
growing	O
wild	O
in	O
the	O
mountains	O
and	O
its	O
subsequent	O
chemical	O
conversion	O
to	O
methamphetamine	B-Drug
has	O
also	O
emerged	O
recent	O
years	O
grown	O
rival	O
opium	B-Drug
some	O
areas	O

Levothyroxine	B-Drug
absorption	O
is	O
increased	O
by	O
fasting	O
and	O
decreased	O
in	O
certain	O
malabsorption	O
syndromes	O
foods	O
with	O
age	O

The	O
figures	O
for	O
the	O
6020	O
powder	O
cocaine	B-Drug
convictions	O
in	O
contrast	O
were	O
as	O
follows:	O
17%	O
of	O
these	O
offenders	O
white	O
28%	O
black	O
and	O
53%	O
Hispanic	O

Codeine	B-Drug
though	O
a	O
mild	O
painkiller	O
is	O
converted	O
into	O
morphine	B-Drug
in	O
the	O
liver	O

In	O
the	O
US	O
FDA	O
advises	O
against	O
use	O
of	O
benzodiazepines	O
such	O
as	O
lorazepam	B-Drug
for	O
longer	O
than	O
four	O
weeks	O

The	O
drug	O
can	O
be	O
made	O
from	O
codeine	B-Drug
and	O
iodine	O
derived	O
over-the-counter	O
medications	O
red	O
phosphorus	O
match	O
strikers	O
in	O
a	O
process	O
similar	O
to	O
the	O
manufacturing	O
of	O
methamphetamine	B-Drug
pseudoephedrine	O

As	O
shown	O
in	O
the	O
image	O
below	O
N-carbethoxyphthalimide	O
1	O
can	O
react	O
with	O
L-glutamine	B-Drug
to	O
yield	O
N-phthaloyl-L-glutamine	O
2	O

District	O
Court	O
Judge	O
Gladys	O
Kessler	O
found	O
that	O
the	O
Government	O
had	O
proven	O
its	O
case	O
and	O
tobacco	B-Drug
company	O
defendants	O
violated	O
Racketeer	O
Influenced	O
Corrupt	O
Organizations	O
Act	O
RICO	O

Over	O
the	O
following	O
years	O
Zeff	O
traveled	O
around	O
United	O
States	O
and	O
occasionally	O
to	O
Europe	O
eventually	O
training	O
an	O
estimated	O
four	O
thousand	O
psychotherapists	O
in	O
therapeutic	O
use	O
of	O
MDMA	B-Drug

and	O
American	O
Home	O
Products	O
Corporation	O
which	O
marketed	O
meprobamate	B-Drug
as	O
Equanil	B-Drug
were	O
charged	O
with	O
having	O
conspired	O
to	O
monopolize	O
the	O
market	O
in	O
mild	O
tranquilizers	O

Opium	B-Drug
became	O
a	O
major	O
colonial	O
commodity	O
moving	O
legally	O
and	O
illegally	O
through	O
trade	O
networks	O
on	O
the	O
Indian	O
subcontinent	O
Colonial	O
America	O
Qing	O
China	O
others	O

Tobacco	B-Drug
the	O
most	O
common	O
source	O
of	O
nicotine	B-Drug
has	O
an	O
overall	O
harm	O
to	O
user	O
and	O
self	O
score	O
3	O
percent	O
below	O
cocaine	B-Drug
13	O
above	O
amphetamines	O
ranking	O
6th	O
harmful	O
20	O
drugs	O
assessed	O
as	O
determined	O
by	O
a	O
multi-criteria	O
decision	O
analysis	O

Michael	O
Cera	O
used	O
real	O
mescaline	B-Drug
for	O
the	O
movie	O
Crystal	O
Fairy	O
&	O
Magical	O
Cactus	O
as	O
expressed	O
in	O
an	O
interview	O

Veterinarians	O
often	O
use	O
ketamine	B-Drug
with	O
sedative	O
drugs	O
to	O
produce	O
balanced	O
anaesthesia	O
and	O
analgesia	O
as	O
a	O
constant-rate	O
infusion	O
help	O
prevent	O
pain	O
wind-up	O

Haloperidol	B-Drug
is	O
the	O
INN	O
BAN	O
USAN	O
AAN	O
approved	O
name	O

The	O
Global	O
Ibogaine	B-Drug
Therapy	O
Alliance	O
publishes	O
a	O
map	O
of	O
ibogaine	B-Drug
legal	O
status	O
in	O
various	O
countries	O
around	O
the	O
world	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state	O

Temazepam	B-Drug
was	O
found	O
in	O
26%	O
of	O
heroin-related	O
deaths	O

Ethisterone	O
has	O
about	O
20-fold	O
lower	O
potency	O
as	O
a	O
progestogen	O
relative	O
to	O
norethisterone	B-Drug

The	O
Las	O
Vegas	O
Sun	O
reported	O
that	O
online	O
sales	O
of	O
Cocaine	B-Drug
had	O
quadrupled	O
two	O
weeks	O
after	O
the	O
FDA's	O
warning	O
letter	O

The	O
generic	O
name	O
of	O
the	O
drug	O
is	O
methyltestosterone	B-Drug
in	O
Latin	O
methyltestosteron	O
German	O
and	O
metiltestosterona	O
Spanish	O

Methadone	B-Drug
and	O
its	O
major	O
metabolite	O
2-ethylidene-15-dimethyl-33-diphenylpyrrolidine	O
EDDP	O
are	O
often	O
measured	O
in	O
urine	O
as	O
part	O
of	O
a	O
drug	O
abuse	O
testing	O
program	O
plasma	O
or	O
serum	O
to	O
confirm	O
diagnosis	O
poisoning	O
hospitalized	O
victims	O
whole	O
blood	O
assist	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
case	O
sudden	O
death	O

EAM-2201	B-Drug
acts	O
as	O
a	O
full	O
agonist	O
with	O
binding	O
affinity	O
of	O
0	O

Triamterene	B-Drug
can	O
also	O
cause	O
kidney	O
stones	O
through	O
direct	O
crystallization	O
or	O
by	O
seeding	O
calcium	O
oxalate	O

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months	O

In	O
contrast	O
to	O
norbuprenorphine	O
buprenorphine	B-Drug
and	O
its	O
glucuronide	O
metabolites	O
are	O
negligibly	O
transported	O
by	O
P-glycoprotein	O

Naloxone	B-Drug
or	O
naltrexone	B-Drug
is	O
the	O
preferred	O
human	O
opioid	O
receptor	O
antagonist	O

Respiratory	O
depression	O
euphoria	O
excessive	O
sedation	O
and	O
somnolence	O
so-called	O
'nodding'	O
by	O
recreational	O
opioid	O
users	O
constipation	O
miosis	O
pinpoint	O
pupils	O
nausea	O
bradycardia	O
behavioral	O
disturbances	O
severe	O
physical	O
psychological	O
dependence	O
on	O
morphine	B-Drug
is	O
more	O
likely	O
with	O
the	O
use	O
of	O
versus	O
dipropanoylmorphine	B-Drug

Hypersensitivity	O
reactions	O
drug	O
allergy	O
like	O
angioedema	O
and	O
hives	O
have	O
also	O
uncommonly	O
been	O
reported	O
in	O
association	O
with	O
bicalutamide	B-Drug

Fries	O
rearrangement	O
product	O
of	O
aspirin	B-Drug
used	O
to	O
make	O
salbutamol	B-Drug

In	O
Singapore	O
Nimetazepam	B-Drug
is	O
a	O
physician	O
prescribed	O
drug	O
and	O
regulated	O
under	O
the	O
Misuse	O
of	O
Drugs	O
Act	O

GHB	B-Drug
and	O
sodium	B-Drug
oxybate	I-Drug
were	O
also	O
studied	O
for	O
use	O
in	O
narcolepsy	O
from	O
the	O
1960s	O
onwards	O

The	O
contention	O
that	O
methylphenidate	B-Drug
acts	O
as	O
a	O
gateway	O
drug	O
has	O
been	O
discredited	O
by	O
multiple	O
sources	O
according	O
to	O
which	O
abuse	O
is	O
statistically	O
very	O
low	O
and	O
stimulant	O
therapy	O
in	O
childhood	O
does	O
not	O
increase	O
the	O
risk	O
for	O
subsequent	O
alcohol	O
disorders	O
later	O
life	O

Therefore	O
spironolactone	B-Drug
should	O
be	O
avoided	O
in	O
prostate	O
cancer	O
people	O
with	O
treatment-associated	O
mineralocorticoid	O
side	O
effects	O
of	O
abiraterone	B-Drug
acetate	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

Mephedrone	B-Drug
administration	O
caused	O
about	O
a	O
500%	O
increase	O
in	O
dopamine	O
and	O
950%	O
serotonin	O

The	O
World	O
Health	O
Organization	O
recommends	O
the	O
use	O
of	O
single-use	O
syringes	O
with	O
both	O
reuse	O
prevention	O
devices	O
and	O
a	O
needlestick	O
injury	O
mechanism	O
for	O
all	O
injections	B-Drug
to	O
prevent	O
accidental	O
disease	O
transmission	O

Long	O
term	O
use	O
of	O
high	O
doses	O
kratom	B-Drug
may	O
lead	O
to	O
development	O
tolerance	O
dependence	O
and	O
withdrawal	O
symptoms	O
on	O
stopping	O
including	O
loss	O
appetite	O
weight	O
decreased	O
sexual	O
drive	O
trouble	O
sleeping	O
muscle	O
spasms	O
bone	O
pains	O
jerky	O
movement	O
watery	O
eyes	O
hot	O
flushes	O
fever	O
diarrhea	O
restlessness	O
anger	O
sadness	O

Armodafinil	B-Drug
like	O
racemic	O
modafinil	B-Drug
may	O
also	O
possess	O
reinforcing	O
properties	O
as	O
evidenced	O
by	O
its	O
self-administration	O
in	O
monkeys	O
previously	O
trained	O
to	O
administer	O
cocaine;	O
armodafinil	B-Drug
was	O
partially	O
discriminated	O
stimulant-like	O
cocaine	B-Drug

CBD	B-Drug
also	O
acts	O
as	O
an	O
allosteric	O
modulator	O
of	O
the	O
-	O
and	O
-opioid	O
receptors	O

Diazepam	B-Drug
appears	O
to	O
act	O
on	O
areas	O
of	O
the	O
limbic	O
system	O
thalamus	O
and	O
hypothalamus	O
inducing	O
anxiolytic	O
effects	O

The	O
dose	O
of	O
oxycodone	B-Drug
must	O
be	O
reduced	O
in	O
patients	O
with	O
liver	O
function	O

JWH-018	B-Drug
has	O
an	O
EC50	O
of	O
102	O
nM	O
for	O
human	O
CB1	O
receptors	O
and	O
133	O
CB2	O

While	O
research	O
into	O
the	O
effects	O
of	O
kratom	B-Drug
have	O
begun	O
to	O
emerge	O
investigations	O
on	O
active	O
compound	O
mitragynine	B-Drug
are	O
less	O
common	O

Bicalutamide	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Casodex	B-Drug
among	O
others	O
is	O
an	O
antiandrogen	O
medication	O
that	O
primarily	O
used	O
to	O
treat	O
prostate	O
cancer	O

It	O
was	O
discovered	O
shortly	O
after	O
the	O
development	O
of	O
dihydromorphine	B-Drug
in	O
nature	O
and/or	O
first	O
synthesised	O
circa	O
1880	O
commercially	O
available	O
1900	O
hydromorphone	B-Drug
1924	O
and	O
oxymorphone	B-Drug
1914	O
that	O
mono	O
di	O
tri	O
perhaps	O
tetra	O
esters	O
could	O
be	O
developed	O
from	O
them	O
as	O
well	O

Ergolines	O
such	O
as	O
lysergic	O
acid	B-Drug
include	O
structural	O
elements	O
of	O
both	O
tryptamine	O
and	O
phenylethylamine	B-Drug
thus	O
act	O
on	O
the	O
whole	O
group	O
5-HT	O
receptors	O
adrenoceptors	O
mostly	O
type	O
dopamine	O
D2	O

9	O
lb	O
of	O
methamphetamine	B-Drug
shabu	B-Drug

The	O
alpha	O
position	O
adjacent	O
to	O
the	O
ketone	O
is	O
first	O
brominated	O
followed	O
by	O
nucleophilic	O
displacement	O
of	O
resulting	O
alpha-bromoketone	O
with	O
t-butylamine	O
and	O
treated	O
hydrochloric	O
acid	O
give	O
bupropion	B-Drug
as	O
hydrochloride	O
salt	O
in	O
7585%	O
overall	O
yield	O

Issajenko	O
and	O
later	O
the	O
Commission's	O
Chief	O
Justice	O
Charles	O
Dubin	O
concluded	O
Astaphan	O
had	O
been	O
peddling	O
Stanozolol	B-Drug
to	O
Johnson	O
other	O
Canadian	O
team	O
members	O
all	O
along	O
that	O
Furazabol	B-Drug
was	O
either	O
a	O
figment	O
of	O
his	O
imagination	O
or	O
an	O
outright	O
lie	O

In	O
genetically	O
engineered	O
mice	O
lacking	O
the	O
dopamine	O
transporter	O
modafinil	B-Drug
lacked	O
wake-promoting	O
activity	O
suggesting	O
that	O
this	O
was	O
DAT-dependent	O

Treatment	O
with	O
buprenorphine	B-Drug
may	O
be	O
associated	O
reduced	O
mortality	O

Apixaban	B-Drug
can	O
increase	O
the	O
risk	O
of	O
bleeding	O
which	O
may	O
be	O
serious	O
and	O
potentially	O
fatal	O

Research	O
on	O
LSD	B-Drug
peaked	O
in	O
the	O
1950s	O
and	O
early	O
1960s	O

In	O
1961	O
orciprenaline	B-Drug
a	O
longer	O
acting	O
2-agonist	O
was	O
found	O
but	O
it	O
not	O
as	O
potent	O
isoproterenol	O

Buspirone	B-Drug
has	O
also	O
been	O
found	O
to	O
bind	O
with	O
much	O
higher	O
affinity	O
the	O
dopamine	O
D3	O
and	O
D4	O
receptors	O
where	O
it	O
is	O
similarly	O
an	O
antagonist	O

The	O
SMH	O
initially	O
focused	O
on	O
heroin	B-Drug
use	O
but	O
a	O
follow-up	O
paper	O
added	O
cocaine	B-Drug

As	O
had	O
been	O
the	O
case	O
in	O
Indochina	O
during	O
Vietnam	O
War	O
US	O
invasion	O
has	O
fact	O
caused	O
a	O
massive	O
increase	O
opium	B-Drug
production	O
aforementioned	O
eradication	O
efforts	O
being	O
largely	O
window	O
dressing	O

In	O
November	O
1961	O
thalidomide	B-Drug
was	O
taken	O
off	O
the	O
market	O
due	O
to	O
massive	O
pressure	O
from	O
press	O
and	O
public	O

Nicotine	B-Drug
addicts	O
need	O
the	O
nicotine	B-Drug
to	O
temporarily	O
feel	O
normal	O

SSRI	O
and	O
SNRI	O
antidepressants	O
such	O
as	O
paroxetine	B-Drug
venlafaxine	B-Drug
may	O
cause	O
jaw	O
pain/jaw	O
spasm	O
reversible	O
syndrome	O
although	O
it	O
is	O
not	O
common	O
buspirone	B-Drug
appears	O
to	O
be	O
successful	O
in	O
treating	O
bruxism	O
on	O
SSRI/SNRI-induced	O
clenching	O

Trileptal	B-Drug
oxcarbazepine	B-Drug
an	O
anticonvulsant	O
used	O
as	O
a	O
mood	O
stabilizer	O

A	O
single	O
case	O
of	O
desomorphine	B-Drug
use	O
was	O
reported	O
in	O
Spain	O
2014	O
with	O
the	O
drug	O
consumed	O
orally	O
rather	O
than	O
by	O
injection	O

Compared	O
to	O
ephedrine	B-Drug
Oberlin	O
observed	O
that	O
it	O
had	O
similar	O
effects	O
on	O
vascular	O
smooth	O
muscle	O
tissue	O
stronger	O
at	O
the	O
uterus	O
and	O
no	O
local	O
effect	O
eye	O

At	O
the	O
same	O
time	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	O
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights	O

While	O
benzodiazepine	O
drugs	O
such	O
as	O
diazepam	B-Drug
can	O
cause	O
anterograde	O
amnesia	O
they	O
do	O
not	O
retrograde	O
amnesia;	O
information	O
learned	O
before	O
using	O
benzodiazepines	O
is	O
impaired	O

In	O
2018	O
Bourne	O
introduced	O
and	O
passed	O
multiple	O
bills	O
on	O
issues	O
ranging	O
from	O
keeping	O
children	O
in	O
the	O
classroom	O
by	O
limiting	O
long-term	O
school	O
suspensions	O
to	O
45	O
days	O
HB	O
1600	O
combatting	O
opiod	O
crisis	O
expanding	O
list	O
of	O
individuals	O
who	O
may	O
possess	O
administer	O
Naloxone	B-Drug
322	O

Slang	O
terms	O
for	O
GHB	B-Drug
include	O
liquid	O
ecstasy	B-Drug
lollipops	O
X	O
or	O
E	O
due	O
to	O
its	O
tendency	O
produce	O
euphoria	O
and	O
sociability	O
use	O
in	O
the	O
dance	O
party	O
scene	O

Norethisterone	B-Drug
was	O
discovered	O
in	O
1951	O
and	O
one	O
of	O
the	O
first	O
progestins	O
to	O
be	O
developed	O

Between	O
50	O
and	O
64%	O
of	O
rats	O
will	O
self-administer	O
diazepam	B-Drug

He	O
cites	O
the	O
criminalization	O
of	O
crack	O
cocaine	B-Drug
typically	O
associated	O
with	O
black	O
communities	O
and	O
lack	O
similar	O
powder	O
traditionally	O
white	O
as	O
an	O
example	O
how	O
drug	O
has	O
been	O
based	O
on	O
social	O
problems	O
rather	O
than	O
scientific	O
fact	O

In	O
Canada	O
the	O
history	O
of	O
thalidomide	B-Drug
dates	O
back	O
to	O
April	O
1	O
1961	O

Methylnaltrexone	B-Drug
is	O
unable	O
to	O
enter	O
the	O
brain	O
primarily	O
because	O
it	O
carries	O
a	O
positive	O
charge	O
on	O
its	O
nitrogen	O
atom	O

Chronic	O
or	O
excessive	O
use	O
of	O
temazepam	B-Drug
may	O
cause	O
drug	O
tolerance	O
which	O
can	O
develop	O
rapidly	O
so	O
this	O
is	O
not	O
recommended	O
for	O
long-term	O

25B-NBOMe	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic	O

Diamorphine	B-Drug
is	O
used	O
medically	O
in	O
several	O
countries	O
to	O
relieve	O
pain	O
such	O
as	O
during	O
childbirth	O
or	O
a	O
heart	O
attack	O
well	O
opioid	O
replacement	O
therapy	O

In	O
order	O
to	O
curb	O
misuse	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions	O

Androstenedione	B-Drug
is	O
the	O
common	O
precursor	O
of	O
androgen	O
and	O
estrogen	O
sex	O
hormones	O

Rifampicin	B-Drug
greatly	O
reduces	O
plasma	O
concentrations	O
of	O
oxycodone	B-Drug
due	O
to	O
strong	O
induction	O
CYP3A4	O

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
including	O
doxorubicin	B-Drug
and	O
melphalan	O
concurrently	O

A	O
radiolabelled	O
form	O
of	O
25I-NBOMe	B-Drug
can	O
be	O
used	O
for	O
mapping	O
the	O
distribution	O
5-HT2A	O
receptors	O
in	O
brain	O

Formally	O
known	O
as	O
the	O
National	O
Commission	O
on	O
Marihuana	B-Drug
and	O
Drug	O
Abuse	O
Shafer	O
led	O
by	O
former	O
Pennsylvania	O
governor	O
Raymond	O
P	O

Although	O
not	O
esters	O
the	O
following	O
ethers	O
of	O
natural	O
AAS	O
have	O
been	O
marketed	O
as	O
well:	O
Cloxotestosterone	O
acetate	O
Caprosem	O
17-O-chloral	O
hemiacetal	O
ether	O
testosterone	O
And	O
marketed:	O
Silandrone	O
SC-16148	O
17-O-trimethylsilyl	O
Methandriol	O
bisenanthoyl	O
Notandron-Depot	O
dipropionate	O
Arbolic	O
Durabolic	O
Or-Bolic	O
Probolik	O
Protabolin	O
propionate	O
Metilbisexovis	O
diacetate	O
Many	O
synthetic	O
nandrolone	B-Drug
19-nortestosterone	B-Drug
including	O
major	O
esters:	O
Nandrolone	B-Drug
decanoate	I-Drug
Deca-Durabolin	B-Drug
others	O
phenylpropionate	I-Drug
Durabolin	B-Drug
othersAnd	O
less	O
commonly	O
used	O
caproate	O
Anabolin	O
Depot	O
cyclohexanecarboxylate	O
Nor-Durandron	O
Norlongandron	O
cyclohexylpropionate	O
Andol	O
Fherbolico	O
Megabolin	O
Retar	O
Pluropon	O
Proteron-Depot	O
Sanabolicum	O
cypionate	O
Anabo	O
Depo-Nortestonate	O
Dynabol	O
Nortestrionate	O
Sterocrinolo	O
furylpropionate	O
Demelon	O
hexyloxyphenylpropionate	O
Anador	O
Anadur	O
Anadurine	O
hydrogen	O
succinate	O
Anabolico	O
Menidrabol	O
laurate	O
Clinibolin	O
Fortadex	O
Laurabolin	O
Anabolicus	O
Nor-Anabol	O
Nortesto	O
Norbyol	O
19	O
Pondus	O
Testobolin	O
sulfate	O
Keratyl	O
Nandrol	O
Nandain	O
Colirio	O
Ocul	O
undecanoate	O
Dynabolin	O
Dynabolon	O
Psychobolan	O
The	O
exist	O
but	O
were	O
never	O
Bolmantalate	O
17-adamantoate	O
benzoate	O
cyclotate	O
enanthate	O
formateLS-1727	O
is	O
a	O
nitrosocarbamate	O
ester	O
that	O
was	O
developed	O
cytostatic	O
antineoplastic	O
agent	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

Bicalutamide	B-Drug
does	O
not	O
share	O
the	O
risk	O
of	O
neuropsychiatric	O
side	O
effects	O
like	O
depression	O
and	O
fatigue	O
as	O
well	O
cardiovascular	O
coagulation	O
changes	O
blood	O
clots	O
fluid	O
retention	O
ischemic	O
cardiomyopathy	O
adverse	O
serum	O
lipid	O
that	O
CPA	O
has	O
been	O
associated	O
with	O

Nandrolone	B-Drug
phenylpropionate	I-Drug
or	O
nandrolone	B-Drug
17-phenylpropionate	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
derivative	O
of	O
testosterone	O

Amphetamine	B-Drug
also	O
has	O
a	O
slight	O
analgesic	O
effect	O
and	O
can	O
enhance	O
the	O
pain	O
relieving	O
effects	O
of	O
opioids	O

Psychotic	O
symptoms	O
are	O
associated	O
with	O
factors	O
such	O
as	O
higher	O
doses	O
of	O
bupropion	B-Drug
a	O
history	O
bipolar	O
disorder	O
or	O
psychosis	O
concomitant	O
medications	O
for	O
example	O
lithium	O
benzodiazepines	O
old	O
age	O
substance	O
abuse	O

Diamorphine	B-Drug
continues	O
to	O
be	O
widely	O
used	O
in	O
palliative	O
care	O
the	O
UK	O
where	O
it	O
is	O
commonly	O
given	O
by	O
subcutaneous	O
route	O
often	O
via	O
a	O
syringe	O
driver	O
if	O
patients	O
cannot	O
easily	O
swallow	O
morphine	B-Drug
solution	O

Russian	O
doctor	O
Evgeny	O
Krupitsky	O
has	O
claimed	O
to	O
have	O
obtained	O
encouraging	O
results	O
by	O
using	O
ketamine	B-Drug
as	O
part	O
of	O
a	O
treatment	O
for	O
alcohol	O
use	O
disorder	O
which	O
combines	O
psychedelic	O
and	O
aversive	O
techniques	O

Unlike	O
nonselective	O
benzodiazepine	O
drugs	O
and	O
zopiclone	B-Drug
which	O
distort	O
the	O
sleep	O
pattern	O
zaleplon	B-Drug
appears	O
to	O
induce	O
without	O
disrupting	O
natural	O
architecture	O

Its	O
formation	O
explains	O
why	O
the	O
solubility	O
of	O
iodine	O
in	O
water	O
may	O
be	O
increased	O
by	O
addition	O
potassium	B-Drug
iodide	I-Drug
solution:	O
I2	O
+	O
I	O
I3	O
Keq	O
=	O
~700	O
at	O
20	O
CMany	O
other	O
polyiodides	O
found	O
when	O
solutions	O
containing	O
and	O
crystallise	O
such	O
as	O
I5	O
I9	O
I24	O
I28	O
whose	O
salts	O
with	O
large	O
weakly	O
polarising	O
cations	O
Cs+	O
isolated	O

Levomethadone	B-Drug
has	O
been	O
sold	O
under	O
brand	O
names	O
including	O
L-Polaflux	O
L-Polamidon	O
L-Polamivet	O
Levadone	O
Levo-Methasan	O
Levothyl	O
Mevodict	O
and	O
Vistadict	O
among	O
others	O

Oxycodone	B-Drug
is	O
eliminated	O
in	O
the	O
urine	O
10%	O
as	O
unchanged	O
oxycodone	B-Drug
45%	O
21%	O
N-demethylated	O
metabolites	O
noroxycodone	O
noroxymorphone	B-Drug
noroxycodols	O
11	O
6%	O
O-demethylated	O
oxymorphone	B-Drug
oxymorphols	O
and	O
8%	O
6-keto-reduced	O
oxycodols	O

Carisoprodol	B-Drug
meprobamate	B-Drug
and	O
related	O
drugs	O
such	O
as	O
tybamate	O
have	O
the	O
potential	O
to	O
produce	O
physical	O
dependence	O
of	O
barbiturate	O
type	O
following	O
periods	O
prolonged	O
use	O

As	O
a	O
glucocorticoid	O
dexamethasone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
receptor	O
GR	O

One	O
study	O
found	O
that	O
the	O
depressed	O
testosterone	O
levels	O
of	O
heroin	B-Drug
addicts	O
returned	O
to	O
normal	O
within	O
one	O
month	O
abstinence	O
suggesting	O
effect	O
is	O
readily	O
reversible	O
and	O
not	O
permanent	O

Severe	O
injection	O
site	O
necrosis	O
and	O
sepsis	O
has	O
occurred	O
sometimes	O
requiring	O
amputation	O
of	O
limb	O
with	O
multiple	O
pentazocine	B-Drug
lactate	O

In	O
2016	O
Merck	O
was	O
a	O
defendant	O
in	O
approximately	O
1370	O
product	O
liability	O
lawsuits	O
which	O
had	O
been	O
filed	O
by	O
customers	O
alleging	O
they	O
have	O
experienced	O
persistent	O
sexual	O
side	O
effects	O
following	O
cessation	O
of	O
treatment	O
with	O
finasteride	B-Drug

It	O
is	O
recommended	O
that	O
sofosbuvir/ribarivin	O
combinations	O
be	O
avoided	O
in	O
pregnant	O
females	O
and	O
their	O
male	O
sexual	O
partners	O
order	O
to	O
reduce	O
harmful	O
fetal	O
defects	O
caused	O
by	O
ribavirin	B-Drug
sofosbuvir	B-Drug

Military	O
Needs	O
its	O
Speedpublished	O
in	O
Wired	O
on	O
February	O
10	O
2003reports:	O
But	O
the	O
Defense	O
Department	O
which	O
distributed	O
millions	O
of	O
amphetamine	B-Drug
tablets	O
to	O
troops	O
during	O
World	O
War	O
II	O
Vietnam	O
and	O
Gulf	O
soldiers	O
insisting	O
that	O
they	O
are	O
not	O
only	O
harmless	O
but	O
beneficial	O

Diazepam	B-Drug
has	O
been	O
found	O
as	O
an	O
adulterant	O
in	O
heroin	B-Drug

Cocaine	B-Drug
is	O
smoked	O
by	O
inhaling	O
the	O
vapor	O
produced	O
when	O
solid	O
cocaine	B-Drug
heated	O
to	O
point	O
that	O
it	O
sublimates	O

Other	O
5-HT2A	O
agonists	O
like	O
LSD	B-Drug
also	O
have	O
potent	O
anti-inflammatory	O
effects	O
against	O
TNF-alpha-induced	O
inflammation	O

Beginning	O
in	O
2015	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses	O

By	O
2000	O
the	O
Flenory	O
brothers	O
had	O
established	O
a	O
large	O
organization	O
overseeing	O
multi-kilogram	O
cocaine	B-Drug
distribution	O
cells	O
in	O
numerous	O
U	O

The	O
synthesis	O
of	O
cannabidiol	B-Drug
has	O
been	O
accomplished	O
by	O
several	O
research	O
groups	O

Clinical	O
trials	O
on	O
humans	O
involving	O
either	O
PO	O
doses	O
of	O
methyltestosterone	B-Drug
or	O
injections	B-Drug
testosterone	O
propionate	O
began	O
as	O
early	O
1937	O

The	O
differential	O
diagnosis	O
should	O
include	O
intoxication	O
by	O
other	O
substances	O
with	O
sedative	O
effects	O
such	O
as	O
benzodiazepines	O
anticonvulsants	O
carbamazepine	B-Drug
alcohols	O
ethanol	O
ethylene	O
glycol	O
methanol	O
opioids	O
carbon	O
monoxide	O
sleep	O
aids	O
and	O
gamma-Hydroxybutyric	B-Drug
acid	I-Drug
GHB	B-Drug
a	O
known	O
date	O
rape	O
drug	O

The	O
progestin	O
tibolone	O
7-methyl-17-ethynyl-510-19-nortestosterone	O
is	O
also	O
closely	O
related	O
to	O
trestolone	O
19-nortestosterone	B-Drug

At	O
the	O
same	O
time	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	O
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights	O

United	O
Kingdom:	O
On	O
January	O
14	O
2016	O
the	O
Advisory	O
Council	O
on	O
Misuse	O
of	O
Drugs	O
ACMD	O
wrote	O
a	O
letter	O
to	O
Home	O
Office	O
ministers	O
recommending	O
that	O
pregabalin	B-Drug
alongside	O
gabapentin	B-Drug
should	O
be	O
controlled	O
under	O
Act	O
1971	O

Over-the-counter	O
use	O
of	O
substituted	O
amphetamines	O
was	O
initiated	O
in	O
the	O
early	O
1930s	O
by	O
pharmaceutical	O
company	O
Smith	O
Kline	O
&	O
French	O
now	O
part	O
GlaxoSmithKline	O
as	O
a	O
medicine	O
Benzedrine	B-Drug
for	O
colds	O
and	O
nasal	O
congestion	O

The	O
leaves	O
and	O
bark	O
also	O
contain	O
small	O
amounts	O
of	O
DMT	O
5-MeO-DMT	B-Drug
related	O
compounds	O

MDMA	B-Drug
was	O
first	O
developed	O
in	O
1912	O
by	O
Merck	O

Spironolactone	B-Drug
bodies	O
are	O
eosinophilic	O
round	O
concentrically	O
laminated	O
cytoplasmic	O
inclusions	O
surrounded	O
by	O
clear	O
halos	O
in	O
preparations	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
which	O
included	O
PCP	B-Drug
to	O
schizophrenia	O
was	O
26%	O

Dichloralphenazone	B-Drug
is	O
a	O
1:2	O
mixture	O
of	O
antipyrine	O
with	O
chloral	O
hydrate	O

Cannabis	O
dependence	O
develops	O
in	O
9%	O
of	O
users	O
significantly	O
less	O
than	O
that	O
heroin	B-Drug
cocaine	B-Drug
alcohol	O
and	O
prescribed	O
anxiolytics	O
but	O
slightly	O
higher	O
for	O
psilocybin	O
mescaline	B-Drug
or	O
LSD	B-Drug

Nortriptyline	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1964	O

Heroin's	O
oral	O
bioavailability	O
is	O
both	O
dose-dependent	O
as	O
morphine's	O
and	O
significantly	O
higher	O
than	O
use	O
of	O
morphine	B-Drug
itself	O
reaching	O
up	O
to	O
64	O
Heroin	B-Drug

In	O
drug-substitution	O
experiments	O
in	O
rats	O
TCB-2	O
was	O
found	O
to	O
be	O
of	O
similar	O
potency	O
both	O
LSD	B-Drug
and	O
Bromo-DragonFLY	O
ranking	O
it	O
among	O
the	O
most	O
potent	O
phenethylamine	O
hallucinogens	O
yet	O
discovered	O

Studies	O
have	O
found	O
that	O
combined	O
birth	O
control	O
pills	O
containing	O
newer-generation	O
progestins	O
such	O
as	O
desogestrel	B-Drug
gestodene	O
norgestimate	B-Drug
drospirenone	O
and	O
cyproterone	O
acetate	O
are	O
associated	O
with	O
a	O
1	O

Buprenorphine	B-Drug
is	O
a	O
partial	O
opioid	O
receptor	O
agonist	O

His	O
invention	O
of	O
propranolol	B-Drug
the	O
beta	O
adrenergic	O
receptor	O
antagonist	O
that	O
revolutionised	O
medical	O
management	O
angina	O
pectoris	O
is	O
considered	O
to	O
be	O
one	O
most	O
important	O
contributions	O
clinical	O
medicine	O
and	O
pharmacology	O
20th	O
century	O

In	O
2013	O
another	O
hypnotic	O
medication	O
zaleplon	B-Drug
was	O
found	O
to	O
have	O
been	O
used	O
as	O
an	O
active	O
ingredient	O
in	O
a	O
blend	O
that	O
had	O
sold	O
New	O
Zealand	O
during	O
2011	O
and	O
2012	O

In	O
the	O
horror	O
video-game	O
Amnesia:	O
The	O
Dark	O
Descent	O
2010	O
laudanum	B-Drug
can	O
be	O
found	O
at	O
several	O
places	O
in	O
castle	O
and	O
used	O
to	O
regain	O
health	O

Except	O
as	O
specifically	O
authorized	O
it	O
is	O
illegal	O
for	O
any	O
person:	O
to	O
manufacture	O
distribute	O
or	O
dispense	O
possess	O
with	O
intent	O
a	O
controlled	O
substance;	O
create	O
counterfeit	O
substance	B-Drug

-Endorphin	O
has	O
approximately	O
18	O
to	O
33	O
times	O
the	O
analgesic	O
potency	O
of	O
morphine	B-Drug
though	O
its	O
hormonal	O
effect	O
is	O
species	O
dependent	O

In	O
addition	O
to	O
its	O
well	O
explored	O
interactions	O
with	O
NMDA	O
receptors	O
PCP	B-Drug
has	O
also	O
been	O
shown	O
inhibit	O
dopamine	O
reuptake	O
and	O
thereby	O
leads	O
increased	O
extracellular	O
levels	O
of	O
hence	O
dopaminergic	O
neurotransmission	O

Pharmacokinetic	O
interactions	O
with	O
anesthetics	O
are	O
unlikely	O
given	O
that	O
tranylcypromine	B-Drug
is	O
a	O
high-affinity	O
substrate	O
for	O
CYP2A6	O
and	O
does	O
not	O
inhibit	O
CYP	O
enzymes	O
at	O
therapeutic	O
concentrations	O

In	O
another	O
approach	O
to	O
analogues	O
nortestosterone	B-Drug
1	O
is	O
first	O
converted	O
the	O
dithioketal	O
2	O
by	O
treatment	O
with	O
dithioglycol	O
in	O
presence	O
of	O
boron	O
trifluoride	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state	O

Due	O
to	O
clomethiazole's	O
action	O
at	O
the	O
barbiturate	O
complex	O
benzodiazepine	O
antidote	O
flumazenil	B-Drug
cannot	O
reverse	O
effects	O
of	O
overdose;	O
overdose	O
treatment	O
is	O
restricted	O
application	O
a	O
mechanical	O
ventilation	O
apparatus	O
until	O
enough	O
drug	O
has	O
been	O
metabolized	O
and/or	O
excreted	O
for	O
patient	O
breathe	O
sufficiently	O
without	O
assistance	O

An	O
International	O
Opium	B-Drug
Convention	O
was	O
signed	O
by	O
13	O
nations	O
at	O
The	O
Hague	O
on	O
January	O
23	O
1912	O
during	O
the	O
First	O
Conference	O

In	O
the	O
setting	O
of	O
a	O
colonoscopy	O
naloxone	B-Drug
is	O
rarely	O
administered	O
but	O
when	O
it	O
its	O
half-life	O
shorter	O
than	O
some	O
common	O
opioid	O
agonists	O

The	O
World	O
2010	O
cannabis	O
mushrooms	O
Scrooged	O
1988	O
marijuana	O
and	O
heroin	B-Drug
Secrets	O
of	O
Chinatown	O
1935	O
opium	O
Serpent	O
the	O
Rainbow	O
Haitian	O
witch	O
concoction	O
containing	O
scopolamine	O
Seven-Per-Cent	O
Solution	O
1976	O
cocaine	B-Drug
Sex	O
City	O
2008	O
&	O
Drugs	O
Rock	O
Roll	O
amphetamines	B-Drug
Sexy	O
Bitches	O
2005	O
Killer	O
Shank	O
khat	O
She	O
Shoulda	O
Said	O
'No'!	O
1949	O
Sherrybaby	O
2004	O
Shot	O
List	O
2009	O
LSD	B-Drug
Shrink	O
amphetamine	B-Drug
Shrooms	O
2007	O
magic	O
Siberia	O
1998	O
MDMA	B-Drug
amyl	O
nitrate	O
Sid	O
Nancy	O
1986	O
methadone	B-Drug
Skeleton	O
Twins	O
2014	O
nitrous	O
oxide	O
alcohol	O
Skidoo	O
1968	O
Slackers	O
2002	O
SLC	O
Punk!	O
1999	O
oxycodone	B-Drug
Percocet	B-Drug
Sleepaway	O
Camp	O
II:	O
Unhappy	O
Campers	O
Slim	O
Susie	O
2003	O
Smiley	O
Face	O
Smoked	O

Since	O
2015	O
several	O
reports	O
of	O
sometimes-fatal	O
cardiotoxicity	O
due	O
to	O
high-dose	O
loperamide	B-Drug
abuse	O
have	O
been	O
published	O

Nalbuphine	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Nubain	B-Drug
among	O
others	O
is	O
an	O
opioid	O
analgesic	O
which	O
used	O
in	O
treatment	O
of	O
pain	O

The	O
relationship	O
between	O
the	O
effect	O
of	O
MDMA	B-Drug
and	O
serotonin's	O
role	O
in	O
visual	O
orientation	O
processing	O
has	O
been	O
investigated	O
following	O
a	O
prior	O
study	O
conducted	O
1990s	O
by	O
Maisini	O
Antonietti	O
Moja	O
1990	O

The	O
safety	O
and	O
efficacy	O
of	O
Belviq	B-Drug
were	O
evaluated	O
in	O
three	O
randomized	O
placebo-controlled	O
trials	O
that	O
included	O
nearly	O
8000	O
obese	O
overweight	O
patients	O
with	O
without	O
type	O
2	O
diabetes	O
treated	O
for	O
52	O
to	O
104	O
weeks	O

This	O
method	O
is	O
more	O
cost	O
effective	O
and	O
therefore	O
prevalent	O
on	O
the	O
inner-city	O
streets	O
while	O
powder	O
cocaine	B-Drug
remains	O
popular	O
in	O
white	O
suburbia	O

The	O
brand	O
name	O
Durabolin	B-Drug
O	O
is	O
a	O
contraction	O
of	O
Oral	O
being	O
the	O
nandrolone	B-Drug
ester	O
phenylpropionate	I-Drug

In	O
contrast	O
to	O
the	O
other	O
gabapentinoids	O
pharmacokinetics	O
of	O
phenibut	B-Drug
have	O
been	O
little-studied	O
and	O
its	O
oral	O
bioavailability	O
is	O
unknown	O

Bromazepam	B-Drug
is	O
similar	O
in	O
side	O
effects	O
to	O
other	O
benzodiazepines	O

75%	O
mannitol	B-Drug

Nubain	B-Drug
was	O
approved	O
for	O
marketing	O
in	O
the	O
United	O
States	O
1978	O
and	O
remains	O
as	O
only	O
opioid	O
analgesic	O
of	O
this	O
type	O
marketed	O
U	O

The	O
principle	O
synthetic	O
drugs	O
manufactured	O
clandestinely	O
are	O
the	O
amphetamine-type	O
stimulants	O
ATS	O
which	O
include	O
widely	O
abused	O
amphetamine	B-Drug
and	O
methamphetamine	B-Drug
as	O
well	O
more	O
recently	O
popularized	O
methylenedioxymethamphetamine	B-Drug
MDMA	B-Drug
known	O
ecstasy	B-Drug

Studies	O
have	O
suggested	O
cocaethylene	B-Drug
is	O
both	O
more	O
euphoric	O
and	O
has	O
a	O
higher	O
cardiovascular	O
toxicity	O
than	O
cocaine	B-Drug
by	O
itself	O

For	O
humans	O
the	O
LD50	O
of	O
mescaline	B-Drug
has	O
been	O
reported	O
to	O
be	O
approximately	O
880	O
mg/kg	O

Benzodiazepines	O
such	O
as	O
lorazepam	B-Drug
are	O
the	O
drugs	O
of	O
choice	O
to	O
control	O
agitation	O
and	O
seizures	O
when	O
present	O

A	O
number	O
of	O
derivatives	O
PCP	B-Drug
have	O
been	O
sold	O
for	O
recreational	O
and	O
non-medical	O
use	O

THC	O
hashish	B-Drug
and	O
marijuana	O
Synthetic	O
cannabimimetics	O
e	O

Each	O
g	O
RAE	O
corresponds	O
to	O
1	O
retinol	B-Drug
2	O
of	O
-carotene	O
in	O
oil	O
12	O
dietary	O
beta-carotene	O
or	O
24	O
the	O
three	O
other	O
provitamin-A	O
carotenoids	O

solved	O
the	O
crystal	O
structure	O
of	O
4-HO-MiPT	B-Drug
fumarate	O

Opium	B-Drug
and	O
after	O
1820	O
morphine	B-Drug
was	O
mixed	O
with	O
everything	O
imaginable:	O
mercury	O
hashish	B-Drug
cayenne	O
pepper	O
ether	O
chloroform	O
belladonna	O
whiskey	O
wine	O
brandy	O

By	O
blocking	O
the	O
MR	O
spironolactone	B-Drug
inhibits	O
effects	O
of	O
mineralocorticoids	O
in	O
body	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

A	O
randomized	O
controlled	O
trial	O
demonstrated	O
however	O
that	O
even	O
in	O
novice	O
athletes	O
a	O
10-week	O
strength	O
training	O
program	O
accompanied	O
by	O
testosterone	B-Drug
enanthate	I-Drug
at	O
600	O
mg/week	O
may	O
improve	O
more	O
than	O
alone	O
does	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
which	O
included	O
PCP	B-Drug
to	O
schizophrenia	O
was	O
26%	O

Overdose	O
of	O
levonorgestrel	B-Drug
as	O
an	O
emergency	O
contraceptive	O
has	O
not	O
been	O
described	O

For	O
instance	O
propofol	B-Drug
injection	O
might	O
be	O
used	O
to	O
start	O
the	O
anesthetic	O
fentanyl	B-Drug
blunt	O
stress	O
response	O
midazolam	B-Drug
given	O
ensure	O
amnesia	O
and	O
sevoflurane	B-Drug
inhaled	O
during	O
procedure	O
maintain	O
effects	O

Often	O
Ecstasy	B-Drug
is	O
combined	O
with	O
amphetamines	O
or	O
other	O
drugs	O

PRO-LAD	B-Drug
is	O
illegal	O
in	O
Switzerland	O
as	O
of	O
December	O
2015	O

Bioequivalence	O
studies	O
have	O
shown	O
that	O
benzhydrocodone/APAP	O
is	O
bioequivalent	O
to	O
other	O
immediate-release	O
hydrocodone	B-Drug
combination	O
products	O
such	O
as	O
7	O
APAP	B-Drug

Clobazam	B-Drug
is	O
a	O
15-benzodiazepine	O
meaning	O
that	O
its	O
diazepine	O
ring	O
has	O
nitrogen	O
atoms	O
at	O
the	O
1	O
and	O
5	O
positions	O
instead	O
of	O
usual	O
4	O

The	O
nearest	O
Opioid	O
Treatment	O
Program	O
OTP	O
could	O
be	O
up	O
to	O
an	O
hour	O
away	O
and	O
when	O
daily	O
methadone	B-Drug
doses	O
are	O
required	O
for	O
treatment	O
this	O
may	O
interfere	O
with	O
the	O
success	O
of	O
MAT	O
or	O
client's	O
compliance	O
in	O
program	O

Celgene	O
has	O
sponsored	O
numerous	O
clinical	O
trials	O
with	O
analogues	O
to	O
thalidomide	B-Drug
such	O
as	O
lenalidomide	B-Drug
that	O
are	O
substantially	O
more	O
powerful	O
and	O
have	O
fewer	O
side	O
effects	O
except	O
for	O
greater	O
myelosuppression	O

025%	O
mescaline	B-Drug
Echinopsis	O
terscheckii	O
syn	O

Opium	B-Drug
and	O
after	O
1820	O
morphine	B-Drug
was	O
mixed	O
with	O
everything	O
imaginable:	O
mercury	O
hashish	B-Drug
cayenne	O
pepper	O
ether	O
chloroform	O
belladonna	O
whiskey	O
wine	O
brandy	O

MDMA	B-Drug
tablets	O
typically	O
have	O
low	O
purity	O
due	O
to	O
bulking	O
agents	O
that	O
are	O
added	O
dilute	O
the	O
drug	O
and	O
increase	O
profits	O
notably	O
lactose	O
binding	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Thus	O
methadone	B-Drug
which	O
mimics	O
the	O
effects	O
of	O
opioids	O
and	O
renders	O
addict	O
compliant	O
is	O
labeled	O
as	O
a	O
treatment	O
so	O
achieves	O
disciplinary	O
objectives	O
managing	O
undesirables	O

Methohexital	B-Drug
is	O
primarily	O
used	O
to	O
induce	O
anesthesia	O
and	O
generally	O
provided	O
as	O
a	O
sodium	O
salt	O
i	O

Oldham	O
Kelsey	O
was	O
given	O
a	O
Presidential	O
award	O
for	O
distinguished	O
service	O
from	O
the	O
federal	O
government	O
not	O
allowing	O
thalidomide	B-Drug
to	O
be	O
approved	O
sale	O
in	O
US	O

A	O
1913	O
New	O
York	O
state	O
law	O
limited	O
druggists	O
cocaine	B-Drug
stocks	O
to	O
under	O
5	O
ounces	O

In	O
dopaminergic	O
cells	O
in	O
the	O
brain	O
tyrosine	O
is	O
converted	O
to	O
L-DOPA	B-Drug
by	O
enzyme	O
hydroxylase	O
TH	O

Nirvana	O
lead	O
singer	O
Kurt	O
Cobain's	O
heroin	B-Drug
addiction	O
was	O
well	O
documented	O

Codeine	B-Drug
clopidogrel	B-Drug
tamoxifen	B-Drug
and	O
warfarin	B-Drug
a	O
few	O
examples	O
of	O
medications	O
that	O
follow	O
the	O
above	O
metabolic	O
pathways	O

In	O
1969	O
Graham	O
Liggins	O
a	O
medical	O
research	O
scientist	O
began	O
investigating	O
the	O
effects	O
of	O
dexamethasone	B-Drug
administration	O
on	O
timing	O
labor	O
in	O
pregnant	O
sheep	O

Zolpidem	B-Drug
is	O
a	O
GABAA	O
receptor	O
agonist	O
of	O
the	O
imidazopyridine	O
class	O

The	O
relatively	O
mild	O
stimulant	O
effects	O
of	O
pipradrol	B-Drug
meant	O
that	O
it	O
was	O
scheduled	O
under	O
the	O
less	O
restrictive	O
classes	O
in	O
most	O
countries	O
i	O

In	O
June	O
2012	O
two	O
teens	O
in	O
Grand	O
Forks	O
North	O
Dakota	O
and	O
East	O
Minnesota	O
fatally	O
overdosed	O
on	O
a	O
substance	O
that	O
was	O
allegedly	O
25I-NBOMe	B-Drug
resulting	O
lengthy	O
sentences	O
for	O
of	O
the	O
parties	O
involved	O
Federal	O
indictment	O
against	O
Texas-based	O
online	O
vendor	O

Cocaine	B-Drug
was	O
introduced	O
into	O
clinical	O
use	O
as	O
a	O
local	O
anesthetic	O
in	O
Germany	O
1884	O
about	O
the	O
same	O
time	O
Sigmund	O
Freud	O
published	O
his	O
work	O
ber	O
Coca	B-Drug
which	O
he	O
wrote	O
that	O
cocaine	B-Drug
causes:	O
Exhilaration	O
and	O
lasting	O
euphoria	O
no	O
way	O
differs	O
from	O
normal	O
of	O
healthy	O
person	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia	O

2006	O
film	O
The	O
Good	O
Shepherd	O
depicts	O
a	O
defector	O
who	O
takes	O
his	O
own	O
life	O
by	O
jumping	O
from	O
high	O
window	O
after	O
interrogation	O
using	O
torture	O
and	O
LSD	B-Drug

In	O
2016	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day	O

Based	O
upon	O
drug	O
and	O
precursor	O
seizures	O
worldwide	O
illicit	O
amphetamine	B-Drug
production	O
trafficking	O
is	O
much	O
less	O
prevalent	O
than	O
that	O
of	O
methamphetamine	B-Drug

Armodafinil	B-Drug
has	O
wake-promoting	O
actions	O
similar	O
to	O
sympathomimetic	O
agents	O
including	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
although	O
its	O
pharmacologic	O
profile	O
is	O
not	O
identical	O
that	O
of	O
the	O
amines	O

Methazolamide	B-Drug

Some	O
heroin	B-Drug
dealers	O
mix	O
fentanyl	B-Drug
powder	O
with	O
to	O
increase	O
potency	O
or	O
compensate	O
for	O
low-quality	O

Transdermal	O
patches	B-Drug
providing	O
a	O
combination	O
of	O
50	O
g/day	O
estradiol	O
and	O
0	O

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug
nitrous	O
oxide	O
and	O
dizocilpine	O
MK-801	O

Inhibition	O
of	O
the	O
5-HT2C	O
receptor	O
is	O
a	O
suggested	O
factor	O
in	O
mechanism	O
anti-depressant	O
effects	O
agomelatine	O
and	O
maprotiline	B-Drug

As	O
had	O
been	O
initially	O
hoped	O
dextromethorphan	B-Drug
was	O
a	O
solution	O
for	O
some	O
of	O
the	O
problems	O
associated	O
with	O
use	O
codeine	B-Drug
phosphate	I-Drug
as	O
cough	O
suppressant	O
such	O
sedation	O
and	O
opiate	O
dependence	O
but	O
like	O
dissociative	O
anesthetics	O
phencyclidine	B-Drug
ketamine	B-Drug
later	O
became	O
nonmedical	O

Illegal	O
heroin	B-Drug
is	O
often	O
mixed	O
with	O
other	O
substances	O
such	O
as	O
sugar	O
starch	O
caffeine	O
quinine	B-Drug
or	O
opioids	O
like	O
fentanyl	B-Drug

In	O
addition	O
the	O
authors	O
found	O
covert	O
duplication	O
of	O
reports	O
on	O
ondansetron	B-Drug
was	O
not	O
easy	O
to	O
detect	O
because	O
lack	O
cross-referencing	O
between	O
papers	O
and	O
containing	O
duplicate	O
findings	O
were	O
cited	O
in	O
eight	O
reviews	O
drug	O

Tolerance	O
to	O
opioids	O
is	O
attenuated	O
by	O
a	O
number	O
of	O
substances	O
including:	O
calcium	O
channel	O
blockers	O
intrathecal	O
magnesium	O
and	O
zinc	O
NMDA	O
antagonists	O
such	O
as	O
dextromethorphan	B-Drug
ketamine	B-Drug
memantine	B-Drug

Amphetamine	B-Drug
is	O
a	O
weak	O
base	O
with	O
pKa	O
of	O
9	O

In	O
one	O
study	O
buprenorphine	B-Drug
was	O
found	O
to	O
be	O
effective	O
in	O
a	O
subset	O
of	O
individuals	O
with	O
treatment-refractory	O
obsessivecompulsive	O
disorder	O

The	O
vast	O
majority	O
of	O
valproate	B-Drug
metabolism	O
occurs	O
in	O
the	O
liver	O

When	O
taken	O
in	O
prescribed	O
quantities	O
cough	O
syrup	O
is	O
quite	O
safe	O
but	O
dangers	O
arise	O
higher	O
doses	O
since	O
promethazine	B-Drug
a	O
depressant	O
of	O
the	O
central	O
nervous	O
system	O
CNS	O
and	O
codeine	B-Drug
respiratory	O

Lorazepam	B-Drug
by	O
mouth	O
is	O
given	O
90	O
to	O
120	O
minutes	O
before	O
procedures	O
and	O
intravenous	O
lorazepam	B-Drug
as	O
late	O
10	O

In	O
the	O
United	O
States	O
CB1	O
receptor	O
agonists	O
of	O
1-1-naphthylmethyleneindene	O
class	O
such	O
as	O
JWH-176	B-Drug
and	O
JWH-171	B-Drug
are	O
Schedule	O
I	O
Controlled	O
Substances	O

The	O
oil	O
may	O
be	O
further	O
refined	O
by	O
1	O
alkali	O
washing	O
or	O
removing	O
the	O
heavy	O
aromatic	O
carboxylic	O
acids	O
with	O
antibiotic	O
properties	O
which	O
cause	O
heartburn	O
gallbladder	O
and	O
pancreas	O
irritation	O
resistance	O
to	O
hemp	O
antibiotics;	O
2	O
conversion	O
of	O
CBD	B-Drug
THC	O

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body	O
to	O
develop	O
safer	O
analogs	O
find	O
further	O
uses	O
for	O

Poor	O
compliance	O
in	O
taking	O
the	O
medicine	O
is	O
most	O
common	O
cause	O
of	O
elevated	O
TSH	O
levels	O
people	O
receiving	O
appropriate	O
doses	O
levothyroxine	B-Drug

The	O
promethazine	B-Drug
and	O
codeine	B-Drug
concoction	O
first	O
gained	O
popularity	O
in	O
the	O
underground	O
hip	O
hop	O
scene	O
Houston	O
where	O
musician	O
Big	O
Hawk	O
said	O
it	O
was	O
consumed	O
as	O
early	O
1960s	O
1970s	O
becoming	O
more	O
widely	O
used	O
1990s	O

Amphetamine	B-Drug
stimulates	O
the	O
medullary	O
respiratory	O
centers	O
producing	O
faster	O
and	O
deeper	O
breaths	O

Desomorphine	B-Drug
abuse	O
in	O
Russia	O
attracted	O
international	O
attention	O
2010	O
due	O
to	O
an	O
increase	O
clandestine	O
production	O
presumably	O
its	O
relatively	O
simple	O
synthesis	O
from	O
codeine	B-Drug
available	O
over-the-counter	O

25I-NBOMe	B-Drug
acts	O
as	O
a	O
highly	O
potent	O
full	O
agonist	O
for	O
the	O
human	O
5-HT2A	O
receptor	O
with	O
dissociation	O
constant	O
Ki	O
of	O
0	O

Following	O
administration	O
of	O
danazol	B-Drug
peak	O
concentrations	O
occur	O
after	O
2	O
to	O
8	O
hours	O
with	O
a	O
median	O
4	O

European	O
literature	O
such	O
as	O
Confessions	O
of	O
an	O
English	O
Opium-Eater	O
by	O
Thomas	O
De	O
Quincey	O
one	O
the	O
first	O
commentators	O
on	O
Kant	O
and	O
Samuel	O
Taylor	O
Coleridge's	O
Kubla	O
Khan	O
described	O
use	O
phenomenal	O
character	O
mind-altering	O
substances	O
Opium	B-Drug

Lisdexamfetamine	B-Drug
is	O
taken	O
by	O
mouth	O

Reports	O
indicate	O
that	O
acetic	O
anhydride	O
is	O
diverted	O
from	O
China	O
to	O
morphine	B-Drug
and	O
heroin	B-Drug
refineries	O
in	O
the	O
Golden	O
Triangle	O

In	O
response	O
to	O
the	O
demonstrations	O
Deputy	O
Minister	O
of	O
Labour	O
Mackenzie	O
King	O
travelled	O
British	O
Columbia	O
and	O
interviewed	O
two	O
opium	B-Drug
merchants	O

Endo	O
responded	O
by	O
voluntarily	O
removing	O
Opana	B-Drug
ER	I-Drug
from	O
the	O
market	O
a	O
month	O
later	O

Medication	O
like	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
can	O
be	O
used	O
to	O
treat	O
addiction	O
prescription	O
opiates	O
behavioral	O
therapies	O
stimulants	O
benzodiazepines	O
other	O
drugs	O

In	O
2013	O
Contador's	O
teammate	O
on	O
the	O
Team	O
Saxo	O
Bank	O
squad	O
Michael	O
Rogers	O
tested	O
positive	O
for	O
clenbuterol	B-Drug
at	O
Japan	O
Cup	O
bike	O
race	O

NETA	O
is	O
taken	O
by	O
mouth	O
similarly	O
to	O
norethisterone	B-Drug
while	O
NETE	O
given	O
injection	O
into	O
muscle	O

In	O
rats	O
roxibolone	O
counteracts	O
the	O
catabolic	O
effects	O
control	O
of	O
nitrogen	O
balance	O
and	O
increased	O
alkaline	O
phosphatase	O
levels	O
induced	O
by	O
potent	O
glucocorticoid	O
dexamethasone	B-Drug
phosphate	I-Drug

Caffeine	O
diet	B-Drug
pills	I-Drug
painkillers	O
and	O
alcohol	O
are	O
not	O
featured	O
in	O
the	O
list	O
neither	O
is	O
non-administrated	O
illegal	O
usage	O

Hash	B-Drug
consumption	O
is	O
also	O
popular	O
in	O
Europe	O
where	O
it	O
the	O
most	O
common	O
form	O
of	O
cannabis	O
use	O

MDMB-CHMICA's	O
main	O
metabolic	O
reactions	O
comprise	O
mono-hydroxylations	O
and	O
hydrolysis	O
of	O
the	O
carboxylic	O
ester	O
function	O
MDMB-CHMICA	B-Drug

Up	O
to	O
700	O
hospitalisations	O
and	O
25	O
deaths	O
were	O
initially	O
linked	O
MDMB-FUBINACA	B-Drug
in	O
media	O
government	O
reports	O
subsequent	O
testing	O
confirmed	O
that	O
at	O
least	O
1000	O
40	O
had	O
occurred	O
as	O
a	O
consequence	O
of	O
intoxication	O
by	O
March	O
2015	O

Tablets	O
white	O
round	O
tablet	O
Depakine	O
Chinese:	O
;	O
pinyin:	O
di-ba-dian	O
by	O
Sanofi	O
Winthrop	O
Industrie	O
France	O
Epival	O
200	O
enteric	O
coated	O
and	O
500	O
extended	O
release	O
Iran	O
Najo	O
Slow	O
tablets	O
Chrono	O
Depalept	O
are	O
equivalent	O
to	O
Epilim	B-Drug
above	O

The	O
medication	O
is	O
a	O
prodrug	O
of	O
norethisterone	B-Drug
in	O
the	O
body	O

In	O
the	O
United	O
States	O
all	O
CB1	O
receptor	O
agonists	O
of	O
3-1-naphthoylindole	O
class	O
such	O
as	O
JWH-116	B-Drug
are	O
Schedule	O
I	O
Controlled	O
Substances	O

Other	O
SERMs	O
like	O
raloxifene	O
are	O
structurally	O
distinct	O
from	O
tamoxifen	B-Drug
and	O
other	O
triphenylethylenes	O

The	O
independent	O
discovery	O
of	O
the	O
effect	O
-methyl	O
group	O
on	O
fentanyl	B-Drug
also	O
marked	O
first	O
time	O
clandestine	O
recreational-drug	O
research	O
had	O
an	O
practical	O
scientific	O

An	O
August	O
1970	O
report	O
at	O
a	O
meeting	O
of	O
crime	O
laboratory	O
chemists	O
indicates	O
MDMA	B-Drug
was	O
being	O
used	O
recreationally	O
in	O
the	O
Chicago	O
area	O
by	O

Conversely	O
doses	O
of	O
5	O
and	O
10	O
mg	O
norethisterone	B-Drug
which	O
are	O
used	O
in	O
the	O
treatment	O
gynecological	O
disorders	O
converted	O
at	O
rates	O
0	O

Fenfluramine	B-Drug
causes	O
the	O
release	O
of	O
serotonin	O
by	O
disrupting	O
vesicular	O
storage	O
neurotransmitter	O
and	O
reversing	O
transporter	O
function	O

Compared	O
to	O
heroin	B-Drug
it	O
is	O
more	O
potent	O
has	O
higher	O
profit	O
margins	O
and	O
because	O
compact	O
simpler	O
logistics	O

Poppy	O
tea	O
is	O
highly	O
variable	O
in	O
potency	O
this	O
accounts	O
for	O
almost	O
all	O
deaths	O
related	O
to	O
the	O
substance	O
assume	O
a	O
saturated	O
morphine	B-Drug
solution	O
when	O
choosing	O
appropriate	O
dose	O

DHEA	O
is	O
then	O
converted	O
to	O
androstenedione	B-Drug
by	O
3-hydroxysteroid	O
dehydrogenase	O
3-HSD	O
and	O
finally	O
testosterone	O
17-hydroxysteroid	O
HSD17B	O

2]octane	O
system	O
in	O
ibogaine	B-Drug
is	O
replaced	O
with	O
an	O
endo	O
ethyl	O
then	O
epiibogaine	O
formed	O

Tetrahydrocannabinol	O
THC	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant	O
including	O
at	O
least	O
65	O
other	O
cannabinoids	O
cannabidiol	B-Drug
CBD	B-Drug

The	O
following	O
are	O
carboxamides:	O
Carbamazepine	B-Drug
1963	O

Alirocumab	B-Drug
is	O
the	O
International	O
nonproprietary	O
name	O

When	O
discontinuing	O
clozapine	B-Drug
gradual	O
dose	O
reduction	O
is	O
recommended	O
to	O
reduce	O
the	O
intensity	O
of	O
withdrawal	O
effects	O

Venlafaxine	B-Drug
blocks	O
the	O
neuronal	O
reuptake	O
of	O
serotonin	O
noradrenaline	O
and	O
to	O
a	O
lesser	O
extent	O
dopamine	O
in	O
central	O
nervous	O
system	O

China	O
is	O
developing	O
a	O
significant	O
MDMA	B-Drug
production	O
trafficking	O
and	O
consumption	O
problem	O

Sibutramine	B-Drug
is	O
not	O
listed	O
on	O
the	O
product	O
label	O

Fenfluramine	B-Drug
of	O
the	O
1990s	O
Fen-Phen	B-Drug
combo	O
forced	O
excess	O
release	O
neurotransmittersa	O
different	O
action	O

Opium-producing	O
nations	O
are	O
required	O
to	O
designate	O
a	O
government	O
agency	O
take	O
physical	O
possession	O
of	O
licit	O
opium	B-Drug
crops	O
as	O
soon	O
possible	O
after	O
harvest	O
and	O
conduct	O
all	O
wholesaling	O
exporting	O
through	O
that	O

Contrave	O
naltrexone/bupropion	O
a	O
combination	O
drug	O
used	O
for	O
weight	O
loss	O
in	O
those	O
that	O
are	O
either	O
obese	O
or	O
overweight	O
with	O
some	O
weight-related	O
illnesses	O
naltrexone	B-Drug
bupropion	B-Drug

Janssen	O
then	O
turned	O
to	O
making	O
pethidine	B-Drug
analogues	O
due	O
in	O
part	O
the	O
less	O
complicated	O
chemistry	O
of	O
compound	O

As	O
of	O
2018	O
review	O
mental	O
health	O
aspects	O
kratom	B-Drug
use	O
mention	O
opioid	O
replacement	O
and	O
withdrawal	O
as	O
a	O
primary	O
motivations	O
for	O
use:	O
almost	O
50%	O
the	O
approximately	O
8000	O
users	O
surveyed	O
in	O
one	O
study	O
indicated	O
that	O
resulted	O
reduced	O
or	O
discontinued	O
opioids	O

Absorption	O
by	O
any	O
administered	O
route	O
and	O
the	O
risk	O
of	O
accumulation	O
is	O
significantly	O
increased	O
in	O
neonate	O
withdrawal	O
diazepam	B-Drug
during	O
pregnancy	O
breast	O
feeding	O
clinically	O
justified	O

In	O
the	O
same	O
month	O
death	O
of	O
a	O
man	O
in	O
Queensland	O
Australia	O
was	O
attributed	O
to	O
PMMA	B-Drug

Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
heart	O
failure	O
lacks	O
antiandrogenic	O
effects	O
spironolactone	B-Drug

It	O
was	O
found	O
to	O
bind	O
many	O
of	O
the	O
same	O
receptors	O
as	O
LSD	B-Drug
but	O
acting	O
a	O
neutral	O
antagonist	O
rather	O
than	O
an	O
agonist	O

Aspirin	B-Drug
inhibits	O
platelet	O
aggregation	O
by	O
inhibiting	O
the	O
action	O
of	O
thromboxane	O
A2	O

On	O
January	O
14	O
2021	O
the	O
US	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
announced	O
that	O
waiver	O
would	O
no	O
longer	O
be	O
required	O
to	O
prescribe	O
buprenorphine	B-Drug
treat	O
up	O
30	O
people	O
concurrently	O

Podophyllum	O
Etoposide	B-Drug
Teniposide;	O
3a	O
Teniposide	B-Drug

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine	B-Drug
a	O
structurally	O
similar	O
drug	O
far	O
beyond	O
recreational	O
doses	O
but	O
due	O
to	O
never	O
having	O
been	O
published	O
its	O
validity	O
is	O
controversial	O

Psychedelic	O
art	O
was	O
also	O
applied	O
to	O
the	O
LSD	B-Drug
itself	O

1985	O
reviewed	O
the	O
preclinical	O
pharmacology	O
of	O
nalbuphine	B-Drug
and	O
reported	O
comparative	O
data	O
relative	O
to	O
other	O
types	O
opioid	O
compounds	O

Dosage	O
of	O
mushrooms	O
containing	O
psilocybin	O
depends	O
on	O
the	O
and	O
psilocin	B-Drug
content	O
mushroom	O
which	O
can	O
vary	O
significantly	O
between	O
within	O
same	O
species	O
but	O
is	O
typically	O
around	O
0	O

As	O
of	O
2016	O
the	O
combination	O
efavirenz	B-Drug
tenofovir	B-Drug
and	O
emtricitabine	B-Drug
is	O
marketed	O
in	O
various	O
jurisdictions	O
under	O
brand	O
names	O
Atripla	B-Drug
Atroiza	O
Citenvir	O
Oditec	O
Teevir	O
Trustiva	O
Viraday	B-Drug
Vonavir	O

The	O
plasma	O
protein	O
binding	O
of	O
apalutamide	B-Drug
is	O
96%	O
while	O
that	O
its	O
major	O
metabolite	O
N-desmethylapalutamide	O
95%	O
both	O
irrespective	O
concentration	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

PCP	B-Drug
is	O
notably	O
a	O
high-affinity	O
ligand	O
of	O
the	O
site	O
2	O
Ki	O
=	O
154	O
nM	O
not-well-characterized	O
associated	O
with	O
monoamine	O
reuptake	O
inhibition	O

Chlorpromazine	B-Drug
can	O
also	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
drugs	O
like	O
barbiturates	O
benzodiazepines	O
opioids	O
lithium	O
and	O
anesthetics	O
hence	O
increase	O
potential	O
for	O
adverse	O
such	O
as	O
respiratory	O
depression	O
sedation	O

Phenethylamine	B-Drug
has	O
been	O
shown	O
to	O
bind	O
human	O
trace	O
amine-associated	O
receptor	O
1	O
hTAAR1	O
as	O
an	O
agonist	O

It	O
had	O
never	O
previously	O
been	O
reported	O
in	O
the	O
scientific	O
or	O
patent	O
literature	O
and	O
was	O
first	O
identified	O
by	O
laboratories	O
Japan	O
March	O
2012	O
as	O
an	O
ingredient	O
synthetic	O
cannabis	O
smoking	O
blends	O
along	O
with	O
its	O
indazole	O
derivative	O
APINACA	B-Drug
sold	O
AKB48	O

A	O
range	O
of	O
synthetic	O
opioids	O
such	O
as	O
methadone	B-Drug
1937	O
pethidine	B-Drug
1939	O
fentanyl	B-Drug
late	O
1950s	O
and	O
derivatives	O
thereof	O
have	O
been	O
introduced	O
each	O
is	O
preferred	O
for	O
certain	O
specialized	O
applications	O

Since	O
the	O
final	O
active	O
metabolite	O
is	O
slightly	O
stronger	O
opiate	O
dihydromorphine	B-Drug
rather	O
than	O
morphine	B-Drug
nicodicodine	O
can	O
be	O
expected	O
to	O
marginally	O
more	O
potent	O
and	O
longer	O
acting	O
nicocodeine	B-Drug

Cocaine	B-Drug
is	O
the	O
second	O
most	O
popular	O
illegal	O
recreational	O
drug	O
in	O
United	O
States	O
behind	O
cannabis	O
and	O
U	O

338	O
was	O
exactly	O
8	O
times	O
the	O
strength	O
of	O
Tincture	O
Opium	B-Drug
Camphorated	O
Paregoric	O
[italics	O
in	O
original]	O
U	O

Similarly	O
at	O
a	O
cost	O
of	O
$36	O
per	O
pint	O
Opium	B-Drug
Concentrated	O
for	O
U	O

For	O
example	O
amyl	O
nitrite	O
poppers	O
nitrous	O
oxide	O
and	O
toluene	O
a	O
solvent	O
widely	O
used	O
in	O
contact	O
cement	O
permanent	O
markers	O
certain	O
types	O
of	O
glue	O
are	O
considered	O
inhalants	O
but	O
smoking	O
tobacco	B-Drug
cannabis	O
crack	O
not	O
even	O
though	O
these	O
drugs	O
inhaled	O
as	O
smoke	O
or	O
vapor	O

before	O
going	O
on	O
to	O
describe	O
that	O
after	O
taking	O
it	O
the	O
user	O
had	O
a	O
fantastic	O
sense	O
of	O
well-being	O
I	O
havent	O
got	O
from	O
any	O
drug	O
except	O
my	O
beloved	O
Ecstasy	B-Drug

For	O
example	O
a	O
1985	O
study	O
that	O
showed	O
harmful	O
effects	O
of	O
cocaine	B-Drug
use	O
during	O
pregnancy	O
created	O
huge	O
media	O
buzz	O

CPA	O
has	O
comparable	O
effectiveness	O
to	O
medroxyprogesterone	B-Drug
acetate	I-Drug
in	O
suppressing	O
sexual	O
urges	O
and	O
function	O
but	O
appears	O
be	O
less	O
effective	O
than	O
GnRH	O
modulators	O
like	O
leuprorelin	B-Drug
more	O
side	O
effects	O

There	O
is	O
low-quality	O
evidence	O
that	O
trifluoperazine	B-Drug
reduces	O
the	O
risk	O
of	O
relapse	O
when	O
compared	O
with	O
placebo	O
people	O
are	O
followed	O
for	O
5	O
months	O

It	O
means	O
that	O
butyrfentantyl	O
is	O
a	O
less	O
potent	O
opioid-agonist	O
than	O
fentanyl	B-Drug

Oxymetholone	B-Drug
has	O
very	O
low	O
affinity	O
for	O
human	O
serum	O
sex	O
hormone-binding	O
globulin	O
SHBG	O
less	O
than	O
5%	O
of	O
that	O
testosterone	O
and	O
1%	O
DHT	O

Cocaine	B-Drug
effects	O
further	O
are	O
shown	O
to	O
be	O
potentiated	O
for	O
the	O
user	O
when	O
used	O
in	O
conjunction	O
with	O
new	O
surroundings	O
and	O
stimuli	O
otherwise	O
novel	O
environs	O

Most	O
notably	O
it	O
found	O
the	O
legal	O
status	O
of	O
most	O
drugs	O
bears	O
little	O
relation	O
to	O
harms	O
associated	O
with	O
them	O
several	O
class	O
A	O
including	O
ecstasy	B-Drug
MDMA	B-Drug
LSD	B-Drug
and	O
magic	O
mushrooms	O
featured	O
at	O
very	O
bottom	O
list	O

The	O
program	O
also	O
offered	O
a	O
treatment	O
for	O
heroin	B-Drug
addicts	O

However	O
the	O
survey	O
also	O
found	O
144000	O
hectares	O
of	O
coca	B-Drug
under	O
cultivation	O
in	O
2005	O
a	O
search	O
area	O
that	O
was	O
81	O
percent	O
larger	O
than	O
used	O
2004	O

Side	O
effects	O
of	O
nandrolone	B-Drug
esters	O
include	O
symptoms	O
masculinization	O
like	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
decreased	O
sexual	O
desire	O
due	O
to	O
its	O
ability	O
suppress	O
endogenous	O
testosterone	O
synthesis	O
while	O
not	O
being	O
a	O
sufficient	O
androgen	O
itself	O

NMDA	O
antagonists	O
such	O
as	O
dextromethorphan	B-Drug
DXM	B-Drug
a	O
cough	O
suppressant	O
ketamine	B-Drug
dissociative	O
anaesthetic	O
tiletamine	B-Drug
veterinary	O
and	O
ibogaine	B-Drug
from	O
the	O
African	O
tree	O
Tabernanthe	O
iboga	O
are	O
being	O
studied	O
for	O
their	O
role	O
in	O
decreasing	O
development	O
of	O
tolerance	O
to	O
opioids	O
possible	O
eliminating	O
addiction/tolerance/withdrawal	O
possibly	O
by	O
disrupting	O
memory	O
circuitry	O

figure	O
20-80	O
times	O
as	O
potent	O
pethidine	B-Drug
an	O
analgesic	O

These	O
changes	O
have	O
coincided	O
with	O
other	O
in	O
Ontario's	O
legislation	O
to	O
target	O
the	O
misuse	O
of	O
painkillers	O
and	O
high	O
addiction	O
rates	O
drugs	O
such	O
as	O
oxycodone	B-Drug

Pethidinic	O
acid	O
is	O
a	O
controlled	O
drug	O
because	O
of	O
its	O
potential	O
uses	O
in	O
manufacturing	O
both	O
pethidine	B-Drug
itself	O
and	O
some	O
substituted	O
derivatives	O
but	O
it	O
has	O
little	O
opioid	O
activity	O
own	O
right	O

Less	O
than	O
10%	O
of	O
the	O
orally	O
administered	O
dose	O
is	O
excreted	O
in	O
urine	O
as	O
racemic	O
zopiclone	B-Drug

JWH-018	B-Drug
and	O
its	O
N-dealkylated	O
metabolite	O
were	O
only	O
detected	O
in	O
small	O
amounts	O
with	O
hydroxylated	O
metabolites	O
comprising	O
the	O
primary	O
signal	O

Phenylpiracetam	B-Drug
was	O
created	O
at	O
the	O
Russian	O
Academy	O
of	O
Sciences	O
Institute	O
Biomedical	O
Problems	O
in	O
an	O
effort	O
led	O
by	O
psychopharmacologist	O
Valentina	O
Ivanovna	O
Akhapkina	O

Sedatives	O
most	O
commonly	O
alcohol	O
but	O
also	O
GHB	B-Drug
Flunitrazepam	B-Drug
Rohypnol	B-Drug
and	O
to	O
a	O
lesser	O
extent	O
temazepam	B-Drug
Restoril	B-Drug
midazolam	B-Drug
Versed	B-Drug
have	O
been	O
reported	O
for	O
their	O
use	O
as	O
date	O
rape	O
drugs	O
called	O
Mickey	O
being	O
administered	O
unsuspecting	O
patrons	O
in	O
bars	O
or	O
guests	O
at	O
parties	O
reduce	O
the	O
intended	O
victims'	O
defenses	O

Brand	O
names	O
include	O
Eskazinyl	O
Eskazine	O
Jatroneural	O
Modalina	O
Stelazine	B-Drug
Stilizan	O
Terfluzine	O
Trifluoperaz	O
Triftazin	O

And	O
if	O
it	O
does	O
so	O
much	O
for	O
outward	O
ailments	O
will	O
not	O
its	O
singular	O
virtue	O
have	O
even	O
greater	O
effect	O
in	O
the	O
entrails	O
of	O
those	O
who	O
eat	O
it?	O
Although	O
stimulant	O
and	O
hunger-suppressant	O
properties	O
coca	B-Drug
had	O
been	O
known	O
many	O
centuries	O
isolation	O
cocaine	B-Drug
alkaloid	O
was	O
achieved	O
until	O
1855	O

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC	O

However	O
there	O
is	O
consistent	O
evidence	O
of	O
structural	O
and	O
functional	O
deficits	O
in	O
MDMA	B-Drug
users	O
with	O
high	O
lifetime	O
exposure	O

Keppra	B-Drug
levetiracetam	B-Drug
an	O
anticonvulsant	O
drug	O
which	O
is	O
sometimes	O
used	O
as	O
a	O
mood	O
stabilizer	O
and	O
has	O
potential	O
benefits	O
for	O
other	O
psychiatric	O
neurologic	O
conditions	O
such	O
Tourette	O
syndrome	O
anxiety	O
disorder	O
Alzheimer's	O
disease	O

Most	O
commercial	O
opiate	O
screening	O
tests	O
cross-react	O
appreciably	O
with	O
these	O
metabolites	O
as	O
well	O
other	O
biotransformation	O
products	O
likely	O
to	O
be	O
present	O
following	O
usage	O
of	O
street-grade	O
diamorphine	B-Drug
such	O
6-acetylcholine	O
and	O
codeine	B-Drug

Ketoprofen	B-Drug
can	O
also	O
be	O
used	O
for	O
treatment	O
of	O
some	O
pain	O
especially	O
nerve	O
such	O
as	O
sciatica	O
postherpetic	O
neuralgia	O
and	O
referred	O
radiculopathy	O
in	O
the	O
form	O
a	O
cream	O
ointment	O
liquid	O
spray	O
or	O
gel	O
which	O
may	O
contain	O
ketamine	B-Drug
lidocaine	B-Drug
along	O
with	O
other	O
agents	O
useful	O
cyclobenzaprine	B-Drug
amitriptyline	B-Drug
acyclovir	B-Drug
gabapentin	B-Drug
orphenadrine	B-Drug
drugs	O
NSAIDs	O
adjuvant	O
atypical	O
potentiators	O

Synthetic	O
cocaine	B-Drug
would	O
be	O
highly	O
desirable	O
to	O
the	O
illegal	O
drug	O
industry	O
as	O
it	O
eliminate	O
high	O
visibility	O
and	O
low	O
reliability	O
of	O
offshore	O
sources	O
international	O
smuggling	O
replacing	O
them	O
with	O
clandestine	O
domestic	O
laboratories	O
are	O
common	O
for	O
illicit	O
methamphetamine	B-Drug

High	O
cross-reactivity	O
may	O
be	O
the	O
effect	O
of	O
shape	O
molecule	O
-	O
butyrfentanyl	B-Drug
is	O
closest	O
to	O
original	O
fentanyl	B-Drug
which	O
makes	O
it	O
easy	O
bind	O
by	O
antibodies	O

Sultiame	B-Drug

Office	O
of	O
National	O
Drug	O
Control	O
Policy	O
cocaine	B-Drug
use	O
had	O
stabilized	O
across	O
the	O
country	O
with	O
a	O
few	O
increases	O
reported	O
in	O
San	O
Diego	O
Bridgeport	O
Miami	O
and	O
Boston	O

Taken	O
together	O
these	O
findings	O
show	O
mephedrone	B-Drug
induces	O
a	O
massive	O
increase	O
in	O
both	O
DA	O
and	O
5-HT	O
combined	O
with	O
rapid	O
clearance	O

In	O
the	O
US	O
men	O
are	O
over	O
twice	O
as	O
likely	O
to	O
use	O
marijuana	B-Drug
women	O
and	O
1829-year-olds	O
six	O
times	O
more	O
over-65-year-olds	O

It	O
was	O
invented	O
in	O
the	O
early	O
20th	O
century	O
and	O
subsequently	O
used	O
as	O
an	O
anorectic	O
or	O
appetite	O
suppressant	O
1950s	O
but	O
not	O
commonly	O
other	O
amphetamines	O
such	O
amphetamine	B-Drug
methamphetamine	B-Drug
benzphetamine	B-Drug
largely	O
discontinued	O
once	O
newer	O
drugs	O
phenmetrazine	B-Drug
were	O
introduced	O

Potential	O
drug	O
interactions	O
involving	O
at	O
least	O
one	O
CNS	O
depressant	O
were	O
observed	O
for	O
84%	O
of	O
midazolam	B-Drug
users	O
who	O
subsequently	O
required	O
to	O
receive	O
the	O
benzodiazepine	O
antagonist	O
flumazenil	B-Drug

Guidelines	O
from	O
the	O
Royal	O
College	O
of	O
Obstetricians	O
and	O
Gynaecologists	O
describe	O
medical	O
abortion	O
using	O
mifepristone	B-Drug
misoprostol	B-Drug
as	O
effective	O
appropriate	O
at	O
any	O
gestational	O
age	O

Its	O
call	O
is	O
described	O
as	O
a	O
weak	O
low-pitched	O
toot	B-Drug
lasting	O
less	O
than	O
second	O

The	O
drug	O
is	O
a	O
potent	O
anabolic	O
when	O
administered	O
via	O
injection	O
with	O
an	O
anabolic:androgenic	O
ratio	O
of	O
approximately	O
54:27	O
relative	O
to	O
testosterone	O
propionate	O
and	O
90:625	O
nandrolone	B-Drug

Women	O
should	O
be	O
offered	O
diamorphine	B-Drug
0	O

Brand	O
names	O
include	O
Thorazine	B-Drug
Largactil	B-Drug
Hibernal	O
and	O
Megaphen	O
sold	O
by	O
Bayer	O
in	O
West-Germany	O
since	O
July	O
1953	O

An	O
extended-release	O
morphine	B-Drug
confers	O
a	O
possible	O
reduction	O
of	O
opioid	O
use	O
and	O
with	O
fewer	O
depressive	O
symptoms	O
but	O
overall	O
more	O
adverse	O
effects	O
when	O
compared	O
to	O
other	O
forms	O
long-acting	O
opioids	O

In	O
2020	O
the	O
FDA	O
conducted	O
a	O
study	O
of	O
147	O
CBD	B-Drug
products	O
and	O
found	O
that	O
half	O
contained	O
THC	O

In	O
children	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated	O

The	O
South	O
Carolina	O
Opioid	O
Overdose	O
Prevention	O
Bill	O
if	O
passed	O
would	O
require	O
prescribers	O
to	O
offer	O
a	O
prescription	O
for	O
naloxone	B-Drug
or	O
other	O
equivalent	O
opioid	O
overdose	O
medication	O
patients	O
at	O
high	O
risk	O
of	O
an	O

Many	O
of	O
the	O
alkaloids	O
and	O
other	O
derivatives	O
opium	O
poppy	O
are	O
not	O
opioids	O
or	O
narcotics;	O
best	O
example	O
is	O
smooth-muscle	O
relaxant	O
papaverine	B-Drug

These	O
brand	O
names	O
include	O
Norco	O
Lortab	B-Drug
and	O
Vicodin	B-Drug

25I-NBOMe	B-Drug
presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
triggering	O
blood	O
platelet	O
aggregation	O

In	O
May	O
2019	O
the	O
United	O
States	O
Court	O
of	O
Appeals	O
for	O
Federal	O
Circuit	O
upheld	O
a	O
Patent	O
Trial	O
and	O
Appeal	O
Board	O
decision	O
invalidating	O
patent	O
by	O
Johnson	O
&	O
on	O
abiraterone	B-Drug
acetate	O

Due	O
to	O
its	O
quick	O
metabolism	O
and	O
short	O
effects	O
remifentanil	B-Drug
has	O
opened	O
up	O
new	O
possibilities	O
in	O
anesthesia	O

Physical	O
side	O
effects	O
from	O
chronic	O
smoking	O
of	O
cocaine	B-Drug
include	O
coughing	O
up	O
blood	O
bronchospasm	O
itching	O
fever	O
diffuse	O
alveolar	O
infiltrates	O
without	O
effusions	O
pulmonary	O
and	O
systemic	O
eosinophilia	O
chest	O
pain	O
lung	O
trauma	O
sore	O
throat	O
asthma	O
hoarse	O
voice	O
dyspnea	O
shortness	O
breath	O
an	O
aching	O
flu-like	O
syndrome	O

Research	O
also	O
indicates	O
that	O
PCP	B-Drug
inhibits	O
nicotinic	O
acetylcholine	O
receptors	O
nAChRs	O
among	O
other	O
mechanisms	O

Some	O
indications	O
exist	O
that	O
naltrexone	B-Drug
might	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
impulse-control	O
disorders	O
such	O
as	O
kleptomania	O
compulsive	O
gambling	O
or	O
trichotillomania	O
hair	O
pulling	O
but	O
evidence	O
its	O
effectiveness	O
for	O
is	O
conflicting	O

Self-harm	O
non-epileptic	O
seizures	O
flashbacks	B-Drug
with	O
amnesia	O
for	O
content	O
of	O
anxiety	O
disorders	O
and	O
suicidality	O
are	O
also	O
common	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
PCP	B-Drug
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects	O

Longer-acting	O
substances	O
such	O
as	O
bupivacaine	B-Drug
are	O
sometimes	O
given	O
preference	O
for	O
spinal	O
and	O
epidural	O
anaesthesias;	O
lidocaine	B-Drug
though	O
has	O
the	O
advantage	O
of	O
a	O
rapid	O
onset	O
action	O

Lipitor	B-Drug
was	O
developed	O
by	O
Pfizer	O
legacy	O
company	O
Parke-Davis	O
a	O
subsidiary	O
of	O
Warner-Lambert	O
and	O
first	O
marketed	O
in	O
1996	O

The	O
prescription	O
heroin	B-Drug
can	O
be	O
accessed	O
by	O
doctors	O
through	O
Health	O
Canada's	O
Special	O
Access	O
Programme	O
SAP	O
for	O
emergency	O
access	O
to	O
drugs	O
patients	O
with	O
serious	O
or	O
life-threatening	O
conditions	O
when	O
conventional	O
treatments	O
have	O
failed	O
are	O
unsuitable	O
unavailable	O

It	O
is	O
a	O
metabolite	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
physostigmine	B-Drug
but	O
unlike	O
inhibition	O
produced	O
by	O
eseroline	O
weak	O
and	O
easily	O
reversible	O
it	O
produces	O
fairly	O
potent	O
analgesic	O
effects	O
mediated	O
through	O
-opioid	O
receptor	O

15	O
mg/kg	O
of	O
midazolam	B-Drug
may	O
cause	O
respiratory	O
depression	O
which	O
is	O
postulated	O
to	O
be	O
a	O
central	O
nervous	O
system	O
CNS	O
effect	O

Almost	O
simultaneously	O
a	O
study	O
in	O
Annals	O
of	O
Internal	O
Medicine	O
found	O
that	O
ephedrine	B-Drug
alkaloids	O
were	O
100	O
to	O
700	O
times	O
more	O
likely	O
cause	O
significant	O
adverse	O
reaction	O
than	O
other	O
commonly	O
used	O
supplements	O
such	O
as	O
kava	O
or	O
Ginkgo	O
biloba	O

DMPA	B-Drug
has	O
a	O
number	O
of	O
advantages	O
and	O
benefits:	O
Highly	O
effective	O
at	O
preventing	O
pregnancy	O

Cimetidine	B-Drug
was	O
first	O
marketed	O
in	O
the	O
United	O
Kingdom	O
1976	O
and	O
U	O

Cocaine	B-Drug
in	O
its	O
purest	O
form	O
is	O
a	O
white	O
pearly	O
product	O

Supplemental	O
magnesium	O
treatment	O
has	O
been	O
shown	O
to	O
reduce	O
amphetamine	B-Drug
self-administration	O
i	O

Dutasteride	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Avodart	B-Drug
among	O
others	O
is	O
a	O
medication	O
primarily	O
used	O
to	O
treat	O
symptoms	O
of	O
an	O
enlarged	O
prostate	O

5%	O
of	O
women	O
who	O
took	O
only	O
tamoxifen	B-Drug
had	O
a	O
recurrence	O
compared	O
with	O
16%	O
either	O
paroxetine	B-Drug
fluoxetine	B-Drug
or	O
sertraline	B-Drug
drugs	O
considered	O
to	O
be	O
the	O
most	O
potent	O
CYP2D6	O
inhibitors	O

LSD	B-Drug
had	O
a	O
strong	O
influence	O
on	O
the	O
Grateful	O
Dead	O
and	O
culture	O
of	O
Deadheads	O

After	O
Pervitin	B-Drug
a	O
methamphetamine	B-Drug
drug	O
newly	O
developed	O
by	O
the	O
Berlin-based	O
Temmler	O
pharmaceutical	O
company	O
first	O
entered	O
civilian	O
market	O
in	O
1938	O
it	O
quickly	O
became	O
top	O
seller	O
among	O
German	O
population	O

Diazepam	B-Drug
has	O
a	O
biphasic	O
half-life	O
of	O
about	O
one	O
to	O
three	O
days	O
and	O
two	O
seven	O
for	O
the	O
active	O
metabolite	O
desmethyldiazepam	B-Drug

Imipramine	B-Drug
was	O
first	O
tried	O
against	O
psychotic	O
disorders	O
such	O
as	O
schizophrenia	O
but	O
proved	O
ineffective	O

The	O
best	O
studied	O
cannabinoids	O
include	O
tetrahydrocannabinol	O
THC	O
cannabidiol	B-Drug
CBD	B-Drug
and	O
cannabinol	O
CBN	O

In	O
Iceland	O
Flunitrazepam	B-Drug
is	O
a	O
controlled	O
substance	O
available	O
from	O
Mylan	O

It	O
has	O
a	O
reduced	O
tendency	O
to	O
produce	O
severe	O
hyperthermia	O
at	O
low	O
dosages	O
but	O
higher	O
side	O
effects	O
and	O
risk	O
of	O
death	O
becomes	O
similar	O
those	O
PMA	B-Drug

Cyproheptadine	B-Drug
is	O
sometimes	O
used	O
off-label	O
to	O
improve	O
akathisia	O
in	O
people	O
on	O
antipsychotic	O
medications	O

Extraction	O
of	O
opium	B-Drug
from	O
the	O
plants	O
is	O
prohibited	O
by	O
law	O
15	O
letter	O
d/	O
act	O

The	O
risk	O
of	O
hepatotoxicity	O
with	O
flutamide	O
treatment	O
is	O
far	O
higher	O
than	O
nilutamide	O
or	O
bicalutamide	B-Drug

However	O
with	O
repeated	O
dosing	O
for	O
more	O
than	O
one	O
day	O
premazepam	O
causes	O
less	O
sedation	O
and	O
psychomotor	O
impairment	O
diazepam	B-Drug

The	O
speed	B-Drug
of	O
onset	O
action	O
a	O
particular	O
benzodiazepine	O
correlates	O
well	O
with	O
the	O
'popularity'	O
that	O
drug	O
for	O
abuse	O

In	O
the	O
Bah	O
Faith	O
smoking	O
tobacco	B-Drug
is	O
discouraged	O
though	O
not	O
forbidden	O

In	O
humans	O
GBL	O
acts	O
as	O
a	O
prodrug	O
for	O
-hydroxybutyric	O
acid	O
GHB	B-Drug
and	O
it	O
is	O
used	O
recreational	O
CNS	O
depressant	O
with	O
effects	O
similar	O
to	O
those	O
of	O
barbiturates	O

Therefore	O
heroin	B-Drug
acts	O
as	O
a	O
pro-drug	O
serving	O
lipophilic	O
transporter	O
for	O
the	O
systemic	O
delivery	O
of	O
morphine	B-Drug
which	O
actively	O
binds	O
with	O
-opioid	O
receptors	O

The	O
effects	O
of	O
GHB	B-Drug
can	O
last	O
from	O
1	O

Clozapine	B-Drug
induces	O
the	O
release	O
of	O
glutamate	O
and	O
D-serine	O
an	O
agonist	O
at	O
glycine	O
site	O
NMDA	O
receptor	O
from	O
astrocytes	O
reduces	O
expression	O
astrocytic	O
transporters	O

As	O
of	O
2017	O
MDMA	B-Drug
has	O
no	O
accepted	O
medical	O
indications	O

It	O
is	O
unclear	O
if	O
Fruhstorfer	O
investigated	O
the	O
effects	O
of	O
MDMA	B-Drug
in	O
humans	O

Glucuronidation	O
and	O
oxidative	O
metabolism	O
of	O
nicotine	B-Drug
to	O
cotinine	O
are	O
both	O
inhibited	O
by	O
menthol	O
an	O
additive	O
mentholated	O
cigarettes	O
thus	O
increasing	O
the	O
half-life	O
in	O
vivo	O

Apalutamide	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN	O

Chlortalidone	O
is	O
more	O
effective	O
than	O
hydrochlorothiazide	B-Drug
for	O
lowering	O
urine	O
calcium	O
levels	O
and	O
therefore	O
probably	O

Spironolactone	B-Drug
was	O
discovered	O
in	O
1957	O
and	O
introduced	O
1959	O

The	O
claim	O
that	O
cocaine	B-Drug
is	O
much	O
more	O
addictive	O
when	O
smoked	O
must	O
be	O
reexamined	O

The	O
cultivation	O
and	O
manufacture	O
of	O
Indian	O
opium	B-Drug
was	O
further	O
centralized	O
controlled	O
through	O
a	O
series	O
acts	O
issued	O
between	O
1797	O
1949	O

Unlike	O
gabapentin	B-Drug
which	O
is	O
transported	O
solely	O
by	O
the	O
LAT1	O
pregabalin	B-Drug
seems	O
to	O
be	O
not	O
only	O
but	O
also	O
other	O
carriers	O

Lafon	O
on	O
May	O
22	O
1990	O
covering	O
the	O
chemical	O
compound	O
modafinil	B-Drug

The	O
biological	O
half-life	O
of	O
methyltestosterone	B-Drug
is	O
approximately	O
3	O
hours	O
range	O
2	O

The	O
only	O
complaint	O
surely	O
is	O
that	O
the	O
duo	O
dropped	O
original	O
title:	O
Cocaine	B-Drug
Piata	O

2]oct-5-ene	O
and	O
cesium	O
carbonate	O
in	O
acetonitrile	O
the	O
ibogaine	B-Drug
precursor	O
7-ethyl-2-2-2-iodo-1H-indol-3-ylethyl-2-azabicyclo[2	O

The	O
plasma	O
protein	O
binding	O
of	O
ketamine	B-Drug
is	O
variable	O
at	O
23	O
to	O
47%	O

Of	O
the	O
nine	O
that	O
coroners	O
had	O
finished	O
investigating	O
two	O
were	O
caused	O
directly	O
by	O
mephedrone	B-Drug

Dihydrocodeine	B-Drug
is	O
the	O
parent	O
drug	O
of	O
a	O
series	O
moderately	O
strong	O
narcotics	O
including	O
among	O
others	O
hydrocodone	B-Drug
nicocodeine	B-Drug
nicodicodeine	O
thebaine	O
and	O
acetyldihydrocodeine	B-Drug

The	O
pharmacologic	O
and	O
behavioral	O
characteristics	O
that	O
determine	O
tobacco	O
addiction	O
are	O
similar	O
to	O
those	O
drugs	O
such	O
as	O
heroin	B-Drug
cocaine	B-Drug

They	O
may	O
be	O
the	O
endogenous	O
ligands	O
of	O
2	O
subunit	O
and	O
they	O
competitively	O
antagonize	O
effects	O
gabapentin	B-Drug

Other	O
CBD	B-Drug
formulations	O
remain	O
Schedule	O
1	O
except	O
for	O
those	O
derived	O
from	O
hemp	O
which	O
are	O
unscheduled	O
but	O
still	O
FDA-regulated	O

The	O
mutagenic	O
potential	O
of	O
LSD	B-Drug
is	O
unclear	O

Paracelsus	O
a	O
16th-century	O
Swiss-German	O
alchemist	O
experimented	O
with	O
various	O
opium	B-Drug
concoctions	O
and	O
recommended	O
for	O
reducing	O
pain	O

Since	O
1994	O
the	O
production	O
dispensing	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests	O

Parahexyl	B-Drug
was	O
made	O
illegal	O
under	O
UN	O
convention	O
in	O
1982	O
on	O
the	O
basis	O
of	O
its	O
structural	O
similarity	O
and	O
similar	O
effects	O
profile	O
to	O
THC	O

5	O
million	O
people	O
consuming	O
39000	O
tons	O
of	O
opium	B-Drug
yearly	O

On	O
December	O
30	O
2003	O
the	O
FDA	O
issued	O
a	O
press	O
release	O
recommending	O
that	O
consumers	O
stop	O
buying	O
and	O
using	O
products	O
containing	O
ephedrine	B-Drug
alkaloids	O
indicating	O
its	O
intention	O
to	O
ban	O
sale	O
of	O
alkaloid-containing	O
supplements	O

5-MAPB	O
binds	O
to	O
the	O
dopamine	O
transporter	O
in	O
rat	O
brain	O
cells	O
with	O
a	O
lower	O
potency	O
than	O
cocaine	B-Drug

PMA	B-Drug
pills	O
could	O
be	O
a	O
variety	O
of	O
colours	O
or	O
imprints	O
and	O
there	O
is	O
no	O
way	O
knowing	O
just	O
from	O
the	O
appearance	O
pill	O
what	O
drugs	O
it	O
might	O
contain	O

Correlation	O
between	O
severity	O
of	O
symptoms	O
and	O
measured	O
ibuprofen	B-Drug
plasma	O
levels	O
is	O
weak	O

Oldham	O
Kelsey	O
was	O
given	O
a	O
Presidential	O
award	O
for	O
distinguished	O
service	O
from	O
the	O
federal	O
government	O
not	O
allowing	O
thalidomide	B-Drug
to	O
be	O
approved	O
sale	O
in	O
US	O

Independent	O
ibogaine	B-Drug
treatment	O
clinics	O
have	O
emerged	O
in	O
Mexico	O
Canada	O
the	O
Netherlands	O
South	O
Africa	O
and	O
New	O
Zealand	O
all	O
operating	O
what	O
has	O
been	O
described	O
as	O
a	O
legal	O
gray	O
area	O

Boldenone	B-Drug
was	O
reportedly	O
patented	O
by	O
Ciba	O
in	O
1949	O
and	O
esters	O
of	O
the	O
compound	O
were	O
developed	O
company	O
1950s	O
1960s	O

The	O
psychedelic	O
quality	O
of	O
MDMA	B-Drug
and	O
its	O
amphetamine-like	O
energizing	O
effect	O
offers	O
multiple	O
reasons	O
for	O
appeal	O
to	O
users	O
in	O
the	O
rave	O
setting	O

The	O
study	O
represents	O
in	O
part	O
MAPS'	O
clinical	O
plan	O
to	O
develop	O
MDMA	B-Drug
as	O
a	O
prescription	O
medication	O
with	O
both	O
FDA	O
and	O
European	O
Medicines	O
Agency	O
EMEA	O
approval	O

The	O
use	O
of	O
medications	O
may	O
also	O
be	O
used	O
in	O
this	O
approach	O
such	O
as	O
using	O
disulfiram	B-Drug
to	O
pair	O
unpleasant	O
effects	O
with	O
the	O
thought	O
alcohol	O

Propranolol	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication	O

A	O
survey	O
of	O
2000	O
students	O
in	O
the	O
UK	O
2014	O
found	O
that	O
one	O
five	O
people	O
had	O
used	O
Modafinil	B-Drug
to	O
stay	O
awake	O
and	O
study	O

The	O
first	O
and	O
only	O
modafinil	B-Drug
products	O
was	O
approved	O
in	O
November	O
2017	O
but	O
its	O
marketing	O
status	O
mainland	O
China	O
is	O
still	O
unknown	O

Between	O
2000	O
and	O
2003	O
the	O
aerial	O
eradication	O
program	O
sprayed	O
over	O
380000	O
hectares	O
of	O
coca	B-Drug
which	O
is	O
equivalent	O
to	O
more	O
than	O
8%	O
Colombia's	O
arable	O
land	O

Use	O
of	O
perampanel	B-Drug
with	O
strong	O
CYP3A	O
inducers	O
like	O
rifampin	B-Drug
or	O
St	O

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies	O

Smoking	O
heroin	B-Drug
refers	O
to	O
vaporizing	O
it	O
inhale	O
the	O
resulting	O
fumes	O
rather	O
than	O
burning	O
and	O
inhaling	O
smoke	O

Cannabidiol	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN	O

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio	O

In	O
addition	O
to	O
this	O
due	O
the	O
typically	O
higher	O
concentration	O
of	O
cannabidiol	B-Drug
CBD	B-Drug
ruderalis	O
plants	O
are	O
valuable	O
for	O
patients	O
looking	O
treat	O
anxiety	O
or	O
epilepsy	O

Novartis	O
manufactures	O
the	O
drugs	O
clozapine	B-Drug
Clozaril	B-Drug
diclofenac	B-Drug
Voltaren	B-Drug
carbamazepine	B-Drug
Tegretol	B-Drug
valsartan	B-Drug
Diovan	B-Drug
imatinib	B-Drug
mesylate	I-Drug
Gleevec/Glivec	O
cyclosporine	B-Drug
Neoral/Sandimmune	O
letrozole	B-Drug
Femara	B-Drug
methylphenidate	B-Drug
Ritalin	B-Drug
terbinafine	B-Drug
Lamisil	B-Drug
deferasirox	B-Drug
Exjade	O
and	O
others	O
Gleevec	B-Drug
Glivec	B-Drug
Sandimmune	B-Drug

A	O
study	O
done	O
in	O
wide	O
range	O
of	O
bacteria	O
and	O
different	O
classes	O
antibiotics	O
showed	O
that	O
Pseudomonas	O
aeruginosa	O
Stenotrophomonas	O
maltophilia	O
already	O
resistant	O
to	O
triclosan	O
had	O
increased	O
resistance	O
against	O
tetracycline	O
norfloxacin	B-Drug
when	O
exposed	O

Naltrexone	B-Drug
a	O
-opioid	O
receptor	O
antagonist	O
also	O
blocks	O
the	O
euphoric	O
effects	O
of	O
opioids	O
by	O
occupying	O
opioid	O
but	O
it	O
does	O
not	O
activate	O
so	O
produce	O
sedation	O
analgesia	O
or	O
euphoria	O
and	O
thus	O
has	O
no	O
potential	O
for	O
abuse	O
diversion	O

Animal	O
studies	O
have	O
also	O
shown	O
that	O
tiletamine	B-Drug
produces	O
rewarding	O
and	O
reinforcing	O
effects	O

Side	O
effects	O
of	O
testosterone	B-Drug
cypionate	I-Drug
include	O
symptoms	O
masculinization	O
like	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
sexual	O
desire	O

The	O
most	O
common	O
side	O
effect	O
of	O
verapamil	B-Drug
is	O
constipation	O
7	O

Analysis	O
of	O
Explosion	O
has	O
confirmed	O
that	O
the	O
active	O
ingredient	O
is	O
methylone	B-Drug

coca	B-Drug
derivative	O
means:	O
a	O
crude	O
cocaine	B-Drug
that	O
is	O
any	O
extract	O
of	O
leaf	O
which	O
can	O
be	O
used	O
directly	O
or	O
indirectly	O
for	O
the	O
manufacture	O
cocaine;	O
b	O
ecgonine	O
and	O
all	O
derivatives	O
from	O
it	O
recovered;	O
c	O
methyl	O
ester	O
benzoyl-ecgonine	O
its	O
salts;	O
d	O
preparations	O
containing	O
more	O
than	O
0	O

Estonia	O
in	O
known	O
to	O
have	O
been	O
home	O
the	O
world's	O
longest	O
documented	O
fentanyl	B-Drug
epidemic	O
especially	O
following	O
Taliban	O
ban	O
on	O
opium	B-Drug
poppy	I-Drug
cultivation	O
Afghanistan	O

CYP3A4	O
inhibitors	O
including	O
strong	O
like	O
clarithromycin	O
itraconazole	B-Drug
and	O
ketoconazole	B-Drug
moderate	O
diltiazem	B-Drug
erythromycin	B-Drug
fluconazole	B-Drug
may	O
increase	O
levels	O
of	O
desogestrel	B-Drug
etonogestrel	B-Drug

gamma-Hydroxybutyric	B-Drug
acid	B-Drug
or	O
-Hydroxybutyric	O
GHB	B-Drug
also	O
known	O
as	O
4-hydroxybutanoic	O
is	O
a	O
naturally	O
occurring	O
neurotransmitter	O
and	O
psychoactive	O
drug	O

A	O
potent	O
inhibitor	O
of	O
CYP2C19	O
and	O
other	O
cytochromes	O
fluvoxamine	B-Drug
increases	O
the	O
level	O
amitriptyline	B-Drug
two-fold	O
while	O
slightly	O
decreasing	O
nortriptyline	B-Drug

Following	O
absorption	O
amphetamine	B-Drug
readily	O
distributes	O
into	O
most	O
tissues	O
in	O
the	O
body	O
with	O
high	O
concentrations	O
occurring	O
cerebrospinal	O
fluid	O
and	O
brain	O
tissue	O

MDMA	B-Drug
tablets	O
typically	O
have	O
low	O
purity	O
due	O
to	O
bulking	O
agents	O
that	O
are	O
added	O
dilute	O
the	O
drug	O
and	O
increase	O
profits	O
notably	O
lactose	O
binding	O

Largely	O
effects	O
reported	O
were	O
similar	O
to	O
that	O
of	O
the	O
drug	O
MDMA	B-Drug
but	O
not	O
as	O
strong	O

Cocaine	B-Drug
use	O
also	O
promotes	O
the	O
formation	O
of	O
blood	O
clots	O

However	O
urinalysis	O
conducted	O
by	O
the	O
Department	O
of	O
Defense	O
has	O
been	O
challenged	O
for	O
reliability	O
testing	O
metabolite	O
cocaine	B-Drug

Levomethamphetamine	B-Drug
is	O
available	O
as	O
an	O
over-the-counter	O
OTC	O
drug	O
for	O
use	O
inhaled	O
nasal	O
decongestant	O
in	O
the	O
United	O
States	O

Caution	O
should	O
be	O
used	O
if	O
butorphanol	B-Drug
is	O
administered	O
in	O
addition	O
to	O
other	O
narcotics	O
sedatives	O
depressants	O
or	O
antihistamines	O
as	O
it	O
will	O
cause	O
an	O
additive	O
effect	O

The	O
BAN	O
was	O
formerly	O
ethyloestrenol	B-Drug
but	O
it	O
eventually	O
changed	O

Tetrazepam	B-Drug
is	O
not	O
generally	O
recommended	O
for	O
use	O
in	O
children	O
except	O
on	O
the	O
advice	O
of	O
a	O
specialist	O

As	O
of	O
August	O
2016	O
perampanel	B-Drug
had	O
been	O
studied	O
and	O
development	O
discontinued	O
in	O
migraine	O
multiple	O
sclerosis	O
neuropathic	O
pain	O
Parkinson's	O
disease	O

From	O
then	O
on	O
the	O
cocaine	B-Drug
trade	O
became	O
a	O
strictly	O
illegal	O
network	O

Law	O
enforcement's	O
struggle	O
to	O
put	O
an	O
end	O
the	O
influx	O
of	O
cocaine	B-Drug
into	O
Miami	O
led	O
creation	O
CENTAC	O
26	O
Central	O
Tactical	O
Unit	O
a	O
joint	O
operation	O
between	O
Miami-Dade	O
Police	O
Department	O
and	O
DEA	O
anti-drug	O

FDA-approved	O
and	O
commercially	O
available	O
bupropion	B-Drug
is	O
racemic	O

In	O
October	O
a	O
similar	O
therapy	O
called	O
axicabtagene	B-Drug
ciloleucel	I-Drug
was	O
approved	O
for	O
non-Hodgkin	O
lymphoma	O

The	O
three	O
main	O
forms	O
of	O
cannabis	O
products	O
are	O
the	O
flower/fruit	O
resin	O
hashish	B-Drug
and	O
oil	I-Drug
hash	B-Drug

Jack	O
Dreyfus	O
founder	O
of	O
the	O
Fund	O
became	O
a	O
major	O
proponent	O
phenytoin	B-Drug
as	O
means	O
to	O
control	O
nervousness	O
and	O
depression	O
when	O
he	O
received	O
prescription	O
for	O
Dilantin	B-Drug
in	O
1966	O

Also	O
in	O
accordance	O
considerably	O
disproportionate	O
formation	O
of	O
ethinylestradiol	O
occurs	O
when	O
norethisterone	B-Drug
is	O
taken	O
orally	O
and	O
hence	O
undergoes	O
first-pass	O
metabolism	O
the	O
liver	O
relative	O
to	O
parenterally	O
despite	O
absence	O
aromatase	O
adult	O
human	O

Cy	O
a	O
34-year-old	O
heroin	B-Drug
addict	O
undergoes	O
ibogaine	B-Drug
treatment	O
with	O
Dr	O

Fenethylline	B-Drug
was	O
first	O
synthesized	O
by	O
the	O
German	O
Degussa	O
AG	O
in	O
1961	O
and	O
used	O
for	O
around	O
25	O
years	O
as	O
a	O
milder	O
alternative	O
to	O
amphetamine	B-Drug
related	O
compounds	O

There	O
is	O
no	O
specific	O
antidote	O
for	O
overdose	O
of	O
darolutamide	B-Drug

Moore	O
received	O
a	O
lethal	O
injection	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious	O

Due	O
to	O
the	O
ease	O
of	O
manufacturing	O
methamphetamine	B-Drug
methcathinone	B-Drug
and	O
certain	O
other	O
stimulants	O
control	O
measures	O
are	O
focusing	O
less	O
on	O
preventing	O
drugs	O
from	O
crossing	O
borders	O

As	O
of	O
July	O
12	O
2015	O
law	O
enforcement	O
departments	O
in	O
28	O
states	O
are	O
allowed	O
to	O
or	O
required	O
carry	O
naloxone	B-Drug
quickly	O
respond	O
opioid	O
overdoses	O

Under	O
the	O
DEA's	O
interpretation	O
of	O
CSA	O
a	O
drug	O
does	O
not	O
necessarily	O
have	O
to	O
same	O
high	O
potential	O
for	O
abuse	O
as	O
heroin	B-Drug
example	O
merit	O
placement	O
in	O
Schedule	O
I:	O
[W]hen	O
it	O
comes	O
that	O
is	O
currently	O
listed	O
schedule	O
I	O
if	O
undisputed	O
such	O
has	O
no	O
accepted	O
medical	O
use	O
treatment	O
United	O
States	O
and	O
lack	O
safety	O
under	O
supervision	O
further	O
at	O
least	O
some	O
sufficient	O
warrant	O
control	O
must	O
remain	O

For	O
the	O
treatment	O
of	O
cases	O
with	O
cirrhosis	O
or	O
liver	O
transplant	O
patients	O
weight-based	O
ribavirin	B-Drug
is	O
sometimes	O
added	O

Naloxone	B-Drug
is	O
useful	O
in	O
treating	O
both	O
acute	O
opioid	O
overdose	O
and	O
respiratory	O
or	O
mental	O
depression	O
due	O
to	O
opioids	O

Case	O
reports	O
of	O
seven	O
British	O
males	O
who	O
presented	O
to	O
an	O
emergency	O
room	O
following	O
analytically	O
confirmed	O
25I-NBOMe	B-Drug
intoxication	O
suggest	O
the	O
potential	O
adverse	O
effects:	O
tachycardia	O
n	O
=	O
7	O
hypertension	O
4	O
agitation	O
6	O
aggression	O
visual	O
and	O
auditory	O
hallucinations	O
seizures	O
3	O
hyperpyrexia	O
clonus	O
2	O
elevated	O
white	O
cell	O
count	O
creatine	O
kinase	O
metabolic	O
acidosis	O
acute	O
kidney	O
injury	O
1	O

It	O
tends	O
to	O
build	O
connections	O
between	O
people	O
who	O
are	O
generally	O
much	O
more	O
in	O
communication	O
than	O
when	O
they	O
use	O
LSD	B-Drug

Morphine	B-Drug
is	O
converted	O
into	O
heroin	B-Drug
by	O
a	O
simple	O
chemical	O
reaction	O
with	O
acetic	O
anhydride	O
followed	O
purification	O

However	O
food	O
has	O
been	O
found	O
to	O
substantially	O
delay	O
the	O
absorption	O
of	O
pregabalin	B-Drug
and	O
significantly	O
reduce	O
peak	O
levels	O
without	O
affecting	O
bioavailability	O
drug;	O
Tmax	O
values	O
for	O
0	O

His	O
initial	O
work	O
starting	O
with	O
methadone	B-Drug
yielded	O
dextromoramide	B-Drug
in	O
1954	O

The	O
elimination	O
half-life	O
and	O
duration	O
of	O
action	O
NPP	O
are	O
much	O
shorter	O
than	O
those	O
nandrolone	B-Drug
decanoate	O

In	O
2015	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
high	O
quality	O
clinical	O
trials	O
found	O
that	O
when	O
used	O
at	O
low	O
therapeutic	O
doses	O
amphetamine	B-Drug
produces	O
modest	O
yet	O
unambiguous	O
improvements	O
in	O
cognition	O
including	O
working	O
memory	O
long-term	O
episodic	O
inhibitory	O
control	O
some	O
aspects	O
attention	O
normal	O
healthy	O
adults;	O
these	O
cognition-enhancing	O
effects	O
are	O
known	O
to	O
be	O
partially	O
mediated	O
through	O
the	O
indirect	O
activation	O
both	O
dopamine	O
receptor	O
D1	O
adrenoceptor	O
2	O
prefrontal	O
cortex	O

Delorazepam	B-Drug
is	O
generally	O
considered	O
to	O
be	O
contraindicated	O
in	O
patients	O
with	O
severe	O
acute	O
or	O
chronic	O
illnesses	O
but	O
occasionally	O
used	O
the	O
palliative	O
care	O
of	O
terminal	O
during	O
their	O
last	O
days/weeks	O
life	O

In	O
1934	O
Smith	O
Kline	O
&	O
French	O
made	O
the	O
first	O
amphetamine	B-Drug
pharmaceutical	O
when	O
they	O
began	O
selling	O
a	O
decongestant	O
inhaler	O
containing	O
volatile	O
free	O
base	O
under	O
trade	O
name	O
Benzedrine	O

Liver	O
toxicity	O
of	O
ketamine	B-Drug
also	O
involves	O
higher	O
doses	O
and	O
repeated	O
administration	O

Those	O
either	O
are	O
not	O
found	O
in	O
proteins	O
for	O
example	O
carnitine	B-Drug
GABA	O
levothyroxine	B-Drug
or	O
produced	O
directly	O
and	O
isolation	O
by	O
standard	O
cellular	O
machinery	O
hydroxyproline	O
selenomethionine	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
base	O
is	O
dissolved	O
most	O
often	O
ether	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis	O
mint	O
oregano	O
tobacco	B-Drug
parsley	O
or	O
ginger	O
leaves	O
then	O
smoked	O

Generic	O
versions	O
of	O
extended-release	O
oxymorphone	B-Drug
such	O
as	O
those	O
manufactured	O
by	O
Amneal	O
Pharmaceuticals	O
are	O
still	O
available	O
in	O
the	O
US	O

Clinical	O
studies	O
of	O
ibogaine	B-Drug
to	O
treat	O
drug	O
addiction	O
began	O
in	O
the	O
early	O
1990s	O
but	O
concerns	O
about	O
cardiotoxicity	O
led	O
termination	O
those	O

PeptidesLeu-enkephalin	O
Met-enkephalin	O
Deltorphins	O
DADLE	O
DPDPENon-peptides7-Spiroindanyloxymorphone	O
N-Phenethyl-14-ethoxymetopon	O
ADL-5859	O
BU-48	O
SNC-80	O
BW373U86	O
DPI-221	O
DPI-287	O
DPI-3290	O
TAN-67	O
RWJ-394674	O
Desmethylclozapine	O
Norbuprenorphine	O
peripherally	O
restricted	O
Cannabidiol	B-Drug
allosteric	O
modulator	O
non-selective	O
Tetrahydrocannabinol	O
XorphanolMitragyna	O
speciosa	O
kratom	B-Drug
indole	O
derivatives:	O
Mitragynine	B-Drug
pseudoindoxyl	O
Buprenorphine	B-Drug
Naltriben	O
Naltrindole	O
-opioid	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
2	O
adrenergic	O
arrestin	O
1	O
and	O
GPRASP1	O

The	O
psychedelic	O
amphetamine	B-Drug
quality	O
of	O
MDMA	B-Drug
offers	O
multiple	O
appealing	O
aspects	O
to	O
users	O
in	O
the	O
rave	O
setting	O

In	O
mice	O
ephedrine	B-Drug
is	O
known	O
to	O
stimulate	O
thermogenesis	O
in	O
the	O
brown	O
adipose	O
tissue	O
but	O
because	O
adult	O
humans	O
have	O
only	O
small	O
amounts	O
of	O
fat	O
assumed	O
take	O
place	O
mostly	O
skeletal	O
muscle	O

A	O
Phase	O
3	O
study	O
found	O
that	O
the	O
addition	O
of	O
samidorphan	O
to	O
olanzapine	B-Drug
significantly	O
reduced	O
weight	O
gain	O
compared	O
alone	O

The	O
spontaneous	O
breakdown	O
of	O
cathinone	B-Drug
is	O
the	O
reason	O
it	O
must	O
be	O
chewed	O
fresh	O
after	O
cultivation	O

Smuggling	O
cocaine	B-Drug
has	O
become	O
increasingly	O
innovative	O
as	O
criminal	O
organisations	O
try	O
to	O
avoid	O
detection	O
by	O
authorities	O

JWH-018	B-Drug
1-pentyl-3-1-naphthoylindole	O
or	O
AM-678	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
full	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors	O
with	O
some	O
selectivity	O
for	O

As	O
of	O
October	O
6	O
2014	O
Percodan	B-Drug
is	O
becoming	O
something	O
a	O
relic	O
in	O
the	O
United	O
States	O
at	O
least	O
as	O
number	O
prescriptions	O
has	O
fallen	O
precipitously	O
since	O
1960s	O
light	O
alternate	O
drugs	O
available	O
containing	O
oxycodone	B-Drug
Percocet	B-Drug
Tylox	B-Drug
OxyContin	B-Drug
Roxicodone	B-Drug

As	O
with	O
most	O
barbiturates	O
butalbital	B-Drug
is	O
a	O
general	O
inducer	O
of	O
P450	O
enzymes	O
in	O
both	O
rodents	O
and	O
humans	O
particularly	O
CYP3A4	O
hence	O
inducing	O
its	O
own	O
metabolism	O
CYP2D6	O
CYP2C9	O
although	O
enzyme	O
induction	O
capability	O
far	O
less	O
than	O
that	O
equivalent	O
doses	O
phenobarbital	B-Drug
or	O
secobarbital	B-Drug
the	O
potent	O
known	O
inducers	O
barbiturate	O
molecular	O
family	O

In	O
contrast	O
to	O
ethyltestosterone	O
its	O
19-demethyl	O
variant	O
norethandrolone	B-Drug
is	O
a	O
potent	O
AAS	O
comparable	O
in	O
anabolic	O
activity	O
testosterone	O
propionate	O

In	O
case	O
of	O
overdose	O
or	O
adverse	O
reaction	O
the	O
immediate	O
intravenous	O
administration	O
naloxone	B-Drug
Narcan	B-Drug
is	O
a	O
specific	O
antidote	O

There	O
is	O
low-quality	O
evidence	O
of	O
serious	O
or	O
non-serious	O
harmful	O
side	O
effects	O
due	O
to	O
methylphenidate	B-Drug
taken	O
by	O
children	O
and	O
adolescents	O

Wealth	O
distribution	O
for	O
example	O
has	O
changed	O
significantly	O
as	O
the	O
opium	B-Drug
economy	O
created	O
a	O
new	O
rich	O
in	O
which	O
young	O
men	O
have	O
control	O

36-Diacetyloxymorphone	O
is	O
a	O
third	O
acetylated	O
oxymorphone	B-Drug
derivative	O
the	O
analogue	O
of	O
acetylmorphone	O
and	O
expected	O
to	O
be	O
intermediate	O
in	O
strength	O
betwixt	O
two	O
aforementioned	O
drugs	O

An	O
early	O
example	O
of	O
what	O
today	O
would	O
be	O
labelled	O
a	O
'designer	O
drug'	O
was	O
LSD	B-Drug
which	O
synthesised	O
from	O
ergot	O

Nalbuphine	B-Drug
is	O
available	O
in	O
two	O
concentrations	O
10	O
mg	O
and	O
20	O
of	O
nalbuphine	B-Drug
hydrochloride	O
per	O
mL	O

Remifentanil	B-Drug
is	O
metabolized	O
to	O
a	O
compound	O
remifentanil	B-Drug
acid	O
which	O
has	O
1/4600th	O
the	O
potency	O
of	O
parent	O

The	O
substitution	O
of	O
certain	O
bulky	O
groups	O
on	O
nitrogen	O
17	O
converts	O
an	O
opioid	O
agonist	O
into	O
antagonist	O
the	O
most	O
important	O
which	O
is	O
naloxone	B-Drug
a	O
non-selective	O
with	O
no	O
properties	O
whatsoever	O
silent	O

This	O
drug	O
is	O
also	O
known	O
as	O
Whitleys	O
Trip-and-Fall	O
Ruffies	O
Rophies	O
Rope	O
Roopies	O
Roofies	O
Roches	O
Roach-2	O
Roach	O
Mind	O
Erasers	O
Rib	O
Lunch	O
Money	O
R-2	O
Poor	O
Mans	O
Quaalude	B-Drug
Mexican	O
Valium	B-Drug
LA	O
Rochas	O
Forget	O
Pill	O
and	O
Circles	O

The	O
comic	O
features	O
31	O
underground	O
artists	O
contributing	O
mostly	O
one-pagers	O
about	O
drug	O
experiences	O
primarily	O
LSD	B-Drug

Remifentanil's	O
short	O
context-sensitive	O
half-life	O
makes	O
it	O
ideal	O
for	O
intense	O
pain	O
of	O
duration	O
Remifentanil	B-Drug

Les	O
King	O
a	O
former	O
member	O
of	O
the	O
ACMD	O
has	O
stated	O
mephedrone	B-Drug
appears	O
to	O
be	O
less	O
potent	O
than	O
amphetamine	O
and	O
ecstasy	B-Drug
but	O
that	O
any	O
benefit	O
associated	O
with	O
this	O
could	O
negated	O
by	O
users	O
taking	O
larger	O
amounts	O

Louisiana:In	O
January	O
2011	O
Louisiana	O
Governor	O
Bobby	O
Jindal	O
emergency	O
scheduled	O
34-methylenedioxymethcathinone	O
methylone	B-Drug
34-methyenedioxypyrovalerone	O
MDPV	B-Drug
4-methylmethcathinone	B-Drug
mephedrone	B-Drug
4-methoxymethcathinone	O
methedrone	O
4-fluoromethcathinone	B-Drug
flephedrone	B-Drug
and	O
3-fluoromethcathinone	B-Drug
3-FMC	B-Drug
methylenedioxymethcathinone	B-Drug

A	O
newer	O
NSAA	O
darolutamide	B-Drug
is	O
not	O
affected	O
by	O
this	O
mutation	O
nor	O
has	O
it	O
been	O
found	O
to	O
be	O
any	O
other	O
tested/well-known	O
AR	O
mutations	O

Dextromethorphan	B-Drug
does	O
not	O
have	O
a	O
significant	O
affinity	O
for	O
the	O
mu-opioid	O
receptor	O
activity	O
typical	O
of	O
morphinan	O
compounds	O
and	O
exerts	O
its	O
therapeutic	O
effects	O
through	O
several	O
other	O
receptors	O

Tolerance	O
to	O
the	O
different	O
physiological	O
effects	O
of	O
methadone	B-Drug
varies;	O
tolerance	O
analgesic	O
properties	O
may	O
or	O
not	O
develop	O
quickly	O
but	O
euphoria	O
usually	O
develops	O
rapidly	O
whereas	O
constipation	O
sedation	O
and	O
respiratory	O
depression	O
slowly	O
if	O
ever	O

Oral	O
dosage	O
forms	O
of	O
methaqualone	B-Drug
hydrochloride	O
were	O
manufactured	O
as	O
capsules	O
whereas	O
oral	O
free-base	O
tablets	O

Like	O
other	O
AAS	O
trenbolone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
androgen	O
receptor	O
AR	O
and	O
hence	O
has	O
anabolic	O
androgenic	O
activity	O
as	O
well	O
antigonadotropic	O

According	O
to	O
the	O
National	O
Institute	O
on	O
Drug	O
Abuse	O
approximately	O
14600	O
deaths	O
occurred	O
in	O
US	O
2017	O
due	O
cocaine	B-Drug
overdose	O

Mercdes	O
Benegbi	O
born	O
with	O
phocomelia	O
of	O
both	O
arms	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide	B-Drug

These	O
two	O
facets	O
of	O
cognitive	O
liberty	O
are	O
reminiscent	O
Timothy	O
Leary's	O
Two	O
Commandments	O
for	O
the	O
Molecular	O
Age	O
from	O
his	O
1968	O
book	O
The	O
Politics	O
Ecstasy:	O
Supporters	O
therefore	O
seek	O
to	O
impose	O
both	O
a	O
negative	O
and	O
positive	O
obligation	O
on	O
states:	O
refrain	O
non-consensually	O
interfering	O
with	O
an	O
individual's	O
processes	O
allow	O
individuals	O
self-determine	O
their	O
own	O
inner	O
realm	O
control	O
mental	O
functions	O
Ecstasy	B-Drug

An	O
editorial	O
he	O
wrote	O
in	O
the	O
Journal	O
of	O
Psychopharmacology	O
where	O
compared	O
risk	O
harm	O
for	O
horse	O
riding	O
1	O
adverse	O
event	O
350	O
to	O
that	O
ecstasy	B-Drug
10000	O
resulted	O
his	O
dismissal	O
as	O
well	O
resignation	O
colleagues	O
from	O
ACMD	O

After	O
a	O
set	O
of	O
successful	O
clinical	O
trials	O
Duragesic	B-Drug
fentanyl	B-Drug
patches	O
were	O
introduced	O
into	O
medical	O
practice	O

Pregabalin	B-Drug
is	O
rapidly	O
absorbed	O
when	O
administered	O
on	O
an	O
empty	O
stomach	O
with	O
a	O
Tmax	O
time	O
to	O
peak	O
levels	O
of	O
generally	O
less	O
than	O
or	O
equal	O
1	O
hour	O
at	O
doses	O
300	O
mg	O

IC50	O
value	O
for	O
displacement	O
of	O
[3H]cocaine	O
The	O
hydroxylated	O
2-OH	O
analogue	O
exhibited	O
a	O
tenfold	O
increase	O
in	O
potency	O
over	O
cocaine	B-Drug

Zaleplon	B-Drug
has	O
the	O
potential	O
to	O
be	O
a	O
drug	O
of	O
recreational	O
use	O
and	O
been	O
found	O
have	O
an	O
addictive	O
similar	O
benzodiazepine	O
benzodiazepine-like	O
hypnotics	O

The	O
metabolite	O
N-3-hydroxypentyl	O
JWH-018	B-Drug
was	O
found	O
to	O
have	O
toxic	O
effects	O
that	O
its	O
parent	O
compound	O
does	O
not	O

Tianeptine	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
depression	O
people	O
with	O
Parkinson's	O
disease	O
and	O
post-traumatic	O
stress	O
disorder	O
for	O
which	O
it	O
was	O
as	O
safe	O
fluoxetine	B-Drug
moclobemide	O

As	O
a	O
2	O
sympathomimetic	O
clenbuterol	B-Drug
has	O
also	O
been	O
used	O
as	O
performance-enhancing	O
drug	O

The	O
chemical	O
structure	O
of	O
ostarine	B-Drug
has	O
not	O
been	O
publicly	O
disclosed	O

In	O
2004	O
Warner-Lambert	O
which	O
subsequently	O
was	O
acquired	O
by	O
Pfizer	O
agreed	O
to	O
plead	O
guilty	O
for	O
activities	O
of	O
its	O
Parke-Davis	O
subsidiary	O
and	O
pay	O
$430	O
million	O
in	O
fines	O
settle	O
civil	O
criminal	O
charges	O
regarding	O
the	O
marketing	O
Neurontin	B-Drug
off-label	O
purposes	O

In	O
1952	O
thalidomide	B-Drug
was	O
synthesised	O
by	O
Chemical	O
Industry	O
Basel	O
CIBA	O
but	O
found	O
to	O
have	O
no	O
effect	O
on	O
animals	O
and	O
discarded	O
that	O
basis	O

Because	O
MDMA	B-Drug
releases	O
dopamine	O
in	O
the	O
striatum	O
mechanisms	O
by	O
which	O
it	O
induces	O
FosB	O
nucleus	O
accumbens	O
are	O
analogous	O
to	O
other	O
dopaminergic	O
psychostimulants	O

D2	O
receptor	O
antagonists	O
like	O
domperidone	O
metoclopramide	B-Drug
and	O
sulpiride	O
are	O
used	O
as	O
galactogogues	O
to	O
increase	O
prolactin	O
secretion	O
in	O
pituitary	O
gland	O
induce	O
lactation	O
humans	O

If	O
high	O
boluses	O
of	O
fentanyl	B-Drug
are	O
administered	O
quickly	O
muscle	O
rigidity	O
the	O
vocal	O
cords	O
can	O
make	O
bag-mask	O
ventilation	O
very	O
difficult	O

Coca	B-Drug
cultivation	O
reached	O
its	O
highest	O
point	O
during	O
the	O
program	O
in	O
2002	O
at	O
2671	O
square	O
kilometers	O

The	O
patent	O
protection	O
of	O
dutasteride	B-Drug
expired	O
in	O
November	O
2015	O
and	O
the	O
drug	O
has	O
since	O
become	O
available	O
United	O
States	O
a	O
variety	O
low-cost	O
generic	O
formulations	O

Most	O
people	O
who	O
have	O
overdosed	O
on	O
methadone	B-Drug
may	O
show	O
some	O
of	O
the	O
following	O
symptoms:	O
Miosis	O
constricted	O
pupils	O
Vomiting	O
Hypoventilation	O
breathing	O
that	O
is	O
too	O
slow/shallow	O
Drowsiness	O
sleepiness	O
disorientation	O
sedation	O
unresponsiveness	O
Skin	O
cool	O
clammy	O
damp	O
and	O
pale	O
Limp	O
muscles	O
trouble	O
staying	O
awake	O
nausea	O
Unconsciousness	O
comaThe	O
respiratory	O
depression	O
an	O
overdose	O
can	O
be	O
treated	O
with	O
naloxone	B-Drug

Beclometasone	O
betamethasone	B-Drug
dexamethasone	B-Drug
fluocortolone	O
halometasone	O
and	O
mometasone	O

In	O
2005	O
researchers	O
proposed	O
the	O
use	O
of	O
cocaine	B-Drug
in	O
conjunction	O
with	O
phenylephrine	B-Drug
administered	O
form	O
an	O
eye	O
drop	O
as	O
a	O
diagnostic	O
test	O
for	O
Parkinson's	O
disease	O

People	O
taking	O
dutasteride	B-Drug
should	O
not	O
donate	O
blood	O
to	O
prevent	O
birth	O
defects	O
if	O
a	O
pregnant	O
women	O
receives	O
and	O
due	O
its	O
long	O
elimination	O
half-life	O
also	O
for	O
at	O
least	O
6	O
months	O
after	O
the	O
cessation	O
of	O
treatment	O

When	O
researchers	O
control	O
for	O
use	O
of	O
other	O
drugs	O
many	O
the	O
seeming	O
effects	O
cocaine	B-Drug
on	O
head	O
size	O
birth	O
weight	O
Apgar	O
scores	O
and	O
prematurity	O
disappear	O

By	O
the	O
mid-1950s	O
14	O
pharmaceutical	O
companies	O
were	O
marketing	O
thalidomide	B-Drug
in	O
46	O
countries	O
under	O
at	O
least	O
37	O
different	O
trade	O
names	O

Levomethadone	B-Drug
the	O
L	O
enantiomer	O
is	O
a	O
-opioid	O
receptor	O
agonist	O
with	O
higher	O
intrinsic	O
activity	O
than	O
morphine	B-Drug
but	O
lower	O
affinity	O

The	O
corresponding	O
alcohol	O
cathine	B-Drug
is	O
a	O
less	O
powerful	O
stimulant	O

AMB-FUBINACA	B-Drug
itself	O
was	O
found	O
in	O
a	O
sample	O
from	O
the	O
product	O
smoked	O
by	O
another	O
patient	O

Outside	O
of	O
the	O
US	O
drug	O
thalidomide	B-Drug
was	O
marketed	O
for	O
relief	O
general	O
nausea	O
and	O
morning	O
sickness	O
but	O
caused	O
birth	O
defects	O
even	O
death	O
thousands	O
babies	O
when	O
taken	O
during	O
pregnancy	O

George	O
Jacob	O
Jung	O
born	O
August	O
6	O
1942	O
nicknamed	O
Boston	O
and	O
El	O
Americano	O
is	O
an	O
American	O
former	O
drug	O
trafficker	O
smuggler	O
who	O
was	O
a	O
major	O
figure	O
in	O
the	O
cocaine	B-Drug
trade	O
United	O
States	O
1970s	O
early	O
1980s	O

In	O
the	O
United	O
States	O
kratom	B-Drug
and	O
its	O
active	O
ingredients	O
are	O
not	O
scheduled	O
under	O
DEA	O
guidelines	O

The	O
conversion	O
of	O
tilidine	B-Drug
into	O
the	O
more	O
active	O
metabolite	O
nortilidine	O
occurs	O
with	O
participation	O
CYP3A4	O
and	O
CYP2C19	O

Buprenorphine	B-Drug
is	O
similar	O
to	O
methadone	B-Drug
in	O
that	O
it	O
used	O
opioid	O
replacement	O
therapy	O
as	O
well	O
pain	O
management	O

In	O
a	O
separate	O
study	O
conducted	O
by	O
the	O
CDC	O
82%	O
of	O
fentanyl	B-Drug
overdose	O
deaths	O
involved	O
illegally	O
manufactured	O
while	O
only	O
4%	O
were	O
suspected	O
to	O
originate	O
from	O
prescription	O

The	O
work	O
mentions	O
the	O
painkillers	O
willow	O
leading	O
ultimately	O
to	O
aspirin	B-Drug
she	O
writes	O
autumn	O
crocus	O
and	O
opium	B-Drug
which	O
however	O
is	O
also	O
narcotic	O

Metabolic	O
studies	O
show	O
that	O
the	O
pyridine	O
ring	O
of	O
nicotine	B-Drug
is	O
derived	O
from	O
niacin	B-Drug
nicotinic	O
acid	O
while	O
pyrrolidine	O
N-methyl-1-pyrrollidium	O
cation	O

There	O
is	O
significantly	O
less	O
potential	O
for	O
quazepam	B-Drug
to	O
induce	O
respiratory	O
depression	O
or	O
adversely	O
affect	O
motor	O
coordination	O
than	O
other	O
benzodiazepines	O

The	O
rates	O
of	O
gynecomastia	O
with	O
leuprorelin	B-Drug
have	O
been	O
found	O
to	O
range	O
from	O
3	O
16%	O

Clomifene	B-Drug
is	O
an	O
inhibitor	O
of	O
the	O
conversion	O
desmosterol	O
into	O
cholesterol	O
by	O
enzyme	O
24-dehydrocholesterol	O
reductase	O

Modafinil	B-Drug
is	O
a	O
highly	O
researched	O
compound	O
with	O
many	O
derivatives	O
created	O
and	O
studied	O
some	O
examples	O
their	O
differences	O
between	O
dopamine	O
serotonin	O
&	O
norepinephrine	O
affect	O
given	O
in	O
bundled	O
table	O
form	O
below	O

A	O
popular	O
legend	O
dating	O
back	O
to	O
the	O
1960s	O
it	O
has	O
been	O
claimed	O
that	O
several	O
people	O
took	O
LSD	B-Drug
and	O
stared	O
at	O
sun	O
going	O
blind	O
as	O
a	O
result	O

The	O
original	O
brand	O
name	O
of	O
oxandrolone	B-Drug
was	O
Anavar	O
which	O
marketed	O
in	O
the	O
United	O
States	O
and	O
Netherlands	O

25I-NBOMe	B-Drug
is	O
a	O
relatively	O
new	O
substance	O
and	O
little	O
known	O
about	O
its	O
pharmacological	O
risks	O
or	O
interaction	O
with	O
other	O
substances	O

Unlike	O
phenmetrazine	B-Drug
ethcathinone	O
and	O
therefore	O
amfepramone	B-Drug
as	O
well	O
are	O
mostly	O
selective	O
noradrenaline	O
releasing	O
agents	O

Cocaine	B-Drug
in	O
its	O
purest	O
form	O
is	O
a	O
white	O
pearly	O
product	O

Piroxicam	B-Drug
exists	O
as	O
alkenol	O
tautomer	O
in	O
organic	O
solvents	O
and	O
zwitterionic	O
form	O
water	O

Diprenorphine	O
M5050	O
is	O
the	O
recommended	O
etorphine	B-Drug
M99	O
antagonist	O
but	O
it	O
not	O
a	O
pure	O
opioid	O
i	O

Under	O
normal	O
circumstances	O
bicalutamide	B-Drug
has	O
no	O
capacity	O
to	O
activate	O
the	O
AR	O

As	O
of	O
October	O
2015	O
betahydroxythiofentanyl	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

Compared	O
to	O
THC	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors	O
JWH-018	B-Drug
and	O
many	O
synthetic	O
cannabinoids	O
are	O
full	O
agonists	O

If	O
the	O
supply	O
of	O
drugs	O
such	O
as	O
ecstasy	B-Drug
came	O
from	O
legitimate	O
pharmaceutical	O
companies	O
their	O
product	O
would	O
be	O
far	O
less	O
likely	O
to	O
contain	O
toxic	O
additives	O
or	O
varying	O
dosages	O

Diazepam	B-Drug
is	O
not	O
the	O
only	O
drug	O
to	O
target	O
these	O
GABAA	O
receptors	O

The	O
degree	O
of	O
bluing	O
in	O
a	O
Psilocybe	O
fruit	O
body	O
roughly	O
correlates	O
with	O
the	O
concentration	O
psilocin	B-Drug
mushroom	O

Although	O
it	O
does	O
not	O
bind	O
to	O
the	O
estrogen	O
receptors	O
ERs	O
bicalutamide	B-Drug
can	O
increase	O
levels	O
secondarily	O
AR	O
blockade	O
when	O
used	O
as	O
a	O
monotherapy	O
in	O
males	O
and	O
hence	O
have	O
some	O
indirect	O
estrogenic	O
effects	O

The	O
most-studied	O
therapeutic	O
effect	O
of	O
ibogaine	B-Drug
is	O
the	O
reduction	O
or	O
elimination	O
addiction	O
to	O
opioids	O

At	O
the	O
start	O
of	O
2000	O
widespread	O
reports	O
OxyContin	B-Drug
abuse	O
surfaced	O

Researchers	O
at	O
Chemie	O
Grnenthal	O
found	O
that	O
thalidomide	B-Drug
was	O
a	O
particularly	O
effective	O
antiemetic	O
had	O
an	O
inhibitory	O
effect	O
on	O
morning	O
sickness	O

It	O
is	O
also	O
contraindicated	O
in	O
HIV	O
positive	O
patients	O
taking	O
protease	O
inhibitors	O
delavirdine	B-Drug
and	O
efavirenz	B-Drug
which	O
an	O
agonist	O
at	O
the	O
5HT2A-mGlu2	O
receptor	O
protomer	O
increases	O
chances	O
of	O
a	O
patient	O
experiencing	O
hallucinations	O
during	O
methylergometrine	O
therapy	O

Sofosbuvir	B-Drug
is	O
in	O
the	O
nucleotide	O
analog	O
family	O
of	O
medication	O
and	O
works	O
by	O
blocking	O
hepatitis	O
C	O
NS5B	O
protein	O

Therefore	O
people	O
driving	O
or	O
conducting	O
activities	O
which	O
require	O
vigilance	O
should	O
exercise	O
caution	O
in	O
using	O
nitrazepam	B-Drug
possibly	O
avoid	O
it	O
altogether	O

In	O
relation	O
to	O
the	O
fact	O
that	O
it	O
is	O
not	O
17-alkylated	O
boldenone	B-Drug
and	O
undecylenate	I-Drug
have	O
little	O
or	O
no	O
risk	O
of	O
hepatotoxicity	O

The	O
anticonvulsant	O
properties	O
of	O
nitrazepam	B-Drug
and	O
other	O
benzodiazepines	O
may	O
be	O
in	O
part	O
or	O
entirely	O
due	O
to	O
binding	O
voltage-dependent	O
sodium	O
channels	O
rather	O
than	O
benzodiazepine	O
receptors	O

Mirtazapine	B-Drug
also	O
has	O
an	O
antagonistic	O
effect	O
on	O
H1	O
histamine	O
receptors	O

In	O
humans	O
the	O
volume	O
of	O
distribution	O
an	O
orally	O
administered	O
dose	O
pregabalin	B-Drug
is	O
approximately	O
0	O

Remifentanil	B-Drug
is	O
a	O
potent	O
short-acting	O
synthetic	O
opioid	O
analgesic	O
drug	O

Sufentanil	B-Drug
has	O
been	O
associated	O
with	O
extremely	O
rare	O
instances	O
of	O
life-threatening	O
anaphylaxis	O

The	O
birth	O
defects	O
caused	O
by	O
thalidomide	B-Drug
led	O
to	O
the	O
development	O
of	O
greater	O
drug	O
regulation	O
and	O
monitoring	O
in	O
many	O
countries	O

Due	O
to	O
the	O
high	O
lipophilicity	O
of	O
methamphetamine	B-Drug
it	O
can	O
readily	O
move	O
through	O
bloodbrain	O
barrier	O
faster	O
than	O
other	O
stimulants	O
where	O
is	O
more	O
resistant	O
degradation	O
by	O
monoamine	O
oxidase	O

There	O
are	O
numerous	O
methods	O
available	O
to	O
synthesize	O
MDMA	B-Drug
via	O
different	O
intermediates	O

Ketobemidone	B-Drug
is	O
mostly	O
used	O
in	O
the	O
Scandinavian	O
countries	O
with	O
Denmark	O
topping	O
statistics	O

Functions	O
as	O
a	O
vasodilator	O
during	O
cryopreservation	O
when	O
used	O
in	O
conjunction	O
with	O
verapamil	B-Drug
phentolamine	B-Drug
nifedipine	O
tolazoline	O
or	O
nitroprusside	B-Drug

Although	O
older	O
data	O
suggested	O
a	O
possible	O
disulfiram-like	O
effect	O
of	O
metronidazole	B-Drug
newer	O
has	O
challenged	O
this	O
and	O
suggests	O
it	O
does	O
not	O
actually	O
have	O

Despite	O
being	O
a	O
more	O
potent	O
analgesic	O
fentanyl	B-Drug
tends	O
to	O
induce	O
less	O
nausea	O
as	O
well	O
histamine-mediated	O
itching	O
than	O
morphine	B-Drug

Midazolam	B-Drug
has	O
also	O
been	O
used	O
along	O
with	O
hydromorphone	B-Drug
in	O
a	O
two-drug	O
protocol	O
Ohio	O
and	O
Arizona	O

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O

Previously	O
a	O
relatively	O
unknown	O
drug	O
to	O
North	O
American	O
athletes	O
Furazabol	B-Drug
gained	O
notoriety	O
in	O
the	O
Commission	O
of	O
Inquiry	O
into	O
Use	O
Drugs	O
and	O
Banned	O
Practices	O
Intended	O
Increase	O
Athletic	O
Performance	O
known	O
colloquially	O
as	O
The	O
Dubin	O

Parecoxib	O
along	O
with	O
other	O
COX-2	O
selective	O
inhibitors	O
celecoxib	B-Drug
valdecoxib	O
and	O
mavacoxib	O
were	O
discovered	O
by	O
a	O
team	O
at	O
the	O
Searle	O
division	O
of	O
Monsanto	O
led	O
John	O
Talley	O

Cocaine	B-Drug
and	O
heroin	B-Drug
combined	O
caused	O
fewer	O
deaths	O
than	O
prescriptions	O
drugs	O
in	O
the	O
United	O
Kingdom	O
2013	O
prescription	O
opiates	O
alone	O
States	O
2008	O

Acidic	O
substances	O
reduce	O
the	O
absorption	O
of	O
amphetamine	B-Drug
and	O
increase	O
urinary	O
excretion	O
alkaline	O
do	O
opposite	O

4	O
t	O
of	O
oxycodone	B-Drug
were	O
manufactured	O
worldwide	O
in	O
1998;	O
by	O
2007	O
this	O
figure	O
had	O
grown	O
to	O
75	O

Amitriptyline	B-Drug
is	O
metabolized	O
mostly	O
by	O
CYP2C19	O
into	O
nortriptyline	B-Drug
and	O
CYP2D6	O
leading	O
to	O
a	O
variety	O
of	O
hydroxylated	O
metabolites	O
with	O
the	O
principal	O
one	O
among	O
them	O
being	O
E-10-hydroxynortriptyline	O
see	O
metabolism	O
scheme	O
lesser	O
degree	O
CYP3A4	O

The	O
most	O
high-profile	O
death	O
involving	O
an	O
accidental	O
overdose	O
of	O
fentanyl	B-Drug
was	O
singer	O
Prince	O

Numerous	O
fire	O
safe	O
cigarette	O
designs	O
have	O
been	O
proposed	O
some	O
by	O
tobacco	B-Drug
companies	O
themselves	O
which	O
would	O
extinguish	O
a	O
left	O
unattended	O
for	O
more	O
than	O
minute	O
or	O
two	O
thereby	O
reducing	O
the	O
risk	O
of	O

The	O
leaves	O
are	O
believed	O
to	O
also	O
contain	O
an	O
additional	O
unidentified	O
toxin	O
which	O
might	O
be	O
anthraquinone	O
glycoside	O
known	O
as	O
senna	B-Drug
glycosides	I-Drug

It	O
is	O
possible	O
for	O
oral	O
ingestion	O
of	O
GBL	O
to	O
cause	O
nausea	O
and	O
other	O
similar	O
problems	O
possibly	O
more	O
so	O
than	O
with	O
GHB	B-Drug

Propiram	B-Drug
has	O
been	O
available	O
in	O
oral	O
rectal	O
and	O
injectable	O
formulations	O
with	O
bioavailability	O
above	O
97%	O
after	O
administration	O

[6][7]Especially	O
when	O
using	O
a	O
short-acting	O
substance	B-Drug
such	O
as	O
smoked	O
DMT	O
or	O
Salvia	O
divinorum	O
it	O
may	O
be	O
possible	O
for	O
two	O
people	O
to	O
take	O
turns	O
with	O
one	O
being	O
the	O
sitter	O
while	O
other	O
takes	O
psychedelic	O

had	O
been	O
the	O
first	O
to	O
publish	O
a	O
synthesis	O
of	O
physostigmine	B-Drug
but	O
Julian	O
noticed	O
that	O
melting	O
point	O
Robinson's	O
end	O
product	O
was	O
wrong	O
indicating	O
he	O
not	O
created	O
it	O

It	O
can	O
be	O
cut	O
into	O
or	O
even	O
replace	O
entirely	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates	O

On	O
December	O
15	O
2008	O
it	O
was	O
reported	O
by	O
German	O
pharmaceutical	O
companies	O
that	O
JWH-018	B-Drug
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002	O

Darolutamide	B-Drug
and	O
ketodarolutamide	O
appear	O
to	O
negligibly	O
cross	O
the	O
bloodbrain	O
barrier	O
both	O
in	O
mice	O
humans	O

Intravenous	O
dexamethasone	B-Drug
is	O
effective	O
for	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
in	O
people	O
who	O
had	O
surgery	O
whose	O
post-operative	O
pain	O
was	O
treated	O
with	O
long-acting	O
spinal	O
or	O
epidural	O
opioids	O

China	O
ceased	O
producing	O
licit	O
opium	B-Drug
after	O
2001	O

Less	O
frequently	O
in	O
3-10%	O
of	O
people	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain	O
headache	O
fatigue	O
anorexia	O
and	O
weight	O
loss	O
dizziness	O
nervousness	O
hallucinations	O
anxiety	O
depression	O
flu-like	O
symptoms	O
dyspepsia	O
indigestion	O
shortness	O
breath	O
hypoventilation	O
apnoea	O
urinary	O
retention	O

A	O
radiolabelled	O
form	O
of	O
25I-NBOMe	B-Drug
can	O
be	O
used	O
for	O
mapping	O
the	O
distribution	O
5-HT2A	O
receptors	O
in	O
brain	O

The	O
usual	O
means	O
of	O
protection	O
against	O
the	O
negative	O
effects	O
iodine-131	O
is	O
by	O
saturating	O
thyroid	O
gland	O
with	O
stable	O
iodine-127	O
in	O
form	O
potassium	B-Drug
iodide	I-Drug
tablets	O
taken	O
daily	O
for	O
optimal	O
prophylaxis	O

Another	O
harm	O
reduction	O
measure	O
employed	O
for	O
example	O
in	O
Europe	O
Canada	O
and	O
Australia	O
are	O
safe	O
injection	O
sites	O
where	O
users	O
can	O
inject	O
diamorphine	B-Drug
cocaine	B-Drug
under	O
the	O
supervision	O
of	O
medically	O
trained	O
staff	O

A	O
review	O
of	O
benzodiazepine	O
poisonings	O
in	O
cats	O
and	O
dogs	O
from	O
1991-1994	O
found	O
bromazepam	B-Drug
to	O
be	O
responsible	O
for	O
significantly	O
more	O
than	O
any	O
other	O

It	O
is	O
closely	O
related	O
in	O
structure	O
to	O
mescaline	B-Drug

Conversely	O
it	O
was	O
found	O
to	O
decrease	O
sebum	O
DHT	O
levels	O
by	O
55%	O
in	O
men	O
versus	O
a	O
modest	O
reduction	O
of	O
only	O
15%	O
for	O
finasteride	B-Drug

It	O
has	O
weaker	O
analgesic	O
effects	O
than	O
dextropropoxyphene	B-Drug
itself	O
but	O
is	O
a	O
relatively	O
potent	O
pro-convulsant	O
and	O
blocker	O
of	O
sodium	O
potassium	O
channels	O
particularly	O
in	O
heart	O
tissue	O
which	O
produces	O
prolonged	O
intracardiac	O
conduction	O
time	O
can	O
lead	O
to	O
failure	O
following	O
even	O
minor	O
overdoses	O

In	O
June	O
2009	O
an	O
FDA	O
advisory	O
committee	O
recommended	O
that	O
new	O
restrictions	O
be	O
placed	O
on	O
paracetamol	B-Drug
use	O
in	O
the	O
United	O
States	O
to	O
help	O
protect	O
people	O
from	O
potential	O
toxic	O
effects	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
tissue	O

Mitragyna	B-Drug
speciosa	I-Drug
is	O
an	O
evergreen	O
tree	O
that	O
can	O
grow	O
to	O
a	O
height	O
of	O
25	O
m	O
82	O
ft	O

Her	O
death	O
was	O
seen	O
as	O
unusual	O
because	O
in	O
1995	O
the	O
number	O
of	O
people	O
who	O
had	O
died	O
from	O
ecstasy	B-Drug
use	O
very	O
low	O

The	O
antagonist	O
prevents	O
synaptic	O
dopamine	O
released	O
by	O
cathinone	B-Drug
from	O
exerting	O
its	O
effect	O
binding	O
to	O
receptors	O

Upon	O
oral	O
ingestion	O
it	O
is	O
rapidly	O
converted	O
into	O
norethisterone	B-Drug
by	O
esterases	O
during	O
intestinal	O
and	O
first-pass	O
hepatic	O
metabolism	O

The	O
same	O
may	O
be	O
true	O
of	O
illicit	O
drugs	O
such	O
as	O
opiates	O
cocaine	B-Drug
and	O
amphetamine	B-Drug
in	O
developed	O
societies	O

34-Methylenedioxyamphetamine	O
MDA	O
known	O
commonly	O
as	O
sass	O
is	O
an	O
empathogen-entactogen	O
psychostimulant	O
and	O
psychedelic	O
drug	O
of	O
the	O
amphetamine	B-Drug
family	O
that	O
encountered	O
mainly	O
a	O
recreational	O

A	O
cocaine	B-Drug
analogue	O
is	O
a	O
usually	O
artificial	O
construct	O
of	O
novel	O
chemical	O
compound	O
from	O
often	O
the	O
starting	O
point	O
natural	O
cocaine's	O
molecular	O
structure	O
with	O
result	O
product	O
sufficiently	O
similar	O
to	O
display	O
similarity	O
in	O
but	O
alteration	O
its	O
function	O

1%	O
incidence	O
adverse	O
effects	O
include:	O
Constipation	O
Urinary	O
retention	O
Hallucinations	O
Agitation	O
Confusion	O
Restlessness	O
SeizuresUnknown	O
frequency	O
Anaphylactic	O
shock	O
or	O
reactions	O
Dyspnea	O
shortness	O
of	O
breath	O
Rash	O
Erythema	O
Other	O
hypersensitivity	O
Blurred	O
vision	O
Mydriasis	O
dilated	O
pupils	O
Drowsiness	O
Dizziness	O
Somnolence	O
Physostigmine	B-Drug
a	O
cholinergic	O
drug	O
that	O
readily	O
crosses	O
the	O
blood-brain	O
barrier	O
has	O
been	O
used	O
as	O
an	O
antidote	O
to	O
treat	O
central	O
nervous	O
system	O
depression	O
symptoms	O
hyoscine	O
overdose	O

Indeed	O
in	O
2005	O
labels	O
for	O
opium	B-Drug
tincture	O
began	O
to	O
include	O
the	O
concentration	O
of	O
morphine	B-Drug
10	O
mg/mL	O
large	O
text	O
beneath	O
words	O
Opium	B-Drug
Tincture	O

Dutasteride	B-Drug
inhibits	O
5-reductase	O
isoenzymes	O
type	O
1	O
and	O
2	O
better	O
than	O
finasteride	B-Drug
leading	O
to	O
a	O
more	O
complete	O
reduction	O
in	O
DHT	O
at	O
24	O
weeks	O
94	O

In	O
1953	O
and	O
1954	O
the	O
United	O
States	O
Army	O
commissioned	O
a	O
study	O
of	O
toxicity	O
behavioral	O
effects	O
in	O
animals	O
injected	O
with	O
mescaline	B-Drug
several	O
analogues	O
including	O
MDMA	B-Drug

Marijuana	B-Drug
use	O
is	O
also	O
linked	O
to	O
other	O
substance	O
disorders	O
including	O
nicotine	B-Drug
addiction	O

One	O
study	O
reported	O
psychotic	O
relapses	O
and	O
anxiety	O
symptoms	O
in	O
well-treated	O
patients	O
with	O
mental	O
illness	O
following	O
JWH-018	B-Drug
inhalation	O

This	O
may	O
play	O
a	O
role	O
in	O
nicotine	B-Drug
addiction	O
by	O
facilitating	O
dopamine	O
release	O
the	O
nucleus	O
accumbens	O
as	O
response	O
to	O
stimuli	O

Ecstasy	B-Drug
sometimes	O
contains	O
10	O
mg	O
to	O
20	O
of	O
baclofen	B-Drug
reduce	O
overheating	O
caused	O
by	O
ecstasy	B-Drug

After	O
12	O
years	O
of	O
debilitating	O
painful	O
dependence	O
on	O
methadone	B-Drug
Scott	O
turns	O
to	O
ibogaine	B-Drug

Typically	O
the	O
base	O
for	O
lean	O
has	O
been	O
prescription	O
cold	O
medicine	O
specifically	O
cough	O
syrup	O
one	O
that	O
contains	O
both	O
promethazine	B-Drug
and	O
codeine	B-Drug
but	O
over-the-counter	O
lists	O
dextromethorphan	B-Drug
as	O
active	O
ingredient	O
also	O
used	O
it	O
can	O
produce	O
similar	O
effects	O
eliminate	O
need	O
a	O
doctor's	O
visit	O

Death	O
a	O
drug	O
that	O
causes	O
so	O
much	O
overheating	O
it	O
can	O
kill	O
within	O
40	O
minutes	O
is	O
sometimes	O
sold	O
as	O
ecstasy	B-Drug

Although	O
hashish	B-Drug
is	O
sometimes	O
eaten	O
raw	O
or	O
mixed	O
with	O
boiling	O
water	O
THC	O
and	O
other	O
cannabinoids	O
are	O
more	O
efficiently	O
absorbed	O
into	O
the	O
bloodstream	O
when	O
combined	O
butter	O
lipids	O
less	O
so	O
dissolved	O
in	O
ethanol	O

However	O
for	O
every	O
70	O
high-dose	O
opioid	O
prescription	O
only	O
one	O
naloxone	B-Drug
is	O
dispensed	O

Early	O
CIA	O
efforts	O
focused	O
on	O
LSD-25	B-Drug
which	O
later	O
came	O
to	O
dominate	O
many	O
of	O
MKUltra's	O
programs	O

Ibuprofen	B-Drug
was	O
discovered	O
in	O
1961	O
by	O
Stewart	O
Adams	O
at	O
Boots	O
UK	O
Limited	O
and	O
initially	O
marketed	O
as	O
Brufen	B-Drug

Goeders	O
concluded	O
that	O
Without	O
a	O
doubt	O
methamphetamine	B-Drug
when	O
injected	O
in	O
sufficient	O
purity	O
and	O
dose	O
can	O
produce	O
subjective	O
physiological	O
response	O
women	O
is	O
indistinguishable	O
from	O
an	O
orgasm	O

The	O
early	O
20th	O
century	O
brought	O
increased	O
regulation	O
of	O
all	O
manner	O
narcotics	O
including	O
laudanum	B-Drug
as	O
the	O
addictive	O
properties	O
opium	B-Drug
became	O
more	O
widely	O
understood	O
and	O
patent	O
medicines	O
came	O
under	O
fire	O
largely	O
because	O
their	O
mysterious	O
compositions	O

Tolerance	O
is	O
expected	O
to	O
develop	O
with	O
regular	O
methamphetamine	B-Drug
use	O
and	O
when	O
used	O
recreationally	O
this	O
tolerance	O
develops	O
rapidly	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma	O

PCP	B-Drug
works	O
primarily	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O

Opium	B-Drug
Camphorated	O
for	O
U	O

If	O
this	O
occurs	O
the	O
people	O
should	O
be	O
tapered	O
off	O
prednisone	B-Drug
slowly	O
to	O
give	O
adrenal	O
gland	O
enough	O
time	O
regain	O
its	O
function	O
and	O
endogenous	O
production	O
of	O
steroids	O

The	O
ethanol	O
in	O
wine	O
acted	O
as	O
a	O
solvent	O
and	O
extracted	O
the	O
cocaine	B-Drug
from	O
coca	B-Drug
leaves	O
altering	O
drink's	O
effect	O

Weeks	O
before	O
his	O
death	O
in	O
a	O
TV	O
interview	O
Surez	O
expressed	O
remorse	O
for	O
crimes	O
and	O
stated	O
The	O
worst	O
mistake	O
I	O
ever	O
made	O
my	O
life	O
was	O
to	O
have	O
gotten	O
involved	O
cocaine	B-Drug
trafficking	O

Obetrolling	O
or	O
doubling	O
were	O
the	O
terms	O
used	O
by	O
character	O
to	O
refer	O
tripping	O
on	O
Obetrol	B-Drug
which	O
increased	O
his	O
self-awareness	O
and	O
made	O
him	O
feel	O
alive	O

High	O
dosages	O
of	O
as	O
much	O
60	O
mg/day	O
norethisterone	B-Drug
have	O
been	O
studied	O
for	O
extended	O
treatment	O
durations	O
without	O
serious	O
adverse	O
effects	O
described	O

65	O
mL	O
for	O
contraceptionIt	O
is	O
also	O
available	O
in	O
combination	O
with	O
an	O
estrogen	O
the	O
following	O
formulations:	O
Oral	O
pills:	O
CEEs	O
and	O
MPA	O
Prempro	B-Drug
Premarin	O
Cycrin	O
Premphase	O
14/14	O
Prempro/Premphase	O
0	O
pills	B-Drug

Due	O
to	O
inactivation	O
by	O
3-hydroxysteroid	O
dehydrogenase	O
3-HSD	O
in	O
skeletal	O
muscle	O
mestanolone	B-Drug
is	O
described	O
as	O
a	O
very	O
poor	O
anabolic	O
agent	O
similarly	O
androstanolone	O
and	O
mesterolone	B-Drug

The	O
origins	O
of	O
the	O
present	O
international	O
illegal	O
heroin	B-Drug
trade	O
can	O
be	O
traced	O
back	O
to	O
laws	O
passed	O
in	O
many	O
countries	O
early	O
1900s	O
that	O
closely	O
regulated	O
production	O
and	O
sale	O
opium	B-Drug
its	O
derivatives	O
including	O

Baclofen	B-Drug
was	O
first	O
suggested	O
as	O
an	O
adjunct	O
because	O
benzodiazepines	O
do	O
not	O
affect	O
GABAB	O
receptors	O
and	O
therefore	O
have	O
no	O
cross-tolerance	O
with	O
GHB	O
while	O
baclofen	B-Drug
which	O
works	O
via	O
is	O
cross-tolerant	O
may	O
be	O
more	O
effective	O
in	O
alleviating	O
withdrawal	O
effects	O
of	O

An	O
analogue	O
of	O
ADB-FUBINACA	B-Drug
ADSB-FUB-187	O
containing	O
a	O
more	O
functionalized	O
carboxamide	O
substituent	O
was	O
recently	O
reported	O

It	O
is	O
2-	O
to	O
3-fold	O
as	O
potent	O
spironolactone	B-Drug
a	O
progestogen	O
and	O
antigonadotropin	O
but	O
its	O
antiandrogenic	O
activity	O
markedly	O
reduced	O
weak	O
though	O
still	O
of	O
significance	O
in	O
comparison	O

Following	O
ED	O
discharge	O
it	O
is	O
advised	O
to	O
prescribed	O
a	O
five-day	O
course	O
of	O
methylprednisolone	B-Drug
decrease	O
the	O
probability	O
relapse	O
or	O
withdrawal	O
symptoms	O

Veronal	B-Drug
was	O
the	O
first	O
commercially	O
available	O
barbiturate	O
sedative	O
in	O
any	O
country	O

Though	O
its	O
absolute	O
bioavailability	O
in	O
humans	O
is	O
unknown	O
bicalutamide	B-Drug
known	O
to	O
be	O
extensively	O
and	O
well-absorbed	O

Programs	O
training	O
police	O
and	O
fire	O
personnel	O
in	O
opioid	O
overdose	O
response	O
using	O
naloxone	B-Drug
have	O
also	O
shown	O
promise	O
the	O
US	O
effort	O
is	O
increasing	O
to	O
integrate	O
fatality	O
prevention	O
overall	O
crisis	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O

It	O
is	O
an	O
androgen	O
prohormone	O
of	O
nandrolone	B-Drug
and	O
other	O
19-norandrostanes	O

MDMA	B-Drug
was	O
also	O
found	O
to	O
have	O
effects	O
on	O
blood	O
sugar	O
levels	O
comparable	O
high	O
doses	O
of	O
ephedrine	B-Drug

A	O
number	O
of	O
derivatives	O
phenylisobutylamine	O
are	O
known	O
including	O
BDB	O
MBDB	O
EBDB	O
butylone	B-Drug
bk-MBDB	B-Drug
eutylone	O
bk-EBDB	O
Ariadne	O
-Et-DOM	O
4-CAB	O
and	O
4-MAB	O

In	O
most	O
countries	O
of	O
the	O
world	O
methadone	B-Drug
is	O
similarly	O
restricted	O

Other	O
trenbolone	B-Drug
esters	O
include	O
enanthate	I-Drug
hexahydrobenzylcarbonate	O
and	O
undecanoate	O

Etifoxine	B-Drug
stimulates	O
the	O
biosynthesis	O
of	O
endogenous	O
neurosteroids	O
for	O
example:	O
allopregnanolone	B-Drug
3-alpha5-alpha	O
THP	O
a	O
nanomolar	O
potentiator	O
GABA	O
activity	O

Heating	O
is	O
used	O
mainly	O
with	O
heroin	B-Drug
though	O
not	O
always	O
depending	O
on	O
the	O
type	O
of	O
but	O
also	O
often	O
other	O
drugs	O
especially	O
crushed	O
tablets	O

Methylphenidate	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
vitamin	O
K	O
anticoagulants	O
certain	O
anticonvulsants	O
and	O
some	O
antidepressants	O
tricyclic	O
selective	O
serotonin	O
reuptake	O
inhibitors	O

Chronic	O
overuse	O
of	O
dextroamphetamine	B-Drug
can	O
lead	O
to	O
severe	O
drug	O
dependence	O
resulting	O
in	O
withdrawal	O
symptoms	O
when	O
use	O
stops	O

and	O
Canadian	O
drug	O
markets	O
are	O
experiencing	O
prolonged	O
shortages	O
of	O
cocaine	B-Drug

-NO3	O
The	O
additional	O
carbon	O
atoms	O
required	O
for	O
the	O
synthesis	O
of	O
cocaine	B-Drug
are	O
derived	O
from	O
acetyl-CoA	O
by	O
addition	O
two	O
units	O
to	O
N-methyl-1-pyrrolinium	O
cation	O

To	O
induce	O
anesthesia	O
it	O
is	O
given	O
with	O
a	O
sedative-hypnotic	O
like	O
propofol	B-Drug
or	O
thiopental	B-Drug
and	O
muscle	O
relaxant	O

The	O
proportion	O
of	O
seized	O
ecstasy	B-Drug
tablets	O
with	O
MDMA-like	O
impurities	O
has	O
varied	O
annually	O
and	O
by	O
country	O

JWH-175	B-Drug
is	O
closely	O
related	O
to	O
the	O
widely	O
used	O
cannabinoid	O
designer	O
drug	O
JWH-018	B-Drug
but	O
with	O
ketone	O
bridge	O
replaced	O
by	O
a	O
simpler	O
methylene	O

Fluoxymesterone	B-Drug
has	O
been	O
reported	O
to	O
be	O
non-aromatizable	O
due	O
steric	O
hindrance	O
by	O
its	O
C11	O
hydroxyl	O
group	O
and	O
hence	O
is	O
not	O
considered	O
have	O
a	O
propensity	O
for	O
producing	O
estrogenic	O
effects	O
such	O
as	O
gynecomastia	O
or	O
fluid	O
retention	O

Drug	O
rash	O
and	O
drug-induced	O
eosinophilia	O
with	O
systemic	O
symptoms	O
is	O
a	O
known	O
complication	O
of	O
tetrazepam	B-Drug
exposure	O

Clortermine	B-Drug
Voranil	O
was	O
developed	O
by	O
Ciba	O
in	O
the	O
1960s	O
and	O
is	O
an	O
anorectic	O
drug	O
of	O
amphetamine	O
class	O

Chronic	O
hydrocodone	B-Drug
use	O
can	O
lead	O
to	O
androgen	O
deficiency	O
which	O
may	O
result	O
in	O
low	O
libido	O
impotence	O
erectile	O
dysfunction	O
amenorrhea	O
or	O
infertility	O

did	O
not	O
sell	O
metopon	B-Drug
to	O
pharmacies	O

The	O
principal	O
adverse	O
effects	O
of	O
oxymorphone	B-Drug
are	O
similar	O
to	O
other	O
opioids	O
with	O
constipation	O
nausea	O
vomiting	O
dizziness	O
dry	O
mouth	O
and	O
drowsiness	O
being	O
the	O
most	O
common	O

2C-T-4	O
25-dimethoxy-4-isopropylthiophenethylamine	O
is	O
a	O
psychedelic	O
phenethylamine	B-Drug
of	O
the	O
2C	O
family	O

The	O
hepatic	O
cytochrome	O
P450	O
enzyme	O
system	O
metabolises	O
paracetamol	B-Drug
mainly	O
CYP2E1	O
forming	O
a	O
minor	O
yet	O
significant	O
alkylating	O
metabolite	O
known	O
as	O
NAPQI	O
N-acetyl-p-benzoquinone	O
imine	O
also	O
N-acetylimidoquinone	O

In	O
humans	O
tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
diazepam	B-Drug
occurs	O
frequently	O

The	O
term	O
laudanum	B-Drug
was	O
used	O
generically	O
for	O
a	O
useful	O
medicine	O
until	O
the	O
17th	O
century	O

Ibogaine	B-Drug
decreases	O
body	O
temperature	O

Sophisticated	O
drug	O
subs	O
are	O
the	O
latest	O
tool	O
runners	O
using	O
to	O
bring	O
cocaine	B-Drug
north	O
from	O
Colombia	O
it	O
was	O
reported	O
on	O
20	O
March	O
2008	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
tissue	O

In	O
the	O
early	O
1960s	O
use	O
of	O
LSD	B-Drug
and	O
other	O
psychedelics	O
was	O
advocated	O
by	O
new	O
proponents	O
consciousness	O
expansion	O
such	O
as	O
Timothy	O
Leary	O
Alan	O
Watts	O
Aldous	O
Huxley	O
Arthur	O
Koestler	O
according	O
to	O
Laurence	O
Veysey	O
they	O
profoundly	O
influenced	O
thinking	O
generation	O
youth	O

Paliperidone	B-Drug
binds	O
D2	O
D3	O
and	O
D4	O
with	O
high	O
affinity;	O
can	O
also	O
bind	O
D1	O
D5	O

4-Methylmethamphetamine	B-Drug
4-MMA	O
is	O
a	O
putative	O
stimulant	O
and	O
entactogen	O
drug	O
of	O
the	O
amphetamine	B-Drug
class	O

There	O
are	O
commercially	O
available	O
EMIT	O
kits	O
for	O
the	O
screening	O
of	O
synthetic	O
cannabinoids	O
JWH-018	B-Drug
JWH-073	B-Drug
JWH-398	B-Drug
JWH-200	B-Drug
JWH-019	B-Drug
JWH-122	B-Drug
JWH-081	B-Drug
JWH-250	B-Drug
JWH-203	B-Drug
CP-47497	O
CP-47497-C8	O
HU-210	B-Drug
HU-211	O
AM-2201	B-Drug
AM-694	B-Drug
RCS-4	B-Drug
and	O
RCS-8	B-Drug
through	O
companies	O
like	O
NMS	O
Labs	O
Cayman	O
Chemical	O
Immunoanalysis	O
Corporation	O

Norethandrolone	B-Drug
was	O
introduced	O
for	O
medical	O
use	O
in	O
1956	O
and	O
quickly	O
followed	O
by	O
numerous	O
similar	O
steroids	O
instance	O
nandrolone	B-Drug
phenylpropionate	I-Drug
1959	O
stanozolol	B-Drug
1962	O

Urgent	O
action	O
by	O
national	O
governments	O
has	O
been	O
recommended	O
to	O
improve	O
prescribing	O
patterns	O
of	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug

In	O
2010	O
the	O
World	O
Health	O
Organization	O
WHO	O
stated	O
that	O
it	O
did	O
not	O
recommend	O
thalidomide	B-Drug
for	O
leprosy	O
due	O
to	O
difficulty	O
of	O
adequately	O
controlling	O
its	O
use	O
and	O
availability	O
clofazimine	B-Drug

As	O
with	O
other	O
pure-opioid	O
agonists	O
fentanyl	B-Drug
can	O
be	O
associated	O
dysphoria	O
in	O
both	O
dogs	O
and	O
cats	O

In	O
the	O
US	O
FDA	O
granted	O
approval	O
for	O
marketing	O
of	O
bupropion	B-Drug
depression	O
and	O
smoking	O
cessation	O

More	O
than	O
12	O
different	O
analogues	O
of	O
fentanyl	B-Drug
all	O
unapproved	O
and	O
clandestinely	O
produced	O
have	O
been	O
identified	O
in	O
the	O
U	O

Some	O
researchers	O
hypothesize	O
that	O
high	O
disease	O
activity	O
activates	O
mGR	O
expression	O
and	O
upon	O
administering	O
methylprednisolone	B-Drug
creates	O
a	O
negative	O
feedback	O
loop	O
by	O
inducing	O
apoptosis	O

It	O
may	O
interact	O
with	O
the	O
following	O
drugs:	O
heart	O
rhythm	O
medications	O
such	O
as	O
flecainide	B-Drug
Tambocor	B-Drug
propafenone	B-Drug
Rhythmol	O
or	O
quinidine	B-Drug
Cardioquin	O
Quinidex	O
Quinaglute	O
cimetidine	B-Drug
guanethidine	O
reserpine	O
Nortriptyline	B-Drug
is	O
an	O
active	O
metabolite	O
of	O
amitriptyline	B-Drug
by	O
demethylation	O
in	O
liver	O

Amiloride	B-Drug
has	O
an	O
oral	O
bioavailability	O
of	O
50%	O
meaning	O
that	O
about	O
dose	O
is	O
absorbed	O
into	O
the	O
blood	O
stream	O

However	O
during	O
the	O
same	O
period	O
use	O
of	O
heroin	B-Drug
and	O
cannabis	O
also	O
increased	O
in	O
Spain	O
Italy	O
where	O
drugs	O
for	O
personal	O
was	O
decriminalised	O
many	O
years	O
earlier	O
than	O
Portugal	O
while	O
Cannabis	O
decreased	O
rest	O
Western	O
Europe	O

Flutamide	O
has	O
been	O
found	O
to	O
be	O
similarly	O
effective	O
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
bicalutamide	B-Drug
although	O
indications	O
inferior	O
efficacy	O
including	O
greater	O
compensatory	O
increases	O
testosterone	O
levels	O
and	O
reductions	O
PSA	O
with	O
were	O
observed	O

Prudent	O
medical	O
judgment	O
necessitates	O
toward	O
dispensing	O
very	O
small	O
quantities	O
of	O
opium	B-Drug
tincture	O
in	O
dropper	O
bottles	O
or	O
pre-filled	O
syringes	O
to	O
reduce	O
the	O
risk	O
intentional	O
accidental	O
overdose	O

Cymbalta	B-Drug
duloxetine	B-Drug
an	O
antidepressant	O
of	O
the	O
serotonin-norepinephrine	O
reuptake	O
inhibitors	O
class	O

LSD	B-Drug
is	O
not	O
believed	O
to	O
have	O
been	O
manufactured	O
locally	O
in	O
a	O
significant	O
quantity	O
if	O
at	O
all	O
and	O
most	O
supplies	O
were	O
sourced	O
from	O
overseas	O

As	O
with	O
intestinal	O
absorption	O
of	O
gabapentin	B-Drug
mediated	O
by	O
LAT1	O
transport	O
across	O
the	O
bloodbrain	O
barrier	O
is	O
saturable	O

Diazepam	B-Drug
is	O
often	O
recommended	O
due	O
to	O
its	O
long	O
elimination	O
half-life	O
and	O
also	O
because	O
of	O
availability	O
in	O
low	O
potency	O
doses	O

2	O
mg	O
of	O
belladonna	O
and	O
60	O
1	O
grain	O
opium	B-Drug

Based	O
on	O
animal	O
studies	O
with	O
rats	O
and	O
dogs	O
it	O
was	O
thought	O
that	O
bicalutamide	B-Drug
could	O
not	O
cross	O
the	O
bloodbrain	O
barrier	O
hence	O
enter	O
brain	O

Short-term	O
side	O
effects	O
as	O
with	O
all	O
glucocorticoids	O
include	O
high	O
blood	O
glucose	O
levels	O
especially	O
in	O
patients	O
diabetes	O
mellitus	O
or	O
on	O
other	O
medications	O
that	O
increase	O
such	O
tacrolimus	B-Drug
and	O
mineralocorticoid	O
fluid	O
retention	O

Specifically	O
acidic	O
substances	O
will	O
reduce	O
the	O
absorption	O
of	O
methamphetamine	B-Drug
and	O
increase	O
urinary	O
excretion	O
while	O
alkaline	O
do	O
opposite	O

Darolutamide	B-Drug
has	O
no	O
contraindications	O
in	O
men	O

Mephedrone	B-Drug
can	O
come	O
in	O
the	O
form	O
of	O
capsules	O
tablets	O
or	O
white	O
powder	O
that	O
users	O
may	O
swallow	O
snort	O
inject	O
smoke	O
use	O
rectally	O

PCP	B-Drug
is	O
an	O
arylcyclohexylamine	O

In	O
August	O
2017	O
UFC	O
Light	O
Heavyweight	O
Champion	O
Jon	O
Jones	O
tested	O
positive	O
for	O
turinabol	B-Drug
in	O
a	O
drug	O
test	O
administered	O
by	O
USADA	O
following	O
his	O
victory	O
over	O
Daniel	O
Cormier	O
at	O
214	O
the	O
month	O
prior	O

Ethylestrenol	B-Drug
is	O
a	O
prodrug	O
of	O
norethandrolone	B-Drug

Clomifene	B-Drug
produces	O
N-desmethylclomifene	O
clomifenoxide	O
clomifene	B-Drug
N-oxide	O
4-hydroxyclomifene	O
and	O
4-hydroxy-N-desmethylclomifene	O
as	O
metabolites	O

A	O
2009	O
Cochrane	O
review	O
found	O
methadone	B-Drug
was	O
effective	O
in	O
retaining	O
people	O
treatment	O
and	O
the	O
reduction	O
or	O
cessation	O
of	O
heroin	B-Drug
use	O
as	O
measured	O
by	O
self-report	O
urine/hair	O
analysis	O
but	O
did	O
not	O
affect	O
criminal	O
activity	O
risk	O
death	O

Legal	O
cocaine	B-Drug
quantities	O
did	O
not	O
decrease	O
until	O
the	O
JonesMiller	O
Act	O
of	O
1922	O
put	O
serious	O
restrictions	O
on	O
manufactures	O

Fewer	O
than	O
30	O
different	O
analogs	O
of	O
PCP	B-Drug
were	O
reported	O
as	O
being	O
used	O
on	O
the	O
street	O
during	O
1970s	O
and	O
1980s	O
mainly	O
in	O
United	O
States	O

Opioid	O
effects	O
adverse	O
or	O
otherwise	O
can	O
be	O
reversed	O
with	O
an	O
opioid	O
antagonist	O
such	O
as	O
naloxone	B-Drug
naltrexone	B-Drug

When	O
given	O
by	O
injection	O
into	O
a	O
vein	O
heroin	B-Drug
has	O
two	O
to	O
three	O
times	O
the	O
effect	O
of	O
similar	O
dose	O
morphine	B-Drug

However	O
for	O
those	O
with	O
hypotension	O
midazolam	B-Drug
can	O
further	O
reduce	O
the	O
blood	O
pressure	O
and	O
has	O
cardiac	O
depressive	O
effects	O

Outside	O
of	O
the	O
US	O
MAPS	O
is	O
pursuing	O
implementation	O
MDMA/PTSD	O
studies	O
in	O
Canada	O
Israel	O
Jordan	O
and	O
Switzerland	O
MDMA	B-Drug

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches	O

Once	O
the	O
term	O
acid	B-Drug
house	O
became	O
more	O
widely	O
used	O
participants	O
at	O
house-themed	O
events	O
in	O
UK	O
and	O
Ibiza	O
made	O
psychedelic	O
drug	O
connotations	O
a	O
reality	O
by	O
using	O
club	O
drugs	O
such	O
as	O
ecstasy	B-Drug
LSD	B-Drug

Despite	O
the	O
side	O
effects	O
thalidomide	B-Drug
was	O
sold	O
in	O
pharmacies	O
Canada	O
until	O
1962	O

These	O
results	O
suggest	O
that	O
PCP	B-Drug
is	O
a	O
highly	O
selective	O
ligand	O
of	O
the	O
NMDAR	O
and	O
2	O
receptor	O

These	O
alkaloids	O
include	O
among	O
others	O
atropine	O
cocaine	B-Drug
scopolamine	O
and	O
hyoscyamine	B-Drug

Formation	O
of	O
inactive	O
stereoisomers	O
cocaine	B-Drug
has	O
4	O
chiral	O
centres	O
1R	O
2R	O
3S	O
and	O
5S	O
2	O
them	O
dependent	O
hence	O
a	O
total	O
potential	O
8	O
possible	O
plus	O
synthetic	O
by-products	O
limits	O
the	O
yield	O
purity	O

Side	O
effects	O
of	O
metandienone	B-Drug
include	O
symptoms	O
masculinization	O
like	O
acne	O
increased	O
hair	O
growth	O
voice	O
changes	O
and	O
sexual	O
desire	O
estrogenic	O
fluid	O
retention	O
breast	O
enlargement	O
liver	O
damage	O

According	O
to	O
the	O
DEA's	O
Microgram	O
from	O
December	O
2007	O
Concord	O
Police	O
Department	O
in	O
Contra	O
Costa	O
County	O
California	O
US	O
seized	O
a	O
small	O
piece	O
of	O
crudely	O
lined	O
white	O
blotter	O
paper	O
without	O
any	O
design	O
suspected	O
LSD	B-Drug
'blotter	O
acid'	O
acid	B-Drug

Doctors	O
in	O
the	O
1990s	O
often	O
would	O
switch	O
their	O
patients	O
to	O
a	O
dosing	O
schedule	O
of	O
once	O
every	O
eight	O
hours	O
when	O
they	O
complained	O
that	O
duration	O
action	O
for	O
OxyContin	B-Drug
was	O
too	O
short	O
be	O
only	O
taken	O
twice	O
day	O

Mifepristone	B-Drug
followed	O
by	O
a	O
prostaglandin	O
analog	O
misoprostol	B-Drug
or	O
gemeprost	O
is	O
used	O
for	O
medical	O
abortion	O

Raised	O
liver	O
enzymes	O
and	O
hyperlipidemia	O
both	O
hypertriglyceridemia	O
hypercholesterolemia	O
are	O
also	O
commonly	O
observed	O
during	O
lopinavir/ritonavir	O
treatment	O
lopinavir	B-Drug
ritonavir	B-Drug

Crack	O
cocaine	B-Drug
is	O
a	O
smokeable	O
form	O
of	O
made	O
into	O
small	O
rocks	O
by	O
processing	O
with	O
sodium	O
bicarbonate	O
baking	O
soda	O
and	O
water	O

There	O
is	O
a	O
risk	O
of	O
misuse	O
and	O
dependence	O
in	O
both	O
patients	O
non-medical	O
users	O
Nimetazepam	B-Drug

morphine	B-Drug
and	O
codeine	B-Drug
but	O
it	O
does	O
not	O
act	O
at	O
the	O
classic	O
opioid	O
receptors	O
namely	O
mu	O
kappa	O
delta	O
which	O
typically	O
as	O
pain	O
relievers	O

Addiction	O
specialists	O
warn	O
that	O
the	O
treatment	O
of	O
drug	O
dependence	O
with	O
ibogaine	B-Drug
in	O
non-medical	O
settings	O
without	O
expert	O
supervision	O
and	O
unaccompanied	O
by	O
appropriate	O
psychosocial	O
care	O
can	O
be	O
dangerous	O
approximately	O
one	O
case	O
300	O
potentially	O
fatal	O

A	O
series	O
of	O
Class	O
II	O
recalls	O
was	O
initiated	O
in	O
March	O
2004	O
and	O
February	O
2008	O
ALZA	O
Corporation	O
recalled	O
their	O
25	O
g/h	O
Duragesic	B-Drug
patches	O
due	O
to	O
a	O
concern	O
that	O
small	O
cuts	O
the	O
gel	O
reservoir	O
could	O
result	O
accidental	O
exposure	O
patients	O
or	O
health	O
care	O
providers	O
fentanyl	B-Drug

Internationally	O
methylphenidate	B-Drug
is	O
a	O
Schedule	O
II	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

Norpethidine	B-Drug
can	O
be	O
used	O
as	O
a	O
precursor	O
in	O
synthesis	O
of	O
other	O
drugs	O
including	O
etoxeridine	B-Drug
benzethidine	B-Drug
furethidine	B-Drug
morpheridine	B-Drug
anileridine	B-Drug
phenoperidine	B-Drug
piminodine	O
and	O
oxpheneridine	O

Other	O
molecular	O
biomarkers	O
may	O
also	O
be	O
used	O
to	O
select	O
appropriate	O
patients	O
likely	O
benefit	O
from	O
tamoxifen	B-Drug

However	O
Voltarol	O
Emulgel	O
contains	O
diclofenac	B-Drug
diethylammonium	O
in	O
which	O
a	O
1	O

Dextrorphan	B-Drug
has	O
a	O
notably	O
longer	O
elimination	O
half-life	O
than	O
its	O
parent	O
compound	O
and	O
therefore	O
tendency	O
to	O
accumulate	O
in	O
the	O
blood	O
after	O
repeated	O
administration	O
of	O
normally	O
dosed	O
dextromethorphan	B-Drug
formulations	O

They	O
lived	O
there	O
during	O
a	O
period	O
in	O
the	O
late	O
1980s	O
and	O
early	O
1990s	O
when	O
Detroit	O
many	O
other	O
major	O
American	O
cities	O
were	O
gaining	O
widespread	O
reputations	O
for	O
crime	O
violence	O
largely	O
due	O
to	O
an	O
influx	O
of	O
cocaine	B-Drug
emergence	O
crack	O
epidemic	O

Demand	O
for	O
illicit	O
opiates	O
would	O
not	O
disappear	O
even	O
if	O
Afghan	O
opium	B-Drug
were	O
used	O
licit	O
purposes	O
and	O
a	O
vacuum	O
open	O
that	O
traffickers	O
could	O
exploit	O

Desmetramadol	O
INN	O
also	O
known	O
as	O
O-desmethyltramadol	O
O-DSMT	O
is	O
an	O
opioid	O
analgesic	O
and	O
the	O
main	O
active	O
metabolite	O
of	O
tramadol	B-Drug

Spironolactone	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Aldactone	B-Drug
among	O
others	O
is	O
a	O
medication	O
that	O
primarily	O
used	O
to	O
treat	O
fluid	O
build-up	O
due	O
heart	O
failure	O
liver	O
scarring	O
or	O
kidney	O
disease	O

While	O
dextromethamphetamine	B-Drug
is	O
a	O
more	O
potent	O
drug	O
racemic	O
methamphetamine	B-Drug
sometimes	O
illicitly	O
produced	O
due	O
to	O
the	O
relative	O
ease	O
of	O
synthesis	O
and	O
limited	O
availability	O
chemical	O
precursors	O

Side	O
effects	O
from	O
lofentanil	B-Drug
might	O
be	O
particularly	O
problematic	O
given	O
its	O
reportedly	O
long	O
duration	O
of	O
action	O

The	O
safety	O
profile	O
of	O
oliceridine	B-Drug
is	O
similar	O
to	O
other	O
opioids	O

By	O
November	O
1989	O
57	O
cases	O
of	O
illness	O
caused	O
by	O
the	O
GHB	B-Drug
supplements	O
had	O
been	O
reported	O
to	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
with	O
people	O
having	O
taken	O
up	O
three	O
teaspoons	O
GHB;	O
there	O
were	O
no	O
deaths	O
but	O
nine	O
needed	O
care	O
in	O
an	O
intensive	O
unit	O

Butorphanol	B-Drug
is	O
a	O
morphinan-type	O
synthetic	O
agonistantagonist	O
opioid	O
analgesic	O
developed	O
by	O
Bristol-Myers	O

D4A	O
is	O
an	O
inhibitor	O
of	O
CYP17A1	O
3-hydroxysteroid	O
dehydrogenase/5-4	O
isomerase	O
and	O
5-reductase	O
has	O
also	O
been	O
found	O
to	O
act	O
as	O
a	O
competitive	O
antagonist	O
the	O
AR	O
reportedly	O
comparable	O
potent	O
enzalutamide	B-Drug

Street	O
cocaine	B-Drug
is	O
often	O
adulterated	O
or	O
cut	O
with	O
talc	O
lactose	O
sucrose	O
glucose	O
mannitol	B-Drug
inositol	O
caffeine	O
procaine	O
phencyclidine	B-Drug
phenytoin	B-Drug
lignocaine	B-Drug
strychnine	O
amphetamine	B-Drug
heroin	B-Drug

Ephedrine	B-Drug
was	O
freely	O
available	O
in	O
pharmacies	O
Germany	O
until	O
2001	O

Some	O
androstenedione	B-Drug
is	O
also	O
secreted	O
into	O
the	O
plasma	O
and	O
may	O
be	O
converted	O
in	O
peripheral	O
tissues	O
to	O
testosterone	O
estrogens	O

While	O
the	O
salt	O
methaqualone	B-Drug
hydrochloride	O
is	O
typically	O
used	O
clinically	O
free-base	O
was	O
also	O
marketed	O
namely	O
as	O
component	O
of	O
Mandrax	B-Drug
a	O
combination	O
drug	O
which	O
contained	O
250	O
mg	O
and	O
25	O
diphenhydramine	B-Drug
within	O
same	O
tablet	O

Bicalutamide	B-Drug
is	O
considerably	O
less	O
costly	O
than	O
GnRH	O
analogues	O
which	O
in	O
spite	O
of	O
some	O
having	O
been	O
off-patent	O
many	O
years	O
have	O
reported	O
2013	O
to	O
typically	O
cost	O
US$10000$15000	O
per	O
year	O
or	O
about	O
US$1000	O
month	O
treatment	O

government	O
and	O
formal	O
apologies	O
from	O
President	O
Gerald	O
Ford	O
CIA	O
Director	O
William	O
Colby	O
though	O
their	O
were	O
limited	O
to	O
informed	O
consent	O
issues	O
concerning	O
Olson's	O
ingestion	O
of	O
LSD	B-Drug

John's	O
wort	O
and	O
topiramate	B-Drug

In	O
northern	O
Burma	O
bans	O
have	O
ended	O
a	O
century-old	O
tradition	O
of	O
growing	O
the	O
opium	B-Drug
poppy	I-Drug

5-MeO-DMT	B-Drug
was	O
first	O
synthesized	O
in	O
1936	O
and	O
1959	O
it	O
isolated	O
as	O
one	O
of	O
the	O
psychoactive	O
ingredients	O
Anadenanthera	O
peregrina	O
seeds	O
used	O
preparing	O
Yopo	O
snuff	B-Drug

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O
Sleep	O
Older	O
age	O
Concomitant	O
use	O
CNS	O
depressants	O
like	O
benzodiazepines	O
barbiturates	O
alcohol	O
and	O
inhaled	O
anesthetics	O
Hyperventilation	O
Decreased	O
CO2	O
levels	O
in	O
serum	O
Respiratory	O
acidosis	O
clearance	O
from	O
body	O
blood	O
flow	O
to	O
liver	O
Renal	O
insufficiencySustained	O
release	O
preparations	O
such	O
as	O
patches	O
may	O
also	O
produce	O
unexpected	O
delayed	O

Because	O
of	O
thalidomide's	O
potential	O
for	O
causing	O
birth	O
defects	O
the	O
drug	O
may	O
be	O
distributed	O
only	O
under	O
tightly	O
controlled	O
conditions	O
thalidomide	B-Drug

A	O
bubblegum	O
flavored	O
oral	O
solution	O
is	O
available	O
under	O
the	O
brand	O
name	O
ProCentra	O
manufactured	O
by	O
FSC	O
Pediatrics	O
which	O
designed	O
to	O
be	O
an	O
easier	O
method	O
of	O
administration	O
in	O
children	O
who	O
have	O
difficulty	O
swallowing	O
tablets	O
each	O
5	O
mL	O
contains	O
mg	O
dextroamphetamine	B-Drug

Its	O
psychoactive	O
properties	O
are	O
not	O
like	O
those	O
of	O
LSD	B-Drug
and	O
that	O
Salvia	O
divinorum	O
is	O
generally	O
understood	O
to	O
be	O
either	O
addictive	O
or	O
toxic	O

While	O
the	O
19-nortestosterone	B-Drug
progestins	O
are	O
consistently	O
grouped	O
into	O
generations	O
pregnane	O
that	O
or	O
have	O
been	O
used	O
in	O
birth	O
control	O
pills	O
typically	O
omitted	O
from	O
such	O
classifications	O
simply	O
as	O
miscellaneous	O
pregnanes	O

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
including	O
doxorubicin	B-Drug
and	O
melphalan	O
concurrently	O

Legally	O
marketed	O
as	O
a	O
treatment	O
for	O
narcolepsy	O
and	O
sleep	O
disorders	O
modafinil	B-Drug
is	O
not	O
regarded	O
high-risk	O
drug	O
by	O
athletic	O
governing	O
bodies	O
but	O
still	O
banned	O
from	O
competition	O

4-Methylaminorex	B-Drug
4-MAR	O
4-MAX	O
is	O
a	O
stimulant	O
drug	O
of	O
the	O
2-amino-5-aryloxazoline	O
class	O
that	O
was	O
first	O
synthesized	O
in	O
1960	O
by	O
McNeil	O
Laboratories	O

Substituted	O
amphetamines	O
are	O
a	O
class	O
of	O
compounds	O
based	O
upon	O
the	O
amphetamine	B-Drug
structure;	O
it	O
includes	O
all	O
derivative	O
which	O
formed	O
by	O
replacing	O
or	O
substituting	O
one	O
more	O
hydrogen	O
atoms	O
in	O
core	O
structure	O
with	O
substituents	O

In	O
another	O
seizure	O
the	O
following	O
year	O
a	O
USCS	O
wiretap	O
on	O
Harold	O
Ackerman	O
whose	O
affiliation	O
was	O
derived	O
from	O
1991	O
enabled	O
arrest	O
of	O
seven	O
individuals	O
and	O
6000	O
kilograms	O
13228	O
lb	O
cocaine	B-Drug
hidden	O
in	O
load	O
broccoli	O

2011	O
7623	O
9577-9583]	O
from	O
a	O
South	O
Korean	O
team	O
outlined	O
novel	O
one-pot	O
synthesis	O
for	O
substituted	O
and	O
unsubstituted	O
2-benzyl-benzimidazoles	O
that	O
can	O
be	O
easily	O
adapted	O
to	O
the	O
preparation	O
of	O
etonitazene	B-Drug

The	O
US	O
federal	O
government	O
instituted	O
a	O
national	O
labeling	O
requirement	O
for	O
cocaine	B-Drug
and	O
cocaine-containing	O
products	O
through	O
the	O
Pure	O
Food	O
Drug	O
Act	O
of	O
1906	O

Other	O
terms	O
are	O
cocaine	B-Drug
baby	O
and	O
crack	O
kid	O

BenzoGynoestryl	O
Retard	O
Ginestryl-15-Depot	O
Menodin	O
Tardoginestryl	O
Estradiol	O
palmitate	O
Esmopal	O
phenylpropionate	O
Dimenformon	O
Prolongatum;	O
Estandron	O
Prolongatum	O
Lynandron	O
Mixogen	O
pivalate	O
Estrotate;	O
Estrotate	O
with	O
Progesterone	O
propionate	O
estradiol	O
17-propionate	O
Acrofollin	O
Akrofollin	O
Follhormon	O
propoxyphenylpropionate	O
Durovex	O
stearate	O
Depofollan	O
sulfate	O
a	O
minor	O
constituent	O
of	O
conjugated	O
estrogens	O
PremarinThe	O
following	O
nitrogen	O
mustard	O
ester	O
is	O
cytostatic	O
antineoplastic	O
agent	O
and	O
has	O
been	O
marketed:	O
Estramustine	O
phosphate	O
Emcyt	O
Estracyt;	O
3-normustine	O
17-phosphate	O
A	O
few	O
other	O
esters	O
which	O
are	O
notable	O
but	O
have	O
not	O
marketed	O
include:	O
3-furoate	O
3-propionate	O
to	O
be	O
confused	O
monopropionate	O
17-1-4-aminosulfonylbenzoyl-L-proline	O
EC508	O
acetate	O
benzoate	O
17-acetate	O
17-benzoate	O
acetylsalicylate	O
3-acetylsalicylate	O
anthranilate	O
3-anthranilate	O
arachidonate	O
cyclooctenyl	O
ether	O
3-benzoate	O
17-cyclooctenyl	O
ether;	O
EBCO	O
caprylate	O
octanoate	O
cyclooctyl	O
E2CoA	O
decanoate	O
17-decanoate	O
diacetate	O
dioleate	O
dipalmitate	O
distearate	O
disulfate	O
glucuronide	O
linoleate	O
oleate	O
salicylate	O
3-salicylate	O
sulfamate	O
E2MATE;	O
J995	O
PGL-2	O
PGL-2001	O
ZK-190628;	O
estradiol-3-O-sulfamate	O
undecylenate	O
SH-368	O
Estrapronicate	O
17-nicotinate;	O
Trophobolene	O
Trophoboline	O
Orestrate	O
17-1-cyclohexenyl	O
etherThe	O
Alestramustine	O
3-bis2-chloroethylcarbamate	O
17-ester	O
L-alanine	O
Atrimustine	O
KM-2210;	O
bestrabucil	O
busramustine	O
NSC-112259;	O
chlorphenacyl	O
diester	O
Leo	O
275;	O
Ro	O
21-8837	O
Estromustine	O
271	O
f;	O
estrone	O
17-3-N-bis2-chloroethylcarbamate	O
estronecytostatic	O
complex	O
Esters	O
that	O
Estrone	O
Hovigal	O
as	O
the	O
primary	O
component	O
Premarin	O
Estropipate	O
Ogen	O
Ortho-Est	O
salt	O
piperazine	O
tetraacetylglucoside	O
Glucovex	O
Glycovex	O
Other	O
cyanate	O
enanthate	O
benzilic	O
acid	O
hydrazone	O
EMATE;	O
J994;	O
estrone-3-O-sulfamate	O
estriol	O
Estriol	O
3-glucuronide	O
Emmenin	O
Progynon	O
Holin-Depot	O
succinate	O
Sinapause	O
Styptanon	O
Synapause	O
sodium	O
Pausan	O
tripropionate	O
Estriel	O
Polyestriol	O
Gynsan	O
Klimadurin	O
Triodurin	O
an	O
in	O
polymeric	O
form	O
The	O
was	O
never	O
dihexanoate	O
dipropionate	O
E3P	O
E3MATE;	O
J1034;	O
estriol-3-O-sulfamate	O
triacetate	O
ethinylestradiol	O
exist	O
Ethinylestradiol	O
sulfonate	O
Turisteron;	O
3-isopropylsulfonate	O
NN-diethylsulfamate	O
J271	O
3-NN-diethylsulfamate	O
pyrrolidinosulfonate	O
J272	O
3-pyrrolidinosulfonate	O
J1028	O
3-sulfamate	O
Hydroxyestrone	O
Colpoginon	O
Colpormon	O
Hormobion	O
Hormocervix	O
316-diacetate	O
16-hydroxyestrone	O
number	O
estrogen	O
ethers	O
also	O
including:	O
Clomestrone	O
Arterolo	O
Atheran	O
Colesterel	O
Iposclerone	O
Liprotene	O
Persclerol	O
3-methyl	O
16-chloroestrone	O
Cloxestradiol	O
Genovul	O
OO-diacetate	O
cloxestradiol	O
17-chloral	O
hemiacetal	O
Mestranol	O
Devocin	O
Ovastol	O
Tranel	O
Enovid	O
Enavid	O
Ortho-Novin	O
Femigen	O
Norbiogest	O
Moxestrol	O
Surestryl	O
11-methoxy	O
derivative	O
hence	O
11-methyl	O
11-hydroxyl	O
Nilestriol	O
Wei	O
Ni	O
An	O
3-cyclopentyl	O
ethinylestriol	O
Promestriene	O
Colpotrofin	O
Colpotrophine	O
Delipoderm	O
3-propyl	O
17-methyl	O
diether	O
Quinestradol	O
Colpovis	O
Colpovister	O
Pentovis	O
Quinestrol	O
Agalacto-Quilea	O
Basaquines	O
Eston	O
Estrovis	O
Estrovister	O
Plestrovis	O
Qui-lea	O
3-saccharinylmethyl	O
3-tetrahydropyranyl	O
3-tetrahydropyran-2-yl	O
17-tetrahydropyranyl	O
17-tetrahydropyran-2-yl	O
methyl	O
Mytatrienediol	O
16-methyl-16-epiestriol	O
Major	O
diethylstilbestrol	O
Diethylstilbestrol	O
Agostilben	O
Biokeral	O
Clinestrol	O
Cyclen	O
Estilbin	O
Estril	O
Neobenzoestrol	O
Orestol	O
Oroestrol	O
Ostregenin	O
Prostilbene	O
Stilbestriol	O
DP	O
Stilboestrolum	O
Dipropionicum	O
Stilboestrol	O
Synestrin	O
Willestrol	O
Fosfestrol	O
diphosphate	O
Honvan	O
Difostilben	O
Fosfostilben	O
Fostrolin	O
Stilbol	O
Stilphostrol	O
VagestrolLess	O
commonly	O
used	O
Hormostilboral	O
Stark	O
dilaurate	O
Acnestrol-Lotion	O
stilpalmitate	O
Palmestril	O
Stilpalmitate	O
Hydroestryl	O
Idroestril	O
Furostilbestrol	O
difuroate	O
Polydiethylstilbestrol	O
phosphateAs	O
well	O
ester:	O
ICI-85966	O
Stilbostat;	O
bisdi2-chloroethylcarbamate	O
Hexestrol	O
Retalon	O
Lingual	O
Robal	O
Sintestrol	O
Sintofolin	O
dicaprylate	O
dioctanoylhexestrol	O
Taston	O
Cytostesin	O
Pharmestrin	O
Aquosum	O
Hexanoestrol	O
Oleosum	O
hexestrol	O
Phenestrol	O
fenestrol;	O
bis[4-[bis2-chloroethylamino]phenylacetate	O
Dienestrol	O
Faragynol	O
Gynocyrol	O
Methestrol	O
promethestrol	O
dimethylhexestrol	O
Meprane	O
Dipropionate	O
monobenzyl	O
benzelstilbestrol	O
Monozol	O
Hypantin	O
Pituitrope	O
Dimestrol	O
dianisylhexene	O
dimethyl	O
dimethoxydiethylstilbestrol	O
Depot-Ostromon	O
Synthila	O
Mestilbol	O
monomethyl	O
Monomestro	O
or	O
Monomestrol	O
nicotinate	B-Drug

Ketamine	B-Drug
has	O
been	O
found	O
to	O
increase	O
dopaminergic	O
neurotransmission	O
in	O
the	O
brain	O
but	O
instead	O
of	O
being	O
due	O
dopamine	O
reuptake	O
inhibition	O
this	O
may	O
be	O
via	O
indirect/downstream	O
mechanisms	O
namely	O
through	O
antagonism	O
NMDA	O
receptor	O

After	O
oral	O
administration	O
of	O
100	O
mg	O
tilidine	B-Drug
plus	O
8	O
naloxone	B-Drug
the	O
maximum	O
effect	O
is	O
reached	O
in	O
about	O
25-50	O
minutes	O

Likewise	O
Duchaine	O
erred	O
in	O
promoting	O
the	O
drug	O
Gamma-hydroxybutyric	O
acid	B-Drug
GHB	B-Drug
as	O
an	O
anabolic	O
agent	O
and	O
served	O
time	O
for	O
unlawful	O
possession	O
distribution	O
of	O
mid-1990s	O

Zolpidem	B-Drug
has	O
also	O
been	O
studied	O
in	O
persistent	O
vegetative	O
states	O
with	O
unclear	O
effect	O

It	O
has	O
grown	O
to	O
be	O
a	O
unifying	O
symbol	O
of	O
family	O
and	O
community	O
dedication	O
preventing	O
the	O
use	O
alcohol	O
tobacco	B-Drug
illicit	O
drugs	O
among	O
youth	O

Distressing	O
flashbacks	B-Drug
might	O
occur	O
in	O
spite	O
of	O
no	O
further	O
use	O
a	O
condition	O
called	O
hallucinogen	O
persisting	O
perception	O
disorder	O

Many	O
anthelmintic	O
drugs	O
albendazole	B-Drug
mebendazole	B-Drug
triclabendazole	B-Drug
etc	O

There	O
is	O
a	O
tremendous	O
demand	O
for	O
cocaine	B-Drug
in	O
the	O
U	O

Single	O
intramuscular	O
injections	B-Drug
of	O
100	O
mg	O
nandrolone	B-Drug
phenylpropionate	I-Drug
or	O
decanoate	O
have	O
been	O
found	O
to	O
produce	O
an	O
anabolic	O
effect	O
for	O
10	O
14	O
days	O
and	O
20	O
25	O
respectively	O

All	O
these	O
symptoms	O
subside	O
when	O
gabapentin	B-Drug
is	O
re-instated	O

By	O
1984	O
the	O
DEA	O
had	O
announced	O
its	O
intention	O
to	O
designate	O
MDMA	B-Drug
as	O
a	O
Schedule	O
I	O
substance	B-Drug
categorization	O
that	O
would	O
greatly	O
restrict	O
and	O
regulate	O
drug's	O
availability	O
well	O
indicate	O
it	O
held	O
no	O
accepted	O
medical	O
use	O
high	O
abuse	O
potential	O

Bicalutamide	B-Drug
acts	O
as	O
a	O
highly	O
selective	O
competitive	O
silent	O
antagonist	O
of	O
the	O
AR	O
IC50	O
=	O
159243	O
nM	O
major	O
biological	O
target	O
androgen	O
sex	O
hormones	O
testosterone	O
and	O
DHT	O
hence	O
is	O
an	O
antiandrogen	O

For	O
this	O
reason	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia	O

8%	O
of	O
men	O
treated	O
with	O
finasteride	B-Drug
or	O
dutasteride	B-Drug

In	O
January	O
2013	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
CDC	O
reported	O
an	O
illness	O
associated	O
with	O
intravenous	O
IV	O
abuse	O
of	O
oral	O
Opana	B-Drug
ER	I-Drug
oxymorphone	B-Drug
in	O
Tennessee	O

Internationally	O
DOET	B-Drug
is	O
a	O
Schedule	O
I	O
controlled	O
medicine	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O
it's	O
legal	O
only	O
for	O
medical	O
uses	O
or	O
scientific	O
research:[1]	O

Chemically	O
it	O
is	O
closely	O
related	O
to	O
another	O
indole-3-carboxamide	O
synthetic	O
cannabinoid	O
Org	O
28611	O
but	O
with	O
a	O
different	O
cycloalkyl	O
substitution	O
on	O
the	O
carboxamide	O
and	O
cyclohexylmethyl	O
group	O
replaced	O
by	O
morpholinylethyl	O
as	O
in	O
JWH-200	B-Drug
or	O
A-796260	O

After	O
paying	O
Marks	O
5000	O
for	O
his	O
work	O
in	O
Frankfurt	O
Plinston	O
then	O
sold	O
hashish	B-Drug
on	O
to	O
and	O
three	O
friends	O
Radcliffe	O
Weatherly	O
Jarvis	O
London;	O
selling	O
650	O
kilos	O
within	O
a	O
week	O
the	O
four	O
men	O
made	O
profit	O
of	O
20000	O

Cannabis	O
plants	O
tend	O
to	O
vary	O
with	O
different	O
strains	O
producing	O
dynamic	O
balances	O
of	O
cannabinoids	O
THC	O
CBD	B-Drug
etc	O

If	O
these	O
fail	O
then	O
phenytoin	B-Drug
may	O
be	O
used	O
with	O
phenobarbital	B-Drug
being	O
an	O
alternative	O
in	O
the	O
US	O
but	O
only	O
third-line	O
UK	O

Intramuscular	O
injections	B-Drug
of	O
200	O
mg	O
NETE	O
once	O
every	O
3	O
weeks	O
have	O
also	O
been	O
found	O
to	O
suppress	O
spermatogenesis	O
in	O
men	O

Ketamine	B-Drug
is	O
frequently	O
used	O
in	O
severely	O
injured	O
people	O
and	O
appears	O
to	O
be	O
safe	O
this	O
group	O

Levonorgestrel-only	O
emergency	O
contraception	O
was	O
approved	O
in	O
the	O
United	O
States	O
under	O
brand	O
name	O
Plan	B-Drug
B	I-Drug
1999	O
and	O
has	O
also	O
been	O
marketed	O
widely	O
elsewhere	O
throughout	O
world	O
other	O
names	O
such	O
as	O
Levonelle	O
NorLevo	B-Drug
addition	O
to	O
Postinor	O

Compared	O
to	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
which	O
calls	O
for	O
uprooting	O
of	O
all	O
coca	B-Drug
bushes	O
grow	O
wild	O
and	O
governmental	O
licensing	O
purchasing	O
wholesaling	O
licit	O
opium	B-Drug
cannabis	O
crops	O
Psychotropic	O
Substances	O
devotes	O
few	O
words	O
subject	O
psychoactive	O
plants	O

Concentrated	O
aqueous	O
solutions	O
of	O
hydromorphone	B-Drug
hydrochloride	O
have	O
a	O
visibly	O
different	O
refractive	O
index	O
from	O
pure	O
water	O
isotonic	O
9	O
09	O
per	O
cent	O
saline	O
and	O
the	O
like	O
especially	O
when	O
stored	O
in	O
clear	O
ampoules	O
phials	O
may	O
acquire	O
slight	O
amber	O
discolouration	O
upon	O
exposure	O
to	O
light;	O
this	O
reportedly	O
has	O
no	O
effect	O
on	O
potency	O
solution	O
but	O
14-dihydromorphinones	O
such	O
as	O
oxymorphone	B-Drug
relatives	O
come	O
with	O
instructions	O
protect	O
light	O

5	O
million	O
people	O
in	O
the	O
United	O
States	O
used	O
cocaine	B-Drug
2010	O
down	O
from	O
2	O

Case	O
reports	O
of	O
seven	O
British	O
males	O
who	O
presented	O
to	O
an	O
emergency	O
room	O
following	O
analytically	O
confirmed	O
25I-NBOMe	B-Drug
intoxication	O
suggest	O
the	O
potential	O
adverse	O
effects:	O
tachycardia	O
n	O
=	O
7	O
hypertension	O
4	O
agitation	O
6	O
aggression	O
visual	O
and	O
auditory	O
hallucinations	O
seizures	O
3	O
hyperpyrexia	O
clonus	O
2	O
elevated	O
white	O
cell	O
count	O
creatine	O
kinase	O
metabolic	O
acidosis	O
acute	O
kidney	O
injury	O
1	O

There	O
can	O
also	O
be	O
very	O
substantial	O
differences	O
between	O
the	O
drugs;	O
for	O
instance	O
5-MeO-DMT	B-Drug
rarely	O
produces	O
visual	O
effects	O
typical	O
of	O
other	O
psychedelics	O

Sufentanil	B-Drug
with	O
and	O
without	O
lidocaine	B-Drug
or	O
mepivacaine	O
is	O
available	O
as	O
a	O
transdermal	O
patch	O
similar	O
to	O
Duragesic	B-Drug
in	O
Europe	O
under	O
trade	O
names	O
such	O
Chronogesic	O

Yield	O
is	O
typically	O
50%:50%	O
although	O
slightly	O
alkaline	O
reaction	O
conditions	O
can	O
increase	O
mannitol	B-Drug
yields	O

Indeed	O
DHT	O
has	O
less	O
than	O
1%	O
of	O
the	O
affinity	O
testosterone	O
for	O
ZIP9	O
and	O
synthetic	O
AAS	O
metribolone	O
mibolerone	B-Drug
are	O
ineffective	O
competitors	O
receptor	O
similarly	O

Opiates	O
such	O
as	O
heroin	B-Drug
and	O
morphine	B-Drug
function	O
an	O
analgesic	O
by	O
binding	O
to	O
opioid	O
receptors	O
in	O
the	O
brain	O
gastrointestinal	O
tract	O

Danazol	B-Drug
sold	O
as	O
Danocrine	O
and	O
other	O
brand	O
names	O
is	O
a	O
medication	O
used	O
in	O
the	O
treatment	O
of	O
endometriosis	O
fibrocystic	O
breast	O
disease	O
hereditary	O
angioedema	O
conditions	O

For	O
pain	O
relief	O
a	O
unit	O
of	O
carfentanil	B-Drug
is	O
100	O
times	O
as	O
potent	O
the	O
same	O
amount	O
fentanyl	B-Drug
5000	O
heroin	B-Drug
and	O
10000	O
morphine	B-Drug

25I-NBOMe	B-Drug
presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
triggering	O
blood	O
platelet	O
aggregation	O

Lormetazepam	B-Drug
may	O
be	O
unsuitable	O
for	O
the	O
elderly	O
due	O
to	O
residual	O
effects	O
on	O
memory	O
and	O
body	O
sway	O
which	O
result	O
in	O
falls	O

Furazabol	B-Drug
INN	O
JAN	O
brand	O
names	O
Frazalon	O
Miotalon	O
Qu	O
Zhi	O
Shu	O
also	O
known	O
as	O
androfurazanol	O
is	O
a	O
synthetic	O
orally	O
active	O
anabolic-androgenic	O
steroid	O
which	O
has	O
been	O
marketed	O
in	O
Japan	O
since	O
1969	O

Furethidine	B-Drug
is	O
not	O
currently	O
used	O
in	O
medicine	O
and	O
a	O
Class	O
A/Schedule	O
I	O
drug	O
which	O
controlled	O
under	O
UN	O
conventions	O

It	O
uses	O
a	O
medication	O
delivery	O
technology	O
called	O
BEMA	O
BioErodible	O
MucoAdhesive	O
small	O
dissolvable	O
polymer	O
film	O
containing	O
various	O
fentanyl	B-Drug
doses	O
applied	O
to	O
the	O
inner	O
lining	O
of	O
cheek	O

Clonazepam	B-Drug
and	O
7-aminoclonazepam	O
may	O
be	O
quantified	O
in	O
plasma	O
serum	O
or	O
whole	O
blood	O
order	O
to	O
monitor	O
compliance	O
those	O
receiving	O
the	O
drug	O
therapeutically	O

Methylphenidate	B-Drug
has	O
a	O
higher	O
affinity	O
for	O
the	O
dopamine	O
transporter	O
than	O
norepinephrine	O
and	O
so	O
its	O
effects	O
are	O
mainly	O
due	O
to	O
elevated	O
levels	O
caused	O
by	O
inhibited	O
reuptake	O
of	O
however	O
increased	O
also	O
contribute	O
various	O
drug	O

According	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
ibuprofen	B-Drug
can	O
interfere	O
with	O
antiplatelet	O
effect	O
of	O
low-dose	O
aspirin	B-Drug
potentially	O
rendering	O
less	O
effective	O
when	O
used	O
for	O
cardioprotection	O
stroke	O
prevention	O

Cocaine	B-Drug
and/or	O
associated	O
hyperthermia	O
may	O
cause	O
muscle	O
cell	O
destruction	O
rhabdomyolysis	O
and	O
myoglobinuria	O
resulting	O
in	O
kidney	O
failure	O

In	O
2006	O
the	O
FDA	O
approved	O
risperidone	B-Drug
for	O
treatment	O
of	O
irritability	O
in	O
autistic	O
children	O
and	O
adolescents	O

Anticoagulants	O
cardiac	O
glycosides	O
may	O
have	O
their	O
effects	O
potentiated	O
by	O
acetazolamide	B-Drug

Isoquinolines	O
such	O
as	O
papaverine	B-Drug
and	O
noscapine	O
have	O
no	O
significant	O
central	O
nervous	O
system	O
effects	O

In	O
this	O
age	O
group	O
lorazepam	B-Drug
is	O
associated	O
with	O
falls	O
and	O
hip	O
fractures	O

Amphetamine	B-Drug
is	O
eliminated	O
via	O
the	O
kidneys	O
with	O
3040%	O
of	O
drug	O
being	O
excreted	O
unchanged	O
at	O
normal	O
urinary	O
pH	O

Medium	O
volumes	O
of	O
cocaine	B-Drug
go	O
directly	O
from	O
South	O
America	O
to	O
East	O
and	O
South-East	O
Asia	O
Oceania	O
Australia	O
in	O
particular	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s	O

Cannabidiol	B-Drug
CBD	B-Drug
is	O
non-psychotropic	O

Likewise	O
a	O
2010	O
Dutch	O
study	O
ranked	O
the	O
relative	O
harm	O
of	O
psilocybin	O
mushrooms	O
compared	O
to	O
selection	O
19	O
recreational	O
drugs	O
including	O
alcohol	O
cannabis	O
cocaine	B-Drug
ecstasy	B-Drug
heroin	B-Drug
and	O
tobacco	B-Drug

The	O
various	O
benzodiazepines	O
differ	O
in	O
their	O
toxicity;	O
temazepam	B-Drug
appears	O
most	O
toxic	O
overdose	O
and	O
when	O
used	O
with	O
other	O
drugs	O

In	O
the	O
Soviet	O
Union	O
pods	O
were	O
typically	O
scored	O
horizontally	O
and	O
opium	B-Drug
was	O
collected	O
three	O
times	O
or	O
else	O
one	O
two	O
collections	O
followed	O
by	O
isolation	O
of	O
opiates	O
from	O
ripe	O
capsules	O

Some	O
scientists	O
and	O
women's	O
groups	O
in	O
India	O
continue	O
to	O
oppose	O
DMPA	B-Drug

Methohexital	B-Drug
binds	O
to	O
a	O
distinct	O
site	O
which	O
is	O
associated	O
with	O
Cl	O
ionophores	O
at	O
GABAA	O
receptors	O

Chocolate	O
contains	O
alkaloids	O
such	O
as	O
theobromine	O
and	O
phenethylamine	B-Drug
which	O
have	O
physiological	O
effects	O
in	O
humans	O
but	O
the	O
presence	O
of	O
renders	O
it	O
toxic	O
to	O
some	O
animals	O
including	O
dogs	O
cats	O

Further	O
cocaine	B-Drug
binds	O
in	O
such	O
a	O
way	O
as	O
to	O
inhibit	O
hydrogen	O
bond	O
innate	O
DAT	O

Beside	O
plants	O
alkaloids	O
are	O
found	O
in	O
certain	O
types	O
of	O
fungi	O
such	O
as	O
psilocybin	O
the	O
fungus	O
genus	O
Psilocybe	O
and	O
animals	O
bufotenin	B-Drug
skin	O
some	O
toads	O
a	O
number	O
insects	O
markedly	O
ants	O

In	O
the	O
1960s	O
thalidomide	B-Drug
was	O
successfully	O
marketed	O
as	O
a	O
safer	O
alternative	O
to	O
barbiturates	O

Metenolone	B-Drug
enanthate	I-Drug
is	O
or	O
has	O
been	O
marketed	O
under	O
the	O
brand	O
names	O
Nibal	O
Injection	O
and	O
Primobolan	O
Depot	O

Both	O
enantiomers	O
of	O
propranolol	B-Drug
have	O
a	O
local	O
anesthetic	O
topical	O
effect	O
which	O
is	O
normally	O
mediated	O
by	O
blockade	O
voltage-gated	O
sodium	O
channels	O

Mild	O
withdrawal	O
symptoms	O
from	O
the	O
discontinuation	O
of	O
amphetamine	B-Drug
treatment	O
at	O
therapeutic	O
doses	O
can	O
be	O
avoided	O
by	O
tapering	O
dose	O

Prior	O
to	O
the	O
ban	O
taking	O
effect	O
mephedrone	B-Drug
was	O
not	O
covered	O
by	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O

This	O
was	O
eventually	O
modified	O
to	O
allow	O
approved	O
physicians	O
treat	O
up	O
100	O
people	O
with	O
buprenorphine	B-Drug
for	O
opioid	O
addiction	O
in	O
an	O
outpatient	O
setting	O

Ketazolam	B-Drug
is	O
a	O
List	O
II	O
drugs	O
of	O
the	O
Opium	O
Law	O
in	O
Netherlands	O

Russian	O
Spetsnaz	O
security	O
forces	O
used	O
a	O
fentanyl	B-Drug
analogue	O
or	O
derivative	O
to	O
incapacitate	O
people	O
rapidly	O
in	O
the	O
Moscow	O
theater	O
hostage	O
crisis	O
2002	O

In	O
the	O
United	O
States	O
medical	O
use	O
of	O
cannabis	O
further	O
declined	O
with	O
passage	O
Marihuana	B-Drug
Tax	O
Act	O
1937	O
which	O
imposed	O
new	O
regulations	O
and	O
fees	O
on	O
physicians	O
prescribing	O

Sedation:	O
Fentanyl	B-Drug
produces	O
sleep	O
and	O
drowsiness	O
as	O
dosage	O
is	O
increased	O
can	O
produce	O
the	O
-waves	O
often	O
seen	O
in	O
natural	O
on	O
electroencephalogram	O

Psilocybin	O
and	O
its	O
metabolized	O
counterpart	O
psilocin	B-Drug
are	O
Schedule	O
1	O
on	O
the	O
California	O
Uniform	O
Controlled	O
Substances	O
Act	O

GHB	B-Drug
is	O
produced	O
in	O
the	O
body	O
very	O
small	O
amounts	O
and	O
blood	O
levels	O
may	O
climb	O
after	O
death	O
to	O
range	O
of	O
3050	O
mg/L	O

Compared	O
to	O
THC	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors	O
JWH-018	B-Drug
and	O
many	O
synthetic	O
cannabinoids	O
are	O
full	O
agonists	O

Powder	O
cocaine	B-Drug
hydrochloride	I-Drug
must	O
be	O
heated	O
to	O
a	O
high	O
temperature	O
about	O
197	O
C	O
and	O
considerable	O
decomposition/burning	O
occurs	O
at	O
these	O
temperatures	O

desipramine	B-Drug

Benzphetamine	B-Drug
should	O
not	O
be	O
given	O
to	O
patients	O
who	O
are	O
in	O
an	O
agitated	O
state	O
or	O
have	O
a	O
history	O
of	O
drug	O
abuse	O

Fentanyl	B-Drug
in	O
injectable	O
formulation	O
is	O
commonly	O
used	O
for	O
analgesia	O
and	O
as	O
a	O
component	O
of	O
balanced	O
sedation	O
general	O
anesthesia	O
small	O
animal	O
patients	O

67	O
mg	O
of	O
benzhydrocodone	O
hydrochloride	O
and	O
325	O
acetaminophen	B-Drug

The	O
medication	O
is	O
also	O
available	O
in	O
combination	O
with	O
other	O
medications	O
such	O
as	O
hydrochlorothiazide	B-Drug
brand	O
name	O
Aldactazide	O
others	O

Phenobarbital	B-Drug
may	O
provide	O
a	O
clinical	O
advantage	O
over	O
carbamazepine	B-Drug
for	O
treating	O
partial	O
onset	O
seizures	O

These	O
low	O
levels	O
are	O
not	O
expected	O
to	O
pose	O
any	O
risk	O
the	O
breastfeeding	O
infant	O
and	O
American	O
Academy	O
of	O
Pediatrics	O
considers	O
propranolol	B-Drug
therapy	O
generally	O
compatible	O
with	O

Positive	O
results	O
for	O
phase	O
III	O
trials	O
were	O
first	O
described	O
in	O
2017	O
and	O
Janssen	O
submitted	O
a	O
New	O
Drug	O
Application	O
apalutamide	B-Drug
to	O
the	O
United	O
States	O
Food	O
Administration	O
on	O
11	O
October	O

It	O
has	O
been	O
implicated	O
in	O
addictions	O
to	O
alcohol	O
cannabinoids	O
cocaine	B-Drug
methylphenidate	B-Drug
nicotine	B-Drug
opioids	O
phencyclidine	B-Drug
propofol	B-Drug
and	O
substituted	O
amphetamines	O
among	O
others	O

Some	O
research	O
chemicals	O
on	O
the	O
market	O
were	O
not	O
psychoactive	O
but	O
can	O
be	O
used	O
as	O
precursors	O
in	O
synthesis	O
of	O
other	O
potentially	O
substances	O
for	O
example	O
2C-H	O
which	O
could	O
to	O
make	O
2C-B	B-Drug
and	O
2C-I	O
among	O
others	O

In	O
addition	O
to	O
the	O
amounts	O
previously	O
mentioned	O
cocaine	B-Drug
can	O
be	O
sold	O
in	O
bill	O
sizes:	O
As	O
of	O
2007	O
for	O
example	O
$10	O
might	O
purchase	O
a	O
dime	O
bag	O
very	O
small	O
amount	O
0	O

The	O
primary	O
pathway	O
involves	O
conversion	O
of	O
17-hydroxypregnenolone	O
to	O
DHEA	O
by	O
way	O
1720-lyase	O
with	O
subsequent	O
androstenedione	B-Drug
via	O
the	O
enzyme	O
3-hydroxysteroid	O
dehydrogenase	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are	O
like	O
marijuana	O
typically	O
used	O
before	O
person	O
progresses	O
more	O
harmful	O
substances	O

Anxiety	O
Irritability	O
Insomnia	O
Tremors	O
Headaches	O
Stomach	O
pain	O
Nausea	O
Hallucinations	O
Suicidal	O
thoughts	O
or	O
urges	O
Depression	O
Fatigue	O
Dizziness	O
Sweating	O
Confusion	O
Potential	O
to	O
exacerbate	O
existing	O
panic	O
disorder	O
upon	O
discontinuation	O
Seizures	O
similar	O
delirium	O
tremens	O
with	O
long-term	O
use	O
of	O
excessive	O
dosesBenzodiazepines	O
such	O
as	O
clonazepam	B-Drug
can	O
be	O
very	O
effective	O
in	O
controlling	O
status	O
epilepticus	O
but	O
when	O
used	O
for	O
longer	O
periods	O
time	O
some	O
potentially	O
serious	O
side-effects	O
may	O
develop	O
interference	O
cognitive	O
functions	O
and	O
behavior	O

Ibuprofen	B-Drug
is	O
commonly	O
available	O
in	O
the	O
United	O
States	O
up	O
to	O
FDA's	O
1984	O
dose	O
limit	O
OTC	O
rarely	O
used	O
higher	O
by	O
prescription	O

Tolerance	O
often	O
develops	O
to	O
the	O
muscle	O
relaxant	O
effects	O
of	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug

Esterified	O
estrogens/methyltestosterone	O
EEs/MT	O
sold	O
under	O
brand	O
names	O
such	O
as	O
Covaryx	O
Eemt	O
Essian	O
Estratest	B-Drug
Menogen	O
and	O
Syntest	O
is	O
a	O
hormonal	O
preparation	O
that	O
combines	O
esterified	O
estrogens	O
EEs	O
with	O
methyltestosterone	B-Drug
MT	O
in	O
one	O
tablet	O
used	O
menopausal	O
hormone	O
therapy	O

Black	O
cocaine	B-Drug
was	O
detected	O
in	O
Bogota	O
Colombia	O
May	O
1998	O

Some	O
growers	O
in	O
the	O
US	O
succeeded	O
lowering	O
proportion	O
of	O
CBD-to-THC	O
to	O
accommodate	O
customers	O
who	O
preferred	O
varietals	O
that	O
were	O
more	O
mind-altering	O
due	O
higher	O
THC	O
and	O
lower	O
CBD	B-Drug
content	O

Amphetamine	B-Drug
was	O
eventually	O
developed	O
for	O
the	O
treatment	O
of	O
narcolepsy	O
post-encephalitic	O
parkinsonism	O
and	O
mood	O
elevation	O
in	O
depression	O
other	O
psychiatric	O
indications	O

Bolandiol	O
dipropionate	O
USAN	O
brand	O
names	O
Anabiol	O
Storinal;	O
former	O
developmental	O
code	O
name	O
SC-7525	O
or	O
bolandiol	O
propionate	O
JAN	O
also	O
known	O
as	O
norpropandrolate	O
19-nor-4-androstenediol	O
well	O
estr-4-ene-317-diol	O
317-dipropionate	O
is	O
a	O
synthetic	O
anabolic-androgenic	O
steroid	O
AAS	O
and	O
derivative	O
of	O
19-nortestosterone	B-Drug
nandrolone	B-Drug

However	O
the	O
FDA	O
closely	O
monitors	O
labeling	O
of	O
opium	B-Drug
tincture	O

As	O
nalorphine	O
dinicotinate	B-Drug
is	O
only	O
regulated	O
at	O
the	O
Rx	O
prescription	O
required	O
drug	O
it	O
would	O
be	O
legal	O
to	O
possess	O
with	O
a	O
valid	O
should	O
patient	O
manage	O
acquire	O

However	O
some	O
drugs	O
are	O
created	O
which	O
means	O
made	O
in	O
the	O
laboratorium	O
like	O
cocaine	B-Drug
ecstasy	B-Drug
MDMA	B-Drug
and	O
more	O

Australia:	O
GBL	O
is	O
not	O
classified	O
as	O
a	O
drug	O
but	O
health-endangering	O
substance	B-Drug

Oxycodone	B-Drug
is	O
the	O
most	O
widely	O
recreationally	O
used	O
opioid	O
in	O
America	O

He	O
contracted	O
with	O
a	O
Belgian	O
company	O
to	O
produce	O
ibogaine	B-Drug
in	O
tablet	O
form	O
for	O
clinical	O
trials	O
the	O
Netherlands	O
and	O
was	O
awarded	O
United	O
States	O
patent	O
product	O
1985	O

Many	O
research	O
compounds	O
have	O
produced	O
unexpected	O
side-effects	O
and	O
adverse	O
incidents	O
due	O
to	O
the	O
lack	O
of	O
screening	O
for	O
off-target	O
effects	O
prior	O
marketing;	O
both	O
bromo-dragonfly	O
mephedrone	B-Drug
seem	O
be	O
capable	O
producing	O
pronounced	O
vasoconstriction	O
under	O
some	O
circumstances	O
which	O
has	O
resulted	O
in	O
several	O
deaths	O
although	O
mechanism	O
remains	O
unclear	O

attributed	O
to	O
the	O
United	O
States	O
Pharmacoepia	O
of	O
1863:	O
Macerate	O
212	O
ounces	O
opium	B-Drug
in	O
moderately	O
fine	O
powder	O
1	O
pint	O
water	O
for	O
3	O
days	O
with	O
frequent	O
agitation	O

In	O
women	O
nandrolone	B-Drug
and	O
esters	O
have	O
been	O
reported	O
to	O
produce	O
increased	O
libido	O
acne	O
facial	O
body	O
hair	O
growth	O
voice	O
changes	O
clitoral	O
enlargement	O

The	O
FDA	O
gave	O
Sterling	O
six	O
months	O
to	O
stop	O
marketing	O
stanozolol	B-Drug
for	O
the	O
indications	O
which	O
there	O
was	O
no	O
evidence	O
efficacy	O
and	O
one	O
year	O
submit	O
further	O
data	O
two	O
it	O
found	O
probable	O

The	O
state	O
responded	O
by	O
incorporating	O
recommendations	O
from	O
the	O
Commissioner's	O
Committee	O
on	O
Chronic	O
Pain	O
Guidelines	O
that	O
support	O
co-prescribing	O
naloxone	B-Drug
to	O
certain	O
high-risk	O
populations	O

Cocaine	B-Drug
may	O
also	O
greatly	O
increase	O
the	O
risk	O
of	O
developing	O
rare	O
autoimmune	O
or	O
connective	O
tissue	O
diseases	O
such	O
as	O
lupus	O
Goodpasture	O
syndrome	O
vasculitis	O
glomerulonephritis	O
StevensJohnson	O
and	O
other	O

Rats	O
which	O
were	O
treated	O
by	O
octreotide	B-Drug
experienced	O
erectile	O
dysfunction	O
in	O
a	O
1998	O
study	O

Oripavine	O
possesses	O
an	O
analgesic	O
potency	O
comparable	O
to	O
morphine;	O
however	O
it	O
is	O
not	O
clinically	O
useful	O
due	O
severe	O
toxicity	O
and	O
low	O
therapeutic	O
index	O
morphine	B-Drug

Aleph	O
also	O
known	O
as	O
DOT	O
or	O
25-dimethoxy-4-methylthioamphetamine	O
is	O
a	O
psychedelic	O
hallucinogenic	O
drug	O
and	O
substituted	O
amphetamine	O
of	O
the	O
phenethylamine	B-Drug
class	O
compounds	O
which	O
can	O
be	O
used	O
an	O
entheogen	O

For	O
this	O
reason	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia	O

Although	O
millennia	O
older	O
the	O
production	O
of	O
poppy	O
head	O
decoctions	O
can	O
be	O
seen	O
as	O
a	O
quick-and-dirty	O
variant	O
Kby	O
straw	O
process	O
which	O
since	O
its	O
publication	O
in	O
1930	O
has	O
become	O
major	O
method	O
obtaining	O
licit	O
opium	B-Drug
alkaloids	O
worldwide	O
discussed	O
Morphine	B-Drug

Methadone	B-Drug
is	O
usually	O
taken	O
by	O
mouth	O
and	O
rarely	O
injection	O
into	O
a	O
muscle	O
or	O
vein	O

Following	O
oral	O
administration	O
methamphetamine	B-Drug
is	O
well-absorbed	O
into	O
the	O
bloodstream	O
with	O
peak	O
plasma	O
concentrations	O
achieved	O
in	O
approximately	O
3	O

GHB	B-Drug
is	O
a	O
naturally	O
occurring	O
substance	O
that	O
acts	O
in	O
similar	O
fashion	O
to	O
some	O
neurotransmitters	O
the	O
mammalian	O
brain	O

Propranolol	B-Drug
is	O
able	O
to	O
cross	O
the	O
bloodbrain	O
barrier	O
and	O
exert	O
effects	O
in	O
central	O
nervous	O
system	O
addition	O
its	O
peripheral	O
activity	O

025%	O
Aristocort	B-Drug
A	O
cream	O
Kenalog	O
lotion	O
Fluocinolone	B-Drug
acetonide	I-Drug
0	O

One	O
US	O
Department	O
of	O
Justice	O
publication	O
lists	O
China	O
White	O
as	O
a	O
synonym	O
for	O
number	O
fentanyl	B-Drug
analogues	O
including	O
3-methylfentanyl	B-Drug
and	O
-methylfentanyl	O
which	O
today	O
are	O
classified	O
Schedule	O
I	O
drugs	O
in	O
the	O
United	O
States	O

Before	O
long	O
however	O
it	O
had	O
become	O
clear	O
that	O
glutethimide	B-Drug
was	O
just	O
as	O
likely	O
to	O
cause	O
addiction	O
and	O
caused	O
similar	O
withdrawal	O
symptoms	O

The	O
short-term	O
physiological	O
effects	O
of	O
cocaine	B-Drug
include	O
constricted	O
blood	O
vessels	O
dilated	O
pupils	O
and	O
increased	O
temperature	O
heart	O
rate	O
pressure	O

In	O
December	O
2016	O
the	O
Drug	O
Enforcement	O
Administration	O
added	O
marijuana	O
extracts	B-Drug
which	O
are	O
defined	O
as	O
any	O
extract	O
containing	O
one	O
or	O
more	O
cannabinoids	O
that	O
has	O
been	O
derived	O
from	O
plant	O
of	O
genus	O
Cannabis	O
other	O
than	O
separated	O
resin	B-Drug
to	O
Schedule	O
I	O

In	O
contrast	O
to	O
the	O
aformentioned	O
drugs's	O
potent	O
selective	O
and	O
most	O
importantly	O
full	O
agonism	O
meaning	O
drug	O
can	O
fully	O
activate	O
receptor	O
100%	O
of	O
its	O
activation	O
potential	O
does	O
so	O
even	O
with	O
miniscule	O
amoubts	O
due	O
high	O
potency	O
LSD	B-Drug
like	O
other	O
safe	O
psychedelics	O
which	O
are	O
almost	O
impossible	O
overdose	O
fatally	O
on	O
is	O
a	O
partial	O
agonist	O
this	O
means	O
it	O
has	O
limit	O
how	O
much	O
basically	O
exceed	O
exponentially	O
larger	O
amounts	O

Ketamine	B-Drug
also	O
relieves	O
bronchospasm	O
by	O
relaxing	O
bronchiolar	O
smooth	O
muscles	O

Nalmefene	O
is	O
an	O
opiate	O
derivative	O
similar	O
in	O
both	O
structure	O
and	O
activity	O
to	O
the	O
opioid	O
antagonist	O
naltrexone	B-Drug

The	O
254	O
pounds	O
115	O
kg	O
of	O
fentanyl	B-Drug
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3	O

In	O
order	O
to	O
curb	O
misuse	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions	O

It	O
is	O
more	O
effective	O
than	O
metoclopramide	B-Drug
and	O
less	O
sedating	O
cyclizine	B-Drug
or	O
droperidol	B-Drug

And	O
this	O
is	O
a	O
much	O
better	O
way	O
to	O
prepare	O
it	O
than	O
putting	O
the	O
opium	B-Drug
into	O
alcohol	O
or	O
any	O
other	O
spirits	O
alone	O
for	O
in	O
that	O
case	O
of	O
does	O
not	O
dissolve	O

Dimethyltrienolone	O
also	O
known	O
as	O
717-dimethyl-911-19-nortestosterone	O
or	O
717-dimethylestra-4911-trien-17-ol-3-one	O
well	O
717-dimethyltrenbolone	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
17-alkylated	O
derivative	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug

To	O
synthesize	O
dexamethasone	B-Drug
16-methylprednisolone	O
acetate	I-Drug
is	O
dehydrated	O
to	O
the	O
911-dehydro	O
derivative	O
methylprednisolone	B-Drug

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

Modafinil	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1998	O

Tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	B-Drug
occurs	O
in	O
both	O
animals	O
and	O
humans	O

Unlike	O
bufotenin	B-Drug
both	O
DMT	O
and	O
5-MeO-DMT	B-Drug
are	O
relatively	O
unstable	O
begin	O
to	O
degrade	O
rather	O
quickly	O

The	O
initial	O
symptoms	O
of	O
a	O
nicotine	B-Drug
overdose	O
typically	O
include	O
nausea	O
vomiting	O
diarrhea	O
hypersalivation	O
abdominal	O
pain	O
tachycardia	O
rapid	O
heart	O
rate	O
hypertension	O
high	O
blood	O
pressure	O
tachypnea	O
breathing	O
headache	O
dizziness	O
pallor	O
pale	O
skin	O
auditory	O
or	O
visual	O
disturbances	O
and	O
perspiration	O
followed	O
shortly	O
after	O
by	O
marked	O
bradycardia	O
slow	O
bradypnea	O
hypotension	O
low	O

Early	O
medical	O
trials	O
of	O
humans	O
taking	O
desomorphine	B-Drug
have	O
resulted	O
in	O
the	O
finding	O
that	O
like	O
morphine	B-Drug
and	O
most	O
other	O
analgesics	O
type	O
small	O
amounts	O
are	O
highly	O
addictive	O
tolerance	O
to	O
drug	O
develops	O
quickly	O

trade	O
name	O
Suboxone	B-Drug
achieves	O
higher	O
buprenorphine	B-Drug
maximum	O
plasma	O
concentrations	O
Cmax	O
and	O
area	O
under	O
the	O
curve	O
AUC	O
a	O
measure	O
of	O
total	O
drug	O
exposure	O
than	O
original	O
buprenorphine/naloxone	O
sublingual	O
tablets	O
at	O
equal	O
doses	O
naloxone	B-Drug

nicotine	B-Drug
suppressing	O
prolactin	O
levels	O
are	O
responsible	O
for	O
the	O
lower	O
rates	O
of	O
breast	O
feeding	O
in	O
women	O
who	O
do	O
smoke	O

Article	O
21	O
bis	O
added	O
to	O
the	O
treaty	O
by	O
a	O
1971	O
amendment	O
gives	O
INCB	O
more	O
enforcement	O
power	O
allowing	O
it	O
deduct	O
from	O
nation's	O
production	O
quota	O
of	O
cannabis	O
opium	B-Drug
and	O
coca	B-Drug
amounts	O
determines	O
have	O
been	O
produced	O
within	O
that	O
nation	O
introduced	O
into	O
illicit	O
traffic	O

BOP	O
said	O
that	O
these	O
concerns	O
were	O
not	O
justified	O
and	O
their	O
two	O
expert	O
witness	O
the	O
use	O
of	O
pentobarbital	B-Drug
was	O
humane	O

Currently	O
sufentanil	B-Drug
is	O
the	O
most	O
potent	O
opioid	O
painkiller	O
available	O
for	O
use	O
in	O
humans	O

Dormicum	B-Drug
midazolam	B-Drug
for	O
insomnia	O
and	O
procedural	O
sedation	O
analgesia	O

On	O
September	O
19	O
1966	O
Leary	O
founded	O
the	O
League	O
for	O
Spiritual	O
Discovery	O
a	O
religion	O
declaring	O
LSD	B-Drug
as	O
its	O
holy	O
sacrament	O
in	O
part	O
an	O
unsuccessful	O
attempt	O
to	O
maintain	O
legal	O
status	O
use	O
of	O
and	O
other	O
psychedelics	O
religion's	O
adherents	O
based	O
on	O
freedom	O
argument	O

Amiloride	B-Drug
is	O
generally	O
well	O
tolerated	O

In	O
February	O
2009	O
at	O
least	O
70	O
people	O
in	O
one	O
Chinese	O
province	O
Guangdong	O
suffered	O
food	O
poisoning	O
after	O
eating	O
pig	O
organs	O
believed	O
to	O
contain	O
clenbuterol	B-Drug
residue	O

One	O
of	O
the	O
major	O
active	O
metabolites	O
buprenorphine	B-Drug
is	O
norbuprenorphine	O
which	O
in	O
contrast	O
to	O
itself	O
a	O
full	O
agonist	O
MOR	O
DOR	O
and	O
ORL-1	O
partial	O
at	O
KOR	O

Mifepristone	B-Drug
is	O
used	O
for	O
the	O
medical	O
treatment	O
of	O
high	O
blood	O
sugar	O
caused	O
by	O
cortisol	O
levels	O
in	O
hypercortisolism	O
adults	O
with	O
endogenous	O
Cushing's	O
syndrome	O
who	O
have	O
type	O
2	O
diabetes	O
mellitus	O
or	O
glucose	O
intolerance	O
and	O
failed	O
surgery	O
cannot	O

Abiraterone	B-Drug
acetate	I-Drug
is	O
marketed	O
by	O
Janssen	O
Biotech	O
a	O
subsidiary	O
of	O
Johnson	O
&	O
under	O
the	O
brand	O
name	O
Zytiga	O
and	O
Sun	O
Pharmaceutical	O
Yonsa	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

Spironolactone	B-Drug
is	O
bound	O
equivalently	O
to	O
albumin	O
and	O
1-acid	O
glycoprotein	O
while	O
canrenone	O
only	O

Antacids	O
slow	O
chlorpromazine	B-Drug
absorption	O

Because	O
of	O
the	O
faster	O
and	O
more	O
complete	O
absorption	O
GBL	O
relative	O
to	O
GHB	B-Drug
its	O
dose-response	O
curve	O
is	O
steeper	O
overdoses	O
tend	O
be	O
dangerous	O
problematic	O
than	O
involving	O
only	O
or	O
14-B	O

As	O
early	O
as	O
the	O
19th	O
century	O
mitragynine	B-Drug
ingested	O
via	O
kratom	B-Drug
leaves	O
was	O
reportedly	O
in	O
use	O
for	O
treatment	O
of	O
opium	B-Drug
addiction	O
and	O
withdrawal	O

As	O
of	O
2005	O
cocaine	B-Drug
shipments	O
from	O
South	O
America	O
transported	O
through	O
Mexico	O
or	O
Central	O
were	O
generally	O
moved	O
over	O
land	O
by	O
air	O
to	O
staging	O
sites	O
in	O
northern	O

Tetronal	B-Drug
was	O
introduced	O
by	O
Eugen	O
Baumann	O
and	O
Alfred	O
Kast	O
in	O
1888	O

Pantopon	O
is	O
prepared	O
by	O
treating	O
standardized	O
medicinal	O
opium	B-Drug
with	O
hydrochloric	O
acid	O
or	O
more	O
commonly	O
mixing	O
20	O
parts	O
morphine	B-Drug
HCl	O
5	O
codeine	B-Drug
6	O
thebaine	O
8	O
noscapine	O
2	O
narcotine	O
miscellaneous	O
alkaloids	O
hydrochlorides	O

Midazolam	B-Drug
is	O
metabolised	O
into	O
an	O
active	O
metabolite	O
alpha1-hydroxymidazolam	O

DMPA	B-Drug
is	O
registered	O
for	O
use	O
as	O
a	O
form	O
of	O
birth	O
control	O
in	O
more	O
than	O
100	O
countries	O
worldwide	O

Pentoxifylline	B-Drug
can	O
increase	O
the	O
risk	O
of	O
bleeding	O

Mebutamate	B-Drug
Capla	O
Dormate	O
is	O
an	O
anxiolytic	O
and	O
sedative	O
drug	O
with	O
antihypertensive	O
effects	O
of	O
the	O
carbamate	O
class	O

This	O
combination	O
of	O
characteristics	O
led	O
them	O
to	O
propose	O
methadone	B-Drug
administration	O
as	O
a	O
way	O
facilitating	O
morphine	B-Drug
withdrawal	O

It	O
has	O
been	O
found	O
that	O
LSD	B-Drug
is	O
a	O
fairly	O
effective	O
treatment	O
for	O
mental	O
disorders	O
such	O
as	O
obsessive	O
compulsive	O
disorder	O
OCD	O

On	O
October	O
1	O
1957	O
the	O
company	O
launched	O
thalidomide	B-Drug
and	O
began	O
marketing	O
it	O
under	O
trade	O
name	O
Contergan	B-Drug

and	O
this	O
agent	O
is	O
significantly	O
less	O
neurotoxic	O
than	O
methamphetamine	B-Drug
or	O
MDMA	B-Drug

Ketoconazole	B-Drug
can	O
achieve	O
similar	O
decreases	O
in	O
steroid	O
hormone	O
levels	O
as	O
AG	O
but	O
is	O
more	O
effective	O
promoting	O
tumor	O
regression	O
and	O
moderately	O
less	O
toxic	O
comparison	O

According	O
to	O
the	O
CDC	O
tighter	O
prescription	O
policies	O
by	O
doctors	O
did	O
not	O
necessarily	O
lead	O
this	O
increased	O
heroin	B-Drug
use	O

25-isosorbide	O
dinitrate	O
is	O
suitable	O
just	O
like	O
its	O
major	O
metabolite	O
5-isosorbide	O
mononitrate	I-Drug
ISMN	O
for	O
the	O
treatment	O
of	O
angina	O
pectoris	O
due	O
to	O
vasodilator	O
effect	O
isosorbide	B-Drug

When	O
people	O
die	O
from	O
overdosing	O
on	O
a	O
drug	O
the	O
is	O
usually	O
an	O
opioid	O
and	O
often	O
heroin	B-Drug

The	O
potential	O
selectivity	O
and	O
favorable	O
side	O
effect	O
profile	O
of	O
desmetramadol	O
compared	O
to	O
its	O
prodrug	O
tramadol	B-Drug
makes	O
it	O
more	O
suitable	O
for	O
clinical	O
use	O
although	O
no	O
such	O
large	O
scale	O
controlled	O
trials	O
have	O
been	O
conducted	O
with	O
patients	O

This	O
was	O
verified	O
with	O
documents	O
tied	O
to	O
a	O
lawsuit	O
which	O
filed	O
by	O
the	O
Massachusetts	O
attorney	O
general	O
Maura	O
Healey	O
claiming	O
that	O
Purdue	O
Pharma	O
and	O
members	O
of	O
Sackler	O
family	O
knew	O
high	O
doses	O
OxyContin	B-Drug
over	O
long	O
periods	O
would	O
increase	O
risk	O
serious	O
side	O
effects	O
including	O
addiction	O

Isotretinoin	B-Drug
also	O
has	O
been	O
shown	O
to	O
initiate	O
remodeling	O
of	O
the	O
sebaceous	O
glands;	O
triggering	O
changes	O
in	O
gene	O
expression	O
that	O
selectively	O
induce	O
apoptosis	O

Conversely	O
4-hydroxylation	O
of	O
tamoxifen	B-Drug
into	O
afimoxifene	O
is	O
responsible	O
for	O
only	O
about	O
7%	O
metabolism	O

The	O
S-enantiomer	O
of	O
ADB-FUBINACA	B-Drug
is	O
described	O
in	O
a	O
2009	O
Pfizer	O
patent	O
and	O
has	O
been	O
reported	O
to	O
be	O
potent	O
agonist	O
the	O
CB1	O
receptor	O
CB2	O
with	O
EC50	O
values	O
1	O

CBD	B-Drug
derived	O
from	O
hemp	O
with	O
0	O

A	O
recent	O
trend	O
in	O
bodybuilding	O
is	O
to	O
inject	O
synthol	O
into	O
muscles	O
create	O
larger	O
bulges	O
or	O
injecting	O
PMMA	B-Drug
shape	O
them	O

Octreotide	B-Drug
can	O
also	O
be	O
used	O
in	O
the	O
treatment	O
of	O
acromegaly	O
a	O
disorder	O
excessive	O
growth	O
hormone	O
GH	O

This	O
new	O
law	O
prevents	O
people	O
with	O
small	O
amounts	O
of	O
cocaine	B-Drug
from	O
facing	O
jail	O
time	O

Enzalutamide	B-Drug
has	O
approximately	O
8-fold	O
higher	O
binding	O
affinity	O
for	O
the	O
androgen	O
receptor	O
AR	O
compared	O
to	O
bicalutamide	B-Drug

Tac	O
EVE	O
which	O
also	O
includes	O
dl-methylephedrine	O
HCl	O
chlorpheniramine	B-Drug
anhydrous	O
caffeine	O
and	O
vitamins	O
B1	B-Drug
C	O

Zopiclone	B-Drug
is	O
currently	O
available	O
off-patent	O
in	O
a	O
number	O
of	O
European	O
countries	O
as	O
well	O
Brazil	O
Canada	O
and	O
Hong	O
Kong	O

Upon	O
its	O
release	O
in	O
1995	O
OxyContin	B-Drug
was	O
hailed	O
as	O
a	O
medical	O
breakthrough	O
long-lasting	O
narcotic	O
that	O
could	O
help	O
patients	O
suffering	O
from	O
moderate	O
to	O
severe	O
pain	O

Unlike	O
other	O
synthetic	O
opioids	O
which	O
are	O
hepatically	O
metabolized	O
remifentanil	B-Drug
has	O
an	O
ester	O
linkage	O
undergoes	O
rapid	O
hydrolysis	O
by	O
non-specific	O
tissue	O
and	O
plasma	O
esterases	O

The	O
strict	O
legal	O
restrictions	O
nimetazepam	B-Drug
is	O
subject	O
to	O
in	O
Malaysia	O
has	O
made	O
the	O
drug	O
scare	O
but	O
many	O
pills	O
sold	O
as	O
black	O
market	O
are	O
counterfeit	O

This	O
opposition	O
led	O
the	O
DEA	O
to	O
withdraw	O
its	O
report	O
of	O
intent	O
in	O
October	O
2016	O
allowing	O
for	O
unencumbered	O
research	O
into	O
potential	O
benefits	O
and	O
health	O
risks	O
associated	O
with	O
mitragynine	B-Drug
other	O
alkaloids	O
kratom	B-Drug
plant	O

The	O
Russian	O
Health	O
Minister	O
later	O
stated	O
that	O
the	O
gas	O
was	O
based	O
on	O
fentanyl	B-Drug
but	O
exact	O
chemical	O
agent	O
has	O
not	O
been	O
identified	O

In	O
1888	O
Broomhall	O
formed	O
and	O
became	O
secretary	O
of	O
the	O
Christian	O
Union	O
for	O
Severance	O
British	O
Empire	O
with	O
Opium	B-Drug
Traffic	O
editor	O
its	O
periodical	O
National	O
Righteousness	O

Cocaine	B-Drug
use	O
is	O
prevalent	O
across	O
all	O
socioeconomic	O
strata	O
including	O
age	O
demographics	O
economic	O
social	O
political	O
religious	O
and	O
livelihood	O

7	O
the	O
analgesic	O
potency	O
of	O
morphine	B-Drug
an	O
opioid	O
to	O
which	O
codeine	B-Drug
is	O
by	O
comparison	O
only	O
8%12%	O
as	O
potent	O
relatively	O
or	O
0	O

However	O
norepinephrine-selective	O
antidepressants	O
such	O
as	O
reboxetine	B-Drug
and	O
desipramine	B-Drug
have	O
successfully	O
treated	O
anxiety	O
disorders	O

Compared	O
to	O
THC	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors	O
JWH-018	B-Drug
and	O
many	O
synthetic	O
cannabinoids	O
are	O
full	O
agonists	O

GHB	B-Drug
withdrawal	O
is	O
not	O
widely	O
discussed	O
in	O
textbooks	O
and	O
some	O
psychiatrists	O
general	O
practitioners	O
even	O
hospital	O
emergency	O
physicians	O
may	O
be	O
familiar	O
with	O
this	O
syndrome	O

8	O
million	O
thalidomide	B-Drug
pills	O
were	O
distributed	O
throughout	O
Brazil	O
in	O
this	O
time	O
period	O
largely	O
to	O
poor	O
Brazilians	O
areas	O
with	O
access	O
healthcare	O
and	O
these	O
cases	O
have	O
occurred	O
despite	O
the	O
controls	O

The	O
abbreviation	O
DTO	O
traditionally	O
used	O
to	O
refer	O
Deodorized	O
Tincture	O
of	O
Opium	B-Drug
is	O
sometimes	O
also	O
erroneously	O
employed	O
abbreviate	O
diluted	O
tincture	O
opium	B-Drug

The	O
aim	O
of	O
this	O
program	O
was	O
to	O
maintain	O
the	O
health	O
user	O
by	O
avoiding	O
medical	O
problems	O
stemming	O
from	O
illicit	O
use	O
diamorphine	B-Drug

If	O
abiraterone	B-Drug
acetate	O
is	O
used	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
it	O
should	O
be	O
combined	O
with	O
an	O
estrogen	O
receptor	O
antagonist	O
like	O
fulvestrant	B-Drug

Similarly	O
to	O
nandrolone	B-Drug
dimethandrolone	O
and	O
other	O
19-nortestosterone	B-Drug
derivatives	O
11-MNT	O
has	O
been	O
found	O
possess	O
progestogenic	O
activity	O

OTC	O
drugs	O
are	O
usually	O
also	O
required	O
to	O
have	O
little	O
or	O
no	O
abuse	O
potential	O
although	O
in	O
some	O
areas	O
such	O
as	O
codeine	B-Drug
available	O
strictly	O
limited	O
formulations	O
requiring	O
paperwork	O
identification	O
be	O
submitted	O
during	O
purchase	O

An	O
analysis	O
of	O
samples	O
acquired	O
four	O
weeks	O
after	O
the	O
German	O
prohibition	O
JWH-018	B-Drug
took	O
place	O
found	O
that	O
manufacturers	O
had	O
shortened	O
alkyl	O
chain	O
by	O
one	O
carbon	O
to	O
circumvent	O
ban	O

Heroin	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
myocardial	O
infarction	O

He	O
reported	O
that	O
the	O
seeds	O
of	O
Ipomoea	O
violacea	O
were	O
used	O
as	O
sacraments	O
by	O
certain	O
Zapotecs	O
sometimes	O
in	O
conjunction	O
with	O
Rivea	O
corymbosa	O
another	O
species	O
which	O
has	O
a	O
similar	O
chemical	O
composition	O
lysergol	O
instead	O
ergometrine	B-Drug

5	O
million	O
people	O
in	O
the	O
United	O
States	O
used	O
cocaine	B-Drug
2010	O
down	O
from	O
2	O

Some	O
psilocin	B-Drug
is	O
not	O
broken	O
down	O
by	O
enzymes	O
and	O
instead	O
forms	O
a	O
glucuronide;	O
this	O
biochemical	O
mechanism	O
animals	O
use	O
to	O
eliminate	O
toxic	O
substances	O
linking	O
them	O
with	O
glucuronic	O
acid	O
which	O
can	O
then	O
be	O
excreted	O
in	O
the	O
urine	O

25I-NBOMe	B-Drug
presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
triggering	O
blood	O
platelet	O
aggregation	O

DihydrotestosteroneDHT	O
androstenedione	B-Drug
are	O
of	O
equal	O
importance	O
in	O
male	O
development	O

Urine	O
was	O
collected	O
for	O
24	O
hours	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O

There	O
is	O
a	O
tremendous	O
demand	O
for	O
cocaine	B-Drug
in	O
the	O
U	O

A	O
Desbutal	O
overdose	O
typically	O
becomes	O
life-threatening	O
as	O
a	O
result	O
of	O
acute	O
toxicity	O
from	O
pentobarbital	B-Drug
poisoning	O
since	O
the	O
oral	O
median	O
lethal	O
dose	O
LD50	O
sodium	O
is	O
reached	O
significantly	O
sooner	O
than	O
methamphetamine	B-Drug
hydrochloride	I-Drug
when	O
consumed	O
dosage	O
units	O
with	O
mass	O
ratio	O
present	O
in	O

O-Acetylpsilocin	B-Drug
can	O
be	O
obtained	O
by	O
acetylation	O
of	O
psilocin	B-Drug
under	O
alkaline	O
or	O
strongly	O
acidic	O
conditions	O

Zopiclone	B-Drug
reduces	O
the	O
total	O
amount	O
of	O
time	O
spent	O
in	O
REM	O
sleep	O
as	O
well	O
delaying	O
its	O
onset	O

As	O
per	O
UN	O
drug	O
report	O
of	O
2011	O
Iran	O
accounts	O
for	O
highest	O
rate	O
opium	B-Drug
and	O
heroin	B-Drug
seizure	O
rates	O
in	O
the	O
world	O
intercepting	O
89%	O
all	O
seized	O

4-Fluorofentanyl	B-Drug
is	O
made	O
with	O
the	O
same	O
synthetic	O
route	O
as	O
fentanyl	B-Drug
but	O
by	O
substituting	O
para-fluoroaniline	O
for	O
aniline	O
in	O
synthesis	O

The	O
gabapentin	B-Drug
label	O
contains	O
a	O
warning	O
of	O
an	O
increased	O
risk	O
suicidal	O
thoughts	O
and	O
behaviors	O

This	O
research	O
produced	O
the	O
analgesic	O
alphaprodine	B-Drug
Nisentil	O
Prisilidine	O
a	O
very	O
closely	O
related	O
compound	O

The	O
cognitive	O
enhancing	O
effects	O
of	O
pramipexole	B-Drug
guanfacine	B-Drug
clonidine	B-Drug
and	O
fexofenadine	B-Drug
have	O
been	O
tested	O
but	O
no	O
significant	O
cognition-enhancing	O
in	O
healthy	O
individuals	O
were	O
found	O

Ingestion	O
does	O
not	O
produce	O
a	O
rush	O
as	O
forerunner	O
to	O
the	O
high	O
experienced	O
with	O
use	O
of	O
heroin	B-Drug
which	O
is	O
most	O
pronounced	O
intravenous	O

Nevertheless	O
the	O
number	O
of	O
cocaine	B-Drug
users	O
remain	O
high	O
with	O
a	O
large	O
concentration	O
among	O
urban	O
youth	O

5	O
times	O
the	O
effect	O
of	O
equivalent	O
amount	O
morphine	B-Drug

Osmotic	O
laxatives	O
including	O
lactulose	B-Drug
polyethylene	O
glycol	O
and	O
milk	O
of	O
magnesia	O
magnesium	O
hydroxide	O
as	O
well	O
mineral	O
oil	O
a	O
lubricant	O
laxative	O
are	O
also	O
commonly	O
used	O
for	O
OIC	O

It	O
is	O
then	O
converted	O
to	O
heroin	B-Drug
which	O
almost	O
twice	O
as	O
potent	O
and	O
increases	O
the	O
value	O
by	O
a	O
similar	O
factor	O

Naloxone	B-Drug
is	O
increasingly	O
available	O
to	O
the	O
public	O

Use	O
of	O
another	O
illicit	O
drug	O
hashish	B-Drug
has	O
also	O
increased	O
in	O
Europe	O

Subjects	O
in	O
some	O
of	O
the	O
more	O
extreme	O
psychedelic	O
experiments	O
LSD	B-Drug
doses	O
for	O
77	O
days	O
a	O
row	O
were	O
all	O
Negro	O
males	O
though	O
this	O
is	O
not	O
regular	O
pattern	O
e	O

Long-acting	O
benzodiazepines	O
with	O
long-acting	O
active	O
metabolites	O
such	O
as	O
diazepam	B-Drug
and	O
chlordiazepoxide	B-Drug
are	O
often	O
prescribed	O
for	O
benzodiazepine	O
or	O
alcohol	O
withdrawal	O
well	O
anxiety	O
if	O
constant	O
dose	O
levels	O
required	O
throughout	O
the	O
day	O

Clonazepam	B-Drug
decreases	O
the	O
levels	O
of	O
carbamazepine	B-Drug
and	O
likewise	O
clonazepam's	O
level	O
is	O
reduced	O
by	O
clonazepam	B-Drug

The	O
antihistamine	O
promethazine	B-Drug
Phenergan	B-Drug
may	O
also	O
have	O
a	O
positive	O
effect	O
on	O
hepatic	O
metabolism	O
of	O
dihydrocodeine	B-Drug
as	O
it	O
does	O
with	O
codeine	B-Drug

Buprenorphine	B-Drug
on	O
the	O
other	O
hand	O
is	O
not	O
covered	O
by	O
Medicaid	O
or	O
often	O
even	O
private	O
health	O
insurers	O

Ibuprofen/paracetamol	O
is	O
one	O
such	O
preformulated	O
combination	O
drug	O
Ibuprofen	B-Drug
paracetamol	B-Drug

Following	O
the	O
patch	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq	B-Drug
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain	O

Frequently	O
prepared	O
solid	O
salts	O
of	O
amphetamine	B-Drug
include	O
adipate	O
aspartate	O
hydrochloride	O
phosphate	O
saccharate	O
sulfate	O
and	O
tannate	O

Dexamethasone	B-Drug
is	O
given	O
in	O
legal	O
Bangladesh	O
brothels	O
to	O
prostitutes	O
not	O
yet	O
of	O
age	O
causing	O
weight	O
gain	O
aimed	O
at	O
making	O
them	O
appear	O
older	O
and	O
healthier	O
customers	O
police	O

It	O
is	O
closely	O
related	O
to	O
oliceridine	B-Drug
and	O
has	O
a	O
similar	O
pharmacological	O
profile	O
but	O
unlike	O
which	O
be	O
injected	O
TRV734	O
suitable	O
administered	O
orally	O

Alfaxalone	B-Drug
was	O
marketed	O
in	O
1971	O
combination	O
with	O
alfadolone	O
acetate	O
under	O
the	O
brand	O
name	O
Althesin	O
for	O
human	O
use	O
and	O
Saffan	O
veterinary	O

Although	O
trenbolone	B-Drug
acetate	O
was	O
very	O
popular	O
for	O
a	O
short	O
amount	O
of	O
time	O
the	O
large	O
amounts	O
supplies	O
were	O
discontinued	O
in	O
1987	O

Ethchlorvynol	B-Drug
was	O
used	O
to	O
treat	O
insomnia	O
but	O
prescriptions	O
for	O
the	O
drug	O
had	O
fallen	O
significantly	O
by	O
1990	O
as	O
other	O
hypnotics	O
that	O
were	O
considered	O
safer	O
i	O

In	O
2019	O
the	O
European	O
Commission	O
announced	O
that	O
CBD	B-Drug
and	O
other	O
cannabinoids	O
would	O
be	O
classified	O
as	O
novel	O
foods	O
meaning	O
products	O
require	O
authorization	O
under	O
EU	O
Novel	O
Food	O
Regulation	O
stating	O
because	O
this	O
product	O
was	O
not	O
used	O
a	O
food	O
or	O
ingredient	O
before	O
May	O
15	O
1997	O
it	O
may	O
placed	O
on	O
market	O
in	O
safety	O
assessment	O
is	O
required	O

Inversely	O
PCP	B-Drug
can	O
have	O
more	O
unpredictable	O
effects	O
and	O
has	O
often	O
been	O
classified	O
as	O
a	O
stimulant	O
depressant	O
in	O
some	O
texts	O
along	O
with	O
being	O
dissociative	O

Androstenedione	B-Drug
has	O
been	O
shown	O
to	O
increase	O
serum	O
testosterone	O
levels	O
over	O
an	O
eight-hour	O
period	O
in	O
men	O
when	O
taken	O
as	O
a	O
single	O
oral	O
dose	O
of	O
300	O
mg	O
per	O
day	O
but	O
100	O
had	O
no	O
significant	O
effect	O
on	O

state	O
to	O
decriminalize	O
cocaine	B-Drug

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

Primidone	B-Drug
reduces	O
plasma	O
levels	O
of	O
primidone	B-Drug

The	O
introduction	O
of	O
increasingly	O
formalised	O
testing	O
procedures	O
especially	O
with	O
the	O
creation	O
World	O
Anti-Doping	O
Agency	O
in	O
1999	O
made	O
it	O
much	O
more	O
difficult	O
for	O
athletes	O
to	O
get	O
away	O
using	O
these	O
drugs	O
without	O
detection	O
which	O
then	O
led	O
synthesis	O
novel	O
and	O
potent	O
anabolic	O
steroid	O
such	O
as	O
tetrahydrogestrinone	B-Drug
THG	B-Drug
were	O
not	O
detectable	O
by	O
standard	O
tests	O

During	O
this	O
time	O
drug	O
cartels	O
expanded	O
their	O
power	O
and	O
corruption	O
anti-drug	O
operations	O
focused	O
mainly	O
on	O
destroying	O
marijuana	O
opium	B-Drug
crops	O
in	O
mountainous	O
regions	O

Most	O
of	O
the	O
research	O
on	O
gene	O
regulation	O
and	O
addiction	O
is	O
based	O
upon	O
animal	O
studies	O
with	O
intravenous	O
amphetamine	B-Drug
administration	O
at	O
very	O
high	O
doses	O

-Methylfentanyl	O
has	O
similar	O
effects	O
to	O
fentanyl	B-Drug

In	O
addition	O
people	O
on	O
daily	O
aspirin	B-Drug
therapy	O
e	O

Bulk	O
cargo	O
ships	O
are	O
also	O
used	O
to	O
smuggle	O
cocaine	B-Drug
staging	O
sites	O
in	O
the	O
western	O
CaribbeanGulf	O
of	O
Mexico	O
area	O

Trimethoprim	B-Drug
was	O
first	O
used	O
in	O
1962	O

A	O
2018	O
report	O
by	O
The	O
Guardian	O
indicated	O
that	O
many	O
major	O
drug	O
suppliers	O
on	O
the	O
dark	O
web	O
have	O
voluntarily	O
banned	O
trafficking	O
of	O
fentanyl	B-Drug

Clonazepam	B-Drug
is	O
mainly	O
prescribed	O
for	O
the	O
acute	O
management	O
of	O
epilepsies	O

Julio	O
Zavala	O
also	O
convicted	O
on	O
trafficking	O
charges	O
said	O
that	O
he	O
supplied	O
$500000	O
to	O
two	O
Costa	O
Rican-based	O
Contra	O
groups	O
and	O
the	O
majority	O
of	O
it	O
came	O
from	O
cocaine	B-Drug
in	O
San	O
Francisco	O
Bay	O
area	O
Miami	O
New	O
Orleans	O

Other	O
classical	O
benzodiazepines	O
include	O
chlordiazepoxide	B-Drug
clonazepam	B-Drug
lorazepam	B-Drug
oxazepam	B-Drug
nitrazepam	B-Drug
temazepam	B-Drug
flurazepam	B-Drug
bromazepam	B-Drug
and	O
clorazepate	B-Drug

Fentanyl	B-Drug
has	O
been	O
discovered	O
for	O
sale	O
in	O
illicit	O
markets	O
Australia	O
2017	O
and	O
New	O
Zealand	O
2018	O

However	O
a	O
serendipitous	O
discovery	O
found	O
that	O
2-bromo-LSD	O
is	O
also	O
able	O
to	O
produce	O
this	O
therapeutic	O
effect	O
despite	O
lacking	O
the	O
other	O
effects	O
of	O
LSD	B-Drug

25I-NBOMe	B-Drug
can	O
be	O
consumed	O
in	O
liquid	O
powder	O
or	O
paper	O
form	O
and	O
snorted	O
injected	O
mixed	O
with	O
food	O
smoked	O
but	O
sublingual	O
administration	O
is	O
most	O
common	O

Brifentanil	O
A-3331	O
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
fentanyl	B-Drug
and	O
was	O
developed	O
in	O
the	O
early	O
1990s	O

Clonazepam	B-Drug
may	O
affect	O
levels	O
of	O
phenytoin	B-Drug
diphenylhydantoin	B-Drug

5%	O
of	O
18	O
to	O
25	O
year-olds	O
had	O
used	O
MDMA	B-Drug
in	O
the	O
United	O
States	O

Researchers	O
are	O
attempting	O
to	O
reproduce	O
the	O
biosynthetic	O
pathway	O
that	O
produces	O
morphine	B-Drug
in	O
genetically	O
engineered	O
yeast	O

The	O
popularity	O
of	O
cocaine	B-Drug
faded	O
in	O
the	O
1950s	O
and	O
by	O
late	O
many	O
considered	O
drug	O
to	O
be	O
a	O
problem	O
past	O

Due	O
to	O
a	O
successful	O
marketing	O
campaign	O
thalidomide	B-Drug
was	O
widely	O
used	O
by	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy	O

They	O
include	O
what	O
are	O
probably	O
cardamom	O
nard	O
valerian	O
cassia	O
or	O
senna	B-Drug
cinnamon	O
balm	O
of	O
Gilead	O
hops	O
mastic	O
turpentine	O
pine	O
resin	O
bitumen	O
heather	O
quince	O
apple	O
peach	O
apricot	O
lemon	O
pear	O
medlar	O
plum	O
and	O
many	O
others	O

The	O
opium	B-Drug
poppy	O
as	O
its	O
name	O
indicates	O
is	O
the	O
principal	O
source	O
of	O
dried	O
latex	O
produced	O
by	O
seed	O
pods	O

Amobarbital	B-Drug
was	O
also	O
widely	O
abused	O
known	O
on	O
the	O
streets	O
as	O
blue	O
heavens	O
because	O
of	O
their	O
capsule	O

Naloxegol	B-Drug
a	O
peripherally-selective	O
opioid	O
antagonist	O
is	O
now	O
available	O
to	O
treat	O
induced	O
constipation	O

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21	O
2016	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O

Although	O
MDMA	B-Drug
was	O
not	O
named	O
explicitly	O
in	O
this	O
legislation	O
the	O
order	O
extended	O
definition	O
of	O
Class	O
A	O
drugs	O
to	O
include	O
various	O
ring-substituted	O
phenethylamines	O

Etonogestrel	B-Drug
is	O
available	O
widely	O
throughout	O
the	O
world	O
including	O
in	O
United	O
States	O
Canada	O
Kingdom	O
Ireland	O
elsewhere	O
Europe	O
South	O
Africa	O
Latin	O
America	O
East	O
and	O
Southeast	O
Asia	O

PCP	B-Drug
works	O
primarily	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O

3-fold	O
more	O
potent	O
as	O
an	O
antimineralocorticoid	O
relative	O
to	O
spironolactone	B-Drug

The	O
herb	O
m	O
hung	O
Ephedra	O
sinica	O
used	O
in	O
traditional	O
Chinese	O
medicine	O
TCM	O
contains	O
ephedrine	B-Drug
and	O
pseudoephedrine	O
as	O
its	O
principal	O
active	O
constituents	O

Experts	O
estimate	O
that	O
were	O
thalidomide	B-Drug
led	O
to	O
the	O
death	O
of	O
approximately	O
2000	O
children	O
and	O
serious	O
birth	O
defects	O
in	O
more	O
than	O
10000	O
about	O
5000	O
them	O
West	O
Germany	O

The	O
Dutch	O
Pharmacogenetics	O
Working	O
Group	O
also	O
recommends	O
selecting	O
an	O
alternative	O
drug	O
or	O
monitoring	O
plasma	O
concentrations	O
of	O
amitriptyline	B-Drug
in	O
patients	O
who	O
are	O
CYP2D6	O
poor	O
ultrarapid	O
metabolizers	O
and	O
reducing	O
initial	O
dose	O
intermediate	O

The	O
metabolism	O
of	O
tetrazepam	B-Drug
has	O
led	O
to	O
false	O
accusations	O
prisoners	O
prescribed	O
taking	O
illicit	O
diazepam;	O
this	O
can	O
lead	O
increased	O
prison	O
sentences	O
for	O
diazepam	B-Drug

Mestanolone	B-Drug
was	O
discovered	O
in	O
1935	O
and	O
introduced	O
for	O
medical	O
use	O
the	O
1950s	O

Triazolam	B-Drug
is	O
frequently	O
prescribed	O
as	O
a	O
sleep	O
aid	O
for	O
passengers	O
travelling	O
on	O
short-	O
to	O
medium-duration	O
flights	O

Myocarditis	O
is	O
a	O
sometimes	O
fatal	O
side	O
effect	O
of	O
clozapine	B-Drug
which	O
usually	O
develops	O
within	O
the	O
first	O
month	O
commencement	O

Organised	O
crime	O
became	O
an	O
unfortunate	O
side-story	O
to	O
Madchester	O
with	O
the	O
vibrancy	O
of	O
clubbing	O
scene	O
in	O
city	O
and	O
popularity	O
illegal	O
drugs	O
particularly	O
ecstasy	B-Drug
providing	O
a	O
fertile	O
environment	O
for	O
opportunist	O
gangsterism	O

As	O
such	O
as	O
tramadol	B-Drug
is	O
related	O
to	O
venlafaxine	B-Drug
the	O
same	O
conditions	O
apply	O

ETH-LAD	O
is	O
a	O
psychedelic	O
drug	O
similar	O
to	O
LSD	B-Drug
and	O
slightly	O
more	O
potent	O
than	O
itself	O
with	O
an	O
active	O
dose	O
reported	O
at	O
between	O
20	O
150	O
micrograms	O

Akira	O
Ogata	O
October	O
26	O
1887	O
in	O
Osaka	O
Prefecture	O
Japan	O
August	O
22	O
1978	O
was	O
a	O
Japanese	O
chemist	O
and	O
the	O
first	O
to	O
synthesize	O
methamphetamine	B-Drug
crystalline	O
form	O
1919	O

Sofosbuvir	B-Drug
allows	O
most	O
people	O
to	O
be	O
treated	O
successfully	O
without	O
the	O
use	O
of	O
peginterferon	O
an	O
injectable	O
drug	O
with	O
severe	O
side	O
effects	O
that	O
is	O
a	O
key	O
component	O
older	O
combinations	O
for	O
treatment	O
hepatitis	O
C	O
virus	O

Under	O
the	O
generic	O
name	O
diamorphine	B-Drug
heroin	B-Drug
is	O
prescribed	O
as	O
a	O
strong	O
pain	O
medication	O
in	O
United	O
Kingdom	O
where	O
it	O
administered	O
via	O
oral	O
subcutaneous	O
intramuscular	O
intrathecal	O
intranasal	O
or	O
intravenous	O
routes	O

In	O
July	O
2014	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
MHRA	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches	O
particularly	O
in	O
children	O
advised	O
that	O
they	O
should	O
be	O
folded	O
with	O
adhesive	O
side	O
before	O
being	O
discarded	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

False	O
positives	O
have	O
been	O
known	O
to	O
be	O
triggered	O
by	O
consuming	O
hemp-seed	O
bars	O
low	O
THC	O
cannabis	O
and	O
CBD	B-Drug
supplements	O
although	O
the	O
more	O
detailed	O
expensive	O
gas	O
chromatography-mass	O
spectrometer	O
GCMS	O
test	O
can	O
tell	O
difference	O

Haloperidol	B-Drug
is	O
relatively	O
inexpensive	O
being	O
up	O
to	O
100	O
fold	O
less	O
expensive	O
than	O
newer	O
antipsychotics	O

The	O
conceptually	O
similar	O
Emde	O
route	O
involves	O
reduction	O
of	O
ephedrine	B-Drug
to	O
chloroephedrine	O
using	O
thionyl	O
chloride	O
SOCl2	O
followed	O
by	O
catalytic	O
hydrogenation	O

The	O
tertiary	O
butyl	O
group	O
in	O
salbutamol	B-Drug
makes	O
it	O
more	O
selective	O
for	O
2	O
receptors	O
which	O
are	O
the	O
predominant	O
on	O
bronchial	O
smooth	O
muscles	O

nicotine	B-Drug
withdrawal	O
gabapentinoids	O
such	O
as	O
gabapentin	B-Drug
Neurontin	B-Drug
pregabalin	B-Drug
Lyrica	B-Drug
and	O
phenibut	B-Drug
Noofen	O
which	O
are	O
inhibitors	O
of	O
2	O
subunit-containing	O
VDCCs	O
antiepileptic	O
drugs	O
valproate	B-Drug
lamotrigine	B-Drug
tiagabine	B-Drug
vigabatrin	B-Drug
carbamazepine	B-Drug
oxcarbazepine	B-Drug
topiramate	B-Drug
antipsychotic	O
clozapine	B-Drug
risperidone	B-Drug
olanzapine	B-Drug
haloperidol	B-Drug
thioridazine	O
etc	O

When	O
combined	O
with	O
hydrochlorothiazide	B-Drug
the	O
addition	O
of	O
amiloride	B-Drug
had	O
positive	O
effects	O
on	O
blood	O
pressure	O
and	O
sugar	O
tolerance	O

ADB-CHMINACA	B-Drug
is	O
illegal	O
in	O
Switzerland	O
as	O
of	O
December	O
2015	O

The	O
hydrocodone	B-Drug
synthesis	O
of	O
Kenner	O
C	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
tissue	O

The	O
internal	O
temperature	O
of	O
the	O
reagent	O
is	O
then	O
cooled	O
to	O
1015	O
C	O
before	O
adding	O
commercially	O
available	O
boldenone	B-Drug
androsta-14-dien-17-ol-3-one	O

In	O
chemical	O
structure	O
ketamine	B-Drug
is	O
an	O
arylcyclohexylamine	O
derivative	O

Additionally	O
nitrous	O
oxide	O
depletes	O
vitamin	B-Drug
B12	I-Drug
levels	O

Opium	B-Drug
addiction	O
in	O
the	O
later	O
19th	O
century	O
received	O
a	O
hereditary	O
definition	O

The	O
addition	O
of	O
a	O
low	O
dose	O
50	O
or	O
100	O
mg/week	O
intramuscular	O
testosterone	B-Drug
enanthate	I-Drug
after	O
3	O
weeks	O
increased	O
levels	O
and	O
further	O
suppressed	O
LH	O
FSH	O
to	O
the	O
limits	O
assay	O
detection	O
i	O

Also	O
under	O
legislation	O
specifically	O
about	O
drugs	O
alcohol	O
and	O
nicotine	B-Drug
are	O
not	O
usually	O
included	O

Norethisterone	B-Drug
was	O
patented	O
in	O
1951	O
and	O
came	O
into	O
medical	O
use	O
1957	O

Shulgin	O
a	O
former	O
research	O
chemist	O
at	O
the	O
Dow	O
Chemical	O
Company	O
re-discovered	O
synthesis	O
for	O
MDMA	B-Drug
in	O
1976	O
and	O
published	O
syntheses	O
more	O
than	O
200	O
phenethylamine	B-Drug
compounds	O
of	O
his	O
own	O
invention	O
55	O
tryptamine	O
many	O
which	O
were	O
also	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
releasing	O
more	O
fentanyl	B-Drug
together	O
with	O
acidosis	O
which	O
reduces	O
protein	O
binding	O
of	O
yet	O

Subsequently	O
it	O
was	O
largely	O
superseded	O
by	O
the	O
more	O
effective	O
proton-pump	O
inhibitor	O
PPI	O
class	O
of	O
drugs	O
with	O
omeprazole	B-Drug
becoming	O
biggest-selling	O
drug	O
for	O
many	O
years	O

morphine	B-Drug
and	O
codeine	B-Drug
but	O
it	O
does	O
not	O
act	O
at	O
the	O
classic	O
opioid	O
receptors	O
namely	O
mu	O
kappa	O
delta	O
which	O
typically	O
as	O
pain	O
relievers	O

Uncommon	O
side	O
effects	O
of	O
nandrolone	B-Drug
decanoate	O
at	O
recommended	O
dosages	O
include	O
fluid	O
retention	O
inhibition	O
spermatogenesis	O
testicular	O
atrophy	O
erectile	O
dysfunction	O
gynecomastia	O
increased	O
frequency	O
penile	O
erections	O
penis	O
size	O
in	O
pre-pubertal	O
boys	O
clitoral	O
hypertrophy	O
pubic	O
hair	O
growth	O
oligomenorrhea	O
amenorrhea	O
hyperlipidemia	O
decreased	O
HDL	O
cholesterol	O
hemoglobin	O
to	O
abnormal	O
high	O
levels	O
hypertension	O
nausea	O
epididymitis	O
bladder	O
irritability	O
reduced	O
urine	O
flow	O
benign	O
prostatic	O
hyperplasia	O
priapism	O
premature	O
epiphyseal	O
closure	O
children	O
and	O
acne	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds	O
reversibly	O
non-competitively	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell	O
thereby	O
inhibiting	O
depolarisation	O

As	O
in	O
homebake	O
heroin	B-Drug
Australia	O
and	O
New	O
Zealand	O
the	O
crude	O
acetylation	O
results	O
a	O
gooey	O
mass	O

The	O
charges	O
linked	O
the	O
Contra	O
trafficking	O
to	O
Sebastin	O
Gonzlez	O
Mendiola	O
who	O
was	O
charged	O
with	O
cocaine	B-Drug
on	O
November	O
26	O
1984	O
in	O
Costa	O
Rica	O

Gladstone	O
lambasted	O
it	O
as	O
Palmerston's	O
Opium	B-Drug
War	O
and	O
said	O
that	O
he	O
felt	O
in	O
dread	O
of	O
the	O
judgments	O
God	O
upon	O
England	O
for	O
our	O
national	O
iniquity	O
towards	O
China	O
May	O
1840	O

The	O
agency	O
used	O
two	O
prescription	O
products	O
in	O
its	O
test:	O
the	O
prefilled	O
auto-injector	O
Evzio	O
and	O
nasal	O
spray	O
Narcan	B-Drug
both	O
approved	O
for	O
community	O
use	O
2016	O

While	O
many	O
have	O
reported	O
that	O
they	O
feel	O
no	O
pain	O
while	O
under	O
the	O
effects	O
of	O
PCP	B-Drug
DXM	B-Drug
and	O
Ketamine	B-Drug
this	O
does	O
not	O
fall	O
usual	O
classification	O
anesthetics	O
in	O
recreational	O
doses	O
anesthetic	O
may	O
be	O
dangerous	O

Ketamine	B-Drug
was	O
first	O
synthesized	O
in	O
1962	O
by	O
Calvin	O
L	O

state	O
to	O
decriminalize	O
possession	O
of	O
small	O
amounts	O
LSD	B-Drug

When	O
given	O
intravenously	O
lorazepam	B-Drug
appears	O
to	O
be	O
superior	O
diazepam	B-Drug
for	O
stopping	O
seizure	O
activity	O

The	O
first	O
dose	O
for	O
patients	O
who	O
have	O
been	O
receiving	O
methadone	B-Drug
will	O
be	O
a	O
little	O
higher	O
than	O
the	O
amount	O
of	O
that	O
was	O
being	O
taken	O
every	O
day	O
but	O
not	O
more	O
120	O
mg	O

Subsequent	O
testing	O
identified	O
5F-ADB	B-Drug
to	O
have	O
been	O
present	O
in	O
a	O
total	O
of	O
ten	O
people	O
who	O
had	O
died	O
from	O
unexplained	O
drug	O
overdoses	O
Japan	O
between	O
September	O
2014	O
and	O
December	O

Another	O
popular	O
method	O
is	O
to	O
combine	O
methamphetamine	B-Drug
with	O
other	O
stimulant	O
substances	O
such	O
as	O
caffeine	O
or	O
cathine	B-Drug
into	O
a	O
pill	O
known	O
Kamikaze	O
which	O
can	O
be	O
particularly	O
dangerous	O
due	O
the	O
synergistic	O
effects	O
of	O
multiple	O
stimulants	O

Instead	O
the	O
experiment	O
produced	O
an	O
acetylated	O
form	O
of	O
morphine	B-Drug
one	O
and	O
a	O
half	O
to	O
two	O
times	O
more	O
potent	O
than	O
itself	O

Various	O
physical	O
and	O
psychological	O
adverse	O
effects	O
have	O
been	O
reported	O
from	O
JWH-018	B-Drug
use	O

Pharmacology	O
developed	O
in	O
part	O
from	O
herbalism	O
and	O
some	O
drugs	O
are	O
still	O
derived	O
plants	O
atropine	O
ephedrine	B-Drug
warfarin	B-Drug
aspirin	B-Drug
digoxin	B-Drug
vinca	O
alkaloids	O
taxol	B-Drug
hyoscine	O
etc	O

However	O
maternal	O
use	O
of	O
marijuana	O
during	O
pregnancy	O
does	O
not	O
appear	O
to	O
be	O
associated	O
with	O
low	O
birth	O
weight	O
or	O
early	O
delivery	O
after	O
controlling	O
for	O
tobacco	B-Drug
and	O
other	O
confounding	O
factors	O

Mephedrone	B-Drug
was	O
first	O
synthesized	O
in	O
1929	O
but	O
did	O
not	O
become	O
widely	O
known	O
until	O
it	O
rediscovered	O
2003	O

states	O
in	O
order	O
to	O
settle	O
claims	O
that	O
it	O
had	O
promoted	O
risperidone	B-Drug
and	O
paliperidone	B-Drug
for	O
off-label	O
uses	O
including	O
dementia	O
anger	O
management	O
anxiety	O

This	O
adverse	O
effect	O
is	O
not	O
unique	O
to	O
zolpidem	B-Drug
but	O
also	O
occurs	O
with	O
other	O
hypnotic	O
drugs	O

A	O
research	O
project	O
from	O
the	O
University	O
of	O
Kentucky's	O
Institute	O
for	O
Pharmaceutical	O
Outcomes	O
and	O
Policy	O
at	O
College	O
Pharmacy	O
studied	O
association	O
between	O
legally	O
mandated	O
naloxone	B-Drug
co-prescription	O
dispensing	O
drug	O
to	O
patients	O
across	O
United	O
States	O

It	O
has	O
also	O
been	O
shown	O
to	O
have	O
therapeutic	O
use	O
in	O
polydrug	O
abuse	O
when	O
combined	O
with	O
anesthetics	O
opioids	O
ethanol	O
cocaine	B-Drug
and	O
methamphetamine	B-Drug

Amphetamine	B-Drug
is	O
generally	O
only	O
detectable	O
by	O
a	O
standard	O
drug	O
test	O
for	O
approximately	O
24	O
hours	O
although	O
high	O
dose	O
may	O
be	O
days	O

d	O
1-Phenylcyclohexylamine	O
or	O
any	O
compound	O
not	O
being	O
ketamine	B-Drug
tiletamine	B-Drug
a	O
for	O
the	O
time	O
specified	O
in	O
paragraph	O
1a	O
of	O
Part	O
1	O
this	O
Schedule	O
structurally	O
derived	O
from	O
1-phenylcyclohexylamine	O
2-amino-2-phenylcyclohexanone	O
by	O
modification	O
following	O
ways	O
that	O
is	O
to	O
say	O
i	O
substitution	O
at	O
nitrogen	O
atom	O
extent	O
alkyl	O
alkenyl	O
hydroxyalkyl	O
groups	O
replacement	O
amino	O
group	O
with	O
1-piperidyl	O
1-pyrrolidyl	O
1-azepyl	O
whether	O
containing	O
ring	O
further	O
substituted	O
one	O
more	O
groups;	O
ii	O
phenyl	O
hydroxy	O
alkoxy	O
halide	O
substituents	O
extent;	O
iii	O
cyclohexyl	O
cyclohexanone	O
substituents;	O
iv	O
thienyl	O

After	O
prolonged	O
use	O
the	O
body	O
can	O
become	O
accustomed	O
to	O
effects	O
of	O
zopiclone	B-Drug

Overdose	O
of	O
mianserin	B-Drug
is	O
known	O
to	O
produce	O
sedation	O
coma	O
hypotension	O
or	O
hypertension	O
tachycardia	O
and	O
QT	O
interval	O
prolongation	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

See	O
also:	O
Guzikowski	O
&	O
Tamiz	O
had	O
some	O
interesting	O
example	O
too:	O
JNJ-40068782	O
MA	O
1598	O
CAS:	O
[56079-61-9]4-phenylpiperdine	O
core	O
include:	O
Haloperidol	B-Drug
Enefexine	O
HuntexilA	O
related	O
compound	O
is	O
4-benzylpiperidine	O
in	O
which	O
the	O
rings	O
are	O
separated	O
by	O
a	O
methylene	O
bridge	O

A	O
1960	O
Polish	O
paper	O
by	O
Biniecki	O
and	O
Krajewski	O
describing	O
the	O
synthesis	O
of	O
MDMA	B-Drug
as	O
an	O
intermediate	O
was	O
first	O
published	O
scientific	O
on	O
substance	O

People	O
should	O
not	O
consume	O
alcohol	O
while	O
taking	O
zolpidem	B-Drug
and	O
be	O
prescribed	O
opioid	O
drugs	O
nor	O
take	O
such	O
illicit	O
recreationally	O

Later	O
writers	O
have	O
asserted	O
that	O
Paracelsus'	O
recipe	O
for	O
laudanum	B-Drug
contained	O
opium	B-Drug
but	O
its	O
composition	O
remains	O
unknown	O

Internationally	O
phentermine	B-Drug
is	O
a	O
schedule	O
IV	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

Trimethoprim	B-Drug
has	O
been	O
used	O
in	O
trials	O
to	O
treat	O
retinitis	O

Another	O
study	O
indicated	O
that	O
paranoid	O
violent	O
offenders	O
or	O
those	O
who	O
committed	O
behaviour	O
towards	O
family	O
members	O
have	O
higher	O
bufotenin	B-Drug
levels	O
in	O
their	O
urine	O
than	O
other	O

Wooden	O
chest	O
also	O
called	O
fentanyl	B-Drug
wall	O
rigidity	O
syndrome	O
is	O
a	O
rare	O
side	O
effect	O
of	O
synthetic	O
opioids	O
such	O
as	O
Fentanyl	B-Drug
Sulfentanil	O
Alfentanil	B-Drug
Remifentanil	B-Drug

Expanded	O
expressions	O
for	O
the	O
compound	O
oxycodone	B-Drug
in	O
academic	O
literature	O
include	O
dihydrohydroxycodeinone	O
Eucodal	O
Eukodal	B-Drug
14-hydroxydihydrocodeinone	O
and	O
Nucodan	O

Tolerance	O
often	O
develops	O
to	O
the	O
muscle	O
relaxant	O
effects	O
of	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug

Entactogen	O
means	O
touching	O
within	O
and	O
is	O
a	O
term	O
used	O
by	O
psychiatrists	O
to	O
classify	O
MDMA	B-Drug
related	O
drugs	O

Management	O
of	O
PCP	B-Drug
intoxication	O
mostly	O
consists	O
supportive	O
care	O
controlling	O
breathing	O
circulation	O
and	O
body	O
temperature	O
in	O
the	O
early	O
stages	O
treating	O
psychiatric	O
symptoms	O

Several	O
large	O
quantities	O
of	O
illicitly	O
produced	O
fentanyl	B-Drug
have	O
been	O
seized	O
by	O
U	O

Constipation	O
Itching	O
Drowsiness	O
Sore	O
throat	O
Impaired	O
alertness	O
Confusion	O
Serious	O
or	O
fatal	O
heart	O
rhythms	O
Nausea	O
Dextropropoxyphene	B-Drug
acts	O
as	O
a	O
mu-opioid	O
receptor	O
agonist	O

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
including	O
doxorubicin	B-Drug
and	O
melphalan	O
concurrently	O

A	O
benzodiazepine	O
such	O
as	O
diazepam	B-Drug
or	O
lorazepam	B-Drug
can	O
be	O
used	O
to	O
control	O
combativeness	O
agitation	O
muscular	O
overactivity	O
and	O
seizures	O

MDMA	B-Drug
acts	O
primarily	O
by	O
increasing	O
the	O
activity	O
of	O
neurotransmitters	O
serotonin	O
dopamine	O
and	O
noradrenaline	O
in	O
parts	O
brain	O

Combinations	O
include:	O
Butalbital	B-Drug
and	O
acetaminophen	B-Drug
paracetamol	B-Drug
trade	O
names:	O
Axocet	O
Bucet	O
Bupap	O
Cephadyn	O
Dolgic	O
Phrenilin	O
Forte	O
Sedapap	O
caffeine	O
Fioricet	O
Esgic	O
Esgic-Plus	O
Orbivan	O
aspirin	B-Drug
name:	O
Axotal	O
Fiorinal	B-Drug
Fiormor	O
Fiortal	O
Fortabs	O
Laniroif	O
codeine	B-Drug
phosphate	I-Drug
Fioricet#3	O
with	O
Codeine	B-Drug
Fiorinal#3	O
Ergotamine	B-Drug
tartrate	O
butalbital	B-Drug
belladonna	O
alkaloids	O
Cafergot-PB	O
There	O
are	O
specific	O
treatments	O
which	O
appropriate	O
for	O
targeting	O
migraines	O
headaches	O

Jon	O
Gettman	O
and	O
other	O
supporters	O
of	O
removal	O
cannabis	O
from	O
Schedule	O
I	O
the	O
Controlled	O
Substances	O
Act	O
have	O
questioned	O
legality	O
basing	O
scheduling	O
decisions	O
on	O
such	O
considerations	O
rather	O
than	O
physical	O
addiction	O
harm;	O
stated	O
If	O
federal	O
government	O
wants	O
to	O
keep	O
marijuana	O
in	O
schedule	O
1	O
or	O
if	O
they	O
believe	O
that	O
placing	O
2	O
is	O
a	O
viable	O
policy	O
then	O
we're	O
going	O
cross-examine	O
under	O
oath	O
penalty	O
perjury	O
every	O
HHS	O
official	O
scientist	O
who	O
claims	O
use	O
as	O
dangerous	O
cocaine	B-Drug
heroin	B-Drug

843	O
Moramide	B-Drug
intermediate	I-Drug
is	O
listed	O
separately	O
as	O
a	O
Schedule	O
II	O
Narcotic	O
controlled	O
substance	O
ACSCN	O
9802	O
also	O
with	O
zero	O
quota	O

72	O
tons	O
of	O
cocaine	B-Drug

Most	O
of	O
this	O
funding	O
was	O
earmarked	O
for	O
training	O
and	O
equipping	O
new	O
Colombian	O
army	O
counternarcotics	O
battalions	O
providing	O
them	O
with	O
helicopters	O
transport	O
intelligence	O
assistance	O
supplies	O
coca	B-Drug
eradication	O

It	O
is	O
similar	O
to	O
tramadol	B-Drug
in	O
its	O
dual	O
mechanism	O
of	O
action	O
but	O
unlike	O
it	O
has	O
much	O
weaker	O
effects	O
on	O
the	O
reuptake	O
serotonin	O
and	O
a	O
significantly	O
more	O
potent	O
opioid	O
with	O
no	O
known	O
active	O
metabolites	O

The	O
majority	O
of	O
reports	O
tardive	O
dyskinesia	O
occur	O
in	O
people	O
who	O
have	O
used	O
metoclopramide	B-Drug
for	O
more	O
than	O
three	O
months	O

If	O
the	O
victim	O
overdosed	O
on	O
Rohypnol	B-Drug
antidote	O
flumazenil	B-Drug
can	O
be	O
given;	O
this	O
is	O
only	O
club	O
drug	O
for	O
which	O
there	O
an	O

Rats	O
given	O
1	O
mg/kg	O
amphetamine	B-Drug
performed	O
an	O
average	O
of	O
150%	O
as	O
much	O
work	O
and	O
consumed	O
50%	O
non-preferred	O
rat	O
chow	O
than	O
control	O
rats;	O
rats	O
10	O
Methylphenidate	B-Drug
170%	O
similarly;	O
100	O
Phenylpiracetam	B-Drug
375%	O
little	O

Many	O
fentanyl	B-Drug
overdoses	O
are	O
initially	O
classified	O
as	O
heroin	B-Drug

The	O
Black	O
Mafia	O
Family	O
was	O
founded	O
in	O
1989	O
Detroit	O
by	O
brothers	O
Demetrius	O
Big	O
Meech	O
Flenory	O
and	O
Terry	O
Southwest	O
T	O
2000	O
had	O
established	O
cocaine	B-Drug
distribution	O
sales	O
throughout	O
the	O
United	O
States	O
through	O
their	O
Los	O
Angelesbased	O
drug	O
source	O
direct	O
links	O
to	O
Mexican	O
cartels	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O

Diphenoxylate	B-Drug
is	O
an	O
opioid	O
and	O
acts	O
by	O
slowing	O
intestinal	O
contractions;	O
the	O
atropine	O
present	O
to	O
prevent	O
drug	O
abuse	O
overdose	O

At	O
the	O
beginning	O
of	O
20th	O
century	O
majority	O
hashish	B-Drug
in	O
Europe	O
came	O
from	O
Kashmir	O
and	O
other	O
parts	O
India	O
Afghanistan	O
as	O
well	O
Greece	O
Syria	O
Nepal	O
Lebanon	O
Turkey	O

Coca	B-Drug
herbal	O
infusion	O
also	O
referred	O
to	O
as	O
coca	B-Drug
tea	O
is	O
used	O
in	O
coca-leaf	O
producing	O
countries	O
much	O
any	O
medicinal	O
would	O
elsewhere	O
the	O
world	O

In	O
1986	O
Bristol-Myers	O
Squibb	O
gained	O
FDA	O
approval	O
for	O
buspirone	B-Drug
in	O
the	O
treatment	O
of	O
GAD	O

The	O
most	O
significant	O
adverse	O
effect	O
of	O
LSD	B-Drug
was	O
impairment	O
mental	O
functioning	O
while	O
intoxicated	O

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968	O

AM-2233	O
was	O
found	O
to	O
fully	O
substitute	O
for	O
THC	O
in	O
rats	O
with	O
a	O
potency	O
lower	O
than	O
that	O
of	O
JWH-018	B-Drug
but	O
higher	O
WIN	O
55212-2	O

In	O
non-nmCRPC	O
individuals	O
with	O
severe	O
renal	O
impairment	O
not	O
on	O
dialysis	O
exposure	O
to	O
darolutamide	B-Drug
was	O
increased	O
by	O
about	O
2	O

in	O
2000	O
Blakey	O
moved	O
to	O
Switzerland	O
and	O
set	O
up	O
large	O
grows	O
where	O
he	O
became	O
the	O
first	O
person	O
cultivate	O
strains	O
of	O
cannabis	O
with	O
high	O
levels	O
cannabidiol	B-Drug
CBD	B-Drug
for	O
commercial	O
purposes	O

Nitrazepam	B-Drug
is	O
used	O
to	O
treat	O
short-term	O
sleeping	O
problems	O
insomnia	O
namely	O
difficulty	O
falling	O
asleep	O
frequent	O
awakening	O
early	O
or	O
a	O
combination	O
of	O
each	O

Gynecomastia	O
was	O
first	O
reported	O
with	O
spironolactone	B-Drug
in	O
1962	O
and	O
the	O
antiandrogenic	O
activity	O
of	O
medication	O
described	O
1969	O

Similarly	O
to	O
megestrol	O
acetate	I-Drug
and	O
medroxyprogesterone	B-Drug
CMA	O
appears	O
show	O
less	O
potential	O
for	O
liver	O
genotoxicity	O
carcinogenicity	O
than	O
CPA	O
in	O
bioassays	O

In	O
certain	O
countries	O
triazolam	B-Drug
flunitrazepam	B-Drug
flutoprazepam	B-Drug
and	O
midazolam	B-Drug
are	O
also	O
restricted	O
or	O
controlled	O
to	O
degrees	O

Nicotine	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
by	O
cytochrome	O
P450	O
enzymes	O
mostly	O
CYP2A6	O
and	O
also	O
CYP2B6	O
FMO3	O
which	O
selectively	O
metabolizes	O
S-nicotine	O

Tuberculin	B-Drug
syringes	O
and	O
types	O
of	O
used	O
to	O
inject	O
insulin	O
are	O
commonly	O

Office	O
of	O
National	O
Drug	O
Control	O
Policy	O
cocaine	B-Drug
use	O
had	O
stabilized	O
across	O
the	O
country	O
with	O
a	O
few	O
increases	O
reported	O
in	O
San	O
Diego	O
Bridgeport	O
Miami	O
and	O
Boston	O

These	O
include:	O
plant-based	O
products	O
such	O
as	O
opium	O
and	O
its	O
derivatives	O
morphine	B-Drug
codeine	B-Drug
heroin	B-Drug
the	O
primary	O
category	O
of	O
drug	O
listed	O
in	O
Convention;	O
synthetic	O
narcotics	O
methadone	B-Drug
pethidine;	O
cannabis	O
coca	B-Drug
cocaine	B-Drug
pethidine	B-Drug

5	O
mg	O
codeine	B-Drug
282	O
-	O
contains	O
15	O
292	O
30	O
293	O
60	O

The	O
combination	O
oxycodone/aspirin	B-Drug
is	O
also	O
sold	O
under	O
the	O
brand	O
name	O
Endodan	O

Health	O
Canada	O
announced	O
that	O
ranitidine	B-Drug
drugs	O
were	O
being	O
recalled	O
by	O
Sandoz	O
Apotex	O
Inc	O

The	O
governors	O
of	O
Nevada	O
and	O
California	O
both	O
signed	O
bills	O
into	O
law	O
on	O
May	O
30	O
1966	O
to	O
control	O
LSD	B-Drug
making	O
them	O
the	O
first	O
two	O
states	O
outlaw	O
manufacture	O
sale	O
possession	O
drug	O

federal	O
guidelines	O
recommend	O
that	O
doctors	O
co-prescribe	O
naloxone	B-Drug
for	O
all	O
patients	O
who	O
are	O
prescribed	O
opioids	O
and	O
also	O
meet	O
at	O
least	O
one	O
of	O
the	O
following	O
criteria:	O
Receive	O
50	O
or	O
more	O
morphine	B-Drug
milligram	O
equivalents	O
per	O
day	O
MME/d	O
Have	O
a	O
respiratory	O
condition	O
example	O
COPD	O
sleep	O
apnea	O
Are	O
benzodiazepine	O
drugs	O
substance	O
abuse	O
disorder	O
substances	O
other	O
than	O
Drink	O
heavily	O
mental	O
health	O
disorderAdditionally	O
prescribers	O
encouraged	O
to	O
authorize	O
outright	O
not	O
if	O
they	O
use	O
illegal	O
street	O
engage	O
in	O
high-risk	O
behavior	O

Of	O
these	O
analogues	O
only	O
etonitazene	B-Drug
and	O
clonitazene	B-Drug
are	O
explicitly	O
listed	O
under	O
UN	O
conventions	O
so	O
controlled	O
throughout	O
the	O
world	O

Other	O
stimulants	O
and	O
MAOIs	O
are	O
contraindicated	O
with	O
pemoline	B-Drug

Racemoramide	B-Drug
and	O
moramide	B-Drug
intermediate	I-Drug
are	O
also	O
controlled	O

Osilodrostat	B-Drug
was	O
investigated	O
for	O
the	O
treatment	O
of	O
hypertension	O
heart	O
failure	O
and	O
renal	O
disease	O
but	O
development	O
these	O
indications	O
discontinued	O

Fentanyl	B-Drug
citrate	O
entered	O
medical	O
use	O
as	O
a	O
general	O
anaesthetic	O
in	O
1968	O
manufactured	O
by	O
McNeil	O
Laboratories	O
under	O
the	O
trade	O
name	O
Sublimaze	O

The	O
pharmacokinetics	O
of	O
norethisterone	B-Drug
have	O
been	O
reviewed	O

The	O
false	O
claim	O
states	O
that	O
it	O
is	O
possible	O
to	O
synthesize	O
LSD	B-Drug
or	O
some	O
similar	O
hallucinogenic	O
drug	O
called	O
bananadine	O
from	O
banana	O
peels	O
other	O
common	O
household	O
foods	O
and	O
chemicals	O

25I-NBOMe	B-Drug
25B-NBOMe	B-Drug
and	O
25C-NBOMe	B-Drug
are	O
currently	O
Schedule	O
1	O
Substances	O
according	O
to	O
21	O
CFR	O
1308	O

The	O
2010	O
Mixmag	O
survey	O
of	O
2500	O
nightclubbers	O
found	O
one	O
quarter	O
had	O
used	O
mephedrone	B-Drug
in	O
the	O
previous	O
month	O
price	O
roughly	O
doubled	O
since	O
it	O
was	O
made	O
illegal	O
and	O
more	O
likely	O
to	O
be	O
cut	O
with	O
other	O
substances	O

Cannabis	O
is	O
classified	O
as	O
a	O
Schedule	O
I	O
drug	O
under	O
the	O
Single	O
Convention	O
treaty	O
meaning	O
that	O
medical	O
use	O
allowed	O
but	O
it	O
considered	O
to	O
be	O
an	O
addictive	O
with	O
serious	O
risk	O
of	O
abuse	O
along	O
other	O
drugs	O
such	O
opium	B-Drug
and	O
cocaine	B-Drug

The	O
Celts	O
may	O
have	O
also	O
used	O
cannabis	O
as	O
evidence	O
of	O
hashish	B-Drug
traces	O
were	O
found	O
in	O
Hallstatt	O
birthplace	O
Celtic	O
culture	O

Quazepam	B-Drug
has	O
an	O
absorption	O
half-life	O
of	O
0	O

Ergometrine	B-Drug
is	O
listed	O
as	O
Table	O
I	O
precursors	O
under	O
the	O
United	O
Nations	O
Convention	O
Against	O
Illicit	O
Traffic	O
in	O
Narcotic	O
Drugs	O
and	O
Psychotropic	O
Substances	O
possible	O
precursor	O
compound	O
for	O
LSD	B-Drug

MDPV	B-Drug
acts	O
as	O
a	O
stimulant	O
and	O
has	O
been	O
reported	O
to	O
produce	O
effects	O
similar	O
those	O
of	O
cocaine	B-Drug
methylphenidate	B-Drug
amphetamines	O

Other	O
tropane	O
derivative	O
drugs	O
related	O
to	O
cocaine	B-Drug
are	O
also	O
known	O
such	O
as	O
troparil	O
and	O
lometopane	O
but	O
have	O
not	O
been	O
widely	O
sold	O
or	O
used	O
recreationally	O

Unlike	O
norbuprenorphine	O
but	O
similarly	O
to	O
buprenorphine	B-Drug
and	O
buprenorphine-3-glucuronide	O
N3G	O
is	O
not	O
a	O
substrate	O
for	O
P-glycoprotein	O

It	O
is	O
sold	O
under	O
a	O
number	O
of	O
brand	O
names	O
including	O
Xylocaine	B-Drug

PCP	B-Drug
is	O
a	O
Schedule	O
II	O
substance	O
in	O
the	O
United	O
States	O
and	O
its	O
ACSCN	O
7471	O

Also	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana	B-Drug

When	O
originally	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
loperamide	B-Drug
was	O
considered	O
a	O
narcotic	O
and	O
put	O
into	O
Schedule	O
II	O
of	O
Controlled	O
Substances	O
Act	O
1970	O

A	O
loss	O
of	O
ability	O
to	O
activate	O
the	O
AR	O
is	O
also	O
seen	O
with	O
other	O
testosterone	O
derivatives	O
extended-length	O
C17	O
substitutions	O
such	O
as	O
topterone	O
propyltestosterone	O
compare	O
AAS	O
ethyltestosterone	O
and	O
methyltestosterone	B-Drug
allylestrenol	O
ethylestrenol	B-Drug

The	O
hydrochloride	O
HCl	O
salt	O
of	O
cocaine	B-Drug
is	O
by	O
far	O
the	O
most	O
commonly	O
encountered	O
although	O
sulfate	O
SO42-	O
and	O
nitrate	O
NO3	O
salts	O
are	O
occasionally	O
seen	O

On	O
October	O
15	O
2011	O
Anderson	O
County	O
coroner	O
Greg	O
Shore	O
attributed	O
the	O
death	O
of	O
a	O
South	O
Carolina	O
college	O
basketball	O
player	O
to	O
drug	O
toxicity	O
and	O
organ	O
failure	O
caused	O
by	O
JWH-018	B-Drug

Thebacon	B-Drug
is	O
an	O
opioid	O
agonist	O
narcotic	O
analgesic	O
of	O
the	O
middle	O
range	O
and	O
a	O
strong	O
antitussive	O
primarily	O
used	O
in	O
Europe	O
although	O
it	O
no	O
longer	O
common	O
use	O

Mesuximide	B-Drug

Although	O
not	O
listed	O
as	O
a	O
Schedule	O
1	O
substance	B-Drug
Health	O
Canada	O
reports	O
that	O
methylone	B-Drug
falls	O
under	O
the	O
scheduling	O
an	O
analogue	O
of	O
amphetamine	B-Drug

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens	O
accordingly	O
excessive	O
use	O
known	O
to	O
cause	O
addiction	O

Aminoalkylindoles	O
are	O
structurally	O
dissimilar	O
to	O
THC	O
and	O
include	O
naphthoylindoles	O
JWH-018	B-Drug
phenylacetylindoles	O
JWH-250	B-Drug
benzoylindoles	O
AM-2233	O

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU	O
due	O
to	O
its	O
high	O
recreational	O
use	O

Spironolactone	B-Drug
should	O
be	O
considered	O
a	O
good	O
add-on	O
agent	O
particularly	O
in	O
those	O
patients	O
not	O
yet	O
optimized	O
on	O
ACE	O
inhibitors	O
and	O
beta-blockers	O

///	O
Heroin	B-Drug
is	O
Schedule	O
1	O
on	O
the	O
California	O
Uniform	O
Controlled	O
Substances	O
Act	O

Pethidine	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
pain	O
and	O
delivered	O
as	O
a	O
hydrochloride	O
salt	O
in	O
tablets	O
syrup	O
or	O
by	O
intramuscular	O
subcutaneous	O
intravenous	O
injection	O

In	O
1970	O
the	O
US	O
adopted	O
Uniform	O
Controlled	O
Substances	O
Act	O
which	O
regulated	O
opium	B-Drug
tincture	O
Laudanum	B-Drug
as	O
a	O
Schedule	O
II	O
substance	O
currently	O
DEA	O
#9630	O
placing	O
even	O
tighter	O
controls	O
on	O
drug	O

In	O
the	O
UK	O
flubromazolam	B-Drug
has	O
been	O
classified	O
as	O
a	O
Class	O
C	O
drug	O
by	O
May	O
2017	O
amendment	O
to	O
The	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
along	O
with	O
several	O
other	O
designer	O
benzodiazepine	O
drugs	O

Side	O
effects	O
of	O
lormetazepam	B-Drug
include:	O
somnolence	O
paradoxical	O
increase	O
in	O
aggression	O
lightheadedness	O
confusion	O
muscle	O
weakness	O
ataxia	O
particularly	O
the	O
elderly	O
anterograde	O
amnesia	O
headache	O
vertigo	O
hypotension	O
salivation	O
changes	O
gastro-intestinal	O
disturbances	O
visual	O
dysarthria	O
tremor	O
libido	O
incontinence	O
urinary	O
retention	O
blood	O
disorders	O
and	O
jaundice	O
skin	O
reactions	O
dependence	O
withdrawal	O
reactionsResidual	O
hangover	O
after	O
nighttime	O
administration	O
such	O
as	O
sleepiness	O
impaired	O
psychomotor	O
cognitive	O
functions	O
may	O
persist	O
into	O
next	O
day	O
which	O
impair	O
ability	O
users	O
to	O
drive	O
safely	O
risks	O
falls	O
hip	O
fractures	O

This	O
was	O
primarily	O
generated	O
by	O
people	O
who	O
used	O
psychedelic	O
drugs	O
such	O
as	O
LSD	B-Drug
mescaline	B-Drug
found	O
in	O
peyote	O
and	O
psilocybin	O
magic	O
mushrooms	O
also	O
non-users	O
were	O
participants	O
aficionados	O
of	O
this	O
subculture	O

Ketamine	B-Drug
is	O
very	O
different	O
from	O
the	O
main	O
chemsex	O
drugs	O
as	O
it	O
a	O
dissociative	O
hallucinogen	O
that	O
distorts	O
perceptions	O
and	O
creates	O
sense	O
of	O
detachment	O

Ro4-1539	B-Drug
has	O
never	O
formally	O
undergone	O
clinical	O
trials	O
in	O
humans	O
but	O
based	O
on	O
its	O
effects	O
animals	O
it	O
would	O
be	O
expected	O
to	O
produce	O
similar	O
those	O
of	O
other	O
potent	O
opioid	O
agonists	O
including	O
strong	O
analgesia	O
sedation	O
euphoria	O
constipation	O
itching	O
tachyphylaxis	O
and	O
respiratory	O
depression	O
which	O
could	O
harmful	O
or	O
fatal	O

BML-190	O
is	O
structurally	O
derived	O
from	O
the	O
NSAID	O
indomethacin	B-Drug
but	O
has	O
a	O
quite	O
different	O
biological	O
activity	O

When	O
assayed	O
in	O
mice	O
repeated	O
exposure	O
to	O
MDPV	B-Drug
causes	O
not	O
only	O
an	O
anxiogenic	O
effect	O
but	O
also	O
increased	O
aggressive	O
behaviour	O
a	O
feature	O
that	O
has	O
already	O
been	O
observed	O
humans	O

Marijuana	O
or	O
marihuana	B-Drug
herbal	O
cannabis	O
consists	O
of	O
the	O
dried	O
flowers	O
and	O
fruits	O
subtending	O
leaves	O
stems	O
female	O
Cannabis	O
plant	O

Depot	O
injections	B-Drug
are	O
usually	O
either	O
oil-based	O
or	O
an	O
aqueous	O
suspension	O

The	O
execution	O
of	O
Ronald	O
Bert	O
Smith	O
in	O
the	O
state	O
Alabama	O
on	O
December	O
8	O
2016	O
went	O
awry	O
soon	O
after	O
midazolam	B-Drug
was	O
administered	O
again	O
putting	O
effectiveness	O
drug	O
question	O

There	O
is	O
probably	O
no	O
single	O
reference	O
that	O
lists	O
all	O
the	O
pharmaceutical	O
variations	O
of	O
laudanum	B-Drug
were	O
created	O
and	O
used	O
in	O
different	O
countries	O
during	O
centuries	O
since	O
it	O
was	O
initially	O
formulated	O

It	O
has	O
also	O
been	O
said	O
that	O
given	O
by	O
intramuscular	O
injection	O
250	O
mg	O
OHPC	O
in	O
oil	O
solution	O
is	O
equivalent	O
progestogenic	O
potency	O
to	O
50	O
medroxyprogesterone	B-Drug
acetate	I-Drug
microcrystalline	O
aqueous	O
suspension	O

Levothyroxine	B-Drug
is	O
a	O
synthetic	O
form	O
of	O
thyroxine	O
T4	O
an	O
endogenous	O
hormone	O
secreted	O
by	O
the	O
thyroid	O
gland	O
which	O
converted	O
to	O
its	O
active	O
metabolite	O
L-triiodothyronine	O
T3	O

Protective	O
airway	O
reflexes	O
are	O
preserved	O
and	O
it	O
is	O
sometimes	O
possible	O
to	O
administer	O
ketamine	B-Drug
anesthesia	O
without	O
protective	O
measures	O
the	O
airways	O

Examples	O
of	O
psychoactive	O
substances	O
include	O
caffeine	O
alcohol	O
cocaine	B-Drug
LSD	B-Drug
nicotine	B-Drug
and	O
cannabis	O

Opium	B-Drug
smoking	O
and	O
eating	O
coca	B-Drug
leaf	O
chewing	O
cannabis	O
resin	O
the	O
non-medical	O
use	O
of	O
are	O
prohibited	O

Lidocaine	B-Drug
alters	O
signal	O
conduction	O
in	O
neurons	O
by	O
prolonging	O
the	O
inactivation	O
of	O
fast	O
voltage-gated	O
Na+	O
channels	O
neuronal	O
cell	O
membrane	O
responsible	O
for	O
action	O
potential	O
propagation	O

Acetic	O
acid	O
is	O
used	O
rather	O
than	O
acetic	O
anhydride	O
as	O
not	O
strong	O
enough	O
to	O
acetylate	O
the	O
phenolic	O
3-hydroxy	O
group	O
but	O
able	O
6-hydroxy	O
thus	O
selectively	O
producing	O
6-MAM	O
heroin	B-Drug

The	O
exploration	O
of	O
the	O
antiangiogenic	O
and	O
immunomodulatory	O
activities	O
thalidomide	B-Drug
has	O
led	O
to	O
study	O
creation	O
analogs	O

Coadministration	O
of	O
ritonavir	B-Drug
and	O
fluticasone	O
may	O
lead	O
to	O
increased	O
levels	O
in	O
the	O
body	O
which	O
Cushing's	O
Syndrome	O
adrenal	O
insufficiency	O

Side	O
effects	O
for	O
any	O
psychoactive	O
drug	O
are	O
difficult	O
to	O
predict	O
though	O
butalbital	B-Drug
is	O
usually	O
well	O
tolerated	O

Fewer	O
than	O
30	O
different	O
analogs	O
of	O
PCP	B-Drug
were	O
reported	O
as	O
being	O
used	O
on	O
the	O
street	O
during	O
1970s	O
and	O
1980s	O
mainly	O
in	O
United	O
States	O

Certain	O
combinations	O
can	O
cause	O
lethal	O
reactions	O
common	O
examples	O
including	O
SSRIs	O
tricyclics	O
MDMA	B-Drug
meperidine	B-Drug
tramadol	B-Drug
and	O
dextromethorphan	B-Drug

In	O
1773	O
the	O
Governor	O
of	O
Bengal	O
established	O
a	O
monopoly	O
on	O
production	O
opium	B-Drug
behalf	O
East	O
India	O
Company	O
administration	O

In	O
addition	O
to	O
its	O
wake-promoting	O
effects	O
and	O
ability	O
increase	O
locomotor	O
activity	O
in	O
animals	O
according	O
Nuvigil	B-Drug
prescribing	O
information	O
from	O
manufacturer	O
Cephalon	O
armodafinil	B-Drug
produces	O
psychoactive	O
euphoric	O
alterations	O
mood	O
perception	O
thinking	O
feelings	O
typical	O
of	O
other	O
central	O
nervous	O
system	O
CNS	O
stimulants	O
humans	O

On	O
August	O
21	O
2014	O
the	O
FDA	O
approved	O
apixaban	B-Drug
for	O
additional	O
indication	O
of	O
treatment	O
recurring	O
deep	O
vein	O
thrombosis	O
and	O
pulmonary	O
embolism	O

You	O
can	O
find	O
strains	O
with	O
the	O
same	O
THC	O
and	O
CBD	B-Drug
levels	O
in	O
both	O
versions	O
auto	O
photoperiod	O

In	O
women	O
spironolactone	B-Drug
can	O
cause	O
menstrual	O
irregularities	O
breast	O
tenderness	O
and	O
enlargement	O

American	O
rapper	O
Lil	O
Peep	O
also	O
died	O
of	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O
on	O
November	O
15	O
2017	O

Depression	O
is	O
often	O
self-medicated	O
with	O
alcohol	O
tobacco	B-Drug
cannabis	O
or	O
other	O
mind-altering	O
drug	O
use	O

Heroin	B-Drug
also	O
known	O
as	O
diacetylmorphine	B-Drug
and	O
diamorphine	B-Drug
among	O
other	O
names	O
is	O
an	O
opioid	O
used	O
a	O
recreational	O
drug	O
for	O
its	O
euphoric	O
effects	O

In	O
the	O
United	O
States	O
there	O
is	O
no	O
federal	O
law	O
mentioning	O
possession	O
of	O
Psilocybe	O
spores	O
this	O
because	O
only	O
psilocybin	O
and	O
psilocin	B-Drug
compounds	O
are	O
considered	O
Schedule	O
I	O
drugs	O
presence	O
these	O
in	O
themselves	O
fruiting	O
body	O
cultivated	O

However	O
triamcinolone	B-Drug
acetonide	O
has	O
15%	O
of	O
the	O
affinity	O
progesterone	O
for	O
receptor	O

The	O
sedativehypnotic	O
activity	O
of	O
methaqualone	B-Drug
was	O
first	O
noted	O
in	O
1955	O

A	O
study	O
released	O
in	O
1997	O
examined	O
the	O
addictive	O
nature	O
of	O
both	O
crack	O
and	O
powder	O
cocaine	B-Drug
concluded	O
that	O
one	O
was	O
no	O
more	O
than	O
other	O

It	O
has	O
been	O
found	O
to	O
possess	O
30%	O
of	O
the	O
affinity	O
corticosteroid	O
dexamethasone	B-Drug
for	O
this	O
receptor	O

As	O
a	O
structural	O
analog	O
of	O
NN-dimethyltryptamine	O
DMT	O
5-MeO-DMT	B-Drug
is	O
Schedule	O
9	O
prohibited	O
substance	O
under	O
the	O
Poisons	O
Standard	O

6	O
billion	O
in	O
2013;	O
the	O
US	O
patent	O
on	O
Lyrica	B-Drug
was	O
challenged	O
by	O
generic	O
manufacturers	O
and	O
upheld	O
2014	O
giving	O
Pfizer	O
exclusivity	O
for	O
until	O
2018	O

Because	O
norpropoxyphene	O
has	O
a	O
long	O
half-life	O
in	O
the	O
body	O
of	O
up	O
to	O
36	O
hours	O
compared	O
around	O
612	O
for	O
dextropropoxyphene	B-Drug
it	O
can	O
accumulate	O
tissues	O
during	O
chronic	O
use	O
dextropropoxyphene-containing	O
medications	O
especially	O
people	O
whose	O
excretion	O
drugs	O
is	O
slower	O
than	O
normal	O
such	O
as	O
young	O
children	O
elderly	O
and	O
individuals	O
with	O
reduced	O
kidney	O
or	O
liver	O
function	O
so	O
side	O
effects	O
including	O
serious	O
adverse	O
events	O
are	O
more	O
common	O
these	O
groups	O
should	O
be	O
avoided	O
where	O
possible	O

The	O
Agency	O
added	O
modafinil	B-Drug
to	O
its	O
list	O
of	O
prohibited	O
substances	O
on	O
August	O
3	O
2004	O
ten	O
days	O
before	O
the	O
start	O
Summer	O
Olympics	O

As	O
of	O
2019	O
clinical	O
research	O
on	O
CBD	B-Drug
included	O
studies	O
related	O
to	O
anxiety	O
cognition	O
movement	O
disorders	O
and	O
pain	O
but	O
there	O
is	O
insufficient	O
high-quality	O
evidence	O
that	O
cannabidiol	B-Drug
effective	O
for	O
these	O
conditions	O

Compared	O
with	O
the	O
benzodiazepines	O
nonbenzodiazepine	O
sedative-hypnotics	O
including	O
eszopiclone	B-Drug
appeared	O
to	O
offer	O
few	O
if	O
any	O
significant	O
clinical	O
advantages	O
in	O
efficacy	O
or	O
tolerability	O
elderly	O
persons	O

At	O
least	O
one	O
case	O
of	O
JWH-018	B-Drug
dependence	O
has	O
been	O
reported	O
by	O
the	O
media	O

These	O
metabolites	O
show	O
approximately	O
20%	O
of	O
the	O
inhibitory	O
activity	O
finasteride	B-Drug
on	O
5-reductase	O

In	O
particular	O
the	O
long-term	O
effects	O
of	O
regular	O
aerobic	O
exercise	O
in	O
ADHD	O
individuals	O
include	O
better	O
behavior	O
and	O
motor	O
abilities	O
improved	O
executive	O
functions	O
including	O
attention	O
inhibitory	O
control	O
planning	O
among	O
other	O
cognitive	O
domains	O
faster	O
information	O
processing	O
speed	B-Drug
memory	O

Celgene	O
has	O
sponsored	O
numerous	O
clinical	O
trials	O
with	O
analogues	O
to	O
thalidomide	B-Drug
such	O
as	O
lenalidomide	B-Drug
that	O
are	O
substantially	O
more	O
powerful	O
and	O
have	O
fewer	O
side	O
effects	O
except	O
for	O
greater	O
myelosuppression	O

In	O
February	O
2004	O
a	O
leading	O
fentanyl	B-Drug
supplier	O
Janssen	O
Pharmaceutica	O
Products	O
L	O

Cortisol	O
or	O
hydrocortisone	B-Drug
is	O
the	O
most	O
important	O
human	O
glucocorticoid	O

The	O
original	O
MDMA	B-Drug
synthesis	O
described	O
in	O
Merck's	O
patent	O
involves	O
brominating	O
safrole	O
to	O
1-34-methylenedioxyphenyl-2-bromopropane	O
and	O
then	O
reacting	O
this	O
adduct	O
with	O
methylamine	O

Examples	O
of	O
well	O
known	O
stimulants	O
include	O
caffeine	O
cocaine	B-Drug
amphetamine	B-Drug
modafinil	B-Drug
and	O
ephedrine	B-Drug

The	O
personalities	O
associated	O
with	O
the	O
subculture	O
gurus	O
such	O
as	O
Timothy	O
Leary	O
and	O
psychedelic	O
rock	O
musicians	O
Grateful	O
Dead	O
Pink	O
Floyd	O
Jimi	O
Hendrix	O
Byrds	O
13th	O
Floor	O
Elevators	O
Ultimate	O
Spinach	O
Janis	O
Joplin	O
Crosby	O
Stills	O
&	O
Nash	O
Doors	O
Blue	O
Cheer	O
Chambers	O
Brothers	O
Country	O
Joe	O
Fish	O
Big	O
Brother	O
Holding	O
Company	O
Jefferson	O
Airplane	O
Beatles	O
soon	O
attracted	O
a	O
great	O
deal	O
of	O
publicity	O
generating	O
further	O
interest	O
in	O
LSD	B-Drug

As	O
a	O
phenethylamine	B-Drug
ephedrine	B-Drug
has	O
similar	O
chemical	O
structure	O
to	O
amphetamines	O
and	O
is	O
methamphetamine	B-Drug
analogue	O
having	O
the	O
with	O
hydroxyl	O
group	O
at	O
position	O

Triazolam	B-Drug
causes	O
anterograde	O
amnesia	O
which	O
is	O
why	O
so	O
many	O
dentists	O
administer	O
it	O
to	O
patients	O
undergoing	O
even	O
minor	O
dental	O
procedures	O

Hydrolysis	O
under	O
more	O
strenuous	O
conditions	O
mineral	O
acids	O
results	O
in	O
migration/conjugation	O
of	O
the	O
olefin	O
to	O
yield	O
nandrolone	B-Drug
4	O

Several	O
of	O
the	O
immediate	O
metabolites	O
oxycodone	B-Drug
are	O
subsequently	O
conjugated	O
with	O
glucuronic	O
acid	O
and	O
excreted	O
in	O
urine	O

Two	O
years	O
later	O
in	O
1942	O
American	O
chemist	O
Roger	O
Adams	O
made	O
history	O
when	O
he	O
discovered	O
Cannabidiol	B-Drug
CBD	B-Drug

Charlotte's	O
Web	O
is	O
a	O
brand	O
of	O
high-cannabidiol	O
CBD	B-Drug
low-tetrahydrocannabinol	O
THC	O
products	O
derived	O
from	O
industrial	O
hemp	O
marketed	O
as	O
dietary	O
supplements	O
and	O
cosmetics	O
under	O
federal	O
law	O
the	O
United	O
States	O

Overall	O
LSD	B-Drug
was	O
prescribed	O
as	O
treatment	O
to	O
over	O
40000	O
patients	O

For	O
this	O
reason	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia	O

After	O
menopause	O
androstenedione	B-Drug
production	O
is	O
about	O
halved	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary	O

Gabapentin	B-Drug
can	O
cross	O
the	O
bloodbrain	O
barrier	O
and	O
enter	O
central	O
nervous	O
system	O

Clobazam	B-Drug
was	O
discovered	O
at	O
the	O
Maestretti	O
Research	O
Laboratories	O
in	O
Milan	O
and	O
first	O
published	O
1969;	O
acquired	O
by	O
Roussel	O
Uclaf	O
which	O
became	O
part	O
of	O
Sanofi	O

Nalbuphine	B-Drug
has	O
limited	O
ability	O
to	O
depress	O
respiratory	O
function	O
Gal	O
et	O
al	O

The	O
Riksdag	O
added	O
4-AcO-DMT	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
swedish	O
schedule	O
I	O
substances	O
plant	O
materials	O
and	O
fungi	O
which	O
normally	O
do	O
not	O
have	O
medical	O
use	O
as	O
of	O
January	O
25	O
2017	O
published	O
by	O
Medical	O
Products	O
Agency	O
MPA	O
in	O
regulation	O
HSLF-FS	O
2017:1	O
listed	O
4-acetoxi-NN-dimetyltryptamin	O

Vitamin	O
A	O
can	O
be	O
found	O
in	O
two	O
principal	O
forms	O
foods:	O
Retinol	B-Drug
the	O
form	O
of	O
vitamin	O
absorbed	O
when	O
eating	O
animal	O
food	O
sources	O
is	O
a	O
yellow	O
fat-soluble	O
substance	O

Chronic	O
methamphetamine	B-Drug
use	O
caused	O
gene-specific	O
histone	O
acetylations	O
deacetylations	O
and	O
methylations	O

Oxymorphone	B-Drug
elicits	O
its	O
effects	O
by	O
binding	O
to	O
and	O
activating	O
the	O
-opioid	O
receptor	O
MOR	O
a	O
much	O
lesser	O
extent	O
DOR	O
KOR	O

This	O
strain	O
also	O
exhibits	O
lower	O
levels	O
of	O
other	O
minor	O
cannabinoids	O
with	O
approximately	O
1-2%	O
cannabinol	O
CBN	O
which	O
can	O
be	O
traced	O
to	O
its	O
Super	O
Silver	O
Haze	O
lineage	O
and	O
less	O
than	O
1%	O
CBD	B-Drug
content	O

Mood	O
stabilizers	O
include	O
lithium	O
and	O
many	O
anticonvulsants	O
such	O
as	O
carbamazepine	B-Drug
lamotrigine	B-Drug
are	O
also	O
used	O
for	O
mood	O
disorders	O

The	O
clearance	O
of	O
oxycodone	B-Drug
is	O
0	O

This	O
applies	O
particularly	O
to	O
prescription	O
opioids	O
since	O
some	O
opioid	O
addicts	O
already	O
inject	O
heroin	B-Drug

Pantera	O
frontman	O
Phil	O
Anselmo	O
turned	O
to	O
heroin	B-Drug
while	O
touring	O
during	O
the	O
1990s	O
cope	O
with	O
his	O
back	O
pain	O

This	O
created	O
harsher	O
penalties	O
for	O
drug	O
offenders	O
and	O
also	O
expanded	O
the	O
list	O
of	O
prohibited	O
drugs	O
to	O
include	O
morphine	B-Drug
cocaine	B-Drug
while	O
cannabis	O
was	O
included	O
in	O
1923	O

Analgesic	O
drugs	O
act	O
in	O
various	O
ways	O
on	O
the	O
peripheral	O
and	O
central	O
nervous	O
systems;	O
they	O
include	O
paracetamol	B-Drug
also	O
known	O
US	O
as	O
acetaminophen	B-Drug
nonsteroidal	O
anti-inflammatory	O
NSAIDs	O
such	O
salicylates	O
opioid	O
hydrocodone	B-Drug
codeine	B-Drug
heroin	B-Drug
oxycodone	B-Drug

Amphetamine	B-Drug
addiction	O
is	O
largely	O
mediated	O
through	O
increased	O
activation	O
of	O
dopamine	O
receptors	O
and	O
co-localized	O
NMDA	O
in	O
the	O
nucleus	O
accumbens;	O
magnesium	O
ions	O
inhibit	O
by	O
blocking	O
receptor	O
calcium	O
channel	O

The	O
long	O
half-lives	O
of	O
tamoxifen	B-Drug
and	O
afimoxifene	O
are	O
attributed	O
to	O
their	O
high	O
plasma	O
protein	O
binding	O
as	O
well	O
enterohepatic	O
recirculation	O

These	O
parotoid	O
glands	O
also	O
produce	O
the	O
5-MeO-DMT	B-Drug
and	O
Bufotenin	B-Drug
which	O
is	O
named	O
after	O
Bufo	O
genus	O
of	O
toads;	O
both	O
these	O
chemicals	O
belong	O
to	O
family	O
hallucinogenic	O
tryptamines	O

'	O
Although	O
there	O
is	O
significant	O
dialogue	O
about	O
drug	O
use	O
contained	O
in	O
the	O
film	O
specifically	O
MDMA	B-Drug
ecstasy	B-Drug
marijuana	O
and	O
one	O
sarcastic	O
discussion	O
heroin	B-Drug
crack	B-Drug
cocaine	I-Drug
only	O
by	O
main	O
characters	O
a	O
scene	O
where	O
Jip	O
Koop	O
are	O
having	O
an	O
intimate	O
conversation	O
at	O
house	O
party	O
they	O
seen	O
cutting	O
up	O
line	O
of	O
white	O
powder	O

Cells	O
produce	O
GHB	B-Drug
by	O
reduction	O
of	O
succinic	O
semialdehyde	O
via	O
reductase	O
SSR	O

;	O
and	O
b	O
the	O
plant	O
of	O
any	O
other	O
species	O
Papaver	O
from	O
which	O
opium	B-Drug
or	O
phenanthrene	O
alkaloid	O
can	O
be	O
extracted	O
Central	O
Government	O
may	O
by	O
notification	O
in	O
Official	O
Gazette	O
declare	O
to	O
poppy	O
for	O
purposes	O
this	O
Act;	O
straw	O
means	O
all	O
parts	O
except	O
seeds	O
after	O
harvesting	O
whether	O
their	O
original	O
form	O
cut	O
crushed	O
powdered	O
not	O
juice	O
has	O
been	O
there	O
from;	O
concentrate	O
material	O
arising	O
when	O
entered	O
into	O
a	O
process	O
concentration	O
its	O
alkaloids;	O
preparation	O
relation	O
narcotic	O
drug	O
psychotropic	O
substance	O
one	O
more	O
such	O
drugs	O
substances	O
dosage	O
solution	O
mixture	O
whatever	O
physical	O
state	O
containing	O
substances;	O
production	O
separation	O
coca	B-Drug
leaves	O
cannabis	O
plants	O
they	O
are	O
obtained;	O
natural	O
synthetic	O
salt	O
included	O
list	O
specified	O
Schedule;	O
use	O
kind	O
personal	O
consumption	O

Phenibut	B-Drug
also	O
is	O
taken	O
3	O
times	O
per	O
day	O

In	O
1975	O
Pablo	O
Escobar	O
started	O
developing	O
his	O
cocaine	B-Drug
operation	O

This	O
epidemic	O
caused	O
the	O
risk	O
of	O
acquiring	O
a	O
blood	O
borne	O
infection	O
with	O
use	O
injectable	O
opioids	O
to	O
increase	O
in	O
comparison	O
an	O
when	O
using	O
heroin	B-Drug
or	O
cocaine	B-Drug

In	O
1959	O
Wolfgang	O
Fruhstorfer	O
synthesized	O
MDMA	B-Drug
for	O
pharmacological	O
testing	O
while	O
researching	O
stimulants	O

In	O
turn	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas	O
thus	O
leading	O
gateway	O
sequence	O
those	O
individuals	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered	O

5-Reductase	O
inhibitors	O
5-ARIs	O
such	O
as	O
finasteride	B-Drug
dutasteride	B-Drug
epristeride	O
and	O
alfatradiol	B-Drug
prevent	O
the	O
conversion	O
of	O
testosterone	O
into	O
more	O
potent	O
androgen	O
dihydrotestosterone	O
DHT	O
are	O
used	O
in	O
treatment	O
benign	O
prostatic	O
hyperplasia	O
BPH	O
androgenic	O
alopecia	O
pattern	O
hair	O
loss	O

25I-NBOMe	B-Drug
has	O
been	O
linked	O
to	O
a	O
major	O
case	O
on	O
January	O
20	O
2016	O
in	O
Cork	O
Republic	O
of	O
Ireland	O
which	O
left	O
six	O
teenagers	O
hospitalized	O
one	O
whom	O
later	O
died	O

Cuscohygrine	O
along	O
with	O
the	O
related	O
metabolite	B-Drug
hygrine	O
was	O
first	O
isolated	O
by	O
Carl	O
Liebermann	O
in	O
1889	O
as	O
an	O
alkaloid	O
accompanying	O
cocaine	B-Drug
coca	B-Drug
leaves	O
also	O
known	O
Cusco-leaves	O

However	O
unlike	O
bicalutamide	B-Drug
it	O
is	O
a	O
reversible	O
covalent	O
antagonist	O
and	O
stays	O
bound	O
to	O
the	O
receptor	O
for	O
far	O
longer	O
amount	O
of	O
time	O

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2	O

Relative	O
to	O
testosterone	O
nandrolone	B-Drug
decanoate	O
has	O
enhanced	O
anabolic	O
effects	O
and	O
reduced	O
androgenic	O

In	O
1924	O
hydromorphone	B-Drug
was	O
synthesized	O
by	O
adding	O
hydrogen	O
to	O
morphine	B-Drug

According	O
to	O
a	O
2020	O
article	O
by	O
Health	O
Crisis	O
Alert:The	O
study	O
A	O
Way	O
Forward:	O
How	O
Naloxone	B-Drug
Saves	O
Lives	O
from	O
Overdoses	O
published	O
CME	O
Outfitters	O
continuing	O
medical	O
education	O
organization	O
suggests	O
that	O
co-prescribing	O
naloxone	B-Drug
is	O
not	O
only	O
life-saving	O
measure	O
for	O
those	O
with	O
opioid	O
use	O
disorder	O
OUD	O
but	O
way	O
prescribers	O
talk	O
patients	O
about	O
the	O
risk	O
of	O
accidental	O
overdose	O

Methylphenidate	B-Drug
has	O
been	O
the	O
subject	O
of	O
controversy	O
in	O
relation	O
to	O
its	O
use	O
treatment	O
ADHD	O

Still	O
a	O
student	O
Paul	O
Janssen	O
assisted	O
in	O
the	O
development	O
of	O
paracetamol	B-Drug
USP:	O
acetaminophen	B-Drug
often	O
referred	O
to	O
generically	O
under	O
trademark	O
Tylenol	O
name	O
Perdolan	B-Drug
which	O
would	O
later	O
become	O
well-known	O

It	O
is	O
the	O
C17	O
enanthate	O
heptanoate	O
ester	O
of	O
metenolone	B-Drug
which	O
itself	O
1-methyl-1-45-dihydrotestosterone	O
1-methyl-1-DHT	O
or	O
1-methyl-5-androst-1-en-17-ol-3-one	O

When	O
LNCaP	O
cells	O
a	O
prostate	O
cancer	O
cell	O
line	O
engineered	O
to	O
express	O
elevated	O
levels	O
of	O
AR	O
as	O
found	O
in	O
patients	O
with	O
advanced	O
were	O
treated	O
enzalutamide	B-Drug
the	O
expression	O
androgen-dependent	O
genes	O
PSA	O
and	O
TMPRSS2	O
was	O
down	O
regulated	O
contrast	O
bicalutamide	B-Drug
where	O
upregulated	O

The	O
study	O
was	O
funded	O
by	O
the	O
Boston-based	O
biotech	O
Alkermes	O
firm	O
which	O
produces	O
and	O
markets	O
naltrexone	B-Drug
in	O
United	O
States	O

It	O
interacts	O
with	O
cocaine	B-Drug
in	O
vivo	O
to	O
produce	O
cocaethylene	B-Drug
another	O
psychoactive	O
substance	O

The	O
first	O
TCA	O
reported	O
for	O
the	O
treatment	O
of	O
depression	O
was	O
imipramine	B-Drug
a	O
dibenzazepine	O
analogue	O
chlorpromazine	B-Drug
code-named	O
G22355	O

Protease	O
inhibitors	O
nefazodone	O
sertraline	B-Drug
grapefruit	O
fluoxetine	B-Drug
erythromycin	B-Drug
diltiazem	B-Drug
clarithromycin	O
inhibit	O
the	O
metabolism	O
of	O
midazolam	B-Drug
leading	O
to	O
a	O
prolonged	O
action	O

Formoterol	B-Drug
has	O
been	O
demonstrated	O
to	O
have	O
a	O
faster	O
onset	O
of	O
action	O
than	O
salmeterol	B-Drug
as	O
result	O
lower	O
lipophilicity	O
and	O
also	O
be	O
more	O
potenta	O
12	O
g	O
dose	O
formoterol	B-Drug
equivalent	O
50	O

These	O
regulations	O
were	O
applied	O
initially	O
only	O
to	O
brotizolam	B-Drug
triazolam	B-Drug
and	O
flunitrazepam	B-Drug
as	O
they	O
the	O
major	O
benzodiazepines	O
of	O
abuse	O

Naloxone's	O
binding	O
affinity	O
is	O
highest	O
for	O
the	O
-opioid	O
receptor	O
then	O
and	O
lowest	O
Naloxone	B-Drug

A	O
smaller	O
number	O
of	O
esters	O
codeine	B-Drug
hydrocodone	B-Drug
and	O
dihydrocodeine	B-Drug
one	O
or	O
two	O
oxycodone	B-Drug
are	O
also	O
known	O
used	O
in	O
medicine	O

In	O
England	O
the	O
home	O
director	O
of	O
China	O
Inland	O
Mission	O
Benjamin	O
Broomhall	O
was	O
an	O
active	O
opponent	O
opium	B-Drug
trade	O
writing	O
two	O
books	O
to	O
promote	O
banning	O
smoking:	O
The	O
Truth	O
about	O
Opium	B-Drug
Smoking	O
and	O
Chinese	O
Smoker	O

Methyltestosterone	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
delayed	O
puberty	O
hypogonadism	O
cryptorchidism	O
and	O
erectile	O
dysfunction	O
males	O
low	O
doses	O
to	O
treat	O
menopausal	O
symptoms	O
specifically	O
for	O
osteoporosis	O
hot	O
flashes	O
increase	O
libido	O
energy	O
postpartum	O
breast	O
pain	O
engorgement	O
cancer	O
women	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

There	O
have	O
been	O
reported	O
cases	O
of	O
false-positive	O
urine	O
amphetamine	B-Drug
tests	O
in	O
persons	O
taking	O
bupropion	B-Drug

Because	O
of	O
sofosbuvir's	O
high	O
price	O
in	O
the	O
United	O
States	O
by	O
2017	O
some	O
statessuch	O
as	O
Louisianawere	O
withholding	O
medicine	O
from	O
Medicaid	O
patients	O
with	O
hepatitis	O
until	O
their	O
livers	O
were	O
severely	O
damaged	O
sofosbuvir	B-Drug

Thalidomide	B-Drug
can	O
prevent	O
menstruation	O

Side	O
effects	O
of	O
benzimidazole	O
derived	O
opioids	O
are	O
expected	O
to	O
be	O
similar	O
those	O
fentanyl	B-Drug
which	O
include	O
itching	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
can	O
life-threatening	O

Etizolam	B-Drug
overdose	O
deaths	O
are	O
rising	O
-	O
for	O
instance	O
the	O
National	O
Records	O
of	O
Scotland	O
report	O
on	O
drug-related	O
implicated	O
548	O
from	O
'street'	O
in	O
2018	O
almost	O
double	O
number	O
2017	O
299	O
and	O
only	O
six	O
years	O
first	O
recorded	O
death	O
2012	O

The	O
alcohol	O
content	O
of	O
Laudanum	B-Drug
probably	O
varied	O
substantially;	O
on	O
the	O
labels	O
turn-of-the-century	O
bottles	O
alcoholic	O
is	O
stated	O
as	O
48%	O

Applications	O
of	O
tincture	O
iodine	O
or	O
Betadine	B-Drug
can	O
cause	O
rashes	O
sometimes	O
severe	O

Pregabalin	B-Drug
is	O
eliminated	O
by	O
the	O
kidneys	O
in	O
urine	O
mainly	O
its	O
unchanged	O
form	O

In	O
1889	O
the	O
72-year-old	O
Mauritian	O
neurologist	O
Charles-douard	O
Brown-Squard	O
injected	O
himself	O
with	O
an	O
extract	O
of	O
dog	O
and	O
guinea	O
pig	O
testicles	O
reported	O
at	O
a	O
scientific	O
meeting	O
that	O
these	O
injections	B-Drug
had	O
led	O
to	O
variety	O
beneficial	O
effects	O

In	O
1978	O
People	O
magazine	O
and	O
Mike	O
Wallace	O
of	O
60	O
Minutes	O
called	O
PCP	B-Drug
the	O
country's	O
number	O
one	O
drug	O
problem	O

Although	O
BDB	O
itself	O
has	O
not	O
been	O
reported	O
as	O
being	O
sold	O
Ecstasy	B-Drug
urine	O
analysis	O
of	O
users	O
suggest	O
that	O
this	O
drug	O
may	O
have	O
appeared	O
a	O
street	O
although	O
it	O
is	O
unclear	O
whether	O
the	O
positive	O
test	O
for	O
resulted	O
from	O
consumption	O
or	O
merely	O
metabolite	O
MBDB	O

Oxycodone	B-Drug
has	O
a	O
half-life	O
of	O
4	O

Orciprenaline	B-Drug
does	O
not	O
have	O
the	O
catechol	O
structure	O
which	O
was	O
reason	O
for	O
longer	O
action	O
time	O

Bicalutamide	B-Drug
has	O
been	O
studied	O
in	O
combination	O
with	O
the	O
5-reductase	O
inhibitors	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
prostate	O
cancer	O

Meanwhile	O
Mort	O
detects	O
the	O
symptoms	O
of	O
cocaine	B-Drug
abuse	O
and	O
confronts	O
his	O
friend	O
but	O
Eddie	O
claims	O
to	O
be	O
nothing	O
more	O
than	O
a	O
casual	O
user	O

This	O
category	O
also	O
includes	O
narcotic	O
treatment	O
programs	O
that	O
administer	O
and	O
dispense	O
primarily	O
methadone	B-Drug
for	O
addiction	O

It	O
can	O
only	O
detect	O
drugs	O
with	O
an	O
indole	O
moiety	O
but	O
this	O
is	O
useful	O
because	O
from	O
the	O
NBOMe	O
class	O
do	O
not	O
have	O
and	O
are	O
often	O
sold	O
as	O
LSD	B-Drug
which	O
does	O

5	O
mg	O
with	O
ibuprofen	B-Drug
USP	O
200	O

The	O
active	O
component	O
of	O
Desoxyn	B-Drug
is	O
dextromethamphetamine	B-Drug
hydrochloride	O

Topical	O
budesonide	B-Drug
has	O
considerable	O
effects	O
in	O
eosinophilic	O
esophagitis	O

In	O
Denmark	O
mifepristone	B-Drug
was	O
used	O
in	O
between	O
3000	O
and	O
4000	O
of	O
just	O
over	O
15000	O
abortions	O
2005	O

Progesterone	O
in	O
turn	O
is	O
the	O
precursor	O
of	O
mineralocorticoid	O
aldosterone	O
and	O
after	O
conversion	O
to	O
17-hydroxyprogesterone	O
cortisol	O
androstenedione	B-Drug

There	O
is	O
also	O
a	O
case	O
report	O
of	O
fosphenytoin	O
CYP3A4	O
inducer	O
dramatically	O
reducing	O
the	O
analgesic	O
effects	O
oxycodone	B-Drug
in	O
chronic	O
pain	O
patient	O

Paracetamol	B-Drug
is	O
also	O
used	O
for	O
severe	O
pain	O
such	O
as	O
cancer	O
and	O
after	O
surgery	O
in	O
combination	O
with	O
opioid	O
medication	O

Likewise	O
Canadian	O
Psychiatric	O
Association	O
CPA	O
recommends	O
benzodiazepines	O
alprazolam	B-Drug
bromazepam	B-Drug
lorazepam	B-Drug
and	O
diazepam	B-Drug
only	O
as	O
a	O
second-line	O
choice	O
if	O
the	O
treatment	O
with	O
two	O
different	O
antidepressants	O
was	O
unsuccessful	O

Relief	O
of	O
symptoms	O
due	O
to	O
the	O
use	O
ranitidine	B-Drug
does	O
not	O
exclude	O
presence	O
a	O
gastric	O
malignancy	O

The	O
studies	O
of	O
4-MTA	B-Drug
by	O
David	O
Nichols	O
were	O
then	O
linked	O
to	O
the	O
tablets	O
found	O
in	O
all	O
different	O
countries	O

The	O
elimination	O
half-life	O
of	O
delorazepam	B-Drug
is	O
80115	O
hours	O

According	O
to	O
David	O
Nutt	O
when	O
safrole	O
was	O
restricted	O
by	O
the	O
United	O
Nations	O
in	O
order	O
reduce	O
supply	O
of	O
MDMA	B-Drug
producers	O
China	O
began	O
using	O
anethole	O
instead	O
but	O
this	O
gives	O
para-methoxyamphetamine	B-Drug
PMA	B-Drug
also	O
known	O
as	O
Dr	O
Death	O
which	O
is	O
much	O
more	O
toxic	O
than	O
and	O
can	O
cause	O
overheating	O
muscle	O
spasms	O
seizures	O
unconsciousness	O
death	O

Chlorpromazine	B-Drug
was	O
distributed	O
for	O
testing	O
to	O
physicians	O
between	O
April	O
and	O
August	O
1951	O

Chlorpromazine	B-Drug
has	O
tentative	O
benefit	O
in	O
animals	O
infected	O
with	O
Naegleria	O
fowleri	O

When	O
codeine	B-Drug
is	O
taken	O
in	O
very	O
large	O
amounts	O
it	O
can	O
cause	O
one	O
to	O
stop	O
breathing	O

A	O
systematic	O
review	O
of	O
ADHD	O
biomarkers	O
also	O
indicated	O
that	O
urinary	O
phenethylamine	B-Drug
levels	O
could	O
be	O
a	O
diagnostic	O
biomarker	O
for	O

DMPA	B-Drug
under	O
brand	O
names	O
such	O
as	O
Depo-Provera	B-Drug
and	O
Depo-SubQ	O
Provera	B-Drug
104	O
is	O
used	O
in	O
hormonal	O
birth	O
control	O
a	O
long-lasting	O
progestogen-only	O
injectable	O
contraceptive	O
to	O
prevent	O
pregnancy	O
women	O

Isoquinoline	O
was	O
first	O
isolated	O
from	O
coal	B-Drug
tar	I-Drug
in	O
1885	O
by	O
Hoogewerf	O
and	O
van	O
Dorp	O

JZ-IV-10	O
a	O
Modafinil	B-Drug
hybrid	O
with	O
nocaine	O

The	O
remaining	O
three	O
formulas	O
are	O
copied	O
from	O
an	O
1890	O
publication	O
of	O
the	O
day:	O
Sydenham's	O
Laudanum:	O
According	O
to	O
Paris	O
Codex	O
this	O
is	O
prepared	O
as	O
follows:	O
opium	B-Drug
2	O
ounces;	O
saffron	O
1	O
ounce;	O
bruised	O
cinnamon	O
and	O
cloves	O
each	O
drachm;	O
sherry	O
wine	O
pint	O
Laudanum	B-Drug

Androstenedione	B-Drug
is	O
banned	O
by	O
the	O
World	O
Anti-Doping	O
Agency	O
and	O
from	O
Olympic	O
Games	O

There	O
were	O
no	O
antibiotics	O
so	O
the	O
surgeons	O
prescribed	O
coffee	O
whiskey	O
and	O
quinine	B-Drug

As	O
sofosbuvir	B-Drug
clinical	O
development	O
progressed	O
physicians	O
began	O
to	O
warehouse	O
people	O
in	O
anticipation	O
of	O
its	O
availability	O

The	O
starting	O
of	O
methadone	B-Drug
and	O
the	O
time	O
immediately	O
after	O
leaving	O
treatment	O
with	O
both	O
drugs	O
are	O
periods	O
particularly	O
increased	O
mortality	O
risk	O
which	O
should	O
be	O
dealt	O
by	O
public	O
health	O
clinical	O
strategies	O

Hypnotica	O
was	O
a	O
class	O
of	O
somniferous	O
drugs	O
and	O
substances	O
tested	O
in	O
medicine	O
the	O
1890s	O
later	O
including:	O
Urethan	O
Acetal	O
Methylal	O
Sulfonal	B-Drug
paraldehyde	O
Amylenhydrate	O
Hypnon	O
Chloralurethan	O
Ohloralamid	O
or	O
Chloralimid	O

Cats	O
that	O
received	O
meloxicam	B-Drug
had	O
greater	O
proteinuria	O
at	O
6	O
months	O
than	O
cats	O
placebo	O

He	O
does	O
not	O
state	O
however	O
that	O
nalbuphine's	O
pharmacological	O
mechanism	O
of	O
action	O
for	O
pruritus	O
is	O
the	O
result	O
this	O
interaction	O
between	O
two	O
opioid	O
receptors	O
nalbuphine	B-Drug

Phenobarbital	B-Drug
was	O
used	O
to	O
treat	O
neonatal	O
jaundice	O
by	O
increasing	O
liver	O
metabolism	O
and	O
thus	O
lowering	O
bilirubin	O
levels	O

By	O
the	O
late	O
20th	O
century	O
laudanum's	O
use	O
was	O
almost	O
exclusively	O
confined	O
to	O
treating	O
severe	O
diarrhea	O
laudanum	B-Drug

-Methylacetylfentanyl	O
has	O
similar	O
effects	O
to	O
fentanyl	B-Drug

Therefore	O
anyone	O
caught	O
with	O
MDPV	B-Drug
can	O
be	O
charged	O
possession	O
selling	O
supplying	O
or	O
intent	O
to	O
sell	O
supply	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market	O
including	O
Cephalon's	O
sales	O
promotional	O
practices	O
for	O
Provigil	B-Drug
Actiq	B-Drug
Gabitril	B-Drug

By	O
substituting	O
the	O
bromine	O
atom	O
with	O
an	O
amino	O
group	O
conferred	O
by	O
ammonia	O
it	O
forms	O
alprazolam	B-Drug
triazolobenzophenone	O
following	O
which	O
intermolecular	O
heterocyclization	O
takes	O
place	O
to	O
obtain	O

At	O
the	O
first	O
international	O
congress	O
of	O
neuropharmacology	O
in	O
Rome	O
September	O
1958	O
Dr	O
Freyhan	O
from	O
University	O
Pennsylvania	O
discussed	O
as	O
one	O
clinicians	O
effects	O
imipramine	B-Drug
a	O
group	O
46	O
patients	O
most	O
them	O
diagnosed	O
depressive	O
psychosis	O

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
such	O
as	O
haloperidol	B-Drug
in	O
treatment	O
psychosis	O

In	O
2003	O
the	O
FDA	O
approved	O
another	O
sustained-release	O
formulation	O
called	O
Wellbutrin	B-Drug
XL	O
intended	O
for	O
once-daily	O
dosing	O

The	O
binding	O
affinity	O
of	O
JWH-184	B-Drug
for	O
the	O
CB1	O
receptor	O
is	O
reported	O
as	O
Ki	O
=	O
23	O
6	O
nM	O

Extracts	O
such	O
as	O
hashish	B-Drug
and	O
hash	B-Drug
oil	I-Drug
typically	O
contain	O
more	O
THC	O
than	O
high	O
potency	O
cannabis	O
infructescences	O

People	O
can	O
be	O
exposed	O
to	O
nicotine	B-Drug
in	O
the	O
workplace	O
by	O
breathing	O
it	O
skin	O
absorption	O
swallowing	O
or	O
eye	O
contact	O

The	O
two	O
substances	O
are	O
not	O
chemically	O
similar	O
or	O
related	O
as	O
salvinorin	O
A	O
is	O
found	O
naturally	O
in	O
a	O
single	O
plant	O
while	O
LSD	B-Drug
semisynthesized	O
from	O
lysergamides	O
like	O
ergotamine	B-Drug

Nonselective	O
MAO-A/MAO-B	O
inhibitors	O
Hydrazine	O
antidepressant	O
Isocarboxazid	O
Marplan	O
Hydracarbazine	O
Phenelzine	B-Drug
Nardil	B-Drug
Non-hydrazines	O
Tranylcypromine	B-Drug
Parnate	B-Drug
Jatrosom	O
Selective	O
MAO-A	O
Bifemelane	O
Alnert	O
Celeport	O
available	O
in	O
Japan	O
Moclobemide	O
Aurorix	O
Manerix	O
Pirlindole	O
Pirazidol	O
Russia	O
Toloxatone	O
Humoryl	O
France	O
MAO-B	O
Rasagiline	B-Drug
Azilect	B-Drug
Selegiline	B-Drug
Deprenyl	B-Drug
Eldepryl	O
Emsam	B-Drug
Zelapar	O
Safinamide	B-Drug
XadagoLinezolid	O
is	O
an	O
antibiotic	O
drug	O
with	O
weak	O
reversible	O
MAO-inhibiting	O
activity	O

Hydrocodone	B-Drug
is	O
believed	O
to	O
work	O
by	O
activating	O
opioid	O
receptors	O
mainly	O
in	O
the	O
brain	O
and	O
spinal	O
cord	O

Like	O
other	O
2C-X-NBOMe	O
molecules	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL	O

Medications	O
can	O
include	O
buprenorphine	B-Drug
methadone	B-Drug
or	O
naltrexone	B-Drug

This	O
policy	O
proposal	O
published	O
by	O
Amanda	O
Feilding	O
examines	O
the	O
acute	O
sub-acute	O
and	O
chronic	O
harms	O
related	O
to	O
MDMA	B-Drug
use	O
in	O
detail	O

Small-scale	O
clinical	O
trials	O
in	O
very	O
high-risk	O
people	O
belonging	O
to	O
FAP	O
families	O
showed	O
celecoxib	B-Drug
can	O
prevent	O
polyp	O
growth	O

The	O
US	O
Attorney	O
for	O
the	O
Northern	O
District	O
of	O
Ohio	O
stated:One	O
truly	O
terrifying	O
things	O
is	O
pills	O
are	O
pressed	O
and	O
dyed	O
to	O
look	O
like	O
oxycodone	B-Drug

riding	O
a	O
bicycle	O
at	O
appropriate	O
age	O
Sensory	O
processing	O
and	O
soft	O
neurological	O
problems:	O
sensory	O
disorder	O
defensiveness	O
undersensitivity	O
to	O
stimulation	O
Social	O
communication:	O
Intrude	O
into	O
conversations	O
inability	O
read	B-Drug
nonverbal	O
or	O
social	O
cues	O
chatty	O
but	O
without	O
substance	O
The	O
secondary	O
disabilities	O
of	O
FAS	O
are	O
those	O
that	O
arise	O
later	O
in	O
life	O
CNS	O
damage	O

Those	O
who	O
have	O
been	O
taking	O
methylprednisolone	B-Drug
as	O
a	O
long-term	O
treatment	O
may	O
be	O
gradually	O
tapered	O
off	O
to	O
minimize	O
withdrawal	O
symptoms	O
and	O
potential	O
for	O
relapse	O

Like	O
other	O
benzodiazepines	O
diazepam	B-Drug
can	O
impair	O
short-term	O
memory	O
and	O
learning	O
of	O
new	O
information	O

All	O
of	O
these	O
effects	O
ephedrine	B-Drug
would	O
suggest	O
why	O
warriors	O
feel	O
stronger	O
or	O
more	O
effective	O
on	O
the	O
battlefield	O

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family	O
which	O
includes	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
and	O
carfentanil	B-Drug

A	O
meta-analysis	O
demonstrated	O
that	O
residual	O
hangover	O
effects	O
after	O
nighttime	O
administration	O
of	O
triazolam	B-Drug
such	O
as	O
sleepiness	O
psychomotor	O
impairment	O
and	O
diminished	O
cognitive	O
functions	O
may	O
persist	O
into	O
the	O
next	O
day	O
which	O
impair	O
ability	O
users	O
to	O
drive	O
safely	O
increase	O
risks	O
falls	O
hip	O
fractures	O

Thus	O
high	O
extracellular	O
MDMA	B-Drug
can	O
reverse	O
the	O
transport	O

Zopiclone	B-Drug
induces	O
impairment	O
of	O
psychomotor	O
function	O

Micronized	O
progesterone	O
which	O
behaves	O
reliably	O
as	O
a	O
prodrug	O
to	O
allopregnanolone	B-Drug
has	O
been	O
suggested	O
treatment	O
for	O
catamenial	O
epilepsy	O
in	O
the	O
same	O
manner	O

CBD	B-Drug
does	O
not	O
have	O
the	O
same	O
psychoactivity	O
as	O
THC	O
and	O
may	O
change	O
effects	O
of	O
on	O
body	O
if	O
both	O
are	O
present	O

They	O
are	O
the	O
dibenzazepines	O
imipramine	B-Drug
desipramine	B-Drug
clomipramine	B-Drug
trimipramine	B-Drug
lofepramine	O
and	O
dibenzocycloheptadienes	O
amitriptyline	B-Drug
nortriptyline	B-Drug
protriptyline	O
butriptyline	O

Cimetidine	B-Drug
has	O
been	O
found	O
to	O
possess	O
weak	O
antiandrogenic	O
activity	O
at	O
high	O
doses	O

Darolutamide	B-Drug
Nubeqa:	O
Marketed	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O

Prior	O
to	O
the	O
introduction	O
of	O
paracetamol	B-Drug
Percodan	B-Drug
was	O
mainstay	O
in	O
post-operative	O
oral	O
pain	O
treatment	O
due	O
potency	O
and	O
long	O
half-life	O
oxycodone	B-Drug

Nordazepam	B-Drug
like	O
other	O
benzodiazepines	O
easily	O
crosses	O
the	O
placental	O
barrier	O
so	O
drug	O
should	O
not	O
be	O
administered	O
during	O
first	O
trimester	O
of	O
pregnancy	O

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine	B-Drug
a	O
structurally	O
similar	O
drug	O
far	O
beyond	O
recreational	O
doses	O
but	O
due	O
to	O
never	O
having	O
been	O
published	O
its	O
validity	O
is	O
controversial	O

Whereas	O
opioids	O
like	O
codeine	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
and	O
hydromorphone	B-Drug
are	O
synthesized	O
by	O
simple	O
modifications	O
of	O
morphine	B-Drug
fentanyl	B-Drug
its	O
relatives	O
meperidine	B-Drug

Butalbital	B-Drug
can	O
cause	O
dependence	O
or	O
addiction	O

Moreover	O
no	O
difference	O
was	O
observed	O
between	O
spironolactone	B-Drug
and	O
placebo	O
with	O
regard	O
to	O
volume	O
of	O
residual	O
urine	O
or	O
prostate	O
size	O

Bicalutamide	B-Drug
is	O
approved	O
for	O
and	O
mainly	O
used	O
in	O
the	O
following	O
indications:	O
Metastatic	O
prostate	O
cancer	O
mPC	O
men	O
combination	O
with	O
a	O
gonadotropin-releasing	O
hormone	O
GnRH	O
analogue	O
or	O
surgical	O
castration	O
at	O
50	O
mg/day	O
Locally	O
advanced	O
LAPC	O
as	O
monotherapy	O
150	O
not	O
this	O
use	O
United	O
StatesIn	O
Japan	O
bicalutamide	B-Drug
uniquely	O
dosage	O
of	O
80	O
both	O
treatment	O

Trimethoprim's	O
affinity	O
for	O
bacterial	O
dihydrofolate	O
reductase	O
is	O
several	O
thousand	O
times	O
greater	O
than	O
its	O
human	O
Trimethoprim	B-Drug

Delorazepam	B-Drug
is	O
well	O
absorbed	O
after	O
administration	O
reaching	O
peak	O
plasma	O
levels	O
within	O
1	O
2	O
hours	O

Spironolactone	B-Drug
should	O
be	O
discontinued	O
in	O
people	O
with	O
impaired	O
kidney	O
function	O
or	O
hyperkalemia	O

Preparations	O
of	O
the	O
drug	O
such	O
as	O
oxycodone	B-Drug
with	O
paracetamol	B-Drug
and	O
extended	O
release	O
remain	O
popular	O
to	O
this	O
day	O

law-enforcement	O
authorities	O
encountered	O
55	O
tons	O
of	O
kratom	B-Drug
or	O
roughly	O
50	O
million	O
individual	O
doses	O
according	O
to	O
the	O
International	O
Narcotics	O
Control	O
Board	O

Abiraterone	B-Drug
acetate	I-Drug
has	O
received	O
Food	O
and	O
Drug	O
Administration	O
FDA	O
28	O
April	O
2011	O
European	O
Medicines	O
Agency	O
EMA	O
23	O
September	O
Healthcare	O
products	O
Regulatory	O
MHRA	O
5	O
Therapeutic	O
Goods	O
TGA	O
1	O
March	O
2012	O
approval	O
for	O
this	O
indication	O

Chlorodehydromethyltestosterone	B-Drug
Oral	B-Drug
Turinabol	I-Drug
combining	O
the	O
chemical	O
structures	O
of	O
clostebol	O
and	O
metandienone	B-Drug
was	O
widely	O
used	O
in	O
East	O
German	O
state-sponsored	O
doping	O
program	O

Since	O
a	O
partial	O
cause	O
of	O
the	O
refractory	O
period	O
is	O
inhibition	O
dopamine	O
by	O
an	O
orgasm-induced	O
secretion	O
prolactin	O
such	O
potent	O
receptor	O
agonists	O
as	O
cabergoline	B-Drug
may	O
help	O
achieve	O
multiple	O
orgasms	O
well	O
retention	O
sexual	O
arousal	O
for	O
longer	O
periods	O
time	O

Numerous	O
professional	O
athletes	O
use	O
CBD	B-Drug
primarily	O
for	O
treating	O
pain	O

In	O
the	O
case	O
of	O
discriminate	O
use	O
amphetamine	B-Drug
similar	O
drugs	O
and	O
some	O
other	O
stimulants	O
work	O
capacity	O
actually	O
increases	O
which	O
in	O
itself	O
raises	O
additional	O
ethical	O
considerations	O

In	O
the	O
United	O
States	O
prescription	O
cannabidiol	B-Drug
Epidiolex	O
is	O
indicated	O
for	O
treatment	O
of	O
seizures	O
associated	O
with	O
Dravet	O
syndrome	O
Lennox-Gastaut	O
or	O
tuberous	O
sclerosis	O
complex	O
in	O
people	O
one	O
year	O
age	O
and	O
older	O

Of	O
those	O
Evekeo	B-Drug
including	O
ODT	O
is	O
the	O
only	O
product	O
containing	O
racemic	O
amphetamine	B-Drug
as	O
sulfate	O
and	O
therefore	O
one	O
whose	O
active	O
moiety	O
can	O
be	O
accurately	O
referred	O
to	O
simply	O

Hash	B-Drug
oil	I-Drug
is	O
consumed	O
usually	O
by	O
ingestion	O
smoking	O
or	O
vaporization	O

These	O
medications	O
could	O
potentially	O
interact	O
with	O
the	O
metabolism	O
of	O
hyoscine:	O
analgesics/pain	O
ethanol	O
zolpidem	B-Drug
thiazide	O
diuretics	O
buprenorphine	B-Drug
anticholinergic	O
drugs	O
such	O
as	O
tiotropium	B-Drug
etc	O

The	O
broad	O
class	O
of	O
barbiturates	O
is	O
further	O
broken	O
down	O
and	O
classified	O
according	O
to	O
speed	B-Drug
onset	O
duration	O
action	O

In	O
addition	O
mirtazapine's	O
antagonism	O
of	O
5-HT2A	O
receptors	O
has	O
beneficial	O
effects	O
on	O
anxiety	O
sleep	O
and	O
appetite	O
as	O
well	O
sexual	O
function	O
regarding	O
the	O
latter	O
receptor	O
mirtazapine	B-Drug

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself	O
which	O
include	O
itching	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
can	O
be	O
life-threatening	O

How	O
could	O
anyone	O
seek	O
the	O
fruit	O
of	O
infernal	O
tree	O
and	O
by	O
partaking	O
it	O
be	O
led	O
to	O
exemplify	O
qualities	O
a	O
monster?	O
one	O
use	O
this	O
forbidden	O
drug	O
thus	O
deprive	O
himself	O
blessings	O
All-Merciful?	O
Alcohol	O
consumeth	O
mind	O
causeth	O
man	O
commit	O
acts	O
absurdity	O
but	O
opium	B-Drug
foul	O
wicked	O
hashish	B-Drug
extinguish	O
freeze	O
spirit	O
petrify	O
soul	O
waste	O
body	O
leave	O
frustrated	O
lost	O

]	O
As	O
for	O
his	O
comments	O
about	O
horse	O
riding	O
being	O
more	O
dangerous	O
than	O
ecstasy	B-Drug
which	O
you	O
quote	O
with	O
such	O
reverence	O
it	O
is	O
of	O
course	O
a	O
political	O
rather	O
scientific	O
point	O

For	O
example	O
both	O
uracil	O
and	O
5-fluorouracil	O
are	O
colourless	O
high-melting	O
crystalline	O
solids	O
but	O
the	O
latter	O
is	O
a	O
potent	O
anti-cancer	O
drug	O
fluorouracil	B-Drug

Psychic	O
manifestations	O
may	O
appear	O
while	O
taking	O
methylprednisolone	B-Drug
ranging	O
from	O
euphoria	O
insomnia	O
personality	O
changes	O
to	O
depression	O

It	O
was	O
developed	O
chiefly	O
as	O
a	O
morphine	B-Drug
substitute	O
for	O
cough	O
suppressants	O
that	O
did	O
not	O
have	O
morphine's	O
addictive	O
side-effects	O

In	O
Sweden	O
physicians	O
had	O
long	O
been	O
discouraged	O
by	O
the	O
medical	O
products	O
agency	O
to	O
prescribe	O
dextropropoxyphene	B-Drug
due	O
risk	O
of	O
respiratory	O
depression	O
and	O
even	O
death	O
when	O
taken	O
with	O
alcohol	O

Loperamide	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication	O

In	O
some	O
patients	O
however	O
and/or	O
early	O
in	O
therapy	O
carisoprodol	B-Drug
can	O
have	O
the	O
full	O
spectrum	O
of	O
sedative	O
side	O
effects	O
and	O
impair	O
patient's	O
ability	O
to	O
operate	O
a	O
firearm	O
motor	O
vehicles	O
other	O
machinery	O
various	O
types	O
especially	O
when	O
taken	O
with	O
medications	O
containing	O
alcohol	O
which	O
case	O
an	O
alternative	O
medication	O
would	O
be	O
considered	O

Tramadol	B-Drug
can	O
interact	O
with	O
other	O
medications	O
similar	O
mechanisms	O
of	O
action	O

6-Methylenedihydrodesoxymorphine	O
is	O
synthesised	O
in	O
two	O
steps;	O
first	O
a	O
Wittig	O
reaction	O
used	O
reacting	O
hydrocodone	B-Drug
with	O
methylenetriphenylphosphorane	O
and	O
an	O
alkyl	O
lithium	O
reagent	O
diethyl	O
ether	O
to	O
form	O
6-Methylenedihydrodesoxycodeine	O

Fentanyl	B-Drug
analogues	O
may	O
be	O
hundreds	O
of	O
times	O
more	O
potent	O
than	O
heroin	B-Drug

It	O
requires	O
a	O
processing	O
licence	O
to	O
manufacture	O
products	O
containing	O
CBD	B-Drug
for	O
sale	O
no	O
matter	O
what	O
the	O
source	O
of	O
is	O
and	O
that	O
such	O
as	O
cannabis	O
oil	O
may	O
only	O
be	O
sold	O
by	O
an	O
authorized	O
retailer	O
or	O
licensed	O
seller	O
medical	O

In	O
2018	O
the	O
Massachusetts	O
Supreme	O
Judicial	O
Court	O
found	O
that	O
a	O
probationer	O
with	O
opioid	O
use	O
disorder	O
could	O
be	O
detained	O
for	O
parole	O
violation	O
after	O
she	O
tested	O
positive	O
fentanyl	B-Drug

Diclofenac	B-Drug
formulations	O
are	O
available	O
worldwide	O
under	O
many	O
different	O
trade	O
names	O

Morpheridine	B-Drug
Morpholinoethylnorpethidine	O
is	O
a	O
4-phenylpiperidine	O
derivative	O
that	O
related	O
to	O
the	O
clinically	O
used	O
opioid	O
analgesic	O
drug	O
pethidine	B-Drug
meperidine	B-Drug

In	O
an	O
in	O
vitro	O
study	O
fat	O
thalamic	O
slices	O
amobarbital	B-Drug
worked	O
by	O
activating	O
GABAA	O
receptors	O
which	O
decreased	O
input	O
resistance	O
depressed	O
burst	O
and	O
tonic	O
firing	O
especially	O
ventrobasal	O
intralaminar	O
neurons	O
while	O
at	O
the	O
same	O
time	O
increasing	O
duration	O
mean	O
conductance	O
individual	O
chloride	O
channels;	O
this	O
increased	O
both	O
amplitude	O
decay	O
of	O
inhibitory	O
postsynaptic	O
currents	O

All	O
of	O
the	O
above	O
have	O
annual	O
manufacturing	O
quotas	O
2	O
grams	O
as	O
2013	O
except	O
LAAM	B-Drug
which	O
is	O
4	O

Pregabalin	B-Drug
may	O
enhance	O
the	O
fluid-retaining	O
effect	O
of	O
certain	O
anti-diabetic	O
agents	O
thiazolidinediones	O

LSD	B-Drug
is	O
rapidly	O
absorbed	O
so	O
activated	O
charcoal	O
and	O
emptying	O
of	O
the	O
stomach	O
little	O
benefit	O
unless	O
done	O
within	O
3060	O
minutes	O
ingesting	O
an	O
overdose	O

25I-NBOMe	B-Drug
is	O
usually	O
synthesised	O
from	O
2C-I	O
and	O
2-methoxybenzaldehyde	O
via	O
reductive	O
alkylation	O

LSD	B-Drug
mescaline	B-Drug
and	O
psilocybin	O
cause	O
their	O
effects	O
by	O
initially	O
disrupting	O
the	O
interaction	O
of	O
nerve	O
cells	O
neurotransmitter	O
serotonin	O

Ergotamine	B-Drug
is	O
an	O
ergopeptine	O
and	O
part	O
of	O
the	O
ergot	O
family	O
alkaloids;	O
it	O
structurally	O
biochemically	O
closely	O
related	O
to	O
ergoline	O

The	O
majority	O
of	O
research	O
shows	O
that	O
nicotine	B-Drug
reduces	O
body	O
weight	O
but	O
some	O
researchers	O
have	O
found	O
may	O
result	O
in	O
gain	O
under	O
specific	O
types	O
eating	O
habits	O
animal	O
models	O

Ibogaine	B-Drug
is	O
also	O
used	O
to	O
facilitate	O
psychological	O
introspection	O
and	O
spiritual	O
exploration	O

However	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state	O

amitriptyline	B-Drug
clomipramine	B-Drug
doxepin	B-Drug
imipramine	B-Drug
trimipramine	B-Drug

The	O
biophysiological	O
conversion	O
from	O
cathinone	B-Drug
to	O
cathine	B-Drug
is	O
blame	O
for	O
the	O
depotentiation	O
of	O
khat	O
leaves	O
over	O
time	O

The	O
fructose	O
is	O
then	O
hydrogenated	O
over	O
a	O
nickel	O
catalyst	O
into	O
mixture	O
of	O
isomers	O
sorbitol	O
and	O
mannitol	B-Drug

According	O
to	O
a	O
2014	O
survey	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series	O

This	O
helped	O
the	O
development	O
of	O
Golden	O
Triangle	O
opium	B-Drug
production	O
region	O
which	O
supplied	O
about	O
one-third	O
heroin	B-Drug
consumed	O
in	O
US	O
after	O
1973	O
American	O
withdrawal	O
from	O
Vietnam	O

Clomifene	B-Drug
has	O
been	O
found	O
to	O
decrease	O
insulin-like	O
growth	O
factor	O
1	O
IGF-1	O
levels	O
in	O
women	O

hypokalemia	O
/	O
hypomagnesia	O
The	O
research	O
team	O
of	O
Merck	O
Sharp	O
and	O
Dohme	O
Research	O
Laboratories	O
Beyer	O
Sprague	O
Baer	O
Novello	O
created	O
a	O
new	O
series	O
medications	O
the	O
thiazide	O
diuretics	O
which	O
includes	O
chlorothiazide	B-Drug

The	O
psychotomimetic	O
psychosis-mimicking	O
effects	O
of	O
psilocin	B-Drug
can	O
be	O
blocked	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
the	O
5-HT2A	O
antagonist	O
drug	O
ketanserin	O

Novartis	O
and	O
Roche	O
which	O
respectively	O
have	O
marketing	O
rights	O
ownership	O
for	O
Avastin	B-Drug
had	O
not	O
conducted	O
clinical	O
trials	O
to	O
get	O
approval	O
wet	O
AMD	O
no	O
intention	O
of	O
doing	O
so	O

If	O
high	O
boluses	O
of	O
fentanyl	B-Drug
are	O
administered	O
quickly	O
muscle	O
rigidity	O
the	O
vocal	O
cords	O
can	O
make	O
bag-mask	O
ventilation	O
very	O
difficult	O

List	O
of	O
modafinil	B-Drug
analogues	O
Nocaine	O
A	O
somewhat	O
recent	O
occurrence	O
among	O
tentative	O
modern	O
folklore	O
which	O
has	O
traversed	O
the	O
circling	O
rumors	O
mostly	O
confined	O
to	O
likes	O
universities	O
and	O
popular	O
culture	O
trivia	O
been	O
that	O
cocaine	B-Drug
is	O
one	O
element	O
or	O
molecule	O
increment	O
weight	O
charge	O
etc	O

It	O
contains	O
salts	O
of	O
various	O
alkaloids	O
and	O
can	O
range	O
from	O
nine	O
to	O
30	O
times	O
the	O
morphine	B-Drug
concentration	O
poppy	O
straw	O

Most	O
people	O
who	O
have	O
overdosed	O
on	O
methadone	B-Drug
may	O
show	O
some	O
of	O
the	O
following	O
symptoms:	O
Miosis	O
constricted	O
pupils	O
Vomiting	O
Hypoventilation	O
breathing	O
that	O
is	O
too	O
slow/shallow	O
Drowsiness	O
sleepiness	O
disorientation	O
sedation	O
unresponsiveness	O
Skin	O
cool	O
clammy	O
damp	O
and	O
pale	O
Limp	O
muscles	O
trouble	O
staying	O
awake	O
nausea	O
Unconsciousness	O
comaThe	O
respiratory	O
depression	O
an	O
overdose	O
can	O
be	O
treated	O
with	O
naloxone	B-Drug

In	O
tests	O
against	O
a	O
control	O
Sprague-Dawley	O
rats	O
given	O
free	O
access	O
to	O
less-preferred	O
rat	O
chow	O
and	O
trained	O
operate	O
lever	O
repeatedly	O
obtain	O
preferred	O
performed	O
additional	O
work	O
when	O
methylphenidate	B-Drug
d-amphetamine	B-Drug
phenylpiracetam	B-Drug

In	O
September	O
2014	O
the	O
European	O
Union	O
implemented	O
a	O
ban	O
of	O
25I-NBOMe	B-Drug
in	O
all	O
its	O
member	O
states	O

Pervitin	B-Drug
was	O
commonly	O
used	O
by	O
the	O
German	O
and	O
Finnish	O
militaries	O

Studies	O
in	O
both	O
animals	O
and	O
humans	O
have	O
demonstrated	O
that	O
EEG	O
changes	O
induced	O
by	O
quazepam	B-Drug
resemble	O
normal	O
sleep	O
patterns	O
whereas	O
other	O
benzodiazepines	O
disrupt	O

In	O
the	O
mid	O
1980s	O
neuroactive	O
steroids	O
35-tetrahydroprogesterone	O
or	O
allopregnanolone	B-Drug
35-THP	O
and	O
35-tetrahydrodeoxycorticosterone	O
35-THDOC	O
were	O
shown	O
to	O
modulate	O
neuronal	O
excitability	O
via	O
their	O
interaction	O
with	O
GABAA	O
receptors	O

Therefore	O
trimethoprim	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
individuals	O
kidney	O
and	O
liver	O
impairments	O

Of	O
note	O
is	O
a	O
study	O
investigating	O
the	O
efficacy	O
of	O
using	O
psilocybin	O
as	O
an	O
aid	O
to	O
psychotherapy	O
in	O
overcoming	O
depression	O
and	O
nicotine	B-Drug
addiction	O
brain	O
imaging	O
effects	O
MDMA	B-Drug
on	O
cerebral	O
blood	O
supply	O
examination	O
cannabis	O
creativity	O
importance	O
THC/CBD	O
ratio	O
mental	O
health	O
first	O
LSD	B-Drug
CBD	B-Drug

As	O
of	O
2017	O
MDMA	B-Drug
has	O
no	O
accepted	O
medical	O
indications	O

Ltd	O
now	O
part	O
of	O
Diageo	O
plc	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK	O
Australia	O
and	O
New	O
Zealand	O
under	O
brand	O
name	O
Distaval	O
as	O
a	O
remedy	O
for	O
morning	O
sickness	O

mesterolone	B-Drug
metenolone	B-Drug
2-substitution	O
e	O

Phenoperidine	B-Drug
is	O
an	O
opioid	O
pain	O
killer	O
--	O
narcotic	O
analgesic	O

In	O
Canada	O
MDMA	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
1	O
it	O
an	O
analogue	O
of	O
amphetamine	B-Drug

Haldol	B-Drug
haloperidol	B-Drug
typical	O
antipsychotic	O

In	O
2016	O
a	O
randomized	O
trial	O
provided	O
strong	O
evidence	O
that	O
treatment	O
with	O
celecoxib	B-Drug
is	O
not	O
more	O
likely	O
to	O
result	O
in	O
poor	O
cardiovascular	O
outcomes	O
than	O
naproxen	B-Drug
or	O
ibuprofen	B-Drug

Crack	O
vaporizes	O
near	O
temperature	O
90	O
C	O
194	O
F	O
much	O
lower	O
than	O
the	O
cocaine	B-Drug
hydrochloride	I-Drug
melting	O
point	O
of	O
190	O
374	O

Lecter	O
administers	O
Naloxone	B-Drug
to	O
Jack	O
Crawford's	O
wife	O
after	O
she	O
tries	O
commit	O
suicide	O
by	O
overdosing	O
on	O
morphine	B-Drug

Alphamethadol	B-Drug
is	O
composed	O
of	O
two	O
isomers	O
itself	O
L--methadol	O
and	O
D--methadol	O
methadol	B-Drug

In	O
addition	O
since	O
androstenedione	B-Drug
is	O
the	O
major	O
precursor	O
of	O
estrogens	O
estrogen	O
levels	O
are	O
decreased	O
as	O
well	O

Psilocin	B-Drug
antagonizes	O
H1	O
receptors	O
with	O
moderate	O
affinity	O
compared	O
to	O
LSD	B-Drug
which	O
has	O
a	O
lower	O

A	O
newer	O
medication	O
eplerenone	B-Drug
has	O
been	O
approved	O
by	O
the	O
U	O

Lormetazepam	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Noctamid	O
among	O
others	O
is	O
a	O
drug	O
which	O
short	O
to	O
intermediate	O
acting	O
3-hydroxy	O
benzodiazepine	O
derivative	O
and	O
temazepam	B-Drug
analogue	O

RIMAs	O
should	O
be	O
used	O
with	O
caution	O
as	O
they	O
can	O
have	O
fatal	O
interactions	O
some	O
prescription	O
drugs	O
such	O
SSRI	O
antidepressants	O
and	O
over-the-counter	O
known	O
sympathomimetics	O
Ephedrine	B-Drug
or	O
certain	O
cough	O
medicines	O
even	O
herbal	O
remedies	O

law	O
due	O
to	O
its	O
numbing	O
properties	O
cocaine	B-Drug
is	O
also	O
considered	O
a	O
narcotic	O

Originally	O
believed	O
to	O
exert	O
its	O
effects	O
predominantly	O
via	O
monoamine	O
oxidase	O
inhibition	O
alpha-ethyltryptamine	B-Drug
was	O
developed	O
during	O
the	O
1960s	O
as	O
an	O
antidepressant	O
by	O
Upjohn	O
chemical	O
company	O
in	O
United	O
States	O
under	O
name	O
Monase	O
but	O
withdrawn	O
from	O
potential	O
commercial	O
use	O
due	O
incidence	O
of	O
idiosyncratic	O
agranulocytosis	O

After	O
CIBA's	O
patent	O
exclusivity	O
period	O
lapsed	O
other	O
manufacturers	O
began	O
to	O
market	O
generic	O
metandienone	B-Drug
in	O
the	O
U	O

There	O
has	O
been	O
criticism	O
of	O
the	O
Senlis	O
report	O
findings	O
by	O
Macfarlan	O
Smith	O
who	O
argue	O
that	O
though	O
they	O
produce	O
morphine	B-Drug
in	O
Europe	O
were	O
never	O
asked	O
to	O
contribute	O

25I-NBOMe	B-Drug
2C-I-NBOMe	B-Drug
Cimbi-5	O
also	O
shortened	O
to	O
25I	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

In	O
children	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated	O

methaqualone	B-Drug
etaqualone	O
diproqualone	O
neuroactive	O
steroids	O
niacin/niacinamide	O
nonbenzodiazepines	O
ex	O
niacin	B-Drug
niacinamide	B-Drug

Some	O
bodybuilders	O
and	O
athletes	O
use	O
trenbolone	B-Drug
esters	O
for	O
their	O
muscle-building	O
otherwise	O
performance-enhancing	O
effects	O

Forced	O
acid	O
diuresis	O
with	O
ammonium	O
chloride	O
or	O
more	O
safely	O
ascorbic	O
may	O
increase	O
clearance	O
of	O
PCP	B-Drug
from	O
the	O
body	O
and	O
was	O
somewhat	O
controversially	O
recommended	O
in	O
past	O
as	O
a	O
decontamination	O
measure	O

As	O
of	O
October	O
2020	O
cannabidiol	B-Drug
extracted	O
from	O
marijuana	O
remains	O
a	O
Schedule	O
I	O
Controlled	O
Substance	O
and	O
is	O
not	O
approved	O
as	O
prescription	O
drug	O
or	O
dietary	O
supplement	O
allowed	O
for	O
interstate	O
commerce	O
in	O
the	O
United	O
States	O

Said	O
one	O
former	O
member	O
whenever	O
we	O
took	O
tramadol	B-Drug
nothing	O
mattered	O
to	O
us	O
anymore	O
except	O
what	O
were	O
sent	O
do	O
because	O
it	O
made	O
very	O
high	O
and	O
bold	O
was	O
impossible	O
go	O
on	O
a	O
mission	O
without	O
taking	O

G	O
-	O
the	O
Green	O
PlaceSeed	O
Company	O
HashThe	O
Wheezy	O
Reserva	O
Privada	O
Tangerine	O
Compound	O
Rare	O
Dankness	O
Seeds	O
The	O
Tangie	O
DNA	O
GeneticsImport	O
HashSharkberry	O
Cream	O
House	O
Coffeeshop	O
Twizzler	O
Place	O
Maroc	O
Lemon	O
Haze	O
BushdocterProduct	O
CupBig	O
Buddha	O
Goodie	O
Bag	O
Big	O
PUFFiT	O
Inhaler/Vaporizer	O
VapoShop	O
and	O
Discreet	O
Vape	O
Tiny	O
Sister	O
RoorBest	O
BoothBig	O
Cali	O
Connection	O
RoorGlass	O
CupDrill	O
Bill	O
Roor	O
Glass	O
Puk	O
Pipe	O
MF	O
Doom	O
Borch	O
Genetics	O
Hitman	O
GlassCBD	O
AwardLion's	O
Tabernacle	O
ConnectionFreedom	O
Fighter	O
of	O
YearMason	O
TvertDutch	O
Master	O
HonoreesWernard	O
Bruining	O
Nol	O
van	O
Schaik	O
Cannabis	O
CupRollex	O
OG	O
Kush	O
Flowerbomb	O
Bushdoctor	O
CoffeeshopIndica	O
CupWhitewalker	O
Gold	O
Coast	O
Extract	O
True	O
Elemental	O
KnightsBridge	O
Lady	O
Sativa	O
GeneticsSativa	O
CupTangie	O
Sour	O
Power	O
Hortilab	O
Headbangar-	O
Karma	O
GeneticsHybridSomari	O
Soma's	O
Sacred	O
Girl	O
Scout	O
Cookies	O
Tahoe	O
Wellness	O
Cooperatives	O
Dieseltonic	O
Resin	O
SeedsNeder	O
HashLemon	O
Crystal	O
Shoreline	O
Solventless	O
Wax	O
CoffeeshopSeed	O
Cleaner	O
Nectar	O
TCLabs/TerpX/EmoTex	O
Whitewalker	O
Extracts	O
Chemblend	O
Seeds/Essential	O
Extracts/	O
Johnny	O
TrillImport	O
HashTwizzla	O
Chemdog	O
Cream-	O
CupBuddha	O
Giftbag	O
Cloud	O
V	O
Sublimator	O
SublimatorBest	O
Devil's	O
Harvest	O
Sensi	O
SeedsGlass	O
CupMaster	O
Yoda/Big	O
Honey	O
Collabs	O
Collection	O
Loud/Silka	O
Sika	O
Ray	O
Pack	O
RoorCBD	O
AwardCannatonic-	O
SeedsInductee	O
High	O
Times	O
Hall	O
FameBen	O
Dronkers	O
CupBest	O
Flowers	O
Barneys	O
Coffeeshop-	O
Reekn	O
Pure	O
KushBest	O
by	O
a	O
Seed	O
Crockett	O
Family	O
Farms	O
Crockett's	O
Cut	O
PhenoFinders	O
BubbleBest	O
Indica	O
Vault	O
Colorado	O
Bubba	O
Canna	O
Truth	O
Kosher	O
Hybrid	O
Larry	O
Star	O
Killer	O
BC	O
Bud	O
Depot	O
Night	O
NurseBest	O
Import	O
Hash	B-Drug
Concentrates	O
Loud	O
Extractions	O
&	O
Greenwolf	O
LA	O
Super	O
Concentrate	O
Oasis	O
Medical	O
in	O
Flint	O
MI	O
Paris	O
Shatter	O
Dab	O
Vader	O
Unlimited	O
18	O
Live	O
ResinBest	O
Neder	O
Ice-Cream	O
-Green	O
Ice	O
Grey	O
Area	O
CrystanBest	O
Carmella	O
TwislaBest	O
Kong	O
73	O
Non-Solvent	O
Grow	O
Your	O
Own	O
Betty	O
Ross	O
Drysift	O
Great	O
Gardener	O
-Barb	O
99CBD	O
CBD	B-Drug
Rene	O
CannaVest	O
SimpleBest	O
Product	O
Gift	O
Devils	O
SeedsBest	O
Flav421	O
History	O
Making	O
Dampkring	O
Gallery	O
Team	O
Japan	O
Onigari/	O
Demon	O
Hunter	O

Amfepramone	B-Drug
also	O
known	O
as	O
diethylpropion	B-Drug
is	O
a	O
stimulant	O
drug	O
of	O
the	O
phenethylamine	O
amphetamine	B-Drug
and	O
cathinone	B-Drug
classes	O
that	O
used	O
an	O
appetite	O
suppressant	O

The	O
committee	O
made	O
this	O
recommendation	O
on	O
the	O
basis	O
of	O
pharmacological	O
similarity	O
MDMA	B-Drug
to	O
previously	O
scheduled	O
drugs	O
reports	O
illicit	O
trafficking	O
in	O
Canada	O
drug	O
seizures	O
United	O
States	O
and	O
lack	O
well-defined	O
therapeutic	O
use	O

The	O
bioavailability	O
of	O
meloxicam	B-Drug
is	O
decreased	O
when	O
administered	O
orally	O
compared	O
to	O
an	O
equivalent	O
IV	O
bolus	O
dose	O

As	O
of	O
the	O
end	O
2011	O
seizure	O
operations	O
Colombian	O
cocaine	B-Drug
carried	O
out	O
in	O
different	O
countries	O
have	O
totaled	O
351	O

World	O
annual	O
cocaine	B-Drug
consumption	O
as	O
of	O
2000	O
stood	O
at	O
around	O
600	O
tonnes	O
with	O
the	O
United	O
States	O
consuming	O
300	O
t	O
50%	O
total	O
Europe	O
about	O
150	O
25%	O
and	O
rest	O
world	O
remaining	O
or	O

nimetazepam	B-Drug
flutoprazepam	B-Drug
etc	O

The	O
psychoactive	O
substance	O
in	O
Cannabis	O
THC	O
is	O
unique	O
that	O
it	O
contains	O
no	O
nitrogen	O
and	O
not	O
an	O
indole	O
tryptamine	O
phenethylamine	B-Drug
anticholinergic	O
deliriant	O
or	O
a	O
dissociative	O
drug	O

The	O
term	O
laudanum	B-Drug
was	O
used	O
generically	O
for	O
a	O
useful	O
medicine	O
until	O
the	O
17th	O
century	O

For	O
example	O
a	O
recent	O
study	O
with	O
malignant	O
tumor	O
cells	O
showed	O
celecoxib	B-Drug
could	O
inhibit	O
the	O
growth	O
of	O
these	O
in	O
vitro	O
but	O
COX-2	O
played	O
no	O
role	O
this	O
outcome;	O
even	O
more	O
strikingly	O
anticancer	O
effects	O
were	O
also	O
obtained	O
use	O
cancer	O
cell	O
types	O
that	O
do	O
not	O
contain	O

Acacia	O
berlandieri	O
DMT	O
amphetamines	B-Drug
mescaline	B-Drug
nicotine	B-Drug
catechu	O
and	O
other	O
tryptamines	O
in	O
leaf	O
bark	O
caven	O
Psychoactive	O
chundra	O
colei	O
complanata	O
0	O

Androstenedione	B-Drug
has	O
been	O
found	O
to	O
possess	O
some	O
estrogenic	O
activity	O
similarly	O
other	O
DHEA	O
metabolites	O

It's	O
worth	O
noting	O
that	O
the	O
unawareness	O
concerning	O
effects	O
of	O
illicit	O
substances	O
such	O
as	O
cocaine	B-Drug
methamphetamine	B-Drug
or	O
mephedrone	B-Drug
can	O
result	O
in	O
self-medication	O
with	O
these	O
drugs	O
by	O
individuals	O
affected	O
ADHD	O
symptoms	O

In	O
veterinary	O
anaesthesia	O
ketamine	B-Drug
is	O
often	O
used	O
for	O
its	O
anaesthetic	O
and	O
analgesic	O
effects	O
on	O
cats	O
dogs	O
rabbits	O
rats	O
other	O
small	O
animals	O

In	O
late	O
1959	O
it	O
was	O
noticed	O
that	O
peripheral	O
neuritis	O
developed	O
in	O
patients	O
who	O
took	O
the	O
drug	O
over	O
a	O
period	O
of	O
time	O
and	O
only	O
after	O
this	O
point	O
thalidomide	B-Drug
ceased	O
to	O
be	O
provided	O
counter	O

Ciclosporin	B-Drug
may	O
increase	O
plasma	O
levels	O
of	O
ciclosporin	B-Drug

It	O
fully	O
substitutes	O
for	O
MBDB	O
but	O
not	O
amphetamine	B-Drug
in	O
trained	O
animals	O
though	O
it	O
does	O
produce	O
disruption	O
the	O
latter	O
at	O
high	O
doses	O

Nitrazepam	B-Drug
is	O
teratogenic	O
if	O
taken	O
in	O
overdose	O
during	O
pregnancy	O
with	O
30%	O
of	O
births	O
showing	O
congenital	O
abnormalities	O

Fentanyl	B-Drug
was	O
among	O
many	O
substances	O
identified	O
in	O
counterfeit	O
pills	O
recovered	O
from	O
his	O
home	O
especially	O
some	O
that	O
were	O
mislabeled	O
as	O
Watson	O
385	O
a	O
combination	O
of	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug

Ephedrine	B-Drug
works	O
by	O
increasing	O
the	O
activity	O
of	O
and	O
adrenergic	O
receptors	O

It	O
does	O
not	O
possess	O
the	O
potential	O
for	O
euphoria	O
or	O
addiction	O
that	O
dextromethamphetamine	B-Drug
possesses	O

Phentermine	B-Drug
can	O
be	O
produced	O
from	O
benzaldehyde	O
and	O
2-nitropropane	O
as	O
follows:	O
Benzaldehyde	O
are	O
cross-reacted	O
in	O
a	O
variant	O
of	O
the	O
Henry	O
reaction	O
The	O
nitro	O
group	O
is	O
reduced	O
with	O
hydrogen	O
gas	O
over	O
Raney	O
nickel	O
catalyst	O
hydroxyl	O
chlorinated	O
thionyl	O
chloride	O
to	O
yield	O
2-amino-1-chloro-2-methyl-1-phenylpropane	O
This	O
palladium	O
on	O
magnesium	O
glycinate	O
product	O
phentermine	B-Drug
contracted	O
phenyl-tertiary-butylamine	O

The	O
fentanyl	B-Drug
patch	O
is	O
one	O
of	O
a	O
few	O
medications	O
that	O
may	O
be	O
especially	O
harmful	O
and	O
in	O
some	O
cases	O
fatal	O
with	O
just	O
dose	O
if	O
used	O
by	O
someone	O
other	O
than	O
the	O
person	O
for	O
whom	O
medication	O
was	O
prescribed	O

If	O
a	O
person	O
is	O
taking	O
both	O
carbamazepine	B-Drug
and	O
risperidone	B-Drug
the	O
dose	O
of	O
will	O
likely	O
need	O
to	O
be	O
increased	O

80%	O
of	O
MDMA	B-Drug
is	O
metabolised	O
in	O
the	O
liver	O
and	O
about	O
20%	O
excreted	O
unchanged	O
urine	O

MDMA	B-Drug
was	O
openly	O
distributed	O
in	O
Austin	O
and	O
DallasFort	O
Worth	O
area	O
bars	O
nightclubs	O
becoming	O
popular	O
with	O
yuppies	O
college	O
students	O
gays	O

Trenbolone	B-Drug
is	O
classified	O
as	O
a	O
Schedule	O
4	O
drug	O
in	O
Canada	O
and	O
class	O
C	O
with	O
no	O
penalty	O
for	O
personal	O
use	O
or	O
possession	O
the	O
United	O
Kingdom	O

Tramadol	B-Drug
acts	O
as	O
a	O
serotonin-norephinephrine	O
reuptake	O
inhibitor	O
and	O
thus	O
can	O
interact	O
with	O
other	O
serotonergic	O
medications	O
selective	O
serotonin	O
inhibitors	O
serotoninnorepinephrine	O
tricyclic	O
antidepressants	O
triptans	O
cough	O
cold	O
containing	O
dextromethorphan	B-Drug
herbal	O
products	O
St	O

In	O
November	O
2016	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights	O
Utah	O

In	O
the	O
case	O
of	O
diamorphine	B-Drug
this	O
includes	O
promoting	O
safer	O
means	O
taking	O
drug	O
such	O
as	O
smoking	O
nasal	O
use	O
oral	O
or	O
rectal	O
insertion	O

Other	O
analogues	O
with	O
potency	O
higher	O
than	O
that	O
of	O
ohmefentanyl	B-Drug
itself	O
include	O
the	O
2-fluoro	O
derivative	O
i	O

As	O
such	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O

Newer	O
drugs	O
such	O
as	O
BIMU-8	O
and	O
CX-546	B-Drug
may	O
be	O
much	O
more	O
effective	O

In	O
a	O
1991	O
study	O
triazolam	B-Drug
had	O
the	O
highest	O
self-administration	O
rate	O
in	O
cocaine	B-Drug
trained	O
baboons	O
among	O
five	O
benzodiazepines	O
examined:	O
alprazolam	B-Drug
bromazepam	B-Drug
chlordiazepoxide	B-Drug
lorazepam	B-Drug

This	O
legend	O
may	O
have	O
been	O
inadvertently	O
inspired	O
by	O
Narconon	O
a	O
Scientology-based	O
drug	O
rehabilitation	O
program	O
that	O
uses	O
exercise	O
saunas	O
and	O
dangerously	O
high	O
doses	O
of	O
niacin	B-Drug
other	O
vitamins	O
to	O
detox	O

Studies	O
of	O
divalproex	B-Drug
have	O
found	O
no	O
significant	O
benefit	O
though	O
some	O
studies	O
mixed	O
results	O

Fentanyl	B-Drug
was	O
among	O
many	O
substances	O
identified	O
in	O
counterfeit	O
pills	O
recovered	O
from	O
his	O
home	O
especially	O
some	O
that	O
were	O
mislabeled	O
as	O
Watson	O
385	O
a	O
combination	O
of	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug

Also	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana	B-Drug

Case	O
reports	O
of	O
seven	O
British	O
males	O
who	O
presented	O
to	O
an	O
emergency	O
room	O
following	O
analytically	O
confirmed	O
25I-NBOMe	B-Drug
intoxication	O
suggest	O
the	O
potential	O
adverse	O
effects:	O
tachycardia	O
n	O
=	O
7	O
hypertension	O
4	O
agitation	O
6	O
aggression	O
visual	O
and	O
auditory	O
hallucinations	O
seizures	O
3	O
hyperpyrexia	O
clonus	O
2	O
elevated	O
white	O
cell	O
count	O
creatine	O
kinase	O
metabolic	O
acidosis	O
acute	O
kidney	O
injury	O
1	O

It	O
is	O
not	O
available	O
in	O
the	O
United	O
Kingdom	O
though	O
combination	O
codeine/paracetamol	O
codeine	B-Drug
paracetamol	B-Drug

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths	O

Marijuana	B-Drug
reports	O
are	O
mixed	O
with	O
half	O
of	O
users	O
claiming	O
an	O
increase	O
in	O
sexual	O
desire	O
and	O
pleasure	O
while	O
the	O
other	O
no	O
effect	O

The	O
suggested	O
mechanism	O
by	O
which	O
fenfluramine	B-Drug
causes	O
damage	O
is	O
through	O
over	O
or	O
inappropriate	O
stimulation	O
of	O
these	O
receptors	O
leading	O
to	O
valve	O
cell	O
division	O

The	O
risks	O
of	O
tolerance	O
dependence	O
and	O
withdrawal	O
are	O
very	O
low	O
when	O
the	O
drug	O
is	O
used	O
for	O
24	O
weeks	O
only	O
lormetazepam	B-Drug
generally	O
a	O
safe	O
effective	O
no	O
longer	O
than	O

In	O
modern	O
popular	O
culture	O
references	O
to	O
cocaine	B-Drug
are	O
common	O

On	O
October	O
27	O
1970	O
both	O
psilocybin	O
and	O
psilocin	B-Drug
became	O
classified	O
as	O
Schedule	O
I	O
drugs	O
were	O
simultaneously	O
labeled	O
hallucinogens	O
under	O
a	O
section	O
of	O
the	O
Comprehensive	O
Drug	O
Abuse	O
Prevention	O
Control	O
Act	O
known	O
Controlled	O
Substances	O

Charlotte's	O
Web	O
is	O
a	O
high-cannabidiol	O
CBD	B-Drug
low-tetrahydrocannabinol	O
THC	O
cannabis	O
variety	O
and	O
extract	O
marketed	O
as	O
dietary	O
supplement	O
under	O
federal	O
law	O
of	O
the	O
United	O
States	O

The	O
half-life	O
of	O
naloxone	B-Drug
is	O
shorter	O
than	O
some	O
opioids	O
such	O
that	O
it	O
may	O
need	O
to	O
be	O
given	O
multiple	O
times	O
until	O
the	O
opioid	O
has	O
been	O
metabolized	O
by	O
body	O

The	O
combination	O
of	O
BZP	B-Drug
and	O
TFMPP	B-Drug
has	O
been	O
associated	O
with	O
a	O
range	O
side	O
effects	O
including	O
insomnia	O
anxiety	O
nausea	O
vomiting	O
headaches	O
muscle	O
aches	O
which	O
may	O
resemble	O
migraine	O
seizures	O
impotence	O
rarely	O
psychosis	O
as	O
well	O
prolonged	O
unpleasant	O
hangover	O
effect	O

The	O
DEA	O
lists	O
oxycodone	B-Drug
both	O
for	O
sale	O
and	O
use	O
in	O
manufacturing	O
other	O
opioids	O
as	O
ACSCN	O
9143	O
2013	O
approved	O
the	O
following	O
annual	O
aggregate	O
quotas:	O
131	O

Smoking	O
is	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Parkinson's	O
Disease;	O
however	O
it	O
unknown	O
whether	O
this	O
due	O
to	O
people	O
healthier	O
brain	O
dopaminergic	O
reward	O
centers	O
the	O
area	O
affected	O
by	O
being	O
more	O
likely	O
enjoy	O
smoking	O
and	O
thus	O
pick	O
up	O
habit	O
nicotine	B-Drug
directly	O
acting	O
as	O
neuroprotective	O
agent	O
or	O
other	O
compounds	O
in	O
cigarette	O
smoke	O
agents	O

Agricultural	O
producers	O
in	O
these	O
countries	O
are	O
pushed	O
further	O
to	O
grow	O
coca	B-Drug
for	O
the	O
cocaine	B-Drug
trade	O
by	O
dumping	O
of	O
subsidised	O
farming	O
products	O
fruit	O
vegetables	O
grain	O
etc	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2	O
2019	O
by	O
U	O

Class	O
B	O
includes	O
amphetamines	O
barbiturates	O
cannabis	O
codeine	B-Drug
ketamine	B-Drug
methoxetamine	B-Drug
and	O
methylphenidate	B-Drug

Cocaine	B-Drug
and	O
its	O
major	O
metabolites	O
may	O
be	O
quantified	O
in	O
blood	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
the	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
sudden	O
death	O

For	O
adults	O
a	O
randomized	O
controlled	O
trial	O
found	O
PEG	B-Drug
MiraLax	O
or	O
GlycoLax	O
17	O
grams	O
once	O
per	O
day	O
to	O
be	O
superior	O
tegaserod	O
at	O
6	O
mg	O
twice	O

On	O
July	O
5	O
2010	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile	O
Alabama	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription	O

Because	O
mesterolone	B-Drug
is	O
not	O
17-alkylated	O
it	O
has	O
little	O
or	O
no	O
potential	O
for	O
hepatotoxicity	O

Zolpidem	B-Drug
can	O
typically	O
be	O
detected	O
in	O
bodily	O
fluids	O
for	O
36	O
hours	O
though	O
it	O
may	O
possible	O
to	O
detect	O
by	O
hair	O
testing	O
much	O
later	O
which	O
is	O
due	O
the	O
short	O
elimination	O
half-life	O
of	O
2	O

A	O
2017	O
study	O
in	O
children	O
with	O
drug-resistant	O
Dravet	O
syndrome	O
using	O
a	O
comparatively	O
high	O
dose	O
of	O
20	O
mg/kg	O
found	O
cannabidiol	B-Drug
reduced	O
convulsive	O
seizures	O
but	O
not	O
non-convulsive	O
and	O
resulted	O
more	O
side	O
effects	O
compared	O
placebo	O

Clozapine	B-Drug
is	O
usually	O
given	O
by	O
mouth	O
in	O
tablet	O
or	O
liquid	O
form	O
however	O
an	O
unlicensed	O
short-acting	O
intramuscular	O
injectable	O
formulation	O
available	O

Dihydrotestosterone	O
also	O
plays	O
an	O
important	O
role	O
in	O
male	O
sexual	O
function	O
and	O
may	O
be	O
a	O
contributing	O
factor	O
of	O
ischemic	O
priapism	O
males	O
as	O
shown	O
study	O
conducted	O
on	O
the	O
use	O
finasteride	B-Drug
to	O
treat	O

According	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
CDC	O
death	O
rates	O
from	O
synthetic	O
opioids	O
including	O
fentanyl	B-Drug
increased	O
over	O
72%	O
2014	O
2015	O

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
at	O
an	O
earlier	O
age	O
than	O
illegal	O
hard	O
drugs	O

An	O
ELISA	O
immunoassay	O
technique	O
for	O
detecting	O
UR-144	B-Drug
in	O
urine	O
as	O
part	O
of	O
general	O
drug	O
screens	O
has	O
been	O
developed	O
by	O
Tulip	O
Biolabs	O
Inc	O

If	O
used	O
concomitantly	O
with	O
lithium	O
celecoxib	B-Drug
increases	O
plasma	O
levels	O

Bicalutamide	B-Drug
is	O
a	O
prescription	O
drug	O

The	O
use	O
of	O
alprazolam	B-Drug
during	O
pregnancy	O
is	O
associated	O
with	O
congenital	O
abnormalities	O
and	O
in	O
the	O
last	O
trimester	O
may	O
cause	O
fetal	O
drug	O
dependence	O
withdrawal	O
symptoms	O
post-natal	O
period	O
as	O
well	O
neonatal	O
flaccidity	O
respiratory	O
problems	O

JWH-018	B-Drug
will	O
not	O
be	O
detected	O
by	O
older	O
methods	O
employed	O
for	O
detecting	O
THC	O
and	O
other	O
cannabis	O
terpenoids	O

On	O
December	O
22	O
2008	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
issued	O
an	O
alert	O
to	O
consumers	O
naming	O
27	O
different	O
products	O
marketed	O
as	O
dietary	O
supplements	O
for	O
weight	O
loss	O
that	O
illegally	O
contain	O
undisclosed	O
amounts	O
of	O
sibutramine	B-Drug

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia	O

For	O
example	O
savvy	O
drug	O
dealers	O
have	O
learned	O
how	O
to	O
market	O
drugs	O
like	O
Ecstasy	B-Drug
youth	O

They	O
were	O
warned	O
against	O
making	O
medical	O
claims	O
about	O
cannabidiol	B-Drug
CBD	B-Drug

The	O
spores	O
of	O
these	O
mushrooms	O
do	O
not	O
contain	O
psilocybin	O
or	O
psilocin	B-Drug

They	O
are	O
very	O
close	O
to	O
bicalutamide	B-Drug
structurally	O
with	O
the	O
key	O
differences	O
being	O
that	O
linker	O
sulfone	O
of	O
has	O
been	O
replaced	O
an	O
ether	O
or	O
thioether	O
group	O
confer	O
agonism	O
AR	O
and	O
4-fluoro	O
atom	O
pertinent	O
phenyl	O
ring	O
substituted	O
acetamido	O
cyano	O
eliminate	O
reactivity	O
at	O
position	O

Merrell	O
Chemical	O
Company	O
led	O
by	O
Frank	O
Palopoli	O
synthesized	O
clomifene	B-Drug
in	O
1956;	O
after	O
its	O
biological	O
activity	O
was	O
confirmed	O
a	O
patent	O
filed	O
and	O
issued	O
November	O
1959	O

Some	O
laboratory	O
operators	O
in	O
China	O
mix	O
MDMA	B-Drug
powder	O
imported	O
from	O
Europe	O
with	O
substances	O
such	O
as	O
caffeine	O
and	O
ketamine	B-Drug
while	O
making	O
the	O
Ecstasy	B-Drug
tablets	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

They	O
can	O
orally	O
consume	O
100	O
ml	O
of	O
concentrated	O
syrup	O
containing	O
either	O
15	O
grams	O
pentobarbital	B-Drug
or	O
secobarbital	B-Drug
they	O
choose	O
to	O
have	O
2	O
thiopental	B-Drug
1	O
gram	O
propofol	B-Drug
administered	O
intravenously	O
by	O
a	O
doctor	O
followed	O
muscle	O
relaxant	O

In	O
any	O
case	O
spironolactone	B-Drug
is	O
nonetheless	O
not	O
recommended	O
during	O
pregnancy	O
due	O
to	O
theoretical	O
concerns	O
relating	O
feminization	O
of	O
males	O
and	O
also	O
potential	O
alteration	O
fetal	O
potassium	O
levels	O

4-Hydroxy-N-methyl-N-propyltryptamine	O
commonly	O
known	O
as	O
4-HO-MPT	O
or	O
meprocin	O
is	O
a	O
psychedelic	O
drug	O
in	O
the	O
tryptamine	O
class	O
of	O
chemical	O
compounds	O
and	O
higher	O
homologue	O
naturally	O
occurring	O
substituted	O
psilocin	B-Drug
well	O
being	O
4-hydroxyl	O
analog	O
MPT	O

Vendors	O
would	O
import	O
25I-NBOMe	B-Drug
in	O
bulk	O
E	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

Food	O
and	O
Drug	O
Administration	O
FDA;	O
the	O
marketing	O
distribution	O
of	O
opium	B-Drug
tincture	O
prevails	O
today	O
only	O
because	O
was	O
sold	O
prior	O
to	O
Federal	O
&	O
Cosmetic	O
Act	O
1938	O

Some	O
fentanyl	B-Drug
analogues	O
such	O
as	O
carfentanil	B-Drug
are	O
up	O
to	O
~10000	O
times	O
stronger	O
than	O
morphine	B-Drug

It	O
is	O
not	O
safe	O
to	O
use	O
nicotine	B-Drug
during	O
pregnancy	O
or	O
breastfeeding	O
although	O
it	O
safer	O
than	O
smoking;	O
the	O
desirability	O
of	O
NRT	O
in	O
therefore	O
debated	O

PCP	B-Drug
may	O
cause	O
hallucinations	O
distorted	O
perceptions	O
of	O
sounds	O
and	O
violent	O
behavior	O

Mannitol	B-Drug
is	O
commonly	O
produced	O
via	O
the	O
hydrogenation	O
of	O
fructose	O
which	O
formed	O
from	O
either	O
starch	O
or	O
sucrose	O
common	O
table	O
sugar	O

However	O
when	O
GHB	B-Drug
is	O
consumed	O
for	O
recreational	O
or	O
health	O
promotion	O
purposes	O
its	O
concentration	O
in	O
the	O
body	O
much	O
higher	O
than	O
normal	O
which	O
changes	O
enzyme	O
kinetics	O
so	O
that	O
these	O
pathways	O
operate	O
to	O
metabolise	O
rather	O
producing	O
it	O

This	O
causes	O
increased	O
release	O
of	O
dopamine	O
in	O
the	O
brain	O
which	O
is	O
reason	O
for	O
euphoric	O
and	O
rewarding	O
effects	O
heroin	B-Drug

Norethisterone	B-Drug
was	O
the	O
first	O
highly	O
active	O
oral	O
progestogen	O
to	O
be	O
synthesized	O
and	O
preceded	O
as	O
a	O
by	O
progesterone	O
1934	O
ethisterone	O
1938	O
19-norprogesterone	O
1944	O
17-methylprogesterone	O
1949	O
well	O
nandrolone	B-Drug
1950	O
whereas	O
noretynodrel	O
1952	O
norethandrolone	B-Drug
1953	O
followed	O
synthesis	O
of	O
norethisterone	B-Drug

In	O
cell-based	O
in	O
vitro	O
research	O
oliceridine	B-Drug
elicits	O
robust	O
G	O
protein	O
signaling	O
with	O
potency	O
and	O
efficacy	O
similar	O
to	O
that	O
of	O
morphine	B-Drug
but	O
less	O
-arrestin	O
2	O
recruitment	O
receptor	O
internalization	O

Codeine/paracetamol	O
also	O
known	O
as	O
codeine/acetaminophen	O
and	O
co-codamol	O
is	O
a	O
compound	O
analgesic	O
consisting	O
of	O
combination	O
codeine	B-Drug
phosphate	I-Drug
paracetamol	B-Drug
acetaminophen	B-Drug
Codeine	B-Drug

The	O
following	O
drugs	O
should	O
be	O
avoided	O
when	O
taking	O
amobarbital:	O
Antiarrhythmics	O
such	O
as	O
verapamil	B-Drug
and	O
digoxin	B-Drug
Antiepileptics	O
phenobarbital	B-Drug
or	O
carbamazepine	B-Drug
Antihistamines	O
doxylamine	B-Drug
clemastine	O
Antihypertensives	O
atenolol	O
propranolol	B-Drug
Ethanol	O
Benzodiazepines	O
diazepam	B-Drug
clonazepam	B-Drug
nitrazepam	B-Drug
alprazolam	B-Drug
lorazepam	B-Drug
Chloramphenicol	B-Drug
Chlorpromazine	B-Drug
Cyclophosphamide	B-Drug
Ciclosporin	B-Drug
Digitoxin	O
Doxorubicin	B-Drug
Doxycycline	B-Drug
Methoxyflurane	O
Metronidazole	B-Drug
Narcotic	O
analgesics	O
morphine	B-Drug
oxycodone	B-Drug
Quinine	B-Drug
Steroids	O
prednisone	B-Drug
cortisone	O
Theophylline	B-Drug
Warfarin	B-Drug
Amobarbital	B-Drug
has	O
been	O
known	O
to	O
decrease	O
the	O
effects	O
of	O
hormonal	O
birth	O
control	O
sometimes	O
point	O
uselessness	O
amobarbital	B-Drug

Apalutamide	B-Drug
was	O
originated	O
by	O
the	O
University	O
of	O
California	O
system	O
and	O
developed	O
primarily	O
Janssen	O
Research	O
&	O
Development	O
a	O
division	O
Johnson	O

All	O
of	O
these	O
derivatives	O
are	O
likely	O
to	O
share	O
some	O
their	O
psychoactive	O
effects	O
with	O
PCP	B-Drug
itself	O
although	O
a	O
range	O
potencies	O
and	O
varying	O
mixtures	O
anesthetic	O
dissociative	O
stimulant	O
known	O
depending	O
on	O
the	O
particular	O
drug	O
its	O
substituents	O

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States	O

If	O
you	O
develop	O
signs	O
of	O
allergy	O
such	O
as	O
a	O
rash	O
or	O
difficulty	O
breathing	O
stop	O
taking	O
hydrocodone	B-Drug
bitartrate	O
and	O
paracetamol	B-Drug
tablets	O
contact	O
your	O
healthcare	O
provider	O
immediately	O

Heroin	B-Drug
purity	O
has	O
been	O
classified	O
into	O
four	O
grades	O

As	O
of	O
August	O
2015	O
Gilead	O
had	O
licensed	O
its	O
partners	O
in	O
India	O
to	O
sell	O
sofosbuvir	B-Drug
Algeria	O

Racecadotril	O
is	O
used	O
for	O
the	O
treatment	O
of	O
acute	O
diarrhea	O
in	O
children	O
and	O
adults	O
has	O
better	O
tolerability	O
than	O
loperamide	B-Drug
as	O
it	O
causes	O
less	O
constipation	O
flatulence	O

Studies	O
from	O
the	O
2000s	O
and	O
2010s	O
are	O
conflicted	O
on	O
whether	O
PCE	O
adolescents	O
at	O
greater	O
risk	O
for	O
use	O
of	O
drugs	O
such	O
as	O
cocaine	B-Drug
alcohol	O
marijuana	O

Due	O
to	O
this	O
issue	O
the	O
usefulness	O
of	O
oral	O
naltrexone	B-Drug
in	O
opioid	O
use	O
disorders	O
is	O
limited	O
by	O
low	O
retention	O
treatment	O

In	O
1991	O
the	O
sales	O
of	O
flunitrazepam	B-Drug
and	O
triazolam	B-Drug
fell	O
but	O
five	O
unrestricted	O
benzodiazepines	O
increased	O

Due	O
to	O
its	O
short	O
half-life	O
triazolam	B-Drug
is	O
not	O
effective	O
for	O
patients	O
who	O
experience	O
frequent	O
awakenings	O
or	O
early	O
wakening	O

Moreover	O
caution	O
has	O
been	O
recommended	O
when	O
prescribing	O
finasteride	B-Drug
to	O
transgender	O
women	O
as	O
may	O
be	O
associated	O
with	O
side	O
effects	O
such	O
depression	O
anxiety	O
and	O
suicidal	O
ideation	O
symptoms	O
that	O
are	O
particularly	O
prevalent	O
in	O
the	O
population	O
others	O
at	O
high	O
risk	O
already	O

This	O
group	O
includes	O
terpene-like	O
and	O
steroid-like	O
alkaloids	O
as	O
well	O
purine-like	O
such	O
caffeine	O
theobromine	O
theacrine	O
theophylline	B-Drug

Because	O
of	O
these	O
active	O
metabolites	O
the	O
serum	O
values	O
diazepam	B-Drug
alone	O
are	O
not	O
useful	O
in	O
predicting	O
effects	O
drug	O

Androstenedione	B-Drug
is	O
currently	O
banned	O
by	O
the	O
U	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco	B-Drug
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine	B-Drug

On	O
July	O
5	O
2010	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile	O
Alabama	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription	O

Selegiline	B-Drug
was	O
approved	O
for	O
Parkinson's	O
disease	O
by	O
the	O
FDA	O
in	O
1989	O

It	O
is	O
closely	O
related	O
to	O
enzalutamide	B-Drug
and	O
apalutamide	B-Drug

The	O
article	O
states:	O
high	O
risk-factor	O
obtained	O
is	O
a	O
product	O
not	O
of	O
the	O
fact	O
that	O
so	O
many	O
marijuana	O
users	O
use	O
cocaine	B-Drug
but	O
used	O
previously	O

Pregabalin	B-Drug
was	O
found	O
to	O
possess	O
6-fold	O
higher	O
affinity	O
than	O
gabapentin	B-Drug
for	O
2	O
subunit-containing	O
VDCCs	O
in	O
one	O
study	O

Its	O
action	O
and	O
degree	O
of	O
relation	O
to	O
pethidine	B-Drug
means	O
that	O
it	O
may	O
be	O
controlled	O
in	O
those	O
countries	O
which	O
have	O
laws	O
about	O
controlled-substance	O
analogues;	O
is	O
not	O
itself	O
listed	O
the	O
Controlled	O
Substances	O
Act	O
1970	O

It	O
is	O
around	O
half	O
the	O
potency	O
of	O
morphine	B-Drug
as	O
an	O
analgesic	O
and	O
has	O
been	O
widely	O
used	O
for	O
treatment	O
pain	O

In	O
contrast	O
a	O
systematic	O
review	O
documents	O
moderate	O
and	O
growing	O
evidence	O
that	O
retail	O
greater	O
availability	O
is	O
associated	O
with	O
relapse	O
to	O
smoked	O
tobacco	B-Drug

Amphetamine	B-Drug
improves	O
endurance	O
and	O
reaction	O
time	O
primarily	O
through	O
reuptake	O
inhibition	O
release	O
of	O
dopamine	O
in	O
the	O
central	O
nervous	O
system	O

On	O
8	O
May	O
2008	O
Grnenthal	O
announced	O
it	O
would	O
voluntarily	O
pay	O
further	O
50	O
million	O
to	O
the	O
Thalidomide	B-Drug
Foundation	O
help	O
improve	O
lives	O
of	O
thalidomide	B-Drug
victims	O

The	O
effects	O
of	O
tamoxifen	B-Drug
on	O
breast	O
cancer	O
Ki-67	O
expression	O
sex	O
hormone-binding	O
globulin	O
SHBG	O
levels	O
and	O
IGF-1	O
are	O
dose-dependent	O
across	O
a	O
dosage	O
range	O
1	O
to	O
20	O
mg/day	O
in	O
women	O
with	O

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds	O

There	O
are	O
no	O
specific	O
antidotes	O
available	O
for	O
ethchlorvynol	B-Drug
and	O
treatment	O
is	O
supportive	O
with	O
protocols	O
resembling	O
those	O
the	O
of	O
barbiturate	O
overdose	O

Subsequently	O
other	O
benzomorphans	O
such	O
as	O
pentazocine	B-Drug
an	O
N-dimethylallylbenzomorphan	O
cyclazocine	O
N-cyclopropylmethylbenzomorphan	O
and	O
phenazocine	B-Drug
N-phenylethylbenzomorphan	O
were	O
developed	O
some	O
have	O
been	O
marketed	O
for	O
use	O
analgesics	O

Benzodiazepines	O
including	O
diazepam	B-Drug
nitrazepam	B-Drug
and	O
flunitrazepam	B-Drug
account	O
for	O
the	O
largest	O
volume	O
of	O
forged	O
drug	O
prescriptions	O
in	O
Sweden	O
a	O
total	O
52%	O
forgeries	O
being	O
benzodiazepines	O

Efflux	O
by	O
P-glycoprotein	O
in	O
the	O
intestinal	O
wall	O
reduces	O
passage	O
of	O
loperamide	B-Drug
and	O
fraction	O
drug	O
crossing	O
is	O
then	O
further	O
reduced	O
through	O
first-pass	O
metabolism	O
liver	O

As	O
of	O
August	O
2015	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States	O

Thalidomide	B-Drug
was	O
studied	O
in	O
a	O
Phase	O
II	O
trial	O
for	O
Kaposi's	O
sarcoma	O
rare	O
soft-tissue	O
cancer	O
most	O
commonly	O
seen	O
the	O
immunocompromised	O
that	O
is	O
caused	O
by	O
sarcoma-associated	O
herpesvirus	O
KSHV	O

Foreign	O
traders	O
including	O
those	O
employed	O
by	O
Jardine	O
Matheson	O
and	O
the	O
East	O
India	O
Company	O
smuggled	O
opium	B-Drug
into	O
China	O
in	O
order	O
to	O
balance	O
high	O
trade	O
deficits	O

Pure	O
lorazepam	B-Drug
is	O
an	O
almost	O
white	O
powder	O
that	O
nearly	O
insoluble	O
in	O
water	O
and	O
oil	O

1980	O
saw	O
the	O
publication	O
of	O
first	O
trial	O
to	O
show	O
that	O
tamoxifen	B-Drug
given	O
in	O
addition	O
chemotherapy	O
improved	O
survival	O
for	O
patients	O
with	O
early	O
breast	O
cancer	O

As	O
such	O
norgestrel	B-Drug
is	O
identical	O
in	O
its	O
hormonal	O
activity	O
to	O
levonorgestrel	B-Drug
except	O
that	O
it	O
half	O
as	O
potent	O
by	O
weight	O

Unlike	O
other	O
steroidal	O
antiandrogens	O
like	O
cyproterone	O
acetate	O
but	O
similarly	O
to	O
nonsteroidal	O
bicalutamide	B-Drug
and	O
enzalutamide	B-Drug
EM-5854	O
is	O
a	O
pure	O
or	O
silent	O
antagonist	O
of	O
the	O
AR	O
shows	O
no	O
intrinsic	O
partial	O
androgenic	O
activity	O

Natural	O
genetic	O
variation	O
in	O
these	O
enzymes	O
can	O
also	O
influence	O
the	O
clearance	O
of	O
oxycodone	B-Drug
which	O
may	O
be	O
related	O
to	O
wide	O
inter-individual	O
variability	O
its	O
half-life	O
and	O
potency	O

Fry	O
or	O
sherm	O
are	O
street	O
terms	O
for	O
marijuana	O
tobacco	O
cigarettes	O
that	O
dipped	O
in	O
PCP	B-Drug
and	O
then	O
dried	O

As	O
examples	O
fluoxetine	B-Drug
and	O
paroxetine	B-Drug
inhibitors	O
of	O
these	O
enzymes	O
are	O
known	O
to	O
modestly	O
increase	O
mirtazapine	B-Drug
levels	O
while	O
carbamazepine	B-Drug
an	O
inducer	O
considerably	O
decreases	O
them	O

Metolazone	O
is	O
around	O
ten	O
times	O
as	O
potent	O
hydrochlorothiazide	B-Drug

While	O
pasteurization	O
killed	O
bacteria	O
it	O
also	O
destroyed	O
vitamin	B-Drug
C	I-Drug

When	O
first	O
introduced	O
in	O
Germany	O
during	O
World	O
War	O
I	O
both	O
IV	O
and	O
IM	O
administrations	O
of	O
oxycodone	B-Drug
were	O
commonly	O
used	O
for	O
postoperative	O
pain	O
management	O
Central	O
Powers	O
soldiers	O

The	O
street	O
name	O
in	O
Russia	O
for	O
homemade	O
desomorphine	B-Drug
is	O
krokodil	O
Russian:	O
crocodile	O
possibly	O
related	O
to	O
the	O
chemical	O
of	O
precursor	O
-chlorocodide	O
or	O
resemblance	O
skin	O
damage	O
caused	O
by	O
drug	O
a	O
crocodile's	O
leather	O

Ritonavir	B-Drug
is	O
thought	O
to	O
enhance	O
or	O
prolong	O
the	O
effects	O
of	O
some	O
street	O
drugs	O
such	O
as	O
MDMA	B-Drug

Administration	O
of	O
theophylline	B-Drug
or	O
aminophylline	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
sedative	O
effects	O
temazepam	B-Drug
and	O
other	O
benzodiazepines	O

Many	O
people	O
thought	O
that	O
the	O
American	O
government	O
had	O
introduced	O
pathogens	O
into	O
Afghanistan	O
atmosphere	O
in	O
order	O
to	O
destroy	O
opium	B-Drug
crop	O
and	O
thus	O
starve	O
insurgents	O
of	O
income	O

Compared	O
to	O
heroin	B-Drug
it	O
is	O
more	O
potent	O
has	O
higher	O
profit	O
margins	O
and	O
because	O
compact	O
simpler	O
logistics	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety	O
agitation	O
and	O
in	O
rare	O
cases	O
generally	O
with	O
non-regular	O
JWH	O
users	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC	O

This	O
may	O
be	O
due	O
to	O
increased	O
seizures	O
during	O
use	O
and	O
decreased	O
production	O
of	O
the	O
precursor	O
chemicals	O
used	O
manufacture	O
MDMA	B-Drug

government	O
statistics	O
show	O
that	O
a	O
significant	O
reduction	O
in	O
leftover	O
coca	B-Drug
total	O
cultivation	O
minus	O
eradicated	O
has	O
been	O
observed	O
from	O
peak	O
2001	O
levels	O
of	O
1698	O
square	O
kilometers	O
to	O
an	O
estimated	O
1140	O
2004	O

A	O
shorter	O
12-hour	O
extended-release	O
formulation	O
is	O
available	O
under	O
the	O
brand	O
Adderall	B-Drug
XR	O
and	O
designed	O
to	O
provide	O
a	O
therapeutic	O
effect	O
plasma	O
concentrations	O
identical	O
taking	O
two	O
doses	O
4	O
hours	O
apart	O

A	O
less	O
expensive	O
alternative	O
is	O
dopamine	O
antagonists	O
such	O
as	O
domperidone	O
and	O
metoclopramide	B-Drug

If	O
caught	O
selling	O
or	O
possessing	O
heroin	B-Drug
a	O
perpetrator	O
can	O
be	O
charged	O
with	O
felony	O
and	O
face	O
twofour	O
years	O
in	O
prison	O
could	O
fined	O
to	O
maximum	O
of	O
$20000	O

25I-NBOMe	B-Drug
induces	O
a	O
head-twitch	O
response	O
in	O
mice	O
which	O
is	O
blocked	O
completely	O
by	O
selective	O
5-HT2A	O
antagonist	O
suggesting	O
its	O
psychedelic	O
effects	O
are	O
mediated	O

Research	O
also	O
indicates	O
that	O
PCP	B-Drug
inhibits	O
nicotinic	O
acetylcholine	O
receptors	O
nAChRs	O
among	O
other	O
mechanisms	O

Illicit	O
synthesis	O
of	O
dihydroheroin	O
from	O
morphine	B-Drug
has	O
been	O
reported	O
and	O
a	O
cook	O
interviewed	O
for	O
National	O
Geographic	O
documentary	O
on	O
drugs	O
in	O
Vancouver	O
lists	O
it	O
along	O
with	O
hydromorphone	B-Drug
heroin	B-Drug
4-methylaminorex	B-Drug
stimulant	O
amongst	O
the	O
products	O
he	O
prepares	O

Opium	B-Drug
tincture	O
is	O
almost	O
always	O
dosed	O
in	O
drops	O
or	O
fractions	O
of	O
a	O
mL	O
less	O
commonly	O
minims	O
while	O
paregoric	O
teaspoons	O
tablespoons	O

Kratom	B-Drug
dried	O
leaves	O
of	O
the	O
tree	O
drank	O
for	O
its	O
medicinal	O
and	O
stimulant	O
effects	O

The	O
Soviet-Afghan	O
war	O
led	O
to	O
increased	O
production	O
in	O
the	O
Pakistani-Afghan	O
border	O
regions	O
as	O
US-backed	O
mujaheddin	O
militants	O
raised	O
money	O
for	O
arms	O
from	O
selling	O
opium	B-Drug
contributing	O
heavily	O
modern	O
Golden	O
Crescent	O
creation	O

First-generation	O
antihistamines	O
such	O
as	O
tripelennamine	O
Pyrabenzamine	O
clemastine	O
Tavist	O
hydroxyzine	O
Atarax	O
diphenhydramine	B-Drug
Benadryl	O
cyproheptadine	B-Drug
Periactin	O
brompheniramine	B-Drug
Dimetapp	O
chlorphenamine	B-Drug
Chlor-Trimeton	O
doxylamine	B-Drug
NyQuil	O
and	O
phenyltoloxamine	O
Percogesic	O
Original	O
Formula	O
not	O
only	O
combat	O
the	O
histamine-driven	O
side-effects	O
but	O
are	O
analgesic-sparing	O
potentiating	O
in	O
various	O
degrees	O

On	O
July	O
26	O
2007	O
the	O
government	O
unsealed	O
indictments	O
charging	O
16	O
BMF	O
members	O
in	O
Atlanta	O
with	O
conspiracy	O
to	O
distribute	O
cocaine	B-Drug

One	O
notable	O
example	O
is	O
the	O
fact	O
that	O
nicocodeine	B-Drug
a	O
Schedule	O
I/Narcotic	O
controlled	O
substance	O
in	O
United	O
States	O
along	O
with	O
heroin	B-Drug
as	O
was	O
never	O
introduced	O
for	O
medical	O
use	O

Canada	O
criminalized	O
cannabis	O
in	O
The	O
Opium	B-Drug
and	O
Narcotic	O
Drug	O
Act	O
1923	O
before	O
any	O
reports	O
of	O
the	O
use	O
drug	O
but	O
eventually	O
legalized	O
its	O
consumption	O
for	O
recreational	O
medicinal	O
purposes	O
2018	O

As	O
of	O
2013	O
Shire	O
plc	O
the	O
company	O
that	O
held	O
original	O
patent	O
for	O
Adderall	B-Drug
and	O
XR	O
still	O
manufactured	O
brand	O
name	O
but	O
not	O
IR	O

Progesterone	O
through	O
its	O
neurosteroid	O
active	O
metabolites	O
such	O
as	O
5-dihydroprogesterone	O
and	O
allopregnanolone	B-Drug
acts	O
indirectly	O
a	O
positive	O
allosteric	O
modulator	O
of	O
the	O
GABAA	O
receptor	O

Low	O
oral	O
bioavailability	O
of	O
ketamine	B-Drug
is	O
due	O
to	O
the	O
first-pass	O
effect	O
and	O
possibly	O
intestinal	O
metabolism	O
by	O
CYP3A4	O

Children	O
who	O
were	O
exposed	O
to	O
cocaine	B-Drug
might	O
be	O
teased	O
by	O
others	O
knew	O
of	O
the	O
exposure	O
and	O
problems	O
these	O
children	O
had	O
misdiagnosed	O
doctors	O
or	O
as	O
resulting	O
from	O
PCE	O
when	O
they	O
may	O
really	O
have	O
been	O
due	O
factors	O
like	O
illness	O
abuse	O

Between	O
1980	O
and	O
1989	O
57%	O
of	O
studies	O
showing	O
cocaine	B-Drug
has	O
effects	O
on	O
a	O
fetus	O
were	O
accepted	O
by	O
the	O
Society	O
for	O
Pediatric	O
Research	O
compared	O
with	O
only	O
11%	O
no	O

The	O
anticonvulsant	O
properties	O
of	O
lorazepam	B-Drug
and	O
other	O
benzodiazepines	O
may	O
be	O
in	O
part	O
or	O
entirely	O
due	O
to	O
binding	O
voltage-dependent	O
sodium	O
channels	O
rather	O
than	O
benzodiazepine	O
receptors	O

As	O
so-called	O
androgenic	O
tissues	O
such	O
as	O
skin/hair	O
follicles	O
and	O
male	O
reproductive	O
are	O
very	O
high	O
in	O
5-reductase	O
expression	O
while	O
skeletal	O
muscle	O
is	O
virtually	O
devoid	O
of	O
this	O
may	O
primarily	O
explain	O
the	O
myotrophicandrogenic	O
ratio	O
dissociation	O
seen	O
with	O
nandrolone	B-Drug
well	O
various	O
other	O
AAS	O

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21	O
2016	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O

Most	O
of	O
these	O
overdose	O
deaths	O
were	O
due	O
to	O
illegally	O
made	O
fentanyl	B-Drug

A	O
similar	O
study	O
of	O
2003	O
urine	O
samples	O
victims	O
suspected	O
drug-facilitated	O
sexual	O
assaults	O
found	O
less	O
than	O
2%	O
tested	O
positive	O
for	O
Rohypnol	B-Drug
or	O
GHB	B-Drug

The	O
Melbourne	O
Australia	O
inner-city	O
suburbs	O
of	O
Richmond	O
and	O
Abbotsford	O
are	O
locations	O
in	O
which	O
the	O
use	O
dealing	O
heroin	B-Drug
has	O
been	O
concentrated	O
for	O
a	O
protracted	O
time	O
period	O

Desomorphine	B-Drug
was	O
used	O
in	O
Switzerland	O
under	O
the	O
brand	O
name	O
Permonid	O
and	O
described	O
as	O
having	O
a	O
fast	O
onset	O
short	O
duration	O
of	O
action	O
with	O
relatively	O
little	O
nausea	O
compared	O
to	O
equivalent	O
doses	O
morphine	B-Drug

In	O
1964	O
the	O
Brain	O
Committee	O
recommended	O
that	O
only	O
selected	O
approved	O
doctors	O
working	O
at	O
specialized	O
centres	O
be	O
allowed	O
to	O
prescribe	O
diamorphine	B-Drug
and	O
cocaine	B-Drug
users	O

Brazilian	O
footballer	O
assistant	O
Robson	O
Oliveira	O
was	O
arrested	O
in	O
2019	O
upon	O
arriving	O
Russia	O
with	O
methadone	B-Drug
tablets	O
sold	O
legally	O
other	O
countries	O
and	O
has	O
been	O
jail	O
since	O
then	O
for	O
what	O
considered	O
drug	O
trafficking	O
under	O
Russian	O
law	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl	B-Drug
people	O
can	O
also	O
experience	O
paradoxical	O
coughing	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood	O

25I-NBOMe	B-Drug
has	O
similar	O
effects	O
to	O
LSD	B-Drug
though	O
users	O
report	O
more	O
negative	O
while	O
under	O
the	O
influence	O
and	O
risk	O
of	O
harm	O
following	O
use	O
as	O
compared	O
classical	O
psychedelics	O

Norethandrolone	B-Drug
has	O
been	O
studied	O
for	O
use	O
in	O
male	O
hormonal	O
contraception	O

In	O
the	O
recent	O
era	O
of	O
cannabis	O
breeding	O
higher-ratio	O
CBD	B-Drug
strains	O
are	O
being	O
developed	O
from	O
Indica	O
origins	O
that	O
may	O
test	O
out	O
as	O
1:1	O
CBD-THC	O
balanced	O
or	O
even	O
high	O
a	O
22:1	O
dominant	O

DMT	O
is	O
produced	O
in	O
many	O
species	O
of	O
plants	O
often	O
conjunction	O
with	O
its	O
close	O
chemical	O
relatives	O
5-methoxy-NN-dimethyltryptamine	O
5-MeO-DMT	B-Drug
and	O
bufotenin	B-Drug
5-OH-DMT	B-Drug

Taking	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
in	O
conjunction	O
with	O
hydromorphone	B-Drug
may	O
increase	O
side	O
effects	O
dizziness	O
and	O
difficulty	O
concentrating	O

For	O
its	O
use	O
in	O
reducing	O
colon	O
polyps	O
celecoxib	B-Drug
affects	O
genes	O
and	O
pathways	O
involved	O
inflammation	O
malignant	O
transformation	O
tumors	O
but	O
not	O
normal	O
tissues	O

In	O
children	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated	O

The	O
speed	B-Drug
and	O
severity	O
of	O
withdrawal	O
depends	O
on	O
the	O
half-life	O
opioid;	O
heroin	O
morphine	B-Drug
occur	O
more	O
quickly	O
than	O
methadone	B-Drug

Fluoxymesterone	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
2	O
5	O
and	O
10	O
mg	O
oral	O
tablets	O

9	O
metric	O
tons	O
of	O
illicit	O
amphetamine	B-Drug
were	O
seized	O
within	O
EU	O
member	O
states;	O
the	O
street	O
price	O
ranged	O
from	O
638	O
per	O
gram	O
during	O
same	O
period	O

For	O
both	O
emergency	O
and	O
palliative	O
use	O
intranasal	O
fentanyl	B-Drug
is	O
available	O
in	O
doses	O
of	O
50	O
100	O
200	O
g	O

Thus	O
zolpidem	B-Drug
favours	O
binding	O
to	O
GABAA	O
receptors	O
located	O
in	O
the	O
brain	O
rather	O
spine	O

Ziegler's	O
work	O
resulted	O
in	O
the	O
production	O
of	O
methandrostenolone	B-Drug
which	O
Ciba	O
Pharmaceuticals	O
marketed	O
as	O
Dianabol	B-Drug

This	O
is	O
significant	O
because	O
a	O
urine	O
immunoassay	O
drug	O
screen	O
typically	O
tests	O
for	O
morphine	B-Drug
which	O
metabolite	O
of	O
number	O
legal	O
and	O
illegal	O
opiates/opioids	O
such	O
as	O
codeine	B-Drug
sulfate	I-Drug
heroin	B-Drug

Symptoms	O
of	O
an	O
overdose	O
include:	O
Coma	O
Hypoventilation	O
respiratory	O
depression	O
Somnolence	O
drowsiness	O
Slurred	O
speech	O
SeizuresDeath	O
can	O
occur	O
from	O
triazolam	B-Drug
but	O
is	O
more	O
likely	O
to	O
in	O
combination	O
with	O
other	O
depressant	O
drugs	O
such	O
as	O
opioids	O
alcohol	O
or	O
tricyclic	O
antidepressants	O

loprazolam	B-Drug
lormetazepam	B-Drug
temazepam	B-Drug

The	O
report	O
made	O
109	O
recommendations	O
aimed	O
to	O
strengthen	O
the	O
NSW	O
Governments	O
response	O
regarding	O
amphetamine-based	O
drugs	O
such	O
as	O
crystal	B-Drug
meth	I-Drug
or	O
ice	O

If	O
consumed	O
with	O
alcohol	O
cocaine	B-Drug
combines	O
in	O
the	O
liver	O
to	O
form	O
cocaethylene	B-Drug

In	O
fact	O
no	O
Shire	O
manufacturing	O
facility	O
other	O
than	O
the	O
Rexar	O
it	O
had	O
acquired	O
produced	O
immediate-release	O
Adderall	B-Drug
at	O
any	O
time	O

21	O
nM	O
making	O
it	O
more	O
potent	O
than	O
the	O
commonly	O
used	O
full	O
agonist	O
HU-210	B-Drug

District	O
Courts	O
for	O
the	O
Western	O
of	O
Pennsylvania	O
Virginia	O
and	O
Columbia	O
used	O
these	O
cases	O
to	O
create	O
one-to-one	O
sentencing	O
ratios	O
crack	O
cocaine	B-Drug
powder	O

Currently	O
over	O
80	O
long-term	O
heroin	B-Drug
addicts	O
who	O
have	O
not	O
been	O
helped	O
by	O
available	O
treatment	O
options	O
are	O
taking	O
part	O
in	O
the	O
North	O
American	O
Opiate	O
Medication	O
Initiative	O
NAOMI	O
trials	O

Long-term	O
exposure	O
to	O
MDMA	B-Drug
in	O
humans	O
has	O
been	O
shown	O
produce	O
marked	O
neurodegeneration	O
striatal	O
hippocampal	O
prefrontal	O
and	O
occipital	O
serotonergic	O
axon	O
terminals	O

Pickard	O
would	O
always	O
arrange	O
for	O
the	O
produced	O
LSD	B-Drug
to	O
be	O
transported	O
Denver	O
Colorado	O
or	O
Boulder	O
area	O
mailed	O
picked	O
up	O
so	O
that	O
Petaluma	O
Al	O
never	O
know	O
where	O
laboratory	O
was	O
located	O

No	O
studies	O
have	O
been	O
done	O
to	O
assess	O
the	O
immunotoxic	O
effects	O
of	O
diazepam	B-Drug
in	O
humans;	O
however	O
high	O
prescribed	O
doses	O
humans	O
has	O
found	O
be	O
a	O
major	O
risk	O
pneumonia	O
based	O
on	O
study	O
people	O
with	O
tetanus	O

Into	O
the	O
early	O
1980s	O
as	O
recreational	O
market	O
slowly	O
expanded	O
production	O
of	O
MDMA	B-Drug
was	O
dominated	O
by	O
a	O
small	O
group	O
therapeutically	O
minded	O
Boston	O
chemists	O

PCP	B-Drug
works	O
primarily	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O

Most	O
commercial	O
immunoassays	O
for	O
the	O
benzodiazepine	O
class	O
of	O
drugs	O
cross-react	O
with	O
diazepam	B-Drug
but	O
confirmation	O
and	O
quantitation	O
are	O
usually	O
performed	O
using	O
chromatographic	O
techniques	O

Of	O
these	O
analogues	O
only	O
4-methyl-GHB	O
-hydroxyvaleric	O
acid	B-Drug
GHV	O
and	O
a	O
prodrug	O
form	O
-valerolactone	O
GVL	O
have	O
been	O
reported	O
as	O
drugs	O
of	O
abuse	O
in	O
humans	O
on	O
the	O
available	O
evidence	O
seem	O
to	O
be	O
less	O
potent	O
but	O
more	O
toxic	O
than	O
GHB	B-Drug
with	O
particular	O
tendency	O
cause	O
nausea	O
vomiting	O

The	O
others	O
are	O
testosterone	B-Drug
cypionate	I-Drug
enanthate	I-Drug
undecanoate	O
oxandrolone	B-Drug
oxymetholone	B-Drug
and	O
fluoxymesterone	B-Drug

Tranylcypromine	B-Drug
may	O
have	O
neuroprotective	O
properties	O
applicable	O
to	O
the	O
treatment	O
of	O
Parkinson's	O
disease	O
similar	O
MAO-B	O
inhibitors	O
selegiline	B-Drug
and	O
rasagiline	B-Drug

In	O
Dan	O
Simmonss	O
novel	O
Drood	O
2009	O
the	O
narrator	O
Wilkie	O
Collins	O
takes	O
laudanum	B-Drug
daily	O
to	O
alleviate	O
a	O
wide	O
variety	O
of	O
pains	O
as	O
well	O
induce	O
sleep	O

It	O
was	O
the	O
second	O
synthetic	O
AAS	O
to	O
be	O
developed	O
following	O
mesterolone	B-Drug
1-methyl-DHT	O
in	O
1934	O
and	O
first	O
17-alkylated	O
synthesized	O

As	O
result	O
of	O
demethylenation	O
followed	O
by	O
O-methylation	O
bk-MBDB	B-Drug
metabolises	O
into	O
4-OH-3-MeO	O
and	O
3-OH-4-MeO	O
metabolites	O
in	O
human	O
urine	O

7	O
tonnes	O
3800	O
lb	O
of	O
cocaine	B-Drug
and	O
on	O
13	O
November	O
the	O
US	O
Coast	O
Guard	O
located	O
seized	O
another	O
one	O
off	O
coast	O
Panama	O

Diamorphine	B-Drug
is	O
produced	O
from	O
acetylation	O
of	O
morphine	B-Drug
derived	O
natural	O
opium	B-Drug
sources	O

Experts	O
estimate	O
that	O
were	O
thalidomide	B-Drug
led	O
to	O
the	O
death	O
of	O
approximately	O
2000	O
children	O
and	O
serious	O
birth	O
defects	O
in	O
more	O
than	O
10000	O
about	O
5000	O
them	O
West	O
Germany	O

When	O
first	O
released	O
thalidomide	B-Drug
was	O
promoted	O
for	O
anxiety	O
trouble	O
sleeping	O
tension	O
and	O
morning	O
sickness	O

Patients	O
dependent	O
on	O
clonazepam	B-Drug
should	O
be	O
slowly	O
titrated	O
off	O
under	O
the	O
supervision	O
of	O
a	O
qualified	O
healthcare	O
professional	O
to	O
reduce	O
intensity	O
withdrawal	O
or	O
rebound	O
symptoms	O

Some	O
cocaine	B-Drug
users	O
also	O
report	O
having	O
similar	O
symptoms	O
to	O
schizophrenia	O
patients	O
and	O
feel	O
that	O
their	O
mind	O
is	O
lost	O

Diminution	O
of	O
morphine	B-Drug
self-administration	O
was	O
reported	O
in	O
preclinical	O
studies	O
by	O
Glick	O
et	O
al	O

Obetrol	B-Drug
was	O
the	O
brand	O
of	O
amphetamine	B-Drug
mixed	I-Drug
salts	I-Drug
based	O
drugs	O
indicated	O
for	O
treatment	O
exogenous	O
obesity	O
by	O
American	O
pharmaceutical	O
company	O
Pharmaceuticals	O

Pentobarbital	B-Drug
was	O
also	O
widely	O
abused	O
known	O
on	O
the	O
street	O
as	O
yellow	O
jackets	O

Meprodine	B-Drug
has	O
similar	O
effects	O
to	O
other	O
opioids	O
and	O
produces	O
analgesia	O
sedation	O
euphoria	O

The	O
duration	O
of	O
action	O
fentanyl	B-Drug
has	O
sometimes	O
been	O
underestimated	O
leading	O
to	O
harm	O
in	O
a	O
medical	O
context	O

Desmethylprodine	B-Drug
was	O
first	O
synthesized	O
in	O
1947	O
at	O
Hoffman-LaRoche	O
Laboratories	O
by	O
Albert	O
Ziering	O
and	O
John	O
Lee	O

In	O
1856	O
while	O
trying	O
to	O
synthesise	O
quinine	B-Drug
von	O
Hofmann's	O
student	O
William	O
Henry	O
Perkin	O
discovered	O
mauveine	O
and	O
went	O
into	O
industry	O
producing	O
the	O
first	O
commercial	O
synthetic	O
dye	O

Pertinent	O
questions	O
include	O
whether	O
modafinil	B-Drug
may	O
be	O
modified	O
or	O
manufactured	O
to	O
avoid	O
the	O
granularities	O
specified	O
in	O
new	O
Cephalon	O
patent	O
and	O
patenting	O
particle	O
size	O
is	O
invalid	O
because	O
particles	O
of	O
appropriate	O
sizes	O
are	O
likely	O
obvious	O
practitioners	O
skilled	O
art	O

A	O
century	O
later	O
Li	O
Shizhen	O
listed	O
standard	O
medical	O
uses	O
of	O
opium	B-Drug
in	O
his	O
renowned	O
Compendium	O
Materia	O
Medica	O
1578	O
but	O
also	O
wrote	O
that	O
lay	O
people	O
use	O
it	O
for	O
the	O
art	O
sex	O
particular	O
ability	O
to	O
arrest	O
seminal	O
emission	O

The	O
duration	O
of	O
action	O
MDMA	B-Drug
is	O
usually	O
four	O
to	O
six	O
hours	O
after	O
which	O
serotonin	O
levels	O
in	O
the	O
brain	O
are	O
depleted	O

Imipramine	B-Drug
is	O
a	O
tertiary	O
amine	O
TCA	O
with	O
its	O
side	O
chain-demethylated	O
metabolite	O
desipramine	B-Drug
being	O
secondary	O

Possession	O
of	O
kratom	B-Drug
leaves	O
Thai:	O
RTGS:	O
ton	O
krathom	O
was	O
illegal	O
in	O
Thailand	O
until	O
2018	O

In	O
the	O
United	O
States	O
in	O
1937	O
Marihuana	B-Drug
Tax	O
Act	O
was	O
passed	O
and	O
prohibited	O
production	O
of	O
hemp	O
addition	O
to	O
cannabis	O

Likewise	O
it	O
is	O
significantly	O
more	O
efficacious	O
as	O
an	O
antiandrogen	O
than	O
other	O
AR	O
antagonists	O
such	O
enzalutamide	B-Drug
and	O
spironolactone	B-Drug
in	O
scalp	O
dermal	O
papilla	O
cells	O
sebocytes	O
vitro	O

d	O
1-Phenylcyclohexylamine	O
or	O
any	O
compound	O
not	O
being	O
ketamine	B-Drug
tiletamine	B-Drug
a	O
for	O
the	O
time	O
specified	O
in	O
paragraph	O
1a	O
of	O
Part	O
1	O
this	O
Schedule	O
structurally	O
derived	O
from	O
1-phenylcyclohexylamine	O
2-amino-2-phenylcyclohexanone	O
by	O
modification	O
following	O
ways	O
that	O
is	O
to	O
say	O
i	O
substitution	O
at	O
nitrogen	O
atom	O
extent	O
alkyl	O
alkenyl	O
hydroxyalkyl	O
groups	O
replacement	O
amino	O
group	O
with	O
1-piperidyl	O
1-pyrrolidyl	O
1-azepyl	O
whether	O
containing	O
ring	O
further	O
substituted	O
one	O
more	O
groups;	O
ii	O
phenyl	O
hydroxy	O
alkoxy	O
halide	O
substituents	O
extent;	O
iii	O
cyclohexyl	O
cyclohexanone	O
substituents;	O
iv	O
thienyl	O

The	O
morphine	B-Drug
base	O
is	O
then	O
reacted	O
with	O
acetic	O
anhydride	O
which	O
forms	O
heroin	B-Drug

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia	O

Although	O
production	O
fell	O
temporarily	O
coca	B-Drug
crops	O
rebounded	O
in	O
numerous	O
smaller	O
fields	O
Colombia	O
rather	O
than	O
the	O
larger	O
plantations	O

Under	O
the	O
brand	O
name	O
Neurontin	B-Drug
it	O
was	O
first	O
approved	O
in	O
May	O
1993	O
for	O
treatment	O
of	O
epilepsy	O
United	O
Kingdom	O

This	O
greatly	O
reduced	O
the	O
clinical	O
research	O
about	O
LSD	B-Drug
although	O
limited	O
experiments	O
continued	O
to	O
take	O
place	O
such	O
as	O
those	O
conducted	O
by	O
Reese	O
Jones	O
in	O
San	O
Francisco	O

Naldemedine	B-Drug
tosylate	O
has	O
46	O
other	O
patents	O
in	O
18	O
different	O
countries	O

At	O
higher	O
doses	O
it	O
becomes	O
much	O
more	O
psychedelic	O
sometimes	O
being	O
compared	O
to	O
5-MeO-DMT	B-Drug

The	O
methamphetamine	B-Drug
produced	O
by	O
this	O
method	O
is	O
racemic	O
consisting	O
partly	O
of	O
the	O
less-desired	O
levomethamphetamine	B-Drug
isomer	O
though	O
separation	O
two	O
enantiomeric	O
forms	O
through	O
selective	O
recrystallization	O
tartrate	O
salt	O
can	O
occur	O
in	O
order	O
to	O
isolate	O
more	O
active	O
dextromethamphetamine	B-Drug

However	O
cocaine	B-Drug
is	O
more	O
active	O
in	O
the	O
dopaminergic	O
neurons	O
of	O
ventral	O
tegmental	O
area	O
than	O
substantia	O
nigra	O

Professor	O
Fiona	O
Measham	O
who	O
led	O
a	O
smoking-related	O
research	O
project	O
stated	O
Among	O
some	O
more	O
experienced	O
vapers	O
prioritise	O
competency	O
in	O
'cloud	O
chasing'	O
skills	O
nicotine	B-Drug
is	O
actively	O
avoided	O
as	O
it	O
could	O
disrupt	O
their	O
vaping	O
'performances'	O
particularly	O
given	O
the	O
quantities	O
consumed	O

For	O
example	O
in	O
ovarian	O
follicles	O
cholesterol	O
is	O
converted	O
to	O
androstenedione	B-Drug
an	O
androgen	O
the	O
theca	O
cells	O
which	O
then	O
further	O
into	O
estrogen	O
granulosa	O

Unlike	O
enzalutamide	B-Drug
bicalutamide	B-Drug
is	O
not	O
associated	O
with	O
seizures	O
or	O
related	O
central	O
side	O
effects	O
like	O
anxiety	O
and	O
insomnia	O

All	O
drugs	O
in	O
the	O
NBOMe	O
family	O
including	O
25I-NBOMe	B-Drug
are	O
illegal	O

Notable	O
batches	O
of	O
pills	O
containing	O
PMA	B-Drug
have	O
included	O
Louis	O
Vuitton	O
Mitsubishi	O
Turbo	O
Blue	O
Transformers	O
Red/Blue	O
and	O
Yellow	O
Euro	O

When	O
authorities	O
searched	O
his	O
Sunnyvale	O
California	O
home	O
they	O
found	O
five	O
drums	O
of	O
precursor	O
chemicals	O
needed	O
to	O
manufacture	O
synthetic	B-Drug
mescaline	I-Drug

Cannabidiol	B-Drug
is	O
listed	O
in	O
the	O
EU	O
Cosmetics	O
Ingredient	O
Database	O
CosIng	O

Several	O
serotonergic	O
recreational	O
drugs	O
including	O
the	O
empathogens	O
MDA	O
and	O
MDMA	B-Drug
ecstasy	B-Drug
some	O
hallucinogens	O
such	O
as	O
DOI	O
Bromo-DragonFLY	O
have	O
all	O
been	O
shown	O
to	O
act	O
5-HT2B	O
agonists	O
in	O
vitro	O
but	O
how	O
significant	O
this	O
may	O
be	O
a	O
risk	O
factor	O
associated	O
with	O
their	O
use	O
is	O
unclear	O

A	O
number	O
of	O
drug	O
interactions	O
can	O
occur	O
between	O
MDMA	B-Drug
and	O
other	O
drugs	O
including	O
serotonergic	O

Darolutamide	B-Drug
is	O
primarily	O
metabolized	O
into	O
ketodarolutamide	O
via	O
dehydrogenation	O
by	O
CYP3A4	O
in	O
the	O
liver	O

Celecoxib	B-Drug
is	O
compound	O
22;	O
the	O
4-sulfamoylphenyl	O
on	O
1-pyrazol	O
substituent	O
required	O
for	O
COX-2	O
inhibition	O
and	O
4-methyl	O
5-pyrazol	O
system	O
has	O
low	O
steric	O
hindrance	O
to	O
maximize	O
potency	O
while	O
3-trifluoromethyl	O
group	O
provides	O
superior	O
selectivity	O

Internationally	O
DET	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O

Numerous	O
professional	O
athletes	O
use	O
CBD	B-Drug
primarily	O
for	O
treating	O
pain	O

NETA	O
is	O
of	O
about	O
12%	O
higher	O
molecular	O
weight	O
than	O
norethisterone	B-Drug
due	O
to	O
the	O
presence	O
its	O
C17	O
acetate	O
ester	O

CART	O
was	O
found	O
by	O
examining	O
changes	O
in	O
the	O
brain	O
following	O
cocaine	B-Drug
or	O
amphetamine	B-Drug
administration	O

Also	O
the	O
production	O
distribution	O
sale	O
and	O
possession	O
of	O
methamphetamine	B-Drug
is	O
restricted	O
or	O
illegal	O
in	O
many	O
other	O
countries	O
due	O
to	O
its	O
placement	O
schedule	O
II	O
United	O
Nations	O
Convention	O
on	O
Psychotropic	O
Substances	O
treaty	O

The	O
Drug	O
Enforcement	O
Administration	O
DEA	O
states	O
as	O
an	O
analogue	O
of	O
methcathinone	B-Drug
possession	O
mephedrone	B-Drug
can	O
be	O
controlled	O
by	O
the	O
Federal	O
Analog	O
Act	O
but	O
according	O
to	O
Los	O
Angeles	O
Times	O
this	O
only	O
applies	O
if	O
it	O
is	O
sold	O
for	O
human	O
consumption	O

Many	O
of	O
these	O
drugs	O
are	O
extremely	O
expensive;	O
for	O
example	O
the	O
anti-cancer	O
drug	O
Avastin	B-Drug
costs	O
$55000	O
a	O
year	O
treatment	O
while	O
enzyme	O
replacement	O
therapy	O
Cerezyme	B-Drug
$200000	O
per	O
and	O
must	O
be	O
taken	O
by	O
Gaucher's	O
Disease	O
patients	O
life	O

In	O
the	O
1980s	O
and	O
1990s	O
formula	O
changed	O
to	O
using	O
codeine	B-Drug
promethazine	B-Drug
cough	O
syrup	O
somewhat	O
like	O
Glutethimide	B-Drug
combination	O
that	O
was	O
popular	O
from	O
seventies	O
up	O
early	O
nineties	O

Alvimopan	B-Drug
competitively	O
binds	O
to	O
-opioid	O
receptor	O
in	O
the	O
gastrointestinal	O
tract	O

Walter	O
White	O
first	O
synthesizes	O
methamphetamine	B-Drug
through	O
the	O
Nagai	O
route	O
using	O
red	O
phosphorus	O
and	O
iodine	O
to	O
reduce	O
pseudoephedrine	O

Robiquet	O
conducted	O
over	O
20	O
years	O
between	O
1815	O
and	O
1835	O
a	O
series	O
of	O
studies	O
in	O
the	O
enhancement	O
methods	O
for	O
isolation	O
morphine	B-Drug
also	O
isolated	O
1832	O
another	O
very	O
important	O
component	O
raw	O
opium	B-Drug
that	O
he	O
called	O
codeine	B-Drug
currently	O
widely	O
used	O
opium-derived	O
compound	O

25I-NBOMe	B-Drug
2C-I-NBOMe	B-Drug
Cimbi-5	O
also	O
shortened	O
to	O
25I	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes	O

The	O
dextrorotary	O
enantiomers	O
are	O
significantly	O
more	O
potent	O
than	O
the	O
levorotary	O
and	O
some	O
medications	O
therefore	O
only	O
contain	O
dexmethylphenidate	B-Drug

The	O
initial	O
discovery	O
of	O
spirorenone	O
was	O
deemed	O
a	O
great	O
success	O
as	O
no	O
compound	O
with	O
greater	O
antimineralocorticoid	O
activity	O
had	O
been	O
developed	O
since	O
spironolactone	B-Drug
in	O
1957	O

Following	O
amphetamine	B-Drug
uptake	O
at	O
VMAT2	O
induces	O
the	O
collapse	O
of	O
vesicular	O
pH	O
gradient	O
which	O
results	O
in	O
release	O
dopamine	O
molecules	O
from	O
synaptic	O
vesicles	O
into	O
cytosol	O
via	O
efflux	O
through	O

Brand	O
names	O
include	O
Contergan	B-Drug
Thalomid	B-Drug
Talidex	O
Talizer	O
Neurosedyn	B-Drug
Distaval	O
and	O
many	O
others	O

Eugeroics	O
armodafinil	B-Drug
and	O
modafinil	B-Drug
are	O
classified	O
as	O
wakefulness-promoting	O
agents;	O
increases	O
alertness	O
particularly	O
in	O
sleep-deprived	O
individuals	O
facilitates	O
reasoning	O
problem	O
solving	O
non-ADHD	O
youth	O

The	O
next	O
step	O
is	O
to	O
provide	O
a	O
lorazepam	B-Drug
challenge	O
in	O
which	O
patients	O
are	O
given	O
2	O
mg	O
of	O
IV	O
or	O
another	O
benzodiazepine	O

Reed	O
commented	O
that	O
the	O
song	O
provided	O
very	O
close	O
to	O
feeling	O
you	O
get	O
from	O
smack	B-Drug
stating:	O
You	O
think	O
you're	O
enjoying	O
it	O

5-MeO-MiPT	O
is	O
in	O
a	O
class	O
of	O
compounds	O
commonly	O
known	O
as	O
tryptamines	O
and	O
the	O
N-methyl-N-isopropyl	O
homologue	O
psychedelic	O
5-MeO-DMT	B-Drug

There	O
is	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
cause	O
excessive	O
blood	O
clots	O

PCP	B-Drug
works	O
primarily	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O

In	O
November	O
2016	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights	O
Utah	O

Naloxone	B-Drug
only	O
partially	O
reverses	O
the	O
toxic	O
effects	O
of	O
tramadol	B-Drug
overdose	O
and	O
may	O
increase	O
risk	O
seizures	O

However	O
this	O
perception	O
is	O
not	O
supported	O
by	O
the	O
results	O
of	O
clinical	O
studies	O
comparing	O
physiological	O
and	O
subjective	O
effects	O
injected	O
heroin	B-Drug
morphine	B-Drug
in	O
individuals	O
formerly	O
addicted	O
to	O
opioids;	O
these	O
subjects	O
showed	O
no	O
preference	O
for	O
one	O
drug	O
over	O
other	O

CBD	B-Drug
is	O
a	O
5-HT1A	O
receptor	O
agonist	O
which	O
under	O
laboratory	O
research	O
to	O
determine	O
if	O
it	O
has	O
an	O
anxiolytic	O
effect	O

Given	O
the	O
known	O
metabolic	O
liberation	O
and	O
presence	O
as	O
an	O
impurity	O
of	O
amantadine	B-Drug
in	O
related	O
compound	O
APINACA	B-Drug
it	O
is	O
suspected	O
that	O
hydrolysis	O
amide	O
group	O
APICA	O
may	O
also	O
release	O

79	O
g/mL	O
and	O
area-under-the-curve	O
levels	O
of	O
darolutamide	B-Drug
over	O
time	O
0	O
to	O
12	O
hours	O
AUC012	O
are	O
52	O

Examples	O
of	O
progonadotropic	O
drugs	O
include	O
gonadotropin-releasing	O
hormone	O
GnRH	O
agonists	O
when	O
administered	O
in	O
a	O
pulsatile	O
as	O
opposed	O
to	O
continuous	O
manner	O
antiestrogens	O
such	O
tamoxifen	B-Drug
clomifene	B-Drug
fulvestrant	B-Drug
and	O
aromatase	O
inhibitors	O
like	O
anastrozole	B-Drug
only	O
men	O
pure	O
antiandrogens	O
flutamide	O
bicalutamide	B-Drug
enzalutamide	B-Drug
apalutamide	B-Drug

Ben	O
Rodham	O
a	O
DJ	O
ingested	O
combination	O
of	O
BZP	B-Drug
and	O
MDMA	B-Drug
in	O
February	O
2007	O
which	O
nearly	O
resulted	O
his	O
death	O

The	O
carbon-11	O
labelled	O
version	O
of	O
25I-NBOMe	B-Drug
[11C]Cimbi-5	O
was	O
synthesized	O
and	O
validated	O
as	O
a	O
radiotracer	O
for	O
positron	O
emission	O
tomography	O
PET	O
in	O
Copenhagen	O

Exposure	O
to	O
cycloxygenase	O
inhibitors	O
such	O
as	O
aspirin	B-Drug
and	O
NSAIDs	O
leads	O
shunting	O
of	O
products	O
through	O
the	O
lipoxygenase	O
pathway	O
leading	O
an	O
increased	O
production	O
that	O
cause	O
inflammation	O

Desipramine	B-Drug
is	O
particularly	O
toxic	O
in	O
cases	O
of	O
overdose	O
compared	O
to	O
other	O
antidepressants	O

In	O
addition	O
to	O
its	O
anabolic	O
and	O
androgenic	O
activity	O
trenbolone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
progesterone	O
receptor	O
PR	O
in	O
relation	O
this	O
has	O
moderate	O
strong	O
progestogenic	O

In	O
a	O
procedure	O
analogous	O
to	O
the	O
production	O
of	O
other	O
amphetamines	O
4-MTA	B-Drug
has	O
been	O
prepared	O
from	O
4-methylthiophenylacetone	O
by	O
Leuckart	O
reaction	O
and	O
byproducts	O
have	O
characterized	O

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine	B-Drug

Reviews	O
of	O
magnetic	O
resonance	O
imaging	O
MRI	O
studies	O
suggest	O
that	O
long-term	O
treatment	O
with	O
amphetamine	B-Drug
decreases	O
abnormalities	O
in	O
brain	O
structure	O
and	O
function	O
found	O
subjects	O
ADHD	O
improves	O
several	O
parts	O
the	O
such	O
as	O
right	O
caudate	O
nucleus	O
basal	O
ganglia	O

A	O
clinical	O
study	O
found	O
that	O
the	O
elimination	O
half-lives	O
of	O
darolutamide	B-Drug
and	O
ketodarolutamide	O
at	O
steady-state	O
were	O
15	O

This	O
distinguishes	O
the	O
anitens	O
novel	O
molecular	O
mechanism	O
from	O
anti	O
androgens	O
that	O
bind	O
C-terminus	O
ligand-binding	O
domain	O
and	O
have	O
stem	O
class	O
lutamide	O
such	O
as	O
flutamide	O
nilutamide	O
bicalutamide	B-Drug
enzalutamide	B-Drug
etc	O

Sometimes	O
the	O
failure	O
of	O
lorazepam	B-Drug
alone	O
is	O
considered	O
to	O
be	O
enough	O
classify	O
a	O
case	O
SE	O
as	O
resistant	O
treatment	O

Brand	O
names	O
of	O
nortriptyline	B-Drug
include	O
Allegron	O
Aventyl	O
Noritren	O
Norpress	O
Nortrilen	O
Norventyl	O
Norzepine	O
Pamelor	O
and	O
Sensoval	O
among	O
many	O
others	O

Neural	O
correlates	O
of	O
the	O
LSD	B-Drug
experience	O
revealed	O
by	O
multimodal	O
neuroimaging	O

On	O
May	O
14	O
2013	O
Drugz	O
released	O
his	O
four	O
previous	O
major	O
solo	O
mixtapes	O
Flight	O
2011	O
and	O
the	O
Cocaine	B-Drug
Riot	O
series	O
for	O
retail	O
sale	O
on	O
iTunes	O

The	O
substances	O
JWH-210	O
JWH-122	B-Drug
and	O
JWH-203	B-Drug
were	O
classified	O
as	O
illegal	O
drugs	O
by	O
the	O
Swedish	O
government	O
of	O
1	O
September	O
2011	O

On	O
14	O
January	O
2015	O
diclofenac	B-Drug
oral	O
preparations	O
were	O
reclassified	O
as	O
prescription-only	O
medicines	O
in	O
the	O
UK	O

The	O
death	O
of	O
Marilyn	O
Monroe	O
in	O
1962	O
was	O
ruled	O
as	O
probable	O
suicide	O
due	O
to	O
an	O
overdose	O
pentobarbital	B-Drug

In-utero	O
exposure	O
to	O
cocaine	B-Drug
is	O
associated	O
with	O
behavioral	O
abnormalities	O
cognitive	O
impairment	O
cardiovascular	O
malformations	O
intrauterine	O
growth	O
restriction	O
preterm	O
birth	O
urinary	O
tract	O
and	O
cleft	O
lip	O
palate	O

Diazepam	B-Drug
does	O
not	O
increase	O
or	O
decrease	O
hepatic	O
enzyme	O
activity	O
and	O
alter	O
the	O
metabolism	O
of	O
other	O
compounds	O

Androstenedione	B-Drug
is	O
a	O
substrate	O
for	O
estrogen	O
production	O
in	O
granulosa	O
cells	O
which	O
produce	O
aromatase	O

During	O
alcohol	O
withdrawal	O
the	O
prophylactic	O
administration	O
of	O
thiamine	B-Drug
folic	O
acid	O
and	O
pyridoxine	B-Drug
intravenously	O
is	O
recommended	O
before	O
starting	O
any	O
carbohydrate-containing	O
fluids	O
or	O
food	O

Female	O
users	O
were	O
more	O
likely	O
than	O
men	O
to	O
be	O
using	O
heroin	B-Drug
whereas	O
male	O
report	O
amphetamine	B-Drug
use	O

The	O
opioid	O
receptor	O
affinity	O
of	O
fentanyl	B-Drug
and	O
its	O
analogs	O
was	O
determined	O
from	O
their	O
inhibitory	O
potency	O
in	O
a	O
binding	O
assay	O
with	O
[3H]	O
as	O
the	O
radioligand	O

Hydrocodone	B-Drug
works	O
by	O
binding	O
to	O
the	O
mu-opioid	O
receptor	O

28	O
mg/mL	O
solution	O
of	O
propranolol	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
proliferating	O
infantile	O
hemangioma	O

LSD	B-Drug
may	O
trigger	O
panic	O
attacks	O
or	O
feelings	O
of	O
extreme	O
anxiety	O
known	O
familiarly	O
as	O
a	O
bad	O
trip	O

Isomethadone	B-Drug
INN	O
BAN;	O
trade	O
nameLiden;	O
also	O
known	O
as	O
isoamidone	O
is	O
a	O
synthetic	O
opioid	O
analgesic	O
and	O
antitussive	O
related	O
to	O
methadone	B-Drug
that	O
was	O
used	O
formerly	O
pharmaceutical	O
drug	O
but	O
now	O
no	O
longer	O
marketed	O

Nitrazepam	B-Drug
interacts	O
with	O
the	O
antibiotic	O
erythromycin	B-Drug
a	O
strong	O
inhibitor	O
of	O
CYP3A4	O
which	O
affects	O
concentration	O
peak	O
time	O

Heroin	B-Drug
is	O
classified	O
as	O
a	O
hard	O
drug	O
in	O
terms	O
of	O
harmfulness	O

In	O
1972	O
it	O
was	O
the	O
sixth-bestselling	O
sedative	O
in	O
US	O
where	O
legal	O
under	O
brand	O
name	O
Quaalude	B-Drug

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
at	O
an	O
earlier	O
age	O
than	O
illegal	O
hard	O
drugs	O

MOHN	O
is	O
the	O
4-hydroxylated	O
derivative	O
of	O
normethandrone	O
17-methyl-19-nortestosterone	O
17-methylated	O
oxabolone	O
4-hydroxy-19-nortestosterone	O
and	O
nandrolone	B-Drug
19-nortestosterone	B-Drug
19-demethylated	O
analogue	O
oxymesterone	O
4-hydroxy-17-methyltestosterone	O
methyltestosterone	B-Drug

In	O
August	O
2011	O
there	O
was	O
a	O
double-blind	O
placebo	O
controlled	O
phase	O
II	O
trial	O
that	O
focused	O
on	O
elderly	O
men	O
and	O
postmenopausal	O
women	O
concluded	O
Enobosarm	B-Drug
showed	O
statistically	O
significant	O
improvements	O
in	O
total	O
lean	O
body	O
mass	O
physical	O
function	O
without	O
the	O
negative	O
side	O
effects	O
are	O
normally	O
present	O
with	O
steroids	O

Men	O
who	O
PNP	O
with	O
methamphetamine	B-Drug
cocaine	B-Drug
MDMA	B-Drug
and	O
ketamine	B-Drug
are	O
twice	O
as	O
likely	O
to	O
have	O
unprotected	O
sex	O
meaning	O
without	O
using	O
a	O
condom	O
according	O
British	O
research	O
from	O
2006	O

While	O
Suboxone	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
of	O
opioid	O
dependence	O
it	O
does	O
contain	O
an	O
which	O
means	O
a	O
person	O
may	O
be	O
at	O
risk	O
developing	O
to	O
as	O
well	O

Lidocaine	B-Drug
along	O
with	O
ethanol	O
ammonia	O
and	O
acetic	O
acid	O
may	O
also	O
help	O
in	O
treating	O
jellyfish	O
stings	O
both	O
numbing	O
the	O
affected	O
area	O
preventing	O
further	O
nematocyst	O
discharge	O

Nicotine	B-Drug
is	O
highly	O
addictive	O
comparable	O
to	O
heroin	B-Drug
or	O
cocaine	B-Drug

Nabilone	B-Drug
is	O
given	O
in	O
1	O
or	O
2	O
mg	O
doses	O
multiple	O
times	O
a	O
day	O
up	O
to	O
total	O
of	O
6	O

JWH-018	B-Drug
produces	O
bradycardia	O
and	O
hypothermia	O
in	O
rats	O
at	O
doses	O
of	O
0	O

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
PCP	B-Drug
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects	O

JWH-164	B-Drug
is	O
a	O
synthetic	O
cannabinoid	O
receptor	O
agonist	O
from	O
the	O
naphthoylindole	O
family	O

Liver	O
toxicity	O
of	O
ketamine	B-Drug
also	O
involves	O
higher	O
doses	O
and	O
repeated	O
administration	O

Andrey	O
Sibiryov	O
the	O
original	O
developer	O
of	O
Cocaine	B-Drug
got	O
idea	O
from	O
Heroku	O
another	O
cloud	O
platform	O
as	O
a	O
service	O

The	O
head	O
of	O
Bayer's	O
research	O
department	O
reputedly	O
coined	O
the	O
drug's	O
new	O
name	O
heroin	B-Drug
based	O
on	O
German	O
heroisch	O
which	O
means	O
heroic	O
strong	O
from	O
ancient	O
Greek	O
word	O
heros	O

Severe	O
overdose	O
resulting	O
in	O
death	O
has	O
also	O
been	O
reported	O
people	O
who	O
took	O
MDMA	B-Drug
combination	O
with	O
certain	O
monoamine	O
oxidase	O
inhibitors	O
such	O
as	O
phenelzine	B-Drug
Nardil	B-Drug
tranylcypromine	B-Drug
Parnate	B-Drug
or	O
moclobemide	O
Aurorix	O
Manerix	O

The	O
definitive	O
synthesis	O
which	O
involves	O
treating	O
anhydrous	O
codeine	B-Drug
base	O
with	O
nicotinic	O
anhydride	O
at	O
130	O
C	O
was	O
published	O
by	O
Pongratz	O
and	O
Zirm	O
in	O
Monatshefte	O
fr	O
Chemie	O
1957	O
simultaneously	O
the	O
two	O
analogues	O
an	O
article	O
about	O
amides	O
esters	O
of	O
various	O
organic	O
acids	O

The	O
medication	O
shows	O
higher	O
affinity	O
and	O
inhibitory	O
potency	O
at	O
the	O
AR	O
relative	O
to	O
enzalutamide	B-Drug
apalutamide	B-Drug
in	O
vitro	O
Ki	O
26	O
nM	O
219	O
for	O
200	O

The	O
chemical	O
names	O
for	O
barbital	B-Drug
are	O
diethylmalonyl	O
urea	O
or	O
diethylbarbituric	O
acid;	O
hence	O
the	O
sodium	O
salt	O
known	O
as	O
medinal	O
a	O
genericised	O
trademark	O
in	O
United	O
Kingdom	O
is	O
also	O
diethylbarbiturate	O

It	O
is	O
the	O
most	O
prominent	O
and	O
widely	O
used	O
of	O
thiambutenes	O
a	O
series	O
open-chain	O
opioids	O
structurally	O
related	O
to	O
methadone	B-Drug
which	O
are	O
also	O
called	O
thienyl	O
derivative	O
includes	O
diethylthiambutene	B-Drug
ethylmethylthiambutene	B-Drug
as	O
well	O
non-opioid	O
cough	O
suppressant	O
tipepidine	O

The	O
head	O
of	O
Bayer's	O
research	O
department	O
reputedly	O
coined	O
the	O
drug's	O
new	O
name	O
heroin	B-Drug
based	O
on	O
German	O
heroisch	O
which	O
means	O
heroic	O
strong	O
from	O
ancient	O
Greek	O
word	O
heros	O

Androstenedione	B-Drug
can	O
be	O
biosynthesized	O
in	O
one	O
of	O
two	O
ways	O

Diazepam	B-Drug
is	O
sometimes	O
used	O
intermittently	O
for	O
the	O
prevention	O
of	O
febrile	O
seizures	O
that	O
may	O
occur	O
in	O
children	O
under	O
five	O
years	O
age	O

Sveriges	O
riksdags	O
health	O
ministry	O
Statens	O
folkhlsoinstitut	O
classified	O
5-MeO-DMT	B-Drug
listed	O
as	O
5-metoxi-NN-dimetyltryptamin	O
in	O
their	O
regulation	O
SFS	O
2004:696	O
hazard	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health	O
October	O
2004	O
making	O
it	O
illegal	O
sell	O
or	O
possess	O

Injecting	O
diamorphine	B-Drug
users	O
are	O
encouraged	O
to	O
use	O
new	O
needles	O
syringes	O
spoons/steri-cups	O
and	O
filters	O
every	O
time	O
they	O
inject	O
not	O
share	O
these	O
with	O
other	O

SSRI/SNRI	O
withdrawal	O
syndrome	O
blood	O
pressure	O
medications	O
including	O
beta	O
blockers	O
such	O
as	O
propanolol	B-Drug
and	O
alpha-adrenergic	O
agonists	O
clonidine	B-Drug
androgenic-anabolic	O
steroids	O
glucocorticoids	O
A	O
wide	O
range	O
of	O
drugs	O
whilst	O
not	O
causing	O
a	O
true	O
physical	O
dependence	O
can	O
still	O
cause	O
symptoms	O
or	O
rebound	O
effects	O
during	O
dosage	O
reduction	O
especially	O
abrupt	O
rapid	O

One	O
MPPP	B-Drug
was	O
found	O
in	O
some	O
cases	O
to	O
contain	O
an	O
impurity	O
called	O
MPTP	O
which	O
caused	O
brain	O
damage	O
that	O
could	O
result	O
a	O
syndrome	O
identical	O
late	O
stage	O
Parkinson's	O
disease	O
from	O
only	O
single	O
dose	O

LSD	B-Drug
like	O
many	O
other	O
drugs	O
of	O
recreational	O
use	O
has	O
been	O
shown	O
to	O
activate	O
DARPP-32-related	O
pathways	O

In	O
the	O
United	O
States	O
opium	B-Drug
tincture	O
is	O
marketed	O
and	O
distributed	O
by	O
several	O
pharmaceutical	O
firms	O
each	O
producing	O
a	O
single	O
formulation	O
of	O
drug	O
which	O
deodorized	O

It	O
is	O
mainly	O
an	O
anti-anxiety	O
agent	O
with	O
similar	O
side	O
effects	O
to	O
diazepam	B-Drug
Valium	B-Drug

The	O
bioavailability	O
of	O
spironolactone	B-Drug
when	O
taken	O
by	O
mouth	O
is	O
60	O
to	O
90%	O

Omission	O
of	O
the	O
amphetamine	B-Drug
related	O
-methyl	O
leads	O
to	O
2C-B	B-Drug
a	O
compound	O
that	O
possesses	O
lower	O
affinity	O
for	O
5-HT2A	O
receptor	O
and	O
is	O
weaker	O
agonist	O
which	O
results	O
in	O
drastically	O
reduced	O
vasoconstriction	O

Ergot	O
alkaloids	O
such	O
as	O
dihydroergotamine	B-Drug
add	O
to	O
the	O
drug's	O
hypertensive	O
effect	O
and	O
should	O
be	O
separated	O
by	O
at	O
least	O
24	O
hours	O

Methylone	B-Drug
also	O
known	O
as	O
34-methylenedioxy-N-methylcathinone	O
MDMC	B-Drug
k-MDMA	O
and	O
by	O
the	O
slang	O
term	O
M1	O
is	O
an	O
empathogen	O
stimulant	O
psychoactive	O
drug	O

Over	O
200	O
naloxone	B-Drug
distribution	O
programs	O
utilize	O
licensed	O
prescribers	O
to	O
distribute	O
the	O
drug	O
often	O
through	O
use	O
of	O
standing	O
medication	O
orders	O
whereby	O
is	O
distributed	O
under	O
medical	O
authority	O
a	O
physician	O
or	O
other	O
prescriber	O
such	O
as	O
pharmacist	O
California's	O
AB1535	O

Examples	O
of	O
KOR	O
agonists	O
that	O
have	O
been	O
used	O
medically	O
as	O
analgesics	O
include	O
butorphanol	B-Drug
nalbuphine	B-Drug
levorphanol	B-Drug
levallorphan	O
pentazocine	B-Drug
phenazocine	B-Drug
and	O
eptazocine	O

However	O
there	O
is	O
little	O
evidence	O
for	O
a	O
specific	O
diagnosable	O
MDMA	B-Drug
dependence	O
syndrome	O
because	O
typically	O
used	O
relatively	O
infrequently	O

Unlike	O
the	O
related	O
piperazine	O
compound	O
meta-chlorophenylpiperazine	O
mCPP	O
TFMPP	B-Drug
has	O
insignificant	O
affinity	O
for	O
5-HT3	O
receptor	O
IC50	O
121	O
nM	O
and	O
evokes	O
release	O
of	O
serotonin	O

This	O
is	O
analogous	O
to	O
the	O
hepatotoxicity	O
that	O
occurs	O
with	O
withdrawn	O
paracetamol	B-Drug
acetominophen-related	O
medication	O
phenacetin	O

Spironolactone	B-Drug
has	O
not	O
been	O
well	O
studied	O
in	O
pregnancy	O
and	O
should	O
be	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
of	O

Amphetamine	B-Drug
is	O
used	O
by	O
some	O
athletes	O
for	O
its	O
psychological	O
and	O
athletic	O
performance-enhancing	O
effects	O
such	O
as	O
increased	O
endurance	O
alertness;	O
however	O
non-medical	O
amphetamine	B-Drug
use	O
prohibited	O
at	O
sporting	O
events	O
that	O
are	O
regulated	O
collegiate	O
national	O
international	O
anti-doping	O
agencies	O

Gestodene	O
is	O
almost	O
identical	O
to	O
levonorgestrel	B-Drug
in	O
terms	O
of	O
chemical	O
structure	O
differing	O
only	O
having	O
an	O
additional	O
double	O
bond	O
between	O
the	O
C15	O
and	O
C16	O
positions	O
for	O
this	O
reason	O
also	O
known	O
as	O
15-norgestrel	O
or	O
15-dehydronorgestrel	O
norgestrel	B-Drug

This	O
was	O
contrary	O
to	O
another	O
study	O
in	O
New	O
Zealand	O
where	O
users	O
of	O
benzylpiperazine	B-Drug
thought	O
that	O
because	O
it	O
legal	O
safe	O

Hair	O
testing	O
however	O
is	O
a	O
different	O
matter	O
particularly	O
with	O
passive	O
exposure	O
to	O
crack/cocaine	O
which	O
can	O
deposit	O
onto	O
hair	O
and	O
be	O
readily	O
incorporated	O
into	O
it	O
cocaine	B-Drug

Because	O
of	O
its	O
DAT	O
inhibitory	O
action	O
pethidine	B-Drug
will	O
substitute	O
for	O
cocaine	B-Drug
in	O
animals	O
trained	O
to	O
discriminate	O
from	O
saline	O

Hydrocodone/ibuprofen	B-Drug
has	O
a	O
labeled	O
indication	O
for	O
short-term	O
generally	O
<10	O
days	O
management	O
of	O
acute	O
pain	O
severe	O
enough	O
to	O
require	O
an	O
opioid	O
analgesic	O
and	O
which	O
alternative	O
treatments	O
are	O
inadequate	O

In	O
2008	O
the	O
European	O
Monitoring	O
Centre	O
for	O
Drugs	O
and	O
Drug	O
Addiction	O
reports	O
that	O
typical	O
retail	O
price	O
of	O
cocaine	B-Drug
varied	O
between	O
50	O
75	O
per	O
gram	O
in	O
most	O
countries	O
although	O
Cyprus	O
Romania	O
Sweden	O
Turkey	O
reported	O
much	O
higher	O
values	O

Rolled	O
up	O
banknotes	O
hollowed-out	O
pens	O
cut	O
straws	O
pointed	O
ends	O
of	O
keys	O
specialized	O
spoons	O
long	O
fingernails	O
and	O
clean	O
tampon	O
applicators	O
are	O
often	O
used	O
to	O
insufflate	O
cocaine	B-Drug

Pentazocine	B-Drug
has	O
a	O
DEA	O
ACSCN	O
of	O
9720;	O
being	O
Schedule	O
IV	O
substance	O
the	O
does	O
not	O
assign	O
an	O
annual	O
manufacturing	O
quota	O
for	O
pentazocine	B-Drug
United	O
States	O

Cases	O
of	O
life-threatening	O
or	O
fatal	O
hyponatremia	O
excessively	O
low	O
sodium	O
concentration	O
in	O
the	O
blood	O
have	O
developed	O
MDMA	B-Drug
users	O
attempting	O
to	O
prevent	O
dehydration	O
by	O
consuming	O
excessive	O
amounts	O
water	O
without	O
replenishing	O
electrolytes	O

Most	O
heroin	B-Drug
deaths	O
result	O
not	O
from	O
overdose	O
per	O
se	O
but	O
combination	O
with	O
other	O
depressant	O
drugs	O
such	O
as	O
alcohol	O
or	O
benzodiazepines	O

It	O
was	O
estimated	O
that	O
worldwide	O
sales	O
of	O
diet	B-Drug
pills	I-Drug
containing	O
stimulants	O
rocketed	O
to	O
over	O
10	O
billion	O
tablets	O
sold	O
and	O
between	O
6%	O
8%	O
the	O
U	O

The	O
ratio	O
of	O
male	O
to	O
female	O
cocaine	B-Drug
overdoses	O
is	O
3:1	O

8	O
million	O
thalidomide	B-Drug
pills	O
were	O
distributed	O
throughout	O
Brazil	O
in	O
this	O
time	O
period	O
largely	O
to	O
poor	O
Brazilians	O
areas	O
with	O
access	O
healthcare	O
and	O
these	O
cases	O
have	O
occurred	O
despite	O
the	O
controls	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are	O
like	O
marijuana	O
typically	O
used	O
before	O
person	O
progresses	O
more	O
harmful	O
substances	O

However	O
another	O
study	O
found	O
that	O
mibolerone	B-Drug
and	O
metribolone	O
had	O
similar	O
affinity	O
for	O
the	O
progesterone	O
receptor	O
PR	O
but	O
only	O
around	O
half	O
of	O
AR	O

Intracellular	O
MDMA	B-Drug
can	O
also	O
bind	O
to	O
monoamine	O
oxidase	O
A	O
MAO-A	O
as	O
an	O
inhibitor	O
and	O
thus	O
prevent	O
it	O
from	O
breaking	O
down	O
cytosolic	O
serotonin	O

Ott	O
reported	O
visionary	O
effects	O
of	O
intranasal	O
bufotenin	B-Drug
and	O
that	O
the	O
threshold	O
dose	O
by	O
this	O
route	O
was	O
40	O
mg	O
with	O
smaller	O
doses	O
eliciting	O
perceptibly	O
psychoactive	O

This	O
action	O
is	O
thought	O
to	O
underlie	O
the	O
efficacy	O
of	O
tamoxifen	B-Drug
in	O
treatment	O
bipolar	O
disorder	O

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months	O

In	O
vitro	O
co-treatment	O
of	O
monocyte	O
derived	O
dendritic	O
cells	O
with	O
DMT	O
and	O
5-MeO-DMT	B-Drug
inhibited	O
the	O
production	O
pro-inflammatory	O
cytokines	O
IL-1	O
IL-6	O
TNF	O
chemokine	O
IL-8	O
while	O
increased	O
secretion	O
anti-inflammatory	O
cytokine	O
IL-10	O
by	O
activating	O
Sigma-1	O
receptor	O

The	O
major	O
disadvantages	O
of	O
this	O
use	O
are	O
cocaine's	O
potential	O
for	O
cardiovascular	O
toxicity	O
glaucoma	O
and	O
pupil	O
dilation	O
cocaine	B-Drug

Examples	O
include	O
testosterone	B-Drug
as	O
cypionate	I-Drug
enanthate	I-Drug
and	O
propionate	O
nandrolone	B-Drug
phenylpropionate	I-Drug
decanoate	O
among	O
many	O
others	O
see	O
here	O
for	O
a	O
full	O
list	O
of	O
esters	O

It	O
is	O
the	O
base	O
structure	O
in	O
a	O
series	O
of	O
opioid	O
analgesics	O
including:	O
Ethoheptazine	B-Drug
Metheptazine	O
Metethoheptazine	O
ProheptazineMeptazinol	O
another	O
analgesic	O
3-phenylazepane	O
derivative	O

Propylhexedrine	B-Drug
differs	O
from	O
methamphetamine	B-Drug
only	O
in	O
that	O
it	O
has	O
a	O
saturated	O
cyclohexane	O
ring	O
where	O
phenyl	O

Cocaine	O
Cowboys	O
is	O
about	O
cocaine	B-Drug
dealing	O
members	O
of	O
a	O
rock	O
band	O
who	O
get	O
into	O
trouble	O
with	O
the	O
American	O
Mafia	O

An	O
individual	O
who	O
has	O
consumed	O
too	O
much	O
diazepam	B-Drug
typically	O
displays	O
one	O
or	O
more	O
of	O
these	O
symptoms	O
in	O
a	O
period	O
approximately	O
four	O
hours	O
immediately	O
following	O
suspected	O
overdose:	O
Drowsiness	O
Mental	O
confusion	O
Hypotension	O
Impaired	O
motor	O
functions	O
reflexes	O
coordination	O
balance	O
Dizziness	O
ComaAlthough	O
not	O
usually	O
fatal	O
when	O
taken	O
alone	O
overdose	O
is	O
considered	O
medical	O
emergency	O
and	O
generally	O
requires	O
the	O
immediate	O
attention	O
personnel	O

The	O
alkaloid	O
profiles	O
of	O
poppy	O
straw	O
and	O
opium	B-Drug
are	O
similar	O
but	O
preliminary	O
research	O
suggests	O
they	O
can	O
be	O
distinguished	O
by	O
relative	O
quantities	O
alkaloids	O

After	O
experiencing	O
long-term	O
in-patient	O
treatment	O
only	O
22	O
percent	O
returned	O
to	O
the	O
use	O
of	O
cocaine	B-Drug

Opium	B-Drug
can	O
be	O
manufactured	O
into	O
codeine	B-Drug
and	O
morphine	B-Drug
which	O
are	O
both	O
legal	O
pain-killers	O

In	O
general	O
there	O
are	O
far	O
lower	O
risks	O
of	O
pulmonary	O
complications	O
for	O
regular	O
cannabis	O
smokers	O
when	O
compared	O
with	O
those	O
tobacco	B-Drug

Respiratory:	O
bronchospasm	O
dyspnea	O
respiratory	O
depression	O
or	O
arrest	O
Gastrointestinal:	O
metallic	O
taste	O
nausea	O
vomiting	O
Ears:	O
tinnitus	O
Eyes:	O
local	O
burning	O
conjunctival	O
hyperemia	O
corneal	O
epithelial	O
changes/ulceration	O
diplopia	O
visual	O
changes	O
opacification	O
Skin:	O
itching	O
depigmentation	O
rash	O
urticaria	O
edema	O
angioedema	O
bruising	O
inflammation	O
of	O
the	O
vein	O
at	O
injection	O
site	O
irritation	O
skin	O
when	O
applied	O
topically	O
Blood:	O
methemoglobinemia	O
AllergyADRs	O
associated	O
with	O
use	O
intravenous	O
lidocaine	B-Drug
are	O
similar	O
to	O
toxic	O
effects	O
from	O
systemic	O
exposure	O
above	O

Darolutamide	B-Drug
is	O
an	O
expected	O
teratogen	O
and	O
has	O
a	O
theoretical	O
risk	O
of	O
birth	O
defects	O
in	O
male	O
infants	O
if	O
taken	O
by	O
women	O
during	O
pregnancy	O

Nalmefene	O
is	O
an	O
opiate	O
derivative	O
similar	O
in	O
both	O
structure	O
and	O
activity	O
to	O
the	O
opioid	O
antagonist	O
naltrexone	B-Drug

Buprenorphine	B-Drug
is	O
metabolized	O
by	O
the	O
liver	O
primarily	O
via	O
cytochrome	O
P450	O
CYP	O
isozyme	O
called	O
CYP3A4	O
into	O
norbuprenorphine	O

Fentanyl	B-Drug
is	O
used	O
orally	O
smoked	O
snorted	O
or	O
injected	O

Treatment	O
of	O
opioid-dependent	O
persons	O
with	O
methadone	B-Drug
follows	O
one	O
two	O
routes:	O
maintenance	O
or	O
detoxification	O

It	O
is	O
a	O
more	O
potent	O
derivative	O
of	O
triamcinolone	B-Drug
and	O
about	O
eight	O
times	O
as	O
prednisone	B-Drug

Orajel	B-Drug
Paste	O
ex	O

It	O
is	O
an	O
amphetamine	B-Drug
derivative	O
which	O
was	O
developed	O
in	O
the	O
1970s	O
and	O
used	O
for	O
treatment	O
of	O
obesity	O

Clomifene	B-Drug
can	O
lead	O
to	O
multiple	O
ovulation	O
hence	O
increasing	O
the	O
chance	O
of	O
twins	O
10%	O
births	O
instead	O
~1%	O
in	O
general	O
population	O
and	O
triplets	O

Metofoline	O
has	O
two	O
enantiomers	O
with	O
the	O
levo	O
R	O
enantiomer	O
being	O
active	O
form	O
around	O
3x	O
potency	O
of	O
codeine	B-Drug
and	O
S	O
inactive	O

State	O
and	O
local	O
governments	O
may	O
also	O
regulate	O
cannabidiol	B-Drug

Binding	O
studies	O
have	O
helped	O
to	O
explain	O
the	O
increased	O
potency	O
of	O
N-phenethylnormorphine	O
showing	O
that	O
phenethyl	O
group	O
extends	O
out	O
reach	O
an	O
additional	O
binding	O
point	O
deeper	O
inside	O
-opioid	O
receptor	O
cleft	O
analogous	O
on	O
fentanyl	B-Drug

On	O
January	O
19	O
2018	O
the	O
medical	O
examiner-coroner	O
for	O
county	O
of	O
Los	O
Angeles	O
said	O
musician	O
Tom	O
Petty	O
died	O
from	O
an	O
accidental	O
drug	O
overdose	O
as	O
a	O
result	O
mixing	O
medications	O
that	O
included	O
fentanyl	B-Drug
acetyl	O
and	O
despropionyl	O
among	O
others	O

Sometimes	O
a	O
joint	O
will	O
contain	O
kief	O
or	O
hashish;	O
hashish	B-Drug
can	O
be	O
heated	O
and	O
made	O
to	O
crumble	O
before	O
placement	O
within	O
the	O

Whereas	O
opioids	O
like	O
codeine	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
and	O
hydromorphone	B-Drug
are	O
synthesized	O
by	O
simple	O
modifications	O
of	O
morphine	B-Drug
fentanyl	B-Drug
its	O
relatives	O
meperidine	B-Drug

The	O
benzodiazepines	O
chlordiazepoxide	B-Drug
Librium	B-Drug
and	O
oxazepam	B-Drug
Serax	B-Drug
have	O
largely	O
replaced	O
phenobarbital	B-Drug
for	O
detoxification	O

Methylphenidate	B-Drug
tablets	O
are	O
crushed	O
and	O
dissolved	O
into	O
solution	O
for	O
IV	O
injection	O

States	O
including	O
Vermont	O
and	O
Virginia	O
have	O
developed	O
programs	O
that	O
mandate	O
the	O
prescription	O
of	O
naloxone	B-Drug
when	O
a	O
has	O
exceeded	O
certain	O
level	O
morphine	B-Drug
milliequivalents	O
per	O
day	O
as	O
preventative	O
measures	O
against	O
overdose	O

Uniquely	O
among	O
17-alkylated	O
AAS	O
oxandrolone	B-Drug
shows	O
little	O
to	O
no	O
hepatotoxicity	O
even	O
at	O
high	O
doses	O

It	O
is	O
the	O
-methoxy	O
analog	O
of	O
methylenedioxyphenethylamine	O
MDPEA	O
and	O
also	O
more	O
distantly	O
related	O
to	O
methylone	B-Drug

Indometacin	B-Drug
therefore	O
like	O
other	O
non-selective	O
COX	O
inhibitors	O
can	O
cause	O
peptic	O
ulcers	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression	O

Legal	O
opium	B-Drug
production	O
is	O
allowed	O
under	O
the	O
United	O
Nations	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
and	O
other	O
international	O
drug	O
treaties	O
subject	O
to	O
strict	O
supervision	O
by	O
law	O
enforcement	O
agencies	O
of	O
individual	O
countries	O

Some	O
inhibition	O
of	O
5-reductase	O
and	O
hepatic	O
cytochrome	O
P450	O
enzymes	O
has	O
been	O
observed	O
with	O
etonogestrel	B-Drug
in	O
vitro	O
similarly	O
to	O
other	O
19-nortestosterone	B-Drug
progestins	O

Tentative	O
evidence	O
suggests	O
that	O
family	O
history	O
and	O
presence	O
of	O
the	O
Asn40Asp	O
polymorphism	O
predicts	O
naltrexone	B-Drug
being	O
effective	O

The	O
other	O
trial	O
showed	O
gabapentin	B-Drug
alone	O
increased	O
pauses	O
in	O
breathing	O
during	O
sleep	O

Also	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana	B-Drug

No	O
acute	O
overdosing	O
of	O
triamcinolone	B-Drug
has	O
been	O
described	O

Bupropion	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Wellbutrin	B-Drug
and	O
Zyban	B-Drug
among	O
others	O
is	O
a	O
medication	O
primarily	O
used	O
to	O
treat	O
major	O
depressive	O
disorder	O
support	O
smoking	O
cessation	O

UR-144	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic	O

There	O
has	O
been	O
controversy	O
between	O
the	O
US	O
and	O
China	O
over	O
whether	O
Chinese	O
ban	O
on	O
sales	O
of	O
fentanyl	B-Drug
derivatives	O
to	O
effective	O

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine	B-Drug
a	O
structurally	O
similar	O
drug	O
far	O
beyond	O
recreational	O
doses	O
but	O
due	O
to	O
never	O
having	O
been	O
published	O
its	O
validity	O
is	O
controversial	O

There	O
is	O
one	O
case	O
of	O
death	O
where	O
a	O
combination	O
propylhexedrine	B-Drug
acetaminophen	B-Drug
morphine	B-Drug
promethazine	B-Drug
and	O
kratom	B-Drug
was	O
detected	O

With	O
the	O
street	O
price	O
for	O
heroin	B-Drug
or	O
oxycodone	B-Drug
much	O
higher	O
than	O
cost	O
of	O
codeine	B-Drug
and	O
chemicals	O
users	O
manufacture	O
krokodil	O
a	O
cheaper	O
comparable	O
high	O

Most	O
cloud-chasers	O
do	O
not	O
use	O
nicotine	B-Drug

The	O
biotransformation	O
shows	O
great	O
similarities	O
to	O
the	O
metabolic	O
pathway	O
of	O
structurally	O
related	O
4-methoxyamphetamine	B-Drug

According	O
to	O
court	O
testimony	O
Pickard's	O
lab	O
produced	O
up	O
a	O
kilogram	O
of	O
LSD	B-Drug
approximately	O
every	O
five	O
weeks	O
for	O
short	O
periods	O

Other	O
known	O
but	O
more	O
minor	O
metabolites	O
of	O
spironolactone	B-Drug
include	O
7-thiospironolactone	O
7-TS	O
which	O
is	O
an	O
important	O
intermediate	O
to	O
the	O
major	O
as	O
well	O
7-methyl	O
ethyl	O
ester	O
and	O
6-hydroxy-7-methyl	O

Low-dose	O
slow	O
subcutaneous	O
flumazenil	B-Drug
administration	O
is	O
a	O
safe	O
procedure	O
for	O
patients	O
withdrawing	O
from	O
long-term	O
high-dose	O
benzodiazepine	O
dependency	O

Amoxapine	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O

Further	O
minor	O
metabolites	O
of	O
cocaine	B-Drug
include	O
norcocaine	O
p-hydroxycocaine	O
m-hydroxycocaine	O
p-hydroxybenzoylecgonine	O
pOHBE	O
and	O
m-hydroxybenzoylecgonine	O

It	O
is	O
absorbed	O
rapidly	O
after	O
administration;	O
administration	O
it	O
metabolized	O
into	O
active	O
metabolites	O
one	O
of	O
which	O
far	O
less	O
potent	O
than	O
brotizolam	B-Drug
and	O
the	O
other	O
only	O
present	O
in	O
very	O
small	O
amounts	O
blood	O
thus	O
do	O
not	O
have	O
significant	O
pharmacological	O
effect	O
humans	O

While	O
it	O
is	O
not	O
easy	O
to	O
destroy	O
opium	B-Drug
storage	O
and	O
heroin	B-Drug
production	O
laboratories	O
far	O
easier	O
drugs	O
at	O
the	O
source	O
than	O
in	O
transit	O

Quazepam	B-Drug
due	O
to	O
its	O
pharmacological	O
profile	O
does	O
not	O
cause	O
next	O
day	O
rebound	O
withdrawal	O
effects	O
during	O
treatment	O

Tramadol	B-Drug
is	O
demethylated	O
by	O
the	O
liver	O
enzyme	O
CYP2D6	O
in	O
same	O
way	O
as	O
codeine	B-Drug
and	O
so	O
similarly	O
to	O
variation	O
effects	O
seen	O
with	O
individuals	O
who	O
have	O
a	O
less	O
active	O
form	O
of	O
poor	O
metabolizers	O
will	O
tend	O
get	O
reduced	O
analgesic	O
from	O
tramadol	B-Drug

Norpethidine	B-Drug
normeperidine	O
pethidine	B-Drug
intermediate	I-Drug
B	I-Drug
is	O
a	O
4-phenylpiperidine	O
derivative	O
that	O
both	O
precursor	O
to	O
and	O
the	O
toxic	O
metabolite	O
of	O
meperidine	B-Drug

The	O
study	O
consisted	O
of	O
two	O
groups	O
Ecstasy	B-Drug
users	O
and	O
controls	O
who	O
were	O
shown	O
brief	O
displays	O
the	O
TAE	O
illusion	O

Opium	B-Drug
tincture	O
is	O
one	O
of	O
the	O
most	O
potent	O
oral	O
formulations	O
morphine	B-Drug
available	O
by	O
prescription	O

It	O
is	O
a	O
17-cycloalkylmethyl	O
derivative	O
of	O
morphinan	O
and	O
as	O
such	O
closely	O
related	O
structurally	O
to	O
butorphanol	B-Drug
cyclorphan	O
oxilorphan	O
proxorphan	O
xorphanol	O
which	O
act	O
preferentially	O
-opioid	O
receptor	O
agonists	O
lesser	O
extent	O
partial	O
agonists/antagonists	O

When	O
used	O
in	O
therapy	O
MDMA	B-Drug
has	O
been	O
reported	O
to	O
increase	O
empathy	O
closeness	O
between	O
patient	O
and	O
therapist	O
relaxation	O
motivation	O
engage	O
with	O
introspective	O
thought	O
reduce	O
depression	O
anxiety	O

9%	O
respectively	O
which	O
was	O
described	O
as	O
close	O
to	O
that	O
of	O
methylphenidate	B-Drug

Unlike	O
the	O
tricyclic	O
antidepressants	O
mirtazapine	B-Drug
showed	O
no	O
significant	O
cardiovascular	O
adverse	O
effects	O
at	O
7	O
to	O
22	O
times	O
maximum	O
recommended	O
dose	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine	B-Drug

Some	O
benzodiazepines	O
have	O
long-acting	O
active	O
metabolites	O
such	O
as	O
diazepam	B-Drug
and	O
chlordiazepoxide	B-Drug
which	O
are	O
metabolised	O
into	O
desmethyldiazepam	B-Drug

MDMA	B-Drug
is	O
less	O
addictive	O
than	O
other	O
stimulants	O
such	O
as	O
methamphetamine	B-Drug
and	O
cocaine	B-Drug

In	O
2011	O
21649	O
emergency	O
room	O
visits	O
in	O
the	O
United	O
States	O
were	O
related	O
to	O
tramadol	B-Drug

Psilocin	B-Drug
binds	O
with	O
high	O
affinity	O
to	O
5-HT2A	O
receptors	O
and	O
low	O
5-HT1	O
including	O
5-HT1A	O
5-HT1D;	O
effects	O
are	O
also	O
mediated	O
via	O
5-HT2C	O

It	O
is	O
thought	O
to	O
be	O
a	O
serotonergic	O
psychedelic	O
similar	O
magic	O
mushrooms	O
LSD	B-Drug
and	O
mescaline	B-Drug

An	O
extended-release	O
formulation	O
of	O
gabapentin	B-Drug
for	O
once-daily	O
administration	O
was	O
introduced	O
in	O
2011	O
postherpetic	O
neuralgia	O
under	O
the	O
brand	O
name	O
Gralise	B-Drug

Approximately	O
50	O
million	O
Europeans	O
were	O
treated	O
with	O
fenfluramine	B-Drug
for	O
appetite	O
suppression	O
between	O
1963	O
and	O
1996	O

Trilostane	O
is	O
not	O
an	O
aromatase	O
inhibitor	O
and	O
hence	O
does	O
inhibit	O
the	O
conversion	O
of	O
androgens	O
like	O
androstenedione	B-Drug
testosterone	O
into	O
estrogens	O
estrone	O
estradiol	O

Cocaine	B-Drug
caffeine	O
and	O
cathinone	B-Drug
are	O
stimulants	O
of	O
the	O
central	O
nervous	O
system	O

Studies	O
have	O
shown	O
hydrocodone	B-Drug
is	O
stronger	O
than	O
codeine	B-Drug
but	O
only	O
one-tenth	O
as	O
potent	O
morphine	B-Drug
at	O
binding	O
to	O
receptors	O
and	O
reported	O
be	O
59%	O
in	O
analgesic	O
properties	O

There	O
is	O
preferential	O
storage	O
of	O
chlordiazepoxide	B-Drug
in	O
some	O
organs	O
including	O
the	O
heart	O
neonate	O

In	O
the	O
United	O
States	O
a	O
majority	O
of	O
heroin	B-Drug
users	O
begin	O
by	O
using	O
prescription	O
opioids	O
that	O
may	O
also	O
be	O
bought	O
illegally	O

In	O
addition	O
to	O
the	O
FDA	O
Cocaine	B-Drug
also	O
faced	O
trouble	O
from	O
specific	O
U	O

On	O
30	O
March	O
2010	O
Alan	O
Johnson	O
the	O
then	O
Home	O
Secretary	O
announced	O
mephedrone	B-Drug
would	O
be	O
made	O
illegal	O
within	O
weeks	O
after	O
ACMD	O
sent	O
him	O
a	O
report	O
on	O
use	O
of	O
cathinones	O

1%	O
which	O
was	O
much	O
lower	O
than	O
that	O
observed	O
for	O
oral	O
norethisterone	B-Drug
and	O
enanthate	O
0	O

Anecdotally	O
MDMA	B-Drug
was	O
said	O
to	O
greatly	O
accelerate	O
therapy	O

With	O
about	O
10%	O
of	O
the	O
analgesic	O
potency	O
morphine	B-Drug
50	O
mg	O
propiram	B-Drug
is	O
equivalent	O
to	O
60	O
codeine	B-Drug
or	O
pentazocine	B-Drug

Both	O
ibogaine	B-Drug
and	O
noribogaine	B-Drug
have	O
a	O
plasma	O
half-life	O
of	O
around	O
two	O
hours	O
in	O
the	O
rat	O
although	O
is	O
slightly	O
longer	O
than	O
that	O
parent	O
compound	O

Lorazepam	B-Drug
is	O
sometimes	O
used	O
as	O
an	O
alternative	O
to	O
haloperidol	B-Drug
when	O
there	O
the	O
need	O
for	O
rapid	O
sedation	O
of	O
violent	O
or	O
agitated	O
individuals	O
but	O
plus	O
promethazine	B-Drug
preferred	O
due	O
better	O
effectiveness	O
and	O
lorazepam's	O
adverse	O
effects	O
on	O
respiratory	O
function	O
lorazepam	B-Drug

Reynolds	O
Tobacco	O
Company	O
and	O
groups	O
representing	O
growers	O
distributors	O
marketers	O
of	O
tobacco	B-Drug
took	O
legal	O
action	O
claiming	O
that	O
the	O
EPA	O
had	O
manipulated	O
this	O
study	O
ignored	O
accepted	O
scientific	O
statistical	O
practices	O

Acylation	O
of	O
4	O
with	O
phenylpropionyl	O
chloride	O
yields	O
nandrolone	B-Drug
phenpropionate	I-Drug

25I-NBOMe	B-Drug
was	O
explicitly	O
scheduled	O
in	O
Queensland	O
drug	O
law	O
April	O
2012	O
and	O
New	O
South	O
Wales	O
October	O
2013	O
as	O
were	O
some	O
related	O
compounds	O
such	O
25B-NBOMe	B-Drug

A	O
study	O
by	O
researchers	O
at	O
Liverpool	O
John	O
Moores	O
University	O
found	O
that	O
only	O
one	O
out	O
of	O
ten	O
products	O
labelled	O
as	O
NRG-1	O
actually	O
contained	O
naphyrone	B-Drug
when	O
they	O
were	O
subjected	O
to	O
laboratory	O
analysis	O

In	O
migraine	O
headaches	O
metoclopramide	B-Drug
may	O
be	O
used	O
in	O
combination	O
with	O
paracetamol	B-Drug
acetaminophen	B-Drug
or	O
aspirin	B-Drug

Official	O
Chinese	O
resistance	O
to	O
opium	B-Drug
was	O
renewed	O
on	O
September	O
20	O
1906	O
with	O
an	O
antiopium	O
initiative	O
intended	O
eliminate	O
the	O
drug	O
problem	O
within	O
10	O
years	O

The	O
blockade	O
of	O
opioid	O
receptors	O
is	O
the	O
basis	O
behind	O
naltrexone's	O
action	O
in	O
management	O
dependenceit	O
reversibly	O
blocks	O
or	O
attenuates	O
effects	O
opioids	O
naltrexone	B-Drug

The	O
experience	O
of	O
ibogaine	B-Drug
occurs	O
in	O
two	O
phases	O
termed	O
the	O
visionary	O
phase	O
and	O
introspection	O

Large	O
recreational	O
doses	O
of	O
dextroamphetamine	B-Drug
may	O
produce	O
symptoms	O
overdose	O

Glutethimide	B-Drug
3-ethyl-3-phenylgutarimide	O
is	O
synthesized	O
by	O
addition	O
of	O
2-phenylbutanenitrile	O
to	O
ethylacrylate	O
in	O
a	O
Michael	O
reaction	O
with	O
subsequent	O
alkaline	O
hydrolysis	O
the	O
nitrile	O
an	O
amide	O
group	O
followed	O
acidic	O
cyclization	O
product	O
into	O
glutethimide	B-Drug

The	O
problem	O
was	O
that	O
amphetamine	B-Drug
leads	O
to	O
a	O
lack	O
of	O
judgement	O
and	O
willingness	O
take	O
risks	O
which	O
in	O
sport	O
could	O
lead	O
better	O
performances	O
but	O
fighters	O
bombers	O
led	O
more	O
crash	O
landings	O
than	O
the	O
RAF	O
tolerate	O

Drugs	O
in	O
this	O
schedule	O
include:	O
Cough	O
suppressants	O
containing	O
small	O
amounts	O
of	O
codeine	B-Drug
e	O

Nalmefene	O
is	O
a	O
partial	O
agonist	O
of	O
the	O
-opioid	O
receptor	O
and	O
may	O
be	O
useful	O
to	O
treat	O
cocaine	B-Drug
addiction	O

Not	O
knowing	O
to	O
expect	O
hundreds	O
of	O
patients	O
exposed	O
high	O
doses	O
strong	O
opioids	O
the	O
emergency	O
workers	O
did	O
not	O
bring	O
enough	O
naloxone	B-Drug
or	O
naltrexone	B-Drug
two	O
most	O
commonly	O
used	O
opioid	O
antagonists	O
counteract	O
carfentanil	B-Drug
and	O
remifentanil	B-Drug
save	O
lives	O
many	O
victims	O

For	O
sublingual	O
and	O
buccal	O
administration	O
25I-NBOMe	B-Drug
is	O
often	O
applied	O
to	O
sheets	O
of	O
blotter	O
paper	O
which	O
small	O
portions	O
tabs	O
are	O
held	O
in	O
the	O
mouth	O
allow	O
absorption	O
through	O
oral	O
mucosa	O

In	O
Chile	O
GHB	B-Drug
is	O
a	O
controlled	O
drug	O
under	O
the	O
law	O
Ley	O
de	O
substancias	O
psicotrpicas	O
y	O
estupefacientes	O
psychotropic	O
substances	O
and	O
narcotics	O

MDMA	B-Drug
also	O
induces	O
significant	O
norepinephrine	O
release	O

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU	O
due	O
to	O
its	O
high	O
recreational	O
use	O

Octreotide	B-Drug
is	O
often	O
given	O
as	O
an	O
infusion	O
for	O
management	O
of	O
acute	O
hemorrhage	O
from	O
esophageal	O
varices	O
in	O
liver	O
cirrhosis	O
on	O
the	O
basis	O
that	O
it	O
reduces	O
portal	O
venous	O
pressure	O
though	O
current	O
evidence	O
suggests	O
this	O
effect	O
transient	O
and	O
does	O
not	O
improve	O
survival	O

Pentazocine	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Talwin	B-Drug
among	O
others	O
is	O
a	O
painkiller	O
used	O
to	O
treat	O
moderate	O
severe	O
pain	O

Hashish	B-Drug
also	O
spelled	O
hasheesh	O
hashisha	O
or	O
simply	O
hash	B-Drug
is	O
a	O
concentrated	O
resin	O
cake	O
ball	O
produced	O
from	O
pressed	O
kief	O
the	O
detached	O
trichomes	O
and	O
fine	O
material	O
that	O
falls	O
off	O
cannabis	O
fruits	O
flowers	O
leaves	O

Triazolam	B-Drug
sold	O
under	O
the	O
brand	O
name	O
Halcion	B-Drug
among	O
others	O
is	O
a	O
central	O
nervous	O
system	O
CNS	O
depressant	O
tranquilizer	O
of	O
triazolobenzodiazepine	O
TBZD	O
class	O
which	O
are	O
benzodiazepine	O
BZD	O
derivatives	O

However	O
although	O
used	O
in	O
the	O
past	O
it	O
has	O
mostly	O
been	O
superseded	O
by	O
newer	O
agents	O
with	O
better	O
efficacy	O
and	O
lower	O
toxicity	O
such	O
as	O
ketoconazole	B-Drug
abiraterone	B-Drug
acetate	O
other	O
aromatase	O
inhibitors	O

Spironolactone	B-Drug
has	O
antiandrogenic	O
activity	O

Opioids	O
include	O
opiates	O
an	O
older	O
term	O
that	O
refers	O
to	O
such	O
drugs	O
derived	O
from	O
opium	B-Drug
including	O
morphine	B-Drug
itself	O

The	O
drink	O
includes	O
a	O
massive	O
amount	O
of	O
the	O
opiate	O
codeine	B-Drug
which	O
can	O
be	O
addictive	O
in	O
high	O
doses	O
and	O
Fallieras	O
states	O
that	O
promethazine	B-Drug
has	O
at	O
least	O
anecdotally	O
been	O
noted	O
to	O
intensify	O
euphoric	O
effects	O
brain	O

Schedule	O
IV	O
is	O
the	O
category	O
of	O
drugs	O
such	O
as	O
heroin	B-Drug
that	O
are	O
considered	O
to	O
have	O
particularly	O
dangerous	O
properties	O
in	O
comparison	O
other	O
ethanol	O
left	O
unregulated	O

Pinazepam	B-Drug
differs	O
from	O
other	O
benzodiazepines	O
in	O
that	O
it	O
has	O
a	O
propargyl	O
group	O
at	O
the	O
N-1	O
position	O
of	O
benzodiazepine	O
structure	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	O
and	O
higher	O
CBD	B-Drug
which	O
gives	O
lesser	O
psychoactive	O
effects	O

Cocaine	B-Drug
Configurable	O
Omnipotent	O
Custom	O
Applications	O
Integrated	O
Network	O
Engine	O
is	O
an	O
open-source	O
PaaS	O
system	O
for	O
creating	O
custom	O
cloud	O
hosting	O
apps	O
that	O
are	O
similar	O
to	O
Bluemix	O
Google	O
App	O
or	O
Heroku	O

For	O
this	O
reason	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia	O

NIDA	O
scientists	O
also	O
developed	O
LAAM	B-Drug
which	O
is	O
used	O
for	O
heroin	B-Drug
addiction	O
treatment	O

If	O
based	O
on	O
clinical	O
decision	O
normal	O
precautions	O
should	O
be	O
exercised	O
and	O
the	O
dosages	O
of	O
mianserin	B-Drug
any	O
concurrent	O
therapy	O
kept	O
under	O
review	O
adjusted	O
as	O
needed	O

An	O
etorphine	B-Drug
antidote	O
Large	O
Animal	O
Revivon	O
contains	O
mainly	O
diprenorphine	O
for	O
animals	O
and	O
a	O
human-specific	O
naloxone-based	O
which	O
should	O
be	O
prepared	O
prior	O
to	O
the	O

It	O
is	O
the	O
N-pentyl	O
analog	O
of	O
JWH-148	B-Drug

Mannitol	B-Drug
is	O
on	O
the	O
World	O
Anti-Doping	O
Agency's	O
banned	O
drug	O
list	O
due	O
to	O
concerns	O
that	O
it	O
may	O
mask	O
other	O
drugs	O

L-tyrosine	O
and	O
its	O
derivatives	O
L-DOPA	B-Drug
melanin	O
phenylpropanoids	O
others	O
are	O
used	O
in	O
pharmaceuticals	O
dietary	O
supplements	O
food	O
additives	O

Once	O
Project	O
MKUltra	O
got	O
underway	O
in	O
April	O
1953	O
experiments	O
included	O
administering	O
LSD	B-Drug
to	O
mental	O
patients	O
prisoners	O
drug	O
addicts	O
and	O
sex	O
workers	O
people	O
who	O
could	O
not	O
fight	O
back	O
as	O
one	O
agency	O
officer	O
put	O
it	O

In	O
addition	O
naloxone	B-Drug
could	O
be	O
used	O
to	O
challenge	O
a	O
person's	O
opioid	O
abstinence	O
status	O
prior	O
starting	O
medication	O
such	O
as	O
naltrexone	B-Drug
which	O
is	O
in	O
the	O
management	O
of	O
addiction	O

As	O
of	O
2005	O
India	O
was	O
the	O
only	O
country	O
producing	O
licit	O
opium	B-Drug
gum	O
for	O
both	O
domestic	O
use	O
and	O
export	O

amphetamine	B-Drug
hallucinogens	O
e	O

On	O
Nov	O
15	O
2013	O
the	O
DEA	O
added	O
25I-NBOMe	B-Drug
and	O
25C-	O
25B-NBOMe	B-Drug
to	O
Schedule	O
I	O
using	O
their	O
emergency	O
scheduling	O
powers	O
making	O
those	O
NBOMe	O
compounds	O
temporarily	O
in	O
for	O
2	O
years	O

Acetothiolutamide	O
is	O
a	O
selective	O
androgen	O
receptor	O
modulator	O
SARM	O
derived	O
from	O
the	O
nonsteroidal	O
antiandrogen	O
bicalutamide	B-Drug
that	O
was	O
described	O
in	O
2002	O
and	O
one	O
of	O
first	O
SARMs	O
to	O
be	O
discovered	O
developed	O

Mescaline	B-Drug
345-trimethoxyphenethylamine	O
is	O
a	O
psychedelic	O
drug	O
and	O
entheogen	O
which	O
also	O
found	O
in	O
some	O
other	O
species	O
of	O
genus	O
Echinopsis	O
i	O

It	O
is	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers	O
levoketoconazole	O
2S4R--ketoconazole	O
and	O
dextroketoconazole	O
2R4S-+-ketoconazole	O
ketoconazole	B-Drug

In	O
addition	O
to	O
its	O
medical	O
use	O
metenolone	B-Drug
enanthate	O
is	O
used	O
improve	O
physique	O
and	O
performance	O

In	O
terms	O
of	O
biosynthesis	O
oxycodone	B-Drug
has	O
been	O
found	O
naturally	O
in	O
nectar	O
extracts	O
from	O
the	O
orchid	O
family	O
Epipactis	O
helleborine;	O
together	O
along	O
with	O
another	O
opioid:	O
3-{2-{3-{3-benzyloxypropyl}-3-indol	O
78-didehydro-	O
45-epoxy-36-d-morphinan	O

Interdiction	O
efforts	O
using	O
current	O
armed	O
forces	O
resources	O
would	O
have	O
almost	O
no	O
effect	O
on	O
cocaine	B-Drug
importation	O
into	O
the	O
United	O
States	O
report	O
concluded	O

The	O
price	O
of	O
alirocumab	B-Drug
was	O
determined	O
based	O
in	O
part	O
on	O
making	O
apheresis	O
no	O
longer	O
necessary	O

The	O
company	O
promised	O
that	O
its	O
cocaine	B-Drug
products	O
would	O
supply	O
the	O
place	O
of	O
food	O
make	O
coward	O
brave	O
silent	O
eloquent	O
and	O
render	O
sufferer	O
insensitive	O
to	O
pain	O

Paracetamol	B-Drug
also	O
known	O
as	O
acetaminophen	B-Drug
is	O
a	O
medication	O
used	O
to	O
treat	O
pain	O
and	O
fever	O

12	O
when	O
dispensing	O
methadone	B-Drug
for	O
the	O
treatment	O
of	O
opioid	O
addiction	O
or	O
detoxification	O

During	O
the	O
mid-1940s	O
amidst	O
World	O
War	O
II	O
cocaine	B-Drug
was	O
considered	O
for	O
inclusion	O
as	O
an	O
ingredient	O
of	O
a	O
future	O
generation	O
'pep	O
pills'	O
German	O
military	O
code	O
named	O
D-IX	O

Opuntia	O
spinosior	O
Mescaline	B-Drug
0	O

Some	O
additional	O
money	O
is	O
made	O
by	O
drying	O
the	O
poppy	O
heads	O
and	O
collecting	O
seeds	O
a	O
small	O
fraction	O
of	O
opium	B-Drug
beyond	O
quota	O
may	O
be	O
consumed	O
locally	O
or	O
diverted	O
to	O
black	O
market	O

Nimetazepam	B-Drug
is	O
also	O
a	O
particularly	O
potent	O
anticonvulsant	O

emphasis	O
added	O
Drugs	O
listed	O
in	O
this	O
control	O
schedule	O
include:	O
MT	O
alpha-methyltryptamine	B-Drug
a	O
psychedelic	O
stimulant	O
and	O
entactogen	O
drug	O
of	O
the	O
tryptamine	O
class	O
that	O
was	O
originally	O
developed	O
as	O
an	O
antidepressant	O
by	O
workers	O
at	O
Upjohn	O
1960s	O

The	O
phenethylamine	B-Drug
psychedelics	O
on	O
the	O
other	O
hand	O
such	O
as	O
mescaline	B-Drug
and	O
compounds	O
of	O
2C	O
family	O
more	O
closely	O
resemble	O
neurotransmitter	O
dopamine	O

Designer	O
cannabinoids	O
are	O
another	O
recent	O
development	O
with	O
two	O
compounds	O
JWH-018	B-Drug
and	O
C8-CP	O
47497	O
initially	O
found	O
in	O
December	O
2008	O
as	O
active	O
components	O
of	O
herbal	O
smoking	O
blends	O
sold	O
legal	O
alternatives	O
to	O
marijuana	O

He	O
was	O
greatly	O
involved	O
in	O
the	O
synthesis	O
of	O
cimetidine	B-Drug
at	O
time	O
a	O
revolutionary	O
drug	O
for	O
treatment	O
and	O
prevention	O
peptic	O
ulcers	O

N1-Methyl-lysergic	O
acid	O
diethylamide	O
MLD-41	O
is	O
a	O
derivative	O
of	O
LSD	B-Drug
that	O
has	O
about	O
one-third	O
the	O
psychoactive	O
effects	O

However	O
it	O
is	O
now	O
known	O
that	O
only	O
around	O
10%	O
of	O
a	O
dose	O
PCP	B-Drug
removed	O
by	O
the	O
kidneys	O
which	O
would	O
make	O
increased	O
urinary	O
clearance	O
little	O
consequence;	O
furthermore	O
acidification	O
dangerous	O
as	O
may	O
induce	O
acidosis	O
and	O
worsen	O
rhabdomyolysis	O
muscle	O
breakdowna	O
not-unusual	O
manifestation	O
toxicity	O

Thalidomide	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
including	O
multiple	O
myeloma	O
graft-versus-host	O
disease	O
skin	O
conditions	O
complications	O
leprosy	O

On	O
June	O
18	O
2019	O
federal	O
authorities	O
seized	O
39525	O
pounds	O
or	O
nearly	O
20	O
tons	O
of	O
cocaine	B-Drug
at	O
the	O
Port	O
Philadelphia's	O
Packer	O
Marine	O
Terminal	O

According	O
to	O
the	O
October	O
2013	O
Esquire	O
article	O
Between	O
1982	O
and	O
1989	O
federal	O
prosecutors	O
estimated	O
Ross	O
bought	O
resold	O
several	O
metric	O
tons	O
of	O
cocaine	B-Drug

This	O
was	O
difficult	O
to	O
accomplish	O
because	O
dapsone	B-Drug
is	O
highly	O
insoluble	O
in	O
aqueous	O
solvents	O

Because	O
it	O
acts	O
on	O
so	O
many	O
receptors	O
chlorpromazine	B-Drug
is	O
often	O
referred	O
to	O
as	O
a	O
dirty	O
drug	O

For	O
this	O
reason	O
alcoholics	O
or	O
recovering	O
may	O
be	O
at	O
increased	O
risk	O
of	O
physical	O
dependency	O
abuse	O
zolpidem	B-Drug

The	O
central	O
nervous	O
system	O
side	O
effects	O
of	O
AG	O
are	O
due	O
to	O
its	O
nature	O
as	O
an	O
anticonvulsant	O
and	O
relation	O
glutethimide	B-Drug

Tejada	O
received	O
a	O
105-game	O
suspension	O
for	O
taking	O
Adderall	B-Drug
which	O
violated	O
the	O
MLB's	O
amphetamine	O
policy	O

In	O
the	O
1994	O
FIFA	O
World	O
Cup	O
Argentine	O
footballer	O
Diego	O
Armando	O
Maradona	O
tested	O
positive	O
for	O
ephedrine	B-Drug

It	O
is	O
the	O
-methoxy	O
analog	O
of	O
methylenedioxyphenethylamine	O
MDPEA	O
and	O
also	O
more	O
distantly	O
related	O
to	O
methylone	B-Drug

phentermine	B-Drug
nasal	O
decongestants	O
and	O
bronchodilators	O
e	O

Morphine	B-Drug
is	O
the	O
most	O
prevalent	O
and	O
important	O
alkaloid	O
in	O
opium	B-Drug
consisting	O
of	O
1016	O
percent	O
total	O
responsible	O
for	O
its	O
harmful	O
effects	O
such	O
as	O
lung	O
edema	O
respiratory	O
difficulties	O
coma	O
or	O
cardiac	O
collapse	O

MDMB-CHMICA	B-Drug
acts	O
as	O
a	O
highly	O
potent	O
full	O
agonist	O
of	O
the	O
CB1	O
receptor	O
with	O
an	O
efficacy	O
94%	O
and	O
EC50	O
value	O
0	O

The	O
FDA	O
required	O
that	O
Celgene	O
Corporation	O
which	O
planned	O
to	O
market	O
thalidomide	B-Drug
under	O
the	O
brand	O
name	O
Thalomid	B-Drug
establish	O
a	O
system	O
for	O
education	O
and	O
prescribing	O
safety	O
STEPS	O
oversight	O
program	O

At	O
therapeutic	O
doses	O
the	O
adverse	O
effects	O
of	O
amphetamine	B-Drug
do	O
not	O
impede	O
athletic	O
performance;	O
however	O
at	O
much	O
higher	O
can	O
induce	O
that	O
severely	O
impair	O
performance	O
such	O
as	O
rapid	O
muscle	O
breakdown	O
and	O
elevated	O
body	O
temperature	O

In	O
February	O
2004	O
a	O
leading	O
fentanyl	B-Drug
supplier	O
Janssen	O
Pharmaceutica	O
Products	O
L	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

The	O
program	O
was	O
counted	O
as	O
a	O
substantial	O
success	O
with	O
cessation	O
of	O
direct	O
British	O
opium	B-Drug
exports	O
to	O
China	O
but	O
not	O
Hong	O
Kong	O
and	O
most	O
provinces	O
declared	O
free	O
production	O

The	O
word	O
endorphin	O
is	O
derived	O
from	O
/	O
Greek:	O
ndon	O
meaning	O
within	O
endogenous	O
endogenes	O
proceeding	O
and	O
morphine	B-Drug
Morpheus	O
Ancient	O
romanized:	O
Morphes	O
the	O
god	O
of	O
dreams	O
in	O
Greek	O
mythology	O

Mirtazapine	B-Drug
is	O
used	O
as	O
an	O
antidepressant	O
in	O
patients	O
dealing	O
with	O
insomnia	O
and	O
weight	O
loss	O

This	O
is	O
a	O
revision	O
on	O
The	O
Methamphetamine	B-Drug
Remediation	O
Research	O
Act	O
of	O
2007	O
EPA	O
develop	O
guidelines	O
for	O
remediating	O
former	O
methamphetamine	B-Drug
labs	O

The	O
production	O
of	O
licit	O
opium	B-Drug
in	O
India	O
was	O
accord	O
with	O
terms	O
the	O
1961	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O

As	O
an	O
antifungal	O
ketoconazole	B-Drug
is	O
structurally	O
similar	O
to	O
imidazole	O
and	O
interferes	O
with	O
the	O
fungal	O
synthesis	O
of	O
ergosterol	O
a	O
constituent	O
cell	O
membranes	O
as	O
well	O
certain	O
enzymes	O

As	O
a	O
result	O
the	O
Drug	O
Enforcement	O
Administration	O
has	O
recommended	O
that	O
officers	O
not	O
field	O
test	O
drugs	O
if	O
fentanyl	B-Drug
is	O
suspected	O
but	O
instead	O
collect	O
and	O
send	O
samples	O
to	O
laboratory	O
for	O
analysis	O

The	O
net	O
effect	O
can	O
be	O
a	O
depression	O
of	O
prices	O
for	O
all	O
crops	O
which	O
both	O
make	O
the	O
farmer's	O
livelihood	O
more	O
precarious	O
and	O
cocaine	B-Drug
producers'	O
coca	B-Drug
supplies	O
cheaper	O

Tolerance	O
to	O
the	O
sleep-inducing	O
effects	O
of	O
nitrazepam	B-Drug
occurs	O
after	O
about	O
seven	O
days;	O
tolerance	O
also	O
frequently	O
its	O
anticonvulsant	O

MDMA	B-Drug
is	O
often	O
considered	O
the	O
drug	O
of	O
choice	O
within	O
rave	O
culture	O
and	O
also	O
used	O
at	O
clubs	O
festivals	O
house	O
parties	O

Serotonergic	O
drugs	O
such	O
as	O
most	O
antidepressants	O
co-administered	O
with	O
amphetamine	B-Drug
increases	O
the	O
risk	O
of	O
serotonin	O
syndrome	O

Much	O
is	O
still	O
not	O
known	O
about	O
what	O
factors	O
may	O
exist	O
to	O
aid	O
children	O
who	O
were	O
exposed	O
cocaine	B-Drug
in	O
utero	O

Boldenone	B-Drug
undecylenate	I-Drug
is	O
used	O
in	O
veterinary	O
medicine	O
mainly	O
horses	O

In	O
2019	O
the	O
FDA	O
warned	O
consumers	O
that	O
kratom	B-Drug
remains	O
unapproved	O
for	O
interstate	O
commerce	O
may	O
be	O
unsafe	O
in	O
commercially	O
available	O
products	O
and	O
is	O
on	O
an	O
import	O
alert	O
which	O
can	O
lead	O
to	O
confiscation	O
of	O
imported	O
supplies	O

Contraindications	O
of	O
desogestrel	B-Drug
include:	O
Allergy	O
to	O
or	O
any	O
other	O
ingredients	O
Active	O
thrombosis	O
deep	O
vein	O
pulmonary	O
embolism	O
Jaundice	O
severe	O
liver	O
disease	O
Hormone-sensitive	O
cancers	O
e	O

Delorazepam	B-Drug
is	O
mainly	O
used	O
as	O
an	O
anxiolytic	O
because	O
of	O
its	O
long	O
elimination	O
half-life;	O
showing	O
superiority	O
over	O
the	O
short-acting	O
drug	O
lorazepam	B-Drug

Methyltestosterone	B-Drug
is	O
highly	O
protein-bound	O
by	O
approximately	O
98%	O

Phase	O
II	O
trials	O
showed	O
effectiveness	O
is	O
analgesia	O
and	O
a	O
wider	O
therapeutic	O
window	O
than	O
morphine	B-Drug

Furthermore	O
enzalutamide	B-Drug
behaves	O
as	O
an	O
antagonist	O
of	O
the	O
W741C	O
mutant	O
AR	O
in	O
contrast	O
to	O
bicalutamide	B-Drug
which	O
a	O
pure	O
agonist	O
when	O
bound	O

New	O
products	O
containing	O
CBD	B-Drug
after	O
this	O
deadline	O
will	O
require	O
a	O
fully	O
approved	O
application	O

By	O
1957	O
over	O
36	O
million	O
prescriptions	O
had	O
been	O
filled	O
for	O
meprobamate	B-Drug
in	O
the	O
US	O
alone	O
a	O
billion	O
pills	B-Drug
manufactured	O
and	O
it	O
accounted	O
fully	O
third	O
of	O
all	O
written	O

Rapid	O
intravenous	O
injections	B-Drug
of	O
small	O
doses	O
0	O

In	O
the	O
early	O
1980s	O
majority	O
of	O
cocaine	B-Drug
being	O
shipped	O
to	O
United	O
States	O
was	O
landing	O
in	O
Miami	O
and	O
originated	O
Colombia	O
trafficked	O
through	O
Bahamas	O
Dominican	O
Republic	O

Salivary	O
levels	O
of	O
valproic	O
acid	O
correlate	O
poorly	O
with	O
serum	O
partly	O
due	O
to	O
valproate's	O
weak	O
property	O
pKa	O
4	O
valproate	B-Drug

It	O
enhances	O
the	O
metabolism	O
of	O
dexamethasone	B-Drug
so	O
hydrocortisone	B-Drug
should	O
be	O
used	O
instead	O

A	O
majority	O
of	O
tamoxifen	B-Drug
is	O
bound	O
to	O
albumin	O

Oxygen-free	O
alkaloids	O
such	O
as	O
nicotine	B-Drug
or	O
coniine	O
are	O
typically	O
volatile	O
colorless	O
oily	O
liquids	O

JWH-098	B-Drug
is	O
a	O
synthetic	O
cannabinoid	O
receptor	O
agonist	O
from	O
the	O
naphthoylindole	O
family	O

American	O
rapper	O
Lil	O
Peep	O
also	O
died	O
of	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O
on	O
November	O
15	O
2017	O

Methamphetamine	B-Drug
psychosis	O
or	O
long-term	O
effects	O
of	O
stimulant	O
use	O
in	O
the	O
brain	O
at	O
molecular	O
level	O
depend	O
upon	O
genetics	O
and	O
may	O
persist	O
for	O
some	O
time	O

This	O
process	O
is	O
described	O
by	O
the	O
Schikorr	O
reaction:	O
3	O
FeOH2	O
Fe3O4	B-Drug
+	O
2	O
H2O	O
H2This	O
occurs	O
during	O
anaerobic	O
corrosion	O
of	O
iron	O
and	O
steel	O
in	O
oxygen-free	O
groundwater	O
reducing	O
soils	O
below	O
water	O
table	O

When	O
stimulant	O
use	O
first	O
became	O
prevalent	O
in	O
Sweden	O
the	O
1950s	O
phenmetrazine	B-Drug
was	O
preferred	O
to	O
amphetamine	B-Drug
and	O
methamphetamine	B-Drug
by	O
users	O

Opioids	O
like	O
oxycodone	B-Drug
are	O
thought	O
to	O
produce	O
their	O
analgesic	O
effects	O
via	O
activation	O
of	O
the	O
MOR	O
in	O
midbrain	O
periaqueductal	O
gray	O
PAG	O
and	O
rostral	O
ventromedial	O
medulla	O
RVM	O

In	O
1986	O
Dyazide	B-Drug
was	O
the	O
most	O
prescribed	O
drug	O
in	O
US	O
and	O
had	O
$325	O
million	O
sales	O
making	O
it	O
SmithKline	O
Beckman's	O
second-biggest	O
seller	O
behind	O
Tagamet	B-Drug

Estazolam	B-Drug
also	O
has	O
anxiolytic	O
properties	O
and	O
due	O
to	O
its	O
long	O
half	O
life	O
can	O
be	O
an	O
effective	O
short-term	O
treatment	O
for	O
insomnia	O
associated	O
with	O
anxiety	O

The	O
Canadian	O
government	O
states	O
that	O
CBD	B-Drug
products	O
are	O
subject	O
to	O
all	O
of	O
the	O
rules	O
and	O
requirements	O
apply	O
cannabis	O
under	O
Cannabis	O
Act	O
its	O
regulations	O

Due	O
to	O
his	O
involvement	O
in	O
trafficking	O
cocaine	B-Drug
from	O
South	O
America	O
Italy	O
Morabito	O
was	O
nicknamed	O
the	O
king	O
of	O
Milan	O

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O
Sleep	O
Older	O
age	O
Concomitant	O
use	O
CNS	O
depressants	O
like	O
benzodiazepines	O
barbiturates	O
alcohol	O
and	O
inhaled	O
anesthetics	O
Hyperventilation	O
Decreased	O
CO2	O
levels	O
in	O
serum	O
Respiratory	O
acidosis	O
clearance	O
from	O
body	O
blood	O
flow	O
to	O
liver	O
Renal	O
insufficiencySustained	O
release	O
preparations	O
such	O
as	O
patches	O
may	O
also	O
produce	O
unexpected	O
delayed	O

THC	O
acetate	O
was	O
also	O
reported	O
to	O
have	O
been	O
found	O
by	O
New	O
Zealand	O
police	O
in	O
1995	O
again	O
made	O
acetylation	O
of	O
purified	O
cannabis	O
extracts	B-Drug
with	O
acetic	O
anhydride	O

As	O
the	O
medically	O
used	O
tartrate	O
salt	O
drug	O
is	O
also	O
known	O
as	O
levorphanol	B-Drug
USAN	O
BANM	O

The	O
clinical	O
benefits	O
of	O
spironolactone	B-Drug
as	O
a	O
diuretic	O
are	O
typically	O
not	O
seen	O
until	O
23	O
days	O
after	O
dosing	O
begins	O

Spironolactone	B-Drug
may	O
put	O
people	O
at	O
a	O
heightened	O
risk	O
for	O
gastrointestinal	O
issues	O
like	O
nausea	O
vomiting	O
diarrhea	O
cramping	O
and	O
gastritis	O

Hashish	B-Drug
also	O
spelled	O
hasheesh	O
hashisha	O
or	O
simply	O
hash	B-Drug
is	O
a	O
concentrated	O
resin	O
cake	O
ball	O
produced	O
from	O
pressed	O
kief	O
the	O
detached	O
trichomes	O
and	O
fine	O
material	O
that	O
falls	O
off	O
cannabis	O
fruits	O
flowers	O
leaves	O

Using	O
Purdue	O
documents	O
and	O
other	O
records	O
they	O
claim	O
that	O
was	O
aware	O
of	O
this	O
problem	O
even	O
before	O
the	O
drug	O
went	O
to	O
market	O
but	O
held	O
fast	O
12-hour	O
relief	O
in	O
part	O
protect	O
its	O
revenue	O
[because]	O
OxyContin's	O
dominance	O
high	O
priceup	O
hundreds	O
dollars	O
per	O
bottlehinge	O
on	O
duration	O
OxyContin	B-Drug

This	O
revised	O
policy	O
accompanied	O
an	O
increase	O
in	O
Nazi	O
Party	O
disapproval	O
of	O
alcohol	O
use	O
the	O
civilian	O
sector	O
reflecting	O
extension	O
to	O
longstanding	O
condemnation	O
tobacco	B-Drug
consumption	O
as	O
diminishing	O
strength	O
and	O
purity	O
Aryan	O
race	O

The	O
discovery	O
of	O
Librium	B-Drug
in	O
1957	O
was	O
due	O
largely	O
to	O
the	O
dedicated	O
work	O
and	O
observational	O
ability	O
a	O
gifted	O
technician	O
Beryl	O
Kappell	O

Fentanyl	B-Drug
was	O
often	O
produced	O
in	O
China	O
and	O
exported	O
illegally	O
to	O
the	O
U	O

Based	O
on	O
in	O
vitro	O
research	O
ethisterone	O
and	O
norethisterone	B-Drug
are	O
about	O
equipotent	O
their	O
EC50	O
values	O
for	O
activation	O
of	O
the	O
androgen	O
receptor	O
AR	O
whereas	O
conversely	O
shows	O
markedly	O
increased	O
potency	O
relative	O
to	O
terms	O
its	O
progesterone	O

Withdrawal	O
symptoms	O
have	O
also	O
been	O
reported	O
in	O
newborns	O
whose	O
mothers	O
had	O
either	O
injecting	O
or	O
orally	O
taking	O
oxycodone	B-Drug
during	O
pregnancy	O

In	O
addition	O
to	O
blockade	O
of	O
the	O
NMDA	O
receptor	O
active	O
metabolite	O
ketamine	B-Drug
hydroxynorketamine	O
which	O
does	O
not	O
interact	O
importantly	O
with	O
but	O
nonetheless	O
indirectly	O
activates	O
AMPA	O
receptors	O
similarly	O
may	O
also	O
or	O
alternatively	O
be	O
involved	O
in	O
rapid-onset	O
antidepressant	O
effects	O

To	O
avoid	O
being	O
controlled	O
by	O
the	O
Medicines	O
Act	O
designer	O
drugs	O
such	O
as	O
mephedrone	B-Drug
have	O
been	O
described	O
bath	O
salts	O
or	O
other	O
misnomers	O
plant	O
food	O
despite	O
compounds	O
having	O
no	O
history	O
of	O
used	O
for	O
these	O
purposes	O

In	O
October	O
2018	O
UFC	O
fighter	O
Sean	O
O'Malley	O
tested	O
positive	O
for	O
Enobosarm	B-Drug
and	O
was	O
suspended	O
by	O
the	O
Nevada	O
State	O
Athletic	O
Commission	O
USADA	O
six	O
months	O

Buspirone	B-Drug
is	O
metabolized	O
primarily	O
by	O
CYP3A4	O
and	O
prominent	O
drug	O
interactions	O
with	O
inhibitors	O
inducers	O
of	O
this	O
enzyme	O
have	O
been	O
observed	O

Ibogaine	B-Drug
has	O
also	O
been	O
reported	O
in	O
multiple	O
small-study	O
cohorts	O
to	O
reduce	O
cravings	O
for	O
methamphetamine	B-Drug

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O

Sydenham's	O
1669	O
recipe	O
for	O
laudanum	B-Drug
mixed	O
opium	B-Drug
with	O
wine	O
saffron	O
clove	O
and	O
cinnamon	O

He	O
later	O
claimed	O
the	O
positive	O
finding	O
was	O
result	O
of	O
sabotage	O
and	O
that	O
he	O
had	O
actually	O
taken	O
Furazabol	B-Drug
which	O
at	O
time	O
could	O
not	O
be	O
detected	O
by	O
Gas	O
Chromatography-Mass	O
Spectrometry	O
assay	O
used	O
to	O
analyze	O
samples	O
Games	O

Some	O
studies	O
show	O
that	O
the	O
increased	O
legalization	O
of	O
cannabis	O
in	O
United	O
States	O
beginning	O
2012	O
with	O
Washington	O
Initiative	O
502	O
and	O
Colorado	O
Amendment	O
64	O
has	O
led	O
Mexican	O
cartels	O
to	O
smuggle	O
less	O
exchange	O
for	O
more	O
heroin	B-Drug

It	O
was	O
developed	O
in	O
the	O
1950s	O
during	O
research	O
into	O
analogues	O
of	O
pethidine	B-Drug
and	O
assessed	O
by	O
United	O
Nations	O
Office	O
on	O
Drugs	O
Crime	O
but	O
not	O
included	O
list	O
drugs	O
under	O
international	O
control	O
probably	O
because	O
it	O
used	O
medicine	O
or	O
widely	O
available	O

This	O
also	O
explains	O
why	O
oral	O
ketamine	B-Drug
levels	O
are	O
independent	O
of	O
CYP2B6	O
activity	O
unlike	O
subcutaneous	O

An	O
extended-release	O
version	O
of	O
hydromorphone	B-Drug
called	O
Palladone	B-Drug
was	O
available	O
for	O
a	O
short	O
time	O
in	O
the	O
United	O
States	O
before	O
being	O
voluntarily	O
withdrawn	O
from	O
market	O
after	O
July	O
2005	O
FDA	O
advisory	O
warned	O
high	O
overdose	O
potential	O
when	O
taken	O
with	O
alcohol	O

It	O
is	O
sold	O
as	O
a	O
combination	O
drug	O
with	O
naltrexone	B-Drug
Contrave	O

This	O
includes	O
common	O
injections	B-Drug
such	O
as	O
subcutaneous	O
intramuscular	O
and	O
intravenous	O
well	O
less	O
intraperitoneal	O
intraosseous	O
intracardiac	O
intraarticular	O
intracavernous	O

highly	O
dosed	O
antacids	O
ranitidine	B-Drug
150	O
mg	O
at	O
bedtime	O
or	O
omeprazole	B-Drug
20	O

Half-life	O
elimination:	O
With	O
normal	O
renal	O
function	O
ranitidine	B-Drug
taken	O
orally	O
has	O
a	O
half-life	O
of	O
2	O

Controlled-release	O
dihydrocodeine	B-Drug
is	O
a	O
non-prescription	O
item	O
in	O
some	O
places	O
especially	O
the	O
60	O
mg	O
strength	O

Under	O
the	O
brand	O
name	O
Metharmon-F	O
and	O
in	O
combination	O
with	O
sex	O
steroids	O
pregnenolone	O
testosterone	O
estrone	O
androstenediol	O
thyroid	O
hormone	O
desiccated	O
androstenedione	B-Drug
is	O
or	O
has	O
been	O
marketed	O
for	O
medical	O
use	O
Thailand	O

Preliminary	O
research	O
for	O
the	O
potential	O
use	O
of	O
ibogaine	B-Drug
in	O
treatment	O
opioid	O
dependence	O
is	O
ongoing	O
21st	O
century	O
with	O
several	O
clinics	O
using	O
Western	O
countries	O
Panama	O
and	O
Caribbean	O
islands	O

In	O
1974	O
Saxena	O
showed	O
that	O
methysergide	B-Drug
had	O
a	O
selective	O
vasoconstrictor	O
effect	O
in	O
the	O
carotid	O
bed	O
and	O
1984	O
he	O
found	O
an	O
atypical	O
receptor	O

Because	O
bicalutamide	B-Drug
circulates	O
at	O
relatively	O
high	O
concentrations	O
and	O
is	O
highly	O
protein-bound	O
it	O
has	O
the	O
potential	O
to	O
displace	O
other	O
drugs	O
like	O
warfarin	B-Drug
phenytoin	B-Drug
theophylline	B-Drug
aspirin	B-Drug
from	O
plasma	O
binding	O
proteins	O

recalled	O
one	O
lot	O
and	O
later	O
additional	O
lots	O
of	O
fentanyl	B-Drug
brand	O
name:	O
Duragesic	B-Drug
patches	O
because	O
seal	O
breaches	O
which	O
might	O
have	O
allowed	O
the	O
medication	O
to	O
leak	O
from	O
patch	O

In	O
2011	O
The	O
Coca-Cola	O
Company	O
filed	O
an	O
opposition	O
to	O
Redux	O
Beverages'	O
trademark	O
of	O
Cocaine	B-Drug
in	O
Chile	O
claiming	O
that	O
the	O
referenced	O
would	O
infringe	O
fair	O
competition	O

The	O
MDMA	B-Drug
concentration	O
in	O
the	O
blood	O
stream	O
starts	O
to	O
rise	O
after	O
about	O
30	O
minutes	O
and	O
reaches	O
its	O
maximal	O
between	O
1	O

Because	O
of	O
these	O
properties	O
milnacipran	B-Drug
exhibits	O
almost	O
ideal	O
pharmacokinetics	O
in	O
humans	O
such	O
as	O
high	O
bioavailability	O
low	O
inter-subject	O
variability	O
limited	O
liver	O
enzyme	O
interaction	O
moderate	O
tissue	O
distribution	O
and	O
a	O
reasonably	O
long	O
elimination	O
half-life	O

Neuropathological	O
examination	O
revealed	O
no	O
evidence	O
of	O
degenerative	O
changes	O
in	O
a	O
woman	O
who	O
had	O
received	O
four	O
separate	O
doses	O
ibogaine	B-Drug
ranging	O
between	O
10	O
and	O
30	O
mg	O
kg	O
over	O
15-month	O
interval	O

Acetyl-L-carnitine	O
lowers	O
hyperammonemia	O
less	O
markedly	O
than	O
L-carnitine	B-Drug

In	O
addition	O
multiple	O
studies	O
suggest	O
the	O
use	O
of	O
H2	O
receptor	O
antagonists	O
such	O
as	O
ranitidine	B-Drug
may	O
increase	O
risk	O
infectious	O
diarrhoea	O
including	O
traveller's	O
and	O
salmonellosis	O

Naltrexone	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
mainly	O
to	O
6-naltrexol	O
by	O
enzyme	O
dihydrodiol	O
dehydrogenase	O

However	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake	O

Mannitol	B-Drug
is	O
one	O
of	O
the	O
most	O
abundant	O
energy	O
and	O
carbon	O
storage	O
molecules	O
in	O
nature	O
produced	O
by	O
a	O
plethora	O
organisms	O
including	O
bacteria	O
yeasts	O
fungi	O
algae	O
lichens	O
many	O
plants	O

The	O
most	O
common	O
adverse	O
effects	O
of	O
intercavernosal	O
injections	B-Drug
include	O
fibrosis	O
and	O
pain	O
as	O
well	O
hematomas	O
or	O
bruising	O
around	O
the	O
injection	O
site	O

As	O
a	O
consequence	O
amphetamine	B-Drug
is	O
illegally	O
manufactured	O
in	O
clandestine	O
labs	O
to	O
be	O
trafficked	O
and	O
sold	O
users	O

A	O
Cochrane	O
review	O
on	O
the	O
treatment	O
of	O
ADHD	O
in	O
children	O
with	O
tic	O
disorders	O
such	O
as	O
Tourette	O
syndrome	O
indicated	O
that	O
stimulants	O
general	O
do	O
not	O
make	O
tics	O
worse	O
but	O
high	O
doses	O
dextroamphetamine	B-Drug
could	O
exacerbate	O
some	O
individuals	O

C6G	O
exhibits	O
decreased	O
immunosuppressive	O
effects	O
compared	O
to	O
codeine	B-Drug

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
spironolactone	B-Drug
to	O
loop	O
diuretics	O
in	O
patients	O
with	O
heart	O
failure	O
was	O
associated	O
a	O
higher	O
risk	O
hyperkalemia	O
and	O
acute	O
kidney	O
injury	O
AKI	O

Several	O
of	O
these	O
have	O
significantly	O
greater	O
in	O
vitro	O
potency	O
compared	O
to	O
desmethylprodine	B-Drug

Modified	O
donor	O
T	O
cells	O
were	O
engineered	O
to	O
attack	O
the	O
leukemia	O
be	O
resistant	O
Alemtuzumab	B-Drug
and	O
evade	O
detection	O
by	O
host	O
immune	O
system	O
after	O
introduction	O

The	O
main	O
use	O
for	O
this	O
drug	O
has	O
been	O
in	O
studies	O
of	O
the	O
binding	O
site	O
at	O
5-HT2A	O
receptor	O
through	O
which	O
LSD	B-Drug
exerts	O
most	O
its	O
pharmacological	O
effects	O
with	O
stereoselective	O
activity	O
these	O
unsymmetric	O
monoalkyl	O
lysergamides	O
foreshadowing	O
subsequent	O
development	O
compounds	O
such	O
as	O
lysergic	O
acid	B-Drug
24-dimethylazetidide	O
LSZ	O

Psilocybin	O
is	O
about	O
100	O
times	O
less	O
potent	O
than	O
LSD	B-Drug
on	O
a	O
weight	O
per	O
basis	O
and	O
the	O
physiological	O
effects	O
last	O
half	O
as	O
long	O

In	O
June	O
2008	O
more	O
than	O
20	O
people	O
were	O
hospitalized	O
with	O
psychosis	O
in	O
Norway	O
after	O
ingesting	O
counterfeit	O
rohypnol	B-Drug
tablets	O
containing	O
hyoscine	O

Androgens	O
and	O
anabolic	O
steroids	O
AR	O
agonists	O
Examples:	O
testosterone	O
androstanolone	O
dihydrotestosterone	O
prasterone	O
dehydroepiandrosterone	O
nandrolone	B-Drug
nortestosterone	B-Drug
methyltestosterone	B-Drug
metandienone	B-Drug
methandrostenolone	B-Drug
oxandrolone	B-Drug
stanozolol	B-Drug
danazol	B-Drug
Selective	O
androgen	O
receptor	O
modulators	O
mixed	O
agonists/antagonists	O
enobosarm	B-Drug
ostarine;	O
GTx-024	O
MK-2866	O
andarine	B-Drug
GTx-007	O
Antiandrogens	O
antagonists	O
cyproterone	O
acetate	I-Drug
chlormadinone	O
spironolactone	B-Drug
flutamide	O
bicalutamide	B-Drug
enzalutamide	B-Drug
apalutamide	B-Drug
Estrogens	O
ER	O
estradiol	O
estrone	O
estriol	O
estetrol	O
conjugated	O
estrogens	O
Premarin	O
ethinylestradiol	O
diethylstilbestrol	O
stilbestrol	O
chlorotrianisene	O
estrogen	O
tamoxifen	B-Drug
clomifene	B-Drug
cyclofenil	O
raloxifene	O
toremifene	O
lasofoxifene	O
ospemifene	B-Drug
bazedoxifene	O
Antiestrogens	O
fulvestrant	B-Drug
ICI-164384	O
TAS-108	O
SR-16234	O
ZB716	O
fulvestrant-3-boronic	O
acid	O
ethamoxytriphetol	O
MER-25	O
Progestogens	O
progestins	O
PR	O
progesterone	O
medroxyprogesterone	B-Drug
norethisterone	B-Drug
norethindrone	O
levonorgestrel	B-Drug
drospirenone	O
dydrogesterone	O
mifepristone	B-Drug
ulipristal	B-Drug
telapristone	O
CDB-4124	O
vilaprisan	O
BAY-1002670	O
Antiprogestogens	O
aglepristone	O
onapristone	O
ZK-89299	O
Drugs	O
that	O
indirectly	O
influence	O
sex	O
hormone	O
systems	O
such	O
as	O
antigonadotropins	O
like	O
GnRH	O
analogues	O
prolactin	O
releasers	O
e	O
ostarine	B-Drug

On	O
February	O
26	O
the	O
FDA	O
warned	O
a	O
California	O
manufacturer	O
of	O
kratom	B-Drug
product	O
called	O
Mitrasafe	O
that	O
supplement	O
was	O
not	O
confirmed	O
as	O
safe	O
approved	O
dietary	O
or	O
drug	O
and	O
illegal	O
for	O
interstate	O
commerce	O

As	O
components	O
of	O
the	O
liana	O
Banisteriopsis	O
caapi	O
-carbolines	O
harmine	O
harmaline	O
and	O
tetrahydroharmine	O
play	O
a	O
pivotal	O
role	O
in	O
pharmacology	O
indigenous	O
psychedelic	O
drug	O
ayahuasca	O
by	O
preventing	O
breakdown	O
dimethyltryptamine	B-Drug
gut	O
reversibly	O
inhibiting	O
monoamine	O
oxidase	O
thus	O
making	O
it	O
psychoactive	O
upon	O
oral	O
administration	O

It	O
was	O
found	O
that	O
its	O
potency	O
10	O
times	O
of	O
levonorgestrel	B-Drug

However	O
the	O
few	O
studies	O
that	O
used	O
amphetamine	B-Drug
bupropion	B-Drug
methylphenidate	B-Drug
and	O
modafinil	B-Drug
as	O
a	O
replacement	O
therapy	O
did	O
not	O
result	O
in	O
less	O
methamphetamine	B-Drug
use	O
or	O
craving	O

LSD	B-Drug
is	O
produced	O
in	O
crystalline	O
form	O
and	O
then	O
mixed	O
with	O
excipients	O
or	O
redissolved	O
for	O
production	O
ingestible	O
forms	O

In	O
the	O
United	O
States	O
deaths	O
linked	O
to	O
methadone	B-Drug
more	O
than	O
quadrupled	O
in	O
five-year	O
period	O
between	O
1999	O
and	O
2004	O

The	O
2018	O
Farm	O
Bill	O
requires	O
that	O
research	O
and	O
development	O
of	O
CBD	B-Drug
for	O
a	O
therapeutic	O
purpose	O
would	O
have	O
to	O
be	O
conducted	O
under	O
notification	O
reporting	O
the	O
FDA	O

An	O
explosion	O
of	O
recreational	O
use	O
during	O
the	O
1960s	O
gained	O
LSD	B-Drug
and	O
Psilocybin	O
a	O
great	O
deal	O
notoriety	O
ultimately	O
led	O
to	O
their	O
categorization	O
as	O
Schedule	O
I	O
illicit	O
drugs	O
in	O
1970	O

In	O
a	O
separate	O
study	O
conducted	O
by	O
the	O
CDC	O
82%	O
of	O
fentanyl	B-Drug
overdose	O
deaths	O
involved	O
illegally	O
manufactured	O
while	O
only	O
4%	O
were	O
suspected	O
to	O
originate	O
from	O
prescription	O

National	O
Center	O
for	O
Health	O
Statistics	O
as	O
well	O
a	O
2006	O
series	O
in	O
the	O
Charleston	O
Gazette	O
West	O
Virginia	O
medical	O
examiners	O
listed	O
methadone	B-Drug
contributing	O
to	O
3849	O
deaths	O
2004	O

PCP	B-Drug
like	O
ketamine	B-Drug
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O

In	O
the	O
mid-1990s	O
Janssen	O
Pharmaceutica	O
developed	O
and	O
introduced	O
into	O
clinical	O
trials	O
Duragesic	B-Drug
patch	O
which	O
is	O
a	O
formulation	O
of	O
an	O
inert	O
alcohol	O
gel	O
infused	O
with	O
select	O
fentanyl	B-Drug
doses	O
are	O
worn	O
to	O
provide	O
constant	O
administration	O
opioid	O
over	O
period	O
48	O
72	O
hours	O

Despite	O
being	O
a	O
more	O
potent	O
analgesic	O
fentanyl	B-Drug
tends	O
to	O
induce	O
less	O
nausea	O
as	O
well	O
histamine-mediated	O
itching	O
than	O
morphine	B-Drug

Methyltestosterone	B-Drug
can	O
sometimes	O
cause	O
hepatotoxicity	O
for	O
instance	O
elevated	O
liver	O
enzymes	O
cholestatic	O
jaundice	O
peliosis	O
hepatis	O
hepatomas	O
and	O
hepatocellular	O
carcinoma	O
with	O
extended	O
use	O

A	O
compromise	O
was	O
also	O
struck	O
that	O
allowed	O
heroin	B-Drug
and	O
some	O
other	O
drugs	O
classified	O
as	O
particularly	O
dangerous	O
to	O
escape	O
absolute	O
prohibition	O

In	O
August	O
2011	O
New	O
Zealand	O
added	O
not	O
only	O
RCS-4	B-Drug
but	O
also	O
its	O
1-butyl	O
homologue	O
and	O
the	O
2-methoxybenzoyl	O
isomers	O
of	O
both	O
these	O
compounds	O
to	O
a	O
temporary	O
class	O
drug	O
schedule	O
i	O

Until	O
2004	O
the	O
government	O
allowed	O
each	O
residential	O
family	O
to	O
grow	O
1600m2	O
of	O
coca	B-Drug
crop	O
enough	O
provide	O
with	O
a	O
monthly	O
minimum	O
wage	O

Myrophine	B-Drug
is	O
a	O
Class	O
A	O
controlled	O
substance	O
in	O
the	O
UK	O
and	O
on	O
UN's	O
Yellow	O
list	O

each	O
tablet	O
contains	O
120	O
mg	O
dihydrocodeine	B-Drug
bitartrate	O
representing	O
80	O
base	O

Accidental	O
or	O
deliberate	O
overdose	O
is	O
common	O
with	O
opium	B-Drug
tincture	O
given	O
the	O
highly	O
concentrated	O
nature	O
of	O
solution	O

It	O
made	O
the	O
use	O
and	O
possession	O
of	O
opium	B-Drug
any	O
its	O
derivatives	O
illegal	O

The	O
5-reduced	O
and	O
1	O
12-dehydrogenated	O
analogue	O
of	O
prasterone	O
is	O
1-dehydroepiandrosterone	O
1-DHEA	O
or	O
1-androsterone	O
which	O
a	O
prohormone	O
1-testosterone	B-Drug
1-DHT	O
dihydroboldenone	O

Serum	O
JWH-018	B-Drug
concentrations	O
are	O
generally	O
in	O
the	O
110	O
g/L	O
range	O
during	O
first	O
few	O
hours	O
after	O
recreational	O
usage	O

For	O
sublingual	O
and	O
buccal	O
administration	O
25I-NBOMe	B-Drug
is	O
often	O
applied	O
to	O
sheets	O
of	O
blotter	O
paper	O
which	O
small	O
portions	O
tabs	O
are	O
held	O
in	O
the	O
mouth	O
allow	O
absorption	O
through	O
oral	O
mucosa	O

Cardiovascular	O
and	O
respiratory	O
adverse	O
effects	O
can	O
occur	O
with	O
tetrazepam	B-Drug
similar	O
to	O
other	O
benzodiazepines	O

One	O
US	O
Department	O
of	O
Justice	O
publication	O
lists	O
China	O
White	O
as	O
a	O
synonym	O
for	O
number	O
fentanyl	B-Drug
analogues	O
including	O
3-methylfentanyl	B-Drug
and	O
-methylfentanyl	O
which	O
today	O
are	O
classified	O
Schedule	O
I	O
drugs	O
in	O
the	O
United	O
States	O

The	O
amount	O
of	O
transfer	O
oxymorphone	B-Drug
into	O
the	O
breast	O
milk	O
is	O
not	O
known	O
and	O
women	O
are	O
cautioned	O
to	O
weigh	O
risks	O
benefits	O
before	O
breastfeeding	O
while	O
on	O
this	O
medication	O

Dipipanone	B-Drug
Pipadone	O
is	O
a	O
strong	O
opioid	O
analgesic	O
drug	O
used	O
for	O
very	O
severe	O
pain	O
in	O
cases	O
where	O
other	O
analgesics	O
are	O
unsuitable	O
instance	O
morphine	B-Drug
indicated	O
but	O
cannot	O
be	O
due	O
to	O
the	O
patient	O
being	O
allergic	O

Bayer	O
scientists	O
were	O
not	O
the	O
first	O
to	O
make	O
heroin	B-Drug
but	O
their	O
discovered	O
ways	O
it	O
and	O
led	O
commercialization	O
of	O

Marijuana	B-Drug
use	O
in	O
the	O
United	O
States	O
is	O
three	O
times	O
above	O
global	O
average	O
but	O
line	O
with	O
other	O
Western	O
democracies	O

Hearing	O
about	O
this	O
problem	O
and	O
the	O
disconnected	O
appearance	O
of	O
patients	O
wife	O
one	O
pharmacologists	O
working	O
on	O
ketamine	B-Drug
Edward	O
Domino	O
suggested	O
dissociative	O
anesthesia	O

Unprocessed	O
cocaine	B-Drug
such	O
as	O
coca	B-Drug
leaves	O
are	O
occasionally	O
purchased	O
and	O
sold	O
but	O
this	O
is	O
exceedingly	O
rare	O
it	O
much	O
easier	O
more	O
profitable	O
to	O
conceal	O
smuggle	O
in	O
powdered	O
form	O

However	O
another	O
study	O
showed	O
marked	O
next	O
day	O
impairments	O
after	O
repeated	O
administration	O
due	O
to	O
accumulation	O
of	O
quazepam	B-Drug
and	O
its	O
long-acting	O
metabolites	O

The	O
severity	O
and	O
location	O
of	O
the	O
deformities	O
depended	O
on	O
how	O
many	O
days	O
into	O
pregnancy	O
mother	O
was	O
before	O
beginning	O
treatment;	O
thalidomide	B-Drug
taken	O
20th	O
day	O
caused	O
central	O
brain	O
damage	O
21	O
would	O
eyes	O
22	O
ears	O
face	O
24	O
arms	O
leg	O
occur	O
if	O
up	O
to	O
28	O

Later	O
that	O
month	O
800000	O
Captagon	B-Drug
pills	O
were	O
found	O
on	O
a	O
boat	O
in	O
the	O
United	O
Arab	O
Emirates	O

However	O
studies	O
show	O
that	O
cocaine	B-Drug
can	O
also	O
cause	O
a	O
decrease	O
in	O
DAT	O
mRNA	O
levels	O
most	O
likely	O
due	O
to	O
blocking	O
dopamine	O
receptors	O
rather	O
than	O
direct	O
interference	O
with	O
transcriptional	O
or	O
translational	O
pathways	O

BZP	B-Drug
is	O
also	O
banned	O
in	O
Greece	O
Poland	O
Italy	O
Ireland	O
Malta	O
Estonia	O
Denmark	O
and	O
Sweden	O

The	O
script	O
described	O
a	O
shipment	O
containing	O
one	O
pound	O
of	O
LSD	B-Drug
[tabs]	O
enough	O
to	O
turn	O
the	O
entire	O
population	O
Los	O
Angeles	O
into	O
dangerous	O
psychotics	O
on	O
premise	O
that	O
dose	O
made	O
person	O
legally	O
insane	O
due	O
recurrence	O
completely	O
unpredictable	O
flashbacks	B-Drug
throughout	O
user's	O
life	O
after	O
single	O

Opioids	O
do	O
not	O
cause	O
any	O
specific	O
organ	O
toxicity	O
unlike	O
many	O
other	O
drugs	O
such	O
as	O
aspirin	B-Drug
and	O
paracetamol	B-Drug

Some	O
Australian	O
cities	O
such	O
as	O
Sydney	O
have	O
instituted	O
legal	O
diamorphine	B-Drug
supervised	O
injecting	O
centers	O
in	O
line	O
with	O
other	O
wider	O
harm	O
minimization	O
programs	O

Other	O
phenethylamines	O
that	O
share	O
this	O
structure	O
include	O
the	O
stimulants	O
methcathinone	B-Drug
MDPV	B-Drug
mephedrone	B-Drug
and	O
antidepressant	O
bupropion	B-Drug

Ergotamine	B-Drug
continues	O
to	O
be	O
prescribed	O
for	O
migraines	O
and	O
cluster	O
headaches	O

6	O
million	O
tablets	O
of	O
LSD	B-Drug
that	O
was	O
distributed	O
under	O
the	O
name	O
orange	O
sunshine	O

Other	O
Z-drugs	O
include	O
zaleplon	B-Drug
and	O
zolpidem	B-Drug
were	O
initially	O
thought	O
to	O
be	O
less	O
addictive	O
than	O
benzodiazepines	O

Opium	B-Drug
cocaine	B-Drug
amphetamine	B-Drug
and	O
methamphetamine	B-Drug
are	O
Schedule	O
II	O
drugs	O
whose	O
manufacturing	O
or	O
distribution	O
is	O
a	O
class	O
B	O
felony	O
can	O
carry	O
sentence	O
up	O
to	O
10	O
years	O

MBDB	O
is	O
a	O
closely	O
related	O
chemical	O
analogue	O
of	O
MDMA	B-Drug
with	O
the	O
only	O
difference	O
between	O
two	O
molecules	O
being	O
an	O
ethyl	O
group	O
instead	O
methyl	O
attached	O
to	O
alpha	O
carbon	O

WarnerLambert	O
which	O
merged	O
with	O
Pfizer	O
in	O
2000	O
used	O
activities	O
not	O
usually	O
associated	O
sales	O
promotion	O
including	O
continuing	O
medical	O
education	O
and	O
research	O
sponsored	O
articles	O
about	O
the	O
drug	O
for	O
literature	O
alleged	O
suppression	O
of	O
unfavorable	O
study	O
results	O
to	O
promote	O
gabapentin	B-Drug

AG	O
is	O
a	O
nonsteroidal	O
compound	O
specifically	O
glutarimide	O
and	O
derivative	O
of	O
glutethimide	B-Drug

naloxone	B-Drug
nalmefene	O
diprenorphineThe	O
initial	O
24	O
hours	O
after	O
opioid	O
administration	O
appear	O
to	O
be	O
the	O
most	O
critical	O
with	O
regard	O
life-threatening	O
OIRD	O
but	O
may	O
preventable	O
a	O
more	O
cautious	O
approach	O
use	O

East	O
India	O
Company	O
merchants	O
balanced	O
an	O
economic	O
deficit	O
from	O
the	O
importation	O
of	O
Chinese	O
tea	O
by	O
selling	O
Indian	O
opium	B-Drug
which	O
was	O
smuggled	O
into	O
China	O
in	O
defiance	O
Qing	O
government	O
bans	O

Some	O
states	O
took	O
the	O
position	O
of	O
outright	O
banning	O
all	O
forms	O
cocaine	B-Drug
sale;	O
Georgia	O
was	O
first	O
to	O
do	O
this	O
in	O
1902	O

Bromazepam	B-Drug
has	O
also	O
been	O
used	O
in	O
serious	O
criminal	O
offences	O
including	O
robbery	O
homicide	O
and	O
sexual	O
assault	O

Like	O
many	O
other	O
drugs	O
PCP	B-Drug
has	O
been	O
known	O
to	O
alter	O
mood	O
states	O
in	O
an	O
unpredictable	O
fashion	O
causing	O
some	O
individuals	O
become	O
detached	O
and	O
others	O
animated	O

Instead	O
the	O
experiment	O
produced	O
an	O
acetylated	O
form	O
of	O
morphine	B-Drug
one	O
and	O
a	O
half	O
to	O
two	O
times	O
more	O
potent	O
than	O
itself	O

The	O
bill	O
passed	O
the	O
Senate	O
on	O
10	O
February	O
2006	O
and	O
mifepristone	B-Drug
is	O
now	O
legal	O
in	O
Australia	O

Two	O
books	O
Estrogen	O
Action	O
Selective	O
Receptor	O
Modulators	O
and	O
Women's	O
Health	O
Imperial	O
College	O
Press	O
2013	O
Tamoxifen	B-Drug
Pioneering	O
Medicine	O
in	O
Breast	O
Cancer	O
Springer	O
tell	O
this	O
story	O

Fentanyl	B-Drug
has	O
a	O
therapeutic	O
index	O
of	O
270	O

Clenbuterol	B-Drug
is	O
occasionally	O
referred	O
to	O
as	O
bute	O
and	O
this	O
risks	O
confusion	O
with	O
phenylbutazone	O
also	O
called	O

Bromazepam	B-Drug
has	O
a	O
similar	O
misuse	O
risk	O
as	O
other	O
benzodiazepines	O
such	O
diazepam	B-Drug

Pethidine	B-Drug
was	O
one	O
of	O
several	O
prescription	O
drugs	O
which	O
Michael	O
Jackson	O
addicted	O
to	O
at	O
the	O
time	O
and	O
singer	O
describes	O
this	O
in	O
lyrics	O
song	O
with	O
phrases	O
such	O
as	O
Relax/This	O
won't	O
hurt	O
you	O
Yesterday	O
had	O
his	O
trust/Today	O
he's	O
taking	O
twice	O
much	O

The	O
other	O
drugs	O
included	O
diazepam	B-Drug
as	O
a	O
tranquilizer	O
cisatracurium	B-Drug
besylate	O
muscle	O
relaxant	O
and	O
potassium	O
chloride	O
to	O
stop	O
the	O
heart	O

In	O
June	O
2017	O
faced	O
with	O
the	O
public	O
health	O
crisis	O
opioid	O
epidemic	O
FDA	O
asked	O
Endo	O
Pharmaceuticals	O
to	O
remove	O
its	O
pain	O
medication	O
reformulated	O
Opana	B-Drug
ER	I-Drug
oxymorphone	B-Drug
hydrochloride	I-Drug
from	O
market	O

Modafinil	B-Drug
originated	O
with	O
the	O
late	O
1970s	O
invention	O
of	O
a	O
series	O
benzhydryl	O
sulfinyl	O
compounds	O
including	O
adrafinil	B-Drug
which	O
was	O
first	O
offered	O
as	O
an	O
experimental	O
treatment	O
for	O
narcolepsy	O
in	O
France	O
1986	O

Many	O
question	O
this	O
as	O
cocaine	B-Drug
is	O
much	O
synthesised	O
heroin	B-Drug
both	O
are	O
produced	O
extracts	O
from	O
plants	O

They	O
can	O
be	O
thought	O
of	O
as	O
the	O
functional	O
opposites	O
AR	O
agonists	O
for	O
instance	O
androgens	O
and	O
anabolic	O
steroids	O
AAS	O
like	O
testosterone	O
DHT	O
nandrolone	B-Drug
selective	O
androgen	O
receptor	O
modulators	O
SARMs	O
enobosarm	B-Drug

The	O
incidence	O
of	O
psychotomimetic	O
effects	O
such	O
as	O
unreality	O
depersonalization	O
delusions	O
dysphoria	O
and	O
hallucinations	O
has	O
been	O
shown	O
to	O
be	O
less	O
than	O
that	O
which	O
occurs	O
with	O
pentazocine	B-Drug

Illicit	O
heroin	B-Drug
is	O
of	O
widely	O
varying	O
and	O
unpredictable	O
purity	O

In	O
1895	O
Bayer	O
marketed	O
diacetylmorphine	B-Drug
as	O
an	O
over-the-counter	O
drug	O
under	O
the	O
trademark	O
name	O
Heroin	B-Drug

In	O
general	O
MDMA	B-Drug
users	O
report	O
feeling	O
the	O
onset	O
of	O
subjective	O
effects	O
within	O
30	O
to	O
60	O
minutes	O
oral	O
consumption	O
and	O
reaching	O
peak	O
effect	O
at	O
75	O
120	O
which	O
then	O
plateaus	O
for	O
about	O
3	O

In	O
general	O
they	O
are	O
used	O
in	O
combination	O
with	O
certain	O
other	O
steroid	O
medications	O
such	O
as	O
dexamethasone	B-Drug

6%	O
incidence	O
of	O
negative	O
outcome	O
with	O
spironolactone	B-Drug

By	O
weight	O
dimenhydrinate	B-Drug
is	O
between	O
53%	O
to	O
55	O

DMT	O
is	O
found	O
as	O
a	O
minor	O
alkaloid	O
in	O
snuff	B-Drug
made	O
from	O
Virola	O
bark	O
resin	O
which	O
5-MeO-DMT	B-Drug
the	O
main	O
active	O

PRO-LAD	B-Drug
is	O
a	O
psychedelic	O
drug	O
similar	O
to	O
LSD	B-Drug
and	O
around	O
as	O
potent	O
itself	O
with	O
an	O
active	O
dose	O
reported	O
at	O
between	O
100	O
200	O
micrograms	O

The	O
many	O
different	O
textures/types	O
of	O
hydrocarbon	O
extracts	B-Drug
include:	O
shatter	O
solid	O
breaks	O
easily	O
glass	O
like	O
oil	O
pull	O
and	O
snap	O
bendable	O
but	O
still	O
breakable	O
taffy-like	O
diamonds/live	O
resin	O
rock	O
hard	O
THCA	O
isolated	O
diamonds	O
drenched	O
in	O
terpene	O
sauce	O
crumble	O
that	O
will	O
break	O
into	O
small	O
crumbs	O
budder/wax	O
soft	O
pliable	O
peanut	O
butter-like	O
consistency	O
Hash	B-Drug
rosin	O
has	O
recently	O
become	O
a	O
top	O
quality	O
highly	O
prized	O
product	O
the	O
cannabis	O
market	O

As	O
such	O
desmetramadol	O
is	O
exclusively	O
responsible	O
for	O
the	O
opioid	O
effects	O
of	O
tramadol	B-Drug

PCP	B-Drug
began	O
to	O
emerge	O
as	O
a	O
recreational	O
drug	O
in	O
major	O
cities	O
the	O
United	O
States	O
1960s	O

Also	O
the	O
antibiotic	O
ciprofloxacin	B-Drug
thujone	O
ginkgo	O
biloba	O
kudzu	O
and	O
muira	O
puama	O
may	O
have	O
properties	O
of	O
GABAA	O
receptor	O
antagonism	O

Some	O
users	O
of	O
cocaine	B-Drug
report	O
feelings	O
restlessness	O
irritability	O
and	O
anxiety	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

Large	O
quantities	O
of	O
LSD	B-Drug
began	O
to	O
appear	O
in	O
Australia	O
around	O
1968	O
and	O
soon	O
permeated	O
the	O
music	O
scene	O
youth	O
culture	O
general	O
especially	O
capital	O
cities	O

Cocaine	B-Drug
can	O
be	O
in	O
the	O
form	O
of	O
fine	O
white	O
powder	O
bitter	O
to	O
taste	O

An	O
annual	O
survey	O
of	O
regular	O
ecstasy	B-Drug
users	O
in	O
Australia	O
2010	O
found	O
21%	O
those	O
surveyed	O
had	O
used	O
mephedrone	B-Drug
with	O
17%	O
having	O
done	O
so	O
the	O
previous	O
six	O
months	O

Pregabalin	B-Drug
has	O
also	O
been	O
approved	O
in	O
the	O
European	O
Union	O
United	O
States	O
and	O
Russia	O
for	O
treatment	O
of	O
generalized	O
anxiety	O
disorder	O

If	O
high	O
boluses	O
of	O
fentanyl	B-Drug
are	O
administered	O
quickly	O
muscle	O
rigidity	O
the	O
vocal	O
cords	O
can	O
make	O
bag-mask	O
ventilation	O
very	O
difficult	O

Noribogaine	B-Drug
is	O
more	O
potent	O
than	O
ibogaine	B-Drug
in	O
rat	O
drug	O
discrimination	O
assays	O
when	O
tested	O
for	O
the	O
subjective	O
effects	O
of	O

The	O
first	O
such	O
drug	O
chlordiazepoxide	B-Drug
Librium	B-Drug
was	O
discovered	O
accidentally	O
by	O
Leo	O
Sternbach	O
in	O
1955	O
and	O
made	O
available	O
1960	O
HoffmannLa	O
Roche	O
which	O
has	O
also	O
marketed	O
the	O
benzodiazepine	O
diazepam	B-Drug
Valium	B-Drug
since	O
1963	O

Research	O
found	O
that	O
modafinil	B-Drug
elevates	O
dopamine	O
levels	O
in	O
the	O
hypothalamus	O
animals	O

government	O
and	O
the	O
Bureau	O
of	O
Alcohol	O
Tobacco	B-Drug
Firearms	O
Explosives	O
ATF	O
revealed	O
that	O
over	O
last	O
years	O
Mexican	O
cartels	O
improved	O
their	O
firearm	O
power	O
71%	O
weapons	O
come	O
from	O
U	O

According	O
to	O
a	O
National	O
Geographic	O
TV	O
documentary	O
on	O
methamphetamine	B-Drug
an	O
entire	O
subculture	O
known	O
as	O
party	O
and	O
play	O
is	O
based	O
around	O
use	O

Individual	O
ciclosporin	B-Drug
metabolites	O
have	O
been	O
isolated	O
and	O
characterized	O
but	O
do	O
not	O
appear	O
to	O
be	O
extensively	O
studied	O

Some	O
researchers	O
such	O
as	O
David	O
Nutt	O
have	O
criticized	O
the	O
current	O
scheduling	O
of	O
MDMA	B-Drug
which	O
he	O
determines	O
to	O
be	O
a	O
relatively	O
harmless	O
drug	O

When	O
not	O
contra-indicated	O
they	O
are	O
favoured	O
over	O
the	O
use	O
of	O
paracetamol	B-Drug
alone	O
due	O
to	O
anti-inflammatory	O
effect	O
provide	O

Naproxen	B-Drug
is	O
a	O
minor	O
substrate	O
of	O
CYP1A2	O
and	O
CYP2C9	O

Ethyldienolone	O
also	O
known	O
as	O
17-methyl-19-nor-9-testosterone	O
well	O
17-methylestra-49-dien-17-ol-3-one	O
is	O
synthetic	O
orally	O
active	O
anabolic-androgenic	O
steroid	O
AAS	O
and	O
a	O
17-alkylated	O
derivative	O
of	O
19-nortestosterone	B-Drug

In	O
1958	O
Chemie	O
Grnenthal	O
reached	O
an	O
agreement	O
with	O
William	O
S	O
Merrell	O
Company	O
in	O
Cincinnati	O
Ohio	O
later	O
Richardson-Merrell	O
now	O
part	O
of	O
Sanofi	O
to	O
market	O
and	O
distribute	O
thalidomide	B-Drug
throughout	O
the	O
USThe	O
US	O
FDA	O
refused	O
approve	O
for	O
marketing	O
distribution	O

Fentanyl	B-Drug
has	O
been	O
discovered	O
for	O
sale	O
in	O
illicit	O
markets	O
Australia	O
2017	O
and	O
New	O
Zealand	O
2018	O

Small	O
doses	O
of	O
theophylline	B-Drug
may	O
inhibit	O
the	O
action	O
diazepam	B-Drug

Approval	O
years	O
for	O
SNRIs:	O
1993:	O
Venlafaxine	B-Drug
1998:	O
Sibutramine	B-Drug
2004:	O
Duloxetine	B-Drug
2008:	O
Desvenlafaxine	B-Drug
2009:	O
Milnacipran	B-Drug
2013:	O
Levomilnacipran	O
In	O
1952	O
iproniazid	O
an	O
antimycobacterial	O
agent	O
was	O
discovered	O
to	O
have	O
psychoactive	O
properties	O
while	O
researched	O
as	O
a	O
possible	O
treatment	O
tuberculosis	O

Side	O
effects	O
of	O
loprazolam	B-Drug
are	O
generally	O
the	O
same	O
as	O
for	O
other	O
benzodiazepines	O
such	O
diazepam	B-Drug

By	O
2009	O
naltrexone	B-Drug
implants	O
showed	O
superior	O
efficacy	O
in	O
the	O
treatment	O
of	O
heroin	O
dependence	O
when	O
compared	O
to	O
oral	O
form	O

Many	O
19-nortestosterone	B-Drug
derivatives	O
including	O
nandrolone	B-Drug
trenbolone	B-Drug
ethylestrenol	B-Drug
ethylnandrol	O
metribolone	O
R-1881	O
trestolone	O
11-MNT	O
dimethandrolone	O
and	O
others	O
are	O
potent	O
agonists	O
of	O
the	O
progesterone	O
receptor	O
AR	O
hence	O
progestogens	O
in	O
addition	O
to	O
AAS	O

In	O
Australia	O
diamorphine	B-Drug
is	O
listed	O
as	O
a	O
schedule	O
9	O
prohibited	O
substance	O
under	O
the	O
Poisons	O
Standard	O
October	O
2015	O

The	O
addiction	O
and	O
dependence	O
liabilities	O
of	O
modafinil	B-Drug
are	O
relatively	O
very	O
low	O

Butorphanol	B-Drug
can	O
cross	O
the	O
placenta	O
and	O
it	O
will	O
be	O
present	O
in	O
milk	O
of	O
lactating	O
mares	O
who	O
are	O
given	O
drug	O

The	O
elderly	O
showed	O
cognitive	O
deficits	O
making	O
significantly	O
more	O
mistakes	O
in	O
psychomotor	O
testing	O
than	O
younger	O
patients	O
despite	O
similar	O
plasma	O
levels	O
of	O
the	O
drug	O
suggesting	O
are	O
sensitive	O
to	O
nitrazepam	B-Drug
due	O
increased	O
sensitivity	O
aging	O
brain	O
it	O

Prolonged	O
use	O
is	O
dangerous	O
and	O
case	O
studies	O
have	O
shown	O
the	O
health	O
risk	O
with	O
celecoxib	B-Drug

Neither	O
the	O
crown	O
fruit	O
mescal	O
button	O
of	O
Peyote	O
cactus	O
nor	O
roots	O
plant	O
Mimosa	O
hostilis	O
Psilocybe	O
mushrooms	O
themselves	O
are	O
included	O
in	O
Schedule	O
1	O
but	O
only	O
their	O
respective	O
principals	O
mescaline	B-Drug
DMT	O
and	O
psilocin	B-Drug

Cebranopadol	O
full	O
agonist	O
at	O
NOP	O
-opioid	O
and	O
receptors	O
partial	O
receptor	O
Etorphine	B-Drug
MCOPPB	O
MT-7716	O
Nociceptin	O
Norbuprenorphine	O
agonist;	O
non-selective	O
also	O
the	O
MOR	O
DOR	O
KOR;	O
peripherally-selective	O
NNC	O
63-0532	O
Ro64-6198	O
Ro65-6570	O
SCH-221510	O
SR-8993	O
SR-16435	O
mixed	O
/	O
TH-030418	O
AT-076	O
JTC-801	O
J-113397	O
LY-2940094	O
SB-612111	O
SR-16430	O
Thienorphine	O
agonists	O
are	O
being	O
studied	O
as	O
treatments	O
for	O
heart	O
failure	O
migraine	O
while	O
nociceptin	O
antagonists	O
such	O
may	O
have	O
analgesic	O
antidepressant	O
qualities	O

Chlordiazepoxide	B-Drug
is	O
a	O
drug	O
of	O
potential	O
misuse	O
and	O
frequently	O
detected	O
in	O
urine	O
samples	O
users	O
who	O
have	O
not	O
been	O
prescribed	O
the	O

Unlike	O
the	O
case	O
of	O
testosterone	O
and	O
DHT	O
5-DHN	O
is	O
a	O
much	O
weaker	O
agonist	O
androgen	O
receptor	O
AR	O
than	O
nandrolone	B-Drug

Unlike	O
cocaine	B-Drug
&	O
phenyltropanes	O
the	O
benztropines	O
GBR	O
compounds	O
and	O
as	O
an	O
exception	O
to	O
pharmacophore	O
itself	O
allotropacocaine	O
among	O
others	O
are	O
considered	O
atypical	O
DAT	O
re-uptake	O
pump	O
ligands	O
because	O
they	O
stabilize	O
dopamine	O
transporter	O
in	O
inward-facing	O
or	O
closed-to-out	O
conformation	O
this	O
contrasts	O
what	O
is	O
cocaine-like	O
affinity	O
DAT;	O
which	O
would	O
instead	O
keep	O
stable	O
open-to-out	O

The	O
company	O
also	O
sponsored	O
a	O
complaint	O
to	O
the	O
FDA	O
expressing	O
concern	O
that	O
buprenorphine/naloxone	O
sublingual	O
tablets	O
very	O
product	O
they	O
formerly	O
produced	O
was	O
unsafe	O
requesting	O
applications	O
for	O
regulatory	O
approval	O
of	O
generic	O
products	O
by	O
other	O
pharmaceutical	O
companies	O
their	O
competitors	O
be	O
rejected	O
US	O
Food	O
and	O
Drug	O
Administration	O
buprenorphine	B-Drug
naloxone	B-Drug

The	O
prescribing	O
information	O
cautions	O
that	O
some	O
patients	O
may	O
experience	O
a	O
large	O
increase	O
in	O
amitriptyline	B-Drug
concentration	O
the	O
presence	O
of	O
topiramate	B-Drug

The	O
anabolic	O
potency	O
of	O
normethandrone	O
is	O
similar	O
to	O
that	O
norethandrolone	B-Drug
and	O
much	O
greater	O
than	O
nandrolone	B-Drug
or	O
metandienone	B-Drug

2a	O
Unlawful	O
possession	O
of	O
methamphetamine	B-Drug
is	O
a	O
Class	O
A	O
misdemeanor	O

Other	O
formulations	O
utilized	O
amphetamines	O
barbiturates	O
and	O
meprobamate	B-Drug
for	O
their	O
ability	O
to	O
potentiate	O
analgesia	O
by	O
combining	O
them	O
with	O
analgesics	O
such	O
as	O
phenacetin	O
aspirin	B-Drug

Levonorgestrel	B-Drug
is	O
very	O
widely	O
marketed	O
throughout	O
the	O
world	O
and	O
available	O
in	O
almost	O
every	O
country	O

Any	O
stereoisomeric	O
form	O
of	O
a	O
substance	O
for	O
the	O
time	O
being	O
specified	O
in	O
paragraph	O
1	O
above	O
not	O
dextromethorphan	B-Drug
or	O
dextrorphan	B-Drug

In	O
the	O
United	O
States	O
Harrison	O
Narcotics	O
Act	O
of	O
1914	O
regulated	O
opium	B-Drug
or	O
coca	B-Drug
leaves	O
any	O
compound	O
manufacture	O
salt	O
derivative	O
preparation	O
thereof	O
but	O
not	O
some	O
medical	O
products	O
containing	O
relatively	O
low	O
concentrations	O
these	O
substances	O

Phenethylamine	B-Drug
PEA	B-Drug
is	O
an	O
organic	O
compound	O
natural	O
monoamine	O
alkaloid	O
and	O
trace	O
amine	O
which	O
acts	O
as	O
a	O
central	O
nervous	O
system	O
stimulant	O
in	O
humans	O

Veterinarians	O
often	O
use	O
ketamine	B-Drug
with	O
sedative	O
drugs	O
to	O
produce	O
balanced	O
anaesthesia	O
and	O
analgesia	O
as	O
a	O
constant-rate	O
infusion	O
help	O
prevent	O
pain	O
wind-up	O

Efavirenz	B-Drug
falls	O
in	O
the	O
NNRTI	O
class	O
of	O
antiretrovirals	O

Cannabidiol	B-Drug
in	O
an	O
oral-mucosal	O
spray	O
formulation	O
combined	O
with	O
Delta-9-tetrahydrocannabinol	O
is	O
a	O
product	O
available	O
by	O
prescription	O
only	O
until	O
2017	O
for	O
the	O
relief	O
of	O
severe	O
spasticity	O
due	O
to	O
multiple	O
sclerosis	O
where	O
other	O
anti-spasmodics	O
have	O
not	O
been	O
effective	O

Ethyldienolone	O
is	O
closely	O
related	O
to	O
dienolone	O
and	O
methyldienolone	B-Drug

In	O
the	O
European	O
Union	O
cannabidiol	B-Drug
Epidyolex	O
is	O
indicated	O
for	O
use	O
as	O
adjunctive	O
therapy	O
of	O
seizures	O
associated	O
with	O
Lennox	O
Gastaut	O
syndrome	O
LGS	O
or	O
Dravet	O
DS	O
in	O
conjunction	O
clobazam	B-Drug
people	O
two	O
years	O
age	O
and	O
older	O

When	O
codeine	B-Drug
is	O
taken	O
in	O
very	O
large	O
amounts	O
it	O
can	O
cause	O
one	O
to	O
stop	O
breathing	O

Isomethadone	B-Drug
was	O
used	O
as	O
both	O
an	O
analgesic	O
and	O
antitussive	O

The	O
review	O
authors	O
conclude	O
that	O
individuals	O
should	O
not	O
use	O
androstenedione	B-Drug
supplements	O
due	O
to	O
the	O
lack	O
of	O
evidence	O
beneficial	O
effects	O
wide	O
variation	O
in	O
individual	O
responses	O
supplement	O
and	O
risk	O
unknown	O
side	O

Neurotoxic	O
effect	O
of	O
mephedrone	B-Drug
on	O
serotonin	O
5-HT	O
and	O
dopamine	O
DA	O
systems	O
remains	O
controversial	O

LSD	B-Drug
is	O
an	O
ergoline	O
derivative	O

In	O
surveys	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990	O

]	O
cottonmouth	O
Slang	O
name	O
for	O
a	O
dry	O
mouth	O
caused	O
by	O
smoking	O
or	O
vaporizing	O
cannabis	O
extracts	B-Drug

Anadenanthera	O
peregrina1234-Tetrahydro-6-methoxy-29-dimethyl-beta-carboline	O
Plant	O
1234-Tetrahydro-6-methoxy-2-methyl-beta-carboline	O
5-Methoxy-NN-dimethyltryptamine	O
Bark	O
5-Methoxy-N-methyltryptamine	O
Bufotenin	B-Drug
plant	O
beans	O
N-oxide	O
Fruit	O
NN-Dimethyltryptamine-oxide	O
peregrina	O
var	O

Clinically	O
significant	O
drug	O
interactions	O
with	O
the	O
CYP1A2	O
substrate	O
theophylline	B-Drug
CYP2C9	O
tolbutamide	B-Drug
CYP2D6	O
desipramine	B-Drug
and	O
CYP3A4	O
triazolam	B-Drug
have	O
all	O
been	O
demonstrated	O
cimetidine	B-Drug
other	O
substrates	O
of	O
these	O
enzymes	O
are	O
likely	O
as	O
well	O

The	O
reason	O
behind	O
this	O
action	O
is	O
because	O
modafinil	B-Drug
an	O
inducer	O
of	O
the	O
CYP3A4	O
enzymes	O

Tilidine	B-Drug
is	O
rapidly	O
absorbed	O
after	O
oral	O
administration	O
and	O
subject	O
to	O
a	O
pronounced	O
first-pass	O
effect	O

Cloxazolam	B-Drug
is	O
a	O
benzodiazepine	O
derivative	O
that	O
has	O
anxiolytic	O
sedative	O
and	O
anticonvulsant	O
properties	O

Nandrolone	B-Drug
decanoate	I-Drug
is	O
approved	O
for	O
this	O
use	O

To	O
maintain	O
anesthesia	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used	O

Felbamate:	O
may	O
increase	O
plasma	O
concentrations	O
of	O
valproate	B-Drug

Steady-state	O
levels	O
of	O
apalutamide	B-Drug
are	O
achieved	O
following	O
4	O
weeks	O
administration	O
with	O
an	O
approximate	O
5-fold	O
accumulation	O

The	O
addition	O
of	O
tobacco	B-Drug
leaf	O
to	O
the	O
chewing	O
mixture	O
is	O
a	O
relatively	O
recent	O
innovation	O
as	O
was	O
not	O
introduced	O
from	O
American	O
continent	O
until	O
colonial	O
era	O

In	O
addition	O
to	O
its	O
medical	O
use	O
testosterone	B-Drug
cypionate	I-Drug
is	O
used	O
improve	O
physique	O
and	O
performance	O

Subsequently	O
with	O
the	O
advent	O
of	O
mass	O
spectroscopy	O
it	O
has	O
been	O
shown	O
that	O
presence	O
amphetamine	B-Drug
in	O
prior	O
studies	O
was	O
an	O
artifact	O
gas	O
chromatography	O
method	O

Amnesic	O
effects:	O
Among	O
benzodiazepines	O
lorazepam	B-Drug
has	O
relatively	O
strong	O
amnesic	O
effects	O
but	O
people	O
soon	O
develop	O
tolerance	O
to	O
this	O
with	O
regular	O
use	O

In	O
1859	O
the	O
ship	O
finished	O
its	O
travels	O
and	O
Whler	O
received	O
a	O
trunk	O
full	O
of	O
coca	B-Drug

Xyrem	B-Drug
Sodium	O
Oxybate	O
a	O
preparation	O
of	O
GHB	B-Drug
used	O
to	O
treat	O
narcolepsy	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself	O
which	O
include	O
itching	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
namely	O
with	O
overdoses	O
or	O
improper	O
drug-combinations	O
such	O
as	O
benzodiazepines	O
can	O
be	O
life-threatening	O

The	O
combination	O
of	O
spironolactone	B-Drug
with	O
a	O
birth	O
control	O
pill	O
in	O
the	O
treatment	O
acne	O
appears	O
to	O
have	O
similar	O
effectiveness	O
alone	O
and	O
cyproterone	O
acetate	O
flutamide	O
or	O
finasteride	B-Drug

The	O
adverse	O
side	O
effects	O
of	O
amphetamine	B-Drug
are	O
many	O
and	O
varied	O
the	O
amount	O
used	O
is	O
primary	O
factor	O
in	O
determining	O
likelihood	O
severity	O

5-HT	O
receptors	O
were	O
split	O
into	O
two	O
classes	O
by	O
John	O
Gaddum	O
and	O
Picarelli	O
when	O
it	O
was	O
discovered	O
that	O
some	O
of	O
the	O
serotonin-induced	O
changes	O
in	O
gut	O
could	O
be	O
blocked	O
morphine	B-Drug
while	O
remainder	O
response	O
inhibited	O
dibenzyline	O
leading	O
to	O
naming	O
M	O
D	O
respectively	O

Similarly	O
in	O
Taiwan	O
and	O
Indonesia	O
Nimetazepam	B-Drug
is	O
also	O
regulated	O
as	O
a	O
controlled	O
prescribed	O
substance	O

Zidovudine:	O
may	O
increase	O
zidovudine	B-Drug
serum	O
concentration	O
and	O
lead	O
to	O
toxicity	O
Zidovudine	B-Drug

However	O
it	O
has	O
a	O
low	O
reportedly	O
4%	O
chance	O
of	O
inducing	O
cutaneous	O
reactions	O
among	O
persons	O
who	O
have	O
history	O
such	O
to	O
aspirin	B-Drug
or	O
nonselective	O
NSAIDs	O

There	O
is	O
an	O
urban	O
legend	O
that	O
a	O
person	O
who	O
has	O
used	O
LSD	B-Drug
more	O
than	O
seven	O
times	O
automatically	O
declared	O
legally	O
insane	O

Oxymorphone	B-Drug
is	O
also	O
available	O
as	O
an	O
injectable	O
for	O
inpatient	O
use	O
IV	O
intravenous	O
IM	O
intramuscular	O
and	O
subcutaneous	O
injection	O

Outsourcing	O
became	O
a	O
huge	O
factor	O
for	O
survival	O
many	O
smugglers	O
and	O
opium	B-Drug
farmers	O

At	O
therapeutic	O
doses	O
phenytoin	B-Drug
may	O
produce	O
nystagmus	O
on	O
lateral	O
gaze	O

A	O
study	O
found	O
that	O
ADHD	O
medication	O
was	O
not	O
associated	O
with	O
increased	O
risk	O
of	O
cigarette	O
use	O
and	O
in	O
fact	O
stimulant	O
treatments	O
such	O
as	O
Ritalin	B-Drug
seemed	O
to	O
lower	O
this	O

However	O
due	O
to	O
the	O
federal	O
ban	O
on	O
androstenedione	B-Drug
supplements	O
it	O
is	O
difficult	O
carry	O
out	O
new	O
research	O
its	O
effects	O

sprint	O
coach	O
Trevor	O
Graham	O
delivered	O
a	O
syringe	O
containing	O
traces	O
of	O
THG	B-Drug
to	O
the	O
United	O
States	O
Anti-Doping	O
Agency	O
USADA	O

Chlorodehydromethyltestosterone	B-Drug
CDMT	O
was	O
the	O
first	O
original	O
product	O
of	O
Jenapharm	O
an	O
East	O
German	O
pharmaceutical	O
company	O

Inversely	O
PCP	B-Drug
can	O
have	O
more	O
unpredictable	O
effects	O
and	O
has	O
often	O
been	O
classified	O
as	O
a	O
stimulant	O
depressant	O
in	O
some	O
texts	O
along	O
with	O
being	O
dissociative	O

JWH-018	B-Drug
1-pentyl-3-1-naphthoylindole	O
or	O
AM-678	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
full	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors	O
with	O
some	O
selectivity	O
for	O

Given	O
the	O
known	O
metabolic	O
liberation	O
and	O
presence	O
as	O
an	O
impurity	O
of	O
amantadine	B-Drug
in	O
related	O
compound	O
APINACA	B-Drug
it	O
is	O
suspected	O
that	O
hydrolysis	O
amide	O
group	O
Adamantyl-THPINACA	O
may	O
also	O
release	O

The	O
Partnership	O
coordinated	O
efforts	O
with	O
Drug	O
Czar	O
Barry	O
McCaffrey	O
a	O
retired	O
general	O
who	O
was	O
the	O
director	O
of	O
Office	O
National	O
Control	O
Policy	O
in	O
targeting	O
against	O
heroin	B-Drug

The	O
study	O
stated	O
that	O
90%	O
of	O
adults	O
who	O
used	O
cocaine	B-Drug
had	O
smoked	O
cigarettes	O
before	O
this	O
was	O
for	O
people	O
ages	O
1834	O

Heroin	B-Drug
is	O
also	O
known	O
by	O
many	O
street	O
names	O
including	O
dope	O
H	O
smack	B-Drug
junk	B-Drug
horse	O
scag	O
and	O
brown	O
among	O
others	O

Under	O
normal	O
circumstances	O
the	O
patch	O
will	O
reach	O
its	O
full	O
effect	O
within	O
12	O
to	O
24	O
hours;	O
thus	O
fentanyl	B-Drug
patches	O
are	O
often	O
prescribed	O
with	O
a	O
fast-acting	O
opioid	O
such	O
as	O
morphine	B-Drug
or	O
oxycodone	B-Drug
handle	O
breakthrough	O
pain	O

There	O
was	O
a	O
new	O
discussion	O
about	O
its	O
fate	O
on	O
April	O
23	O
2012	O
where	O
it	O
decided	O
that	O
the	O
bill	O
would	O
be	O
rewritten	O
and	O
phenazepam	B-Drug
still	O
banned	O

Laudanum	B-Drug
as	O
Tincture	O
No	O

As	O
of	O
2015	O
the	O
Sinaloa	O
Cartel	O
is	O
most	O
active	O
drug	O
cartel	O
involved	O
in	O
smuggling	O
illicit	O
drugs	O
such	O
as	O
heroin	B-Drug
into	O
United	O
States	O
and	O
trafficking	O
them	O
throughout	O

These	O
changes	O
in	O
hormone	O
levels	O
are	O
similar	O
to	O
those	O
with	O
high-dose	O
bicalutamide	B-Drug
monotherapy	O

In	O
the	O
Netherlands	O
fentanyl	B-Drug
is	O
a	O
List	O
I	O
substance	O
of	O
Opium	O
Law	O

United	O
Kingdom	O
In	O
the	O
dihydrocodeine	B-Drug
is	O
a	O
Class	O
B	O
drug;	O
but	O
it	O
available	O
over-the-counter	O
in	O
small	O
amounts	O
less	O
than	O
8	O
mg	O
when	O
combined	O
with	O
paracetamol	B-Drug
see	O
co-dydramol	O

Suppression	O
of	O
the	O
cough	O
reflex:	O
Fentanyl	B-Drug
can	O
decrease	O
struggle	O
against	O
an	O
endotracheal	O
tube	O
and	O
excessive	O
coughing	O
by	O
decreasing	O
reflex	O
becoming	O
useful	O
when	O
intubating	O
people	O
who	O
are	O
awake	O
have	O
compromised	O
airways	O

Alfaxalone	B-Drug
also	O
known	O
as	O
alphaxalone	O
or	O
alphaxolone	B-Drug
and	O
sold	O
under	O
the	O
brand	O
name	O
Alfaxan	O
is	O
a	O
neuroactive	O
steroid	O
general	O
anesthetic	O
which	O
used	O
currently	O
in	O
veterinary	O
practice	O
an	O
induction	O
agent	O
for	O
anesthesia	O
injectable	O

2-Methyl-MDA	O
is	O
also	O
much	O
more	O
potent	O
than	O
MDA	O
but	O
not	O
quite	O
as	O
5-methyl-MDA	B-Drug

A	O
number	O
of	O
other	O
CYP	O
enzymes	O
are	O
implicated	O
as	O
minor	O
pathways	O
dextromethorphan	B-Drug
metabolism	O

In	O
the	O
United	O
States	O
main	O
drug	O
control	O
agency	O
Drug	O
Enforcement	O
Administration	O
reports	O
an	O
increase	O
in	O
annual	O
aggregate	O
production	O
quotas	O
of	O
hydromorphone	B-Drug
from	O
766	O
kilograms	O
1689	O
pounds	O
1998	O
to	O
3300	O
7300	O
lb	O
2006	O
and	O
prescriptions	O
this	O
time	O
289%	O
about	O
470000	O
1830000	O

However	O
other	O
literature	O
states	O
that	O
there	O
is	O
little	O
or	O
no	O
interaction:	O
in	O
a	O
pharmacokinetic	O
study	O
topiramate	B-Drug
only	O
increased	O
the	O
level	O
of	O
amitriptyline	B-Drug
by	O
20%	O
and	O
nortriptyline	B-Drug
33%	O

Diazepam	B-Drug
has	O
been	O
shown	O
to	O
be	O
able	O
substitute	O
for	O
the	O
behavioural	O
effects	O
of	O
barbiturates	O
in	O
a	O
primate	O
study	O

AL-LAD	O
also	O
known	O
as	O
6-allyl-6-nor-LSD	O
is	O
a	O
psychedelic	O
drug	O
and	O
an	O
analog	O
of	O
lysergic	O
acid	B-Drug
diethylamide	O
LSD	B-Drug

The	O
related	O
NSAA	O
bicalutamide	B-Drug
has	O
also	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
women	O
and	O
appears	O
have	O
comparable	O
effectiveness	O
that	O
flutamide	O
but	O
a	O
far	O
lower	O
only	O
small	O
risk	O
hepatotoxicity	O
comparison	O

In	O
the	O
same	O
period	O
Lysergic	B-Drug
acid	B-Drug
diethylamide	I-Drug
better	O
known	O
as	O
LSD	B-Drug
or	O
at	O
time	O
a	O
legal	O
drug	O
began	O
to	O
be	O
used	O
in	O
US	O
and	O
UK	O
an	O
experimental	O
treatment	O
initially	O
promoted	O
potential	O
cure	O
for	O
mental	O
illness	O

It	O
binds	O
to	O
the	O
MOR	O
with	O
similar	O
affinity	O
relative	O
naltrexone	B-Drug
but	O
somewhat	O
more	O
avidly	O
KOR	O
and	O
DOR	O
in	O
comparison	O

DMT	O
became	O
a	O
controlled	O
substance	O
in	O
the	O
US	O
on	O
January	O
4	O
2010	O
and	O
is	O
classified	O
as	O
Schedule	O
III	O
anabolic	O
steroid	O
under	O
United	O
States	O
Controlled	O
Substances	O
Act	O
along	O
with	O
boldione	O
dienedione	B-Drug

Furthermore	O
some	O
testing	O
procedures	O
employ	O
a	O
hydrolysis	O
step	O
before	O
quantitation	O
that	O
converts	O
many	O
of	O
the	O
metabolic	O
products	O
to	O
morphine	B-Drug
yielding	O
result	O
may	O
be	O
2	O
times	O
larger	O
than	O
with	O
method	O
examines	O
each	O
product	O
individually	O

This	O
includes	O
medications	O
such	O
as	O
other	O
anticoagulants	O
heparin	B-Drug
aspirin	B-Drug
antiplatelet	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
norepinephrine	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
NSAIDs	O

Laboratory	O
evidence	O
indicated	O
that	O
cannabidiol	B-Drug
may	O
reduce	O
THC	O
clearance	O
increasing	O
plasma	O
concentrations	O
which	O
raise	O
availability	O
to	O
receptors	O
and	O
enhance	O
its	O
effect	O
in	O
a	O
dose-dependent	O
manner	O

Modafinil	B-Drug
is	O
a	O
mild	O
stimulant	O
designed	O
to	O
be	O
taken	O
right	O
before	O
competition	O
in	O
order	O
sharpen	O
an	O
athlete's	O
senses	O
and	O
performance	O

On	O
July	O
5	O
2010	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile	O
Alabama	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription	O

Ritalin	B-Drug
LA	O
provides	O
two	O
standard	O
doses	O
half	O
the	O
total	O
dose	O
being	O
released	O
immediately	O
and	O
other	O
four	O
hours	O
later	O

Butorphanol	B-Drug
is	O
listed	O
under	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
1961	O
and	O
in	O
United	O
States	O
a	O
Schedule	O
IV	O
controlled	O
substance	O
with	O
DEA	O
ACSCN	O
of	O
9720;	O
being	O
it	O
not	O
subject	O
to	O
annual	O
aggregate	O
manufacturing	O
quotas	O

Abiraterone	B-Drug
acetate	I-Drug
works	O
by	O
suppressing	O
the	O
production	O
of	O
androgens	O
specifically	O
it	O
inhibits	O
CYP17A1	O
and	O
thereby	O
decreases	O
testosterone	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s	O
novel	O
derivatives	O
continue	O
to	O
appear	O

Stimulants	O
and	O
cocaine-related	O
alkaloids:	O
Cocaine	B-Drug
from	O
coca	O
plant	O
Erythroxylum	O
Ecgonine	O
a	O
precursor	O
metabolite	B-Drug
of	O
cocaine	B-Drug
Benzoylecgonine	O
Hydroxytropacocaine	O
Methylecgonine	O
cinnamate	O
Catuabines	O
found	O
in	O
catuaba	O
an	O
infusion	O
or	O
dry	O
extract	O
made	O
vaccinifolium	O
Scopine	O
Ibogaine	B-Drug
VoacangineSynthetic	O
analogs	O
tropane	O
alkaloids	O
also	O
exist	O
such	O
as	O
the	O
phenyltropanes	O

Cocaine	B-Drug
is	O
a	O
Schedule	O
8	O
prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
July	O
2016	O

Once	O
in	O
the	O
brain	O
it	O
then	O
is	O
deacetylated	O
variously	O
into	O
inactive	O
3-monoacetylmorphine	B-Drug
and	O
active	O
6-monoacetylmorphine	O
6-MAM	O
to	O
morphine	B-Drug
which	O
bind	O
-opioid	O
receptors	O
resulting	O
drug's	O
euphoric	O
analgesic	O
pain	O
relief	O
anxiolytic	O
anti-anxiety	O
effects;	O
heroin	B-Drug
itself	O
exhibits	O
relatively	O
low	O
affinity	O
for	O
receptor	O

The	O
half-life	O
of	O
duloxetine	B-Drug
is	O
about	O
12	O
hours	O
range:	O
817	O
and	O
steady-state	O
achieved	O
after	O
3	O
days	O

Hash	B-Drug
has	O
a	O
long	O
history	O
of	O
usage	O
in	O
eastern	O
countries	O
such	O
as	O
Lebanon	O
Afghanistan	O
India	O
Iran	O
Morocco	O
and	O
Pakistan	O

rauwolscine	O
found	O
in	O
Rauvolfia	O
serpentina	O
yohimbine	B-Drug
Procomil;	O
a	O
tryptamine	O
alkaloid	O
Pausinystalia	O
johimbe	O
Alcohol:	O
Euphoria	O
the	O
feeling	O
of	O
well-being	O
has	O
been	O
reported	O
during	O
early	O
1015	O
min	O
phase	O
alcohol	O
consumption	O
e	O

Thalidomide	B-Drug
is	O
used	O
as	O
a	O
first-line	O
treatment	O
in	O
multiple	O
myeloma	O
combination	O
with	O
dexamethasone	B-Drug
or	O
melphalan	O
and	O
prednisone	B-Drug
to	O
treat	O
acute	O
episodes	O
of	O
erythema	O
nodosum	O
leprosum	O
for	O
maintenance	O
therapy	O

Walker	O
was	O
allegedly	O
drinking	O
prior	O
to	O
his	O
emotional	O
outburst	O
and	O
it	O
is	O
believed	O
the	O
combination	O
of	O
amobarbital	B-Drug
alcohol	O
resulted	O
in	O
a	O
severe	O
reaction	O

Methamphetamine	B-Drug
is	O
contraindicated	O
in	O
individuals	O
with	O
a	O
history	O
of	O
substance	O
use	O
disorder	O
heart	O
disease	O
or	O
severe	O
agitation	O
anxiety	O
currently	O
experiencing	O
arteriosclerosis	O
glaucoma	O
hyperthyroidism	O
hypertension	O

In	O
the	O
elderly	O
rate	O
of	O
propofol	B-Drug
clearance	O
is	O
low	O

Similarly	O
to	O
spironolactone	B-Drug
canrenone	O
inhibits	O
steroidogenic	O
enzymes	O
such	O
as	O
11-hydroxylase	O
cholesterol	O
side-chain	O
cleavage	O
enzyme	O
17-hydroxylase	O
1720-lyase	O
and	O
21-hydroxylase	O
but	O
once	O
again	O
is	O
comparatively	O
less	O
potent	O
in	O
doing	O
so	O

4-methylaminorex	B-Drug
can	O
be	O
smoked	O
insufflated	O
or	O
taken	O
orally	O

Nicocodeine	B-Drug
cough	O
medicines	O
are	O
available	O
as	O
syrups	O
extended-release	O
and	O
sublingual	O
drops	O

It	O
was	O
developed	O
by	O
screening	O
chemicals	O
similar	O
to	O
pethidine	B-Drug
meperidine	B-Drug
for	O
opioid	O
activity	O

It	O
may	O
also	O
interact	O
with:	O
Aspirin:	O
increase	O
valproate	B-Drug
concentrations	O
Aspirin	B-Drug

Nitrazepam	B-Drug
taken	O
in	O
overdose	O
is	O
associated	O
with	O
a	O
high	O
level	O
of	O
congenital	O
abnormalities	O
30	O
percent	O
births	O

As	O
recreational	O
doses	O
are	O
generally	O
much	O
larger	O
than	O
prescribed	O
therapeutic	O
use	O
carries	O
a	O
far	O
greater	O
risk	O
of	O
serious	O
side	O
effects	O
such	O
as	O
dependence	O
which	O
only	O
rarely	O
arises	O
with	O
amphetamine	B-Drug

The	O
concentration	O
of	O
desmetramadol	O
in	O
the	O
blood	O
or	O
plasma	O
a	O
person	O
who	O
has	O
taken	O
tramadol	B-Drug
is	O
generally	O
1020%	O
those	O
parent	O
drug	O

It	O
is	O
a	O
direct	O
precursor	O
to	O
the	O
neuromodulator	O
phenethylamine	B-Drug
commonly	O
used	O
dietary	O
supplement	O

The	O
process	O
gave	O
rise	O
to	O
various	O
concentrations	O
of	O
hydromorphone	B-Drug
dihydromorphine	B-Drug
hydromorphinol	B-Drug
and	O
oxymorphone	B-Drug
during	O
the	O
experiments	O

In	O
accordance	O
the	O
combination	O
of	O
paracetamol	B-Drug
acetaminophen	B-Drug
and	O
flutamide	O
appears	O
to	O
result	O
in	O
additive	O
synergistic	O
hepatotoxicity	O
indicating	O
a	O
potential	O
drug	O
interaction	O

Plenty	O
of	O
lollipops	O
in	O
hippy	O
stores	O
sold	O
countries	O
like	O
the	O
UK	O
and	O
Canada	O
have	O
been	O
alleged	O
to	O
contain	O
CBD	B-Drug
a	O
non-psychedelic	O
drug	O
found	O
cannabis;	O
ages	O
limits	O
on	O
these	O
are	O
unclear	O
they	O
passively	O

In	O
the	O
United	O
States	O
all	O
CB1	O
receptor	O
agonists	O
of	O
3-1-naphthoylindole	O
class	O
such	O
as	O
JWH-098	B-Drug
are	O
Schedule	O
I	O
Controlled	O
Substances	O

According	O
to	O
a	O
2016	O
United	O
Nations	O
report	O
England	O
and	O
Wales	O
are	O
the	O
countries	O
with	O
highest	O
rate	O
of	O
cocaine	B-Drug
usage	O
2	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
releasing	O
more	O
fentanyl	B-Drug
together	O
with	O
acidosis	O
which	O
reduces	O
protein	O
binding	O
of	O
yet	O

This	O
effect	O
could	O
be	O
particularly	O
dangerous	O
if	O
flunitrazepam	B-Drug
is	O
used	O
to	O
aid	O
in	O
the	O
commission	O
of	O
sexual	O
assault;	O
victims	O
may	O
unable	O
clearly	O
recall	O
assault	O
assailant	O
or	O
events	O
surrounding	O

Methylphenidate	B-Drug
acts	O
a	O
norepinephrine-dopamine	O
reuptake	O
inhibitor	O
by	O
blocking	O
the	O
norepinephrine	O
transporter	O
NET	O
and	O
dopamine	O
DAT	O

Instead	O
norpethidine	B-Drug
acts	O
as	O
a	O
stimulant	O
and	O
causes	O
convulsions	O

As	O
with	O
other	O
pure-opioid	O
agonists	O
fentanyl	B-Drug
can	O
be	O
associated	O
dysphoria	O
in	O
both	O
dogs	O
and	O
cats	O

Gabapentin	B-Drug
acts	O
by	O
decreasing	O
activity	O
of	O
a	O
subset	O
calcium	O
channels	O

Roughly	O
90%	O
of	O
ingested	O
amphetamine	B-Drug
is	O
eliminated	O
3	O
days	O
after	O
the	O
last	O
oral	O
dose	O

After	O
an	O
intravenous	O
injection	O
of	O
tritium-labelled	O
ketamine	B-Drug
91%	O
the	O
radioactivity	O
is	O
recovered	O
from	O
urine	O
and	O
3%	O
feces	O

Today	O
the	O
focus	O
of	O
world's	O
drug	O
policy	O
reform	O
organisations	O
is	O
on	O
promotion	O
harm	O
reduction	O
in	O
Western	O
World	O
and	O
attempting	O
to	O
prevent	O
catastrophic	O
loss	O
human	O
life	O
developing	O
countries	O
where	O
much	O
supply	O
heroin	B-Drug
cocaine	B-Drug
marijuana	O
are	O
produced	O

One	O
estimate	O
has	O
Colombia's	O
coca	B-Drug
cultivation	O
hectarage	O
growing	O
from	O
13000	O
hectares	O
32000	O
acres	O
in	O
the	O
mid-1980s	O
to	O
80000	O
200000	O
1998	O
99000	O
2007	O

Benzylpiperazine	B-Drug
BZP	B-Drug
is	O
a	O
recreational	O
drug	O
with	O
euphoriant	O
and	O
stimulant	O
properties	O

Ketoconazole	B-Drug
is	O
a	O
racemic	O
mixture	O
consisting	O
of	O
cis-2S4R-	O
and	O
cis-2R4S-+	O
enantiomers	O

In	O
France	O
car	O
accidents	O
involving	O
psychotropic	O
drugs	O
in	O
combination	O
with	O
alcohol	O
itself	O
a	O
major	O
contributor	O
found	O
benzodiazepines	O
mainly	O
diazepam	B-Drug
nordiazepam	B-Drug
and	O
bromazepam	B-Drug
to	O
be	O
the	O
most	O
common	O
drug	O
present	O
blood	O
stream	O
almost	O
twice	O
that	O
of	O
next-most-common	O
cannabis	O

The	O
cultivation	O
of	O
opium	B-Drug
[in	O
Afghanistan]	O
reached	O
its	O
peak	O
in	O
1999	O
when	O
350	O
square	O
miles	O
910	O
km2	O
poppies	O
were	O
sown	O

hemp	O
English	O
or	O
common	O
name	O
for	O
the	O
entire	O
plant	O
cannabis	O
legally	O
named	O
marijuana	O
marihuana	B-Drug
in	O
some	O
jurisdictions	O

There	O
is	O
some	O
evidence	O
that	O
selegiline	B-Drug
acts	O
as	O
a	O
neuroprotectant	O
and	O
reduces	O
the	O
rate	O
of	O
disease	O
progression	O
though	O
this	O
disputed	O

More	O
than	O
90%	O
of	O
verapamil	B-Drug
is	O
absorbed	O
when	O
given	O
orally	O
but	O
due	O
to	O
high	O
first-pass	O
metabolism	O
bioavailability	O
much	O
lower	O
1035%	O

CBD	B-Drug
does	O
not	O
have	O
the	O
same	O
psychoactivity	O
as	O
THC	O
and	O
may	O
change	O
effects	O
of	O
on	O
body	O
if	O
both	O
are	O
present	O

Nordazepam	B-Drug
is	O
a	O
partial	O
agonist	O
at	O
the	O
GABAA	O
receptor	O
which	O
makes	O
it	O
less	O
potent	O
than	O
other	O
benzodiazepines	O
particularly	O
in	O
its	O
amnesic	O
and	O
muscle-relaxing	O
effects	O

Some	O
androstenedione	B-Drug
is	O
also	O
secreted	O
into	O
the	O
plasma	O
and	O
may	O
be	O
converted	O
in	O
peripheral	O
tissues	O
to	O
testosterone	O
estrogens	O

This	O
was	O
evidenced	O
through	O
individuals	O
who	O
solely	O
used	O
MDMA	B-Drug
reporting	O
a	O
greater	O
magnitude	O
of	O
the	O
TAE	O
compared	O
to	O
drug	O
naive	O
controls	O

GHB	B-Drug
is	O
a	O
precursor	O
to	O
GABA	O
glutamate	O
and	O
glycine	O
in	O
certain	O
brain	O
areas	O

In	O
those	O
studies	O
that	O
have	O
compared	O
different	O
species	O
and	O
cultivars	O
when	O
mescaline	B-Drug
has	O
been	O
found	O
it	O
at	O
very	O
much	O
lower	O
concentrations	O
than	O
in	O
the	O
highest	O
yielding	O
forms	O
of	O
other	O
species;	O
for	O
example	O
0	O

In	O
2014	O
the	O
European	O
Association	O
for	O
Palliative	O
Care	O
recommended	O
oxycodone	B-Drug
by	O
mouth	O
as	O
a	O
second-line	O
alternative	O
to	O
morphine	B-Drug
cancer	O
pain	O

If	O
cocaine	B-Drug
is	O
to	O
be	O
reclassified	O
defendant's	O
arguments	O
should	O
made	O
the	O
legislative	O
branch	O
not	O
courts	O

Other	O
important	O
metabolites	O
of	O
spironolactone	B-Drug
include	O
7-thiospironolactone	O
7-TS;	O
SC-24813	O
6-hydroxy-7-thiomethylspironolactone	O
6-OH-7-TMS	O
and	O
canrenone	O
SC-9376	O

There	O
were	O
no	O
legal	O
restrictions	O
on	O
the	O
importation	O
or	O
use	O
of	O
opium	B-Drug
in	O
United	O
States	O
until	O
San	O
Francisco	O
Opium	O
Den	O
Ordinance	O
which	O
banned	O
dens	O
for	O
public	O
smoking	O
1875	O
a	O
measure	O
fueled	O
by	O
anti-Chinese	O
sentiment	O
and	O
perception	O
that	O
whites	O
starting	O
to	O
frequent	O

Additionally	O
it	O
has	O
been	O
claimed	O
that	O
alfatradiol	B-Drug
works	O
through	O
this	O
mechanism	O
of	O
activity	O
5-reductase	O
as	O
well	O
the	O
Ganoderic	O
acids	O
in	O
lingzhi	O
mushroom	O
and	O
Saw	O
Palmetto	O

In	O
dopaminergic	O
cells	O
in	O
the	O
brain	O
tyrosine	O
is	O
converted	O
to	O
L-DOPA	B-Drug
by	O
enzyme	O
hydroxylase	O
TH	O

An	O
estimated	O
17	O
million	O
people	O
as	O
of	O
2015	O
use	O
opiates	O
which	O
heroin	B-Drug
is	O
the	O
most	O
common	O
and	O
opioid	O
resulted	O
in	O
122000	O
deaths	O

MDMA	B-Drug
called	O
methylsafrylamin	O
safrylmethylamin	O
or	O
N-Methyl-a-Methylhomopiperonylamin	O
in	O
Merck	O
laboratory	O
reports	O
was	O
an	O
intermediate	O
compound	O
the	O
synthesis	O
of	O
methylhydrastinine	O

Alfatradiol	B-Drug
acts	O
as	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
5-reductase	O
which	O
is	O
responsible	O
for	O
activation	O
testosterone	O
to	O
dihydrotestosterone	O
and	O
plays	O
a	O
role	O
in	O
regulating	O
hair	O
growth	O

Since	O
then	O
16	O
states	O
have	O
passed	O
laws	O
to	O
allow	O
the	O
use	O
of	O
CBD	B-Drug
products	O
with	O
a	O
physician's	O
recommendation	O
instead	O
prescription	O
for	O
treatment	O
certain	O
medical	O
conditions	O

Amides	O
of	O
lysergic	O
acid	B-Drug
are	O
collectively	O
known	O
as	O
lysergamides	O
and	O
include	O
a	O
number	O
compounds	O
with	O
potent	O
agonist	O
and/or	O
antagonist	O
activity	O
at	O
various	O
serotonin	O
dopamine	O
receptors	O

When	O
given	O
by	O
injection	O
into	O
a	O
vein	O
heroin	B-Drug
has	O
two	O
to	O
three	O
times	O
the	O
effect	O
of	O
similar	O
dose	O
morphine	B-Drug

One	O
agreement	O
is	O
for	O
Lucentis;	O
the	O
other	O
Xolair	O
Lucentis	B-Drug

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose	O

Other	O
pharmaceutical	O
drugs	O
which	O
contain	O
a	O
benzimidazole	O
group	O
include	O
galeterone	O
mavatrep	O
and	O
dovitinib	O
as	O
well	O
the	O
opioids	O
such	O
etonitazene	B-Drug

In	O
the	O
United	O
States	O
heroin	B-Drug
is	O
not	O
accepted	O
as	O
medically	O
useful	O

MDPV	B-Drug
undergoes	O
CYP450	O
2D6	O
2C19	O
1A2	O
and	O
COMT	O
phase	O
1	O
metabolism	O
liver	O
into	O
methylcatechol	O
pyrrolidine	O
which	O
in	O
turn	O
are	O
glucuronated	O
uridine	O
5'-diphospho-glucuronosyl-transferase	O
allowing	O
it	O
to	O
be	O
excreted	O
by	O
the	O
kidneys	O
with	O
only	O
a	O
small	O
fraction	O
of	O
metabolites	O
being	O
stools	O

Tentative	O
evidence	O
supports	O
the	O
use	O
of	O
verapamil	B-Drug
topically	O
to	O
treat	O
plantar	O
fibromatosis	O

It	O
is	O
sometimes	O
thought	O
that	O
heroin	B-Drug
users	O
can	O
walk	O
into	O
a	O
clinic	O
and	O
out	O
with	O
prescription	O
but	O
the	O
process	O
takes	O
many	O
weeks	O
before	O
for	O
diamorphine	B-Drug
issued	O

Henbane	O
leaves	O
and	O
herbage	O
without	O
roots	O
are	O
chopped	O
dried	O
then	O
used	O
for	O
medicinal	O
purposes	O
or	O
in	O
incense	O
smoking	B-Drug
blends	O
making	O
beer	O
tea	O
seasoning	O
wine	O

In	O
addition	O
to	O
this	O
cocaine	B-Drug
has	O
some	O
target	O
binding	O
the	O
site	O
of	O
Kappa-opioid	O
receptor	O
as	O
well	O

Ketamine	B-Drug
appears	O
not	O
to	O
produce	O
sedation	O
or	O
aneasthesia	O
in	O
snails	O

The	O
name	O
of	O
this	O
drug	O
is	O
also	O
given	O
as	O
36-dipropanoylmorphine	O
and	O
its	O
6-mono-acetylated	O
homologue	O
a	O
longer-acting	O
heroin-like	O
are	O
36-diformylmorphine	O
6-formylmorphine	O
dipropanoylmorphine	B-Drug

He	O
is	O
the	O
first	O
person	O
to	O
have	O
prepared	O
amphetamine	B-Drug
sulfate	O
although	O
not	O
molecule	O

Methadone	B-Drug
substitution	O
as	O
a	O
treatment	O
of	O
opioid	O
addiction	O
has	O
been	O
criticized	O
in	O
the	O
social	O
sciences	O
for	O
its	O
role	O
control	O
addicts	O

Drostanolone	O
propionate	O
is	O
a	O
prodrug	O
of	O
drostanolone	B-Drug

CYP2D6	O
inhibitors	O
such	O
as	O
SSRI	O
medications	O
may	O
increase	O
plasma	O
levels	O
of	O
risperidone	B-Drug
and	O
those	O

Cimetidine	B-Drug
is	O
reported	O
to	O
be	O
a	O
competitive	O
and	O
reversible	O
inhibitor	O
of	O
several	O
CYP	O
enzymes	O
although	O
mechanism-based	O
suicide	O
irreversible	O
inhibition	O
has	O
also	O
been	O
identified	O
for	O
cimetidine's	O
CYP2D6	O
cimetidine	B-Drug

Naloxone	B-Drug
is	O
a	O
drug	O
used	O
to	O
counter	O
an	O
overdose	O
from	O
the	O
effect	O
of	O
opioids;	O
for	O
example	O
heroin	B-Drug
or	O
morphine	B-Drug

A	O
cannabis	O
concentrate	O
also	O
called	O
marijuana	O
extract	O
or	O
is	O
a	O
highly	O
potent	O
tetrahydrocannabinol	O
THC	O
and/or	O
cannabidiol	B-Drug
CBD	B-Drug
concentrated	O
mass	O

Excessive	O
glutamate	O
activity	O
is	O
believed	O
to	O
be	O
involved	O
in	O
catatonia;	O
when	O
first-line	O
treatment	O
options	O
fail	O
NMDA	O
antagonists	O
such	O
as	O
amantadine	B-Drug
or	O
memantine	B-Drug
may	O
used	O

In	O
premenopausal	O
women	O
the	O
adrenal	O
glands	O
and	O
ovaries	O
each	O
produce	O
about	O
half	O
of	O
total	O
androstenedione	B-Drug
3	O
mg/day	O

fluoxetine	B-Drug
venlafaxine	B-Drug
serotonin	O
releasing	O
agents	O
e	O

Heterocodeine	B-Drug
is	O
6	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
due	O
to	O
having	O
a	O
substitution	O
at	O
the	O
6-hydroxy	O
position	O
in	O
similar	O
manner	O
6-acetylmorphine	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine	B-Drug

Thebacon	B-Drug
can	O
be	O
said	O
to	O
the	O
3-monoacetylmorphine	B-Drug
analog	O
of	O
hydrocodone	B-Drug
and/or	O
acetylmorphone	O
codeine	B-Drug

The	O
active	O
ingredient	O
ibogaine	B-Drug
is	O
proposed	O
as	O
a	O
treatment	O
of	O
opioid	O
withdrawal	O
and	O
various	O
substance	O
use	O
disorders	O

Chronic	O
imipramine	B-Drug
administration	O
results	O
in	O
increased	O
histone	O
acetylation	O
which	O
is	O
associated	O
with	O
transcriptional	O
activation	O
and	O
decondensed	O
chromatin	O
at	O
the	O
hippocampal	O
BDNF	O
promoter	O
also	O
reduced	O
expression	O
of	O
HDAC5	O

At	O
dosages	O
of	O
50	O
mg	O
or	O
100	O
per	O
day	O
androstenedione	B-Drug
had	O
no	O
effect	O
on	O
muscle	O
strength	O
size	O
body	O
fat	O
levels	O

Bicycle	O
Day	O
is	O
increasingly	O
observed	O
in	O
psychedelic	O
communities	O
as	O
a	O
day	O
to	O
celebrate	O
the	O
discovery	O
of	O
LSD	B-Drug

As	O
to	O
a	O
turn-of-the-century	O
decline	O
in	O
availability	O
due	O
his	O
own	O
arrest	O
Pickard	O
highlights	O
the	O
fact	O
that	O
LSD	B-Drug
had	O
been	O
on	O
since	O
1996	O
which	O
he	O
correlates	O
part	O
with	O
exponential	O
growth	O
of	O
and	O
demand	O
for	O
MDMA	B-Drug
other	O
hallucinogenic	O
drugs	O

ATS	O
when	O
used	O
illicitly	O
has	O
street	O
names	O
including	O
ice	O
meth	B-Drug
crystal	O
crank	O
bennies	O
and	O
speed	B-Drug

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself	O
which	O
include	O
itching	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
can	O
be	O
life-threatening	O

CBD	B-Drug
is	O
a	O
5-HT1A	O
receptor	O
agonist	O
which	O
under	O
laboratory	O
research	O
to	O
determine	O
if	O
it	O
has	O
an	O
anxiolytic	O
effect	O

Many	O
esters	O
of	O
testosterone	O
have	O
been	O
marketed	O
including	O
the	O
following	O
major	O
esters:	O
Testosterone	B-Drug
caproate	O
component	O
Omnadren	O
and	O
Triormon	O
Depositum	O
cypionate	I-Drug
Depo-Testosterone	O
numerous	O
others	O
decanoate	O
Sustanon	O
250	O
enanthate	I-Drug
Delatestryl	B-Drug
Testoviron	O
Depot	O
isobutyrate	O
Agovirin-Depot	O
Perandren	O
M	O
Testocryst	O
Virex-Cryst;	O
Femandren	O
M/Folivirin	O
isocaproate	O
100	O
phenylpropionate	O
propionate	O
undecanoate	O
Aveed	O
Andriol	B-Drug
Nebido	B-Drug
Jatenzo	O
othersAnd	O
less	O
commonly	O
used	O
acetate	O
Aceto-Sterandryl	O
Aceto-Testoviron	O
Amolisin	O
Androtest	O
A	O
Deposteron	O
Farmatest	O
Perandrone	O
cyclohexylpropionate	O
Andromar	O
Femolone	O
Telipex	O
Retard;	O
Trioestrine	O
Retard	O
enantate	O
benzilic	O
acid	O
hydrazone	O
Climacteron	O
furoate	O
Furotest	O
hexahydrobenzoate	O
Sterandryl	O
Trinestril	O
AP	O
hexahydrobenzylcarbonate	O
Lontanyl	O
hexyloxyphenylpropionate	O
Andradurin	O
ketolaurate	O
Androdurin;	O
Testosid-Depot	O
Klimanosid	O
R-Depot	O
nicotinate	O
Bolfortan	O
Linobol	O
phenylacetate	O
Androject	O
phosphate	O
Aquosum	O
undecylenate	O
Durasteron	O
Triolandren	O
valerate	O
Deposterona	O
The	O
ester	O
has	O
not	O
marketed:	O
buciclate	O
20	O
Aet-1	O
CDB-1781	O
a	O
very	O
long-acting	O
that	O
was	O
under	O
development	O
but	O
ultimately	O
did	O
reach	O
marketAnd	O
known	O
also	O
Polytestosterone	O
phloretin	O
17-1-5-aminosulfonyl-2-pyridinylcarbonyl-L-proline	O
EC586	O
butyrate	O
benzoate	O
diacetate	O
dipropionate	O
formate	O
isovalerate	O
palmitate	O
phenylbutyrate	B-Drug
stearate	O
sulfate	O
Several	O
dihydrotestosterone	O
DHT;	O
androstanolone	O
stanolone	O
following:	O
Androstanolone	O
Ermalone-Amp	O
Hermalone	O
Sarcosan	O
Anaboleen	O
Pesomax	O
Apeton	O
DHT	O
Dihydrotestosterone	O
undecanoateTestifenon	O
chlorphenacyl	O
is	O
nitrogen	O
mustard	O
developed	O
as	O
an	O
cytostatic	O
antineoplastic	O
agent	O
never	O

Brivaracetam	B-Drug
2016	O

2	O
5-11-dimethyloctyl-2-[1R3S-3-hydroxycyclohexyl]-phenol	O
cannabicyclohexanol	B-Drug
or	O
CP-47497	O
C8-homolog	O
[Drug	O
Code:	O
7298]	O
Effective	O
January	O
1	O
2016	O
is	O
a	O
regulated	O
drug	O
in	O
Vermont	O
designated	O
as	O
Hallucinogenic	O
Drug	O

Kesey	O
took	O
the	O
parties	O
to	O
public	O
places	O
and	O
advertised	O
with	O
posters	O
that	O
read	O
Can	O
you	O
pass	O
acid	B-Drug
test?	O
name	O
was	O
later	O
popularized	O
in	O
Tom	O
Wolfe's	O
1968	O
book	O
The	O
Electric	O
Kool-Aid	O
Acid	O
Test	O

Sedation:	O
Fentanyl	B-Drug
produces	O
sleep	O
and	O
drowsiness	O
as	O
dosage	O
is	O
increased	O
can	O
produce	O
the	O
-waves	O
often	O
seen	O
in	O
natural	O
on	O
electroencephalogram	O

Zyban	B-Drug
the	O
same	O
medication	O
but	O
marketed	O
as	O
a	O
smoking	O
cessation	O
aid	O

Also	O
similarly	O
again	O
to	O
ketamine	B-Drug
norketamine	O
binds	O
the	O
-	O
and	O
-opioid	O
receptors	O

Thus	O
an	O
order	O
for	O
opium	B-Drug
tincture	O
containing	O
directions	O
in	O
teaspoons	O
is	O
almost	O
certainly	O
error	O

The	O
use	O
of	O
fentanyl	B-Drug
in	O
execution	O
caused	O
concern	O
among	O
death	O
penalty	O
experts	O
because	O
it	O
was	O
part	O
a	O
previously	O
untested	O
drug	O
cocktail	O

JWH-018	B-Drug
and	O
its	O
N-dealkylated	O
metabolite	O
were	O
only	O
detected	O
in	O
small	O
amounts	O
with	O
hydroxylated	O
metabolites	O
comprising	O
the	O
primary	O
signal	O

JWH-018	B-Drug
has	O
been	O
shown	O
to	O
cause	O
profound	O
changes	O
in	O
CB1	O
receptor	O
density	O
following	O
administration	O
causing	O
desensitization	O
its	O
effects	O
more	O
rapidly	O
than	O
related	O
cannabinoids	O

Loprazolam	B-Drug
similar	O
to	O
other	O
benzodiazepines	O
and	O
nonbenzodiazepine	O
hypnotic	O
drugs	O
causes	O
impairments	O
in	O
body	O
balance	O
standing	O
steadiness	O
individuals	O
who	O
wake	O
up	O
at	O
night	O
or	O
the	O
next	O
morning	O

The	O
author	O
noted	O
that	O
oxytocin	O
and	O
D-cycloserine	B-Drug
are	O
potentially	O
safer	O
co-drugs	O
in	O
PTSD	O
treatment	O
albeit	O
with	O
limited	O
evidence	O
of	O
efficacy	O

It	O
has	O
similar	O
activity	O
to	O
that	O
of	O
apalutamide	B-Drug
and	O
with	O
therapy	O
circulates	O
at	O
concentrations	O
those	O
steady	O
state	O

Starting	O
in	O
1983	O
the	O
Texas	O
Group	O
mass-produced	O
MDMA	B-Drug
a	O
lab	O
or	O
imported	O
it	O
from	O
California	O
and	O
marketed	O
tablets	O
using	O
pyramid	O
sales	O
structures	O
toll-free	O
numbers	O

Subsequent	O
legally-approved	O
MDMA	B-Drug
studies	O
in	O
humans	O
have	O
taken	O
place	O
the	O
US	O

As	O
such	O
its	O
pharmacological	O
activity	O
is	O
essentially	O
identical	O
to	O
that	O
of	O
norethisterone	B-Drug

In	O
the	O
UK	O
persons	O
who	O
are	O
prescribed	O
oral	O
methadone	B-Drug
can	O
continue	O
to	O
drive	O
after	O
they	O
have	O
satisfactorily	O
completed	O
an	O
independent	O
medical	O
examination	O
which	O
will	O
include	O
a	O
urine	O
screen	O
for	O
drugs	O

Drugs	O
such	O
as	O
MDMA	B-Drug
commonly	O
sold	O
by	O
the	O
slang	O
names	O
ecstasy	B-Drug
and	O
molly	B-Drug
are	O
often	O
adulterated	O

Since	O
the	O
mid-1990s	O
overall	O
cocaine	B-Drug
usage	O
in	O
Europe	O
has	O
been	O
on	O
rise	O
but	O
rates	O
and	O
attitudes	O
tend	O
to	O
vary	O
between	O
countries	O

However	O
other	O
studies	O
have	O
found	O
that	O
the	O
analgesic	O
effects	O
of	O
tramadol	B-Drug
are	O
significantly	O
decreased	O
or	O
even	O
absent	O
in	O
CYP2D6	O
poor	O
metabolizers	O

Medazepam	B-Drug
acts	O
as	O
a	O
prodrug	O
to	O
diazepam	B-Drug
well	O
nordazepam	B-Drug
temazepam	B-Drug
and	O
oxazepam	B-Drug

Bengal	O
opium	B-Drug
was	O
highly	O
prized	O
commanding	O
twice	O
the	O
price	O
of	O
domestic	O
Chinese	O
product	O
which	O
regarded	O
as	O
inferior	O
in	O
quality	O

A	O
2009	O
meta-analysis	O
found	O
a	O
44%	O
higher	O
rate	O
of	O
mild	O
infections	O
such	O
as	O
pharyngitis	O
or	O
sinusitis	O
in	O
people	O
taking	O
Temazepam	B-Drug
other	O
hypnotic	O
drugs	O
compared	O
to	O
those	O
placebo	O

This	O
elaborate	O
procedure	O
requiring	O
the	O
maintenance	O
of	O
pots	O
opium	B-Drug
at	O
just	O
right	O
temperature	O
for	O
a	O
globule	O
to	O
be	O
scooped	O
up	O
with	O
needle-like	O
skewer	O
smoking	O
formed	O
basis	O
craft	O
paste-scooping	O
by	O
which	O
servant	O
girls	O
could	O
become	O
prostitutes	O
as	O
opportunity	O
arose	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine	B-Drug

It	O
is	O
as	O
effective	O
for	O
this	O
indication	O
gabapentine	O
or	O
pregabalin	B-Drug
but	O
less	O
well	O
tolerated	O

7%	O
cocaine	B-Drug
use	O
more	O
than	O
doubled	O
from	O
0	O

In	O
the	O
province	O
of	O
North-Brabant	O
in	O
south	O
Netherlands	O
organized	O
crime	O
organizations	O
form	O
main	O
producer	O
MDMA	B-Drug
amphetamine	B-Drug
and	O
cannabis	O
Europe	O

Morphine	B-Drug
being	O
a	O
large	O
fraction	O
of	O
the	O
alkaloids	O
found	O
in	O
mature	O
poppy	O
capsules	O
is	O
produced	O
commercially	O
from	O
either	O
opium	B-Drug
or	O
concentrated	O
straw	O

The	O
results	O
of	O
subsequent	O
assays	O
to	O
determine	O
methasterone's	O
anabolic	O
and	O
androgenic	O
activity	O
were	O
published	O
in	O
Vida's	O
Androgens	O
Anabolic	O
Agents	O
a	O
dated	O
but	O
still	O
standard	O
reference	O
where	O
it	O
was	O
noted	O
that	O
methasterone	B-Drug
possessed	O
the	O
oral	O
bioavailability	O
methyltestosterone	B-Drug
while	O
being	O
400%	O
as	O
20%	O
yielding	O
Q-ratio	O
ratio	O
20	O
which	O
is	O
considered	O
very	O
high	O

Swiss-produced	O
heroin	B-Drug
has	O
been	O
imported	O
into	O
Canada	O
with	O
government	O
approval	O

Mercdes	O
Benegbi	O
born	O
with	O
phocomelia	O
of	O
both	O
arms	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide	B-Drug

In	O
1957	O
the	O
anticancer	O
activity	O
of	O
5-fluorouracil	O
was	O
described	O
fluorouracil	B-Drug

This	O
is	O
likely	O
related	O
to	O
the	O
high	O
ratio	O
of	O
anabolic	O
androgenic	O
activity	O
observed	O
with	O
norethandrolone	B-Drug

4-Hydroxyphenylacetone	O
is	O
the	O
para-hydroxy	O
analog	O
of	O
phenylacetone	O
an	O
inactive	O
metabolite	O
amphetamine	B-Drug
in	O
humans	O

Molecularly	O
this	O
is	O
seen	O
as	O
demethylenation	O
of	O
methylenedioxypyrovalerone	B-Drug
CYP2D6	O
followed	O
by	O
methylation	O
the	O
aromatic	O
ring	O
via	O
catechol-O-methyl	O
transferase	O

It	O
can	O
increase	O
the	O
kidney	O
toxicity	O
of	O
ciclosporin	B-Drug
and	O
tacrolimus	B-Drug

Not	O
long	O
afterward	O
a	O
1500-site	O
poster	O
campaign	O
used	O
photograph	O
of	O
smiling	B-Drug
Leah	O
Betts	O
not	O
picture	O
her	O
on	O
deathbed	O
as	O
some	O
sources	O
erroneously	O
claim	O
with	O
the	O
caption	O
Sorted:	O
Just	O
one	O
ecstasy	B-Drug
tablet	O
took	O

The	O
intermediate	O
formyl	O
amide	O
is	O
then	O
hydrolyzed	O
under	O
acidic	O
aqueous	O
conditions	O
to	O
yield	O
methamphetamine	B-Drug
as	O
the	O
final	O
product	O

Magnetic	O
resonance	O
imaging	O
studies	O
on	O
human	O
methamphetamine	B-Drug
users	O
have	O
also	O
found	O
evidence	O
of	O
neurodegeneration	O
or	O
adverse	O
neuroplastic	O
changes	O
in	O
brain	O
structure	O
and	O
function	O

Of	O
the	O
people	O
that	O
were	O
studied	O
66	O
percent	O
cocaine	B-Drug
users	O

A	O
large	O
hairpin	O
was	O
used	O
to	O
make	O
a	O
hole	O
in	O
the	O
skin	O
and	O
dropper	O
containing	O
drug	O
usually	O
heroin	B-Drug
inserted	O
bulb	O
squeezed	O
releasing	O
it	O
into	O
tissues	O

Buspirone	B-Drug
augmentation	O
was	O
not	O
found	O
to	O
increase	O
the	O
discontinuation	O
success	O
rate	O

In	O
the	O
CNS	O
diphenhydramine	B-Drug
readily	O
crosses	O
bloodbrain	O
barrier	O
exerting	O
effects	O
within	O
visual	O
and	O
auditory	O
cortex	O

Wright's	O
invention	O
did	O
not	O
lead	O
to	O
any	O
further	O
developments	O
and	O
diamorphine	B-Drug
became	O
popular	O
only	O
after	O
it	O
was	O
independently	O
re-synthesized	O
23	O
years	O
later	O
by	O
chemist	O
Felix	O
Hoffmann	O

Alvimopan	B-Drug
is	O
only	O
approved	O
for	O
short	O
term	O
use	O
of	O
no	O
more	O
than	O
15	O
doses	O

The	O
GABA	O
chemical	O
and	O
receptor	O
system	O
mediates	O
inhibitory	O
or	O
calming	O
effects	O
of	O
alprazolam	B-Drug
on	O
the	O
nervous	O

The	O
lorazepam	B-Drug
must	O
be	O
tapered	O
slowly	O
otherwise	O
the	O
catatonia	O
symptoms	O
may	O
return	O

Kirby	O
founded	O
Redux	O
Beverages	O
in	O
2006	O
with	O
his	O
wife	O
Hannah	O
and	O
launched	O
Cocaine	B-Drug
autumn	O
of	O
that	O
year	O

Noribogaine	B-Drug
is	O
most	O
potent	O
as	O
a	O
serotonin	O
reuptake	O
inhibitor	O

Substituted	O
phenethylamines	O
are	O
a	O
chemical	O
class	O
of	O
organic	O
compounds	O
based	O
upon	O
the	O
phenethylamine	B-Drug
structure;	O
is	O
composed	O
all	O
derivative	O
which	O
can	O
be	O
formed	O
by	O
replacing	O
or	O
substituting	O
one	O
more	O
hydrogen	O
atoms	O
in	O
core	O
structure	O
with	O
substituents	O

Instead	O
the	O
electronic	O
cigarettes	O
now	O
use	O
an	O
electric	O
vaporizer	O
either	O
in	O
direct	O
contact	O
with	O
absorbent	O
material	O
impregnated	O
atomizer	O
or	O
combination	O
nebulization	O
technology	O
related	O
to	O
a	O
spraying	O
jet	O
form	O
of	O
liquid	O
droplets	O
being	O
out-sprayed	O
by	O
high-speed	O
air	O
stream	O
that	O
passes	O
through	O
some	O
small	O
venturi	O
injection	O
channels	O
drilled	O
absorbed	O
nicotine	B-Drug

Caution	O
should	O
be	O
used	O
when	O
administering	O
dextropropoxyphene	B-Drug
particularly	O
with	O
children	O
and	O
the	O
elderly	O
patients	O
who	O
may	O
pregnant	O
or	O
breastfeeding;	O
other	O
reported	O
problems	O
include	O
kidney	O
liver	O
respiratory	O
disorders	O
prolonged	O
use	O

25I-NBOMe	B-Drug
has	O
been	O
implicated	O
in	O
multiple	O
deaths	O
Australia	O

Drug	O
Czar	O
John	O
Walters	O
stated	O
that	O
the	O
reason	O
for	O
[reductions	O
in	O
supply	O
not	O
immediately	O
driving	O
prices	O
up]	O
is	O
you	O
are	O
seizing	O
and	O
consuming	O
coca	B-Drug
leaves	O
were	O
grown	O
2004	O

In	O
addition	O
to	O
the	O
conversion	O
of	O
ibuprofen	B-Drug
S-enantiomer	O
body	O
can	O
metabolize	O
several	O
other	O
compounds	O
including	O
numerous	O
hydroxyl	O
carboxyl	O
and	O
glucuronyl	O
metabolites	O

In	O
addition	O
to	O
testosterone	O
it	O
is	O
a	O
combined	O
derivative	O
of	O
nandrolone	B-Drug
19-nortestosterone	B-Drug
and	O
ethisterone	O
17-ethynyltestosterone	O

carbidopa	B-Drug
benserazide	O
doubles	O
the	O
half-life	O
of	O
5-HTP	O
to	O
3-4h	O
and	O
enhances	O
exposure	O
several	O
fold	O
depending	O
on	O
dosing	O
regimen	O

In	O
2015	O
Governor	O
Pat	O
McCrory	O
signed	O
into	O
law	O
HB766	O
allowing	O
those	O
with	O
intractable	O
epilepsy	O
to	O
use	O
CBD	B-Drug
oil	I-Drug

Until	O
2017	O
products	O
containing	O
cannabidiol	B-Drug
marketed	O
for	O
medical	O
purposes	O
were	O
classed	O
as	O
medicines	O
by	O
the	O
UK	O
regulatory	O
body	O
Medicines	O
and	O
Healthcare	O
Regulatory	O
Agency	O
MHRA	O
could	O
not	O
be	O
without	O
approval	O
claims	O

In	O
tests	O
on	O
mice	O
PZM21	O
was	O
slightly	O
less	O
potent	O
than	O
morphine	B-Drug
or	O
TRV130	B-Drug
as	O
an	O
analgesic	O
but	O
also	O
had	O
significantly	O
reduced	O
adverse	O
effects	O
with	O
constipation	O
and	O
very	O
little	O
respiratory	O
depression	O
even	O
at	O
high	O
doses	O

In	O
July	O
2014	O
two	O
pharming	O
companies	O
PlantForm	O
and	O
PharmaPraxis	O
announced	O
plans	O
to	O
commercialize	O
a	O
biosimilar	O
version	O
of	O
bevacizumab	B-Drug
made	O
using	O
tobacco	B-Drug
expression	O
system	O
in	O
collaboration	O
with	O
the	O
Fraunhofer	O
Center	O
for	O
Molecular	O
Biology	O

Other	O
synonyms	O
for	O
heroin	B-Drug
include:	O
diacetylmorphine	B-Drug
and	O
morphine	B-Drug
diacetate	O

They	O
are	O
common	O
during	O
spironolactone	B-Drug
therapy	O
with	O
10	O
to	O
50%	O
of	O
women	O
experiencing	O
them	O
at	O
moderate	O
doses	O
and	O
almost	O
all	O
a	O
high	O

In	O
2013	O
the	O
Indian	O
Supreme	O
Court	O
issued	O
a	O
decision	O
rejecting	O
Novartis'	O
patent	O
application	O
in	O
India	O
on	O
final	O
form	O
of	O
Gleevec	B-Drug
Novartis's	O
cancer	O
drug;	O
case	O
caused	O
great	O
controversy	O

Trenbolone	B-Drug
acetate	I-Drug
was	O
discovered	O
in	O
1963	O
and	O
introduced	O
for	O
veterinary	O
use	O
the	O
early	O
1970s	O

The	O
most	O
common	O
adverse	O
reactions	O
experienced	O
by	O
patients	O
who	O
received	O
ivacaftor	B-Drug
in	O
the	O
pooled	O
placebo-controlled	O
Phase	O
III	O
studies	O
were	O
abdominal	O
pain	O
15	O

The	O
benzodiazepines	O
midazolam	B-Drug
and	O
temazepam	B-Drug
were	O
the	O
two	O
most	O
common	O
utilized	O
for	O
date	O
rape	O

Karl	O
Koller	O
a	O
close	O
associate	O
of	O
Sigmund	O
Freud	O
who	O
would	O
write	O
about	O
cocaine	B-Drug
later	O
experimented	O
with	O
for	O
ophthalmic	O
usage	O

Fentanyl	B-Drug
citrate	O
entered	O
medical	O
use	O
as	O
a	O
general	O
anaesthetic	O
in	O
1968	O
manufactured	O
by	O
McNeil	O
Laboratories	O
under	O
the	O
trade	O
name	O
Sublimaze	O

Due	O
to	O
their	O
improved	O
side-effect	O
profiles	O
particularly	O
lack	O
of	O
masculinizing	O
side	O
effects	O
danazol	B-Drug
has	O
largely	O
been	O
replaced	O
by	O
gonadotropin-releasing	O
hormone	O
analogues	O
GnRH	O
in	O
the	O
treatment	O
endometriosis	O

Intravenous	O
or	O
intramuscular	O
injections	B-Drug
in	O
hypotensive	O
people	O
those	O
shock	O
should	O
be	O
administered	O
carefully	O
and	O
vital	O
signs	O
monitored	O

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2	O

Molly	O
short	O
for	O
'molecule'	O
was	O
recognized	O
as	O
a	O
slang	O
term	O
crystalline	O
or	O
powder	O
MDMA	B-Drug
in	O
the	O
2000s	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC	O
CBD	B-Drug
CBC	O
CBCV	O
CBDV	O
CBGV	O
THCV	O
are	O
formed	O

Use	O
of	O
butalbital	B-Drug
and	O
alcohol	O
benzodiazepines	O
other	O
CNS-depressants	O
can	O
contribute	O
to	O
coma	O
in	O
extreme	O
cases	O
fatality	O

Atorvastatin	B-Drug
administration	O
along	O
with	O
midazolam	B-Drug
results	O
in	O
a	O
reduced	O
elimination	O
rate	O
of	O

According	O
to	O
the	O
Royal	O
Canadian	O
Mounted	O
Police	O
90%	O
of	O
heroin	B-Drug
seized	O
in	O
Canada	O
where	O
origin	O
was	O
known	O
came	O
from	O
Afghanistan	O

Forced	O
acid	O
diuresis	O
with	O
ammonium	O
chloride	O
or	O
more	O
safely	O
ascorbic	O
may	O
increase	O
clearance	O
of	O
PCP	B-Drug
from	O
the	O
body	O
and	O
was	O
somewhat	O
controversially	O
recommended	O
in	O
past	O
as	O
a	O
decontamination	O
measure	O

The	O
efficiency	O
of	O
absorption	O
orally	O
administered	O
cocaine	B-Drug
is	O
limited	O
by	O
two	O
additional	O
factors	O

In	O
1981	O
Clegg	O
had	O
coined	O
Ecstasy	B-Drug
as	O
a	O
slang	O
term	O
for	O
MDMA	B-Drug
to	O
increase	O
its	O
marketability	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
learned	O
that	O
some	O
ranitidine	B-Drug
medicines	O
including	O
products	O
sold	O
under	O
the	O
brand	O
name	O
Zantac	B-Drug
contained	O
a	O
nitrosamine	O
impurity	O
called	O
N-nitrosodimethylamine	O
NDMA	O
classified	O
as	O
probable	O
human	O
carcinogen	O
at	O
low	O
levels	O

Researchers	O
at	O
Chemie	O
Grnenthal	O
found	O
that	O
thalidomide	B-Drug
was	O
a	O
particularly	O
effective	O
antiemetic	O
had	O
an	O
inhibitory	O
effect	O
on	O
morning	O
sickness	O

The	O
production	O
of	O
adrenal	O
androstenedione	B-Drug
is	O
governed	O
by	O
adrenocorticotrophic	O
hormone	O
ACTH	O
whereas	O
gonadal	O
under	O
control	O
the	O
gonadotropins	O

A	O
2007	O
analysis	O
estimated	O
MDMA	B-Drug
to	O
have	O
a	O
psychological	O
dependence	O
and	O
physical	O
potential	O
roughly	O
three-fourths	O
four-fifths	O
that	O
of	O
cannabis	O

Female	O
cannabis	O
plants	O
contain	O
at	O
least	O
113	O
cannabinoids	O
including	O
cannabidiol	B-Drug
CBD	B-Drug
thought	O
to	O
be	O
the	O
major	O
anticonvulsant	O
that	O
helps	O
people	O
with	O
multiple	O
sclerosis;	O
and	O
cannabichromene	O
CBC	O
an	O
anti-inflammatory	O
which	O
may	O
contribute	O
pain-killing	O
effect	O
of	O

Paracetamol	B-Drug
is	O
part	O
of	O
the	O
class	O
drugs	O
known	O
as	O
aniline	O
analgesics;	O
it	O
only	O
such	O
drug	O
still	O
in	O
use	O
today	O

Aminorex	B-Drug
Menocil	O
Apiquel	O
aminoxaphen	O
aminoxafen	O
McN-742	O
is	O
a	O
weight	O
loss	O
anorectic	O
stimulant	O
drug	O

An	O
ELISA	O
immunoassay	O
technique	O
for	O
detecting	O
JWH-250	B-Drug
in	O
urine	O
has	O
been	O
reported	O

It	O
is	O
no	O
longer	O
used	O
due	O
mainly	O
to	O
safety	O
concerns	O
as	O
it	O
has	O
a	O
serotonergic	O
effects	O
profile	O
similar	O
other	O
withdrawn	O
appetite	O
suppressants	O
such	O
fenfluramine	B-Drug
and	O
aminorex	B-Drug
which	O
were	O
found	O
cause	O
pulmonary	O
hypertension	O
cardiac	O
fibrosis	O
following	O
prolonged	O
use	O

Due	O
to	O
its	O
potency	O
and	O
much	O
lower	O
cost	O
than	O
so-called	O
classical	O
or	O
traditional	O
psychedelics	O
25I-NBOMe	B-Drug
blotters	O
are	O
sometimes	O
misrepresented	O
as	O
mistaken	O
for	O
LSD	B-Drug

Nonbenzodiazepines	O
such	O
as	O
zaleplon	B-Drug
and	O
zolpidem	B-Drug
low	O
doses	O
of	O
sedating	O
antidepressants	O
are	O
sometimes	O
used	O
alternatives	O
to	O
benzodiazepines	O

Although	O
this	O
is	O
true	O
it	O
believed	O
there	O
was	O
an	O
approximate	O
one	O
year	O
shortage	O
of	O
Dextromoramide	B-Drug
and	O
the	O
real	O
reason	O
that	O
Palfium	B-Drug
not	O
put	O
back	O
into	O
production	O
for	O
UK	O
market	O
because	O
how	O
addictive	O
potent	O
as	O
oral	O
painkiller	O

In	O
1964	O
Israeli	O
physician	O
Jacob	O
Sheskin	O
administered	O
thalidomide	B-Drug
to	O
a	O
patient	O
critically	O
ill	O
with	O
leprosy	O

It	O
is	O
within	O
the	O
legislative	O
prerogative	O
to	O
classify	O
cocaine	B-Drug
which	O
a	O
non-narcotic	O
central	O
nervous	O
system	O
stimulant	O
as	O
narcotic	O
for	O
penalty	O
and	O
regulatory	O
purposes	O

The	O
main	O
active	O
metabolite	O
of	O
diazepam	B-Drug
is	O
desmethyldiazepam	B-Drug
also	O
known	O
as	O
nordazepam	B-Drug
or	O
nordiazepam	B-Drug

In	O
humans	O
MDMA	B-Drug
increases	O
the	O
amount	O
of	O
serotonin	O
in	O
synaptic	O
clefts	O
serotonergic	O
neurons	O
by	O
inhibiting	O
its	O
uptake	O
into	O
and	O
directly	O
releasing	O
it	O
from	O

World	O
War	O
I	O
saw	O
the	O
greatest	O
use	O
of	O
cocaine	B-Drug
amongst	O
militaries	O

Because	O
of	O
thalidomide's	O
potential	O
for	O
causing	O
birth	O
defects	O
the	O
drug	O
may	O
be	O
distributed	O
only	O
under	O
tightly	O
controlled	O
conditions	O
thalidomide	B-Drug

The	O
concentration	O
of	O
ondansetron	B-Drug
in	O
body	O
tissues	O
as	O
opposed	O
to	O
plasma	O
is	O
also	O
higher	O
than	O
healthy	O
people	O

In	O
1942	O
amphetamine	B-Drug
was	O
added	O
to	O
the	O
list	O
of	O
controlled	O
substances	O

Another	O
legend	O
often	O
mentioned	O
together	O
with	O
the	O
holes	O
in	O
brain	O
myth	O
discussed	O
above	O
is	O
that	O
MDMA	B-Drug
causes	O
Parkinson's	O
disease	O
possibly	O
even	O
one	O
night	O
of	O
exposure	O

The	O
medicinal	O
chemistry	O
work	O
turned	O
to	O
improving	O
the	O
lead	O
compound	O
into	O
a	O
suitable	O
drug:	O
result	O
was	O
thalidomide	B-Drug

The	O
cocaine	B-Drug
metabolite	O
benzoylecgonine	O
can	O
be	O
detected	O
in	O
the	O
urine	O
of	O
people	O
a	O
few	O
hours	O
after	O
drinking	O
one	O
cup	O
coca	B-Drug
leaf	O
infusion	O

The	O
blood	O
content	O
of	O
certain	O
neutral	O
amino-acids	O
including	O
tryptophan	O
is	O
also	O
increased	O
by	O
peripheral	O
GHB	B-Drug
administration	O

The	O
Harvard	O
researchers	O
developed	O
a	O
specific	O
protocol	O
for	O
golden	O
retriever	O
named	O
Navy	O
who	O
was	O
cancer-free	O
after	O
receiving	O
the	O
prescribed	O
cocktail	O
of	O
celecoxib	B-Drug
doxycycline	B-Drug
and	O
tamoxifen	B-Drug
treatment	O
subsequently	O
became	O
known	O
as	O
Protocol	O

Studies	O
into	O
the	O
effects	O
of	O
LSD	B-Drug
on	O
human	O
creativity	O
and	O
spirituality	O
were	O
also	O
conducted	O
during	O
this	O
period	O

However	O
alcoholic	O
beverages	O
tobacco	B-Drug
and	O
caffeine	O
are	O
not	O
covered	O
by	O
this	O
law	O

Active	O
substance:	O
loperamide	B-Drug
Motilium	O
against	O
flatulence	O
and	O
bowel	O
impairments	O

In	O
March	O
2010	O
the	O
ACMD	O
published	O
a	O
report	O
Consideration	O
of	O
cathinones	O
which	O
recommended	O
that	O
mephedrone	B-Drug
and	O
other	O
should	O
be	O
made	O
illegal	O

According	O
to	O
The	O
New	O
York	O
Times	O
Palmeiro	O
tested	O
positive	O
for	O
the	O
potent	O
anabolic	O
steroid	O
stanozolol	B-Drug

JWH-018	B-Drug
has	O
an	O
EC50	O
of	O
102	O
nM	O
for	O
human	O
CB1	O
receptors	O
and	O
133	O
CB2	O

The	O
drug	O
has	O
a	O
well-established	O
safety	O
record	O
owing	O
to	O
the	O
use	O
of	O
levonorgestrel	B-Drug
as	O
an	O
oral	O
contraceptive	O
since	O
1960s	O

Trenbolone	B-Drug
increases	O
an	O
inflammatory	O
mediator	O
peptide	O
called	O
bradykinin	O
which	O
facilitates	O
the	O
dilation	O
of	O
blood	O
vessels	O

Hydroxylation	O
of	O
the	O
C3	O
position	O
desogestrel	B-Drug
catalyzed	O
by	O
cytochrome	O
P450-dependent	O
enzymes	O
with	O
3-hydroxydesogestrel	O
and	O
3-hydroxydesogetrel	O
as	O
intermediates	O
followed	O
oxidation	O
hydroxyl	O
group	O
is	O
responsible	O
for	O
transformation	O

Penicillin	O
and	O
aspirin	B-Drug
are	O
common	O
drugs	O
that	O
act	O
in	O
this	O
manner	O

They	O
flew	O
cocaine	B-Drug
in	O
from	O
Colombia	O
by	O
jet	O
and	O
then	O
reloaded	O
it	O
into	O
small	O
aircraft	O

Like	O
all	O
opioids	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone	B-Drug
or	O
other	O
opiate	O
antagonists	O

Whereas	O
opioids	O
like	O
codeine	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
and	O
hydromorphone	B-Drug
are	O
synthesized	O
by	O
simple	O
modifications	O
of	O
morphine	B-Drug
fentanyl	B-Drug
its	O
relatives	O
meperidine	B-Drug

Reviews	O
of	O
ADHD	O
biomarkers	O
have	O
noted	O
that	O
platelet	O
monoamine	O
oxidase	O
expression	O
urinary	O
norepinephrine	O
MHPG	O
and	O
phenethylamine	B-Drug
levels	O
consistently	O
differ	O
between	O
individuals	O
healthy	O
control	O

The	O
approximate	O
cost	O
of	O
a	O
1	O
ml	O
ampoule	O
naloxone	B-Drug
in	O
the	O
US	O
is	O
estimated	O
to	O
be	O
significantly	O
higher	O
than	O
most	O
Western	O
countries	O

In	O
1947	O
David	O
Lester	O
and	O
Leon	O
Greenberg	O
found	O
strong	O
evidence	O
that	O
paracetamol	B-Drug
was	O
a	O
major	O
metabolite	O
of	O
acetanilide	O
in	O
human	O
blood	O
subsequent	O
study	O
they	O
reported	O
large	O
doses	O
given	O
to	O
albino	O
rats	O
did	O
not	O
cause	O
methemoglobinemia	O

The	O
origin	O
of	O
the	O
name	O
crack	O
comes	O
from	O
crackling	O
sound	O
and	O
hence	O
onomatopoeic	O
moniker	O
that	O
is	O
produced	O
when	O
cocaine	B-Drug
its	O
impurities	O
i	O

As	O
a	O
pure	O
herb	O
or	O
tea	O
m	O
hung	O
containing	O
ephedrine	B-Drug
is	O
still	O
sold	O
legally	O
in	O
the	O
USA	O

Estazolam	B-Drug
should	O
only	O
be	O
used	O
short	O
term	O
and	O
at	O
the	O
lowest	O
effective	O
dose	O
to	O
avoid	O
complications	O
related	O
long-term	O
use	O

Dimenhydrinate	B-Drug
marketed	O
as	O
Gravol	O
in	O
Canada	O
and	O
Dramamine	B-Drug
the	O
United	O
Kingdom	O
States	O
is	O
an	O
over-the-counter	O
OTC	O
antihistamine	O
indicated	O
for	O
prevention	O
relief	O
of	O
nausea	O
vomiting	O
from	O
a	O
number	O
causes	O

Prucalopride	B-Drug
is	O
a	O
highly	O
selective	O
5-HT4	O
receptor	O
agonist	O
that	O
can	O
be	O
used	O
to	O
treat	O
certain	O
disorders	O
of	O
gastrointestinal	O
motility	O

Willsttter's	O
synthesis	O
derived	O
cocaine	B-Drug
from	O
tropinone	O

The	O
principal	O
goals	O
of	O
methadone	B-Drug
maintenance	O
are	O
to	O
relieve	O
opioid	O
cravings	O
suppress	O
the	O
abstinence	O
syndrome	O
and	O
block	O
euphoric	O
effects	O
associated	O
with	O
opioids	O

However	O
there	O
is	O
also	O
a	O
response	O
from	O
the	O
Ministry	O
of	O
Health	O
Russian	O
Federation	O
indicating	O
that	O
CBD	B-Drug
can	O
be	O
considered	O
as	O
an	O
isomer	O
restricted	O
THC	O

Diazepam	B-Drug
increases	O
the	O
central	O
depressive	O
effects	O
of	O
alcohol	O
other	O
hypnotics/sedatives	O
e	O

There	O
is	O
a	O
possible	O
interaction	O
that	O
results	O
in	O
hypertensive	O
crisis	O
when	O
mirtazapine	B-Drug
given	O
to	O
patient	O
has	O
already	O
been	O
on	O
steady	O
doses	O
of	O
clonidine	B-Drug

Some	O
bacteria	O
have	O
been	O
shown	O
to	O
be	O
able	O
turn	O
morphine	B-Drug
into	O
closely	O
related	O
drugs	O
including	O
hydromorphone	B-Drug
and	O
dihydromorphine	B-Drug
among	O
others	O

Recreational	O
use	O
of	O
25I-NBOMe	B-Drug
carries	O
a	O
significant	O
risk	O
both	O
pharmacological	O
and	O
behavioral	O
toxicity	O

Food	O
and	O
Drug	O
Administration	O
FDA	O
notes	O
that	O
improper	O
dosing	O
is	O
one	O
of	O
the	O
biggest	O
problems	O
in	O
giving	O
acetaminophen	B-Drug
paracetamol	B-Drug
to	O
children	O

In	O
1953	O
a	O
testosterone-derived	O
steroid	O
known	O
as	O
norethandrolone	B-Drug
17-ethyl-19-nortestosterone	O
was	O
synthesized	O
at	O
G	O

Limited	O
clinical	O
studies	O
suggest	O
ketoconazole	B-Drug
shampoo	O
used	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
treatments	O
may	O
be	O
useful	O
reducing	O
hair	O
loss	O
some	O
cases	O

25I-NBOMe	B-Drug
was	O
explicitly	O
scheduled	O
in	O
Queensland	O
drug	O
law	O
April	O
2012	O
and	O
New	O
South	O
Wales	O
October	O
2013	O
as	O
were	O
some	O
related	O
compounds	O
such	O
25B-NBOMe	B-Drug

The	O
structure	O
of	O
trenbolone	B-Drug
acetate	O
is	O
a	O
19-nor	O
classification	O
which	O
represents	O
structural	O
change	O
the	O
testosterone	O
hormone	O

Metabolites	O
of	O
MDMA	B-Drug
that	O
have	O
been	O
identified	O
in	O
humans	O
include	O
34-methylenedioxyamphetamine	O
MDA	O
4-hydroxy-3-methoxymethamphetamine	O
HMMA	O
4-hydroxy-3-methoxyamphetamine	O
HMA	O
34-dihydroxyamphetamine	O
DHA	O
also	O
called	O
alpha-methyldopamine	O
-Me-DA	O
34-methylenedioxyphenylacetone	O
MDP2P	O
and	O
34-Methylenedioxy-N-hydroxyamphetamine	O
MDOH	B-Drug

Major	O
examples	O
include	O
tetrahydrodeoxycorticosterone	O
THDOC	O
the	O
androstane	O
3-androstanediol	O
cholestane	O
cholesterol	O
and	O
pregnanes	O
pregnanolone	O
eltanolone	O
allopregnanolone	B-Drug
35-THP	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
releasing	O
more	O
fentanyl	B-Drug
together	O
with	O
acidosis	O
which	O
reduces	O
protein	O
binding	O
of	O
yet	O

The	O
combination	O
of	O
30	O
g/day	O
EE	O
and	O
150	O
desogestrel	B-Drug
a	O
progestin	O
with	O
relatively	O
weak	O
androgenicity	O
than	O
levonorgestrel	B-Drug
increases	O
SHBG	O
levels	O
by	O
200%	O
while	O
the	O
35	O
2	O
mg/day	O
cyproterone	O
acetate	O
potent	O
antiandrogenic	O
activity	O
400%	O

Nalbuphine	B-Drug
is	O
said	O
to	O
be	O
more	O
morphine-like	O
at	O
lower	O
doses	O

In	O
the	O
horror	O
video-game	O
Amnesia:	O
Rebirth	O
2020	O
laudanum	B-Drug
can	O
be	O
found	O
scarcely	O
and	O
used	O
to	O
decrease	O
player	O
character's	O
fear	O

198434	O
the	O
California	O
Supreme	O
Court	O
ruled	O
that	O
possession	O
of	O
ecstasy	B-Drug
MDMA	B-Drug
or	O
methylenedioxy-methylamphetamine	O
without	O
additional	O
evidence	O
is	O
insufficient	O
to	O
sustain	O
a	O
conviction	O
for	O
controlled	O
substance	O
11350	O
HS	O

A	O
cross-tolerance	O
can	O
develop	O
between	O
psilocybin	O
and	O
the	O
pharmacologically	O
similar	O
LSD	B-Drug
phenethylamines	O
such	O
as	O
mescaline	B-Drug
DOM	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC	O
CBD	B-Drug
CBC	O
CBCV	O
CBDV	O
CBGV	O
THCV	O
are	O
formed	O

Youth	O
state	O
that	O
they	O
do	O
not	O
use	O
e-liquids	O
containing	O
nicotine	B-Drug
while	O
doing	O
vaping	O
tricks	O

In	O
2007	O
about	O
42800	O
emergency	O
room	O
visits	O
occurred	O
due	O
to	O
episodes	O
involving	O
oxycodone	B-Drug

Cannabis	O
may	O
sometimes	O
be	O
considered	O
a	O
depressant	O
due	O
to	O
one	O
of	O
its	O
components	O
cannabidiol	B-Drug

5	O
to	O
100	O
mg/day	O
in	O
combination	O
with	O
an	O
aromatase	O
inhibitor	O
like	O
anastrozole	B-Drug
especially	O
for	O
familial	O
male-limited	O
precocious	O
puberty	O
testotoxicosis	O
Overly	O
long-lasting	O
erections	O
men	O
at	O
50	O
mg	O
per	O
week	O
every	O
other	O
dayThe	O
medication	O
has	O
been	O
suggested	O
but	O
uncertain	O
effectiveness	O
the	O
following	O
indication:	O
Hypersexuality	O
and	O
paraphilias	O
particularly	O
chemical	O
castrationFor	O
more	O
information	O
on	O
these	O
uses	O
see	O
medical	O
of	O
bicalutamide	B-Drug
article	O

The	O
pH	O
of	O
diazepam	B-Drug
is	O
neutral	O
i	O

However	O
methamphetamine	B-Drug
remains	O
the	O
drug	O
of	O
choice	O
for	O
Koreans	O

Synthetic	O
cocaine	B-Drug
would	O
be	O
highly	O
desirable	O
to	O
the	O
illegal	O
drug	O
industry	O
as	O
it	O
eliminate	O
high	O
visibility	O
and	O
low	O
reliability	O
of	O
offshore	O
sources	O
international	O
smuggling	O
replacing	O
them	O
with	O
clandestine	O
domestic	O
laboratories	O
are	O
common	O
for	O
illicit	O
methamphetamine	B-Drug

The	O
metabolites	O
can	O
also	O
be	O
found	O
in	O
the	O
urine	O
of	O
heroin	B-Drug
users	O
allowing	O
street	O
to	O
distinguished	O
from	O
pharmaceutical	O
diacetylmorphine	B-Drug

5	O
mEq/L	O
or	O
people	O
that	O
are	O
hypersensitive	O
to	O
amiloride	B-Drug
any	O
ingredients	O
within	O
the	O
specific	O
formulation	O

In	O
2017	O
doctors	O
in	O
the	O
UK	O
began	O
first	O
clinical	O
study	O
of	O
MDMA	B-Drug
alcohol	O
use	O
disorder	O

In	O
palliative	O
care	O
transdermal	O
fentanyl	B-Drug
patches	B-Drug
have	O
a	O
definitive	O
but	O
limited	O
role	O
for:	O
people	O
already	O
stabilized	O
on	O
other	O
opioids	O
who	O
persistent	O
swallowing	O
problems	O
and	O
cannot	O
tolerate	O
parenteral	O
routes	O
such	O
as	O
subcutaneous	O
administration	O

At	O
a	O
high	O
dosage	O
of	O
1600	O
mg/day	O
orally	O
for	O
4	O
weeks	O
treatment	O
postmenopausal	O
women	O
with	O
prasterone	O
has	O
been	O
found	O
to	O
increase	O
serum	O
levels	O
DHEA	O
by	O
15-fold	O
testosterone	O
9-fold	O
DHEA-S	O
androstenedione	B-Drug
and	O
DHT	O
all	O
20-fold	O
estrone	O
estradiol	O
both	O
2-fold	O

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

Morphine	B-Drug
itself	O
in	O
trials	O
with	O
rats	O
is	O
1122	O
times	O
more	O
potent	O
than	O
morphine-N-oxide	O
subcutaneously	O
and	O
3989	O
intraperitoneally	O

Calcium	O
channel	O
blockers	O
like	O
verapamil	B-Drug
dilate	O
blood	O
vessels	O
which	O
increases	O
the	O
supply	O
of	O
and	O
oxygen	O
to	O
heart	O

Cannabis	O
the	O
plant	O
that	O
produces	O
hemp	O
and	O
hashish	B-Drug
has	O
been	O
one	O
of	O
most	O
used	O
psychoactive	O
drugs	O
in	O
world	O
since	O
late	O
20th	O
century	O
following	O
only	O
tobacco	B-Drug
alcohol	O
popularity	O

The	O
Registry	O
of	O
Toxic	O
Effects	O
Chemical	O
Substances	O
assigns	O
psilocybin	O
a	O
relatively	O
high	O
therapeutic	O
index	O
641	O
higher	O
values	O
correspond	O
to	O
better	O
safety	O
profile;	O
for	O
comparison	O
the	O
indices	O
aspirin	B-Drug
and	O
nicotine	B-Drug
are	O
199	O
21	O
respectively	O

The	O
chemical	O
name	O
of	O
amitriptyline	B-Drug
is	O
3-1011-dihydro-5H-dibenzo[ad]cycloheptene-5-ylidene-NN-dimethylpropan-1-amine	O
and	O
its	O
free	O
base	O
form	O
has	O
a	O
formula	O
C20H23N	O
with	O
molecular	O
weight	O
277	O

Mifepristone	B-Drug
is	O
a	O
steroidal	O
antiprogestogen	O
IC50	O
2	O

For	O
example	O
the	O
seizure	O
of	O
50	O
grams	O
or	O
more	O
heroin	B-Drug
crystal	B-Drug
methamphetamine	I-Drug
could	O
result	O
in	O
use	O
death	O
penalty	O
by	O
Government	O

Inhibitors	O
of	O
enzymes	O
that	O
directly	O
metabolize	O
amphetamine	B-Drug
particularly	O
CYP2D6	O
and	O
FMO3	O
will	O
prolong	O
the	O
elimination	O
increase	O
drug	O
effects	O

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O

Dextroamphetamine	B-Drug
is	O
a	O
more	O
potent	O
agonist	O
of	O
TAAR1	O
than	O
levoamphetamine	O

In	O
November	O
1961	O
thalidomide	B-Drug
was	O
taken	O
off	O
the	O
market	O
due	O
to	O
massive	O
pressure	O
from	O
press	O
and	O
public	O

In	O
the	O
United	O
States	O
diamorphine	B-Drug
is	O
a	O
Schedule	O
I	O
drug	O
according	O
to	O
Controlled	O
Substances	O
Act	O
of	O
1970	O
making	O
it	O
illegal	O
possess	O
without	O
DEA	O
license	O

The	O
major	O
metabolite	O
of	O
darolutamide	B-Drug
ketodarolutamide	O
has	O
similar	O
antiandrogenic	O
activity	O
relative	O
to	O
Ki	O
38	O
nM	O

Systemic	O
exposure	O
to	O
excessive	O
quantities	O
of	O
lidocaine	B-Drug
mainly	O
result	O
in	O
central	O
nervous	O
system	O
CNS	O
and	O
cardiovascular	O
effects	O
usually	O
occur	O
at	O
lower	O
blood	O
plasma	O
concentrations	O
additional	O
present	O
higher	O
though	O
collapse	O
may	O
also	O
with	O
low	O

The	O
patches	O
work	O
by	O
slowly	O
releasing	O
fentanyl	B-Drug
through	O
the	O
skin	O
into	O
bloodstream	O
over	O
48	O
to	O
72	O
hours	O
allowing	O
for	O
long-lasting	O
pain	O
management	O

Antipyretics	O
work	O
by	O
inhibiting	O
the	O
enzyme	O
COX	O
which	O
causes	O
general	O
inhibition	O
of	O
prostanoid	O
biosynthesis	O
PGE2	B-Drug
within	O
hypothalamus	O

K2	O
and	O
Spice	O
Cocaine	B-Drug
LSD	B-Drug
Opiates	O
e	O

In	O
July	O
2016	O
President	O
Barack	O
Obama	O
signed	O
into	O
law	O
the	O
Comprehensive	O
Addiction	O
and	O
Recovery	O
Act	O
which	O
expands	O
opioid	O
addiction	O
treatment	O
with	O
buprenorphine	B-Drug
authorizes	O
millions	O
of	O
dollars	O
in	O
funding	O
for	O
research	O

Bradycardia:	O
Fentanyl	B-Drug
decreases	O
the	O
heart	O
rate	O
by	O
increasing	O
vagal	O
nerve	O
tone	O
in	O
brainstem	O
which	O
increases	O
parasympathetic	O
drive	O

Kenneth	O
Halliwell's	O
death	O
is	O
also	O
attributed	O
to	O
an	O
overdose	O
of	O
pentobarbital	B-Drug

Androstenedione	B-Drug
is	O
converted	O
to	O
either	O
testosterone	O
or	O
estrone	O

8%	O
of	O
tamoxifen	B-Drug
while	O
other	O
plasma	O
proteins	O
are	O
not	O
greatly	O
involved	O

Providing	O
medical	O
prescriptions	O
for	O
pharmaceutical	O
heroin	B-Drug
diacetylmorphine	B-Drug
to	O
heroin-dependent	O
people	O
has	O
been	O
employed	O
in	O
some	O
countries	O
address	O
problems	O
associated	O
with	O
the	O
illicit	O
use	O
of	O
drug	O
as	O
potential	O
benefits	O
exist	O
individual	O
and	O
broader	O
society	O

25I-NBOMe	B-Drug
acts	O
as	O
a	O
highly	O
potent	O
full	O
agonist	O
for	O
the	O
human	O
5-HT2A	O
receptor	O
with	O
dissociation	O
constant	O
Ki	O
of	O
0	O

Loss	O
of	O
CO2	O
prevents	O
the	O
reaction	O
from	O
reversing	O
back	O
to	O
cocaine	B-Drug
hydrochloride	I-Drug

Nandrolone	B-Drug
use	O
is	O
directly	O
detectable	O
in	O
hair	O
or	O
indirectly	O
urine	O
by	O
testing	O
for	O
the	O
presence	O
of	O
19-norandrosterone	O
a	O
metabolite	O

In	O
the	O
community	O
intravenous	O
administration	O
is	O
not	O
practical	O
and	O
so	O
rectal	O
diazepam	B-Drug
or	O
buccal	O
midazolam	B-Drug
are	O
used	O
with	O
a	O
preference	O
for	O
as	O
its	O
easier	O
more	O
socially	O
acceptable	O

Some	O
claims	O
for	O
example	O
that	O
cannabidiol	B-Drug
can	O
be	O
used	O
to	O
treat	O
cancer	O
fall	O
into	O
the	O
realm	O
of	O
pseudoscience	O

People	O
who	O
are	O
rapid	O
or	O
ultra	O
metabolizers	O
for	O
the	O
CYP2C9	O
CYP2C19	O
and	O
CYP2D6	O
enzymes	O
may	O
not	O
respond	O
adequately	O
to	O
tapentadol	B-Drug
therapy	O

Tennis	O
player	O
Venus	O
Williams	O
had	O
permission	O
from	O
the	O
International	O
Federation	O
to	O
use	O
DHEA	O
along	O
with	O
hydrocortisone	B-Drug
as	O
a	O
treatment	O
for	O
adrenal	O
insufficiency	O
but	O
it	O
was	O
revoked	O
in	O
2016	O
by	O
World	O
Anti-Doping	O
Agency	O
which	O
believed	O
would	O
enhance	O
Williams'	O
athletic	O
performance	O

Patients	O
reporting	O
to	O
two	O
emergency	O
rooms	O
in	O
Canada	O
with	O
violence-related	O
injuries	O
were	O
most	O
often	O
found	O
be	O
intoxicated	O
alcohol	O
and	O
significantly	O
more	O
likely	O
test	O
positive	O
for	O
benzodiazepines	O
commonly	O
temazepam	B-Drug
than	O
other	O
groups	O
of	O
individuals	O
whereas	O
drugs	O
insignificant	O
relation	O
violent	O

Methylone	B-Drug
is	O
the	O
substituted	O
cathinone	O
analog	O
of	O
MDMA	B-Drug
and	O
34-methylenedioxy	O
methcathinone	B-Drug

In	O
a	O
survey	O
of	O
UK	O
users	O
who	O
had	O
previously	O
taken	O
cocaine	B-Drug
most	O
found	O
it	O
produced	O
better-quality	O
and	O
longer-lasting	O
high	O
was	O
less	O
addictive	O

In	O
some	O
places	O
of	O
north	O
Morocco	O
like	O
Chaouen	O
Cannabis	O
is	O
planted	O
for	O
Hashish	B-Drug
production	O

Morphine	B-Drug
was	O
the	O
first	O
pharmaceutical	O
isolated	O
from	O
a	O
natural	O
product	O
and	O
this	O
success	O
encouraged	O
isolation	O
of	O
other	O
alkaloids:	O
by	O
1820	O
isolations	O
noscapine	O
strychnine	O
veratrine	O
colchicine	B-Drug
caffeine	O
quinine	B-Drug
were	O
reported	O

However	O
shifts	O
in	O
the	O
public	O
attitude	O
towards	O
drugsthey	O
were	O
beginning	O
to	O
be	O
associated	O
with	O
prostitution	O
vice	O
and	O
immoralityled	O
government	O
pass	O
further	O
unprecedented	O
laws	O
banning	O
criminalising	O
possession	O
dispensation	O
of	O
all	O
narcotics	O
including	O
opium	B-Drug
cocaine	B-Drug

Some	O
AAS	O
such	O
as	O
testosterone	O
DHT	O
stanozolol	B-Drug
and	O
methyltestosterone	B-Drug
have	O
been	O
found	O
to	O
modulate	O
the	O
GABAA	O
receptor	O
similarly	O
endogenous	O
neurosteroids	O
like	O
allopregnanolone	B-Drug
3-androstanediol	O
dehydroepiandrosterone	O
sulfate	O
pregnenolone	O

A	O
combination	O
formulation	O
of	O
bicalutamide	B-Drug
and	O
goserelin	O
is	O
marketed	O
by	O
AstraZeneca	O
in	O
Australia	O
New	O
Zealand	O
under	O
the	O
brand	O
name	O
ZolaCos-CP	O

25I-NBOMe	B-Drug
effects	O
usually	O
last	O
610	O
hours	O
if	O
taken	O
sublingually	O
or	O
buccally	O
between	O
gum	O
and	O
cheek	O

Nagai	O
Nagayoshi	O
August	O
8	O
1844	O
February	O
10	O
1929	O
was	O
a	O
notable	O
Japanese	O
organic	O
chemist	O
and	O
pharmacologist	O
best	O
known	O
for	O
his	O
study	O
of	O
ephedrine	B-Drug

The	O
patches	O
work	O
by	O
slowly	O
releasing	O
fentanyl	B-Drug
through	O
the	O
skin	O
into	O
bloodstream	O
over	O
48	O
to	O
72	O
hours	O
allowing	O
for	O
long-lasting	O
pain	O
management	O

In	O
February	O
2014	O
Shire	O
announced	O
that	O
two	O
late-stage	O
clinical	O
trials	O
had	O
shown	O
Vyvanse	B-Drug
was	O
not	O
an	O
effective	O
treatment	O
for	O
depression	O

The	O
Muslim	O
nations	O
of	O
Turkey	O
and	O
Egypt	O
were	O
instrumental	O
in	O
banning	O
opium	B-Drug
cocaine	B-Drug
cannabis	O
when	O
the	O
League	O
Nations	O
committed	O
to	O
1925	O
International	O
Convention	O
relating	O
other	O
drugs	O
later	O
1934	O
Dangerous	O
Drugs	O
Act	O

The	O
major	O
metabolites	O
of	O
diamorphine	B-Drug
6-MAM	O
morphine	B-Drug
morphine-3-glucuronide	O
and	O
morphine-6-glucuronide	O
may	O
be	O
quantitated	O
in	O
blood	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use	O
confirm	O
a	O
diagnosis	O
poisoning	O
assist	O
medicolegal	O
death	O
investigation	O

The	O
treatment	O
was	O
attempted	O
despite	O
the	O
ban	O
on	O
thalidomide's	O
use	O
and	O
results	O
were	O
favourable:	O
patient	O
slept	O
for	O
hours	O
able	O
to	O
get	O
out	O
of	O
bed	O
without	O
aid	O
upon	O
awakening	O
thalidomide	B-Drug

Concurrent	O
to	O
the	O
rave	O
movement	O
and	O
in	O
key	O
respects	O
integral	O
it	O
are	O
development	O
of	O
new	O
mind-altering	O
drugs	O
most	O
notably	O
MDMA	B-Drug
Ecstasy	B-Drug

Alder	O
Wright	O
in	O
1874	O
from	O
morphine	B-Drug
a	O
natural	O
product	O
of	O
the	O
opium	O
poppy	O

In	O
the	O
body	O
O-acetylpsilocin	B-Drug
is	O
deacetylated	O
to	O
psilocin	B-Drug
by	O
deacetylases/acetyltransferases	O
during	O
first	O
pass	O
metabolism	O
and	O
subsequent	O
passes	O
through	O
liver	O
evident	O
as	O
psilacetin	O
also	O
active	O
via	O
parenteral	O
routes	O
of	O
ingestion	O

Trading	O
in	O
opium	B-Drug
was	O
lucrative	O
and	O
smoking	O
it	O
had	O
become	O
common	O
for	O
the	O
Chinese	O
19th	O
century	O
so	O
British	O
merchants	O
increased	O
trade	O
with	O

Under	O
the	O
Drug	O
Addiction	O
Treatment	O
Act	O
of	O
2000	O
physicians	O
can	O
obtain	O
an	O
X-waiver	O
to	O
prescribe	O
buprenorphine	B-Drug

Short-acting	O
benzodiazepines	O
such	O
as	O
lorazepam	B-Drug
are	O
more	O
likely	O
to	O
cause	O
a	O
severe	O
withdrawal	O
syndrome	O
compared	O
longer-acting	O

Using	O
formaldehyde	O
and	O
sulfuric	O
acid	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs	O

As	O
such	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O

Pyrolysis	O
products	O
of	O
cocaine	B-Drug
that	O
occur	O
only	O
when	O
heated/smoked	O
have	O
been	O
shown	O
to	O
change	O
the	O
effect	O
profile	O
i	O

NA	O
Piperidine	O
cocaine-homologues	O
Cocaine	B-Drug
hapten	O
analogues	O
===	O
6-2R3S-3-benzoyloxy-8-methyl-8-azabicyclo	O
[3	O

Increased	O
subjective	O
feelings	O
of	O
'high'	O
have	O
been	O
reported	O
in	O
healthy	O
human	O
volunteers	O
exposed	O
to	O
ketamine	B-Drug

25I-NBOMe	B-Drug
effects	O
usually	O
last	O
610	O
hours	O
if	O
taken	O
sublingually	O
or	O
buccally	O
between	O
gum	O
and	O
cheek	O

Caution	O
should	O
be	O
used	O
if	O
butorphanol	B-Drug
is	O
administered	O
in	O
addition	O
to	O
other	O
narcotics	O
sedatives	O
depressants	O
or	O
antihistamines	O
as	O
it	O
will	O
cause	O
an	O
additive	O
effect	O

267000	O
police	O
continue	O
to	O
disburse	O
the	O
drug	O
which	O
resulted	O
in	O
233	O
individuals	O
restored	O
by	O
Narcan	B-Drug
first	O
quarter	O
2020	O

The	O
word	O
endorphin	O
is	O
derived	O
from	O
/	O
Greek:	O
ndon	O
meaning	O
within	O
endogenous	O
endogenes	O
proceeding	O
and	O
morphine	B-Drug
Morpheus	O
Ancient	O
romanized:	O
Morphes	O
the	O
god	O
of	O
dreams	O
in	O
Greek	O
mythology	O

Most	O
important	O
according	O
to	O
the	O
Commentary:	O
[Tobacco]	O
is	O
not	O
suitable	O
for	O
kinds	O
of	O
controls	O
which	O
Vienna	O
Convention	O
provides	O
and	O
if	O
applied	O
would	O
make	O
any	O
useful	O
impact	O
on	O
tobacco	B-Drug
problem	O
Tobacco	B-Drug

In	O
1901	O
the	O
Atlanta	O
Constitution	O
reported	O
that	O
Use	O
of	O
drug	O
[cocaine]	O
among	O
negroes	O
is	O
growing	O
to	O
an	O
alarming	O
extent	O
cocaine	B-Drug

Sleep	O
apnea	O
may	O
be	O
worsened	O
by	O
lorazepam's	O
central	O
nervous	O
system	O
depressant	O
effects	O
lorazepam	B-Drug

The	O
primary	O
cocaine	B-Drug
importation	O
points	O
in	O
the	O
United	O
States	O
have	O
been	O
Arizona	O
southern	O
California	O
Florida	O
and	O
Texas	O

The	O
remains	O
of	O
coca	B-Drug
leaves	O
have	O
been	O
found	O
with	O
ancient	O
Peruvian	O
mummies	O
and	O
pottery	O
from	O
the	O
time	O
period	O
depicts	O
humans	O
bulged	O
cheeks	O
indicating	O
presence	O
something	O
on	O
which	O
they	O
are	O
chewing	O

Ketamine	B-Drug
may	O
also	O
decrease	O
suicidal	O
thoughts	O
for	O
up	O
to	O
three	O
days	O
after	O
the	O
injection	O

As	O
a	O
result	O
of	O
World	O
War	O
I	O
hundreds	O
thousands	O
soldiers	O
developed	O
severe	O
opiate	O
addictions	O
as	O
morphine	B-Drug
was	O
commonly	O
used	O
to	O
treat	O
injuries	O

Their	O
plan	O
was	O
to	O
fly	O
hundreds	O
of	O
kilograms	O
cocaine	B-Drug
from	O
Pablo	O
Escobar's	O
Colombian	O
ranch	O
the	O
U	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
as	O
heroin	B-Drug
or	O
oxycodone	B-Drug
leading	O
to	O
overdoses	O

As	O
specifically	O
noted	O
in	O
the	O
book	O
Acid	O
Dreams	O
it	O
is	O
stated	O
that	O
Augustus	O
Owsley	O
Stansley	O
III	O
one	O
of	O
most	O
prolific	O
producers	O
LSD	B-Drug
1960s	O
observed	O
piezoluminescence	O
compound's	O
purest	O
form	O
which	O
observation	O
confirmed	O
by	O
Alexander	O
Shulgin:	O
A	O
totally	O
pure	O
salt	O
when	O
dry	O
and	O
shaken	O
dark	O
will	O
emit	O
small	O
flashes	O
white	O
light	O

Fentanyl	B-Drug
has	O
a	O
US	O
DEA	O
ACSCN	O
of	O
9801	O
and	O
2013	O
annual	O
aggregate	O
manufacturing	O
quota	O
2108	O

Fentanyl	B-Drug
analogs	O
such	O
as	O
-methylfentanyl	O
and	O
3-methylfentanyl	B-Drug
are	O
often	O
used	O
the	O
cut	O
in	O
small	O
amounts	O
normal	O
heroin	B-Drug
stamps	O
bags	O
making	O
them	O
more	O
potent	O
profitable	O
than	O
when	O
sold	O
alone	O
due	O
to	O
advantage	O
of	O
raising	O
retail	O
price	O
potency	O
per	O
unit	O

While	O
it	O
can	O
be	O
used	O
for	O
severe	O
agitation	O
midazolam	B-Drug
is	O
usually	O
preferred	O

A	O
phase	O
I	O
clinical	O
trial	O
of	O
apalutamide	B-Drug
was	O
completed	O
by	O
March	O
2012	O
and	O
the	O
results	O
this	O
study	O
were	O
published	O
in	O
2013	O

Those	O
convicted	O
of	O
selling	O
cocaine	B-Drug
with	O
prior	O
related	O
offenses	O
may	O
serve	O
many	O
years	O
in	O
the	O
state	O
prison	O
since	O
qualifying	O
convictions	O
add	O
3	O
per	O
conviction	O
to	O
term	O
provided	O
for	O
itself	O

The	O
modern	O
use	O
of	O
the	O
term	O
designer	O
drug	O
was	O
coined	O
in	O
1980s	O
to	O
refer	O
various	O
synthetic	O
opioid	O
drugs	O
based	O
mostly	O
on	O
fentanyl	B-Drug
molecule	O
such	O
as	O
-methylfentanyl	O

A	O
monograph	O
for	O
the	O
drug	O
says:	O
Treatment	O
with	O
nitrazepam	B-Drug
should	O
usually	O
not	O
exceed	O
seven	O
to	O
ten	O
consecutive	O
days	O

Nutmeg	O
although	O
purportedly	O
not	O
as	O
strong	O
or	O
unpleasant	O
feeling	O
diphenhydramine	B-Drug
scopolamine	O
is	O
also	O
considered	O
a	O
deliriant	O
due	O
to	O
its	O
propensity	O
cause	O
anticholinergic-like	O
symptoms	O
when	O
taken	O
in	O
large	O
doses	O

Research	O
indicates	O
that	O
cannabidiol	B-Drug
may	O
reduce	O
adverse	O
effects	O
of	O
THC	O
particularly	O
those	O
causing	O
intoxication	O
and	O
sedation	O
but	O
only	O
at	O
high	O
doses	O

-Methylfentanyl	O
has	O
similar	O
effects	O
to	O
fentanyl	B-Drug

After	O
oral	O
ingestion	O
of	O
a	O
single	O
5	O
mg	O
dose	O
clotiazepam	B-Drug
by	O
three	O
healthy	O
volunteers	O
the	O
drug	O
was	O
rapidly	O
absorbed	O

With	O
additional	O
contingency	O
management	O
support	O
naltrexone	B-Drug
may	O
be	O
effective	O
in	O
a	O
broader	O
population	O

For	O
example	O
AM-4030	O
a	O
derivative	O
of	O
HU-210	B-Drug
is	O
hybrid	O
cannabinoid	O
because	O
it	O
has	O
the	O
dibenzopyran	O
ring	O
common	O
classical	O
cannabinoids	O
and	O
an	O
aliphatic	O
hydroxyl	O
group	O
in	O
CP	O
family	O
nonclassical	O

Vaporizing	O
Chasing	O
the	O
dragon:	O
A	O
user	O
puts	O
heroin	B-Drug
on	O
a	O
piece	O
of	O
foil	O
and	O
heats	O
with	O
lighter	O
underneath	O
it	O

Methamphetamine	B-Drug
is	O
metabolized	O
by	O
the	O
liver	O
enzyme	O
CYP2D6	O
so	O
inhibitors	O
will	O
prolong	O
elimination	O
half-life	O
of	O
methamphetamine	B-Drug

Key	O
points	O
of	O
origin	O
maritime	O
cocaine	B-Drug
smuggling	O
still	O
remain	O
to	O
be	O
from	O
mainly	O
Colombia	O
as	O
well	O
Bolivia	O
and	O
Peru	O

In	O
1909	O
the	O
International	O
Opium	O
Commission	O
was	O
founded	O
and	O
by	O
1914	O
34	O
nations	O
had	O
agreed	O
that	O
production	O
importation	O
of	O
opium	B-Drug
should	O
be	O
diminished	O

It	O
does	O
not	O
produce	O
any	O
significant	O
numbing	O
of	O
the	O
mouth	O
nor	O
it	O
give	O
a	O
rush	O
like	O
snorting	O
cocaine	B-Drug

While	O
some	O
effort	O
was	O
first	O
suggested	O
for	O
drafting	O
of	O
a	O
resolution	O
urging	O
governments	O
to	O
stop	O
manufacture	O
and	O
use	O
ketobemidone	B-Drug

Bupropion	B-Drug
treatment	O
also	O
is	O
not	O
associated	O
with	O
the	O
sleepiness	O
or	O
weight	O
gain	O
that	O
may	O
be	O
produced	O
by	O
other	O
antidepressants	O

The	O
recreational	O
use	O
is	O
not	O
particularly	O
widespread	O
in	O
the	O
EU	O
with	O
exception	O
of	O
Tallinn	O
Estonia	O
where	O
it	O
has	O
largely	O
replaced	O
heroin	B-Drug

A	O
similar	O
and	O
connected	O
nexus	O
of	O
LSD	B-Drug
use	O
in	O
the	O
creative	O
arts	O
developed	O
around	O
same	O
time	O
London	O

Sedation:	O
Fentanyl	B-Drug
produces	O
sleep	O
and	O
drowsiness	O
as	O
dosage	O
is	O
increased	O
can	O
produce	O
the	O
-waves	O
often	O
seen	O
in	O
natural	O
on	O
electroencephalogram	O

The	O
medication	O
shows	O
equivalent	O
or	O
superior	O
effectiveness	O
to	O
other	O
antiandrogens	O
including	O
spironolactone	B-Drug
cyproterone	O
acetate	O
and	O
finasteride	B-Drug
in	O
the	O
treatment	O
of	O
hirsutism	O
although	O
its	O
relatively	O
high	O
risk	O
hepatotoxicity	O
makes	O
it	O
unfavorable	O
compared	O
these	O
options	O

Examples	O
include	O
bicuculline	O
securinine	O
and	O
metrazol	O
the	O
benzodiazepine	O
GABAA	O
receptor	O
antagonist	O
flumazenil	B-Drug

In	O
one	O
case	O
report	O
zolpidem	B-Drug
was	O
found	O
in	O
cord	O
blood	O
at	O
delivery	O

Premedication	O
administering	O
sedative	O
drugs	O
prior	O
to	O
induction	O
increases	O
the	O
potency	O
of	O
alfaxalone	B-Drug
as	O
an	O
agent	O

In	O
China	O
as	O
of	O
January	O
2021	O
proxalutamide	O
is	O
in	O
phase	O
III	O
studies	O
for	O
mCRPC	O
monotherapy	O
and	O
combination	O
with	O
abiraterone	B-Drug

Due	O
to	O
concerns	O
about	O
Reye	O
syndrome	O
it	O
is	O
recommended	O
that	O
aspirin	B-Drug
and	O
combination	O
products	O
contain	O
not	O
be	O
given	O
children	O
or	O
teenagers	O
during	O
episodes	O
of	O
fever-causing	O
illnesses	O

Indometacin	B-Drug
mechanism	O
of	O
action	O
along	O
with	O
several	O
other	O
NSAIDs	O
that	O
inhibit	O
COX	O
was	O
described	O
in	O
1971	O

Speaking	O
in	O
comparative	O
terms	O
regarding	O
animal	O
studies	O
of	O
carcinogenicity	O
for	O
medications	O
a	O
member	O
the	O
FDA's	O
Bureau	O
Drugs	O
testified	O
at	O
an	O
agency	O
DMPA	B-Drug
hearing	O

In	O
addition	O
in	O
vitro	O
models	O
seviteronel	O
appears	O
to	O
possess	O
greater	O
efficacy	O
as	O
an	O
antiandrogen	O
relative	O
abiraterone	B-Drug

00	O
per	O
pint;	O
3	O
Opium	B-Drug
Concentrated	O
Deodorized	O
and	O
Denarcotized	O
Four	O
times	O
the	O
strength	O
of	O
tincture	O
Used	O
when	O
Tinct	O

In	O
addition	O
androstenedione	B-Drug
and	O
testosterone	O
can	O
be	O
converted	O
into	O
estrone	O
estradiol	O
by	O
aromatase	O
respectively	O

CBD	B-Drug
also	O
acts	O
as	O
an	O
allosteric	O
modulator	O
of	O
the	O
-	O
and	O
-opioid	O
receptors	O

Until	O
the	O
full	O
ban	O
on	O
opium-based	O
products	O
came	O
into	O
effect	O
just	O
after	O
beginning	O
of	O
twentieth	O
century	O
physicians	O
in	O
US	O
considered	O
opium	B-Drug
a	O
miracle	O
drug	O
that	O
could	O
help	O
with	O
many	O
ailments	O

Chloromorphide	O
is	O
one	O
of	O
a	O
series	O
opioids	O
known	O
as	O
morphides	O
and	O
codides	O
which	O
are	O
important	O
precursors	O
intermediates	O
in	O
the	O
synthesis	O
semi-synthetic	O
opioid	O
analgesic	O
drugs	O
especially	O
those	O
with	O
additions	O
substitutions	O
or	O
other	O
modifications	O
at	O
7	O
8	O
and/or	O
14	O
positions	O
on	O
morphine	B-Drug
carbon	O
skeleton	O

In	O
the	O
largest	O
nandrolone	B-Drug
study	O
performed	O
on	O
621	O
athletes	O
at	O
1998	O
Nagano	O
Olympic	O
Games	O
no	O
athlete	O
tested	O
over	O
0	O

The	O
two	O
terms	O
are	O
often	O
used	O
interchangeably	O
but	O
acid	O
rock	O
may	O
be	O
distinguished	O
as	O
a	O
more	O
extreme	O
variation	O
that	O
was	O
heavier	O
louder	O
relied	O
on	O
long	O
jams	O
focused	O
directly	O
LSD	B-Drug
and	O
made	O
greater	O
use	O
of	O
distortion	O

On	O
December	O
15	O
2008	O
it	O
was	O
reported	O
by	O
German	O
pharmaceutical	O
companies	O
that	O
JWH-018	B-Drug
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002	O

25I-NBOMe	B-Drug
is	O
widely	O
rumored	O
to	O
be	O
orally	O
inactive;	O
however	O
apparent	O
overdoses	O
have	O
occurred	O
via	O
oral	O
administration	O

In	O
comparison	O
to	O
other	O
exogenous	O
glucocorticoids	O
Methylprednisolone	B-Drug
has	O
a	O
higher	O
affinity	O
glucocorticoid	O
receptors	O
than	O
mineralocorticoid	O

Studies	O
conducted	O
by	O
the	O
FDA	O
from	O
2014	O
through	O
2019	O
have	O
determined	O
that	O
a	O
majority	O
of	O
CBD	B-Drug
products	O
are	O
not	O
accurately	O
labeled	O
with	O
amount	O
they	O
contain	O

Israel	O
banned	O
25I-NBOMe	B-Drug
in	O
2013	O

Eletriptan	B-Drug
is	O
believed	O
to	O
reduce	O
swelling	O
of	O
the	O
blood	O
vessels	O
surrounding	O
brain	O

The	O
full	O
profile	O
of	O
amphetamine's	O
short-term	O
drug	O
effects	O
in	O
humans	O
is	O
mostly	O
derived	O
through	O
increased	O
cellular	O
communication	O
or	O
neurotransmission	O
dopamine	O
serotonin	O
norepinephrine	O
epinephrine	O
histamine	O
CART	O
peptides	O
endogenous	O
opioids	O
adrenocorticotropic	O
hormone	O
corticosteroids	O
and	O
glutamate	O
which	O
it	O
interactions	O
with	O
5-HT1A	O
EAAT3	O
TAAR1	O
VMAT1	O
VMAT2	O
possibly	O
other	O
biological	O
targets	O
amphetamine	B-Drug

Certainly	O
the	O
inhibition	O
of	O
COX-2	O
is	O
paramount	O
for	O
anti-inflammatory	O
and	O
analgesic	O
function	O
celecoxib	B-Drug

Activist	O
Abbie	O
Hoffman	O
also	O
committed	O
suicide	O
by	O
consuming	O
phenobarbital	B-Drug
combined	O
with	O
alcohol	O
on	O
April	O
12	O
1989;	O
the	O
residue	O
of	O
around	O
150	O
pills	O
was	O
found	O
in	O
his	O
body	O
at	O
autopsy	O

Suicide	O
by	O
laudanum	B-Drug
was	O
not	O
uncommon	O
in	O
the	O
mid-19th	O
century	O

Also	O
psychiatric	O
experiments	O
with	O
hashish	B-Drug
were	O
done	O
at	O
the	O
same	O
time	O
Jacques-Joseph	O
Moreau	O
being	O
convinced	O
that	O
it	O
is	O
supreme	O
medicament	O
for	O
use	O
in	O
psychiatry	O

Androgenic	O
effects	O
like	O
virilization	O
are	O
relatively	O
uncommon	O
with	O
nandrolone	B-Drug
decanoate	O
at	O
recommended	O
dosages	O
though	O
may	O
still	O
occur	O
especially	O
higher	O
or	O
extended	O
use	O

Neurotoxic	O
changes	O
including	O
vacuolation	O
have	O
been	O
observed	O
in	O
posterior	O
cingulate	O
and	O
retrosplenial	O
cortices	O
of	O
rats	O
administered	O
other	O
NMDA	O
receptor	O
antagonists	O
such	O
as	O
PCP	B-Drug
but	O
not	O
with	O
dextromethorphan	B-Drug

Benzphetamine	B-Drug
also	O
slightly	O
increases	O
metabolism	O

Some	O
researchers	O
such	O
as	O
David	O
Nutt	O
have	O
criticized	O
the	O
current	O
scheduling	O
of	O
MDMA	B-Drug
which	O
he	O
determines	O
to	O
be	O
a	O
relatively	O
harmless	O
drug	O

As	O
of	O
October	O
2015	O
RCS-4	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China	O

In	O
a	O
New	O
Zealand	O
study	O
2003	O
of	O
200	O
deaths	O
Zopiclone	B-Drug
benzodiazepine	O
receptor	O
agonist	O
had	O
similar	O
overdose	O
potential	O
as	O
benzodiazepines	O

It	O
is	O
also	O
referred	O
to	O
as	O
methandrostenolone	B-Drug
and	O
dehydromethyltestosterone	O

Most	O
hydrocodone	B-Drug
formulations	O
include	O
a	O
second	O
analgesic	O
such	O
as	O
paracetamol	B-Drug
acetaminophen	B-Drug
or	O
ibuprofen	B-Drug

However	O
the	O
2018	O
consensus	O
guidelines	O
on	O
chronic	O
pain	O
concluded	O
that	O
overall	O
there	O
is	O
only	O
weak	O
evidence	O
in	O
favor	O
of	O
ketamine	B-Drug
use	O
spinal	O
injury	O
moderate	O
for	O
CRPS	O
and	O
or	O
no	O
mixed	O
neuropathic	O
fibromyalgia	O
cancer	O

Etizolam's	O
main	O
metabolites	O
in	O
humans	O
are	O
alpha-hydroxyetizolam	O
and	O
8-hydroxyetizolam	O
Etizolam	B-Drug

In	O
response	O
to	O
the	O
proposed	O
scheduling	O
Texas	O
Group	O
increased	O
production	O
from	O
1985	O
estimates	O
of	O
30000	O
tablets	O
a	O
month	O
as	O
many	O
8000	O
per	O
day	O
potentially	O
making	O
two	O
million	O
ecstasy	B-Drug
in	O
months	O
before	O
MDMA	B-Drug
was	O
made	O
illegal	O

In	O
fact	O
in	O
an	O
article	O
published	O
The	O
Lancet	O
journal	O
about	O
the	O
adverse	O
health	O
effects	O
of	O
non-medical	O
cannabis	O
use	O
Professors	O
Hall	O
and	O
Degenhardt	O
clearly	O
stated	O
that	O
public	O
burden	O
is	O
probably	O
modest	O
compared	O
with	O
alcohol	O
tobacco	B-Drug
other	O
illicit	O
drugs	O

Mifepristone	B-Drug
also	O
known	O
as	O
11-4-dimethylaminophenyl-17-1-propynylestra-49-dien-17-ol-3-one	O
is	O
a	O
synthetic	O
estrane	O
steroid	O
and	O
derivative	O
of	O
hormones	O
like	O
progesterone	O
cortisol	O
testosterone	O

Conversely	O
endogeneous	O
GHB	B-Drug
production	O
in	O
those	O
taking	O
valproic	O
acid	O
will	O
be	O
inhibited	O
via	O
inhibition	O
of	O
the	O
conversion	O
from	O
succinic	O
semialdehyde	O
to	O

food	O
ingredient	O
company	O
Calyxt	O
to	O
improve	O
the	O
quality	O
of	O
soybean	B-Drug
oil	I-Drug
products	O
and	O
increase	O
storage	O
potential	O
potatoesSeveral	O
optimizations	O
need	O
be	O
made	O
in	O
order	O
editing	O
plant	O
genomes	O
using	O
ZFN-mediated	O
targeting	O

Tramadol	B-Drug
and	O
desmetramadol	O
themselves	O
do	O
not	O
bind	O
to	O
the	O
5-HT3	O
receptor	O

Major	O
adverse	O
cardiovascular	O
events	O
MACE	O
were	O
increased	O
by	O
about	O
a	O
third	O
diclofenac	B-Drug
chiefly	O
due	O
to	O
an	O
increase	O
in	O
major	O
coronary	O

Liggins	O
found	O
that	O
dexamethasone	B-Drug
caused	O
pregnant	O
sheep	O
to	O
deliver	O
their	O
fetuses	O
prematurely	O
however	O
despite	O
the	O
fact	O
lamb	O
fetus	O
was	O
extremely	O
premature	O
it	O
delivered	O
alive	O

Recreational	O
users	O
of	O
carisoprodol	B-Drug
usually	O
seek	O
its	O
potentially	O
heavy	O
sedating	O
relaxant	O
and	O
anxiolytic	O
effects	O

The	O
combination	O
tablet	O
in	O
with	O
caffeine	O
called	O
Cafergot	B-Drug
contains	O
1	O
mg	O
of	O
ergotamine	B-Drug
and	O
100	O

Withdrawal	O
from	O
stimulants	O
such	O
as	O
cocaine	B-Drug
do	O
not	O
have	O
major	O
medical	O
complications	O

There	O
is	O
no	O
specific	O
antidote	O
for	O
cocaine	B-Drug

Overall	O
some	O
studies	O
suggest	O
that	O
alcohol	O
is	O
one	O
of	O
the	O
most	O
dangerous	O
all	O
recreational	O
drugs;	O
only	O
heroin	B-Drug
crack	O
cocaine	O
and	O
methamphetamines	B-Drug
are	O
judged	O
to	O
be	O
more	O
harmful	O

Cortisol	O
prolactin	O
and	O
oxytocin	O
quantities	O
in	O
blood	O
serum	O
are	O
increased	O
by	O
MDMA	B-Drug

